
<html lang="en"     class="pb-page"  data-request-id="98d275b1-cb66-489e-9049-7ad8023a7fb9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-22;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00435;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential" /></meta><meta name="dc.Creator" content="Liang  Tan" /></meta><meta name="dc.Creator" content="Wenzhong  Yan" /></meta><meta name="dc.Creator" content="John D.  McCorvy" /></meta><meta name="dc.Creator" content="Jianjun  Cheng" /></meta><meta name="dc.Description" content="G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter. Biased ligands s..." /></meta><meta name="Description" content="G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter. Biased ligands s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 25, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00435" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00435" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00435" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00435" /></link>
        
    
    

<title>Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00435" /></meta><meta property="og:title" content="Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0035.jpeg" /></meta><meta property="og:description" content="G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter. Biased ligands selective for either pathway are expected to regulate biological functions of GPCRs in a more precise way, therefore providing new drug molecules with superior efficacy and/or reduced side effects. During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D2 receptor, and many others. In this Perspective, recent advances in this field are reviewed by discussing the structure–functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these molecules. Further understanding of the biological functions associated with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00435"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00435">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00435&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00435&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00435&amp;href=/doi/10.1021/acs.jmedchem.8b00435" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 9841-9878</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00294" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b00864" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Liang Tan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Tan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong District, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Tan">Liang Tan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenzhong Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenzhong Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong District, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenzhong++Yan">Wenzhong Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John D. McCorvy</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John D. McCorvy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, Wisconsin 53226, United States</div></div><span class="conrtib-corresp"><strong>*</strong>J.D.M.: phone, +1 414-955-7635; e-mail, <a href="/cdn-cgi/l/email-protection#0d67606e6e627f7b744d606e7a23686978"><span class="__cf_email__" data-cfemail="42282f21212d30343b022f21356c272637">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++McCorvy">John D. McCorvy</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jianjun Cheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjun Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong District, Shanghai 201210, China</div></div><span class="conrtib-corresp"><strong>*</strong>J.C.: phone, +86 21 20685237; e-mail, <a href="/cdn-cgi/l/email-protection#caa9a2afa4ada0a08ab9a2aba4ada2aba3beafa9a2e4afaebfe4a9a4"><span class="__cf_email__" data-cfemail="cba8a3aea5aca1a18bb8a3aaa5aca3aaa2bfaea8a3e5aeafbee5a8a5">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjun++Cheng">Jianjun Cheng</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6065-2682" title="Orcid link">http://orcid.org/0000-0001-6065-2682</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00435&amp;href=/doi/10.1021%2Facs.jmedchem.8b00435" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 9841–9878</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 25, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 March 2018</li><li><span class="item_label"><b>Published</b> online</span>25 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 21 November 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00435" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00435</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9841%26pageCount%3D38%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLiang%2BTan%252C%2BWenzhong%2BYan%252C%2BJohn%2BD.%2BMcCorvy%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D22%26contentID%3Dacs.jmedchem.8b00435%26title%3DBiased%2BLigands%2Bof%2BG%2BProtein-Coupled%2BReceptors%2B%2528GPCRs%2529%253A%2BStructure%25E2%2580%2593Functional%2BSelectivity%2BRelationships%2B%2528SFSRs%2529%2Band%2BTherapeutic%2BPotential%26numPages%3D38%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9878%26publicationDate%3DNovember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00435"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6589</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">47</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00435" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Wenzhong&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. McCorvy&quot;},{&quot;first_name&quot;:&quot;Jianjun&quot;,&quot;last_name&quot;:&quot;Cheng&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;9841-9878&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00435&quot;},&quot;abstract&quot;:&quot;G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter. Biased ligands selective for either pathway are expected to regulate biological functions of GPCRs in a more precise way, therefore providing new drug molecules with superior efficacy and/or reduced side effects. During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D2 receptor, and many others. In this Perspective, recent advances in this field are reviewed by discussing the structure–functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these molecules. Further understanding of the biological functions associated with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00435&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00435" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00435&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00435" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00435&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00435" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00435&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00435&amp;href=/doi/10.1021/acs.jmedchem.8b00435" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00435" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00435" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26pmid%3D29939744%26genre%3Darticle%26aulast%3DTan%26date%3D2018%26atitle%3DBiased%2BLigands%2Bof%2BG%2BProtein-Coupled%2BReceptors%2B%2528GPCRs%2529%253A%2BStructure%25E2%2580%2593Functional%2BSelectivity%2BRelationships%2B%2528SFSRs%2529%2Band%2BTherapeutic%2BPotential%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D22%26spage%3D9841%26epage%3D9878%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/jmcmar.2018.61.issue-22/20181121/jmcmar.2018.61.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter. Biased ligands selective for either pathway are expected to regulate biological functions of GPCRs in a more precise way, therefore providing new drug molecules with superior efficacy and/or reduced side effects. During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D<sub>2</sub> receptor, and many others. In this Perspective, recent advances in this field are reviewed by discussing the structure–functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these molecules. Further understanding of the biological functions associated with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">G protein-coupled receptors (GPCRs) constitute the largest family of membrane proteins in the human genome, with more than 800 members.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> According to the “GRAFS” classification system, GPCRs can be grouped in five families: Glutamate, Rhodopsin-like, Adhesion, Frizzled/Taste2, and Secretin, while the rhodopsin-like receptors are also known as class A, secretin as class B, and glutamate as class C.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> All GPCRs share a common architecture characterized by the seven-transmembrane (7TM) domains, also known as seven-transmembrane receptors (7TMRs), but they play diverse physiological roles and can be activated by various stimuli, such as photons, ions, neurotransmitters, and hormones.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> GPCRs are the targets for more than 30% of all approved drugs, and they remain the most successful and promising class of target proteins for drug discovery.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a></div><div class="NLM_p">As membrane proteins, GPCRs are responsible for transferring extracellular signals to the cytosol. As indicated by their name, GPCRs couple to G proteins that bind and hydrolyze guanosine 5′-triphosphate (GTP) to mediate downstream signaling. G proteins associated with GPCRs are heterotrimeric and composed of three subunits: Gα, Gβ, and Gγ. Gα proteins are further divided into four main subgroups: Gα<sub>s</sub>, Gα<sub>i/o</sub>, Gα<sub>q/11</sub>, and Gα<sub>12/13</sub>. Depending on the type of G protein that a specific GPCR couples to, receptor activation can lead to secondary messengers, such as inositol triphosphates (G<sub>q</sub>) or cyclic adenosine monophosphate (cAMP) (G<sub>s</sub>/G<sub>i</sub>).</div><div class="NLM_p">Recently, other G-protein-independent pathways have been identified, and the most recognized one is the β-arrestin-dependent signaling pathway.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Upon the activation of GPCRs, a family of protein kinases called G-protein-coupled receptor kinases (GRKs) will phosphorylate the intracellular domains of GPCRs after their associated G proteins have been released and activated. Phosphorylated GPCRs will recruit β-arrestins, which mediate the desensitization of GPCR signaling, internalization of GPCRs and therefore serve to “turn off” signaling, resulting in negative feedback of G-protein-dependent GPCR signaling. β-Arrestins have also been associated with the activation of mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinases 1 and 2 (ERK1/2).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, ERK1/2 signaling can be either G-protein-dependent or β-arrestin-mediated or both, depending on the cellular context in which the response is measured. Two types of β-arrestins (nonvisual arrestins) have been identified, namely, β-arrestin1 (also referred to as arrestin2) and β-arrestin2 (also referred to as arrestin3), along with two visual arrestins, arrestin1 and arrestin4. Although visual arrestins are only expressed in the retina where they regulate the functions of rhodopsin, β-arrestins are widely expressed and they modulate the signaling of other GPCRs. It remains unclear if all GPCRs that recruit β-arrestins cause β-arrestin-dependent signaling and to what extent β-arrestin-dependent signaling occurs.</div><div class="NLM_p">Historically, GPCR signaling resulting from the activation by a specific ligand was assumed to show equal efficacy across systems, a property of the ligand termed “intrinsic efficacy.” In fact, current models of GPCR activation states, including the ternary and extended ternary complex models of receptor activation, propose that receptors exist in either “active” or “inactive” states, and specific states of activation have also been discovered for rhodopsin receptors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The concept of biased signaling of GPCRs was first described by Kenakin more than 2 decades ago in 1995.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> It was not until accumulating evidence demonstrated that ligands could show efficacy for a variety of cellular responses that the notion of functional selectivity or ligand bias began to take hold.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> “Functional selectivity” is an older term and simply denotes difference in efficacy for one or more functional readouts, while “ligand bias” usually involves a formal analysis of opposing pathways (e.g., G protein versus arrestin) and can be quantitative. With the identification of G-protein-independent signaling (e.g., β-arrestins), which can directly bind to GPCRs to stabilize separate receptor active states, GPCRs have now been posited to exist in multiple, distinct conformational states, which is a theoretical notion that GPCRs form ensembles of several active and inactive conformational populations.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Although the detailed molecular mechanisms of biased signaling is not yet well understood, it has been reported that biased GPCR ligands induce a unique receptor conformation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which in turn activates a particular signaling pathway via an effector (e.g., G proteins or β-arrestins). Although theoretically it has been assumed that GPCR conformations stabilized by a G-protein-biased ligand are distinct from the conformations stabilized by a β-arrestin-biased ligand, further study is required to determine how GPCRs adopt specific conformations that lead to preference for either effector.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Biased signaling at a glance. GPCR represented is from the crystal structure of β2 adrenergic receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RH1">2RH1</a>). The GPCR-G protein complex represented is from the β2 adrenergic receptor-G protein complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SN6">3SN6</a>), and the GPCR-β-arrestin complex represented is from the structure of rhodopsin-β-arrestin complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWJ">4ZWJ</a>). Throughout this review, G-protein-dependent activity of ligands is represented in red, and G-protein-independent signaling in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our increased understanding of this phenomenon has opened a new era for the study of GPCR signaling as well as GPCR-targeted drug discovery. Biased ligands have been discovered through evaluating ligand efficacy in various pharmacological assays rather than solely from canonical G-protein-dependent assays. Subsequently, methods of detecting and quantifying bias properties of a given GPCR ligands have been substantially developed and evolved.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> During the past decade, both G-protein-biased and β-arrestin-biased ligands have been discovered and developed for many GPCRs. Although a few previous reviews have summarized the progress in this field,<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17">(13−17)</a> the rapid discovery of new biased ligands in this field necessitates an up-to-date and comprehensive review. In this Perspective, we summarize recent advances in biased ligand discovery for around 30 different GPCRs in classes A, B, and C (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), with an emphasis on structure–functional selectivity relationships (SFSRs) analyzed from a medicinal chemistry perspective. In a number of cases, therapeutic advantages of biased ligands have been studied in preclinical animal models or clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Challenges in the discovery of biased ligands and medicinal chemistry strategies that can be used are also discussed.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Biased ligands have been reported for 30 GPCR targets: ADORA1, adenosine A<sub>1</sub> receptor (A<sub>1</sub>AR); ADORA3, adenosine A<sub>3</sub> receptor (A<sub>3</sub>AR); ADRB1, adrenergic β<sub>1</sub> receptor (β<sub>1</sub>AR); ADRB2, adrenergic β<sub>2</sub> receptor (β<sub>2</sub>AR); AGTR1, angiotensin II receptor type 1 (AT<sub>1</sub>R); AGTRL1, apelin receptor (APJ); CASR, calcium-sensing receptor (CaSR); CNR1, cannabinoid receptor 1 (CB<sub>1</sub>R); CNR2, cannabinoid receptor 2 (CB<sub>2</sub>R); CXCR3, chemokine receptor CXCR3; DRD1, dopamine D<sub>1</sub> receptor (D<sub>1</sub>R); DRD2, dopamine D<sub>2</sub> receptor (D<sub>2</sub>R); EDG1, sphingosine 1-phosphate receptor 1 (S1P<sub>1</sub>R); EDNRA, endothelin A receptor (ET<sub>A</sub>); FPR2, formyl peptide receptor 2; GLP1R, glucagon-like peptide 1 receptor; GRM1, metabotropic glutamate receptor 1 (mGlu<sub>1</sub>R); GRM5, metabotropic glutamate receptor 5 (mGlu<sub>5</sub>R); HM74, niacin receptor (HM74A for GPR109A); HRH2, histamine H<sub>2</sub> receptor (H<sub>2</sub>R); HRH4, histamine H<sub>4</sub> receptor (H<sub>4</sub>R); HTR1A, serotonin 1A receptor (5-HT<sub>1A</sub>R); HTR2B, serotonin 2B receptor (5-HT<sub>2B</sub>R); HTR2C, serotonin 2C receptor (5-HT<sub>2C</sub>R); NTSR1, neurotensin receptor type 1 (NT<sub>1</sub>R); OPRK1, κ opioid receptor (KOR); OPRL1, nociception receptor (NOPR); OPRM1, μ opioid receptor (MOR); PTGER2, prostaglandin E2 receptor 2 (EP<sub>2</sub>R); PTHR1, parathyroid hormone 1 receptor. The graph was produced based on the dendrogram of the human GPCR superfamily (“Figure 1” in Katritch et al., “Structure-Function of the G Protein-Coupled Receptor Superfamily”<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>), with permission from the authors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biased Ligands at Class A, Class B, and Class C GPCRs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">GPCR</th><th class="colsep0 rowsep0" align="center">biased ligand</th><th class="colsep0 rowsep0" align="center">type of ligand bias</th><th class="colsep0 rowsep0" align="center">therapeutic area</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">class A</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β<sub>1</sub>AR</td><td class="colsep0 rowsep0" align="left">metoprolol;<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> alprenolol and carvedilol<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonists</td><td class="colsep0 rowsep0" align="left">heart diseases</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β<sub>2</sub>AR</td><td class="colsep0 rowsep0" align="left">ethylnorepinephrine, isoetharine, <i>N</i>-cyclopentylbutanepherine;<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> carvedilol;<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> propranolol and ICI-118,551<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonists</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AT<sub>1</sub>R</td><td class="colsep0 rowsep0" align="left">TRV120023 and TRV120027<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonists</td><td class="colsep0 rowsep0" align="left">acute heart failure</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MOR</td><td class="colsep0 rowsep0" align="left">TRV130;<a onclick="showRef(event, 'ref35 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref37">(35,37)</a> PZM21;<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> mitragynine and analogues;<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> SR-17018, SR-15099, and SR-15098<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">pain</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KOR</td><td class="colsep0 rowsep0" align="left"><b>33</b>;<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a><b>35</b>;<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> RB-64;<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> 6′-GNTI;<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> nalfurafine<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">pain</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NOPR</td><td class="colsep0 rowsep0" align="left">MCOPPB;<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> NNC 63-0532;<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a>  RTI-4229-819 and RTI-4229-856<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">pain</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2</sub>R</td><td class="colsep0 rowsep0" align="left">UNC9975, UNC9994, and UNC9995;<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a><b>55</b><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonists</td><td class="colsep0 rowsep0" align="left">schizophrenia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>49</b>;<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a><b>50</b>;<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a><b>52</b>;<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> cariprazine;<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a><b>60</b>;<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a><b>63</b><a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BRD5814<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased antagonist/G protein agonist</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>1</sub>R</td><td class="colsep0 rowsep0" align="left">SKF38393, SKF75670, SKF-77434, SKF83959, and SKF82957;<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> PF-8294 and PF-6142<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">cognition; Parkinson’s disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2B</sub></td><td class="colsep0 rowsep0" align="left">ergotamine<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonist</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2C</sub></td><td class="colsep0 rowsep0" align="left"><b>80</b>;<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a><b>81</b><a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">obesity; schizphrenia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub></td><td class="colsep0 rowsep0" align="left"><b>83</b>, <b>84</b>, and <b>85</b><a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">anxiety</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H<sub>4</sub>R</td><td class="colsep0 rowsep0" align="left">JNJ-7777120;<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> VUF5223 and VUF10214<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin biased agonists</td><td class="colsep0 rowsep0" align="left">inflammation and pruritus</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">VUF5222, VUF10778, and VUF10185<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CB<sub>1</sub>R</td><td class="colsep0 rowsep0" align="left">2-AG and AEA<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">Huntington’s disease; pain; nausea; obesity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CP-55940 and THC<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin1-biased agonists</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CB<sub>2</sub>R</td><td class="colsep0 rowsep0" align="left">WIN-55212, THC, JWH-133, HU-308, and JWH-015<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased partial agonists</td><td class="colsep0 rowsep0" align="left">pain, sclerosis and Huntington’s disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AM-1248, STS-135, and UR-144<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonists</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">APJ</td><td class="colsep0 rowsep0" align="left">MM07;<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a><b>110</b>;<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> CMF-019<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">heart failure</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR3</td><td class="colsep0 rowsep0" align="left"><b>113</b><a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased NAM</td><td class="colsep0 rowsep0" align="left">autoimmune diseases and cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>114</b><a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased NAM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FAUC1036<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased allosteric agonist</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">FAUC1104<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased allosteric agonist</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EP<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><b>119</b>, <b>120</b>, <b>121</b>, and <b>123</b><a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">lowing intraocular pressure</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">ET-2 and ET-3<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">pulmonary arterial hypertension (PAH); cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">bosentan<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased antagonist</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GPR109A</td><td class="colsep0 rowsep0" align="left">MK-0354<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonist</td><td class="colsep0 rowsep0" align="left">lowering triglycerides</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S1P<sub>1</sub>R</td><td class="colsep0 rowsep0" align="left">BMS-986104<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonist</td><td class="colsep0 rowsep0" align="left">multiple sclerosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NTR<sub>1</sub></td><td class="colsep0 rowsep0" align="left">ML314<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonist</td><td class="colsep0 rowsep0" align="left">schizophrenia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FPR2</td><td class="colsep0 rowsep0" align="left">F2Pal<sub>10</sub><a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonist</td><td class="colsep0 rowsep0" align="left">inflammation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A<sub>1</sub>AR</td><td class="colsep0 rowsep0" align="left">VCP746;<a onclick="showRef(event, 'ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref165 ref166">(165,166)</a><b>139</b><a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></td><td class="colsep0 rowsep0" align="left">agonists; cAMP inhibition over pERK1/2 or calcium mobilization</td><td class="colsep0 rowsep0" align="left">ischemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>141</b><a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></td><td class="colsep0 rowsep0" align="left">agonist; calcium mobilization over cAMP inhibition</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A<sub>3</sub>AR</td><td class="colsep0 rowsep0" align="left"><b>143</b>–<b>148</b><a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></td><td class="colsep0 rowsep0" align="left">agonist; cell survival over cAMP inhibition</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">class B</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GLP-1R</td><td class="colsep0 rowsep0" align="left">P5<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonist</td><td class="colsep0 rowsep0" align="left">type 2 diabetes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oxyntomodulin;<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> exendin-4;<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a><b>154</b>–<b>156</b><a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonists</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTHR1</td><td class="colsep0 rowsep0" align="left">PTH-barr<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonist</td><td class="colsep0 rowsep0" align="left">osteoporosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">class C</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mGlu<sub>1</sub>R</td><td class="colsep0 rowsep0" align="left">quisqualate;<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> DHPG<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></td><td class="colsep0 rowsep0" align="left">G-protein-biased agonists</td><td class="colsep0 rowsep0" align="left">neuroprotection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">glutaric acid and succinic acid<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></td><td class="colsep0 rowsep0" align="left">β-arrestin-biased agonists</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mGlu<sub>5</sub>R</td><td class="colsep0 rowsep0" align="left">VU0409551;<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> NCFP<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a></td><td class="colsep0 rowsep0" align="left">PAMs that bias toward calcium mobilization over pERK1/2</td><td class="colsep0 rowsep0" align="left">CNS disorders</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CaSR</td><td class="colsep0 rowsep0" align="left">cinacalcet<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></td><td class="colsep0 rowsep0" align="left">bias for Ca<sup>2+</sup> mobilization and IP<sub>1</sub> accumulation</td><td class="colsep0 rowsep0" align="left">hyperparathyroidism; hypercalcemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AC-265347 and <i>R,R</i>-calcimimetic B<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></td><td class="colsep0 rowsep0" align="left">bias for pERK1/2 and IP<sub>1</sub> accumulation</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>S</i>,<i>R</i>-calcimimetic B<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></td><td class="colsep0 rowsep0" align="left">bias for IP<sub>1</sub> accumulation</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Ergotamine is an approved drug for the treatment of migraine but not based on its action at 5-HT<sub>2B</sub>.</p></div></div></div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Biased Ligands of Class A GPCRs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rhodopsin-like or class A is the largest family that accounts for 85% of all GPCRs, including many drug targets as well as olfactory and orphan receptors. Numerous class A GPCRs such as the aminergic receptors and purinergic receptors are well-validated drug targets, and the druggability of many emerging targets is being explored with drug candidates in preclinical studies and clinical trials.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Biased ligands of class A GPCRs are discussed in the following, outlined by the specific targets they interact with.</div><div id="sec1_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> β Adrenergic Receptors (βARs)</h3><div class="NLM_p">βARs can be genetically subdivided into three subtypes: β<sub>1</sub>AR, β<sub>2</sub>AR, and β<sub>3</sub>AR,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> all of which have been long known as drug targets. Among them, the β<sub>2</sub>AR has been the first non-rhodopsin human GPCR for which crystal structures have been solved and remains as a prototype receptor for the structural and functional investigations of GPCRs.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Previously identified βAR ligands have a common structural feature in that they all contain a catecholamine framework, as seen in norepinephrine (<b>1</b>) and isoproterenol (<b>2</b>) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The study by Drake et al. demonstrated that three catecholamine derivatives ethylnorepinephrine (<b>3</b>), isoetharine (<b>4</b>), and <i>N</i>-cyclopentylbutanepherine (CPB, <b>5</b>) show marked bias toward β-arrestin signaling pathway at the β<sub>2</sub>AR.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> These ligands appeared to stimulate β-arrestin-dependent receptor activities (in β-arrestin translocation FRET assays) to a much greater extent than their efficacy in G-protein-dependent signaling (in cAMP FRET assays). Structural comparison between these compounds and compounds <b>1</b> and <b>2</b> clearly shows that the biased ligands share a common structural feature critical for their β-arrestin recruitment activity, which is the ethyl substituent on the catecholamine α-carbon (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compound <b>5</b> was characterized as the most biased agonist among the three (bias factor of >2), and its stimulation of the β<sub>2</sub>AR resulted in rapid β-arrestin-mediated receptor internalization.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Catecholamine derivatives that are β-arrrestin-biased agonists of βARs. The “bias factor” was calculated as a ratio of β-arrestin efficacy (in β-arrestin translocation FRET assay) to G protein efficacy (in cAMP assay).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inserting an “–OCH<sub>2</sub>–” unit between the aryl and the α-carbon of aryl ethanolamine provided a class of βAR antagonists (also known as β blockers) such as metoprolol (<b>6</b>), carazolol (<b>7</b>), and propranolol (<b>8</b>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Their antagonist activity was defined by the inhibition of G-protein-mediated signaling at the receptors, and Nakaya et al. reported that metoprolol shows agonist activity at β<sub>1</sub>AR when tested for β-arrestin2-dependent signaling.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> They found that metoprolol could induce cardiac fibrosis and impaired diastolic function through the β-arrestin2-dependent pathway, although metoprolol is used for the treatment of various heart diseases.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Some β blockers are β-arrestin-biased agonists of βARs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A study conducted by Kim et al. showed that alprenolol (<b>9</b>) and carvedilol (<b>10</b>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) could stimulate β-arrestin-mediated EGFR transactivation and downstream ERK signaling at the β<sub>1</sub>AR.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Wisler et al. also reported that carvedilol is an inverse agonist of G-protein-mediated signaling at β<sub>2</sub>AR but an agonist of β-arrestin signaling, the latter of which was measured by an increase in the phosphorylation of β<sub>2</sub>AR, ERK activation, and receptor internalization.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Furthermore, aryl ethanolamine β-blockers propranolol (<b>8</b>) and ICI-118,551 (<b>11</b>) were also demonstrated by Azzi et al. to induce ERK1/2 phosphorylation via a β-arrestin-mediated mechanism at β<sub>2</sub>AR.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Together, these results suggest that the β-arrestin signaling may play important roles in the therapeutic or adverse effects of β blockers, which do not simply work by “blocking” all the effects mediated by βARs.</div><div class="NLM_p last">For these βAR ligands, Liu et al. studied the structural basis for their biased properties using the <sup>19</sup>F-NMR methodology.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Their results demonstrated that compared to the balanced prototypes isoproterenol and carazolol, respectively, isoetharine and carvedilol induced a larger shift of helix VII (TM7) of β<sub>2</sub>AR, which may form the structural basis for the signaling bias toward β-arrestins at the β<sub>2</sub>AR. By comparison of the structures of isoetharine versus isoproterenol, and carvedilol versus carazolol, the additional ethyl or phenyl substitutions probably directly interacts with TM7 of the receptor or through changing the overall conformation of the ligand itself.</div></div><div id="sec1_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Angiotensin II Type 1 Receptor (AT<sub>1</sub>R)</h3><div class="NLM_p">AT<sub>1</sub>R is a primary blood pressure modulator, and angiotensin receptor blockers (ARBs), which are AT<sub>1</sub>R antagonists, are widely prescribed drugs indicated for hypertension. Unlike the β blockers, most of these ARBs have been demonstrated as balanced antagonists for both the G protein and β-arrestin signaling in subsequent studies.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> It has been anticipated that β-arrestin-biased AT<sub>1</sub>R agonists, which would engage the β-arrestin-mediated receptor desensitization, internalization, and associated signaling pathways, could provide novel therapeutics for congestive heart failure.</div><div class="NLM_p">Through sequence modifications of angiotensin II (Ang II, <b>12</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), Trevena scientists discovered peptide SII (<b>13</b>) as the first β-arrestin-biased agonist of AT<sub>1</sub>R, which was designed by the substitution of Asp<sup>1</sup> with sarcosine, and Tyr<sup>4</sup> and Phe<sup>8</sup> with isoleucines.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> SII binds to AT<sub>1</sub>R in an Ang II competitive manner with moderate affinity (<i>K</i><sub>D</sub> = 300 nM), which was 187 times lower than that of Ang II (<i>K</i><sub>D</sub> = 1.6 nM). The binding of SII did not induce the coupling of AT<sub>1</sub>R to G protein but caused recruitment of β-arrestins and internalization of the receptor and connected the receptor to the β-arrestin-dependent activation of the MAPK pathway. To enhance the binding affinity of SII, a series of new Ang II analogs were designed, and peptides TRV120023 (<b>14</b>) and TRV120027 (<b>15</b>) displayed improved affinity for AT<sub>1</sub>R.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> TRV120023 and TRV120027 selectively induced β-arrestin2 recruitment (EC<sub>50</sub> = 44 nM and 17 nM, respectively, at the human AT<sub>1</sub>R) while antagonizing Ang II stimulated G protein signaling. In vivo studies in rats showed that, unlike the balanced AT<sub>1</sub>R antagonists, which decreased cardiac performance while reducing blood pressure, TRV120027 increased cardiac performance and preserved cardiac stroke volume.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These results support the development of β-arrestin-biased AT<sub>1</sub>R agonists for the treatment of hypertension and heart failure, which would provide cardiac benefits over the existing ARBs. TRV120027 has been advanced into clinical evaluations for the treatment of acute heart failure (AHF); however, it did not confer any benefits over placebo in patients and failed to meet its primary or secondary end points in a phase IIb trial (BLAST-AHF).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> A post hoc analysis revealed that TRV120027 exhibits differential effects depending on systolic blood pressure, and positive data may be extracted for a narrowly defined subgroup.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. β-Arrestin-biased AT<sub>1</sub>R agonists. The amino acid sequences are shown from the N-terminus (left) to the C-terminus (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Opioid Receptors</h3><div class="NLM_p">Opioid receptors play critical roles in pain management, drug abuse/addiction, and mood disorders. There are four major subtypes: the δ opioid receptor (DOR), the κ opioid receptor (KOR), the μ opioid receptor (MOR), and the nociceptin receptor (NOPR). The MOR primarily mediates the most pronounced analgesic effects via opioid drugs. Recently, MOR has become another example of GPCRs that the “on-target” benefits can be separated from adverse effects through selective activation of downstream pathways that couple to the receptor. Studies have suggested that the opioid-induced analgesia results from the G<sub>i/o</sub> signaling through MOR, while the on-target side effects, such as respiratory depression and constipation, may be conferred via the β-arrestin-dependent signaling.<a onclick="showRef(event, 'ref14 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref14 ref33 ref34">(14,33,34)</a> Therefore, G<sub>i/o</sub>-biased agonists of MOR have been investigated to explore their therapeutic potential. A lead discovery was made by Trevena who screened its internal compound collection and identified compound <b>16</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) as a novel MOR agonist. Compound <b>16</b> showed submicromolar activation of G protein signaling (pEC<sub>50</sub> = 6.3) and lower MOR β-arrestin recruitment activity (<i>E</i><sub>max</sub> = 32% compared to 100% for morphine).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> An SAR investigation with the aim of improving its MOR G protein potency while reducing β-arrestin recruitment activity led to the identification of G-protein-biased compound <b>17</b>. Compound <b>17</b> showed much improved bias properties compared to the hit compound; however, it poses a potential risk for arrhythmia (hERG IC<sub>50</sub> = 2.3 μM). Further SAR studies focusing on the thiophene moiety led to the discovery of compound TRV130 (<b>18</b>), which displayed similar bias for G-protein-dependent signaling but with somewhat reduced hERG inhibition (IC<sub>50</sub> = 6.2 μM).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Thiophene is, however, a structural alert in medicinal chemistry that needs special attention due to metabolic liabilities.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In animal models, compound TRV130 showed potent analgesic effects with reduced respiratory depression and constipation compared to morphine.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> These results showed that TRV130 or other G-protein-biased MOR agonists might function as effective analgesics with fewer side effects than existing nonbiased MOR agonists like morphine. TRV130 (also known as oliceridine, OLINVO) has finished phase 3 clinical trials for the treatment of moderate to severe acute pain and is awaiting the approval from U.S. Food and Drug Administration (FDA). If successful, TRV130 will be the first of its kind in the market.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. G-protein-biased ligands at MOR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using a structure-based approach, Manglik et al. recently reported another G-protein-biased MOR agonist.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> On the basis of the crystal structure of MOR,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> three million molecules were computationally docked to the receptor, with the goal of finding novel chemotypes that can stabilize the receptor in unexplored conformations. Compound <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) was identified as a MOR agonist with moderate binding to the receptor (<i>K</i><sub>i</sub> = 2.5 μM) but displayed a strong bias for G<sub>i/o</sub> signaling.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Structural modifications of <b>19</b> led to the discovery of compound <b>20</b> (<i>K</i><sub>i</sub> = 42 nM), which strongly activated G<sub>i/o</sub> (EC<sub>50</sub> = 180 nM, <i>E</i><sub>max</sub> = 88%) with low levels of β-arrestin2 recruitment (EC<sub>50</sub> = 940 nM, <i>E</i><sub>max</sub> = 9.4%). Finally, the structure-guided optimization of <b>20</b>, by synthesizing its stereochemical isomers and introducing a phenolic hydroxyl, provided compound PZM21 (<b>21</b>), which had an EC<sub>50</sub> of 4.6 nM in a G<sub>i/o</sub> activation assay (<i>E</i><sub>max</sub> = 77%) and a <i>K</i><sub>i</sub> of 1.1 nM in a radioligand binding assay.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As a potent G<sub>i/o</sub> activator with exceptional selectivity for MOR and minimal β-arrestin2 recruitment, PZM21 decreases affective pain perception and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equianalgesic doses compared to that of morphine.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> However, in later studies, PZM21 was demonstrated to be a low efficacy MOR agonist in both G protein and β-arrestin2 assays, and it depresses respiration in a manner similar to morphine.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">Another family of natural products that were found to be biased MOR agonists are mitragynine and its analogues. Mitragynine (<b>22</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) has an indole-based scaffold distinct from that of morphine. Mitragynine and an oxidative derivative of this compound, 7-OH mitragynine (<b>23</b>), as well as a further rearrangement product mitragynine pseudoindoxyl (<b>24</b>), are all MOR agonists that showed activity as antinociceptive agents. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, both potency and efficacy at the MOR were gradually increased from mitragynine to 7-OH mitragynine and then to mitragynine pseudoindoxyl. Interestingly, all three compounds were inactive for β-arrestin2 recruitment, suggesting that they are G-protein-biased MOR agonists.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Although all three compounds showed significant binding to the KOR and DOR as well, they function only as weak antagonists rather than as agonists.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In animal tests, mitragynine pseudoindoxyl exhibited better antinociceptive effects than mitragynine and 7-OH mitragynine, which was equal to or more potent than those of morphine.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> However, mitragynine pseudoindoxyl developed tolerance more slowly than morphine, and it showed fewer side effects such as physical dependence, constipation, and respiratory depression, which provided further evidence for the potential of G-protein-biased MOR agonists as a new generation of superior analgesics.</div><div class="NLM_p">More recently, a series of new but structurally related compounds were studied by Schmid et al. for their bias properties at MORs and therapeutic potential as safer opioid analgesics.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Fentanyl (<b>25</b>) and its analogue sufentanil (<b>26</b>) are clinically relevant analgesics, and they show comparable G protein activity (in GTPγS binding assay) and β-arrestin2 recruitment activity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). However, when their activity was compared to DAMGO (GTPγS binding, EC<sub>50</sub> = 33 nM (<i>E</i><sub>max</sub> = 100%); β-arrestin2 recruitment, EC<sub>50</sub> = 229 nM (<i>E</i><sub>max</sub> = 100%)), both compounds are β-arrestin-biased agonists of MORs. Multiple systems were used to study fentanyl, sufentanil, morphine, and piperidine compounds such as SR-17018 (<b>27</b>), SR-15099 (<b>28</b>), SR-15098 (<b>29</b>), and SR-11501 (<b>30</b>), to demonstrate their signaling bias properties. As a result, compounds <b>27</b>, <b>28</b>, and <b>29</b> are G-protein-biased agonists of MOR in both GTPγS binding and cAMP inhibition assays, while compound <b>30</b> is a β-arrestin-biased agonist (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Morphine, on the other hand, was shown as a balanced agonist of MOR. In vivo efficacy of these compounds were tested in the hot plate and tail flick models, and their antinociceptive effects were compared to respiratory suppression effects to calculate the therapeutic window of in vivo efficacy. Results from this study showed that the GTPγS-binding assay-derived bias factors were more predictive of the calculated therapeutic windows than the cAMP assay-derived bias factors, and MOR agonists with higher G-protein-bias factors showed better therapeutic effects and less respiratory suppression.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> A bias factor of 85 was calculated for compound <b>27</b> at human MOR using GTPγS-binding assay-derived method, and this compound showed much broader therapeutic windows compared to either fentanyl or morphine. Although structurally different from fentanyl and sufentanil, compounds <b>27</b>–<b>30</b> share the overall scaffold with them as highlighted in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, and it seems the dichloro substitutions of the right-hand phenyl ring contributed to the G-protein-bias properties of compounds <b>27</b>, <b>28</b>, and <b>29</b>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Further characterization of these compounds as potential drug candidates is to be expected.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Piperidine compounds as G-protein-biased agonists of MOR. DAMGO was the reference compound for the calculation of bias factors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unlike the MOR, KOR agonists have long been recognized to be analgesics with no addiction and tolerance liability.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> However, most KOR agonists cause other CNS side effects such as dysphoria.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Similarly, it has been hypothesized that the analgesia effect results from G-protein-mediated signaling pathway and the side effects are mediated through β-arrestin2 recruitment.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Therefore, developing KOR agonists that are biased toward G protein signaling but devoid of β-arrestin2 recruitment will be therapeutically beneficial and avoid dysphoric side effects.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Recently, a number of selective KOR agonists displaying G-protein-biased properties have been reported. The triazole compound <b>31</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was identified from high-throughput screening (HTS) campaign, which was a KOR agonist showing moderate functional potency in the DiscoveRx β-arrestin PathHunter assay (EC<sub>50</sub> = 0.87 μM, <i>E</i><sub>max</sub> ∼ 140% compared to the reference compound U69,593), with high selectivity over MOR and DOR.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Further structural modifications and SAR studies focused on the benzene ring led to the discovery of a series of triazole analogues that showed G-protein-biased activity. Among them, compound <b>32</b> showed high potency (EC<sub>50</sub> = 31 nM, <i>E</i><sub>max</sub> = 94%) in the [<sup>35</sup>S]GTPγS binding assay, slightly more potent than U69,593 (EC<sub>50</sub> = 52 nM, <i>E</i><sub>max</sub> = 100%).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> However, compound <b>32</b> showed much lower potency in two different β-arrestin2 assays (EC<sub>50</sub> = 4129, 3138 nM for <b>32</b>, versus 131 and 205 nM for U69,593).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In further characterization of the compounds at a downstream signaling pathway, compound <b>32</b> showed lower potency in ERK1/2 phosphorylation (EC<sub>50</sub> = 329 nM) than the unbiased agonist U69,593 (EC<sub>50</sub> = 5.4 nM).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> When the furan substituent was replaced for a pyridine ring, compound <b>33</b> maintained the bias for G protein signaling (EC<sub>50</sub> = 76 nM, <i>E</i><sub>max</sub> = 98%) over β-arrestin2 recruitment (EC<sub>50</sub> = 10,090 nM, <i>E</i><sub>max</sub> = 101%).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In these studies, ERK1/2 activation was tested in parallel with G protein and β-arrestin signaling, which led to the conclusion that bias for ERK1/2 activation can be altered while preserving G-protein-biased properties with respect to β-arrestin recruitment, supporting that KOR ERK activation can occur via G-protein-dependent or β-arrestin-dependent signaling pathways.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. G-protein-biased ligands at KOR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another screening program by Frankowski et al. led to the discovery of the isoquinolinone compound <b>34</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) as a selective KOR agonist in the cAMP inhibition assay (EC<sub>50</sub> = 63 nM), showing high selectivity in binding assays for KOR over MOR, DOR, and other GPCRs.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Interestingly, replacement of the 2-benzyl with a 2-fluorobenzyl group together with the substitution of the chlorine with a methyl provided a G-protein-biased ligand <b>35</b>. It demonstrated comparable potency (EC<sub>50</sub> = 85 nM, <i>E</i><sub>max</sub> = 89%) in a [<sup>35</sup>S]GTPγS binding assay using U69,593 as the reference compound, yet showing weak β-arrestin2 recruitment (EC<sub>50</sub> > 10 μM).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Both compounds <b>32</b> and <b>34</b> were proved to be brain-penetrant and produced antinociception in the mouse tail flick test, which correlates with the ability of these compounds to potently activate G-protein-dependent signaling in cell-based assays.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p">Salvinorin A (<b>36</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) is a terpenoid compound that has recently been characterized by White et al. as a balanced KOR agonist at both the human and the mouse KORs.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> However, replacement of the 2-acetoxy group with a 2-thiocyanatoacetoxy group gave compound RB-64 (<b>37</b>), which showed potent activity stimulating G protein signaling (cAMP assay, EC<sub>50</sub> = 5.2 nM, <i>E</i><sub>max</sub> = 99%) but much less potent in β-arrestin translocation (EC<sub>50</sub> = 1,130 nM) and mouse KOR internalization assays, suggesting that RB-64 was G-protein-biased (bias factor = 96).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In vivo studies using both wild-type and β-arrestin2 knockout mice showed that RB-64 had no effect on motor coordination, sedation, or anhedonia, suggesting that these KOR-related adverse effects are probably mediated by the β-arrestin2 signaling pathway.</div><div class="NLM_p">Rives et al. reported that the naltrindole-derived ligand 6′-GNTI (<b>38</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was a potent partial agonist in both G protein activation (BRET-based) and cAMP inhibition assays compared to the reference agonist ethylketocyclazocine, yet an antagonist for the recruitment of β-arrestin2 (BRET-based) in HEK-293 cells.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Subsequently, Schmid et al. confirmed the delineation of this bias in vitro and further explored it in cultured striatal neurons.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> 6′-GNTI was reported to activate Akt but not ERK1/2 in striatal neurons, while U69,593 activates both kinases, suggesting that KOR utilizes β-arrestin2 to activate ERK in the endogenous setting.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Taken into consideration the conclusion from Lovell et al.,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> which suggested ERK activation can occur via G-protein-dependent or β-arrestin-dependent signaling pathways, understanding the correlation of ERK activation with G protein and β-arrestin signaling pathways requires further studies.</div><div class="NLM_p">Meanwhile, some recent studies have questioned the therapeutic benefits of G-protein-biased KOR agonists for pain management. For example, nalfurafine (<b>39</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) has been demonstrated as a G-protein-biased agonist of both human and rat KORs (hKOR and rKOR, respectively), for which the G protein activity was measured as the early phase ERK phosphorylation and β-arrestin-mediated activity as the late phase of p38 MAPK signaling (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Nalfurafine has been approved in Japan for the treatment of uremic pruritus, but nalfurafine or any other KOR agonists have not been approved for the treatment of pain. Lazenka et al. reported that in animal models, nalfurafine-induced decreases in pain/itch-stimulated behaviors may reflect nonselective decreases in motivated behavior rather than analgesic effects.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Further study is needed to demonstrate whether KOR agonists would serve as effective analgesics and whether G-protein-biased KOR agonists would be clinically safer in the treatment of other KOR-related diseases.</div><div class="NLM_p">The most recently identified member of the opioid receptor family is NOPR, also known as the nociceptin/orphanin FQ (N/OFQ) receptor. The progress in understanding NOPR pharmacology supports it as a potential drug target for pain treatment and substance abuse.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Recently, Chang et al. conducted the first functional selectivity analysis of the NOPR by a quantitative analysis of novel NOPR-selective ligands along with commercially available small-molecule- and peptide-based NOPR ligands.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> As a result, compound MCOPPB (<b>40</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) was characterized as a G-protein-biased NOPR agonist, being approximately 10<sup>5</sup>-fold more potent in the G-protein-mediated cAMP inhibition assay than for β-arrestin1 and β-arrestin2 recruitment. In addition, the spiroxatrine scaffold compound NNC 63-0532 (<b>41</b>),<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> a partial agonist at NOPR, also exhibited marked bias toward the G protein pathway and showed lower efficacies in β-arrestin recruitment assays.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Interestingly, the balanced antagonism of NOPR by J113,397 (<b>42</b>) was converted to G-protein-biased agonism with minor structural modifications to the “message” moiety of the ligand by replacing the cyclo-octymethyl with a decahydronaphthalen-1-methyl as in RTI-4229-819 (<b>43</b>), or an isopropylcyclohexane as in RTI-4229-856 (<b>44</b>). Both compounds exhibited moderate to high potency at NOPR (pEC<sub>50</sub> = 7.14 and 8.14, respectively) and good functional selectivity against the β-arrestin pathway.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. G-protein-biased ligands at NOPR (ND, no determinable EC<sub>50</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The opioid receptors are very important drug targets for pain management, and extensive efforts have been put into the discovery of novel biased agonists of these receptors. While the roles of β-arrestin-mediated signaling in the therapeutic/adverse effects associated with these receptors are not yet fully understood, future explorations will benefit from the availability of biased ligands as tool compounds. A milestone will be achieved if the most advanced compound TRV130 gains FDA approval, which will definitely boost GPCR biased ligand discovery.</div></div><div id="sec1_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Dopamine Receptors</h3><div class="NLM_p">Dopamine receptors comprise five subtypes that can be classified into two subfamilies, the D<sub>1</sub>-like (D<sub>1</sub> and D<sub>5</sub>) and D<sub>2</sub>-like (D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub>) receptors.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The D<sub>2</sub> receptor (D<sub>2</sub>R) is one of the most important drug targets in neurological disease, being one of the primary targets for drugs that treat Parkinson’s disease, schizophrenia, and other affective disorders.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Treatments for schizophrenia have traditionally involved typical antipsychotics, which block the function of D<sub>2</sub>R as antagonists or inverse agonists;<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> however newer generation antipsychotics target D<sub>2</sub>R as partial agonists, represented by aripiprazole (<b>45</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Although these drugs have formed the basis for schizophrenia treatment, most of them either are less efficacious than desired or possess adverse side effects, including tardive dyskinesia, an irreversible movement disorder resulting from prolonged use of typical antipsychotics.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> And aripiprazole has been reported to induce movement disorders as well.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Aripiprazole-based biased agonists at D<sub>2</sub>R (N/A, not applicable).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the scaffold of aripiprazole, a number of biased D<sub>2</sub>R agonists have been discovered and their effects as potential antipsychotics in animal models described.<a onclick="showRef(event, 'ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68 ref69">(66−69)</a> For example, Chen et al. studied the SFSRs of aripiprazole analogues through a diversity-oriented medicinal chemistry strategy.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> As summarized in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, the structural modifications of the piperazine, the linker, and the dihydroquinolinone moieties led to the discovery of compounds UNC9975 (<b>46</b>), UNC9994 (<b>47</b>), and UNC9995 (<b>48</b>), which were demonstrated to be high-affinity β-arrestin-biased ligands at the D<sub>2</sub>R. These compounds were potent for D<sub>2</sub>R β-arrestin recruitment while showing no significant activity in the G-protein-dependent cAMP assays. In animal models of psychosis, compounds UNC9975 and UNC9994 displayed potent inhibition of amphetamine (AMPH)- and phencyclidine (PCP)-stimulated hyperlocomotion, which were attenuated or completely abolished in β-arrestin2 knockout mice.<a onclick="showRef(event, 'ref67 ref70'); return false;" href="javascript:void(0);" class="ref ref67 ref70">(67,70)</a> These results showed that β-arrestin signaling at D<sub>2</sub>R is a significant contributor to the antipsychotic efficacy of these compounds. These β-arrestin-biased D<sub>2</sub>R ligands UNC9975 and UNC9994 also reduced schizophrenia-like behaviors in PCP-treated or NR1-knockdown hypoglutamatergic mice but induced a lower level of catalepsy than the typical antipsychotic and D<sub>2</sub>R antagonist, haloperidol.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The SFSR results from this series of compounds show that slight structural modifications to a GPCR ligand may provide ligands with distinct signaling bias properties, and known drug molecules can be used as lead compounds for discovering novel biased GPCR ligands.</div><div class="NLM_p">Biased ligands with the opposing pharmacology for the D<sub>2</sub>R, that is, biased toward stimulation of G protein signaling pathways, have also been identified based on the same scaffold of aripiprazole. Möller et al. reported that the bioisosteric replacement of the heterocyclic appendage of aripiprazole with a pyrazolo[1,5-<i>a</i>]pyridine moiety led to compound <b>49</b>, which behaved as a potent partial agonist in G-protein-signaling but as an antagonist for β-arrestin2 recruitment.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Also shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, by introducing a 2-methyl group to the benzothiazole of UNC9995 and changing the middle linker from propoxy back to butoxy, Chen et al. unexpectedly converted the β-arrestin-biased UNC9995 to a G-protein-biased D<sub>2</sub>R agonist <b>50</b>.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Further SFSR studies that focus on the two aromatic moieties of compound <b>50</b> led to compound <b>51</b>, which showed no activity for β-arrestin recruitment and therefore a G-protein-biased D<sub>2</sub>R partial agonist. Finally, a structural hybridization of compounds <b>49</b> and <b>51</b> afforded compound <b>52</b>, which was a highly potent G-protein-biased partial agonist devoid of β-arrestin recruitment activity at D<sub>2</sub>R.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In vivo antipsychotic activity of compound <b>52</b> was also studied in rat behavioral models,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> and it seemed more effective than aripiprazole treatment in inhibiting AMPH-induced hyperlocomotor activity. Compared to the results of compounds <b>46</b>–<b>48</b>, since both G-protein-biased and β-arrestin-biased agonists of D<sub>2</sub>R have been shown to be effective as antipsychotic agents, further studies are required for a complete understanding of the roles each signaling pathway plays in the pathology and treatment of schizophrenia.</div><div class="NLM_p">More recently, novel aripiprazole analogs with biased properties have also been discovered through a structure-based approach.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, the dichlorophenyl-piperazine portion of aripiprazole was replaced with an indole-piperazine as in compound <b>53</b>. This indole-piperazine compound displayed comparable activity in both G<sub>i/o</sub>-mediated cAMP inhibition and β-arrestin2 recruitment assays with a weak bias factor of 2.5 for β-arrestin signaling. On the basis of molecular docking with a D<sub>2</sub>R homology model, the indole NH of compound <b>53</b> was predicted to form a hydrogen bond with Ser5.42 in transmembrane 5 (TM5), which has been shown to contribute to G-protein-dependent signaling for β<sub>2</sub> adrenergic receptors (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Inspired by structural information from the serotonin 5-HT<sub>2B</sub> receptor,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> where ligand interactions with hydrophobic residues on EL2 appear to promote β-arrestin recruitment, a methyl group was added to preclude G-protein-dependent signaling via Ser5.42 interactions and instead promote EL2 hydrophobic interactions. This strategy led to the <i>N</i>-methyl compound <b>54</b>, which shows β-arrestin recruitment and no G-protein-dependent signaling activity at D<sub>2</sub>R. To strengthen the hydrophobic interactions with the isoleucine residue on EL2, a second methyl was introduced to position 2 of the indole ring, giving compound <b>55</b>. Both potency and efficacy of compound <b>55</b> with respect to β-arrestin2 recruitment were significantly enhanced compared to those of compound <b>54</b>, leading to a β-arrestin bias factor of 20 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> This is the first example of using GPCR structural information for the rational design of biased ligands of GPCRs.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure-based design of β-arrestin-biased D<sub>2</sub>R agonists. Bias factors were calculated based on transduction coefficients using quinpirole as the reference compound.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cariprazine (<b>56</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) is an analogue of aripiprazole and has been approved by the FDA in 2015 for the treatment of schizophrenia. It shares the 1,4-disubstituted aromatic piperazine (1,4-DAP) scaffold of aripiprazole and is a D<sub>2</sub>R and D<sub>3</sub>R partial agonist with higher affinity toward D<sub>3</sub>R.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Shonberg et al. reported that using dopamine as the reference compound, cariprazine demonstrated a 230-fold bias for the stimulation of D<sub>2</sub>R-mediated inhibition of cAMP production, versus the phosphorylation of ERK1/2.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In their studies, transduction coefficients (τ/<i>K</i><sub>A</sub>) of both cAMP inhibition and ERK1/2 phosphorylation were calculated as a measure of the activity of an agonist. Values of log(τ/<i>K</i><sub>A</sub>) were normalized to dopamine to give values of Δlog(τ/<i>K</i><sub>A</sub>), which were compared across pathways for each ligand to give values of ΔΔlog(τ/<i>K</i><sub>A</sub>), a quantitative measure of bias between two different pathways. Substitution of the <i>N</i>,<i>N</i>-dimethylurea tail group of cariprazine with a <i>tert</i>-butyl carbamate gave compound <b>57</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), which showed decreased bias toward cAMP inhibition versus ERK1/2 phosphorylation.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Molecular modeling studies suggested that these subtle changes in the spacer and tail regions can influence the orientation of the head group within the orthosteric pocket, and these distinct orientations may underlie patterns of biased agonism.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In later studies, Szabo et al. found that the bias for G protein signaling was improved when the cyclohexane was opened to a five-carbon spacer (compound <b>58</b>).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Keeping this five-carbon spacer, when the tail group was changed to a thienopyridine, the substitution pattern had a significant effect on ligand bias. As shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, while the 5-chloro-6-methoxy-4-methyl analogue <b>59</b> is not biased, the 4,6-dimethyl analogue <b>60</b> shows significant bias toward the G protein signaling.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Interestingly, when the 2,3-dichloro substitution pattern of <b>59</b> was changed to 2-methoxyl as in compound <b>61</b>, the compound’s efficacy in cAMP assay was decreased while ERK activity was enhanced, therefore leading to a reversal of bias (a negative ΔΔlog(τ/<i>K</i><sub>A</sub>) value).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Other 1,4-DAPs scaffold-based G-protein-biased agonists of D<sub>2</sub>R. The values of pEC<sub>50</sub> and <i>E</i><sub>max</sub> can be found in the Supporting Information of the refs <a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and <a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a>. Dopamine was used as the reference compound for the calculation of transduction coefficients.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is worth mentioning that although compounds <b>56</b>–<b>61</b> have been studied for their biased agonism of D<sub>2</sub>R in two distinct assays, it is not clear yet whether ERK phosphorylation of D<sub>2</sub>R is G-protein-dependent or β-arrestin-dependent. As a matter of fact, it has been reported that G protein is responsible for the regulation of ERK phosphorylation at D<sub>2</sub>R, and β-arrestin may play an inhibitory role.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Therefore, further study of these compounds (i.e., in β-arrestin recruitment assays) is needed to fully demonstrate their biased properties.</div><div class="NLM_p">Very recently, Bonifazi et al. reported novel bivalent derivatives of sumanirole (<b>62</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), which showed biased properties at the D<sub>2</sub>R.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Sumanirole is a selective D<sub>2</sub>R agonist that had been studied in clinical trials for the treatment of Parkinson’s disease and restless leg syndrome but has never been approved.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> Presumably, sumanirole binds to the orthosteric binding pocket of the D<sub>2</sub>R in the same way as dopamine. A secondary pharmacophore was attached to the primary pharmacophore of sumanirole through a linker, which gave bivalent ligands that presumably bind to both the orthosteric binding pocket and a secondary binding pocket. Three series of compounds were synthesized, and compound <b>63</b> was identified as a biased ligand with a preference for G protein signaling compared to sumanirole, with the EC<sub>50</sub> ratio of β-arrestin/cAMP of 517 (154 nM versus 0.3 nM) indicating preference for G-protein-dependent signaling.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. G-protein-biased D<sub>2</sub>R agonist derived from sumanirole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recently, Weı̈wer et al. characterized β-arrestin biased D<sub>2</sub>R antagonists with a novel scaffold.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, the hit compound BRD7640 (<b>64</b>), which came from a high-throughput screen, is a micromolar antagonist of the D<sub>2</sub>R/β-arrestin pathway (EC<sub>50</sub> = 2.14 μM, <i>E</i><sub>max</sub> = 80%) and a partial agonist of the G<sub>i</sub>/cAMP pathway (EC<sub>50</sub> = 0.12 μM, <i>E</i><sub>max</sub> = 75%). In their initial SAR exploration, the pyrrolidine core of BRD7640 was replaced by an achiral 4-piperidine core, which converted it to an agonist in both assays (<b>65</b>). Introduction of an ortho CF<sub>3</sub> led to the discovery of BRD5814 (<b>66</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), which showed antagonist activity in the β-arrestin assay (EC<sub>50</sub> = 0.061 μM, 80%) but agonist activity in the G protein assay (EC<sub>50</sub> = 0.54 μM, 85%). It was suggested based on docking results that the ortho CF<sub>3</sub> group of BRD5814 interacts with H393<sup>6.55</sup>, a major determinant of biased signaling in D<sub>2</sub>R,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and prevents its rotation, resulting in a G-protein-preferred active conformation. BRD5814 exhibited efficacy in the amphetamine-induced hyperlocomotion mouse model with reduced motoric side effects in a rotarod performance test.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. BRD5814 is a G protein pathway agonist and β-arrestin pathway antagonist at D<sub>2</sub>R (red, inhibition of cAMP accumulation; blue, β-arrestin2 recruitment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The D<sub>2</sub>R has been an extensively studied GPCR with identified biased ligands toward both G protein and β-arrestin pathways, displaying agonist, partial agonist, or antagonist profiles. Therapeutic potential has been demonstrated in both efficacy and side effect models in animals for a number of these ligands. However, at this stage, it is not yet clear which signaling pathway is more relevant to therapeutic or adverse effects at this receptor and what profile an ideal ligand should have in order to show the best therapeutic effects in the clinic. Further studies in this field are warranted. Meanwhile, although D<sub>2</sub>R has been a validated drug target for many years, its crystal structure has only recently been solved in an inactive conformation,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> and more structure-based drug design is expected in the future.</div><div class="NLM_p">The D<sub>1</sub>R is also an important drug target that shows great potential for the treatment of various neuropsychiatric disorders, including Parkinson’s disease and the cognitive impairment associated with schizophrenia. However, significant side effects such as hypotension and tolerance have precluded the approval of a number of candidate compounds. It was thus postulated that biased agonists at the D<sub>1</sub>R might provide novel therapeutics devoid of the aforementioned side effects.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Conroy et al. studied the bias properties of a set of substituted benzazepine compounds which are summarized in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Compounds SKF38393 (<b>67</b>), SKF75670 (<b>68</b>), and SKF-77434 (<b>69</b>), which have hydrogen, methyl, and allyl substituents attached to their nitrogen atoms respectively, behaved as very potent agonists in G-protein-mediated cAMP accumulation assays while showing no discernible β-arrestin recruitment. When tested as antagonists, these compounds showed potent inhibition of dopamine-induced β-arrestin recruitment and D<sub>1</sub>R internalization. The introduction of a chlorine atom to the catechol benzene ring led to the loss of bias in <i>N</i>-H and <i>N</i>-allyl compounds (<b>70</b>, <b>72</b>, <b>73</b>, and <b>75</b>) but not <i>N</i>-methyl compounds SKF83959 (<b>71</b>) and SKF82957 (<b>74</b>). In terms of β-arrestin to cAMP EC<sub>50</sub> ratios, compounds <b>67</b>, <b>68</b>, <b>69</b>, <b>71</b>, and <b>74</b> represent the most biased GPCR ligands reported so far, and further characterization in other assays and animal models are expected which should show their therapeutic advantages compared to balanced D<sub>1</sub>R ligands.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. G-protein-biased agonists at D<sub>1</sub>R (red, stimulation of cAMP accumulation; blue, β-arrestin2 recruitment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, catechols suffer from poor pharmacokinetic properties such as negligible bioavailability and low central nervous system (CNS) penetration, which has prevented the development of such compounds as clinical drugs. More recently, Gray et al. have reported non-catechol agonists of the D<sub>1</sub>R for which G-protein-bias properties have been observed.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, compound PF-4211 (<b>76</b>) was identified from an HTS of about 3 million compounds and displayed modest potency and efficacy as a non-catechol D<sub>1</sub>R agonist (EC<sub>50</sub> = 2,519 nM, <i>E</i><sub>max</sub> = 42% in cAMP assay). Extensive SAR study and iterative medicinal chemistry optimizations led to the discovery of compounds PF-8294 (<b>77</b>) and PF-6142 (<b>78</b>), which are potent and selective D<sub>1</sub>R agonists with good pharmacokinetic profiles. More importantly, these compounds showed no significant desensitization of the receptor after 2 h treatment of the cells with the compounds, whereas significant desensitization was measured for catechol D<sub>1</sub>R ligands such as dopamine and dihydrexidine. In this study, a live cell total internal reflection fluorescence microscopy imaging assay measuring β-arrestin recruitment revealed that compounds <b>77</b> and <b>78</b> showed impaired β-arrestin recruitment. In an animal efficacy study, oral administration of another compound in the series led to robust and more sustained effects in both non-human primate eye blink response<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> and the unilateral 6-OHDA lesion rodent model of parkinsonism.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Non-catechol, G-protein-biased agonists of D<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Serotonin Receptors</h3><div class="NLM_p">The serotonin receptors (also known as 5-HT receptors) are the targets of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, and anorectics.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> All serotonin receptors are GPCRs except the 5-HT<sub>3</sub> receptor, which is a ligand-gated ion channel. In terms of signaling bias, the 5-HT<sub>2A/2C</sub> receptors are among the very first GPCRs for which functionally selective ligands have been reported;<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> however, interrogation of specific downstream signaling pathways (e.g., G protein versus β-arrestin) have only recently been explored.</div><div class="NLM_p">Ergotamine (<b>79</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), a natural ergoline alkaloid that shows antimigraine properties, is an agonist at many serotonin receptors.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Like most ergolines, such as the hallucinogen lysergic acid diethylamide (LSD), ergotamine has been reported to be β-arrestin-biased at the 5-HT<sub>2B</sub> receptor.<a onclick="showRef(event, 'ref75 ref93'); return false;" href="javascript:void(0);" class="ref ref75 ref93">(75,93)</a> Structures of the 5-HT<sub>2B</sub> receptor and 5-HT<sub>1B</sub> receptor co-crystallized with ergotamine revealed a β-arrestin-biased and nonbiased “active” states of these receptors, respectively.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> These studies provided the first structural features for biased signaling, which will in turn guide the rational design of biased ligands of other GPCRs. With the discovery of more biased GPCR ligands, more crystal structures with biased ligands bound to the receptor are to be expected in the future.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Biased agonists at serotonin receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another member of the 5-HT<sub>2</sub> subfamily, the 5-HT<sub>2C</sub> receptor, has been demonstrated as a potential drug target for a variety of CNS diseases, such as obesity, schizophrenia, and drug addiction.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> We have reported that 2-arylcyclopropylmethylamines such as compound <b>80</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) shows functional selectivity for the G protein signaling over β-arrestin2 recruitment.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Compared to serotonin, compound <b>80</b> shows less receptor desensitization in both calcium flux and phosphoinositide hydrolysis assays, which is a result expected with weaker efficacy for β-arrestin2 recruitment. More recently, we discovered that introducing a methyl substitution to the primary amine led to a markedly G-protein-biased compound <b>81</b>, although a 20-fold decrease of potency (EC<sub>50</sub> = 23 nM versus 1.2 nM) in the calcium flux assay was observed.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> When the substituent was enlarged to a 2-methoxybenzyl group as in compound <b>82</b>, the potency in G protein signaling was unchanged but β-arrestin2 recruitment recovered; therefore functional selectivity was reduced compared to <b>81</b>. Future study is needed to shed light on the role of functional selectivity at this receptor with respect to in vivo effects.</div><div class="NLM_p last">For another 5-HT<sub>1</sub> subtype, the 5-HT<sub>1A</sub> receptors, a series of long-chain arylpiperazines have been characterized as functionally selective agonists for G-protein-dependent cAMP inhibition versus β-arrestin2 recruitment.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, all the arylpiperazines (<b>83</b>–<b>85</b>) displayed a sizable preference for G-protein-mediated cAMP inhibition over β-arrestin2 recruitment with respect to both potency and efficacy. The strong pathway preference shown by the naphthalenyl derivative <b>84</b>, compared to those of the tetrahydronaphthalenyl analogs <b>83</b> and <b>85</b>, suggests that modification of the terminal fragment of these arylpiperazine derivatives might provide pathway selective compounds that favor G-protein-dependent signaling over β-arrestin-2 recruitment. In vivo effects of these compounds are not reported.</div></div><div id="sec1_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Histamine Receptors</h3><div class="NLM_p">Histamine is a neurotransmitter that plays physiological roles in cellular events through binding to four types of G-protein-coupled histamine receptors (H<sub>1</sub>R-H<sub>4</sub>R) that are differentially expressed in various cell types. For example, the H<sub>2</sub>R is mainly involved in gastric acid production and has been a classic pharmacological target to treat gastric acid-related conditions.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Regarding ligand bias properties, a retrospective study of the commonly used H<sub>2</sub>R blocker famotidine has proved that, although an inverse agonist in cAMP assays, famotidine mimics the effects of histamine concerning receptor desensitization and internalization.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> This adds to the conclusion that for many known GPCR ligands that have been characterized as antagonists or inverse agonists in the traditional G protein assays, they could have positive efficacy concerning receptor desensitization and internalization which are mediated by β-arrestins.</div><div class="NLM_p">Another subtype of the histamine receptor, H<sub>4</sub>R, represents a promising therapeutic target for pathologies such as airway inflammation, inflammatory bowel disease, and atopic dermatitis.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Recently, a comparative study of biased signaling for a number of H<sub>4</sub>R antagonists has been reported. Compound JNJ-7777120 (<b>86</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>), which had been initially identified as a selective antagonist of the H<sub>4</sub>R,<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> was characterized as a β-arrestin biased agonist. It showed no effects in the [<sup>35</sup>S]GTPγS binding assay but demonstrated potent partial agonist activity in the β-arrestin2 recruitment assay (pEC<sub>50</sub> = 7.9, <i>E</i><sub>max</sub> = 64%).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> On the basis of its indolecarboxamide scaffold, various JNJ-7777120 analogues have been recently developed with similar biased properties toward β-arrestin2, but interestingly the nitrated compound <b>87</b> was found to be a balanced hH<sub>4</sub>R agonist.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Unlike these indolecarboxamides, the isothiourea compounds give a broader spectrum of efficacies upon relatively modest structural changes. For example, introducing a 2-Cl substitution to the phenyl group of the unbiased H<sub>4</sub>R antagonist VUF9107 (<b>88</b>) converts it into a G-protein-biased agonist VUF5222 (<b>89</b>), and a 3-Cl substitution converts it into a β-arrestin2-biased compound VUF5223 (<b>90</b>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Other chemical classes of G-protein-biased ligands including VUF10778 (<b>91</b>) and VUF10185 (<b>92</b>) and β-arrestin2-biased ligand VUF10214 (<b>93</b>) were also reported.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Only a few H<sub>4</sub>R antagonists have entered clinical trials, and JNJ-7777120 has never been advanced into clinical trials due to a short half-life and preclinical toxicity, but it serves as a tool compound for showing the role of the H<sub>4</sub>R in inflammation and pruritus.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Biased ligands at H<sub>4</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cannabinoid Receptors</h3><div class="NLM_p">The cannabinoid receptors are a family of GPCRs that play important roles in physiology,<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> which have mainly two subtypes CB<sub>1</sub>R and CB<sub>2</sub>R (other putative cannabinoid receptors include GPR18 and GPR55). CB<sub>1</sub>R is mainly expressed in the CNS, whereas CB<sub>2</sub>R is expressed in the immune system, and both of them are important drug targets that have drawn a lot of attention.<a onclick="showRef(event, 'ref109 ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref109 ref110 ref111">(109−111)</a> Two recent review articles have summarized the ligand bias phenomenon at these receptors,<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> and some of the studies are highlighted in the following.</div><div class="NLM_p">The CB<sub>1</sub>R couples primarily to G<sub>i/o</sub> but has also been observed to couple with G<sub>s</sub> and G<sub>q</sub> when activated by specific agonists.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> A line of evidence has shown that most CB<sub>1</sub> agonists do not activate associated G proteins equally, therefore showing functional selectivity toward specific downstream signaling pathways. For example, the synthetic cannabinoid WIN-55212 (<b>94</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) is equally efficacious for inhibiting (G<sub>i</sub>) and stimulating (G<sub>s</sub>) cAMP accumulation (<i>E</i><sub>max</sub> both normalized to 100%), while the endogenous cannabinoid anandamide (AEA, <b>95</b>) favors G<sub>i</sub> over G<sub>s</sub> (<i>E</i><sub>max</sub> = 81% versus 27%).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Biased agonists at CB<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Biased properties of CB<sub>1</sub>R ligands between the G-protein-dependent signaling versus β-arrestin signaling have also been studied. For example, using a cell culture model of striatal medium spiny projection neurons, the endogenous cannabinoids 2-arachidonoylglycerol (2-AG, <b>96</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) and AEA, the phytocannabinoids Δ<sup>9</sup>-tetrahydrocannabinol (THC, <b>97</b>) and canabidiol (CBD, <b>98</b>), and the synthetic cannabinoids CP-55940 (<b>99</b>) and WIN-55212 have been evaluated for their signaling bias properties at CB<sub>1</sub>R, in various signaling activities associated with G<sub>i/o</sub>, G<sub>s</sub>, G<sub>q</sub>, and β-arrestin1.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Signaling bias was more recently quantified using the Black and Leff operational model by the same group, and the effects were compared between wild-type and mutant huntingtin protein.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> In these studies, G<sub>i</sub>-mediated activity was evaluated in pERK1/2 assay and the interactions between CB<sub>1</sub>R and β-arrestin1 were quantified via BRET<sup>2</sup>.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Using WIN-55212 as the reference compound, 2-AG and AEA were shown to be G<sub>i</sub>-biased and normalized CB<sub>1</sub>R protein levels and improved cell viability, whereas CP-55940 and THC were β-arrestin1-biased and reduced CB<sub>1</sub>R protein levels and cell viability in Huntington’s disease (HD) cells.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Consistent with the literature, CBD was not a CB<sub>1</sub>R agonist, but it inhibited THC-dependent signaling. The correlation between ligand bias and cell viability suggests that enhancing G<sub>i/o</sub>-biased endocannabinoid signaling may be therapeutically beneficial in HD, while β-arrestin-biased cannabinoids such as THC may be detrimental to CB<sub>1</sub> signaling in HD where CB<sub>1</sub> levels are already reduced.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><div class="NLM_p">Due to the sequence similarity between CB<sub>1</sub>R and CB<sub>2</sub>R (44% overall identity, 68% in the TM region),<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> some of the aforementioned CB<sub>1</sub> agonists activate CB<sub>2</sub>R as well due to their weak selectivity. Such compounds WIN-55212 and CP-55940 have been profiled for their functional selectivity properties at CB<sub>2</sub>R by Atwood et al.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> It was found that compound WIN-55212 induced β-arrestin recruitment to a much less degree than CP-55940 at CB<sub>2</sub>R, and WIN-55212 not only did not lead to receptor internalization but also antagonized the effects induced by CP-55940.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> These compounds were later studied together with more CB<sub>2</sub>R ligands by the same group in more functional assays, for which their biased activities were profiled and bias factors calculated.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>, using CP-55940 as the reference compound, WIN-55212, THC, JWH-133 (<b>100</b>), HU-308 (<b>101</b>), and JWH-015 (<b>102</b>) behaved as G-protein-biased partial agonists, whereas AM-1248 (<b>103</b>), STS-135 (<b>104</b>), and UR-144 (<b>105</b>) show β-arrestin-biased properties. It is also worth noting that within each chemical class, that is, the phytocannabinoids and analogues (CP-55940, THC, JWH-133, and HU-308) or the synthetic indoles (AM-1248, STS-135, UR-144, and JWH-015), opposite biased properties have been observed despite the light structural differences (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). Meanwhile, it has also been reported that while rimonabant (<b>106</b>) behaved as an inverse agonist at CB<sub>2</sub>R in both G<sub>i</sub>-mediated cAMP inhibition and β-arrestin recruitment assays, the indole compound AM-630 (<b>107</b>) displayed inverse agonist activity in G<sub>i</sub> signaling but partial agonist activity in arrestin recruitment (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Biased ligands at CB<sub>2</sub>R. “NA” indicates not applicable (activation <20% threshold), and negative <i>E</i><sub>max</sub> values (for <b>106</b> and <b>107</b>) represent inverse agonist activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Targeting the CB<sub>1</sub>R as an inverse agonist, rimonabant had been approved for the treatment of obesity but was quickly withdrawn due to CNS side effects.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> The phytocannabinoid THC and its analog nabilone have been approved for the treatment of pain and nausea in cancer and HIV patients, but the hallucinogenic effects of THC have been well-known. Whether biased ligands at either CB<sub>1</sub>R or CB<sub>2</sub>R could provide safer therapeutics remains to be seen, as how the above-mentioned biased properties correlate to therapeutic or unwanted side effects are not yet understood. Further research in this area is warranted.</div></div><div id="sec1_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Apelin Receptor (APJ)</h3><div class="NLM_p">APJ is a class A GPCR that has been discovered in 1993,<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> and it has been suggested as a potential target for cardiovascular diseases.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> It has been demonstrated that the activation of APJ by apelin triggers intracellular G-protein-dependent signaling pathways that increase both myocardial contractility and vasodilatation, but mechanical stretch activates APJ-mediated β-arrestin signaling, which leads to cardiac hypertrophy.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Therefore, from a drug discovery point of view, G-protein-biased APJ agonists would be more effective for the treatment of heart failure.</div><div class="NLM_p">On the basis of the peptide sequence of [Pyr<sup>1</sup>]apelin-13 (<b>108</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a><b>)</b>, which is the main active form of apelinergic peptides, Brame et al. designed a series of cyclic analogues with the aim of discovering biased agonists of APJ.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Of more than 100 peptides that were designed, MM07 (<b>109</b>) was identified as a G-protein-biased agonist, which has an intramolecular macrocycle formed by a disulfide bridge between two cysteine residues (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). In the β-arrestin recruitment assay, MM07 was ∼790-fold less potent than [Pyr<sup>1</sup>]apelin-13, and in a receptor internalization assay, MM07 was ∼215-fold less potent.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Given that MM07 has comparable potency in a G-protein-dependent saphenous vein contraction assay to [Pyr<sup>1</sup>]apelin-13 (pEC<sub>50</sub> = 9.54 for MM07 versus 9.93 for [Pyr<sup>1</sup>]apelin-13), these translated into bias factors of ∼350-fold (against β-arrestin recruitment) and ∼1300-fold (against receptor internalization), respectively, for MM07. The therapeutic advantages of MM07 over [Pyr<sup>1</sup>]apelin-13 were demonstrated in a rat cardiac output experiment and a forearm blood flow test in human volunteers, which supports that biased agonism of the APJ receptor could translate to improved efficacy in vivo.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. G-protein-biased APJ agonists. The amino acid sequences of the peptides are shown from the N-terminus (left) to the C-terminus (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Murza et al. also reported a series of macrocylic analogues of apelin such as <b>110</b> that showed biased properties as APJ agonists.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Peptide <b>110</b> incorporates a 17-membered ring in its scaffold and showed nanomolar potency in G protein assays, with excellent functional selectivity against β-arrestin recruitment. Although less potent than [Pyr<sup>1</sup>]apelin-13, significantly improved signaling bias has been demonstrated for <b>110</b>. The authors concluded from the SFSR results that the position and the nature of the C-terminal aromatic residue is a determinant for APJ interaction and β-arrestin recruitment.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> This is in agreement with a previous report that the deletion of the C-terminal phenylalanine provides an analogue with reduced β-arrestin activity and therefore becomes biased toward G protein signaling.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> However, compound <b>110</b> failed to induce hypotensive effect in vivo, whereas a less biased analogue induced a significant drop in mean arterial blood pressure. The reason for this is probably that hypotensive effects of APJ elicited by apelin analogues depend on the ability of these ligands to recruit β-arrestins and induce receptor internalization.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Nevertheless, these results support the idea that the distinct signaling pathways coupled to a specific GPCR could be the mediators of distinct physiological functions of the same receptor, and biased ligands could be useful probes for the study of such effects.</div><div class="NLM_p last">For small molecule APJ agonists, Read et al. reported that compound CMF-019 (<b>111</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>), the carboxylic potassium salt of a benzoimidazole compound patented by Sanofi,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> was a G-protein-biased small molecule agonist of APJ.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Compared to apelin-13, CMF-019 exhibited similar potency in the cAMP assay (pEC<sub>50</sub> = 10.00 versus 9.34 for apelin-13), whereas it was much less potent in β-arrestin recruitment and receptor internalization assays (pEC<sub>50</sub> = 6.65 versus 8.65 and pEC<sub>50</sub> = 6.16 versus 9.28 respectively). These translated into a bias factor of ∼400 for the G<sub>i</sub> signaling over β-arrestin recruitment and ∼6000 over receptor internalization.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Furthermore, CMF-019 induced a significant increase in cardiac contractility in a rat model.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> These results demonstrated that the ligand bias properties at APJ can be retained in a non-peptide compounds and such bias could translate into therapeutic benefits.</div></div><div id="sec1_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemokine Receptors</h3><div class="NLM_p">The chemokine receptors also belong to class A GPCRs, and they bind to chemokines (8–12 kDa peptides). The chemokine receptor family contains 24 members in humans and can be subdivided, based on the class of chemokines they bind, into four subfamilies: CCR1–10, CXCR1–7, CX3CR1, and XCR1. Chemokine receptors mediate the trafficking of leukocytes, and dysregulation of chemokine receptors is involved in autoimmune conditions, inflammatory diseases, viral infections, and cancer.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Two drugs targeting this family of receptors have so far made it to the market: the CCR5 antagonist maraviroc for the treatment of HIV infections, and the CXCR4 antagonist plerixafor for the mobilization of hematopoietic stem cells into the bloodstream in cancer patients. Currently, there are more than 50 chemokines that have been identified, and a complex network between chemokines and chemokine receptors has been depicted.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Bias properties of these chemokines at chemokine receptors have been studied, which could in part explain the ligand redundancy for this family of receptors.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a></div><div class="NLM_p">The chemokine receptor CXCR3 is a potential drug target for the treatment of autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis) and cancer.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Bernat et al. recently reported that for CXCR3, light structural modifications of a negative allosteric modulator (NAM) <b>112</b> (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) led to the discovery of compounds biased for either the β-arrestin or G protein pathway. On the basis of the 8-azaquinazolinone scaffold of compound <b>112</b>, a boronic acid that is known for its unique ability to interact with proteins in a reversible covalent way<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> was used to investigate the allosteric modulation of CXCR3.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> This led to the discovery of compound <b>113</b>, which was reported as the first biased NAM of CXCR3 that preferentially inhibited the CXCL11-mediated recruitment of β-arrestin2 to CXCR3 but not the activation of G proteins. In later work, in order to reduce the scaffold rigidity and therefore improve the physicochemical properties of the compounds, the benzene moiety on the right hand was changed to a flexible fluorooxoalkyl chain as in compound <b>114</b>.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> This compound showed 187-fold preference for the inhibition of G protein signaling versus β-arrestin recruitment. The authors reasoned that structurally similar allosteric modulators can bind to CXCR3 in different orientations, and these orientations elicit different functional responses, leading to biased signal transduction.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Biased allosteric modulators of CXCR3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The same group also reported the discovery and characterization of two strongly biased allosteric agonists of CXCR3.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> On the basis of the tetrahydroisoquinoline carboxamide core of compound VUF10661 (<b>115</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>), the positive charge at the amine on the side chain of the lysine moiety was shown to be dispensable. The elongation of the linker connecting the dibenzyl moiety led to compound FAUC1036 (<b>116</b>), which was characterized as a fully β-arrestin-biased allosteric agonist of CXCR3. Compound FAUC1036 showed improved potency in the β-arrestin2 assay (pEC<sub>50</sub> = 6.64 compared to 5.89 of VUF10661) while displaying no effect in the [<sup>35</sup>S]GTPγS binding assay. Interestingly, an introduction of a para-methoxy group on the upper benzene ring afforded compound FAUC1104 (<b>117</b>), which showed a bias for the G protein pathway.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Although slightly weaker in the G protein assay (pEC<sub>50</sub> = 5.22, <i>E</i><sub>max</sub> = 50%), this compound shows no measurable β-arrestin2 recruitment. In CXCR3 internalization assays, compound FAUC1036 induced receptor internalization at concentrations of 10 μM and 1 μM, similar to the effect observed with 100 nM of CXCL11, the endogenous ligand; but for compound FAUC1104, no internalization was observed. Interestingly, both compounds FAUC1036 and FAUC1104 induced cell migration in a standard Transwell assay, suggesting that both G protein activation and β-arrestin recruitment account for the functional chemotaxis response.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Therapeutic potential of these compounds in a disease context has not been reported yet.</div></div><div id="sec1_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Prostaglandin EP<sub>2</sub> Receptor</h3><div class="NLM_p">Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) exerts a wide variety of biological actions through four receptor subtypes, EP<sub>1</sub>–EP<sub>4</sub>, in various tissues. The EP<sub>2</sub> receptor plays important roles in inflammation and is a potential target for the treatment of various CNS and peripheral diseases.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> The EP<sub>2</sub> receptor modulates beneficial neuroprotective effects in the brain via G-protein-mediated cAMP signaling;<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> however, the activation of β-arrestin-mediated EP<sub>2</sub> receptor signaling led to deleterious effects, such as tumorigenesis and angiogenesis.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Ogawa et al. recently reported the results of their studies of biased ligands at prostanoid receptors. As shown in <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>, the prostacyclin analogue <b>118</b> showed very weak EP<sub>2</sub> agonist activity (EC<sub>50</sub> = 8900 nM in the cAMP assay). Substitution of the upper flexible alkyl chain with a thiazole along with the removal of the 15-hydroxyl group from the ω-chain afforded a potent EP<sub>2</sub> agonist <b>119</b>, which was biased toward the G protein pathway (cAMP assay EC<sub>50</sub> = 3.9 nM, <i>E</i><sub>max</sub> = 98%) and away from the β-arrestin pathway (EC<sub>50</sub> > 10,000 nM, <i>E</i><sub>max</sub> = 38%).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Adjustment of the linker length between the cyclopentane scaffold and the phenoxy moiety provided a short ω chain derivative <b>120</b>, with a similar biased profile.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> SFSR studies around the benzene ring led to the discovery of compound <b>121</b>, with a 3-methyl-4-chloro substitution pattern, which showed enhanced potency in the G protein assay maintaining excellent functional selectivity against β-arrestin recruitment.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Notably, adding another methyl substitution to the benzene ring, as shown with compound <b>122</b>, led to a sharp increase of β-arrestin activity (EC<sub>50</sub> = 2.3 nM, <i>E</i><sub>max</sub> = 98%), thus a significant loss of functional selectivity. The inversion of the hydroxyl group on the cyclopentane moiety of <b>121</b> gave compound <b>123</b>, which showed a 5-fold increase in its G protein activity (EC<sub>50</sub> = 0.14 nM versus 0.69 nM of <b>121</b>) without any increase in β-arrestin activity.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> These results add to the conclusion that subtle modifications of molecular structure could lead to significant changes of bias profiles of the ligands. G-protein-biased EP<sub>2</sub> agonists have been reported to show potent intraocular lowering effects in rabbit and monkey.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Biased prostaglandin EP<sub>2</sub> agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Endothelin A (ET<sub>A</sub>) Receptor</h3><div class="NLM_p">Endothelin peptides mediate their cellular actions via interactions with two GPCRs, ET<sub>A</sub> and ET<sub>B</sub>. Endothelin antagonists are approved drugs for the treatment of pulmonary arterial hypertension (PAH) and hold promise for cancer and fibrosis therapy.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Like other GPCRs, there have been emerging interests in the study of ligand bias properties at these receptors, which were recently reviewed.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> For example, it has been reported that the potency and efficacy of the endogenous ligands ET-1, -2, and -3 vary in the G-protein-dependent saphenous vein constrictor assays and the β-arrestin recruitment assay.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> ET-1 (<b>124</b>) was taken as the reference compound, and transduction efficiency (τ/<i>K</i><sub>A</sub>) was compared between these peptides which showed that both ET-2 (<b>125</b>) and ET-3 (<b>126</b>) are G-protein-biased agonists of ET<sub>A</sub> although ET-3 is much less potent (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Of more importance is the biased profile of bosentan (<b>127</b>), a nonselective ET<sub>A</sub>/ET<sub>B</sub> antagonist that is used in the clinic for the treatment of PAH. It was found that bosentan is a β-arrestin-biased antagonist of ET<sub>A</sub>, whereas it is balanced at ET<sub>B</sub> (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a> It is not yet clear whether the β-arrestin-biased antagonism of ET<sub>A</sub> is beneficial or detrimental for its effects in treating PAH, which necessitate further studies. But as pointed out,<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> ET-1 stimulated ET<sub>A</sub>-mediated β-arrestin signaling leads to activation of the NF-κB in epithelial ovarian cancer,<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> and β-arrestin1 epigenetically regulates ET-1-induced β-catenin signaling;<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147,148)</a> thus the β-arrestin pathway plays important roles in cancer. Better understanding of the signaling pathways will definitely help with further drug discovery efforts targeting the ET<sub>A</sub> receptor.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Biased ligands at the ET<sub>A</sub> receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> GPR109A Receptor</h3><div class="NLM_p">GPR109A (also known as the hydroxycarboxylic acid receptor, HCAR2) is an orphan GPCR which was thought to be the receptor responsible for niacin’s biological effects.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Niacin (<b>128</b>, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>), as both a medication and diet supplement, has been primarily used for lowering triglycerides and raising plasma high-density lipoprotein (HDL). However, niacin causes side effects, among which the most common is facial flushing. It was reported by Walters et al. that niacin was active in a series of assays testing β-arrestin1/2 membrane recruitment, as well as conformational changes in β-arrestin2 upon activation of GPR109A, phosphorylation of ERK and others, demonstrating that β-arrestin1 mediates niacin-induced flushing but not its antilipolytic effect.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> A G-protein-biased GPR109A agonist MK-0354 (<b>129</b>), which is a synthetic tetrazole bioisostere of niacin, was discovered by Merck.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Compared to niacin, stimulation with MK-0354 failed to induce the conformational change of β-arrestin2 upon GPR109A activation and MK-0354 did not induce the recruitment of β-arrestin1.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> As a biased agonist of GPR109A, MK-0354 had been evaluated in clinical trials but failed to elevate HDL levels. This led to the conclusion that the mechanism by which niacin alters HDL levels is GPR109A independent.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Nevertheless, this example provided further evidence that biasing a ligand toward GPCR (in this case GPR109A) agonism could separate the receptor mediated G-protein activation from the known side effect (in this case, flushing) which has been linked to the β-arrestin pathway.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. MK-0354 is a G-protein-biased GPR109A agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Sphingosine 1-Phosphate Receptor 1 (S1P<sub>1</sub>R)</h3><div class="NLM_p">S1P<sub>1</sub>R is a validated drug target for the treatment of multiple sclerosis. Fingolimod, a modulator of S1P<sub>1</sub>R, is the first oral therapy for relapsing remitting multiple sclerosis; however, it causes a dose-dependent reduction in heart rate (bradycardia). Clinical studies with selective S1P<sub>1</sub>R agonists suggested that the bradycardia in human is at least in part mediated by the agonism of S1P<sub>1</sub>R,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> therefore an “on-target” side effect that could only be avoided by biased agonists. Dhar et al. reported the discovery of BMS-986104, a differentiated S1P<sub>1</sub>R modulator with improved side effect profile.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Due to the fact that both fingolimod and BMS-986104 are prodrugs, the phosphate forms were compared to determine their bias profiles. As shown in <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>, both compounds <b>130</b> (fingolimod phosphate) and <b>131</b> (BMS-986104 phosphate) were highly potent in cAMP inhibition, GTPγS binding, ERK phosphorylation, and receptor internalization assays. Compared to <b>130</b>, compound <b>131</b> showed lower efficacy in internalization assays (<i>E</i><sub>max</sub> = 68% versus 100% for <b>130</b>), and an over 1400-fold potency difference between them in ERK phosphorylation was observed (8.16 nM versus 0.0056 nM). In addition, compound <b>131</b> was demonstrated to be cAMP-biased (∼1000-fold) relative to ERK phosphorylation.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> In cultured human cardiomyocytes, compound <b>131</b> showed less reduction in heart rate compared to compound <b>130</b>, and BMS-986104 has been advanced to human clinical trials. It is not clear at this stage whether ERK phosphorylation is G-protein-dependent or β-arrestin-dependent at S1P<sub>1</sub>R, but the overall differential functional profile of <b>131</b> might contribute to its superior safety profile.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. BMS-986104 phosphate is a G-protein-biased agonist at S1P<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Neurotensin Receptor 1 (NTR1)</h3><div class="NLM_p">The physiological roles of neurotensin are mainly mediated by NTR1, which has been demonstrated as a drug target for both CNS disorders such as schizophrenia and drug addiction and peripheral diseases such as cancer.<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> While most known NTR1 agonists are peptide analogues of neurotensin, small molecule agonists have also been reported. For example, to identify nonpeptidic, β-arrestin-biased NTR1 agonists, Peddibhotla et al. carried out a high-content screening (HCS) of receptor/β-arrestin-GFP complexes based on a β-arrestin conjugated green fluorescent protein (GFP) reporter expressed in U2OS cells. The quinazoline compound <b>132</b> (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) was identified as the single hit from the HCS, which showed micromolar potency in the primary assay (EC<sub>50</sub> = 5.9 μM). Optimization of this compound led to the discovery of ML314 (<b>133</b>), in which the cyclobutyl substituent was replaced by a cyclopropyl.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> ML314 showed higher potency in the HCS β-arrestin assay (EC<sub>50</sub> = 2.0 μM), which was confirmed in the DiscoveRx β-arrestin recruitment assay (EC<sub>50</sub> = 3.4 μM). Importantly, ML314 induced no response in G<sub>q</sub>-mediated Ca<sup>2+</sup> mobilization, indicating that it is fully biased toward β-arrestin signaling. In animal studies, ML314 attenuated amphetamine-like hyperlocomotion in dopamine transporter knockout mice and methamphetamine-induced hyperlocomotion.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. ML314 is a β-arrestin-biased agonist at NTR1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Formyl Peptide Receptor 2 (FPR2)</h3><div class="NLM_p">FPR2 (also known as lipoxin A<sub>4</sub> receptor, ALXR) is a promiscuous GPCR that can be activated by an array of ligands, which include structurally unrelated lipids and peptides or proteins.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> It is a potential drug target because its involvement in a range of normal physiological processes and pathological diseases.<a onclick="showRef(event, 'ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref159 ref160">(159,160)</a> F2Pal<sub>10</sub> (<b>135</b>, <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>) is a pepducin (lipidated peptide) for which the peptide moiety shares the amino acid sequence of 10 amino acids in the EL3 of FPR2, and its N-terminal was conjugated to palmitic acid.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Comparing to the FPR2 peptide agonist WKYMVM (<b>134</b>), F2Pal<sub>10</sub> was equally potent in Gq-mediated calcium flux assay, but its activation of the receptor did not lead to β-arrestin recruitment, whereas WKYMVM was a potent agonist (EC<sub>50</sub> = 19 nM).<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Although it appeared that FPR2 desensitization occurred independent of β-arrestins, F2Pal<sub>10</sub>-desensitized and WKYMVM-desensitized neutrophils differed in the reactivation of FPR2 through a cross-talk mechanism with other GPCRs.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Moreover, the inability of F2Pal<sub>10</sub> to recruit β-arrestins was found to be associated with a reduced rate of receptor internalization and impaired chemotaxis in neutrophils. Although the therapeutic advantage due to its biased properties is not yet reported, F2Pal<sub>10</sub> serves as a useful tool for further study of FPR2 functions.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. F2Pal<sub>10</sub> is a G-protein-biased agonist of FPR2. The amino acid sequences of each peptide are shown from the N-terminus (left) to the C-terminus (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Adenosine Receptors</h3><div class="NLM_p">Adenosine receptors are GPCRs for the endogenous molecule adenosine, for which four subtypes have been identified: A<sub>1</sub>AR, A<sub>2A</sub>AR, A<sub>2B</sub>AR, and A<sub>3</sub>AR.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Adenosine receptors play different roles in both the central and peripheral systems, and many ligands for them have been developed as potential therapeutics. Functional selectivity of previously known adenosine receptor ligands has been reviewed, which led to the conclusion that functional selectivity of synthetic ligands has been convincingly shown for the A<sub>1</sub>AR and A<sub>3</sub>AR.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div><div class="NLM_p">A<sub>1</sub>AR is an important drug target for cardioprotection, but current A<sub>1</sub>AR drugs are limited for this indication because of the occurrence of bradycardia as a major adverse effect. A rationally designed bitopic A<sub>1</sub>AR agonist VCP746 (<b>136</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) was recently reported by Valant et al., which is a hybrid molecule comprising adenosine linked to a positive allosteric modulator.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Compound VCP746 is biased toward G<sub>i</sub>-mediated inhibition of forskolin stimulated cAMP accumulation versus ERK1/2 phosphorylation, which was chosen as a noncanonical downstream convergent signaling pathway, because it can be both G-protein-dependent and -independent. By use of R-PIA (<b>137</b>) as the reference compound, the agonist transduction coefficient log(τ/<i>K</i><sub>A</sub>) was used to evaluate compound bias properties. VCP746 showed a 33.9-fold bias for cAMP inhibition relative to ERK1/2 phosphorylation, while this bias was only 1.5- and 2.0-fold for adenosine and VCP900 (<b>138</b>), respectively. In animal tests, VCP746 was found to protect against ischemic insult in native A<sub>1</sub>AR-expressing cardiomyoblasts and cardiomyocytes and did not affect rat atrial heart rate.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Given the undefined relationships between G protein pathway, β-arrestin pathway, and ERK1/2 phosphorylation, future study is needed to better understand the roles that the distinct pathways play in the overall function of the receptor.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. VCP746 and analogues as biased A<sub>1</sub>AR bitopic agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">VCP746 has also been subsequently characterized in further functional assays, which included cAMP inhibition, calcium mobilization, ERK1/2, Akt1/2/3, and cell survival.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> By use of both cAMP inhibition and calcium mobilization to quantify bias properties, further studies around compound VCP746 were recently reported by the same group.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Structural modifications were made to the orthosteric adenosine pharmacophore, the linker, and the allosteric 2-amino-3-benzoylthiophene pharmacophore to study the SFSRs. As shown in <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>, compound VCP746 displays a bias toward cAMP signaling over calcium mobilization. Increasing the linker length by adding an additional methylene group afforded compound <b>139</b>, for which the bias for cAMP signaling was enhanced compared to VCP746. However, when the 4-(trifluoromethyl)phenyl substituent of the thiophene was deleted from the allosteric moiety, compound <b>140</b> became unbiased. Furthermore, when all three substituents of the thiophene were removed as in compound <b>141</b>, a reversal of the bias was observed (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). These results showed that the allosteric moiety of these bitopic agonists of A<sub>1</sub>AR is a very important contributor to their bias properties. This conclusion was supported by docking studies using an A<sub>1</sub>AR homology model based on an active A<sub>2A</sub>AR crystal structure, which indicated that interactions of the allosteric moiety and the linker region of compound VCP746 within the extracellular vestibule may underlie the initial trigger of its bias profile.</div><div class="NLM_p">The A<sub>3</sub>AR is another adenosine receptor that has been reported to play roles in a number of diseases such as cancer, inflammation, and ischemia.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Baltos et al. recently reported the bias properties of a series of (<i>N</i>)-methanocarba 5′-<i>N</i>-methyluronamide nucleoside derivatives <b>143</b>–<b>148</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>).<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In their studies, the A<sub>3</sub>AR agonists were assessed for their ability to inhibit cAMP accumulation, phosphorylate ERK1/2 and Akt, increase intracellular calcium concentrations, and promote cell survival upon serum starvation. By use of IB-MECA (<b>142</b>) as the reference agonist and pERK1/2 as the reference pathway, a significant positive correlation was observed between the C2 substituent length (in Å) of compounds and their bias toward cell survival.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Molecular modeling suggested that extended C2 substituents promote an outward shift of TM2 of the receptor, which may underlie the SFSRs. Although it is not clear whether the ability of A<sub>3</sub>AR agonists to promote cell survival is G-protein-dependent or G-protein-independent, the SFSRs of these compounds proved that profiling of GPCR ligands at multiple pathways is necessary to better predict their therapeutic potential.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Biased agonists of A<sub>3</sub>AR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">For the above A<sub>1</sub>AR and A<sub>3</sub>AR ligands, as well as the D<sub>2</sub>R agonists shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, comparisons have been made between the G protein signaling (cAMP assay) with other “indirect” downstream effects of the receptor (i.e., ERK phosphorylation, calcium mobilization, and cell survival), rather than between G protein signaling and β-arrestin recruitment. Although these add to our understanding of the complexity of GPCR biased signaling, further study is needed to get a clearer picture of all the events that will be initiated upon the activation of a GPCR. Most likely no universal rules could be applied to all the receptors, and profiling a GPCR ligand using various available assays is necessary for a better prediction of potential pharmacological effects in vivo.</div></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Biased Ligands of Class B GPCRs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The majority of biased ligands reported so far target class A GPCRs, and literature on other classes of the GPCR family remains limited. Among them, class B comprises 15 GPCRs that respond to peptide hormones and are the targets of many drugs for the treatment of diabetes and osteoporosis. Class B GPCRs share the 7TM architecture common to all GPCRs, but they also feature a large extracellular N terminus, which is very important for ligand recognition and activation. Similarly as for some of the above-mentioned class A GPCRs, reevaluation of existing ligands has revealed bias properties for a few class B receptors.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> For example, the peptide (<span class="smallcaps smallerCapital">d</span>-Trp<sup>12</sup>,Tyr<sup>34</sup>)-PTH(7–34) (PTH-barr) has been reported as a biased agonist for the parathyroid hormone type 1 receptor (PTH1R), which activates β-arrestin but not the classic G protein signaling and therefore acts as a β-arrestin-biased agonist.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> In mice, PTH-barr induced anabolic bone formation, which can be abrogated in β-arrestin2-null mice.</div><div class="NLM_p">The glucagon-like peptide 1 receptor (GLP-1R) is a class B GPCR that plays very important roles in the pathophysiology of type 2 diabetes (T2D) and obesity and receives extensive attention as a drug target.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Several known agonists and positive allosteric modulators (PAMs) of this receptor have been reported as biased ligands after being evaluated in both G protein and β-arrestin functional assays. For example, relative to the endogenous ligand GLP-1, both oxyntomodulin (<b>151</b>) and exendin-4 (<b>152</b>) are biased toward β-arrestin recruitment in ChoFlpIn cells (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> GLP-1R PAMs, such as BETP and Boc5, also display bias properties when both G-protein-mediated and β-arrestin-mediated activities are tested.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Biased agonists of GLP-1R. The amino acid sequences of the peptides are shown from the N-terminus (left) to the C-terminus (right), while a terminal “–NH<sub>2</sub>” indicates a primary amide at the C-terminus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A G-protein-biased GLP-1R agonist, P5 (<b>153</b>, <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>), was discovered through a high-throughput autocrine-based screening of large combinatorial peptide libraries.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> It has been shown that P5 promotes G protein signaling comparable to GLP-1 and exendin-4 but exhibited a significantly reduced β-arrestin response. It is a weak insulin secretagogue but demonstrated superior antihyperglycemic efficacy in both genetic and diet-induced obese mice.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> The structural difference between P5 and exendin-4 is at the N terminus, where the first eight residues of exendin-4 were removed (to give exendin9–39, which is a GLP-1R antagonist) and new amino acids were appended (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).</div><div class="NLM_p">Although the G-protein-biased agonist P5 displays efficacy in animal models and supports the idea that G-protein-biased agonists may serve as novel therapeutics for T2D, the recruitment of β-arrestin1 has been reported to promote β cell proliferation and protect β cells from apoptosis.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Therefore, the discovery of β-arrestin-biased agonists of GLP-1R could also offer potential therapeutics for T2D. Through the modification of GLP-1 peptides by incorporating unnatural amino acids, a series of β-arrestin-biased agonists of GLP-1R have very recently been reported by Hager et al.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>, the α → β replacements decrease peptide potency in both stimulation of cAMP production and β-arrestin recruitment, but for some replacement sets such as those in peptides <b>154</b>, <b>155</b>, and <b>156</b>, cAMP production is more strongly affected than β-arrestin recruitment, therefore leading to β-arrestin-bias. Both SFSR and modeling results suggested that the central part of these peptides contributed to their biased properties.</div><div class="NLM_p last">Compared to class A, class B GPCRs have been viewed as more challenging for ligand discovery, due to their large extracellular domain which is required for the activation of the receptor. The recently solved structures of GLP-1R have provided much detailed information on ligand recognition and activation mechanism of class B GPCRs and will facilitate future ligand design efforts targeting this important family of receptors.<a onclick="showRef(event, 'ref178 ref179 ref180'); return false;" href="javascript:void(0);" class="ref ref178 ref179 ref180">(178−180)</a> Further study on biased ligands and their therapeutic potential at class B GPCRs is warranted.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Biased Ligands/Allosteric Modulators at Class C GPCRs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53606" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53606" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The class C GPCRs consist of 22 receptors that include very important drug targets such as the metabotropic glutamate receptors (mGluR), the calcium-sensing receptors (CaSR), and the γ-aminobutyric acid (GABA) type B receptors (GABA<sub>B</sub>), among others (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The structures of class C GPCRs differ from class A in that the 7TM domain of these receptors is connected through a cysteine rich region to a large bilobed extracellular aminoterminal domain termed the Venus flytrap domain (VFD), which binds the endogenous ligands.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><div class="NLM_p">The mGluRs bind to the major excitatory neurotransmitter glutamate and modulate synaptic transmission in the CNS. Among the many effects glutamate has upon the activation of mGluRs, cytoprotective effects were recently reported in CHO cells that express the mGlu<sub>1</sub>R.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Both glutamate (<b>158</b>) and the natural compound quisqualate (<b>159</b>) activate the mGlu<sub>1</sub>R as measured in the Gq-mediated PI hydrolysis assay, with the latter being more potent (EC<sub>50</sub> = 16 μM and 0.63 μM, respectively, <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>). However, only glutamate displayed neuronal protective effects against apoptosis induced by conditions of trophic deprivation (EC<sub>50</sub> = 153 μM).<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> The cytoprotective effects were correlated to sustained ERK phosphorylation effects which were G-protein-independent but not with transient ERK phosphorylation, which was believed to be G-protein-mediated. Additionally, further studies showed that β-arrestin1 plays a role in the cytoprotective effects of glutamate.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Using the same method, Emery et al. also reported that like quisqualate, compound DHPG (<b>159</b>, <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>) is also a G-protein-biased agonist of mGlu<sub>1</sub>R, which induced PI hydrolysis but not sustained ERK phosphorylation and cytoprotective effects, whereas glutaric acid (<b>160</b>) and succinic acid (<b>161</b>) are fully β-arrestin1-biased and they did not induce PI hydrolysis but displayed cytoprotective effects.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> These results support that β-arrestin-biased agonists of mGlu<sub>1</sub>R have the therapeutic potential as neuroprotective agents. By mutational analysis, it was found that residue Thr188 is critical for G-protein-mediated signaling of mGlu1R, which interacts with the amino group of glutamate, quisqualate, and DHPG. The removal of this amino group as in glutaric acid and succinic acid abolishes this interaction and makes both compounds β-arrestin1-biased (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>).<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Biased agonists of mGlu<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, all glutamate analogues have poor physiochemical properties that make them poor drug candidates. Therefore, the study of allosteric modulators of these receptors has become the main paradigm of current drug discovery efforts targeting mGluRs.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> It is worth noting that most allosteric modulators of class C GPCRs bind to a pocket formed by the transmembrane helices that resemble the orthosteric binding site of class A receptors.<a onclick="showRef(event, 'ref185 ref186'); return false;" href="javascript:void(0);" class="ref ref185 ref186">(185,186)</a> PAMs of mGlu<sub>5</sub>R have shown promise for the treatment of schizophrenia in both preclinical and clinical studies.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> One possible mechanism for these therapeutic effects has been believed to be the mGlu<sub>5</sub>R-induced potentiation of NMDAR (<i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor) currents, but increased activation of NMDA receptors can also lead to excitotoxicity and neuronal death.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Similar to other GPCRs, this likely “on-target” toxicity could potentially be avoided by biased ligands at this receptor. Recently, Rook et al. reported that the mGlu<sub>5</sub>R PAM VU0409551 (<b>162</b>, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>) induced a robust potentiation of mGlu<sub>5</sub>R coupling to Gq-mediated calcium mobilization and other signaling pathways but does not enhance mGlu<sub>5</sub>R modulation of NMDAR currents in hippocampal neurons.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Importantly, VU0409551 maintains the robust, dose-dependent efficacy in preclinical rodent models of psychosis and cognitive function.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Because the mGlu<sub>5</sub>R-induced potentiation of NMDAR currents in forebrain neurons is mediated by interactions of mGlu<sub>5</sub>R with NMDARs through adaptor proteins that are independent of signaling through Gq, this suggests that functionally selective mGlu<sub>5</sub>R PAMs (e.g., Gq-mediated signaling versus modulation of NMDAR currents) may provide safer drug candidates for further development.</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Biased PAMs of mGlu<sub>5</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It has also been reported that another PAM of mGlu<sub>5</sub>R, NCFP (<b>163</b>, <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>), potentiates mGlu<sub>5</sub>R-mediated responses in the calcium mobilization and ERK1/2 phosphorylation assays, in both recombinant and native systems (rat cortical astrocytes), but does not potentiate responses involved in hippocampal synaptic plasticity (long-term depression and long-term potentiation).<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> One possible reason for this distinct profile of NCFP might be that it binds to a different site on the receptor from the MPEP (2-methyl-6-(phenylethynyl)pyridine) binding site where most other mGlu<sub>5</sub>R PAMs bind.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> However, whether the regulation of hippocampal synaptic plasticity is related to unwanted side effects or is necessary for the therapeutic effects of mGlu<sub>5</sub>R PAMs remains to be demonstrated.</div><div class="NLM_p">The CaSR is responsible for the regulation of extracellular Ca<sup>2+</sup> concentrations in the body, and the activation of CaSR expressed in the parathyroid gland suppresses the secretion of parathyroid hormone (PTH). Various endogenous and exodogenous agonists can activate CaSR, including the divalent cations Ca<sup>2+</sup> and Mg<sup>2+</sup>, polyamines, aminoglycosides, and others.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> These orthosteric agonists have poor drug-like properties and are thus less explored as therapeutic agents. A number of such compounds have been studied for their activities in cellular effects including IP<sub>1</sub> accumulation, cAMP inhibition, and ERK1/2 phosphorylation, and they displayed varied biases toward one signaling pathway or another.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></div><div class="NLM_p">Like the mGluRs, of more therapeutic relevance are the allosteric modulators of CaSR. The calcimimetic drug cinacalcet (<b>164</b>, <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>) was the first allosteric GPCR modulator that reached the pharmaceutical market, which has been approved for the treatment of hyperparathyroidism in 2004.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> This drug, however, causes the adverse side effect hypocalcaemia, likely through the activation of CaSR in tissues other than the parathyroid gland. It has been hypothesized that the distinct therapeutic effects and side effects may be mediated by different signaling pathways associated with CaSR and biased PAMs may provide opportunities in discovering safer therapeutics targeting this receptor.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Recently, Cook et al. evaluated a number of structurally diverse calcimimetics for three key signaling effects associated with this receptor: Ca<sup>2+</sup> mobilization, ERK1/2 phosphorylation, and IP<sub>1</sub> accumulation (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>).<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> The PAM cooperativity (αβ) of these compounds with the CaSR agonist Ca<sup>2+</sup> was calculated as a parameter to evaluate the ligand bias for each signaling effects. It was discovered that cinacalcet shows a bias for Ca<sup>2+</sup> mobilization and IP<sub>1</sub> accumulation and away from pERK1/2.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Compounds AC-265347 (<b>165</b>) and <i>R</i>,<i>R</i>-calcimimetic B (<b>166</b>) are biased for pERK1/2 and IP<sub>1</sub> accumulation but away from Ca<sup>2+</sup> mobilization, while compound <i>S</i>,<i>R</i>-calcimimetic B (<b>167</b>) biases CaSR for IP<sub>1</sub> accumulation only, and nor-calcimimetic B (<b>168</b>) is unbiased. It was proposed that compounds that bias CaSR signaling toward pERK1/2 may achieve tissue-selective suppression of PTH secretion while sparing calcitonin release.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Given that the phosphorylation of ERK1/2 associated with the activation of CaSR can be both G-protein- and β-arrestin-mediated,<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> evaluating compounds in various downstream signaling effects is necessary rather than merely G protein binding and β-arrestin recruitment.</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Biased PAMs of CaSR. PAM cooperativity (αβ) were compared between compounds for quantification. pERK1/2 effects of CaSR can be mediated by both G protein and β-arrestin.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The unique structural feature of class C GPCRs (i.e., the VFD domain) and the distinct binding sites for orthosteric and allosteric ligands (orthosteric agonists bind to the VFD, while allosteric modulators bind to the TM domain) have made the structural basis for ligand bias at these receptors even more elusive. Some key residues related to the observed biased properties of compounds mentioned above have been identified through mutagenesis studies. For example in the mGlu<sub>1</sub>R case, Thr188 is critical for G-protein-mediated signaling whereas Arg323 and Lys409 residues were required for β-arrestin1-mediated effects.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> For CaSR, a naturally occurring R680G mutation selectively enhances β-arrestin signaling by disrupting a salt bridge between Arg680 (on TM3) and Glu767 (on EL2).<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Furthermore, our understanding of the distinct physiological roles each signaling pathway plays is still at a very early stage. The discovery of more biased modulators with better functional selectivity profiles will facilitate the functional study of each signaling pathways and provide opportunities for the identification of better therapeutics.</div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Challenges in the Discovery of Biased Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06183" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06183" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All the above examples have shown that biased ligands represent novel modalities that will potentially provide better therapeutics for a variety of diseases linked to GPCRs. Ligand bias, however, has also added another layer of challenges that medicinal chemists and pharmacologists have to confront when targeting a specific GPCR for drug discovery. We have summarized these main challenges below:</div><div id="sec1_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (1) Mechanism of Action</h3><div class="NLM_p last">In most cases, the etiology of a specific disease is very complicated and can involve many receptors, proteins, and signaling pathways. In cases where a GPCR is involved, it signals through multiple effectors and leads to various changes in downstream signaling events. As discussed above for most GPCRs, it is not clear which signaling pathway is therapeutically most important. For example, as showcased for the D<sub>2</sub>R, biased ligands with varied profiles (G-protein- or β-arrestin-biased; agonist, partial agonist, or antagonist) have been reported, but it is not clear which combination would lead to the most desirable clinical outcomes. Genetic knockout of β-arrestin is a commonly used method for studying the roles of β-arrestin signaling for a given GPCR, and biased ligands serve as useful tools. Although biased ligands have been reported for many GPCRs as summarized in this Perspective, for most GPCRs the ideal tool compounds for the dissection of the signaling pathways is still missing.</div></div><div id="sec1_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (2) Functional Assays</h3><div class="NLM_p last">Secondary messenger assays such as measuring calcium or cAMP levels have been widely used in drug discovery programs for the detection of G protein pathway activity, due to the ease of manipulation, and β-arrestin activation is usually measured by the translocation of the protein. Most of the time, however, overexpression of engineered receptors on model cells (for example, the CHO or HEK-293 cells) is necessary to magnify signals and to enable detection, which does not fully replicate the native biological conditions. Therefore, demonstration of ligand bias in additional cellular models (e.g., neuronal, cancer) may be necessary for the prediction of physiological conditions. One such example listed above is the CB<sub>1</sub>R ligands, which have been tested in a cell culture model of striatal medium spiny projection neurons.<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115,116)</a> Also, it has been recognized that ligand kinetics have an impact on observed biased properties, for example, as demonstrated for the 5-HT<sub>2B</sub> receptor.<a onclick="showRef(event, 'ref75 ref196'); return false;" href="javascript:void(0);" class="ref ref75 ref196">(75,196)</a> Therefore, the readouts from functional assays may vary depending on detection time points.</div></div><div id="sec1_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (3) Quantification of Signaling Bias</h3><div class="NLM_p last">Bias factors are very important for SFSR studies of GPCR biased ligands, but they are often missing for reported ligands or not calculable as can be seen for many examples listed above. Arguably the most widely accepted method for the quantification of bias factors is the calculation based on transduction coefficient (τ/<i>K</i><sub>A</sub>),<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> where the value of log(τ/<i>K</i><sub>A</sub>) reflects the activity of a ligand for a specific pathway, which can be normalized to a reference compound to give Δlog(τ/<i>K</i><sub>A</sub>) and further compared to its activity in another signaling pathway to give ΔΔlog(τ/<i>K</i><sub>A</sub>), from which a bias factor can be calculated as bias factor = 10<sup>ΔΔlog(τ/<i>K</i><sub>A</sub>)</sup>. Importantly, the selection of a reference compound is critical, as the results can vary when a different reference compound is chosen. All of these issues add to the complexity in the data processing step for compound evaluations.</div></div><div id="sec1_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (4) Multiparameter Optimization of GPCR Ligands</h3><div class="NLM_p last">For medicinal chemists, ligand bias would be an extra parameter that must be taken into account when working on GPCR ligands, in addition to ligand affinity, efficacy, off-target activity, physicochemical and ADMET properties, among others. As can be seen from the above examples, subtle structural modifications of a GPCR ligand often lead to significant changes in the functional selectivity of a compound. Compared to SAR data, SFSR conclusions are more difficult to summarize and to interpret and add to the challenges for GPCR-targeted drug discovery.</div></div></div><div id="sec1_5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Medicinal Chemistry Strategies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (1) Re-Evaluating Existing Ligands in Multiple Functional Assays</h3><div class="NLM_p last">Prior to the introduction of the concept of ligand bias, GPCR ligands were often evaluated in a single, normally G-protein-mediated second messenger assay, where results would define the intrinsic activity of a specific ligand (agonist, partial agonist, antagonist, or inverse agonist). Re-evaluating such ligands for β-arrestin recruitment and other functional assays would, therefore, reveal their ligand bias properties. Therefore, known ligands of a specific GPCR serve as a reservoir of preliminary “hit” compounds for the discovery of novel biased ligands. Such examples are the βAR, D<sub>1</sub>R, CB<sub>1</sub>R, CB<sub>2</sub>R, mGluR, and CaSR.</div></div><div id="sec1_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (2) Structure-Based Drug Design</h3><div class="NLM_p last">Numerous GPCR structures have been solved in the past decade, which provide valuable information for structure-based design targeting this important family of drug targets, but the structural basis for biased agonism is far from being understood. Nevertheless, for a limited number of GPCRs, for example, the β<sub>2</sub>AR,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> D<sub>2</sub>R,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> D<sub>1</sub>R,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> and 5-HT<sub>2B</sub>,<a onclick="showRef(event, 'ref75 ref93'); return false;" href="javascript:void(0);" class="ref ref75 ref93">(75,93)</a> the molecular determinants that define biased agonism of GPCRs have been explored, where information could be further used for structure-based design of biased ligands. It is to be anticipated that the discovery of more biased ligands will be useful tools for the structural biological study of the receptors, which will in turn help future design of biased ligands.</div></div><div id="sec1_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (3) Study of SFSRs</h3><div class="NLM_p last">Just as an extensive SAR study around a hit compound could be a powerful approach to the discovery of drug candidates with desirable drug-like properties, a careful study of SFSRs based on a biased compound can be applied in the discovery of biased ligands. This is also necessary in most cases given that a subtle structural modification could lead to significant changes to the bias properties of a specific ligand. Examples are the biased D<sub>2</sub>R ligands based on aripiprazole (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).</div></div><div id="sec1_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (4) Measurement of Binding Kinetics</h3><div class="NLM_p last">Binding kinetics should generally be taken into account as an additional parameter for medicinal chemists.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Recently, it was reported that association rates at D<sub>2</sub>R determine the extrapyramidal side effects of antipsychotics.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> As for ligand bias, binding kinetics may influence or contribute to the bias properties of a specific ligand, for example, in the above-mentioned 5-HT<sub>2B</sub> receptor.<a onclick="showRef(event, 'ref75 ref196'); return false;" href="javascript:void(0);" class="ref ref75 ref196">(75,196)</a> Therefore, this is an important aspect to consider in drug discovery targeting GPCRs, whereby the drug’s residence time at a given receptor may influence its duration and/or select signaling properties.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Besides G-protein-dependent versus G-protein-independent signaling pathways (e.g., β-arrestin recruitment), there have been also some cases where a specific ligand shows bias between different subtypes of G proteins or between different β-arrestins. For example, the aforementioned endocannabinoid AEA is biased for G<sub>i</sub> over G<sub>s</sub> at CB<sub>1</sub>R compared to the synthetic CB<sub>1</sub> agonist WIN-55212.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Bock et al. recently reported that the structural modifications of iperoxo led to the discovery of M<sub>2</sub> acetylcholine receptor agonists biased for either Gα<sub>i</sub> or Gα<sub>s</sub>.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> In addition to the G-protein-biased opioid receptor agonists mentioned above, Pradhan et al. reported agonist-selective recruitment of different arrestin isoforms to DOR.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Given the fact that specific subtypes of G proteins and arrestins may contribute differently to the overall physiology of a given cell type, these biased ligands are also very important for dissecting the roles that each effector plays and offer opportunities for the discovery of novel therapeutics.</div><div class="NLM_p">Biased agonism or functional selectivity provides opportunities for more precise regulations of GPCR functions, therefore affording therapeutics with enhanced efficacy and/or reduced adverse side effects. The advantages of biased ligands as a new generation of drugs have been exemplified at several GPCRs by investigational drugs in human clinical trials, such as TRV130, which is awaiting FDA approval. In fact, biased agonism has become the major paradigm in GPCR drug discovery. However, it is worth noting that the bias property of a ligand at a specific receptor may not always necessarily be therapeutically favorable but nonetheless should be taken into account.</div><div class="NLM_p last">From the above examples, it is clear that in most cases, a very small structural modification of a ligand could lead to a significant change or even the reversal of ligand bias properties. Underlying reasons for this include the relatively high conservative nature of GPCR ligand binding pockets that a given ligand samples, which may lead to favored active GPCR conformations, either a G protein activation-preferred state or β-arrestin recruitment-preferred state. As discussed, ligand bias represents a significant challenge for medicinal chemists, and as more efforts are aimed at targeting GPCRs for drug discovery, SFSR studies will serve to better characterize and benchmark drug-like compounds in biological assays. Although the number of GPCRs that have been crystallized is still rather limited, the development of biased ligands will lead to more accurate “capture” of biased states of GPCRs, which in turn will lead to better advancements in biased ligand design. Progress in structural and functional aspects of GPCR signaling will lead to biased ligands as novel tools to dissect out signaling pathways relevant for disease-related GPCRs and will ultimately lead to a new generation of GPCR-targeted drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00435" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41750" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41750" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. McCorvy</span> - <span class="hlFld-Affiliation affiliation">Department
of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, Wisconsin 53226, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#98f2f5fbfbf7eaeee1d8f5fbefb6fdfced"><span class="__cf_email__" data-cfemail="8ce6e1efefe3fefaf5cce1effba2e9e8f9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjun Cheng</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong District, Shanghai 201210, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6065-2682" title="Orcid link">http://orcid.org/0000-0001-6065-2682</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bcdfd4d9d2dbd6d6fccfd4ddd2dbd4ddd5c8d9dfd492d9d8c992dfd2"><span class="__cf_email__" data-cfemail="e5868d808b828f8fa5968d848b828d848c9180868dcb808190cb868b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Tan</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong District, Shanghai 201210, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenzhong Yan</span> - <span class="hlFld-Affiliation affiliation">iHuman
Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong District, Shanghai 201210, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Liang Tan</b> received his Ph.D. in Medicinal Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in 2017. He is currently a postdoctoral researcher at iHuman Institute, ShanghaiTech University. His research focuses on the aminergic GPCRs, with the goal of identifying novel biased agonists with favorable drug-like properties and studying their therapeutic potential as antipsychotic drugs.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wenzhong Yan</b> received his Ph.D. in Medicinal Chemistry in 2016 from East China University of Science and Technology in Shanghai. After a short period of working at Shanghai ChemPartner Co., Ltd., he joined iHuman Institute, ShanghaiTech University in 2017 as a postdoctoral research associate. His research focuses on the design and discovery of novel GPCR ligands with the goal of identifying novel drug candidates for the treatment of cancer and other diseases.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>John D. McCorvy</b> obtained his Ph.D. from the Department of Medicinal Chemistry and Molecular Pharmacology at Purdue University in 2012 and did his postdoctoral training at the University of North Carolina—Chapel Hill in the Department of Pharmacology. Currently he is a Principal Investigator at Medical College of Wisconsin in the Department of Cell Biology, Neurobiology, and Anatomy. His research focuses on structural determinants of GPCR activation that lead to biased signaling.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jianjun Cheng</b> obtained his Ph.D. in Medicinal Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in 2010 and received his postdoctoral training in the Department of Medicinal Chemistry and Pharmacognosy at University of Illinois at Chicago. He became a Principal Investigator, Research Associate Professor at iHuman Institute, ShanghaiTech University in 2016. His current research focuses on GPCR-targeted drug discovery, with special interests in biased ligands of GPCRs.</p></figure></div><div class="ack" id="ACK-d7e5176-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the Shanghai Municipal Government, ShanghaiTech University, and the National Natural Science Foundation of China (Grant 81703361 to J.C.) for financial support, and Dr. Raymond C. Stevens and Yekaterina Kadyshevskaya for their help in the preparation of Figure 2.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">5-HT<sub>1B</sub>R</td><td class="NLM_def"><p class="first last">serotonin 1B receptor</p></td></tr><tr><td class="NLM_term">5-HT<sub>2B</sub>R</td><td class="NLM_def"><p class="first last">serotonin 2B receptor</p></td></tr><tr><td class="NLM_term">5-HT<sub>2C</sub>R</td><td class="NLM_def"><p class="first last">serotonin 2C receptor</p></td></tr><tr><td class="NLM_term">7TMR</td><td class="NLM_def"><p class="first last">seven-transmembrane receptor</p></td></tr><tr><td class="NLM_term">A<sub>1</sub>AR</td><td class="NLM_def"><p class="first last">adenosine A<sub>1</sub> receptor</p></td></tr><tr><td class="NLM_term">A<sub>2A</sub>AR</td><td class="NLM_def"><p class="first last">adenosine A<sub>2A</sub> receptor</p></td></tr><tr><td class="NLM_term">A<sub>2B</sub>AR</td><td class="NLM_def"><p class="first last">adenosine A<sub>2B</sub> receptor</p></td></tr><tr><td class="NLM_term">A<sub>3</sub>AR</td><td class="NLM_def"><p class="first last">adenosine A<sub>3</sub> receptor</p></td></tr><tr><td class="NLM_term">AEA</td><td class="NLM_def"><p class="first last">anandamide</p></td></tr><tr><td class="NLM_term">AHF</td><td class="NLM_def"><p class="first last">acute heart failure</p></td></tr><tr><td class="NLM_term">AMPH</td><td class="NLM_def"><p class="first last">amphetamine</p></td></tr><tr><td class="NLM_term">APJ</td><td class="NLM_def"><p class="first last">apelin receptor</p></td></tr><tr><td class="NLM_term">ARB</td><td class="NLM_def"><p class="first last">angiotensin receptor blocker</p></td></tr><tr><td class="NLM_term">AT<sub>1</sub>R</td><td class="NLM_def"><p class="first last">angiotensin II receptor type 1</p></td></tr><tr><td class="NLM_term">β<sub>2</sub>AR</td><td class="NLM_def"><p class="first last">β<sub>2</sub> adrenergic receptor</p></td></tr><tr><td class="NLM_term">BRET</td><td class="NLM_def"><p class="first last">bioluminescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CaSR</td><td class="NLM_def"><p class="first last">calcium-sensing receptor</p></td></tr><tr><td class="NLM_term">CBD</td><td class="NLM_def"><p class="first last">canabidiol</p></td></tr><tr><td class="NLM_term">CB<sub>1</sub>R</td><td class="NLM_def"><p class="first last">cannabinoid receptor 1</p></td></tr><tr><td class="NLM_term">CB<sub>2</sub>R</td><td class="NLM_def"><p class="first last">cannabinoid receptor 2</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">D<sub>1</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>1</sub> receptor</p></td></tr><tr><td class="NLM_term">D<sub>2</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>2</sub> receptor</p></td></tr><tr><td class="NLM_term">DAP</td><td class="NLM_def"><p class="first last">disubstituted aromatic piperazine</p></td></tr><tr><td class="NLM_term">DOR</td><td class="NLM_def"><p class="first last">δ opioid receptor</p></td></tr><tr><td class="NLM_term">EL</td><td class="NLM_def"><p class="first last">extracellular loop</p></td></tr><tr><td class="NLM_term">EP<sub>2</sub>R</td><td class="NLM_def"><p class="first last">prostaglandin E2 receptor 2</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">ET<sub>A</sub></td><td class="NLM_def"><p class="first last">endothelin A receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">FPR2</td><td class="NLM_def"><p class="first last">formyl peptide receptor 2</p></td></tr><tr><td class="NLM_term">GABA</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid</p></td></tr><tr><td class="NLM_term">GFP</td><td class="NLM_def"><p class="first last">green fluorescent protein</p></td></tr><tr><td class="NLM_term">GLP-1R</td><td class="NLM_def"><p class="first last">glucagon-like peptide 1 receptor</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">GRK</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor kinase</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine 5′-triphosphate</p></td></tr><tr><td class="NLM_term">GTPγS</td><td class="NLM_def"><p class="first last">guanosine 5′-<i>O</i>-[γ-thio]triphosphate</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>R</td><td class="NLM_def"><p class="first last">histamine H<sub>2</sub> receptor</p></td></tr><tr><td class="NLM_term">H<sub>4</sub>R</td><td class="NLM_def"><p class="first last">histamine H<sub>4</sub> receptor</p></td></tr><tr><td class="NLM_term">HCS</td><td class="NLM_def"><p class="first last">high-content screening</p></td></tr><tr><td class="NLM_term">HDL</td><td class="NLM_def"><p class="first last">high-density lipoprotein</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">IP<sub>1</sub></td><td class="NLM_def"><p class="first last">inositol monophosphate</p></td></tr><tr><td class="NLM_term">mGluR</td><td class="NLM_def"><p class="first last">metabotropic glutamate receptor</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinases</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">μ opioid receptor</p></td></tr><tr><td class="NLM_term">MPEP</td><td class="NLM_def"><p class="first last">2-methyl-6-(phenylethynyl)pyridine</p></td></tr><tr><td class="NLM_term">KOR</td><td class="NLM_def"><p class="first last">κ opioid receptor</p></td></tr><tr><td class="NLM_term">NAM</td><td class="NLM_def"><p class="first last">negative allosteric modulator</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NOPR</td><td class="NLM_def"><p class="first last">nociception receptor</p></td></tr><tr><td class="NLM_term">NT<sub>1</sub>R</td><td class="NLM_def"><p class="first last">neurotensin receptor type 1</p></td></tr><tr><td class="NLM_term">PAH</td><td class="NLM_def"><p class="first last">pulmonary arterial hypertension</p></td></tr><tr><td class="NLM_term">PAM</td><td class="NLM_def"><p class="first last">positive allosteric modulator</p></td></tr><tr><td class="NLM_term">PCP</td><td class="NLM_def"><p class="first last">phencyclidine</p></td></tr><tr><td class="NLM_term">PGE<sub>2</sub></td><td class="NLM_def"><p class="first last">prostaglandin E<sub>2</sub></p></td></tr><tr><td class="NLM_term">PTHR<sub>1</sub></td><td class="NLM_def"><p class="first last">parathyroid hormone 1 receptor</p></td></tr><tr><td class="NLM_term">S1P<sub>1</sub>R</td><td class="NLM_def"><p class="first last">sphingosine 1-phosphate receptor 1</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SFSR</td><td class="NLM_def"><p class="first last">structure–functional selectivity relationship</p></td></tr><tr><td class="NLM_term">THC</td><td class="NLM_def"><p class="first last">tetrahydrocannabinol</p></td></tr><tr><td class="NLM_term">T2D</td><td class="NLM_def"><p class="first last">type 2 diabetes</p></td></tr><tr><td class="NLM_term">VFD</td><td class="NLM_def"><p class="first last">Venus flytrap domain.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64750" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64750" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 200 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural diversity of G protein-coupled receptors and significance for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstromauthor=H.+B.+Schioth&title=Structural+diversity+of+G+protein-coupled+receptors+and+significance+for+drug+discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2eakhW9pgXvcOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520diversity%2520of%2520G%2520protein-coupled%2520receptors%2520and%2520significance%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1124/mol.63.6.1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.63.6.1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=12761335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1256-1272&author=R.+Fredrikssonauthor=M.+C.+Lagerstromauthor=L.+G.+Lundinauthor=H.+B.+Schioth&title=The+G-protein-coupled+receptors+in+the+human+genome+form+five+main+families.+Phylogenetic+analysis%2C+paralogon+groups%2C+and+fingerprints&doi=10.1124%2Fmol.63.6.1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span></div><div class="casAuthors">Fredriksson, Robert; Lagerstrom, Malin C.; Lundin, Lars-Gustav; Schioth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1256-1272</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The superfamily of G-protein-coupled receptors (GPCRs) is very diverse in structure and function and its members are among the most pursued targets for drug development.  We identified more than 800 human GPCR sequences and simultaneously analyzed 342 unique functional nonolfactory human GPCR sequences with phylogenetic analyses.  Our results show, with high bootstrap support, five main families, named glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin, forming the GRAFS classification system.  The rhodopsin family is the largest and forms four main groups with 13 subbranches.  Positions of the GPCRs in chromosomal paralogons regions indicate the importance of tetraploidizations or local gene duplication events for their creation.  We also searched for "fingerprint" motifs using Hidden Markov Models delineating the putative inter-relationship of the GRAFS families.  We show several common structural features indicating that the human GPCRs in the GRAFS families share a common ancestor.  This study represents the first overall map of the GPCRs in a single mammalian genome.  Our novel approach of analyzing such large and diverse sequence sets may be useful for studies on GPCRs in other genomes and divergent protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdX4VhTsaDzrVg90H21EOLACvtfcHk0lhYt0_skJ-1yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D&md5=504ea873ee8469cd0b6016bc94943836</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fmol.63.6.1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.63.6.1256%26sid%3Dliteratum%253Aachs%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DLundin%26aufirst%3DL.%2BG.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DThe%2520G-protein-coupled%2520receptors%2520in%2520the%2520human%2520genome%2520form%2520five%2520main%2520families.%2520Phylogenetic%2520analysis%252C%2520paralogon%2520groups%252C%2520and%2520fingerprints%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D63%26spage%3D1256%26epage%3D1272%26doi%3D10.1124%2Fmol.63.6.1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuthrich, K.</span></span> <span> </span><span class="NLM_article-title">The GPCR network: a large-scale collaboration to determine human GPCR structure and function</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd3859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd3859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23237917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=25-34&author=R.+C.+Stevensauthor=V.+Cherezovauthor=V.+Katritchauthor=R.+Abagyanauthor=P.+Kuhnauthor=H.+Rosenauthor=K.+Wuthrich&title=The+GPCR+network%3A+a+large-scale+collaboration+to+determine+human+GPCR+structure+and+function&doi=10.1038%2Fnrd3859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The GPCR Network: a large-scale collaboration to determine human GPCR structure and function</span></div><div class="casAuthors">Stevens, Raymond C.; Cherezov, Vadim; Katritch, Vsevolod; Abagyan, Ruben; Kuhn, Peter; Rosen, Hugh; Wuethrich, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are targeted by ∼30-40% of marketed drugs, and their key roles in normal physiol. and in disease demonstrate that an understanding of their structure and function is valuable to researchers in both basic science and drug discovery.  However, until recently, detailed structural information on this protein family was limited by challenges in X-ray crystallog. anal. of such membrane proteins.  The GPCR Network was created in 2010 with the goal of structurally characterizing 15-25 representative human GPCRs within 5 years, based on an active outreach program addressing an interdisciplinary community of scientists interested in GPCR structure, chem. and biol.  Here, we provide an overview of how this collaborative effort has enabled the structural detn. and characterization of eight human GPCRs so far, and discuss some of the challenges that remain in gaining more detailed insights into structure-function relationships in this receptor superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBDUU5HjYCg7Vg90H21EOLACvtfcHk0lhYt0_skJ-1yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI&md5=8c303038034b529c6efd3492716fad19</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3859%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DWuthrich%26aufirst%3DK.%26atitle%3DThe%2520GPCR%2520network%253A%2520a%2520large-scale%2520collaboration%2520to%2520determine%2520human%2520GPCR%2520structure%2520and%2520function%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D25%26epage%3D34%26doi%3D10.1038%2Fnrd3859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0lglXiaF_Ikf8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR drug discovery: new agents, targets and indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schiothauthor=D.+E.+Gloriam&title=Trends+in+GPCR+drug+discovery%3A+new+agents%2C+targets+and+indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (∼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which ∼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0lglXiaF_Ikf8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520drug%2520discovery%253A%2520new%2520agents%252C%2520targets%2520and%2520indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.010909.105800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1146%2Fannurev.pharmtox.010909.105800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21942629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=179-197&author=E.+Reiterauthor=S.+Ahnauthor=A.+K.+Shuklaauthor=R.+J.+Lefkowitz&title=Molecular+mechanism+of+%CE%B2-arrestin-biased+agonism+at+seven-transmembrane+receptors&doi=10.1146%2Fannurev.pharmtox.010909.105800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors</span></div><div class="casAuthors">Reiter, Eric; Ahn, Seungkirl; Shukla, Arun K.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-197</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The concept of biased agonism has recently come to the fore with the realization that seven-transmembrane receptors (7TMRs, also known as G protein-coupled receptors, or GPCRs) activate complex signaling networks and can adopt multiple active conformations upon agonist binding.  As a consequence, the "efficacy" of receptors, which was classically considered linear, is now recognized as pluridimensional.  Biased agonists selectively stabilize only a subset of receptor conformations induced by the natural "unbiased" ligand, thus preferentially activating certain signaling mechanisms.  Such agonists thus reveal the intriguing possibility that one can direct cellular signaling with unprecedented precision and specificity and support the notion that biased agonists may identify new classes of therapeutic agents that have fewer side effects.  This review focuses on one particular class of biased ligands that has the ability to alter the balance between G protein-dependent and β-arrestin-dependent signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-dMKnViGurVg90H21EOLACvtfcHk0lh2x6IrVsteXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D&md5=05065a33108ddeebc36923b3cc821037</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.010909.105800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.010909.105800%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520mechanism%2520of%2520%25CE%25B2-arrestin-biased%2520agonism%2520at%2520seven-transmembrane%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2012%26volume%3D52%26spage%3D179%26epage%3D197%26doi%3D10.1146%2Fannurev.pharmtox.010909.105800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Teaching old receptors new tricks: biasing seven-transmembrane receptors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1038/nrd3024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd3024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20431569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=373-386&author=S.+Rajagopalauthor=K.+Rajagopalauthor=R.+J.+Lefkowitz&title=Teaching+old+receptors+new+tricks%3A+biasing+seven-transmembrane+receptors&doi=10.1038%2Fnrd3024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Teaching old receptors new tricks: biasing seven-transmembrane receptors</span></div><div class="casAuthors">Rajagopal, Sudarshan; Rajagopal, Keshava; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-386</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Seven-transmembrane receptors (7TMRs; also known as G protein-coupled receptors) are the largest class of receptors in the human genome and are common targets for therapeutics.  Originally identified as mediators of 7TMR desensitization, β-arrestins (arrestin 2 and arrestin 3) are now recognized as true adaptor proteins that transduce signals to multiple effector pathways.  Signaling that is mediated by β-arrestins has distinct biochem. and functional consequences from those mediated by G proteins, and several biased ligands and receptors have been identified that preferentially signal through either G protein- or β-arrestin-mediated pathways.  These ligands are not only useful tools for investigating the biochem. of 7TMR signaling, but they also have the potential to be developed into new classes of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuN6jivmOErVg90H21EOLACvtfcHk0lh2x6IrVsteXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWjs7k%253D&md5=ff525016c0ba5aa0ebc4ed86f87594d0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd3024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3024%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DRajagopal%26aufirst%3DK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DTeaching%2520old%2520receptors%2520new%2520tricks%253A%2520biasing%2520seven-transmembrane%2520receptors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D373%26epage%3D386%26doi%3D10.1038%2Fnrd3024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, G. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struts, A. V.</span></span> <span> </span><span class="NLM_article-title">Retinal dynamics during light activation of rhodopsin revealed by solid-state NMR spectroscopy</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1798</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2009.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bbamem.2009.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=19716801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1798&publication_year=2010&pages=177-193&author=M.+F.+Brownauthor=G.+F.+J.+Salgadoauthor=A.+V.+Struts&title=Retinal+dynamics+during+light+activation+of+rhodopsin+revealed+by+solid-state+NMR+spectroscopy&doi=10.1016%2Fj.bbamem.2009.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal dynamics during light activation of rhodopsin revealed by solid-state NMR spectroscopy</span></div><div class="casAuthors">Brown, Michael F.; Salgado, Gilmar F. J.; Struts, Andrey V.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1798</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-193</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Rhodopsin (I) is a canonical member of class A of the G protein-coupled receptors (GPCRs) that are implicated in many of the drug interventions in humans and are of great pharmaceutical interest.  The mol. mechanism of I activation remains unknown as atomistic structural information for the active metarhodopsin II state is currently lacking.  Solid-state 2H NMR constitutes a powerful approach to study at.-level dynamics of membrane proteins.  In the present application, the authors describe how information is obtained about interactions of the retinal cofactor with I that change with light activation of the photoreceptor.  The retinal Me groups play an important role in I function by directing conformational changes upon transition into the active state.  Site-specific 2H labels have been introduced into the Me groups of retinal and solid-state 2H NMR methods applied to obtain order parameters and correlation times that quantify the mobility of the cofactor in the inactive dark state, as well as the cryotrapped metarhodopsin I and metarhodopsin II states.  Anal. of the angular-dependent 2H NMR line shapes for selectively deuterated Me groups of I in aligned membranes enables detn. of the av. ligand conformation within the binding pocket.  The relaxation data suggest that the β-ionone ring is not expelled from its hydrophobic pocket in the transition from the pre-activated metarhodopsin I to the active metarhodopsin II state.  Rather, the major structural changes of the retinal cofactor occur already at the metarhodopsin I state in the activation process.  The metarhodopsin I to metarhodopsin II transition involves mainly conformational changes of the protein within the membrane lipid bilayer rather than the ligand.  The dynamics of the retinylidene Me groups upon isomerization are explained by an activation mechanism involving cooperative rearrangements of extracellular loop E2 together with transmembrane helixes H5 and H6.  These activating movements are triggered by steric clashes of the isomerized all-trans retinal with the β4 strand of the E2 loop and the side-chains of Glu-122 and Trp-265 within the binding pocket.  The solid-state 2H NMR data are discussed with regard to the pathway of the energy flow in the receptor activation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvC-879pt3bVg90H21EOLACvtfcHk0lh2x6IrVsteXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGksro%253D&md5=99ce51bdee9eb0eac44f493200f1c675</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2009.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2009.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DSalgado%26aufirst%3DG.%2BF.%2BJ.%26aulast%3DStruts%26aufirst%3DA.%2BV.%26atitle%3DRetinal%2520dynamics%2520during%2520light%2520activation%2520of%2520rhodopsin%2520revealed%2520by%2520solid-state%2520NMR%2520spectroscopy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2010%26volume%3D1798%26spage%3D177%26epage%3D193%26doi%3D10.1016%2Fj.bbamem.2009.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span> <span> </span><span class="NLM_article-title">Agonist-receptor efficacy II: agonist trafficking of receptor signals</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(00)89032-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2FS0165-6147%2800%2989032-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=232-238&author=T.+Kenakin&title=Agonist-receptor+efficacy+II%3A+agonist+trafficking+of+receptor+signals&doi=10.1016%2FS0165-6147%2800%2989032-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2800%2989032-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252800%252989032-X%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DAgonist-receptor%2520efficacy%2520II%253A%2520agonist%2520trafficking%2520of%2520receptor%2520signals%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1995%26volume%3D16%26spage%3D232%26epage%3D238%26doi%3D10.1016%2FS0165-6147%2800%2989032-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spedding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailman, R. B.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity and classical concepts of quantitative pharmacology</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.104463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.106.104463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=16803859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=1-13&author=J.+D.+Urbanauthor=W.+P.+Clarkeauthor=M.+von+Zastrowauthor=D.+E.+Nicholsauthor=B.+Kobilkaauthor=H.+Weinsteinauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=A.+Christopoulosauthor=P.+M.+Sextonauthor=K.+J.+Millerauthor=M.+Speddingauthor=R.+B.+Mailman&title=Functional+selectivity+and+classical+concepts+of+quantitative+pharmacology&doi=10.1124%2Fjpet.106.104463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and classical concepts of quantitative pharmacology</span></div><div class="casAuthors">Urban, Jonathan D.; Clarke, William P.; von Zastrow, Mark; Nichols, David E.; Kobilka, Brian; Weinstein, Harel; Javitch, Jonathan A.; Roth, Bryan L.; Christopoulos, Arthur; Sexton, Patrick M.; Miller, Keith J.; Spedding, Michael; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The concept of intrinsic efficacy has been enshrined in pharmacol. for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy.  Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism.  At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor.  Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems.  A variety of mechanisms may influence this apparently ubiquitous phenomenon.  It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the β2-adrenergic receptor.  Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers.  Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism).  Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action.  It also may be timely to revise classic concepts in quant. pharmacol. and relevant pharmacol. conventions to incorporate these new concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GzdtvWZRkbVg90H21EOLACvtfcHk0lj6c8fSCqyAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D&md5=54465473b5996d0755baeee89eeb0ba9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.104463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.104463%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520and%2520classical%2520concepts%2520of%2520quantitative%2520pharmacology%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D1%26epage%3D13%26doi%3D10.1124%2Fjpet.106.104463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. S. H.</span></span> <span> </span><span class="NLM_article-title">Ensemble of G protein-coupled receptor active states</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1146</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.2174/092986712799320619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.2174%2F092986712799320619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22300048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Kktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1146-1154&author=P.+S.+H.+Park&title=Ensemble+of+G+protein-coupled+receptor+active+states&doi=10.2174%2F092986712799320619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ensemble of G protein-coupled receptor active states</span></div><div class="casAuthors">Park, P. S.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1146-1154</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) play crit. roles in cellular signal transduction and are important targets for therapeutics.  Although these receptors have been intensely studied for quite some time, our understanding about their mechanism of action is still incomplete.  GPCR activity has traditionally been viewed within the context of two-state models where the receptor is in equil. between a single inactive state and a single active state.  This framework is too simple and restrictive to accommodate more recent observations made on these receptors, which instead point to a situation where the receptor can adopt several different active conformational substates with distinct functional effects.  Structural and functional evidence for this emerging view is presented in this review.  Implications of this emerging view in rationalizing diseased states and in drug discovery are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptjXS9j8v_aLVg90H21EOLACvtfcHk0lj6c8fSCqyAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Kktrw%253D&md5=12f9384c6b98cdcb3070e4e84aa7d172</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F092986712799320619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712799320619%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DP.%2BS.%2BH.%26atitle%3DEnsemble%2520of%2520G%2520protein-coupled%2520receptor%2520active%2520states%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D1146%26epage%3D1154%26doi%3D10.2174%2F092986712799320619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+bias+in+new+drug+discovery%3A+detection%2C+quantification+and+therapeutic+impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0lj6c8fSCqyAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520bias%2520in%2520new%2520drug%2520discovery%253A%2520detection%252C%2520quantification%2520and%2520therapeutic%2520impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1330</span>, <span class="refDoi"> DOI: 10.1002/med.21318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmed.21318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24796277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1286-1330&author=J.+Shonbergauthor=L.+Lopezauthor=P.+J.+Scammellsauthor=A.+Christopoulosauthor=B.+Capuanoauthor=J.+R.+Lane&title=Biased+agonism+at+G+protein-coupled+receptors%3A+the+promise+and+the+challenges%2D%2Da+medicinal+chemistry+perspective&doi=10.1002%2Fmed.21318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Agonism at G Protein-Coupled Receptors: The Promise and the Challenges-A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Shonberg, Jeremy; Lopez, Laura; Scammells, Peter J.; Christopoulos, Arthur; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1286-1330</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Historically, detn. of G protein-coupled receptor (GPCR) ligand efficacy has often been restricted to identifying the ligand as an agonist or antagonist at a given signaling pathway.  This classification was deemed sufficient to predict compd. efficacy at all signaling endpoints, including the therapeutically relevant one(s).  However, it is now apparent that ligands acting at the same GPCR can stabilize multiple, distinct, receptor conformations linked to different functional outcomes.  This phenomenon, known as biased agonism, stimulus bias, or functional selectivity offers the opportunity to sep. on-target therapeutic effects from side effects through the design of drugs that show pathway selectivity.  However, the medicinal chemist faces numerous challenges to develop biased ligands, including the detection and quantification of biased agonism.  This review summarizes the current state of the field of research into biased agonism at GPCRs, with a particular focus on efforts to relate biased agonism to ligand structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-egFZpSKvbVg90H21EOLACvtfcHk0ljAxAvgHs-uww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ&md5=85a5b385750d21856ae044391c46ee75</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fmed.21318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21318%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DBiased%2520agonism%2520at%2520G%2520protein-coupled%2520receptors%253A%2520the%2520promise%2520and%2520the%2520challenges--a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D1286%26epage%3D1330%26doi%3D10.1002%2Fmed.21318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span> <span> </span><span class="NLM_article-title">Biased ligands at G-protein-coupled receptors: promise and progress</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.tips.2014.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24878326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=308-316&author=J.+D.+Violinauthor=A.+L.+Crombieauthor=D.+G.+Soergelauthor=M.+W.+Lark&title=Biased+ligands+at+G-protein-coupled+receptors%3A+promise+and+progress&doi=10.1016%2Fj.tips.2014.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligands at G-protein-coupled receptors: promise and progress</span></div><div class="casAuthors">Violin, Jonathan D.; Crombie, Aimee L.; Soergel, David G.; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug discovery targeting G protein-coupled receptors (GPCRs) is no longer limited to seeking agonists or antagonists to stimulate or block cellular responses assocd. with a particular receptor.  GPCRs are now known to support a diversity of pharmacol. profiles, a concept broadly referred to as functional selectivity.  In particular, the concept of ligand bias, whereby a ligand stabilizes subsets of receptor conformations to engender novel pharmacol. profiles, has recently gained increasing prominence.  This review discusses how biased ligands may deliver safer, better tolerated, and more efficacious drugs, and highlights several biased ligands that are in clin. development.  Biased ligands targeting the angiotensin II type 1 receptor and the μ opioid receptor illustrate the translation of the biased ligand concept from basic biol. to clin. drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBma1S1zZ0-7Vg90H21EOLACvtfcHk0ljAxAvgHs-uww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D&md5=768953e7aa5726d1a47ecbdb068469d8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DBiased%2520ligands%2520at%2520G-protein-coupled%2520receptors%253A%2520promise%2520and%2520progress%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D308%26epage%3D316%26doi%3D10.1016%2Fj.tips.2014.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Correll, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span> <span> </span><span class="NLM_article-title">Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6887</span>– <span class="NLM_lpage">6896</span>, <span class="refDoi"> DOI: 10.1021/jm401677g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401677g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Crt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6887-6896&author=C.+C.+Correllauthor=B.+A.+McKittrick&title=Biased+ligand+modulation+of+seven+transmembrane+receptors+%287TMRs%29%3A+functional+implications+for+drug+discovery&doi=10.1021%2Fjm401677g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligand Modulation of Seven Transmembrane Receptors (7TMRs): Functional Implications for Drug Discovery</span></div><div class="casAuthors">Correll, Craig C.; McKittrick, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6887-6896</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Seven transmembrane receptors (7TMRs), also known as G-protein-coupled receptors (GPCRs), have proven to be valuable targets for the development of therapeutics.  The expansion of our understanding of 7TMR downstream signaling pathways beyond G-proteins has broadened our appreciation of the versatility of these cell surface receptors.  In particular, the increased awareness of 7TMR engagement of β-arrestin signaling has opened up addnl. avenues for drug discovery.  7TMRs can adopt different conformations and in response to various ligands can lead to a bias in downstream signaling mechanisms when comparing the overall efficacy between G-protein and β-arrestin dependent pathways.  In 2012, we organized a session at the Spring National Meeting of the American Chem. Society on biased signaling in 7TMRs.  Building on that experience, we provide in this Miniperspective some examples that exemplify developments in the area of biased 7TMR signaling and highlight some cautionary notes as well as some of the exciting opportunities for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKS2Tnu19QArVg90H21EOLACvtfcHk0ljAxAvgHs-uww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Crt7k%253D&md5=8fe16f8a57c68f2134ed15948ee67454</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm401677g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401677g%26sid%3Dliteratum%253Aachs%26aulast%3DCorrell%26aufirst%3DC.%2BC.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26atitle%3DBiased%2520ligand%2520modulation%2520of%2520seven%2520transmembrane%2520receptors%2520%25287TMRs%2529%253A%2520functional%2520implications%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6887%26epage%3D6896%26doi%3D10.1021%2Fjm401677g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Biased agonism: an emerging paradigm in GPCR drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmcl.2015.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26707396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKrur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=241-250&author=Z.+Rankovicauthor=T.+F.+Brustauthor=L.+M.+Bohn&title=Biased+agonism%3A+an+emerging+paradigm+in+GPCR+drug+discovery&doi=10.1016%2Fj.bmcl.2015.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Biased agonism: An emerging paradigm in GPCR drug discovery</span></div><div class="casAuthors">Rankovic, Zoran; Brust, Tarsis F.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-250</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein coupled receptors have historically been one of the most druggable classes of cellular proteins.  The members of this large receptor gene family couple to primary effectors, G proteins, that have built in mechanisms for regeneration and amplification of signaling with each engagement of receptor and ligand, a kinetic event in itself.  In recent years GPCRs, have been found to interact with arrestin proteins to initiate signal propagation in the absence of G protein interactions.  This pinnacle observation has changed a previously held notion of the linear spectrum of GPCR efficacy and uncovered a new paradigm in GPCR research and drug discovery that relies on multidimensionality of GPCR signaling.  Ligands were found that selectively confer activity in one pathway over another, and this phenomenon has been referred to as 'biased agonism' or 'functional selectivity'.  While great strides in the understanding of this phenomenon have been made in recent years, two crit. questions still dominate the field: How can we rationally design biased GPCR ligands, and ultimately, which physiol. responses are due to G protein vs. arrestin interactions.  This review will discuss the current understanding of some of the key aspects of biased signaling that are related to these questions, including mechanistic insights in the nature of biased signaling and methods for measuring ligand bias, as well as relevant examples of drug discovery applications and medicinal chem. strategies that highlight the challenges and opportunities in this rapidly evolving field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3Aj3zqZmKLVg90H21EOLACvtfcHk0liQdiShQh1ApQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKrur%252FL&md5=2e8612099c46749d9ce52b49086a8ef8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DBrust%26aufirst%3DT.%2BF.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBiased%2520agonism%253A%2520an%2520emerging%2520paradigm%2520in%2520GPCR%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D241%26epage%3D250%26doi%3D10.1016%2Fj.bmcl.2015.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bologna, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span> <span> </span><span class="NLM_article-title">Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2016.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.4062%2Fbiomolther.2016.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=12-25&author=Z.+Bolognaauthor=J.+P.+Teohauthor=A.+S.+Bayoumiauthor=Y.+Tangauthor=I.+M.+Kim&title=Biased+G+protein-coupled+receptor+signaling%3A+new+player+in+modulating+physiology+and+pathology&doi=10.4062%2Fbiomolther.2016.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology</span></div><div class="casAuthors">Bologna Zuzana; Teoh Jian-Peng; Bayoumi Ahmed S; Tang Yaoliang; Kim Il-Man; Kim Il-Man</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-25</span>
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are a family of cell-surface proteins that play critical roles in regulating a variety of pathophysiological processes and thus are targeted by almost a third of currently available therapeutics.  It was originally thought that GPCRs convert extracellular stimuli into intracellular signals through activating G proteins, whereas β-arrestins have important roles in internalization and desensitization of the receptor.  Over the past decade, several novel functional aspects of β-arrestins in regulating GPCR signaling have been discovered.  These previously unanticipated roles of β-arrestins to act as signal transducers and mediators of G protein-independent signaling have led to the concept of biased agonism.  Biased GPCR ligands are able to engage with their target receptors in a manner that preferentially activates only G protein- or β-arrestin-mediated downstream signaling.  This offers the potential for next generation drugs with high selectivity to therapeutically relevant GPCR signaling pathways.  In this review, we provide a summary of the recent studies highlighting G protein- or β-arrestin-biased GPCR signaling and the effects of biased ligands on disease pathogenesis and regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRshPzvVvIEzJVVjGoY74BafW6udTcc2eb7qiPIo8if4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D&md5=7cfe8440b5d4e23b6c94d450662e8e54</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2016.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2016.165%26sid%3Dliteratum%253Aachs%26aulast%3DBologna%26aufirst%3DZ.%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DBayoumi%26aufirst%3DA.%2BS.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DI.%2BM.%26atitle%3DBiased%2520G%2520protein-coupled%2520receptor%2520signaling%253A%2520new%2520player%2520in%2520modulating%2520physiology%2520and%2520pathology%26jtitle%3DBiomol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D12%26epage%3D25%26doi%3D10.4062%2Fbiomolther.2016.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure-function of the G protein-coupled receptor superfamily</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-032112-135923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1146%2Fannurev-pharmtox-032112-135923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23140243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1Wgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=531-556&author=V.+Katritchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure-function+of+the+G+protein-coupled+receptor+superfamily&doi=10.1146%2Fannurev-pharmtox-032112-135923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function of the G protein-coupled receptor superfamily</span></div><div class="casAuthors">Katritch, Vsevolod; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">531-556</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  During the past few years, crystallog. of G protein-coupled receptors (GPCRs) has experienced exponential growth, resulting in the detn. of the structures of 16 distinct receptors-9 of them in 2012 alone.  Including closely related subtype homol. models, this coverage amts. to approx. 12% of the human GPCR superfamily.  The adrenergic, rhodopsin, and adenosine receptor systems are also described by agonist-bound active-state structures, including a structure of the receptor-G protein complex for the β2-adrenergic receptor.  Biochem. and biophys. techniques, such as NMR and hydrogen-deuterium exchange coupled with mass spectrometry, are providing complementary insights into ligand-dependent dynamic equil. between different functional states.  Addnl. details revealed by high-resoln. structures illustrate the receptors as allosteric machines that are controlled not only by ligands but also by ions, lipids, cholesterol, and water.  This wealth of data is helping redefine the authors' knowledge of how GPCRs recognize such a diverse array of ligands and how they transmit signals 30 angstroms across the cell membrane; it also is shedding light on a structural basis of GPCR allosteric modulation and biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUVW-rEZbvrVg90H21EOLACvtfcHk0liQdiShQh1ApQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1Wgurc%253D&md5=5e8c26100a9eb33a32755af09199138d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-032112-135923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-032112-135923%26sid%3Dliteratum%253Aachs%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure-function%2520of%2520the%2520G%2520protein-coupled%2520receptor%2520superfamily%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D53%26spage%3D531%26epage%3D556%26doi%3D10.1146%2Fannurev-pharmtox-032112-135923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Seven-transmembrane-spanning receptors and heart function</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1038/415206a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2F415206a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2002&pages=206-212&author=H.+A.+Rockmanauthor=W.+J.+Kochauthor=R.+J.+Lefkowitz&title=Seven-transmembrane-spanning+receptors+and+heart+function&doi=10.1038%2F415206a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F415206a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F415206a%26sid%3Dliteratum%253Aachs%26aulast%3DRockman%26aufirst%3DH.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSeven-transmembrane-spanning%2520receptors%2520and%2520heart%2520function%26jtitle%3DNature%26date%3D2002%26volume%3D415%26spage%3D206%26epage%3D212%26doi%3D10.1038%2F415206a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burghammer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnala, V. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanishvili, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischetti, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schertler, G. F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human β<sub>2</sub> adrenergic G-protein-coupled receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/nature06325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature06325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=17952055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=383-387&author=S.+G.+F.+Rasmussenauthor=H.+J.+Choiauthor=D.+M.+Rosenbaumauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=P.+C.+Edwardsauthor=M.+Burghammerauthor=V.+R.+P.+Ratnalaauthor=R.+Sanishviliauthor=R.+F.+Fischettiauthor=G.+F.+X.+Schertlerauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+human+%CE%B22+adrenergic+G-protein-coupled+receptor&doi=10.1038%2Fnature06325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human β2 adrenergic G-protein-coupled receptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Rosenbaum, Daniel M.; Kobilka, Tong Sun; Thian, Foon Sun; Edwards, Patricia C.; Burghammer, Manfred; Ratnala, Venkata R. P.; Sanishvili, Ruslan; Fischetti, Robert F.; Schertler, Gebhard F. X.; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7168</span>),
    <span class="NLM_cas:pages">383-387</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Structural anal. of G-protein-coupled receptors (GPCRs) for hormones and neurotransmitters has been hindered by their low natural abundance, inherent structural flexibility, and instability in detergent solns.  Here we report a structure of the human β2 adrenoceptor (β2AR), which was crystd. in a lipid environment when bound to an inverse agonist and in complex with a Fab that binds to the third intracellular loop.  Diffraction data were obtained by high-brilliance microcrystallog. and the structure detd. at 3.4 Å/3.7 Å resoln.  The cytoplasmic ends of the β2AR transmembrane segments and the connecting loops are well resolved, whereas the extracellular regions of the β2AR are not seen.  The β2AR structure differs from rhodopsin in having weaker interactions between the cytoplasmic ends of transmembrane (TM)3 and TM6, involving the conserved E/DRY sequences.  These differences may be responsible for the relatively high basal activity and structural instability of the β2AR, and contribute to the challenges in obtaining diffraction-quality crystals of non-rhodopsin GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTx0B_3Vn2M7Vg90H21EOLACvtfcHk0lh8Ab9qKlmxDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N&md5=79026a0a69ddb4b0ea25063e409ad2cd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature06325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06325%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DBurghammer%26aufirst%3DM.%26aulast%3DRatnala%26aufirst%3DV.%2BR.%2BP.%26aulast%3DSanishvili%26aufirst%3DR.%26aulast%3DFischetti%26aufirst%3DR.%2BF.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520%25CE%25B22%2520adrenergic%2520G-protein-coupled%2520receptor%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D383%26epage%3D387%26doi%3D10.1038%2Fnature06325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">High-resolution crystal structure of an engineered human β<sub>2</sub>-adrenergic G protein-coupled receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1126/science.1150577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258-1265&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+F.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.+J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-resolution+crystal+structure+of+an+engineered+human+%CE%B22-adrenergic+G+protein-coupled+receptor&doi=10.1126%2Fscience.1150577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the β2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human β2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the β2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0lh8Ab9qKlmxDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520an%2520engineered%2520human%2520%25CE%25B22-adrenergic%2520G%2520protein-coupled%2520receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26epage%3D1265%26doi%3D10.1126%2Fscience.1150577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-biased agonism at the β<sub>2</sub>-adrenergic receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">5669</span>– <span class="NLM_lpage">5676</span>, <span class="refDoi"> DOI: 10.1074/jbc.M708118200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M708118200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=5669-5676&author=M.+T.+Drakeauthor=J.+D.+Violinauthor=E.+J.+Whalenauthor=J.+W.+Wislerauthor=S.+K.+Shenoyauthor=R.+J.+Lefkowitz&title=%CE%B2-Arrestin-biased+agonism+at+the+%CE%B22-adrenergic+receptor&doi=10.1074%2Fjbc.M708118200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708118200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708118200%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DM.%2BT.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DWisler%26aufirst%3DJ.%2BW.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3D%25CE%25B2-Arrestin-biased%2520agonism%2520at%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D5669%26epage%3D5676%26doi%3D10.1074%2Fjbc.M708118200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakaya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyanagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohdo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, H.</span></span> <span> </span><span class="NLM_article-title">Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent signaling pathways</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">35669</span>– <span class="NLM_lpage">35677</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.357871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M112.357871" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=35669-35677&author=M.+Nakayaauthor=S.+Chikuraauthor=K.+Watariauthor=N.+Mizunoauthor=K.+Mochinagaauthor=S.+Mangmoolauthor=S.+Koyanagiauthor=S.+Ohdoauthor=Y.+Satoauthor=T.+Ideauthor=M.+Nishidaauthor=H.+Kurose&title=Induction+of+cardiac+fibrosis+by+%CE%B2-blocker+in+G+protein-independent+and+G+protein-coupled+receptor+kinase+5%2F%CE%B2-arrestin2-dependent+signaling+pathways&doi=10.1074%2Fjbc.M112.357871"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.357871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.357871%26sid%3Dliteratum%253Aachs%26aulast%3DNakaya%26aufirst%3DM.%26aulast%3DChikura%26aufirst%3DS.%26aulast%3DWatari%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DN.%26aulast%3DMochinaga%26aufirst%3DK.%26aulast%3DMangmool%26aufirst%3DS.%26aulast%3DKoyanagi%26aufirst%3DS.%26aulast%3DOhdo%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DIde%26aufirst%3DT.%26aulast%3DNishida%26aufirst%3DM.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DInduction%2520of%2520cardiac%2520fibrosis%2520by%2520%25CE%25B2-blocker%2520in%2520G%2520protein-independent%2520and%2520G%2520protein-coupled%2520receptor%2520kinase%25205%252F%25CE%25B2-arrestin2-dependent%2520signaling%2520pathways%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D35669%26epage%3D35677%26doi%3D10.1074%2Fjbc.M112.357871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">14555</span>– <span class="NLM_lpage">14560</span>, <span class="refDoi"> DOI: 10.1073/pnas.0804745105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0804745105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=14555-14560&author=I.+M.+Kimauthor=D.+G.+Tilleyauthor=J.+Chenauthor=N.+C.+Salazarauthor=E.+J.+Whalenauthor=J.+D.+Violinauthor=H.+A.+Rockman&title=%CE%B2-Blockers+alprenolol+and+carvedilol+stimulate+%CE%B2-arrestin-mediated+EGFR+transactivation&doi=10.1073%2Fpnas.0804745105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0804745105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0804745105%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%2BM.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSalazar%26aufirst%3DN.%2BC.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-Blockers%2520alprenolol%2520and%2520carvedilol%2520stimulate%2520%25CE%25B2-arrestin-mediated%2520EGFR%2520transactivation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D14555%26epage%3D14560%26doi%3D10.1073%2Fpnas.0804745105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">16657</span>– <span class="NLM_lpage">16662</span>, <span class="refDoi"> DOI: 10.1073/pnas.0707936104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0707936104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=16657-16662&author=J.+W.+Wislerauthor=S.+M.+DeWireauthor=E.+J.+Whalenauthor=J.+D.+Violinauthor=M.+T.+Drakeauthor=S.+Ahnauthor=S.+K.+Shenoyauthor=R.+J.+Lefkowitz&title=A+unique+mechanism+of+%CE%B2-blocker+action%3A+carvedilol+stimulates+%CE%B2-arrestin+signaling&doi=10.1073%2Fpnas.0707936104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0707936104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0707936104%26sid%3Dliteratum%253Aachs%26aulast%3DWisler%26aufirst%3DJ.%2BW.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDrake%26aufirst%3DM.%2BT.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520unique%2520mechanism%2520of%2520%25CE%25B2-blocker%2520action%253A%2520carvedilol%2520stimulates%2520%25CE%25B2-arrestin%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D16657%26epage%3D16662%26doi%3D10.1073%2Fpnas.0707936104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohout, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineyro, G.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">11406</span>– <span class="NLM_lpage">11411</span>, <span class="refDoi"> DOI: 10.1073/pnas.1936664100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1936664100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11406-11411&author=M.+Azziauthor=P.+G.+Charestauthor=S.+Angersauthor=G.+Rousseauauthor=T.+Kohoutauthor=M.+Bouvierauthor=G.+Pineyro&title=%CE%B2-Arrestin-mediated+activation+of+MAPK+by+inverse+agonists+reveals+distinct+active+conformations+for+G+protein-coupled+receptors&doi=10.1073%2Fpnas.1936664100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1936664100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1936664100%26sid%3Dliteratum%253Aachs%26aulast%3DAzzi%26aufirst%3DM.%26aulast%3DCharest%26aufirst%3DP.%2BG.%26aulast%3DAngers%26aufirst%3DS.%26aulast%3DRousseau%26aufirst%3DG.%26aulast%3DKohout%26aufirst%3DT.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DPineyro%26aufirst%3DG.%26atitle%3D%25CE%25B2-Arrestin-mediated%2520activation%2520of%2520MAPK%2520by%2520inverse%2520agonists%2520reveals%2520distinct%2520active%2520conformations%2520for%2520G%2520protein-coupled%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D11406%26epage%3D11411%26doi%3D10.1073%2Fpnas.1936664100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuthrich, K.</span></span> <span> </span><span class="NLM_article-title">Biased signaling pathways in β<sub>2</sub>-adrenergic receptor characterized by <sup>19</sup>F-NMR</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">1106</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1126/science.1215802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1215802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22267580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGhtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2012&pages=1106-1110&author=J.+J.+Liuauthor=R.+Horstauthor=V.+Katritchauthor=R.+C.+Stevensauthor=K.+Wuthrich&title=Biased+signaling+pathways+in+%CE%B22-adrenergic+receptor+characterized+by+19F-NMR&doi=10.1126%2Fscience.1215802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR</span></div><div class="casAuthors">Liu, Jeffrey J.; Horst, Reto; Katritch, Vsevolod; Stevens, Raymond C.; Wuethrich, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">6072</span>),
    <span class="NLM_cas:pages">1106-1110</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Extracellular ligand binding to G protein-coupled receptors (GPCRs) modulates G protein and β-arrestin signaling by changing the conformational states of the cytoplasmic region of the receptor.  Using site-specific 19F-NMR (fluorine-19 NMR) labels in the β2-adrenergic receptor (β2AR) in complexes with various ligands, we obsd. that the cytoplasmic ends of helixes VI and VII adopt two major conformational states.  Changes in the NMR signals reveal that agonist binding primarily shifts the equil. toward the G protein-specific active state of helix VI.  In contrast, β-arrestin-biased ligands predominantly impact the conformational states of helix VII.  The selective effects of different ligands on the conformational equil. involving helixes VI and VII provide insights into the long-range structural plasticity of β2AR in partial and biased agonist signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5pzYJjjhMLVg90H21EOLACvtfcHk0lj_KYpIkcUmJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGhtrs%253D&md5=abae5755ddcacf42a029e7fd0dd4fdc9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.1215802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1215802%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DHorst%26aufirst%3DR.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWuthrich%26aufirst%3DK.%26atitle%3DBiased%2520signaling%2520pathways%2520in%2520%25CE%25B22-adrenergic%2520receptor%2520characterized%2520by%252019F-NMR%26jtitle%3DScience%26date%3D2012%26volume%3D335%26spage%3D1106%26epage%3D1110%26doi%3D10.1126%2Fscience.1215802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span> <span> </span><span class="NLM_article-title">Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.173005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.110.173005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20801892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=572-579&author=J.+D.+Violinauthor=S.+M.+DeWireauthor=D.+Yamashitaauthor=D.+H.+Romingerauthor=L.+Nguyenauthor=K.+Schillerauthor=E.+J.+Whalenauthor=M.+Gowenauthor=M.+W.+Lark&title=Selectively+engaging+%CE%B2-arrestins+at+the+angiotensin+II+type+1+receptor+reduces+blood+pressure+and+increases+cardiac+performance&doi=10.1124%2Fjpet.110.173005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance</span></div><div class="casAuthors">Violin, Jonathan D.; DeWire, Scott M.; Yamashita, Dennis; Rominger, David H.; Nguyen, Lisa; Schiller, Kevin; Whalen, Erin J.; Gowen, Maxine; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-579</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biased G protein-coupled ligands engage subsets of the receptor signals normally stimulated by unbiased agonists.  However, it is unclear whether ligand bias can elicit differentiated pharmacol. in vivo.  Here, we describe the discovery of a potent, selective β-arrestin biased ligand of the angiotensin II type 1 receptor.  TRV 120027 (Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH) competitively antagonizes angiotensin II-stimulated G protein signaling, but stimulates β-arrestin recruitment and activates several kinase pathways, including p42/44 mitogen-activated protein kinase, Src, and endothelial nitric-oxide synthase phosphorylation via β-arrestin coupling.  Consistent with β-arrestin efficacy, and unlike unbiased antagonists, TRV 120027 increased cardiomyocyte contractility in vitro.  In rats, TRV 120027 reduced mean arterial pressure, as did the unbiased antagonists losartan and telmisartan.  However, unlike the unbiased antagonists, which decreased cardiac performance, TRV 120027 increased cardiac performance and preserved cardiac stroke vol.  These striking differences in vivo between unbiased and β-arrestin biased ligands validate the use of biased ligands to selectively target specific receptor functions in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaaai_REGvbVg90H21EOLACvtfcHk0li8h1J_f_sw9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF&md5=a896363e71830f706b103d8153c97f83</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173005%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DGowen%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DSelectively%2520engaging%2520%25CE%25B2-arrestins%2520at%2520the%2520angiotensin%2520II%2520type%25201%2520receptor%2520reduces%2520blood%2520pressure%2520and%2520increases%2520cardiac%2520performance%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D572%26epage%3D579%26doi%3D10.1124%2Fjpet.110.173005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">10782</span>– <span class="NLM_lpage">10787</span>, <span class="refDoi"> DOI: 10.1073/pnas.1834556100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1834556100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=12949261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslyntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=10782-10787&author=H.+J.+Weiauthor=S.+Ahnauthor=S.+K.+Shenoyauthor=S.+S.+Karnikauthor=L.+Hunyadyauthor=L.+M.+Luttrellauthor=R.+J.+Lefkowitz&title=Independent+%CE%B2-arrestin+2+and+G+protein-mediated+pathways+for+angiotensin+II+activation+of+extracellular+signal-regulated+kinases+1+and+2&doi=10.1073%2Fpnas.1834556100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2</span></div><div class="casAuthors">Wei, Huijun; Ahn, Seungkirl; Shenoy, Sudha K.; Karnik, Sadashiva S.; Hunyady, Laszlo; Luttrell, Louis M.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10782-10787</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Stimulation of a mutant angiotensin type 1A receptor (DRY/AAY) with angiotensin II (Ang II) or of a wild-type receptor with an Ang II analog ([sarcosine1,Ile4,Ile8]Ang II) fails to activate classical heterotrimeric G protein signaling but does lead to recruitment of β-arrestin 2-GFP and activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (max. stimulation ≈50% of wild type).  This G protein-independent activation of mitogen-activated protein kinase is abolished by depletion of cellular β-arrestin 2 but is unaffected by the PKC inhibitor Ro-31-8425.  In parallel, stimulation of the wild-type angiotensin type 1A receptor with Ang II robustly stimulates ERK1/2 activation with ≈60% of the response blocked by the PKC inhibitor (G protein dependent) and the rest of the response blocked by depletion of cellular β-arrestin 2 by small interfering RNA (β-arrestin dependent).  These findings imply the existence of independent G protein- and β-arrestin 2-mediated pathways leading to ERK1/2 activation and the existence of distinct "active" conformations of a seven-membrane-spanning receptor coupled to each.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYG_kDWRPMAbVg90H21EOLACvtfcHk0li8h1J_f_sw9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslyntrk%253D&md5=48f0fc02a5f4f7e2616170788a26aa23</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1834556100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1834556100%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DH.%2BJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DHunyady%26aufirst%3DL.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DIndependent%2520%25CE%25B2-arrestin%25202%2520and%2520G%2520protein-mediated%2520pathways%2520for%2520angiotensin%2520II%2520activation%2520of%2520extracellular%2520signal-regulated%2520kinases%25201%2520and%25202%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D10782%26epage%3D10787%26doi%3D10.1073%2Fpnas.1834556100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teerlink, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharucha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felker, G. M.</span></span> <span> </span><span class="NLM_article-title">Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2364</span>– <span class="NLM_lpage">2373</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehx196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1093%2Feurheartj%2Fehx196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28459958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFGksbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=2364-2373&author=P.+S.+Pangauthor=J.+Butlerauthor=S.+P.+Collinsauthor=G.+Cotterauthor=B.+A.+Davisonauthor=J.+A.+Ezekowitzauthor=G.+Filippatosauthor=P.+D.+Levyauthor=M.+Metraauthor=P.+Ponikowskiauthor=J.+R.+Teerlinkauthor=A.+A.+Voorsauthor=D.+Bharuchaauthor=K.+Goinauthor=D.+G.+Soergelauthor=G.+M.+Felker&title=Biased+ligand+of+the+angiotensin+II+type+1+receptor+in+patients+with+acute+heart+failure%3A+a+randomized%2C+double-blind%2C+placebo-controlled%2C+phase+IIB%2C+dose+ranging+trial+%28BLAST-AHF%29&doi=10.1093%2Feurheartj%2Fehx196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)</span></div><div class="casAuthors">Pang, Peter S.; Butler, Javed; Collins, Sean P.; Cotter, Gad; Davison, Beth A.; Ezekowitz, Justin A.; Filippatos, Gerasimos; Levy, Phillip D.; Metra, Marco; Ponikowski, Piotr; Teerlink, John R.; Voors, Adriaan A.; Bharucha, David; Goin, Kathleen; Soergel, David G.; Michael Felker, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">2364-2373</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">1522-9645</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Currently, no acute heart failure (AHF) therapy definitively improves outcomes.  Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need.  TRV027 is a novel 'biased' ligand of the angiotensin II type 1 receptor (AT1R), selectively antagonizing the neg. effects of angiotensin II, while preserving the potential procontractility effects of AT1R stimulation.  BLAST-AHF was designed to det. the safety, efficacy, and opti- mal dose of TRV027 to advance into future studies.  Methods and results: BLAST-AHF was a multi-center, international, randomized, double-blind, placebo-controlled, parallel group, phase IIb dose-ranging study, enrolling patients with AHF into 4 groups: placebo, 1, 5, or 25 mg/h of TRV027.  Treatment was by IV infusion for 48-96 h.  The primary composite endpoint was comprised of the following: (i) time from baseline to death through day 30, (ii) time from baseline to heart failure re-hospitalization through day 30, (iii) the first assessment time point following worsening heart failure through day 5, (iv) change in dyspnea visual analog scale (VAS) score calcd. as the area under the curve (AUC) representing the change from baseline over time from baseline through day 5, and (v) length of initial hospital stay (in days) from baseline.  Analyses were by modified intention-to-treat.  Overall, 621 patients were enrolled.  After 254 patients, a pre-specified interim anal. resulted in several protocol changes, including a lower blood pressure inclusion criterion as well as a new allocation scheme of 2:1:2:1, overweighting both placebo, and the 5 mg/h dose.  TRV027 did not confer any benefit over placebo at any dose with regards to the primary composite endpoint or any of the individual components.  There were no significant safety issues with TRV027.  Conclusion: In this phase IIb dose-ranging AHF study, TRV027 did not improve clin. status through 30-day follow-up compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogmz48ioAiJ7Vg90H21EOLACvtfcHk0li8h1J_f_sw9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFGksbvO&md5=62e28c6fa244809d87e52d8f979ce629</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehx196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehx196%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DS.%2BP.%26aulast%3DCotter%26aufirst%3DG.%26aulast%3DDavison%26aufirst%3DB.%2BA.%26aulast%3DEzekowitz%26aufirst%3DJ.%2BA.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLevy%26aufirst%3DP.%2BD.%26aulast%3DMetra%26aufirst%3DM.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DTeerlink%26aufirst%3DJ.%2BR.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DBharucha%26aufirst%3DD.%26aulast%3DGoin%26aufirst%3DK.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DFelker%26aufirst%3DG.%2BM.%26atitle%3DBiased%2520ligand%2520of%2520the%2520angiotensin%2520II%2520type%25201%2520receptor%2520in%2520patients%2520with%2520acute%2520heart%2520failure%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%2520IIB%252C%2520dose%2520ranging%2520trial%2520%2528BLAST-AHF%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2017%26volume%3D38%26spage%3D2364%26epage%3D2373%26doi%3D10.1093%2Feurheartj%2Fehx196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, P. P.</span></span> <span> </span><span class="NLM_article-title">Relationship between improvements in long term outcomes and baseline systolic blood pressure in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">Suppl. S1</span>),  <span class="NLM_fpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=36&issue=Suppl.+S1&author=G.+Cotterauthor=P.+P.+Pang&title=Relationship+between+improvements+in+long+term+outcomes+and+baseline+systolic+blood+pressure+in+acute+heart+failure+patients+treated+with+TRV027%3A+an+exploratory+subgroup+analysis+of+BLAST-AHF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCotter%26aufirst%3DG.%26aulast%3DPang%26aufirst%3DP.%2BP.%26atitle%3DRelationship%2520between%2520improvements%2520in%2520long%2520term%2520outcomes%2520and%2520baseline%2520systolic%2520blood%2520pressure%2520in%2520acute%2520heart%2520failure%2520patients%2520treated%2520with%2520TRV027%253A%2520an%2520exploratory%2520subgroup%2520analysis%2520of%2520BLAST-AHF%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2017%26volume%3D19%26issue%3DSuppl.%2520S1%26spage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felker, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teerlink, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharucha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, P. S.</span></span> <span> </span><span class="NLM_article-title">Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF</span>. <i>Clin. Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1007/s00392-017-1168-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs00392-017-1168-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28986703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FmtFOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2018&pages=170-181&author=G.+Cotterauthor=B.+A.+Davisonauthor=J.+Butlerauthor=S.+P.+Collinsauthor=J.+A.+Ezekowitzauthor=G.+M.+Felkerauthor=G.+Filippatosauthor=P.+D.+Levyauthor=M.+Metraauthor=P.+Ponikowskiauthor=J.+R.+Teerlinkauthor=A.+A.+Voorsauthor=S.+Sengerauthor=D.+Bharuchaauthor=K.+Goinauthor=D.+G.+Soergelauthor=P.+S.+Pang&title=Relationship+between+baseline+systolic+blood+pressure+and+long-term+outcomes+in+acute+heart+failure+patients+treated+with+TRV027%3A+an+exploratory+subgroup+analysis+of+BLAST-AHF&doi=10.1007%2Fs00392-017-1168-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF</span></div><div class="casAuthors">Cotter Gad; Davison Beth A; Senger Stefanie; Butler Javed; Collins Sean P; Ezekowitz Justin A; Felker G Michael; Filippatos Gerasimos; Levy Phillip D; Metra Marco; Ponikowski Piotr; Teerlink John R; Voors Adriaan A; Bharucha David; Goin Kathleen; Soergel David G; Pang Peter S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical research in cardiology : official journal of the German Cardiac Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  TRV027, a 'biased' ligand of the angiotensin II type 1 receptor (AT1R), did not affect a composite clinical outcome at 30 days in a phase 2b acute heart failure (AHF) trial (BLAST-AHF).  METHODS:  Post-hoc analyses from BLAST-AHF (n = 618) examined the effects of TRV027 by baseline systolic blood pressure (SBP) on changes in renal function and 180-day outcomes.  Interactions between baseline SBP and select endpoints were identified utilizing a subpopulation treatment effect pattern plots (STEPP) analysis, then grouping of patients by SBP tertile: < 127, ≥ 127 to < 140, and ≥ 140 mmHg.  RESULTS:  A trend towards increased creatinine in the first 3 days was noted in the lower SBP tertile, while in those in the higher two tertiles, TRV027, especially the 1 mg/h dose, reduced creatinine at days 5 and 30.  Beneficial effects on 180-day all-cause mortality and cardiovascular (CV) death or readmission were observed in the two higher SBP tertiles (SBP ≥ 127 mmHg) in the TRV027 1 mg/h dose group (all-cause mortality HR 0.39, 95% CI 0.14-1.06, p = 0.056; CV death or HF/RF rehospitalization HR 0.53, 95% CI 0.28-1.01, p = 0.049), while more adverse outcomes were observed in patients in the lower SBP tertile.  CONCLUSIONS:  This post-hoc analysis of the BLAST-AHF study suggests contrasting effects of TRV027 by baseline SBP, with trends towards lower 180-day event rates in patients enrolled with higher baseline SBP, especially when given lower doses of TRV027.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVx3wC5R7hFBgd2Wuil24tfW6udTcc2eZ8SvqPhvI_4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FmtFOgtQ%253D%253D&md5=451991132f97da98640e0ab6788ba182</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00392-017-1168-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00392-017-1168-0%26sid%3Dliteratum%253Aachs%26aulast%3DCotter%26aufirst%3DG.%26aulast%3DDavison%26aufirst%3DB.%2BA.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DS.%2BP.%26aulast%3DEzekowitz%26aufirst%3DJ.%2BA.%26aulast%3DFelker%26aufirst%3DG.%2BM.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLevy%26aufirst%3DP.%2BD.%26aulast%3DMetra%26aufirst%3DM.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DTeerlink%26aufirst%3DJ.%2BR.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DSenger%26aufirst%3DS.%26aulast%3DBharucha%26aufirst%3DD.%26aulast%3DGoin%26aufirst%3DK.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DPang%26aufirst%3DP.%2BS.%26atitle%3DRelationship%2520between%2520baseline%2520systolic%2520blood%2520pressure%2520and%2520long-term%2520outcomes%2520in%2520acute%2520heart%2520failure%2520patients%2520treated%2520with%2520TRV027%253A%2520an%2520exploratory%2520subgroup%2520analysis%2520of%2520BLAST-AHF%26jtitle%3DClin.%2520Res.%2520Cardiol.%26date%3D2018%26volume%3D107%26spage%3D170%26epage%3D181%26doi%3D10.1007%2Fs00392-017-1168-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-T.</span></span> <span> </span><span class="NLM_article-title">Enhanced morphine analgesia in mice lacking β-arrestin 2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">2495</span>– <span class="NLM_lpage">2498</span>, <span class="refDoi"> DOI: 10.1126/science.286.5449.2495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.286.5449.2495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10617462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVKg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=2495-2498&author=L.+M.+Bohnauthor=R.+J.+Lefkowitzauthor=R.+R.+Gainetdinovauthor=K.+Peppelauthor=M.+G.+Caronauthor=F.-T.+Lin&title=Enhanced+morphine+analgesia+in+mice+lacking+%CE%B2-arrestin+2&doi=10.1126%2Fscience.286.5449.2495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced morphine analgesia in mice lacking β-arrestin 2</span></div><div class="casAuthors">Bohn, Laura M.; Lefkowitz, Robert J.; Gainetdinov, Raul R.; Peppel, Karsten; Caron, Marc G.; Lin, Fang-Tsyr</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5449</span>),
    <span class="NLM_cas:pages">2495-2498</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The ability of morphine to alleviate pain is mediated through a heterotrimeric guanine nucleotide binding protein (G protein)-coupled heptahelical receptor (GPCR), the μ opioid receptor (μOR).  The efficiency of GPCR signaling is tightly regulated and ultimately limited by the coordinated phosphorylation of the receptors by specific GPCR kinases and the subsequent interaction of the phosphorylated receptors with β-arrestin 1 and β-arrestin 2.  Functional deletion of the β-arrestin 2 gene in mice resulted in remarkable potentiation and prolongation of the analgesic effect of morphine, suggesting that μOR desensitization was impaired.  These results provide evidence in vivo for the physiol. importance of β-arrestin 2 in regulating the function of a specific GPCR, the μOR.  Moreover, they suggest that inhibition of β-arrestin 2 function might lead to enhanced analgesic effectiveness of morphine and provide potential new avenues for the study and treatment of pain, narcotic tolerance, and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSeiDXvYdnz7Vg90H21EOLACvtfcHk0liTZtfmv5Jt4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVKg&md5=95f67b133e86422f385d1a7f8165d772</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5449.2495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5449.2495%26sid%3Dliteratum%253Aachs%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DPeppel%26aufirst%3DK.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLin%26aufirst%3DF.-T.%26atitle%3DEnhanced%2520morphine%2520analgesia%2520in%2520mice%2520lacking%2520%25CE%25B2-arrestin%25202%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D2495%26epage%3D2498%26doi%3D10.1126%2Fscience.286.5449.2495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raehal, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Morphine side effects in β-arrestin 2 knockout mice</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.087254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.105.087254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=15917400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=1195-1201&author=K.+M.+Raehalauthor=J.+K.+L.+Walkerauthor=L.+M.+Bohn&title=Morphine+side+effects+in+%CE%B2-arrestin+2+knockout+mice&doi=10.1124%2Fjpet.105.087254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Morphine side effects in β-arrestin 2 knockout mice</span></div><div class="casAuthors">Raehal, Kirsten M.; Walker, Julia K. L.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1195-1201</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Morphine is a potent analgesic, yet, like most opioid narcotics, it exerts unwanted side effects such as constipation and respiratory suppression, thereby limiting its clin. utility.  Pharmacol. approaches taken to preserve the analgesic properties, while eliminating the unwanted side effects, have met with very limited success.  Here, we provide evidence that altering μ opioid receptor regulation may provide a novel approach to discriminate morphine's beneficial and deleterious effects in vivo.  We have previously reported that mice lacking the G protein-coupled receptor regulatory protein, β-arrestin 2, display profoundly altered morphine responses.  β-Arrestin 2 knockout mice have enhanced and prolonged morphine analgesia with very little morphine tolerance.  In this report, we examine whether the side effects of morphine treatment are also augmented in this animal model.  Surprisingly, the genetic disruption of opioid receptor regulation, while enhancing and prolonging analgesia, dramatically attenuates the respiratory suppression and acute constipation caused by morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGg-s6s4R0F7Vg90H21EOLACvtfcHk0lhMR49Mc93ZsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsLw%253D&md5=0d3696e563ae3a6f6ce2cb2570cbb890</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.087254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.087254%26sid%3Dliteratum%253Aachs%26aulast%3DRaehal%26aufirst%3DK.%2BM.%26aulast%3DWalker%26aufirst%3DJ.%2BK.%2BL.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DMorphine%2520side%2520effects%2520in%2520%25CE%25B2-arrestin%25202%2520knockout%2520mice%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D1195%26epage%3D1201%26doi%3D10.1124%2Fjpet.105.087254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9<i>R</i>)-9-(pyridin-2-yl)-6- oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&author=X.+T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+Dewireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure-activity+relationships+and+discovery+of+a+G+protein+biased+%CE%BC+opioid+receptor+ligand%2C+%5B%283-methoxythiophen-2-yl%29methyl%5D%28%7B2-%5B%289R%29-9-%28pyridin-2-yl%29-6-+oxaspiro-%5B4.5%5Ddecan-+9-yl%5Dethyl%7D%29amine+%28TRV130%29%2C+for+the+treatment+of+acute+severe+pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDewire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure-activity%2520relationships%2520and%2520discovery%2520of%2520a%2520G%2520protein%2520biased%2520%25CE%25BC%2520opioid%2520receptor%2520ligand%252C%2520%255B%25283-methoxythiophen-2-yl%2529methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528pyridin-2-yl%2529-6-%2520oxaspiro-%255B4.5%255Ddecan-%25209-yl%255Dethyl%257D%2529amine%2520%2528TRV130%2529%252C%2520for%2520the%2520treatment%2520of%2520acute%2520severe%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masic, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolenc, M. S.</span></span> <span> </span><span class="NLM_article-title">Bioactivation potential of thiophene-containing drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1344</span>– <span class="NLM_lpage">1358</span>, <span class="refDoi"> DOI: 10.1021/tx500134g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500134g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFelurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=1344-1358&author=D.+Gramecauthor=L.+P.+Masicauthor=M.+S.+Dolenc&title=Bioactivation+potential+of+thiophene-containing+drugs&doi=10.1021%2Ftx500134g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation Potential of Thiophene-Containing Drugs</span></div><div class="casAuthors">Gramec, Darja; Peterlin Masic, Lucija; Sollner Dolenc, Marija</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1344-1358</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Thiophene is a five-membered, sulfur-contg. heteroarom. ring commonly used as a building block in drugs.  It is considered to be a structural alert, as its metab. can lead to the formation of reactive metabolites.  Thiophene S-oxides and thiophene epoxides are highly reactive electrophilic thiophene metabolites whose formation is cytochrome P 450-dependent.  These reactive thiophene-based metabolites are quite often responsible for drug-induced hepatotoxicity.  Tienilic acid is an example of a thiophene-based drug that was withdrawn from the market after only a few months of use, due to severe cases of immune hepatitis.  However, inclusion of the thiophene moiety in drugs does not necessarily result in toxic effects.  The presence of other, less toxic metabolic pathways, as well as an effective detoxification system in our body, protects us from the bioactivation potential of the thiophene ring.  Thus, the presence of a structural alert itself is insufficient to predict a compd.'s toxicity.  The question therefore arises as to which factors significantly influence the toxicity of thiophene-contg. drugs.  There is no easy way to answer this question.  However, the findings presented here indicate that, for a no. of reasons, daily dose and alternative metabolic pathways are important factors when predicting toxicity and will therefore be discussed together with examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0KnyHFkaMsrVg90H21EOLACvtfcHk0lhMR49Mc93ZsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFelurjL&md5=65733d5665c8ac67050a60707a2e828b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx500134g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500134g%26sid%3Dliteratum%253Aachs%26aulast%3DGramec%26aufirst%3DD.%26aulast%3DMasic%26aufirst%3DL.%2BP.%26aulast%3DDolenc%26aufirst%3DM.%2BS.%26atitle%3DBioactivation%2520potential%2520of%2520thiophene-containing%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D1344%26epage%3D1358%26doi%3D10.1021%2Ftx500134g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graczyk, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.112.201616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23300227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=708-717&author=S.+M.+DeWireauthor=D.+S.+Yamashitaauthor=D.+H.+Romingerauthor=G.+Liuauthor=C.+L.+Cowanauthor=T.+M.+Graczykauthor=X.+T.+Chenauthor=P.+M.+Pitisauthor=D.+Gotchevauthor=C.+Yuanauthor=M.+Koblishauthor=M.+W.+Larkauthor=J.+D.+Violin&title=A+G+protein-biased+ligand+at+the+%CE%BC-opioid+receptor+is+potently+analgesic+with+reduced+gastrointestinal+and+respiratory+dysfunction+compared+with+morphine&doi=10.1124%2Fjpet.112.201616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span></div><div class="casAuthors">DeWire, Scott M.; Yamashita, Dennis S.; Rominger, David H.; Liu, Guodong; Cowan, Conrad L.; Graczyk, Thomas M.; Chen, Xiao-Tao; Pitis, Philip M.; Gotchev, Dimitar; Yuan, Catherine; Koblish, Michael; Lark, Michael W.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics.  Morphine pharmacol. in β-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the μ-opioid receptor (MOR) to G proteins, but not β-arrestins, would result in higher analgesic efficacy, less gastrointestinal dysfunction, and less respiratory suppression than morphine.  Here we report the discovery of TRV130 ([(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine), a novel MOR G protein-biased ligand.  In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization.  In mice and rats, TRV130 is potently analgesic while causing less gastrointestinal dysfunction and respiratory suppression than morphine at equianalgesic doses.  TRV130 successfully translates evidence that analgesic and adverse MOR signaling pathways are distinct into a biased ligand with differentiated pharmacol.  These preclin. data suggest that TRV130 may be a safer and more tolerable therapeutic for treating severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3tTP2BOOKrVg90H21EOLACvtfcHk0lhMR49Mc93ZsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D&md5=33a685cd1952dd9cb1fb82afe78452af</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201616%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DGraczyk%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%2BM.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520G%2520protein-biased%2520ligand%2520at%2520the%2520%25CE%25BC-opioid%2520receptor%2520is%2520potently%2520analgesic%2520with%2520reduced%2520gastrointestinal%2520and%2520respiratory%2520dysfunction%2520compared%2520with%2520morphine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D708%26epage%3D717%26doi%3D10.1124%2Fjpet.112.201616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aryal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of opioid analgesics with reduced side effects</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=X.-P.+Huangauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Daauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Structure-based+discovery+of+opioid+analgesics+with+reduced+side+effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0ljjON4xEmpqrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDa%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-based%2520discovery%2520of%2520opioid%2520analgesics%2520with%2520reduced%2520side%2520effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiesen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the μ-opioid receptor bound to a morphinan antagonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1038/nature10954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature10954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22437502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=321-326&author=A.+Manglikauthor=A.+C.+Kruseauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=J.+M.+Mathiesenauthor=R.+K.+Sunaharaauthor=L.+Pardoauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=S.+Granier&title=Crystal+structure+of+the+%CE%BC-opioid+receptor+bound+to+a+morphinan+antagonist&doi=10.1038%2Fnature10954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the μ-opioid receptor bound to a morphinan antagonist</span></div><div class="casAuthors">Manglik, Aashish; Kruse, Andrew C.; Kobilka, Tong Sun; Thian, Foon Sun; Mathiesen, Jesper M.; Sunahara, Roger K.; Pardo, Leonardo; Weis, William I.; Kobilka, Brian K.; Granier, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7398</span>),
    <span class="NLM_cas:pages">321-326</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opium is one of the world's oldest drugs, and its derivs. morphine and codeine are among the most used clin. drugs to relieve severe pain.  These prototypical opioids produce analgesia as well as many undesirable side effects (sedation, apnea and dependence) by binding to and activating the G-protein-coupled μ-opioid receptor (μ-OR) in the central nervous system.  Here the authors describe the 2.8 Å crystal structure of the mouse μ-OR in complex with an irreversible morphinan antagonist.  Compared to the buried binding pocket obsd. in most G-protein-coupled receptors published so far, the morphinan ligand binds deeply within a large solvent-exposed pocket.  Of particular interest, the μ-OR crystallizes as a two-fold sym. dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6.  These high-resoln. insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2q4tys639jrVg90H21EOLACvtfcHk0ljjON4xEmpqrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D&md5=563d5ebda53f9a408be21d60a7e5a97d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnature10954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10954%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGranier%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520%25CE%25BC-opioid%2520receptor%2520bound%2520to%2520a%2520morphinan%2520antagonist%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D321%26epage%3D326%26doi%3D10.1038%2Fnature10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conibear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, G.</span></span> <span> </span><span class="NLM_article-title">The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2653</span>– <span class="NLM_lpage">2661</span>, <span class="refDoi"> DOI: 10.1111/bph.14224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fbph.14224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29582414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2653-2661&author=R.+Hillauthor=A.+Disneyauthor=A.+Conibearauthor=K.+Sutcliffeauthor=W.+Deweyauthor=S.+Husbandsauthor=C.+Baileyauthor=E.+Kellyauthor=G.+Henderson&title=The+novel+%CE%BC-opioid+receptor+agonist+PZM21+depresses+respiration+and+induces+tolerance+to+antinociception&doi=10.1111%2Fbph.14224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception</span></div><div class="casAuthors">Hill, Rob; Disney, Alex; Conibear, Alex; Sutcliffe, Katy; Dewey, William; Husbands, Stephen; Bailey, Chris; Kelly, Eamonn; Henderson, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2653-2661</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PZM21 is a novel μ-opioid receptor ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ receptor ligands such as morphine.  We have re-examd. the signalling profile of PZM21 and its ability to depress respiration.  G protein (Gi) activation and arrestin-3 translocation were measured in vitro, using BRET assays, in HEK 293 cells expressing μ receptors.  Respiration (rate and tidal vol.) was measured in awake, freely moving mice by whole-body plethysmog., and antinociception was measured by the hot plate test.  PZM21 (10-9 - 3 × 10-5 M) produced concn.-dependent Gi activation and arrestin-3 translocation.  Comparison with responses evoked by morphine and DAMGO revealed that PZM21 was a low efficacy agonist in both signalling assays.  PZM21 (10-80 mg·kg-1) depressed respiration in a dose-dependent manner.  The respiratory depression was due to a decrease in the rate of breathing not a decrease in tidal vol.  On repeated daily administration of PZM21 (twice daily doses of 40 mg·kg-1), complete tolerance developed to the antinociceptive effect of PZM21 over 3 days but no tolerance developed to its respiratory depressant effect.  These data demonstrate that PZM21 is a low efficacy μ receptor agonist for both G protein and arrestin signalling.  Contrary to a previous report, PZM21 depresses respiration in a manner similar to morphine, the classical opioid receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeVaQW_N9c4LVg90H21EOLACvtfcHk0liAs5y3JlKnOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCmt7o%253D&md5=adb5bbba116f6d3df8d860754434af16</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fbph.14224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14224%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%26aulast%3DDisney%26aufirst%3DA.%26aulast%3DConibear%26aufirst%3DA.%26aulast%3DSutcliffe%26aufirst%3DK.%26aulast%3DDewey%26aufirst%3DW.%26aulast%3DHusbands%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DHenderson%26aufirst%3DG.%26atitle%3DThe%2520novel%2520%25CE%25BC-opioid%2520receptor%2520agonist%2520PZM21%2520depresses%2520respiration%2520and%2520induces%2520tolerance%2520to%2520antinociception%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2653%26epage%3D2661%26doi%3D10.1111%2Fbph.14224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rouzic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrath, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunkele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagirsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eans, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span> <span> </span><span class="NLM_article-title">Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8381</span>– <span class="NLM_lpage">8397</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00748</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00748" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8381-8397&author=A.+Varadiauthor=G.+F.+Marroneauthor=T.+C.+Palmerauthor=A.+Narayanauthor=M.+R.+Szaboauthor=V.+Le+Rouzicauthor=S.+G.+Grinnellauthor=J.+J.+Subrathauthor=E.+Warnerauthor=S.+Kalraauthor=A.+Hunkeleauthor=J.+Pagirskyauthor=S.+O.+Eansauthor=J.+M.+Medinaauthor=J.+Xuauthor=Y.+X.+Panauthor=A.+Boricsauthor=G.+W.+Pasternakauthor=J.+P.+McLaughlinauthor=S.+Majumdar&title=Mitragynine%2Fcorynantheidine+pseudoindoxyls+as+opioid+analgesics+with+mu+agonism+and+delta+antagonism%2C+which+do+not+recruit+%CE%B2-arrestin-2&doi=10.1021%2Facs.jmedchem.6b00748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00748%26sid%3Dliteratum%253Aachs%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DMarrone%26aufirst%3DG.%2BF.%26aulast%3DPalmer%26aufirst%3DT.%2BC.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DM.%2BR.%26aulast%3DLe%2BRouzic%26aufirst%3DV.%26aulast%3DGrinnell%26aufirst%3DS.%2BG.%26aulast%3DSubrath%26aufirst%3DJ.%2BJ.%26aulast%3DWarner%26aufirst%3DE.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DHunkele%26aufirst%3DA.%26aulast%3DPagirsky%26aufirst%3DJ.%26aulast%3DEans%26aufirst%3DS.%2BO.%26aulast%3DMedina%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%2BX.%26aulast%3DBorics%26aufirst%3DA.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DMajumdar%26aufirst%3DS.%26atitle%3DMitragynine%252Fcorynantheidine%2520pseudoindoxyls%2520as%2520opioid%2520analgesics%2520with%2520mu%2520agonism%2520and%2520delta%2520antagonism%252C%2520which%2520do%2520not%2520recruit%2520%25CE%25B2-arrestin-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8381%26epage%3D8397%26doi%3D10.1021%2Facs.jmedchem.6b00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenweck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Bias factor and therapeutic window correlate to predict safer opioid analgesics</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1175</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2017.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29149605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=1165-1175&author=C.+L.+Schmidauthor=N.+M.+Kennedyauthor=N.+C.+Rossauthor=K.+M.+Lovellauthor=Z.+Z.+Yueauthor=J.+Morgenweckauthor=M.+D.+Cameronauthor=T.+D.+Bannisterauthor=L.+M.+Bohn&title=Bias+factor+and+therapeutic+window+correlate+to+predict+safer+opioid+analgesics&doi=10.1016%2Fj.cell.2017.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics</span></div><div class="casAuthors">Schmid, Cullen L.; Kennedy, Nicole M.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Morgenweck, Jenny; Cameron, Michael D.; Bannister, Thomas D.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1165-1175.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Biased agonism has been proposed as a means to sep. desirable and adverse drug responses downstream of G protein-coupled receptor (GPCR) targets.  Herein, we describe structural features of a series of mu-opioid-receptor (MOR)-selective agonists that preferentially activate receptors to couple to G proteins or to recruit βarrestin proteins.  By comparing relative bias for MOR-mediated signaling in each pathway, we demonstrate a strong correlation between the respiratory suppression/antinociception therapeutic window in a series of compds. spanning a wide range of signaling bias.  We find that β-arrestin-biased compds., such as fentanyl, are more likely to induce respiratory suppression at weak analgesic doses, while G protein signaling bias broadens the therapeutic window, allowing for antinociception in the absence of respiratory suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfthQaadgklLVg90H21EOLACvtfcHk0liAs5y3JlKnOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE&md5=6d3f21c03fb40bc83adbe62c3ea331fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DRoss%26aufirst%3DN.%2BC.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DYue%26aufirst%3DZ.%2BZ.%26aulast%3DMorgenweck%26aufirst%3DJ.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBias%2520factor%2520and%2520therapeutic%2520window%2520correlate%2520to%2520predict%2520safer%2520opioid%2520analgesics%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D1165%26epage%3D1175%26doi%3D10.1016%2Fj.cell.2017.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slauson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Development of functionally selective, small molecule agonists at kappa opioid receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">36703</span>– <span class="NLM_lpage">36716</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.504381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.504381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24187130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=36703-36716&author=L.+Zhouauthor=K.+M.+Lovellauthor=K.+J.+Frankowskiauthor=S.+R.+Slausonauthor=A.+M.+Phillipsauthor=J.+M.+Streicherauthor=E.+Stahlauthor=C.+L.+Schmidauthor=P.+Hodderauthor=F.+Madouxauthor=M.+D.+Cameronauthor=T.+E.+Prisinzanoauthor=J.+Aub%C3%A9author=L.+M.+Bohn&title=Development+of+functionally+selective%2C+small+molecule+agonists+at+kappa+opioid+receptors&doi=10.1074%2Fjbc.M113.504381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors</span></div><div class="casAuthors">Zhou, Lei; Lovell, Kimberly M.; Frankowski, Kevin J.; Slauson, Stephen R.; Phillips, Angela M.; Streicher, John M.; Stahl, Edward; Schmid, Cullen L.; Hodder, Peter; Madoux, Franck; Cameron, Michael D.; Prisinzano, Thomas E.; Aube, Jeffrey; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">36703-36716</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The kappa opioid receptor (KOR) is widely expressed in the CNS and can serve as a means to modulate pain perception, stress responses, and affective reward states.  Therefore, the KOR has become a prominent drug discovery target toward treating pain, depression, and drug addiction.  Agonists at KOR can promote G protein coupling and βarrestin2 recruitment as well as multiple downstream signaling pathways, including ERK1/2 MAPK activation.  It has been suggested that the physiol. effects of KOR activation result from different signaling cascades, with analgesia being G protein-mediated and dysphoria being mediated through βarrestin2 recruitment.  Dysphoria assocd. with KOR activation limits the therapeutic potential in the use of KOR agonists as analgesics; therefore, it may be beneficial to develop KOR agonists that are biased toward G protein coupling and away from βarrestin2 recruitment.  Here, we describe two classes of biased KOR agonists that potently activate G protein coupling but weakly recruit βarrestin2.  These potent and functionally selective small mol. compds. may prove to be useful tools for refining the therapeutic potential of KOR-directed signaling in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWUfaW03T6nbVg90H21EOLACvtfcHk0lio_s5MwW3m8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF&md5=372edf0156cc1fb156e76e15fa25682a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.504381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.504381%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DSlauson%26aufirst%3DS.%2BR.%26aulast%3DPhillips%26aufirst%3DA.%2BM.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DMadoux%26aufirst%3DF.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DDevelopment%2520of%2520functionally%2520selective%252C%2520small%2520molecule%2520agonists%2520at%2520kappa%2520opioid%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D36703%26epage%3D36716%26doi%3D10.1074%2Fjbc.M113.504381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Land, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melief, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4458-07.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1523%2FJNEUROSCI.4458-07.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18184783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252Fit1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=407-414&author=B.+B.+Landauthor=M.+R.+Bruchasauthor=J.+C.+Lemosauthor=M.+Xuauthor=E.+J.+Meliefauthor=C.+Chavkin&title=The+dysphoric+component+of+stress+is+encoded+by+activation+of+the+dynorphin+%CE%BA-opioid+system&doi=10.1523%2FJNEUROSCI.4458-07.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system</span></div><div class="casAuthors">Land Benjamin B; Bruchas Michael R; Lemos Julia C; Xu Mei; Melief Erica J; Chavkin Charles</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of neuroscience : the official journal of the Society for Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Stress is a complex human experience having both positive and negative motivational properties.  When chronic and uncontrollable, the adverse effects of stress on human health are considerable and yet poorly understood.  Here, we report that the dysphoric properties of chronic stress are encoded by the endogenous opioid peptide dynorphin acting on specific stress-related neuronal circuits.  Using different forms of stress presumed to evoke dysphoria in mice, we found that repeated forced swim and inescapable footshock both produced aversive behaviors that were blocked by a kappa-opioid receptor (KOR) antagonist and absent in mice lacking dynorphin.  Injection of corticotropin-releasing factor (CRF) or urocortin III, key mediators of the stress response, produced place aversion that was also blocked by dynorphin gene deletion or KOR antagonism.  CRF-induced place aversion was blocked by the CRF2 receptor antagonist antisauvigine-30, but not by the CRF1 receptor antagonist antalarmin.  In contrast, place aversion induced by the KOR agonist U50,488 was not blocked by antisauvigine-30.  These results suggest that the aversive effects of stress were mediated by CRF2 receptor stimulation of dynorphin release and subsequent KOR activation.  Using a phospho-selective antibody directed against the activated KOR to image sites of dynorphin action in the brain, we found that stress and CRF each caused dynorphin-dependent KOR activation in the basolateral amygdala, nucleus accumbens, dorsal raphe, and hippocampus.  The convergence of stress-induced aversive inputs on the dynorphin system was unexpected, implicates dynorphin as a key mediator of dysphoria, and emphasizes kappa-receptor antagonists as promising therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQif2_pEJNWVgxyojvcjibhfW6udTcc2ebt5Gcqh3r1crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252Fit1Gltw%253D%253D&md5=ded3df191648ad1c51faa6e2e19fac36</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4458-07.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4458-07.2008%26sid%3Dliteratum%253Aachs%26aulast%3DLand%26aufirst%3DB.%2BB.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DLemos%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DMelief%26aufirst%3DE.%2BJ.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DThe%2520dysphoric%2520component%2520of%2520stress%2520is%2520encoded%2520by%2520activation%2520of%2520the%2520dynorphin%2520%25CE%25BA-opioid%2520system%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D407%26epage%3D414%26doi%3D10.1523%2FJNEUROSCI.4458-07.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Kinase cascades and ligand-directed signaling at the kappa opioid receptor</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1007/s00213-010-1806-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs00213-010-1806-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20401607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVGntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=137-147&author=M.+R.+Bruchasauthor=C.+Chavkin&title=Kinase+cascades+and+ligand-directed+signaling+at+the+kappa+opioid+receptor&doi=10.1007%2Fs00213-010-1806-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase cascades and ligand-directed signaling at the kappa opioid receptor</span></div><div class="casAuthors">Bruchas, Michael R.; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-147</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Background and Rationale: The dynorphin/kappa opioid receptor (KOR) system has been implicated as a crit. component of the stress response.  Stress-induced activation of dynorphin-KOR is well known to produce analgesia, and more recently, it has been implicated as a mediator of stress-induced responses including anxiety, depression, and reinstatement of drug seeking.  Objective: Drugs selectively targeting specific KOR signaling pathways may prove potentially useful as therapeutic treatments for mood and addiction disorders.  Results: KOR is a member of the seven transmembrane spanning (7TM) G-protein coupled receptor (GPCR) superfamily.  KOR activation of pertussis toxin-sensitive G proteins leads to Gαi/o inhibition of adenylyl cyclase prodn. of cAMP and releases Gβγ, which modulates the conductances of Ca+2 and K+ channels.  In addn., KOR agonists activate kinase cascades including G-protein coupled Receptor Kinases (GRK) and members of the mitogen-activated protein kinase (MAPK) family: ERK1/2, p38 and JNK.  Recent pharmacol. data suggests that GPCRs exist as dynamic, multi-conformational protein complexes that can be directed by specific ligands towards distinct signaling pathways.  Ligand-induced conformations of KOR that evoke β-arrestin-dependent p38 MAPK activation result in aversion; whereas ligand-induced conformations that activate JNK without activating arrestin produce long-lasting inactivation of KOR signaling.  Conclusions: In this review, we discuss the current status of KOR signal transduction research and the data that support two novel hypotheses: (1) KOR selective partial agonists that do not efficiently activate p38 MAPK may be useful analgesics without producing the dysphoric or hallucinogenic effects of selective, highly efficacious KOR agonists and (2) KOR antagonists that do not activate JNK may be effective short-acting drugs that may promote stress-resilience.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri-YlQylmWJbVg90H21EOLACvtfcHk0lio_s5MwW3m8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVGntLg%253D&md5=f717d1ea83969f853ad5743b5026e003</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs00213-010-1806-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-010-1806-y%26sid%3Dliteratum%253Aachs%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DKinase%2520cascades%2520and%2520ligand-directed%2520signaling%2520at%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DPsychopharmacology%26date%3D2010%26volume%3D210%26spage%3D137%26epage%3D147%26doi%3D10.1007%2Fs00213-010-1806-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dogra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, P. N.</span></span> <span> </span><span class="NLM_article-title">Biased agonism at kappa opioid receptors: implication in pain and mood disorders</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>763</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.ejphar.2015.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26164787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=763&publication_year=2015&pages=184-190&author=S.+Dograauthor=P.+N.+Yadav&title=Biased+agonism+at+kappa+opioid+receptors%3A+implication+in+pain+and+mood+disorders&doi=10.1016%2Fj.ejphar.2015.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Biased agonism at kappa opioid receptors: Implication in pain and mood disorders</span></div><div class="casAuthors">Dogra, Shalini; Yadav, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">763</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">184-190</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kappa opioid receptor (k receptor) and its endogenous ligand dynorphin have received significant attention due to their involvement in pathophysiol. of mood disorders, drug addiction, psychotic disorders and pain.  Multiple lines of evidences suggest that the k receptor modulates overlapping neurocircuits connecting brainstem monoaminergic nuclei with forebrain limbic structures and thereby regulates neurobiol. effects of stress and psychostimulants.  The emerging concept of "biased agonism" (also known as functional selectivity) for G Protein Coupled Receptor (GPCR) ligands have provided new insights into overall response generated by a ligand, which could be exploited for drug discovery.  According to this concept, every ligand possesses the unique ability (coded in its structure) that dictates distinct signalling pattern, and consequently beneficial or adverse response.  Although still a long way to comprehend the clin. potential of biased GPCR ligands, such ligand could be vital pharmacol. probes.  This article highlights various lines of evidence, which indicates different ligands of k receptor as "biased", and their potential implications in mood and pain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa9u79NzRMt7Vg90H21EOLACvtfcHk0liTqyP8iEQVMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktLjN&md5=2aacd81253e158b23d721eaf1b1985c6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DDogra%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26atitle%3DBiased%2520agonism%2520at%2520kappa%2520opioid%2520receptors%253A%2520implication%2520in%2520pain%2520and%2520mood%2520disorders%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D763%26spage%3D184%26epage%3D190%26doi%3D10.1016%2Fj.ejphar.2015.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosalia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariharan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen-Genel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangravita-Novo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicchiarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1021/cn200128x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200128x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=221-236&author=K.+J.+Frankowskiauthor=M.+P.+Hedrickauthor=P.+Gosaliaauthor=K.+Liauthor=S.+Shiauthor=D.+Whippleauthor=P.+Ghoshauthor=T.+E.+Prisinzanoauthor=F.+J.+Schoenenauthor=Y.+Suauthor=S.+Vasileauthor=E.+Sergienkoauthor=W.+Grayauthor=S.+Hariharanauthor=L.+Milanauthor=S.+Heynen-Genelauthor=A.+Mangravita-Novoauthor=M.+Vicchiarelliauthor=L.+H.+Smithauthor=J.+M.+Streicherauthor=M.+G.+Caronauthor=L.+S.+Barakauthor=L.+M.+Bohnauthor=T.+D.+Y.+Chungauthor=J.+Aub%C3%A9&title=Discovery+of+small+molecule+kappa+opioid+receptor+agonist+and+antagonist+chemotypes+through+a+HTS+and+hit+refinement+strategy&doi=10.1021%2Fcn200128x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of small molecule kappa Opioid receptor agonist and antagonist chemotypes through a HTS and Hit refinement strategy</span></div><div class="casAuthors">Frankowski, Kevin J.; Hedrick, Michael P.; Gosalia, Palak; Li, Kelin; Shi, Shenghua; Whipple, David; Ghosh, Partha; Prisinzano, Thomas E.; Schoenen, Frank J.; Su, Ying; Vasile, S.; Sergienko, Eduard; Gray, Wilson; Hariharan, Santosh; Milan, Loribelle; Heynen-Genel, Susanne; Mangravita-Novo, Arianna; Vicchiarelli, Michael; Smith, Layton H.; Streicher, John M.; Caron, Marc G.; Barak, Lawrence S.; Bohn, Laura M.; Chung, Thomas D. Y.; Aube, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-236</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we present the outcome of a high throughput screening (HTS) campaign-based strategy for the rapid identification and optimization of selective and general chemotypes for both kappa (κ) opioid receptor (KOR) activation and inhibition.  In this program, we have developed potent antagonists (IC50 < 120 nM) or agonists of high binding affinity (Ki < 3 nM).  In contrast to many important KOR ligands, the compds. presented here are highly modular, readily synthesized, and, in most cases, achiral.  The four new chemotypes hold promise for further development into chem. tools for studying the KOR or as potential therapeutic lead candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3ty8Q-FTHjLVg90H21EOLACvtfcHk0liTqyP8iEQVMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslGgug%253D%253D&md5=d8e230e7b797dc2d581d1d7e1dc98ecd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fcn200128x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200128x%26sid%3Dliteratum%253Aachs%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DGosalia%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWhipple%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DSchoenen%26aufirst%3DF.%2BJ.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DSergienko%26aufirst%3DE.%26aulast%3DGray%26aufirst%3DW.%26aulast%3DHariharan%26aufirst%3DS.%26aulast%3DMilan%26aufirst%3DL.%26aulast%3DHeynen-Genel%26aufirst%3DS.%26aulast%3DMangravita-Novo%26aufirst%3DA.%26aulast%3DVicchiarelli%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520small%2520molecule%2520kappa%2520opioid%2520receptor%2520agonist%2520and%2520antagonist%2520chemotypes%2520through%2520a%2520HTS%2520and%2520hit%2520refinement%2520strategy%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D221%26epage%3D236%26doi%3D10.1021%2Fcn200128x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slauson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Development of functionally selective, small molecule agonists at kappa opioid receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">36703</span>– <span class="NLM_lpage">36716</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.504381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.504381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24187130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=36703-36716&author=L.+Zhouauthor=K.+M.+Lovellauthor=K.+J.+Frankowskiauthor=S.+R.+Slausonauthor=A.+M.+Phillipsauthor=J.+M.+Streicherauthor=E.+Stahlauthor=C.+L.+Schmidauthor=P.+Hodderauthor=F.+Madouxauthor=M.+D.+Cameronauthor=T.+E.+Prisinzanoauthor=J.+Aub%C3%A9author=L.+M.+Bohn&title=Development+of+functionally+selective%2C+small+molecule+agonists+at+kappa+opioid+receptors&doi=10.1074%2Fjbc.M113.504381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors</span></div><div class="casAuthors">Zhou, Lei; Lovell, Kimberly M.; Frankowski, Kevin J.; Slauson, Stephen R.; Phillips, Angela M.; Streicher, John M.; Stahl, Edward; Schmid, Cullen L.; Hodder, Peter; Madoux, Franck; Cameron, Michael D.; Prisinzano, Thomas E.; Aube, Jeffrey; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">36703-36716</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The kappa opioid receptor (KOR) is widely expressed in the CNS and can serve as a means to modulate pain perception, stress responses, and affective reward states.  Therefore, the KOR has become a prominent drug discovery target toward treating pain, depression, and drug addiction.  Agonists at KOR can promote G protein coupling and βarrestin2 recruitment as well as multiple downstream signaling pathways, including ERK1/2 MAPK activation.  It has been suggested that the physiol. effects of KOR activation result from different signaling cascades, with analgesia being G protein-mediated and dysphoria being mediated through βarrestin2 recruitment.  Dysphoria assocd. with KOR activation limits the therapeutic potential in the use of KOR agonists as analgesics; therefore, it may be beneficial to develop KOR agonists that are biased toward G protein coupling and away from βarrestin2 recruitment.  Here, we describe two classes of biased KOR agonists that potently activate G protein coupling but weakly recruit βarrestin2.  These potent and functionally selective small mol. compds. may prove to be useful tools for refining the therapeutic potential of KOR-directed signaling in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWUfaW03T6nbVg90H21EOLACvtfcHk0liTqyP8iEQVMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF&md5=372edf0156cc1fb156e76e15fa25682a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.504381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.504381%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DSlauson%26aufirst%3DS.%2BR.%26aulast%3DPhillips%26aufirst%3DA.%2BM.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DMadoux%26aufirst%3DF.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DDevelopment%2520of%2520functionally%2520selective%252C%2520small%2520molecule%2520agonists%2520at%2520kappa%2520opioid%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D36703%26epage%3D36716%26doi%3D10.1074%2Fjbc.M113.504381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slauson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1419</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Ogt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1411-1419&author=K.+M.+Lovellauthor=K.+J.+Frankowskiauthor=E.+L.+Stahlauthor=S.+R.+Slausonauthor=E.+Yooauthor=T.+E.+Prisinzanoauthor=J.+Aub%C3%A9author=L.+M.+Bohn&title=Structure%E2%80%93activity+relationship+studies+of+functionally+selective+kappa+opioid+receptor+agonists+that+modulate+ERK+1%2F2+phosphorylation+while+preserving+G+protein+over+%CE%B2arrestin2+signaling+bias&doi=10.1021%2Facschemneuro.5b00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over βArrestin2 Signaling Bias</span></div><div class="casAuthors">Lovell, Kimberly M.; Frankowski, Kevin J.; Stahl, Edward L.; Slauson, Stephen R.; Yoo, Euna; Prisinzano, Thomas E.; Aube, Jeffrey; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1411-1419</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kappa opioid receptor (KOR) modulation is a promising target for drug discovery efforts due to KOR involvement in pain, depression, and addiction behaviors.  The authors recently reported a new class of triazole KOR agonists that displays significant bias toward G protein signaling over βarrestin2 recruitment; interestingly, these compds. also induce less activation of ERK1/2 map kinases than the balanced agonist, U69,593.  The authors have identified structure-activity relationships around the triazole scaffold that allows for decreasing the bias for G protein signaling over ERK1/2 activation while maintaining the bias for G protein signaling over βarrestin2 recruitment.  The development of novel compds., with different downstream signaling outcomes, independent of G protein/βarrestin2 bias, provides a more diverse pharmacol. toolset for use in defining complex KOR signaling and elucidating the significance of KOR-mediated signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8XRgsF9nR4rVg90H21EOLACvtfcHk0ljwYEw8bKFYRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Ogt7o%253D&md5=ea13ffe0d040ea989d0fd21da421e7d7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00092%26sid%3Dliteratum%253Aachs%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DSlauson%26aufirst%3DS.%2BR.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520studies%2520of%2520functionally%2520selective%2520kappa%2520opioid%2520receptor%2520agonists%2520that%2520modulate%2520ERK%25201%252F2%2520phosphorylation%2520while%2520preserving%2520G%2520protein%2520over%2520%25CE%25B2arrestin2%2520signaling%2520bias%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1411%26epage%3D1419%26doi%3D10.1021%2Facschemneuro.5b00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a novel class of selective and nonbasic nitrogen-containing κ-opioid receptor ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1021/ml100040t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100040t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=189-193&author=K.+J.+Frankowskiauthor=P.+Ghoshauthor=V.+Setolaauthor=T.+B.+Tranauthor=B.+L.+Rothauthor=J.+Aub%C3%A9&title=N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides%3A+a+novel+class+of+selective+and+nonbasic+nitrogen-containing+%CE%BA-opioid+receptor+ligands&doi=10.1021%2Fml100040t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fml100040t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100040t%26sid%3Dliteratum%253Aachs%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26atitle%3DN-Alkyl-octahydroisoquinolin-1-one-8-carboxamides%253A%2520a%2520novel%2520class%2520of%2520selective%2520and%2520nonbasic%2520nitrogen-containing%2520%25CE%25BA-opioid%2520receptor%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D189%26epage%3D193%26doi%3D10.1021%2Fml100040t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scopton, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikbulatov, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepally, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zjawiony, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Identification of novel functionally selective κ-opioid receptor scaffolds</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1124/mol.113.089649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.113.089649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=83-90&author=K.+L.+Whiteauthor=A.+P.+Scoptonauthor=M.+L.+Rivesauthor=R.+V.+Bikbulatovauthor=P.+R.+Polepallyauthor=P.+J.+Brownauthor=T.+Kenakinauthor=J.+A.+Javitchauthor=J.+K.+Zjawionyauthor=B.+L.+Roth&title=Identification+of+novel+functionally+selective+%CE%BA-opioid+receptor+scaffolds&doi=10.1124%2Fmol.113.089649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.089649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.089649%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DScopton%26aufirst%3DA.%2BP.%26aulast%3DRives%26aufirst%3DM.%2BL.%26aulast%3DBikbulatov%26aufirst%3DR.%2BV.%26aulast%3DPolepally%26aufirst%3DP.%2BR.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DZjawiony%26aufirst%3DJ.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DIdentification%2520of%2520novel%2520functionally%2520selective%2520%25CE%25BA-opioid%2520receptor%2520scaffolds%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D85%26spage%3D83%26epage%3D90%26doi%3D10.1124%2Fmol.113.089649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBerto, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepally, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zjawiony, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malanga, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.216820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.114.216820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25320048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=98-109&author=K.+L.+Whiteauthor=J.+E.+Robinsonauthor=H.+Zhuauthor=J.+F.+DiBertoauthor=P.+R.+Polepallyauthor=J.+K.+Zjawionyauthor=D.+E.+Nicholsauthor=C.+J.+Malangaauthor=B.+L.+Roth&title=The+G+protein-biased+%CE%BA-opioid+receptor+agonist+RB-64+is+analgesic+with+a+unique+spectrum+of+activities+in+vivo&doi=10.1124%2Fjpet.114.216820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo</span></div><div class="casAuthors">White, Kate L.; Robinson, J. Elliott; Zhu, Hu; DiBerto, Jeffrey F.; Polepally, Prabhakar R.; Zjawiony, Jordan K.; Nichols, David E.; Malanga, C. J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-109, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The hypothesis that functionally selective G protein-coupled receptor (GPCR) agonists may have enhanced therapeutic benefits has revitalized interest for many GPCR targets.  In particular, although κ-opioid receptor (KOR) agonists are analgesic with a low risk of dependence and abuse, their use is limited by a propensity to induce sedation, motor incoordination, hallucinations, and dysphoria-like states.  Several labs. have produced a body of work suggesting that G protein-biased KOR agonists might be analgesic with fewer side effects.  Although that has been an intriguing hypothesis, suitable KOR-selective and G protein-biased agonists have not been available to test this idea.  Here we provide data using a G protein-biased agonist, RB-64 (22-thiocyanatosalvinorin A), which suggests that KOR-mediated G protein signaling induces analgesia and aversion, whereas β-arrestin-2 signaling may be assocd. with motor incoordination.  Addnl., unlike unbiased KOR agonists, the G protein-biased ligand RB-64 does not induce sedation and does not have anhedonia-like actions, suggesting that a mechanism other than G protein signaling mediates these effects.  Our findings provide the first evidence for a highly selective and G protein-biased tool compd. for which many, but not all, of the neg. side effects of KOR agonists can be minimized by creating G protein-biased KOR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGporsYw3knd37Vg90H21EOLACvtfcHk0ljwYEw8bKFYRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM&md5=686b5b718e2919aaf08e34855cc39ebf</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.216820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.216820%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DDiBerto%26aufirst%3DJ.%2BF.%26aulast%3DPolepally%26aufirst%3DP.%2BR.%26aulast%3DZjawiony%26aufirst%3DJ.%2BK.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMalanga%26aufirst%3DC.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520G%2520protein-biased%2520%25CE%25BA-opioid%2520receptor%2520agonist%2520RB-64%2520is%2520analgesic%2520with%2520a%2520unique%2520spectrum%2520of%2520activities%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D98%26epage%3D109%26doi%3D10.1124%2Fjpet.114.216820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Chen, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span> <span> </span><span class="NLM_article-title">6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">27050</span>– <span class="NLM_lpage">27054</span>, <span class="refDoi"> DOI: 10.1074/jbc.C112.387332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.C112.387332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22736766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFaqtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=27050-27054&author=M.+L.+Rivesauthor=M.+Rossilloauthor=L.+Y.+Liu-Chenauthor=J.+A.+Javitch&title=6%E2%80%B2-Guanidinonaltrindole+%286%E2%80%B2-GNTI%29+is+a+G+protein-biased+%CE%BA-opioid+receptor+agonist+that+inhibits+arrestin+recruitment&doi=10.1074%2Fjbc.C112.387332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">6'-Guanidinonaltrindole (6'-GNTI) Is a G Protein-biased κ-Opioid Receptor Agonist That Inhibits Arrestin Recruitment</span></div><div class="casAuthors">Rives, Marie-Laure; Rossillo, Mary; Liu-Chen, Lee-Yuan; Javitch, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">27050-27054</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">κ-Opioid receptor (KOR) agonists do not activate the reward pathway stimulated by morphine-like μ-opioid receptor (MOR) agonists and thus have been considered to be promising nonaddictive analgesics.  However, KOR agonists produce other adverse effects, including dysphoria, diuresis, and constipation.  The therapeutic promise of KOR agonists has nonetheless recently been revived by studies showing that their dysphoric effects require arrestin recruitment, whereas their analgesic effects do not.  Moreover, KOR agonist-induced antinociceptive tolerance obsd. in vivo has also been proposed to be correlated to the ability to induce arrestin-dependent phosphorylation, desensitization, and internalization of the receptor.  The discovery of functionally selective drugs that are therapeutically effective without the adverse effects triggered by the arrestin pathway is thus an important goal.  We have identified such an extreme G protein-biased KOR compd., 6'-guanidinonaltrindole (6'-GNTI), a potent partial agonist at the KOR receptor for the G protein activation pathway that does not recruit arrestin.  Indeed, 6'-GNTI functions as an antagonist to block the arrestin recruitment and KOR internalization induced by other nonbiased agonists.  As an extremely G protein-biased KOR agonist, 6'-GNTI represents a promising lead compd. in the search for nonaddictive opioid analgesic as its signaling profile suggests that it will be without the dysphoria and other adverse effects promoted by arrestin recruitment and its downstream signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQZcVC9i_2wLVg90H21EOLACvtfcHk0lhGaWGhJEb6Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFaqtrvN&md5=6f1d6365e77b2f318597a6123dcb565c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C112.387332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C112.387332%26sid%3Dliteratum%253Aachs%26aulast%3DRives%26aufirst%3DM.%2BL.%26aulast%3DRossillo%26aufirst%3DM.%26aulast%3DLiu-Chen%26aufirst%3DL.%2BY.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26atitle%3D6%25E2%2580%25B2-Guanidinonaltrindole%2520%25286%25E2%2580%25B2-GNTI%2529%2520is%2520a%2520G%2520protein-biased%2520%25CE%25BA-opioid%2520receptor%2520agonist%2520that%2520inhibits%2520arrestin%2520recruitment%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D27050%26epage%3D27054%26doi%3D10.1074%2Fjbc.C112.387332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity of 6′-guanidinonaltrindole (6′-GNTI) at κ-opioid receptors in striatal neurons</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">22387</span>– <span class="NLM_lpage">22398</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.476234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.476234" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=22387-22398&author=C.+L.+Schmidauthor=J.+M.+Streicherauthor=C.+E.+Groerauthor=T.+A.+Munroauthor=L.+Zhouauthor=L.+M.+Bohn&title=Functional+selectivity+of+6%E2%80%B2-guanidinonaltrindole+%286%E2%80%B2-GNTI%29+at+%CE%BA-opioid+receptors+in+striatal+neurons&doi=10.1074%2Fjbc.M113.476234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.476234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.476234%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DGroer%26aufirst%3DC.%2BE.%26aulast%3DMunro%26aufirst%3DT.%2BA.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DFunctional%2520selectivity%2520of%25206%25E2%2580%25B2-guanidinonaltrindole%2520%25286%25E2%2580%25B2-GNTI%2529%2520at%2520%25CE%25BA-opioid%2520receptors%2520in%2520striatal%2520neurons%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D22387%26epage%3D22398%26doi%3D10.1074%2Fjbc.M113.476234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schattauer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cellsig.2017.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28088389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=59-65&author=S.+S.+Schattauerauthor=J.+R.+Kuharauthor=A.+Songauthor=C.+Chavkin&title=Nalfurafine+is+a+G-protein+biased+agonist+having+significantly+greater+bias+at+the+human+than+rodent+form+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.cellsig.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span></div><div class="casAuthors">Schattauer, Selena S.; Kuhar, Jamie R.; Song, Allisa; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Nalfurafine is a moderately selective kappa opioid receptor (KOR) analgesic with low incidence of dysphoric side effects in clin. development for the treatment of uremic pruritis.  The basis for its reduced dysphoric effect compared to other KOR agonists is not clear, but prior studies suggest that the aversive properties of KOR agonists require p38α MAPK activation through an arrestin-dependent mechanism.  To det. whether nalfurafine is a functionally selective KOR agonist, we measured its potency to activate the G protein-dependent early phase of Extracellular Signal-Regulated Kinase (ERK1/2) phosphorylation and the arrestin-dependent late phase of p38 MAPK signaling.  Nalfurafine was approx. 250 fold more potent for ERK1/2 activation as compared to p38 MAPK activation in human KOR (hKOR) expressing HEK293 cells, and approx. 20 fold more potent for ERK1/2 activation than p38 activation in rodent KOR (rKOR) expressing HEK293 cells.  The 10-fold greater G-bias at the hKOR than rKOR was unexpected, however the G protein biased effect of nalfurafine is consistent with its reduced dysphoric effects in human and rodent models.  Although nalfurafine is reported to have low receptor selectivity in radioligand binding assays, its antinociceptive effect was blocked by the selective KOR antagonist norbinaltorphimine.  Nalfurafine pretreatment also resulted in a KOR-dependent and mu opioid receptor-independent redn. in scratching induced by 5'-GNTI.  These findings suggest that nalfurafine is a functionally selective KOR agonist and that KOR agonists able to selectively activate G protein signaling without activating p38α MAPK may have therapeutic potential as non-dysphoric antipruritic analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqJR2Iu_bivbVg90H21EOLACvtfcHk0lhGaWGhJEb6Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D&md5=13799707352aa7133e92eff7e6f32b71</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DSchattauer%26aufirst%3DS.%2BS.%26aulast%3DKuhar%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DNalfurafine%2520is%2520a%2520G-protein%2520biased%2520agonist%2520having%2520significantly%2520greater%2520bias%2520at%2520the%2520human%2520than%2520rodent%2520form%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DCell.%2520Signalling%26date%3D2017%26volume%3D32%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.cellsig.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazenka, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moerke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s00213-017-4758-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs00213-017-4758-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29063139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2018&pages=203-213&author=M.+L.+Lazenkaauthor=M.+J.+Moerkeauthor=E.+A.+Townsendauthor=K.+B.+Freemanauthor=F.+I.+Carrollauthor=S.+S.+Negus&title=Dissociable+effects+of+the+kappa+opioid+receptor+agonist+nalfurafine+on+pain%2Fitch-stimulated+and+pain%2Fitch-depressed+behaviors+in+male+rats&doi=10.1007%2Fs00213-017-4758-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span></div><div class="casAuthors">Lazenka, Matthew L.; Moerke, Megan J.; Townsend, E. Andrew; Freeman, Kevin B.; Carroll, F. Ivy; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">203-213</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Nalfurafine is a G protein signaling-biased kappa opioid receptor (KOR) agonist approved in Japan for second-line treatment of uremic pruritus.  Neither nalfurafine nor any other KOR agonist is currently approved anywhere for treatment of pain, but recent evidence suggests that G protein signaling-biased KOR agonists may have promise as candidate analgesics/antipruritics with reduced side effects compared to nonbiased or ss-arrestin-signaling-biased KOR agonists.  Objectives: This study compared nalfurafine effects in rats using assays of pain-stimulated and pain-depressed behavior used previously to evaluate other candidate analgesics.  Nalfurafine effects were also examd. in complementary assays of itch-stimulated and itch-depressed behavior.  Methods: I.p. lactic acid (IP acid) and intradermal serotonin (ID 5HT) served as noxious and pruritic stimuli, resp., in male Sprague Dawley rats to stimulate stretching (IP acid) or scratching (ID 5HT) or to depress pos. reinforced operant responding in an assay of intracranial self-stimulation (ICSS; both stimuli).  Results: Nalfurafine was equipotent to decrease IP acid-stimulated stretching and ID 5HT-stimulated scratching; however, doses of nalfurafine that decreased these pain/itch-stimulated behaviors also decreased control ICSS performance.  Moreover, nalfurafine failed to alleviate either IP acid- or ID 5HT-induced depression of ICSS.  Conclusions: These results suggest that nalfurafine-induced decreases in pain/itch-stimulated behaviors may reflect nonselective decreases in motivated behavior rather than analgesia or antipruritus against the noxious and pruritic stimuli used here.  This conclusion agrees with the absence of clin. data for nalfurafine analgesia and the weak clin. data for nalfurafine antipruritus.  Nalfurafine bias for G protein signaling may not be sufficient for clin. safe and reliable analgesia or antipruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkm4nAMagerVg90H21EOLACvtfcHk0lhZEiCgcdt9kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K&md5=13f9d2d5f4340b136971eb1bc2bbfc5e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00213-017-4758-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-017-4758-7%26sid%3Dliteratum%253Aachs%26aulast%3DLazenka%26aufirst%3DM.%2BL.%26aulast%3DMoerke%26aufirst%3DM.%2BJ.%26aulast%3DTownsend%26aufirst%3DE.%2BA.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DDissociable%2520effects%2520of%2520the%2520kappa%2520opioid%2520receptor%2520agonist%2520nalfurafine%2520on%2520pain%252Fitch-stimulated%2520and%2520pain%252Fitch-depressed%2520behaviors%2520in%2520male%2520rats%26jtitle%3DPsychopharmacology%26date%3D2018%26volume%3D235%26spage%3D203%26epage%3D213%26doi%3D10.1007%2Fs00213-017-4758-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7011</span>– <span class="NLM_lpage">7028</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7011-7028&author=N.+T.+Zaveri&title=Nociceptin+opioid+receptor+%28NOP%29+as+a+therapeutic+target%3A+progress+in+translation+from+preclinical+research+to+clinical+utility&doi=10.1021%2Facs.jmedchem.5b01499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility</span></div><div class="casAuthors">Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7011-7028</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the two decades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in understanding the pharmacol. of this fourth opioid receptor/peptide system, aided by genetic and pharmacol. approaches.  This research spawned an explosion of small-mol. NOP receptor ligands from discovery programs in major pharmaceutical companies.  NOP agonists have been investigated for their efficacy in preclin. models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urinary incontinence, whereas NOP antagonists have been investigated for treatment of pain, depression, and motor symptoms in Parkinson's disease.  Translation of preclin. findings into the clinic is guided by PET and receptor occupancy studies, particularly for NOP antagonists.  Recent progress in preclin. NOP research suggests that NOP agonists may have clin. utility for pain treatment and substance abuse pharmacotherapy.  This review discusses the progress toward validating the NOP-N/OFQ system as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo51w0U-7QparVg90H21EOLACvtfcHk0lhZEiCgcdt9kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D&md5=b9746257e225a423dfa0539d8bf407c9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01499%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DNociceptin%2520opioid%2520receptor%2520%2528NOP%2529%2520as%2520a%2520therapeutic%2520target%253A%2520progress%2520in%2520translation%2520from%2520preclinical%2520research%2520to%2520clinical%2520utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7011%26epage%3D7028%26doi%3D10.1021%2Facs.jmedchem.5b01499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarella, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span> <span> </span><span class="NLM_article-title">Quantitative signaling and structure-activity analyses demonstrate functional selectivity at the nociceptin/orphanin FQ opioid receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1124/mol.115.099150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.115.099150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26134494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=502-511&author=S.+D.+Changauthor=S.+W.+Mascarellaauthor=S.+M.+Spanglerauthor=V.+V.+Gurevichauthor=H.+A.+Navarroauthor=F.+I.+Carrollauthor=M.+R.+Bruchas&title=Quantitative+signaling+and+structure-activity+analyses+demonstrate+functional+selectivity+at+the+nociceptin%2Forphanin+FQ+opioid+receptor&doi=10.1124%2Fmol.115.099150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative signaling and structure-activity analyses demonstrate functional selectivity at the nociceptin/orphanin FQ opioid receptor</span></div><div class="casAuthors">Chang, Steven D.; Mascarella, S. Wayne; Spangler, Skylar M.; Gurevich, Vsevolod V.; Navarro, Hernan A.; Carroll, F. Ivy; Bruchas, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">502-511</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pancreatic cancer has the lowest 5-yr survival rate of all major cancers despite decades of effort to design and implement novel, more effective treatment options.  In this study, we tested whether the dual phosphoinositide 3-kinase/mechanistic target of rapamycin inhibitor BEZ235 (BEZ) potentiates the antitumor effects of doxorubicin (DOX) against pancreatic cancer.  Cotreatment of BEZ235 with DOX resulted in dose-dependent inhibition of the phosphoinositide 3-kinase/mechanistic target of rapamycin survival pathway, which corresponded with an increase in poly ADP ribose polymerase cleavage.  Moreover, BEZ cotreatment significantly improved the effects of DOX toward both cell viability and cell death in part through reduced Bcl-2 expression and increased expression of the shorter, more cytotoxic forms of BIM.  BEZ also facilitated intracellular accumulation of DOX, which led to enhanced DNA damage and reactive oxygen species generation.  Furthermore, BEZ in combination with gemcitabine reduced MiaPaca2 cell proliferation but failed to increase reactive oxygen species generation or BIM expression, resulting in reduced necrosis and apoptosis.  Treatment with BEZ and DOX in mice bearing tumor xenographs significantly repressed tumor growth as compared with BEZ, DOX, or gemcitabine.  Addnl., in contrast to the enhanced expression seen in MiaPaca2 cells, BEZ and DOX cotreatment reduced BIM expression in H9C2 cardiomyocytes.  Also, the Bcl-2/Bax ratio was increased, which was assocd. with a redn. in cell death.  In vivo echocardiog. showed decreased cardiac function with DOX treatment, which was not improved by combination treatment with BEZ.  Thus, we propose that combining BEZ with DOX would be a better option for patients than current std. of care by providing a more effective tumor response without the assocd. increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowdAZqtUuLx7Vg90H21EOLACvtfcHk0lhh1DF1wEmqcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLrI&md5=2bbd01f7e2c6b21e01a2406b69971eef</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.099150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.099150%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BD.%26aulast%3DMascarella%26aufirst%3DS.%2BW.%26aulast%3DSpangler%26aufirst%3DS.%2BM.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DNavarro%26aufirst%3DH.%2BA.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26atitle%3DQuantitative%2520signaling%2520and%2520structure-activity%2520analyses%2520demonstrate%2520functional%2520selectivity%2520at%2520the%2520nociceptin%252Forphanin%2520FQ%2520opioid%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D502%26epage%3D511%26doi%3D10.1124%2Fmol.115.099150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohlweg, R.</span></span> <span> </span><span class="NLM_article-title">(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8- triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fsj.bjp.0703661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=11053209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFemsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2000&pages=903-908&author=C.+Thomsenauthor=R.+Hohlweg&title=%288-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1%2C3%2C8-+triaza-spiro%5B4.5%5Ddec-3-yl%29-acetic+acid+methyl+ester+%28NNC+63-0532%29+is+a+novel+potent+nociceptin+receptor+agonist&doi=10.1038%2Fsj.bjp.0703661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl)acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist</span></div><div class="casAuthors">Thomsen, Christian; Hohlweg, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">903-908</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Spiroxatrine was identified as a moderately potent (Ki = 118 nM) but non-selective agonist at the human nociceptin/orphanin FQ receptor, ORL1.  This compd. was subject to chem. modification and one of the resulting compds., NNC 63-0532 was shown to have high affinity for ORL1 (Ki = 7.3 nM).  NNC 63-0532 showed only moderate affinity for the following receptors (Ki values in parentheses): μ-opioid (140 nM), κ-opioid (405 nM), dopamine D2S (209 nM), dopamine D3 (133 nM) and dopamine D4.4 (107 nM) out of 75 different receptors, ion-channels and transporters.  In functional assays, NNC 63-0532 was shown to be an agonist at ORL1 (EC50 = 305 nM), a much weaker agonist at the μ-opioid receptor (EC50>10 μM) and an antagonist or weak partial agonist at dopamine D2S (IC50 = 2830 nM).  Thus, NNC 63-0532 is a novel non-peptide agonist with ∼ 12 fold selectivity for ORL1 and may be useful for exploring the physiol. roles of this receptor owing to its brain-penetrating properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqch9CqavIc-rVg90H21EOLACvtfcHk0lhh1DF1wEmqcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFemsLc%253D&md5=6c28da889af05c7b60a6efb9bf2d901b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703661%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DC.%26aulast%3DHohlweg%26aufirst%3DR.%26atitle%3D%25288-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1%252C3%252C8-%2520triaza-spiro%255B4.5%255Ddec-3-yl%2529-acetic%2520acid%2520methyl%2520ester%2520%2528NNC%252063-0532%2529%2520is%2520a%2520novel%2520potent%2520nociceptin%2520receptor%2520agonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D131%26spage%3D903%26epage%3D908%26doi%3D10.1038%2Fsj.bjp.0703661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">The physiology, signaling, and pharmacology of dopamine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fpr.110.002642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21303898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=182-217&author=J.+M.+Beaulieuauthor=R.+R.+Gainetdinov&title=The+physiology%2C+signaling%2C+and+pharmacology+of+dopamine+receptors&doi=10.1124%2Fpr.110.002642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, signaling, and pharmacology of dopamine receptors</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-217</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiol. functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension.  Pharmacol. agents targeting dopaminergic neurotransmission have been clin. used in the management of several neurol. and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD1), and Tourette's syndrome.  Numerous advances have occurred in understanding the general structural, biochem., and functional properties of dopamine receptors that have led to the development of multiple pharmacol. active compds. that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics.  Recent progress in understanding the complex biol. of dopamine receptor-related signal transduction mechanisms has revealed that, in addn. to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins.  One of the future directions in managing dopamine-related pathol. conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacol.  In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms.  In addn., we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacol. and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp84qmbSbA7Vg90H21EOLACvtfcHk0lhh1DF1wEmqcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D&md5=53e6841062c98abe60c732692109e498</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002642%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DThe%2520physiology%252C%2520signaling%252C%2520and%2520pharmacology%2520of%2520dopamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D182%26epage%3D217%26doi%3D10.1124%2Fpr.110.002642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kehne, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andree, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, J. N.</span></span> <span> </span><span class="NLM_article-title">D2 receptor partial agonists: treatment of CNS disorders of dopamine function</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1088</span>, <span class="refDoi"> DOI: 10.2174/156802608785161394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.2174%2F156802608785161394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18691133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1068-1088&author=J.+H.+Kehneauthor=T.+H.+Andreeauthor=J.+N.+Heinrich&title=D2+receptor+partial+agonists%3A+treatment+of+CNS+disorders+of+dopamine+function&doi=10.2174%2F156802608785161394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">D2 receptor partial agonists: treatment of CNS disorders of dopamine function</span></div><div class="casAuthors">Kehne, John H.; Andree, Terrance H.; Heinrich, Julia N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1068-1088</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  A remarkable diversity of psychiatric and neurol. disorders have been assocd. with dysfunction of dopamine (DA)-contg. neurons, including schizophrenia, bipolar disorder (BD), Parkinson's disease (PD), and restless legs syndrome (RLS).  In such disorders, transmission in discrete DA pathways may range from hypoactivation to hyperactivation of DA receptors, particularly those of the D2 subtype, providing the rationale for treatment approaches that activate or block D2 receptors, resp.  However, full agonists or pure D2 receptor antagonists may not be optimal therapeutic approaches for their resp. disorders for a no. of reasons, including an inability to restore the aberrant DA pathways to a normal level of basal tone.  D2 receptor partial agonists (D2PAs) are proposed to stabilize activity in DA pathways by dampening excessive (and/or by restoring deficient) D2 receptor stimulation thereby shepherding DA neurons back to a desired level of basal activity.  Stabilizing aberrant DA activity without disrupting non-dysfunctional DA neurons may provide a potentially improved approach for treating DA disorders.  The status of DA D2PAs and their potential application to schizophrenia, BD, PD, and RLS is reviewed.  Preclin. and clin. evidence supports the idea that dysfunctions of D2 receptors contribute to these CNS disorders.  Diseases in which both hyper- and hypofunction of DA pathways are present may be particularly promising, and challenging, targets for D2PAs.  Furthermore, different DA disorders may respond optimally to D2PAs with differing levels of intrinsic activity, with "DA deficiency" diseases responding more effectively to higher intrinsic activity D2PAs than "DA hyperactivation" diseases.  Overall, current evidence supports the conclusion that D2PAs have significant potential as improved CNS therapies relative to classic full agonists and antagonists at D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYXnz0ClAI_LVg90H21EOLACvtfcHk0lhh1DF1wEmqcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtbw%253D&md5=e2501665b430e96d34941f0101b98190</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F156802608785161394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161394%26sid%3Dliteratum%253Aachs%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26aulast%3DHeinrich%26aufirst%3DJ.%2BN.%26atitle%3DD2%2520receptor%2520partial%2520agonists%253A%2520treatment%2520of%2520CNS%2520disorders%2520of%2520dopamine%2520function%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1068%26epage%3D1088%26doi%3D10.2174%2F156802608785161394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M.</span></span> <span> </span><span class="NLM_article-title">Dopamine in schizophrenia: a review and reconceptualization</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1474</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1176/ajp.148.11.1474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1176%2Fajp.148.11.1474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1681750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=1991&pages=1474-1486&author=K.+L.+Davisauthor=R.+S.+Kahnauthor=G.+Koauthor=M.+Davidson&title=Dopamine+in+schizophrenia%3A+a+review+and+reconceptualization&doi=10.1176%2Fajp.148.11.1474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine in schizophrenia: a review and reconceptualization</span></div><div class="casAuthors">Davis K L; Kahn R S; Ko G; Davidson M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1474-86</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The initial hypothesis that schizophrenia is a manifestation of hyperdopaminergia has recently been faulted.  However, several new findings suggest that abnormal, although not necessarily excessive, dopamine activity is an important factor in schizophrenia.  The authors discuss these findings and their implications.  METHOD:  All published studies regarding dopamine and schizophrenia and all studies on the role of dopamine in cognition were reviewed.  Attention has focused on post-mortem studies, positron emission tomography, neuroleptic drug actions, plasma levels of the dopamine metabolite homovanillic acid (HVA), and cerebral blood flow.  RESULTS:  Evidence, particularly from intracellular recording studies in animals and plasma HVA measurements, suggests that neuroleptics act by reducing dopamine activity in mesolimbic dopamine neurons.  Post-mortem studies have shown high dopamine and HVA concentrations in various subcortical brain regions and greater than normal dopamine receptor densities in the brains of schizophrenic patients.  On the other hand, the negative/deficit symptom complex of schizophrenia may be associated with low dopamine activity in the prefrontal cortex.  Recent animal and human studies suggest that prefrontal dopamine neurons inhibit subcortical dopamine activity.  The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity (causing deficit symptoms) leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms).  CONCLUSIONS:  The possible co-occurrence of high and low dopamine activity in schizophrenia has implications for the conceptualization of dopamine's role in schizophrenia.  It would explain the concurrent presence of negative and positive symptoms.  This hypothesis is testable and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjdRe5bVrnXhJ5E29YNGvQfW6udTcc2eYDMVAU_qB0mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D&md5=15af042ac86f1634ea1c0b7c0fb76582</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1176%2Fajp.148.11.1474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.148.11.1474%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26aulast%3DKo%26aufirst%3DG.%26aulast%3DDavidson%26aufirst%3DM.%26atitle%3DDopamine%2520in%2520schizophrenia%253A%2520a%2520review%2520and%2520reconceptualization%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1991%26volume%3D148%26spage%3D1474%26epage%3D1486%26doi%3D10.1176%2Fajp.148.11.1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrington, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiodo, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailman, R.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1411</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fsj.npp.1300203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=12784105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1400-1411&author=D.+A.+Shapiroauthor=S.+Renockauthor=E.+Arringtonauthor=L.+A.+Chiodoauthor=L.+X.+Liuauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=R.+Mailman&title=Aripiprazole%2C+a+novel+atypical+antipsychotic+drug+with+a+unique+and+robust+pharmacology&doi=10.1038%2Fsj.npp.1300203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span></div><div class="casAuthors">Shapiro, David A.; Renock, Sean; Arrington, Elaine; Chiodo, Louis A.; Liu, Li-Xin; Sibley, David R.; Roth, Bryan L.; Mailman, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1400-1411</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders.  The current clin. approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)).  Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist.  We now provide a comprehensive pharmacol. profile of aripiprazole at a large no. of cloned G protein-coupled receptors, transporters, and ion channels.  These data reveal a no. of interesting and potentially important mol. targets for which aripiprazole has affinity.  Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3-dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors.  Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors.  Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors.  Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examd.  This mixt. of functional actions at D2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has functionally selective' actions.  Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors-particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc1m1pKWaDH7Vg90H21EOLACvtfcHk0lhLVsiJ6BPELQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D&md5=a90dfc24826c78d9a630ae4831d99cb0</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300203%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DD.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DArrington%26aufirst%3DE.%26aulast%3DChiodo%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMailman%26aufirst%3DR.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520atypical%2520antipsychotic%2520drug%2520with%2520a%2520unique%2520and%2520robust%2520pharmacology%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1400%26epage%3D1411%26doi%3D10.1038%2Fsj.npp.1300203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caroff, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurford, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lybrand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, E. C.</span></span> <span> </span><span class="NLM_article-title">Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial</span>. <i>Neurol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/j.ncl.2010.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.ncl.2010.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21172575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FlslSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=127-148&author=S.+N.+Caroffauthor=I.+Hurfordauthor=J.+Lybrandauthor=E.+C.+Campbell&title=Movement+disorders+induced+by+antipsychotic+drugs%3A+implications+of+the+CATIE+schizophrenia+trial&doi=10.1016%2Fj.ncl.2010.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial</span></div><div class="casAuthors">Caroff Stanley N; Hurford Irene; Lybrand Janice; Campbell E Cabrina</div><div class="citationInfo"><span class="NLM_cas:title">Neurologic clinics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-48, viii</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced movement disorders have dramatically declined with the widespread use of second-generation antipsychotics, but remain important in clinical practice and for understanding antipsychotic pharmacology.  The diagnosis and management of dystonia, parkinsonism, akathisia, catatonia, neuroleptic malignant syndrome, and tardive dyskinesia are reviewed in relation to the decreased liability of the second-generation antipsychotics contrasted with evidence from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.  Data from the CATIE trial imply that advantages of second-generation antipsychotics in significantly reducing extrapyramidal side effects compared with haloperidol may be diminished when compared with modest doses of lower-potency first-generation drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBIN3LUXilvJdYoSR9eyvsfW6udTcc2eYDMVAU_qB0mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FlslSruw%253D%253D&md5=c7fd6d2ec77cd158cd6aec0cce9f91d1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2010.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2010.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DS.%2BN.%26aulast%3DHurford%26aufirst%3DI.%26aulast%3DLybrand%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DE.%2BC.%26atitle%3DMovement%2520disorders%2520induced%2520by%2520antipsychotic%2520drugs%253A%2520implications%2520of%2520the%2520CATIE%2520schizophrenia%2520trial%26jtitle%3DNeurol.%2520Clin.%26date%3D2011%26volume%3D29%26spage%3D127%26epage%3D148%26doi%3D10.1016%2Fj.ncl.2010.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selfani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soland, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span> <span> </span><span class="NLM_article-title">Movement disorders induced by the “atypical” antipsychotic aripiprazole</span>. <i>Neurologist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1097/NRL.0000000000000096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1097%2FNRL.0000000000000096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=24-28&author=K.+Selfaniauthor=V.+L.+Solandauthor=S.+Chouinardauthor=P.+Huot&title=Movement+disorders+induced+by+the+%E2%80%9Catypical%E2%80%9D+antipsychotic+aripiprazole&doi=10.1097%2FNRL.0000000000000096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1097%2FNRL.0000000000000096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FNRL.0000000000000096%26sid%3Dliteratum%253Aachs%26aulast%3DSelfani%26aufirst%3DK.%26aulast%3DSoland%26aufirst%3DV.%2BL.%26aulast%3DChouinard%26aufirst%3DS.%26aulast%3DHuot%26aufirst%3DP.%26atitle%3DMovement%2520disorders%2520induced%2520by%2520the%2520%25E2%2580%259Catypical%25E2%2580%259D%2520antipsychotic%2520aripiprazole%26jtitle%3DNeurologist%26date%3D2017%26volume%3D22%26spage%3D24%26epage%3D28%26doi%3D10.1097%2FNRL.0000000000000096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailman, R. B.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fsj.npp.1301071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=16554739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=67-77&author=J.+D.+Urbanauthor=G.+A.+Vargasauthor=M.+von+Zastrowauthor=R.+B.+Mailman&title=Aripiprazole+has+functionally+selective+actions+at+dopamine+D2+receptor-mediated+signaling+pathways&doi=10.1038%2Fsj.npp.1301071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways</span></div><div class="casAuthors">Urban, Jonathan D.; Vargas, Gabriel A.; von Zastrow, Mark; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aripiprazole is a unique atypical antipsychotic drug with an excellent side-effect profile presumed, in part, to be due to lack of typical D2 dopamine receptor antagonist properties.  Whether aripiprazole is a typical D2 partial agonist, or a functionally selective D2 ligand, remains controversial (eg D2-mediated inhibition of adenylate cyclase is system dependent; aripiprazole antagonizes D2 receptor-mediated G-protein-coupled inwardly rectifying potassium channels and guanosine triphosphate nucleotide (GTP)γS coupling).  The current study examd. the D2L receptor binding properties of aripiprazole, as well as the effects of the drug on three downstream D2 receptor-mediated functional effectors: mitogen-activated protein kinase (MAPK) phosphorylation, potentiation of arachidonic acid (AA) release, and D2 receptor internalization.  Unlike quinpirole (a full D2 agonist) or (-)3PPP (S(-)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochloride, a D2 partial agonist), the apparent D2 affinity of aripiprazole was not decreased significantly by GTP.  Moreover, full or partial agonists are expected to have Hill slopes <1.0, yet that of aripiprazole was significantly >1.0.  Whereas aripiprazole partially activated both the MAPK and AA pathways, its potency vs MAPK phosphorylation was much lower relative to potencies in assays either of AA release or inhibition of cyclic adenosine 3',5'-cyclic monophosphate accumulation.  In addn., unlike typical agonists, neither aripiprazole nor (-)3PPP produced significant internalization of the D2L receptor.  These data are clear evidence that aripiprazole affects D2L-mediated signaling pathways in a differential manner.  The results are consistent with the hypothesis that aripiprazole is a functionally selective D2 ligand rather than a simple partial agonist.  Such data may be useful in understanding the novel clin. actions of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-qAW7cvG3i7Vg90H21EOLACvtfcHk0liShvUsAhmYBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqtbrJ&md5=20b9edb05787dadb09fb4c778205f0b2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301071%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DG.%2BA.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DAripiprazole%2520has%2520functionally%2520selective%2520actions%2520at%2520dopamine%2520D2%2520receptor-mediated%2520signaling%2520pathways%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D67%26epage%3D77%26doi%3D10.1038%2Fsj.npp.1301071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yost, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">18488</span>– <span class="NLM_lpage">18493</span>, <span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22025698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+%CE%B2-arrestin-biased+dopamine+D2+ligands+for+probing+signal+transduction+pathways+essential+for+antipsychotic+efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span></div><div class="casAuthors">Allen, John A.; Yost, Julianne M.; Setola, Vincent; Chen, Xin; Sassano, Maria F.; Chen, Meng; Peterson, Sean; Yadav, Prem N.; Huang, Xi-Ping; Feng, Bo; Jensen, Niels H.; Che, Xin; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Caron, Marc G.; Javitch, Jonathan A.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18488-18493, S18488/1-S18488/15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies.  Recent work has highlighted noncanonical modes of dopamine D2 receptor (D2R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents.  We thus sought to create unique D2R agonists that display signaling bias via β-arrestinergic signaling.  Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3); and UNC9994 (4) as unprecedented β-arrestin-biased D2R ligands.  These compds. also represent unprecedented β-arrestin-biased ligands for a Gi-coupled G protein-coupled receptor (GPCR).  Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of Gi-regulated cAMP prodn. and partial agonists for D2R/β-arrestin-2 interactions.  Importantly, VNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo.  Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic .drug with a high propensity to induce catalepsy.  Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin-biased D2R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice.  Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects.  These functionally selective, β-arrestin-biased D2R ligands represent valuable chem. probes for further investigations of D2R signaling in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87mjP6jm447Vg90H21EOLACvtfcHk0liShvUsAhmYBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK&md5=d5b06e4ac4d2cc4cd04fd1de760ec628</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520%25CE%25B2-arrestin-biased%2520dopamine%2520D2%2520ligands%2520for%2520probing%2520signal%2520transduction%2520pathways%2520essential%2520for%2520antipsychotic%2520efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7141</span>– <span class="NLM_lpage">7153</span>, <span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-functional+selectivity+relationship+studies+of+%CE%B2-arrestin-biased+dopamine+D2+receptor+agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D2 Receptor Agonists</span></div><div class="casAuthors">Chen, Xin; Sassano, Maria F.; Zheng, Lianyou; Setola, Vincent; Chen, Meng; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7141-7153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side effects of drugs.  However, few such ligands have been created, and very little purposeful attention has been devoted to studying what we term: "structure-functional selectivity relationships" (SFSR).  We recently disclosed the first β-arrestin-biased dopamine D2 receptor (D2R) agonists UNC9975 (44) and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities.  Here we report the first comprehensive SFSR studies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery of these β-arrestin-biased D2R agonists.  These studies provide a successful proof-of-concept for how functionally selective ligands can be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoG1fasQ6GLVg90H21EOLACvtfcHk0ljYWTmR9xsKtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK&md5=00b0613e62ce7b5a4c98cb5212fea3b5</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-functional%2520selectivity%2520relationship%2520studies%2520of%2520%25CE%25B2-arrestin-biased%2520dopamine%2520D2%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5130</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1021/jm400520c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400520c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5130-5141&author=C.+Hillerauthor=R.+C.+Klingauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D2%2FD3+receptor+agonists+comprising+an+enyne+moiety&doi=10.1021%2Fjm400520c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Selective Dopamine D2/D3 Receptor Agonists Comprising an Enyne Moiety</span></div><div class="casAuthors">Hiller, Christine; Kling, Ralf C.; Heinemann, Frank W.; Meyer, Karsten; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5130-5141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic ethynylcyclohexynylamines I and ent-I {R = 1,1'-biphenyl-4-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-3-yl, 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl, benzo[b]thiophene-2-yl, ferrocenyl} were prepd. as dopamine receptor agonists with atypical catechol isosteres; their selectivities for dopamine receptors and for activating receptors through G-protein subunits Go and Gi and the metabolic stability of rac-I (R = 4-PhC6H4) were detd.  The ethynylcyclohexynylamines bound to D2-like receptors with high affinities.  Ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) selectively activated D2slow-promoted Go activation over Gi coupling; the most significant functional bias obsd. was for ent-I {R = 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl} which selectively activated Go over Gi coupling at D2long receptors.  Functional selectivity for β-arrestin recruitment over Gi activation was obsd. for I (R = 1,1'-biphenyl-4-yl) and ent-I (R = benzothiophene-2-yl), while ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) preferred β-arrestin recruitment compared to Go coupling.  The structure of a nonracemic N-(ethynylcyclohexenyl)dinitrobenzamide was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXn2SrS-IBCrVg90H21EOLACvtfcHk0ljYWTmR9xsKtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D&md5=3855de949f505a83ed3aa561ca182e75</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm400520c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400520c%26sid%3Dliteratum%253Aachs%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D2%252FD3%2520receptor%2520agonists%2520comprising%2520an%2520enyne%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5130%26epage%3D5141%26doi%3D10.1021%2Fjm400520c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span> <span> </span><span class="NLM_article-title">Effects of β-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnpp.2015.196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26129680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=704-715&author=S.+M.+Parkauthor=M.+Chenauthor=C.+M.+Schmerbergauthor=R.+S.+Dulmanauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=J.+Jinauthor=W.+C.+Wetsel&title=Effects+of+%CE%B2-arrestin-biased+dopamine+D2+receptor+ligands+on+schizophrenia-like+behavior+in+hypoglutamatergic+mice&doi=10.1038%2Fnpp.2015.196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice</span></div><div class="casAuthors">Park, Su M.; Chen, Meng; Schmerberg, Claire M.; Dulman, Russell S.; Rodriguiz, Ramona M.; Caron, Marc G.; Jin, Jian; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">704-715</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Current antipsychotic drugs (APDs) show efficacy with pos. symptoms, but are limited in treating neg. or cognitive features of schizophrenia.  Whereas all currently FDA-approved medications target primarily the dopamine D2 receptor (D2R) to inhibit Gi/o-mediated adenylyl cyclase, a recent study has shown that many APDs affect not only Gi/o- but they can also influence β-arrestin- (βArr)-mediated signaling.  The ability of ligands to differentially affect signaling through these pathways is termed functional selectivity.  We have developed ligands that are devoid of D2R-mediated Gi/o protein signaling, but are simultaneously partial agonists for D2R/βArr interactions.  The purpose of this study was to test the effectiveness of UNC9975 or UNC9994 on schizophrenia-like behaviors in phencyclidine-treated or NR1-knockdown hypoglutamatergic mice.  We have found the UNC compds. reduce hyperlocomotion in the open field, restore PPI, improve novel object recognition memory, partially normalize social behavior, decrease conditioned avoidance responding, and elicit a much lower level of catalepsy than haloperidol.  These preclin. results suggest that exploitation of functional selectivity may provide unique opportunities to develop drugs with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related conditions than medications that are currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuhB8VxuXDbVg90H21EOLACvtfcHk0ljYWTmR9xsKtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO&md5=82de207db3a78d50ff86a48cda2d2e28</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.196%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DDulman%26aufirst%3DR.%2BS.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3DEffects%2520of%2520%25CE%25B2-arrestin-biased%2520dopamine%2520D2%2520receptor%2520ligands%2520on%2520schizophrenia-like%2520behavior%2520in%2520hypoglutamatergic%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26spage%3D704%26epage%3D715%26doi%3D10.1038%2Fnpp.2015.196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Möller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skultety, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Functionally selective dopamine D2, D3 receptor partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4861</span>– <span class="NLM_lpage">4875</span>, <span class="refDoi"> DOI: 10.1021/jm5004039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4861-4875&author=D.+M%C3%B6llerauthor=R.+C.+Klingauthor=M.+Skultetyauthor=K.+Leunerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D2%2C+D3+receptor+partial+agonists&doi=10.1021%2Fjm5004039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm5004039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004039%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DLeuner%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D2%252C%2520D3%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4861%26epage%3D4875%26doi%3D10.1021%2Fjm5004039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein-biased D2 dopamine receptor partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10601</span>– <span class="NLM_lpage">10618</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10601-10618&author=X.+Chenauthor=J.+D.+McCorvyauthor=M.+G.+Fischerauthor=K.+V.+Butlerauthor=Y.+Shenauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+G+protein-biased+D2+dopamine+receptor+partial+agonists&doi=10.1021%2Facs.jmedchem.6b01208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists</span></div><div class="casAuthors">Chen, Xin; McCorvy, John D.; Fischer, Matthew G.; Butler, Kyle V.; Shen, Yudao; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10601-10618</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease.  Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands.  The authors previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist.  In the authors' continuing efforts to identify biased agonists of D2R, the authors unexpectedly discovered a G protein-biased agonist of D2R, compd. 1 (5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[d]thiazole), which is the first G protein-biased D2R agonist from the aripiprazole scaffold.  The authors designed and synthesized novel analogs to explore two regions of 1 and conducted structure-functional selectivity relationship (SFSR) studies.  Here the authors report the discovery of 1, findings from the authors' SFSR studies, and characterization of novel G protein-biased D2R agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeKlhGCqSPxLVg90H21EOLACvtfcHk0ljm8BZWLtFkww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK&md5=81b1435b1ae82438aa3f270f7ee4f853</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DFischer%26aufirst%3DM.%2BG.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520G%2520protein-biased%2520D2%2520dopamine%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10601%26epage%3D10618%26doi%3D10.1021%2Facs.jmedchem.6b01208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Möller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzuneser, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skultety, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzheimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein-biased dopaminergics with a pyrazolo[1,5-a]pyridine substructure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2908</span>– <span class="NLM_lpage">2929</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01857</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01857" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2908-2929&author=D.+M%C3%B6llerauthor=A.+Banerjeeauthor=T.+C.+Uzuneserauthor=M.+Skultetyauthor=T.+Huthauthor=B.+Plouffeauthor=H.+H%C3%BCbnerauthor=C.+Alzheimerauthor=K.+Friedlandauthor=C.+P.+M%C3%BCllerauthor=M.+Bouvierauthor=P.+Gmeiner&title=Discovery+of+G+protein-biased+dopaminergics+with+a+pyrazolo%5B1%2C5-a%5Dpyridine+substructure&doi=10.1021%2Facs.jmedchem.6b01857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure</span></div><div class="casAuthors">Moller Dorothee; Banerjee Ashutosh; Skultety Marika; Hubner Harald; Gmeiner Peter; Uzuneser Taygun C; Muller Christian P; Huth Tobias; Alzheimer Christian; Plouffe Bianca; Bouvier Michel; Friedland Kristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2908-2929</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors.  Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties.  In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists.  Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over β-arrestin recruitment at dopamine D2 receptors.  The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo.  Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSsvEaQplNsM25P7XSLhESfW6udTcc2eYfaD_DVh59Vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D&md5=208855de29fed6b821fd6e4a5bfb412f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01857%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DUzuneser%26aufirst%3DT.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DHuth%26aufirst%3DT.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DAlzheimer%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BP.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520G%2520protein-biased%2520dopaminergics%2520with%2520a%2520pyrazolo%255B1%252C5-a%255Dpyridine%2520substructure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2908%26epage%3D2929%26doi%3D10.1021%2Facs.jmedchem.6b01857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechsteiner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormos, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnchembio.2527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29227473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFGmur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=126-134&author=J.+D.+McCorvyauthor=K.+V.+Butlerauthor=B.+Kellyauthor=K.+Rechsteinerauthor=J.+Karpiakauthor=R.+M.+Betzauthor=B.+L.+Kormosauthor=B.+K.+Shoichetauthor=R.+O.+Drorauthor=J.+Jinauthor=B.+L.+Roth&title=Structure-inspired+design+of+%CE%B2-arrestin-biased+ligands+for+aminergic+GPCRs&doi=10.1038%2Fnchembio.2527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs</span></div><div class="casAuthors">McCorvy, John D.; Butler, Kyle V.; Kelly, Brendan; Rechsteiner, Katie; Karpiak, Joel; Betz, Robin M.; Kormos, Bethany L.; Shoichet, Brian K.; Dror, Ron O.; Jin, Jian; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-134</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Development of biased ligands targeting G protein-coupled receptors (GPCRs) is a promising approach for current drug discovery.  Although structure-based drug design of biased agonists remains challenging even with an abundance of GPCR crystal structures, the authors present an approach for translating GPCR structural data into β-arrestin-biased ligands for aminergic GPCRs.  The authors identified specific amino acid-ligand contacts at transmembrane helix 5 (TM5) and extracellular loop 2 (EL2) responsible for Gi/o and β-arrestin signaling, resp., and targeted those residues to develop biased ligands.  For these ligands, the authors found that bias is conserved at other aminergic GPCRs that retain similar residues at TM5 and EL2.  The authors' approach provides a template for generating arrestin-biased ligands by modifying predicted ligand interactions that block TM5 interactions and promote EL2 interactions.  This strategy may facilitate the structure-guided design of arrestin-biased ligands at other GPCRs, including polypharmacol. biased ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVs9TaoxiFubVg90H21EOLACvtfcHk0ljm8BZWLtFkww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFGmur3I&md5=2725e8487638cc07ce5e6a655fcd29f2</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2527%26sid%3Dliteratum%253Aachs%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKelly%26aufirst%3DB.%26aulast%3DRechsteiner%26aufirst%3DK.%26aulast%3DKarpiak%26aufirst%3DJ.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DKormos%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure-inspired%2520design%2520of%2520%25CE%25B2-arrestin-biased%2520ligands%2520for%2520aminergic%2520GPCRs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D126%26epage%3D134%26doi%3D10.1038%2Fnchembio.2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schools, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of an LSD-bound human serotonin receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2016.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28129538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=377-389&author=D.+Wackerauthor=S.+Wangauthor=J.+D.+McCorvyauthor=R.+M.+Betzauthor=A.+J.+Venkatakrishnanauthor=A.+Levitauthor=K.+Lansuauthor=Z.+L.+Schoolsauthor=T.+Cheauthor=D.+E.+Nicholsauthor=B.+K.+Shoichetauthor=R.+O.+Drorauthor=B.+L.+Roth&title=Crystal+structure+of+an+LSD-bound+human+serotonin+receptor&doi=10.1016%2Fj.cell.2016.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an LSD-bound human serotonin receptor</span></div><div class="casAuthors">Wacker, Daniel; Wang, Sheng; McCorvy, John D.; Betz, Robin M.; Venkatakrishnan, A. J.; Levit, Anat; Lansu, Katherine; Schools, Zachary L.; Che, Tao; Nichols, David E.; Shoichet, Brian K.; Dror, Ron O.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">377-389.e12</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The prototypical hallucinogen, LSD, acts via serotonin receptors, and here the authors describe the crystal structure of LSD in complex with human serotonin receptor 5-HT2B.  The complex revealed conformational rearrangements to accommodate LSD, providing a structural explanation for the conformational selectivity of LSD's key diethylamide moiety.  LSD dissocd. exceptionally slow from both 5-HT2BR and 5-HT2AR, a major target for its psychoactivity.  Mol. dynamics (MD) simulations suggested that LSD's slow binding kinetics may be due to a "lid" formed by extracellular loop 2 (EL2) at the entrance to the binding pocket.  A mutation predicted to increase the mobility of this lid greatly accelerated LSD's binding kinetics and selectively dampened LSD-mediated β-arrestin 2 recruitment.  Thus, this study reveals an unexpected binding mode of LSD, illuminates key features of its kinetics, stereochem., and signaling, and provides a mol. explanation for LSD's actions at human serotonin receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcU-96ccslG7Vg90H21EOLACvtfcHk0lhPo43bnY7cMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaqs7g%253D&md5=5eee71a2d385d97d9891b669e8c5afa1</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DSchools%26aufirst%3DZ.%2BL.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DCrystal%2520structure%2520of%2520an%2520LSD-bound%2520human%2520serotonin%2520receptor%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D377%26epage%3D389%26doi%3D10.1016%2Fj.cell.2016.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agai-Csongor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domany, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogradi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galambos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vago, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlovszky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vastag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tihanyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyertyan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajer-Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemesi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szombathelyi, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3437</span>– <span class="NLM_lpage">3440</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmcl.2012.03.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22537450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3437-3440&author=E.+Agai-Csongorauthor=G.+Domanyauthor=K.+Nogradiauthor=J.+Galambosauthor=I.+Vagoauthor=G.+M.+Keseruauthor=I.+Greinerauthor=I.+Laszlovszkyauthor=A.+Gereauthor=E.+Schmidtauthor=B.+Kissauthor=M.+Vastagauthor=K.+Tihanyiauthor=K.+Saghyauthor=J.+Laszyauthor=I.+Gyertyanauthor=M.+Zajer-Balazsauthor=L.+Gemesiauthor=M.+Kapasauthor=Z.+Szombathelyi&title=Discovery+of+cariprazine+%28RGH-188%29%3A+a+novel+antipsychotic+acting+on+dopamine+D3%2FD2+receptors&doi=10.1016%2Fj.bmcl.2012.03.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors</span></div><div class="casAuthors">Agai-Csongor, Eva; Domany, Gyorgy; Nogradi, Katalin; Galambos, Janos; Vago, Istvan; Keseru, Gyorgy Miklos; Greiner, Istvan; Laszlovszky, Istvan; Gere, Aniko; Schmidt, Eva; Kiss, Bela; Vastag, Monika; Tihanyi, Karoly; Saghy, Katalin; Laszy, Judit; Gyertyan, Istvan; Zajer-Balazs, Maria; Gemesi, Larisza; Kapas, Margit; Szombathelyi, Zsolt</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3437-3440</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Medicinal chem. optimization of an impurity isolated during the scale-up synthesis of a pyridylsulfonamide type dopamine D3/D2 compd. (1, I) led to a series of new piperazine derivs. having affinity to both dopamine D3 and D2 receptors.  Several members of this group showed excellent pharmacokinetic and pharmacodynamic properties as demonstrated by outstanding activities in different antipsychotic tests.  The most promising representative, 2m (cariprazine) had good absorption, excellent brain penetration and advantageous safety profile.  Based on its successful clin. development we are looking forward to the NDA filing of cariprazine in 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgEXo42Fb5i7Vg90H21EOLACvtfcHk0lhPo43bnY7cMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D&md5=c70cd98791c4d5c2da5ac1f3904a8b98</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.104%26sid%3Dliteratum%253Aachs%26aulast%3DAgai-Csongor%26aufirst%3DE.%26aulast%3DDomany%26aufirst%3DG.%26aulast%3DNogradi%26aufirst%3DK.%26aulast%3DGalambos%26aufirst%3DJ.%26aulast%3DVago%26aufirst%3DI.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DGreiner%26aufirst%3DI.%26aulast%3DLaszlovszky%26aufirst%3DI.%26aulast%3DGere%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DE.%26aulast%3DKiss%26aufirst%3DB.%26aulast%3DVastag%26aufirst%3DM.%26aulast%3DTihanyi%26aufirst%3DK.%26aulast%3DSaghy%26aufirst%3DK.%26aulast%3DLaszy%26aufirst%3DJ.%26aulast%3DGyertyan%26aufirst%3DI.%26aulast%3DZajer-Balazs%26aufirst%3DM.%26aulast%3DGemesi%26aufirst%3DL.%26aulast%3DKapas%26aufirst%3DM.%26aulast%3DSzombathelyi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520cariprazine%2520%2528RGH-188%2529%253A%2520a%2520novel%2520antipsychotic%2520acting%2520on%2520dopamine%2520D3%252FD2%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3437%26epage%3D3440%26doi%3D10.1016%2Fj.bmcl.2012.03.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herenbrink, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">A structure-activity analysis of biased agonism at the dopamine D2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9199</span>– <span class="NLM_lpage">9221</span>, <span class="refDoi"> DOI: 10.1021/jm401318w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401318w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9199-9221&author=J.+Shonbergauthor=C.+K.+Herenbrinkauthor=L.+Lopezauthor=A.+Christopoulosauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=J.+R.+Lane&title=A+structure-activity+analysis+of+biased+agonism+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm401318w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Activity Analysis of Biased Agonism at the Dopamine D2 Receptor</span></div><div class="casAuthors">Shonberg, Jeremy; Herenbrink, Carmen Klein; Lopez, Laura; Christopoulos, Arthur; Scammells, Peter J.; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9199-9221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs.  A no. of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia.  As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor.  The authors have generated SAR based on a novel D2R partial agonist, tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate.  This ligand shares structural similarity to cariprazine, a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points.  The authors synthesized a no. of derivs. of tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate with subtle structural modifications, including incorporation of cariprazine fragments.  By combining pharmacol. profiling with anal. methodol. to identify and to quantify bias, the authors have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group contg. the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocktbsOBHWB7Vg90H21EOLACvtfcHk0lhPo43bnY7cMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ&md5=124b940132336819740ec30d2962a3a3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm401318w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401318w%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DHerenbrink%26aufirst%3DC.%2BK.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DA%2520structure-activity%2520analysis%2520of%2520biased%2520agonism%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9199%26epage%3D9221%26doi%3D10.1021%2Fjm401318w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4924</span>– <span class="NLM_lpage">4939</span>, <span class="refDoi"> DOI: 10.1021/jm500457x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500457x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4924-4939&author=M.+Szaboauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Structure-activity+relationships+of+privileged+structures+lead+to+the+discovery+of+novel+biased+ligands+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm500457x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Privileged Structures Lead to the Discovery of Novel Biased Ligands at the Dopamine D2 Receptor</span></div><div class="casAuthors">Szabo, Monika; Klein Herenbrink, Carmen; Christopoulos, Arthur; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4924-4939</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism at GPCRs highlights the potential for the discovery and design of pathway-selective ligands and may confer therapeutic advantages to ligands targeting the dopamine D2 receptor (D2R).  We investigated the determinants of efficacy, affinity, and bias for three privileged structures for the D2R, exploring changes to linker length and incorporation of a heterocyclic unit.  Profiling the compds. in two signaling assays (cAMP and pERK1/2) allowed us to identify and quantify determinants of biased agonism at the D2R.  Substitution on the phenylpiperazine privileged structures (2-methoxy vs 2,3-dichloro) influenced bias when the thienopyridine heterocycle was absent.  Upon inclusion of the thienopyridine unit, the substitution pattern (4,6-di-Me vs 5-chloro-6-methoxy-4-methyl) had a significant effect on bias that overruled the effect of the phenylpiperazine substitution pattern.  This latter observation could be reconciled with an extended binding mode for these compds., whereby the interaction of the heterocycle with a secondary binding pocket may engender bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvED1_D7mzdLVg90H21EOLACvtfcHk0lgEmnQZcZMEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D&md5=944e53ea2b1abf220e4c76a7d33d6f15</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm500457x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500457x%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DStructure-activity%2520relationships%2520of%2520privileged%2520structures%2520lead%2520to%2520the%2520discovery%2520of%2520novel%2520biased%2520ligands%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4924%26epage%3D4939%26doi%3D10.1021%2Fjm500457x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span> <span> </span><span class="NLM_article-title">Multiple signaling routes involved in the regulation of adenylyl cyclase and extracellular regulated kinase by dopamine D<sub>2</sub> and D<sub>3</sub> receptors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.phrs.2012.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23059541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCkurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=31-41&author=M.+Jinauthor=C.+Minauthor=M.+Zhengauthor=D.+I.+Choauthor=S.+J.+Cheongauthor=H.+Kuroseauthor=K.+M.+Kim&title=Multiple+signaling+routes+involved+in+the+regulation+of+adenylyl+cyclase+and+extracellular+regulated+kinase+by+dopamine+D2+and+D3+receptors&doi=10.1016%2Fj.phrs.2012.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple signaling routes involved in the regulation of adenylyl cyclase and extracellular regulated kinase by dopamine D2 and D3 receptors</span></div><div class="casAuthors">Jin, Mingli; Min, Chengchun; Zheng, Mei; Cho, Dong-Im; Cheong, Soo-Jin; Kurose, Hitosh; Kim, Kyeong-Man</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most G protein coupled receptors (GPCR) regulate multiple cellular processes by coupling to more than one kind of G protein.  Furthermore, recent studies have reported G protein-independent/β-arrestin-dependent signaling pathway for some GPCRs.  Dopamine D2 and D3 receptors (D2R, D3R), the major targets of currently used antipsychotic drugs, are co-expressed in some of the same dopaminergic neurons and regulate the same overlapping effectors.  However, the specific subunits of G proteins that regulate each signaling pathway are not clearly identified.  In addn., the existence of β-arrestin-dependent/G protein-independent signaling is not clear for these receptors.  In this study, we detd. the G protein subtypes and β-arrestin dependency involved in the signaling of D2R and D3R, which was measured by inhibition of adenylyl cyclase and extracellular signal-regulated kinase (ERK) activation.  For the inhibition of cAMP prodn. in HEK-293 cells, D2R used the Gαo subunit but D3R used the βγ subunit of Gi family proteins.  For the regulation of ERK activation, D2R used the α subunits of Gi/o proteins both in HEK-293 cells and COS-7 cells, but D3R used Gαo and Gβγ in HEK-293 cells and COS-7 cells, resp. β-Arrestin-dependent/G protein-independent ERK activation was not obsd. for both D2R and D3R.  Agonist-induced β-arrestin translocation was obsd. with D2R but not with D3R, and β-arrestins exerted inhibitory influences on G protein-dependent ERK activation by D2R, but not D3R.  These results show that the D2R and D3R, which have overlapping cellular expressions and functional roles, employ distinct G protein subunits depending on the cell types and the effectors they control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVXecuPvPD8LVg90H21EOLACvtfcHk0lgEmnQZcZMEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCkurvK&md5=87783b85dd9c38aae8c8eb8f3d3f4137</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26aulast%3DMin%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DD.%2BI.%26aulast%3DCheong%26aufirst%3DS.%2BJ.%26aulast%3DKurose%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BM.%26atitle%3DMultiple%2520signaling%2520routes%2520involved%2520in%2520the%2520regulation%2520of%2520adenylyl%2520cyclase%2520and%2520extracellular%2520regulated%2520kinase%2520by%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D67%26spage%3D31%26epage%3D41%26doi%3D10.1016%2Fj.phrs.2012.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) biased agonism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2890-2907&author=A.+Bonifaziauthor=H.+Yanoauthor=M.+P.+Ellenbergerauthor=L.+Mullerauthor=V.+Kumarauthor=M.+F.+Zouauthor=N.+S.+Caiauthor=A.+M.+Guerreroauthor=A.+S.+Woodsauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+bivalent+ligands+based+on+the+sumanirole+pharmacophore+reveal+dopamine+D2+receptor+%28D2R%29+biased+agonism&doi=10.1021%2Facs.jmedchem.6b01875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Ellenberger, Michael P.; Muller, Ludovic; Kumar, Vivek; Zou, Mu-Fa; Cai, Ning Sheng; Guerrero, Adrian M.; Woods, Amina S.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2890-2907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype.  The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways.  Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore.  We found that substitutions in the N-1- and/or N-5-positions, physiochem. properties of those substituents, and secondary arom. pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment.  Compd. 19 was identified as a new lead for its selective D2 G-protein biased agonism with an EC50 in the subnanomolar range.  Structure-activity correlations were obsd. between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compds. to selectively activate G-proteins vs. β-arrestin recruitment in D2R-BRET functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprfScHokUgP7Vg90H21EOLACvtfcHk0lgEmnQZcZMEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D&md5=24bf22a101756e44fbc8f8345d2c1fe4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01875%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520bivalent%2520ligands%2520based%2520on%2520the%2520sumanirole%2520pharmacophore%2520reveal%2520dopamine%2520D2%2520receptor%2520%2528D2R%2529%2520biased%2520agonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2890%26epage%3D2907%26doi%3D10.1021%2Facs.jmedchem.6b01875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, Z.</span></span> <span> </span><span class="NLM_article-title">Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1002/mds.21191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmds.21191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=483-489&author=P.+Baroneauthor=J.+Lambauthor=A.+Ellisauthor=Z.+Clarke&title=Sumanirole+versus+placebo+or+ropinirole+for+the+adjunctive+treatment+of+patients+with+advanced+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.21191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1002%2Fmds.21191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.21191%26sid%3Dliteratum%253Aachs%26aulast%3DBarone%26aufirst%3DP.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DZ.%26atitle%3DSumanirole%2520versus%2520placebo%2520or%2520ropinirole%2520for%2520the%2520adjunctive%2520treatment%2520of%2520patients%2520with%2520advanced%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2007%26volume%3D22%26spage%3D483%26epage%3D489%26doi%3D10.1002%2Fmds.21191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Borreguero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versavel, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study</span>. <i>Sleep Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.sleep.2006.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.sleep.2006.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=17239657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FptlChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=119-127&author=D.+Garcia-Borregueroauthor=J.+Winkelmanauthor=A.+Adamsauthor=A.+Ellisauthor=M.+Morrisauthor=J.+Lambauthor=G.+Laytonauthor=M.+Versavel&title=Efficacy+and+tolerability+of+sumanirole+in+restless+legs+syndrome%3A+a+phase+II%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+dose-response+study&doi=10.1016%2Fj.sleep.2006.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study</span></div><div class="casAuthors">Garcia-Borreguero Diego; Winkelman John; Adams Alieu; Ellis Amanda; Morris Mark; Lamb Janice; Layton Gary; Versavel Mark</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-27</span>
        ISSN:<span class="NLM_cas:issn">1389-9457</span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare the efficacy, safety and tolerability of sumanirole with placebo in patients with idiopathic restless legs syndrome (RLS).  METHODS:  In this double-blind, placebo-controlled, randomized, parallel-group, dose-response study, 270 patients with idiopathic RLS were enrolled and randomized to receive sumanirole 0.5, 1.0, 2.0, or 4.0mg, or placebo.  The primary efficacy endpoint was mean change of the total score of the International Restless Legs Scale (IRLS-10), a 10-item scale, from baseline to end of maintenance.  Secondary assessments included polysomnography (PSG) variables.  RESULTS:  Treatment with sumanirole was well tolerated.  Mean change in IRLS-10 showed no statistically significant change compared with placebo at any dose, although the mean change with the 4.0-mg dose was numerically greater than the other doses and placebo.  PSG variables, specifically the periodic leg movements during sleep, showed statistically significant dose-related improvement in favor of sumanirole.  Consistent with earlier multinational, multicenter studies in RLS, high placebo response rates were seen with IRLS-10 but not with PSG variables.  CONCLUSIONS:  Given data published in Parkinson's disease, the dose range of sumanirole selected here may have been too low.  Alternatively, dopamine D(2) selective agents could be intrinsically less effective than agonists with combined D(2)/D(3) activity.  Sumanirole demonstrated an excellent safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0REIOVoKVNDEwO064Z95rfW6udTcc2eaIX8eS6l1w37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FptlChtw%253D%253D&md5=aeeae1bc95f4cbd3678ad89c9ebd368e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2006.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2006.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Borreguero%26aufirst%3DD.%26aulast%3DWinkelman%26aufirst%3DJ.%26aulast%3DAdams%26aufirst%3DA.%26aulast%3DEllis%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DM.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DLayton%26aufirst%3DG.%26aulast%3DVersavel%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520sumanirole%2520in%2520restless%2520legs%2520syndrome%253A%2520a%2520phase%2520II%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-response%2520study%26jtitle%3DSleep%2520Med.%26date%3D2007%26volume%3D8%26spage%3D119%26epage%3D127%26doi%3D10.1016%2Fj.sleep.2006.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Bittner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Đordevic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacher, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skepner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennehy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faloon, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Functionally biased D2R antagonists: targeting the β-arrestin pathway to improve antipsychotic treatment</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00168</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00168" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlOrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1038-1047&author=M.+We%C3%AFwerauthor=Q.+Xuauthor=J.+P.+Galeauthor=M.+Lewisauthor=A.+J.+Campbellauthor=F.+A.+Schroederauthor=G.+C.+Van+de+Bittnerauthor=M.+Walkauthor=A.+Amayaauthor=P.+Suauthor=L.+%C4%90ordevicauthor=J.+R.+Sacherauthor=A.+Skepnerauthor=D.+Feiauthor=K.+Dennehyauthor=S.+Nguyenauthor=P.+W.+Faloonauthor=J.+Perezauthor=J.+R.+Cottrellauthor=F.+Liuauthor=M.+Palmerauthor=J.+Q.+Panauthor=J.+M.+Hookerauthor=Y.+L.+Zhangauthor=E.+Scolnickauthor=F.+F.+Wagnerauthor=E.+B.+Holson&title=Functionally+biased+D2R+antagonists%3A+targeting+the+%CE%B2-arrestin+pathway+to+improve+antipsychotic+treatment&doi=10.1021%2Facschembio.8b00168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment</span></div><div class="casAuthors">Weiwer, Michel; Xu, Qihong; Gale, Jennifer P.; Lewis, Michael; Campbell, Arthur J.; Schroeder, Frederick A.; Van de Bittner, Genevieve C.; Walk, Michelle; Amaya, Aldo; Su, Ping; Dordevic, Luka; Sacher, Joshua R.; Skepner, Adam; Fei, David; Dennehy, Kelly; Nguyen, Shannon; Faloon, Patrick W.; Perez, Jose; Cottrell, Jeffrey R.; Liu, Fang; Palmer, Michelle; Pan, Jen Q.; Hooker, Jacob M.; Zhang, Yan-Ling; Scolnick, Edward; Wagner, Florence F.; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1038-1047</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Schizophrenia is a severe neuropsychiatric disease that lacks completely effective and safe therapies.  As a polygenic disorder, genetic studies have only started to shed light on its complex etiol.  To date, the pos. symptoms of schizophrenia are well-managed by antipsychotic drugs, which primarily target the dopamine D2 receptor (D2R).  However, these antipsychotics are often accompanied by severe side effects, including motoric symptoms.  At D2R, antipsychotic drugs antagonize both G-protein dependent (Gαi/o) signaling and G-protein independent (β-arrestin) signaling.  However, the relevant contributions of the distinct D2R signaling pathways to antipsychotic efficacy and on-target side effects (motoric) are still incompletely understood.  Recent evidence from mouse genetic and pharmacol. studies point to β-arrestin signaling as the major driver of antipsychotic efficacy and suggest that a β-arrestin biased D2R antagonist could achieve an addnl. level of selectivity at D2R, increasing the therapeutic index of next generation antipsychotics.  Here, we characterize BRD5814, a highly brain penetrant β-arrestin biased D2R antagonist.  BRD5814 demonstrated good target engagement via PET imaging, achieving efficacy in an amphetamine-induced hyperlocomotion mouse model with strongly reduced motoric side effects in a rotarod performance test.  This proof of concept study opens the possibility for the development of a new generation of pathway selective antipsychotics at D2R with reduced side effect profiles for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPBrMik6d7a7Vg90H21EOLACvtfcHk0ljnHijHT3GcuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlOrtbw%253D&md5=51d636dd2a0ebfc83d58a6158a1da40e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00168%26sid%3Dliteratum%253Aachs%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DVan%2Bde%2BBittner%26aufirst%3DG.%2BC.%26aulast%3DWalk%26aufirst%3DM.%26aulast%3DAmaya%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DP.%26aulast%3D%25C4%2590ordevic%26aufirst%3DL.%26aulast%3DSacher%26aufirst%3DJ.%2BR.%26aulast%3DSkepner%26aufirst%3DA.%26aulast%3DFei%26aufirst%3DD.%26aulast%3DDennehy%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DS.%26aulast%3DFaloon%26aufirst%3DP.%2BW.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DCottrell%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DJ.%2BQ.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DScolnick%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DFunctionally%2520biased%2520D2R%2520antagonists%253A%2520targeting%2520the%2520%25CE%25B2-arrestin%2520pathway%2520to%2520improve%2520antipsychotic%2520treatment%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D1038%26epage%3D1047%26doi%3D10.1021%2Facschembio.8b00168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D<sub>2L</sub> receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1124/mol.110.068106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.110.068106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=575-585&author=N.+Tschammerauthor=S.+Bollingerauthor=T.+Kenakinauthor=P.+Gmeiner&title=Histidine+6.55+is+a+major+determinant+of+ligand-biased+signaling+in+dopamine+D2L+receptor&doi=10.1124%2Fmol.110.068106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.068106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.068106%26sid%3Dliteratum%253Aachs%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DBollinger%26aufirst%3DS.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DHistidine%25206.55%2520is%2520a%2520major%2520determinant%2520of%2520ligand-biased%2520signaling%2520in%2520dopamine%2520D2L%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D575%26epage%3D585%26doi%3D10.1124%2Fmol.110.068106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0lhJ26AO5NnJng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12ltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=681-692&author=J.+L.+Conroyauthor=R.+B.+Freeauthor=D.+R.+Sibley&title=Identification+of+G+protein-biased+agonists+that+fail+to+recruit+%CE%B2-arrestin+or+promote+internalization+of+the+D1+dopamine+receptor&doi=10.1021%2Facschemneuro.5b00020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of G Protein-Biased Agonists That Fail To Recruit β-Arrestin or Promote Internalization of the D1 Dopamine Receptor</span></div><div class="casAuthors">Conroy, Jennie L.; Free, R. Benjamin; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-692</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The D1 dopamine receptor (D1R) has been implicated in numerous neuropsychiatric disorders, and D1R-selective ligands have potential as therapeutic agents.  Previous studies have identified substituted benzazepines as D1R-selective agonists, but the in vivo effects of these compds. have not correlated well with their in vitro pharmacol. activities.  A series of substituted benzazepines, and structurally dissimilar D1R-selective agonists, were tested for their functional effects on D1R-mediated cAMP accumulation, D1R-promoted β-arrestin recruitment, and D1R internalization using live cell functional assays.  All compds. tested elicited an increase in the level of cAMP accumulation, albeit with a range of efficacies.  However, when the compds. were evaluated for β-arrestin recruitment, a subset of substituted benzazepines, SKF 83959, SKF 38393, SKF 82957, SKF 77434, and SKF 75670, failed to activate this pathway, whereas the others showed similar activation efficacies as seen with cAMP accumulation.  When tested as antagonists, the five biased compds. all inhibited dopamine-stimulated β-arrestin recruitment.  Further, D1R internalization assays revealed a corroborating pattern of activity in that the G protein-biased compds. failed to promote D1R internalization.  Interestingly, the biased signaling was unique for the D1R, as the same compds. were agonists of the related D5 dopamine receptor (D5R), but revealed no signaling bias.  We have identified a group of substituted benzazepine ligands that are agonists at D1R-mediated G protein signaling, but antagonists of D1R recruitment of β-arrestin, and also devoid of agonist-induced receptor endocytosis.  These data may be useful for interpreting the contrasting effects of these compds. in vitro vs. in vivo, and also for the understanding of pathway-selective signaling of the D1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSzHbUv0uO9LVg90H21EOLACvtfcHk0lhJ26AO5NnJng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12ltbg%253D&md5=5f955a73b220ec7c20e483e6192be737</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00020%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DIdentification%2520of%2520G%2520protein-biased%2520agonists%2520that%2520fail%2520to%2520recruit%2520%25CE%25B2-arrestin%2520or%2520promote%2520internalization%2520of%2520the%2520D1%2520dopamine%2520receptor%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D681%26epage%3D692%26doi%3D10.1021%2Facschemneuro.5b00020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, M. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ghundi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span> <span> </span><span class="NLM_article-title">D1–D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of G<sub>q/11</sub> in the striatum</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1073/pnas.0604049104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0604049104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=654-659&author=A.+J.+Rashidauthor=C.+H.+Soauthor=M.+M.+C.+Kongauthor=T.+Furtakauthor=M.+El-Ghundiauthor=R.+Chengauthor=B.+F.+O%E2%80%99Dowdauthor=S.+R.+George&title=D1%E2%80%93D2+dopamine+receptor+heterooligomers+with+unique+pharmacology+are+coupled+to+rapid+activation+of+Gq%2F11+in+the+striatum&doi=10.1073%2Fpnas.0604049104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0604049104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0604049104%26sid%3Dliteratum%253Aachs%26aulast%3DRashid%26aufirst%3DA.%2BJ.%26aulast%3DSo%26aufirst%3DC.%2BH.%26aulast%3DKong%26aufirst%3DM.%2BM.%2BC.%26aulast%3DFurtak%26aufirst%3DT.%26aulast%3DEl-Ghundi%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26atitle%3DD1%25E2%2580%2593D2%2520dopamine%2520receptor%2520heterooligomers%2520with%2520unique%2520pharmacology%2520are%2520coupled%2520to%2520rapid%2520activation%2520of%2520Gq%252F11%2520in%2520the%2520striatum%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D654%26epage%3D659%26doi%3D10.1073%2Fpnas.0604049104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volfson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilmette, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salafia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M. D.</span></span> <span> </span><span class="NLM_article-title">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">674</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02776-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fs41467-017-02776-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29445200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=674&author=D.+L.+Grayauthor=J.+A.+Allenauthor=S.+Menteauthor=R.+E.+O%E2%80%99Connorauthor=G.+J.+DeMarcoauthor=I.+Efremovauthor=P.+Tierneyauthor=D.+Volfsonauthor=J.+Davorenauthor=E.+Guilmetteauthor=M.+Salafiaauthor=R.+Kozakauthor=M.+D.+Ehlers&title=Impaired+%CE%B2-arrestin+recruitment+and+reduced+desensitization+by+non-catechol+agonists+of+the+D1+dopamine+receptor&doi=10.1038%2Fs41467-017-02776-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span></div><div class="casAuthors">Gray David L; Mente Scot; Efremov Ivan; Davoren Jennifer; Gray David L; Allen John A; Tierney Patrick; Volfson Dmitri; Guilmette Edward; Kozak Rouba; Ehlers Michael D; Allen John A; O'Connor Rebecca E; Salafia Michelle; DeMarco George J; Ehlers Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">674</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Selective activation of dopamine D1 receptors (D1Rs) has been pursued for 40 years as a therapeutic strategy for neurologic and psychiatric diseases due to the fundamental role of D1Rs in motor function, reward processing, and cognition.  All known D1R-selective agonists are catechols, which are rapidly metabolized and desensitize the D1R after prolonged exposure, reducing agonist response.  As such, drug-like selective D1R agonists have remained elusive.  Here we report a novel series of selective, potent non-catechol D1R agonists with promising in vivo pharmacokinetic properties.  These ligands stimulate adenylyl cyclase signaling and are efficacious in a rodent model of Parkinson's disease after oral administration.  They exhibit distinct binding to the D1R orthosteric site and a novel functional profile including minimal receptor desensitization, reduced recruitment of β-arrestin, and sustained in vivo efficacy.  These results reveal a novel class of D1 agonists with favorable drug-like properties, and define the molecular basis for catechol-specific recruitment of β-arrestin to D1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShdJOozuyZkBe4jJGKT5N0fW6udTcc2eYueHri_DZmB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D&md5=2ba64bda304b083647eedff999f3fdcd</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02776-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02776-7%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DD.%2BL.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DDeMarco%26aufirst%3DG.%2BJ.%26aulast%3DEfremov%26aufirst%3DI.%26aulast%3DTierney%26aufirst%3DP.%26aulast%3DVolfson%26aufirst%3DD.%26aulast%3DDavoren%26aufirst%3DJ.%26aulast%3DGuilmette%26aufirst%3DE.%26aulast%3DSalafia%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DR.%26aulast%3DEhlers%26aufirst%3DM.%2BD.%26atitle%3DImpaired%2520%25CE%25B2-arrestin%2520recruitment%2520and%2520reduced%2520desensitization%2520by%2520non-catechol%2520agonists%2520of%2520the%2520D1%2520dopamine%2520receptor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D674%26doi%3D10.1038%2Fs41467-017-02776-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span> <span> </span><span class="NLM_article-title">Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.071092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.104.071092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=15292458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=1008-1015&author=E.+M.+Jutkiewiczauthor=J.+Bergman&title=Effects+of+dopamine+D1+ligands+on+eye+blinking+in+monkeys%3A+efficacy%2C+antagonism%2C+and+D1%2FD2+interactions&doi=10.1124%2Fjpet.104.071092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dopamine D1 ligands on eye blinking in monkeys: Efficacy, antagonism, and D1/D2 interactions</span></div><div class="casAuthors">Jutkiewicz, Emily M.; Bergman, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1008-1015</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dopamine D1 ligands have been classified and ordered according to efficacy in both in vitro and in vivo studies.  In the present expts., dopamine D1 ligands reported to differ in in vitro efficacy were evaluated for efficacy-related effects on eye blinking in squirrel monkeys.  Addnl. comparisons were made with the effects of D2 receptor agonists and indirect dopamine agonists.  The results show that D1 agonists increased eye blinking in an efficacy-related manner, whereas the D1 receptor blocker SCH 39166 only decreased rates of eye blinking.  D1 high-efficacy agonists induced rates of eye blinking that were 2- to 3-fold greater than obsd. with dopamine D2 agonists and indirect agonists.  In drug combination expts., increases in eye blinking induced by the D1 high-efficacy agonist R-(+)-6-Br-APB [R-(+)-6-bromo-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] were antagonized by both the D1 antagonist SCH 39166 and the lower efficacy agonist SKF 83959, consistent with dopamine D1 receptor mediation of these behavioral effects.  The dopamine D2 agonist (+)-PHNO [(+)-N-propyl-hydroxynaphthoxazine], which selectively activates dopamine D2 receptors, also attenuated D1 agonist-induced increase in eye blinking, suggesting that D2 receptor actions may inhibit D1-mediated increases in eye blinking.  Overall, eye blink rate appears to be a robust behavioral measure that can be used to measure changes in dopaminergic D1 signaling and as a functional assay of agonist efficacy at dopamine D1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrldySt7xAQHrVg90H21EOLACvtfcHk0ljH9wK4uX6nAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzF&md5=1071e52cc321c4ec2fb910d0f3fef5a1</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.071092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.071092%26sid%3Dliteratum%253Aachs%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DBergman%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520dopamine%2520D1%2520ligands%2520on%2520eye%2520blinking%2520in%2520monkeys%253A%2520efficacy%252C%2520antagonism%252C%2520and%2520D1%252FD2%2520interactions%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D1008%26epage%3D1015%26doi%3D10.1124%2Fjpet.104.071092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure and function of serotonin G protein-coupled receptors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.pharmthera.2015.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25601315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2015&pages=129-142&author=J.+D.+McCorvyauthor=B.+L.+Roth&title=Structure+and+function+of+serotonin+G+protein-coupled+receptors&doi=10.1016%2Fj.pharmthera.2015.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of serotonin G protein-coupled receptors</span></div><div class="casAuthors">McCorvy, John D.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-142</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Serotonin receptors are prevalent throughout the nervous system and the periphery, and remain one of the most lucrative and promising drug discovery targets for disorders ranging from migraine headaches to neuropsychiatric disorders such as schizophrenia and depression.  There are 14 distinct serotonin receptors, of which 13 are G protein-coupled receptors (GPCRs), which are targets for approx. 40% of the approved medicines.  Recent crystallog. and biochem. evidence has provided a converging understanding of the basic structure and functional mechanics of GPCR activation.  Currently, two GPCR crystal structures exist for the serotonin family, the 5-HT1B and 5-HT2B receptor, with the antimigraine and valvulopathic drug ergotamine bound.  The first serotonin crystal structures not only provide the first evidence of serotonin receptor topog. but also provide mechanistic explanations into functional selectivity or biased agonism.  This review will detail the findings of these crystal structures from a mol. and mutagenesis perspective for driving rational drug design for novel therapeutics incorporating biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpapliz37oS9bVg90H21EOLACvtfcHk0ljH9wK4uX6nAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisbs%253D&md5=0fcfbc57dfb7047f6ffb7c74d437b5b4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520and%2520function%2520of%2520serotonin%2520G%2520protein-coupled%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D150%26spage%3D129%26epage%3D142%26doi%3D10.1016%2Fj.pharmthera.2015.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maayani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramellini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W. P.</span></span> <span> </span><span class="NLM_article-title">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1124/mol.54.1.94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.54.1.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=9658194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=94-104&author=K.+A.+Bergauthor=S.+Maayaniauthor=J.+Goldfarbauthor=C.+Scaramelliniauthor=P.+Leffauthor=W.+P.+Clarke&title=Effector+pathway-dependent+relative+efficacy+at+serotonin+type+2A+and+2C+receptors%3A+evidence+for+agonist-directed+trafficking+of+receptor+stimulus&doi=10.1124%2Fmol.54.1.94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span></div><div class="casAuthors">Berg, Kelly A.; Maayani, Saul; Goldfarb, Joseph; Scaramellini, Clare; Leff, Paul; Clarke, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">There are many examples of a single receptor coupling directly to more than one cellular signal transduction pathway.  Although traditional receptor theory allows for activation of multiple cellular effectors by agonists, it predicts that the relative degree of activation of each effector pathway by an agonist (relative efficacy) must be the same.  In the current expts., we demonstrate that agonists at the human serotonin2A (5-HT2A) and 5-HT2C receptors activate differentially two signal transduction pathways independently coupled to the receptors [phospholipase C (PLC)-mediated inositol phosphate (IP) accumulation and phospholipase A2 (PLA2)-mediated arachidonic acid (AA) release].  The relative efficacies of agonists differed depending on which signal transduction pathway was measured.  Moreover, relative to 5-HT, some 5-HT2C agonists (e.g., 3-trifluoromethylphenyl-piperazine) preferentially activated the PLC-IP pathway, whereas others (e.g., lysergic acid diethylamide) favored the PLA2-AA pathway.  In contrast, when two dependent responses were measured (IP accumulation and calcium mobilization), agonist relative efficacies were not different.  These data strongly support the hypothesis termed "agonist-directed trafficking of receptor stimulus" recently proposed by Kenakin [Trends Pharmacol Sci 16:232-238 (1995)].  Concn.-response curves to 5-HT2C agonists were fit well by a three-state model of receptor activation, suggesting that two active receptor states may be sufficient to explain pathway-dependent agonist efficacy.  Rational drug design that optimizes preferential effector activity within a group of receptor-selective drugs holds the promise of increased selectivity in clin. useful agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpidEqbbZNg07Vg90H21EOLACvtfcHk0ljH9wK4uX6nAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D&md5=99239b54cc498d1254aad42298ea5684</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fmol.54.1.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.54.1.94%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DK.%2BA.%26aulast%3DMaayani%26aufirst%3DS.%26aulast%3DGoldfarb%26aufirst%3DJ.%26aulast%3DScaramellini%26aufirst%3DC.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26atitle%3DEffector%2520pathway-dependent%2520relative%2520efficacy%2520at%2520serotonin%2520type%25202A%2520and%25202C%2520receptors%253A%2520evidence%2520for%2520agonist-directed%2520trafficking%2520of%2520receptor%2520stimulus%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D54%26spage%3D94%26epage%3D104%26doi%3D10.1124%2Fmol.54.1.94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpsoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> receptor structures reveal the structural basis of GPCR polypharmacology</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2018.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29398112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=719-730&author=Y.+Pengauthor=J.+D.+McCorvyauthor=K.+Harpsoeauthor=K.+Lansuauthor=S.+G.+Yuanauthor=P.+Popovauthor=L.+Quauthor=M.+C.+Puauthor=T.+Cheauthor=L.+F.+Nikolajsenauthor=X.+P.+Huangauthor=Y.+R.+Wuauthor=L.+Shenauthor=W.+E.+Bjorn-Yoshimotoauthor=K.+Dingauthor=D.+Wackerauthor=G.+W.+Hanauthor=J.+J.+Chengauthor=V.+Katritchauthor=A.+A.+Jensenauthor=M.+A.+Hansonauthor=S.+W.+Zhaoauthor=D.+E.+Gloriamauthor=B.+L.+Rothauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=5-HT2C+receptor+structures+reveal+the+structural+basis+of+GPCR+polypharmacology&doi=10.1016%2Fj.cell.2018.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span></div><div class="casAuthors">Peng, Yao; McCorvy, John D.; Harpsoee, Kasper; Lansu, Katherine; Yuan, Shuguang; Popov, Petr; Qu, Lu; Pu, Mengchen; Che, Tao; Nikolajsen, Louise F.; Huang, Xi-Ping; Wu, Yiran; Shen, Ling; Bjoern-Yoshimoto, Walden E.; Ding, Kang; Wacker, Daniel; Han, Gye Won; Cheng, Jianjun; Katritch, Vsevolod; Jensen, Anders A.; Hanson, Michael A.; Zhao, Suwen; Gloriam, David E.; Roth, Bryan L.; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-730.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs frequently require interactions with multiple targets-via a process known as polypharmacol.-to achieve their therapeutic actions.  Currently, drugs targeting several serotonin receptors, including the 5-HT2C receptor, are useful for treating obesity, drug abuse, and schizophrenia.  The competing challenges of developing selective 5-HT2C receptor ligands or creating drugs with a defined polypharmacol. profile, esp. aimed at G protein-coupled receptors (GPCRs), remain extremely difficult.  Here, we solved two structures of the 5-HT2C receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT2A-C receptor-selective inverse agonist ritanserin at resolns. of 3.0 Å and 2.7 Å, resp.  We analyzed their resp. binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacol. actions.  This study investigates the structural basis of polypharmacol. at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooMwdaPWz7FLVg90H21EOLACvtfcHk0ljQODpZWY6Rgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D&md5=b6c7f55568544a8c363794fa12f18175</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DHarpsoe%26aufirst%3DK.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DS.%2BG.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%2BC.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DWu%26aufirst%3DY.%2BR.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%2BJ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DZhao%26aufirst%3DS.%2BW.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3D5-HT2C%2520receptor%2520structures%2520reveal%2520the%2520structural%2520basis%2520of%2520GPCR%2520polypharmacology%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D719%26epage%3D730%26doi%3D10.1016%2Fj.cell.2018.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural features for functional selectivity at serotonin receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1126/science.1232808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1232808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23519215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=615-619&author=D.+Wackerauthor=C.+Wangauthor=V.+Katritchauthor=G.+W.+Hanauthor=X.+P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=Y.+Jiangauthor=M.+Chuauthor=F.+Y.+Siuauthor=W.+Liuauthor=H.+E.+Xuauthor=V.+Cherezovauthor=B.+L.+Rothauthor=R.+C.+Stevens&title=Structural+features+for+functional+selectivity+at+serotonin+receptors&doi=10.1126%2Fscience.1232808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Features for Functional Selectivity at Serotonin Receptors</span></div><div class="casAuthors">Wacker, Daniel; Wang, Chong; Katritch, Vsevolod; Han, Gye Won; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Jiang, Yi; Chu, Meihua; Siu, Fai Yiu; Liu, Wei; Xu, H. Eric; Cherezov, Vadim; Roth, Bryan L.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">615-619</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Drugs active at G protein-coupled receptors (GPCRs) can differentially modulate either canonical or noncanonical signaling pathways via a phenomenon known as functional selectivity or biased signaling.  The authors report biochem. studies showing that the hallucinogen lysergic acid diethylamide, its precursor ergotamine (ERG), and related ergolines display strong functional selectivity for β-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are relatively unbiased at the 5-HT1B receptor.  To investigate the structural basis for biased signaling, the authors detd. the crystal structure of the human 5-HT2B receptor bound to ERG and compared it with the 5-HT1B/ERG structure.  Given the relatively poor understanding of GPCR structure and function to date, insight into different GPCR signaling pathways is important to better understand both adverse and favorable therapeutic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreo_QegM-j7bVg90H21EOLACvtfcHk0ljQODpZWY6Rgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksb0%253D&md5=16e96d0255be3ac367aeda7187aa4c15</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232808%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DM.%26aulast%3DSiu%26aufirst%3DF.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DH.%2BE.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520features%2520for%2520functional%2520selectivity%2520at%2520serotonin%2520receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D615%26epage%3D619%26doi%3D10.1126%2Fscience.1232808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for molecular recognition at serotonin receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1126/science.1232807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1232807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23519210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=610-614&author=C.+Wangauthor=Y.+Jiangauthor=J.+M.+Maauthor=H.+X.+Wuauthor=D.+Wackerauthor=V.+Katritchauthor=G.+W.+Hanauthor=W.+Liuauthor=X.+P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=X.+Gaoauthor=X.+E.+Zhouauthor=K.+Melcherauthor=C.+H.+Zhangauthor=F.+Baiauthor=H.+Y.+Yangauthor=L.+L.+Yangauthor=H.+L.+Jiangauthor=B.+L.+Rothauthor=V.+Cherezovauthor=R.+C.+Stevensauthor=H.+E.+Xu&title=Structural+basis+for+molecular+recognition+at+serotonin+receptors&doi=10.1126%2Fscience.1232807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Molecular Recognition at Serotonin Receptors</span></div><div class="casAuthors">Wang, Chong; Jiang, Yi; Ma, Jinming; Wu, Huixian; Wacker, Daniel; Katritch, Vsevolod; Han, Gye Won; Liu, Wei; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Gao, Xiang; Zhou, X. Edward; Melcher, Karsten; Zhang, Chenghai; Bai, Fang; Yang, Huaiyu; Yang, Linlin; Jiang, Hualiang; Roth, Bryan L.; Cherezov, Vadim; Stevens, Raymond C.; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">610-614</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiol. through the 5-HT receptor family.  The authors report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine and dihydroergotamine.  The structures reveal similar binding modes for these ligands, which occupy the orthosteric pocket and an extended binding pocket close to the extracellular loops.  The orthosteric pocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist activity of 5-HT.  Compared with the structure of the 5-HT2B receptor, the 5-HT1B receptor displays a 3 angstrom outward shift at the extracellular end of helix V, resulting in a more open extended pocket that explains subtype selectivity.  Together with docking and mutagenesis studies, these structures provide a comprehensive structural basis for understanding receptor-ligand interactions and designing subtype-selective serotonergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLc0rOIqg_2bVg90H21EOLACvtfcHk0lgMFsSC-PebKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D&md5=ce0773088a86f6a2c83b6cb77a63e708</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232807%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DH.%2BX.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%2BE.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520basis%2520for%2520molecular%2520recognition%2520at%2520serotonin%2520receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D610%26epage%3D614%26doi%3D10.1126%2Fscience.1232807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">We need 2C but not 2B: developing serotonin 2C (5-HT<sub>2C</sub>) receptor agonists for the treatment of CNS disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fcmdc.201500437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26507582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1963-1967&author=J.+J.+Chengauthor=A.+P.+Kozikowski&title=We+need+2C+but+not+2B%3A+developing+serotonin+2C+%285-HT2C%29+receptor+agonists+for+the+treatment+of+CNS+disorders&doi=10.1002%2Fcmdc.201500437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders</span></div><div class="casAuthors">Cheng, Jianjun; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serotonin 2C (5-HT2C) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia.  In this Viewpoint article, recent progress in developing selective 5-HT2C agonists for use in treating these disorders is summarized, including the work of our group.  Challenges in this field and the possible future directions are described.  Homol. modeling as a method to predict the binding modes of 5-HT2C ligands to the receptor is also discussed.  Compared to known ligands, the improved pharmacol. profiles of the 2-phenylcyclopropylmethylamine-based 5-HT2C agonists make them preferred candidates for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr43VsLXn0mBLVg90H21EOLACvtfcHk0lgMFsSC-PebKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J&md5=4a7f2040f4c57da292c7ebac2de8d726</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWe%2520need%25202C%2520but%2520not%25202B%253A%2520developing%2520serotonin%25202C%2520%25285-HT2C%2529%2520receptor%2520agonists%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fcmdc.201500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> agonists modulate schizophrenia-like behaviors in mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2177</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnpp.2017.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28294132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=2163-2177&author=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=J.+Chengauthor=M.+Huangauthor=C.+M.+Schmerbergauthor=H.+Y.+Meltzerauthor=B.+L.+Rothauthor=A.+P.+Kozikowskiauthor=W.+C.+Wetsel&title=5-HT2C+agonists+modulate+schizophrenia-like+behaviors+in+mice&doi=10.1038%2Fnpp.2017.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice</span></div><div class="casAuthors">Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Cheng, Jianjun; Huang, Mei; Schmerberg, Claire M.; Meltzer, Herbert Y.; Roth, Bryan L.; Kozikowski, Alan P.; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2163-2177</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D2 or serotonin (5-HT2A) receptors, or both; however, these medications are not universally effective, they may produce undesirable side effects, and provide only partial amelioration of neg. and cognitive symptoms.  The heterogeneity of pharmacol. responses in schizophrenic patients suggests that addnl. drug targets may be effective in improving aspects of this syndrome.  Recent evidence suggests that 5-HT2C receptors may be a promising target for schizophrenia since their activation reduces mesolimbic nigrostriatal dopamine release (which conveys antipsychotic action), they are expressed almost exclusively in CNS, and have wt.-loss-promoting capabilities.  A difficulty in developing 5-HT2C agonists is that most ligands also possess 5-HT2B and/or 5-HT2A activities.  We have developed selective 5-HT2C ligands and herein describe their preclin. effectiveness for treating schizophrenia-like behaviors.  JJ-3-45, JJ-3-42, and JJ-5-34 reduced amphetamine-stimulated hyperlocomotion, restored amphetamine-disrupted prepulse inhibition, improved social behavior, and novel object recognition memory in NMDA receptor hypofunctioning NR1-knockdown mice, and were essentially devoid of catalepsy.  However, they decreased motivation in a breakpoint assay and did not promote reversal learning in MK-801-treated mice.  Somewhat similar effects were obsd. with lorcaserin, a 5-HT2C agonist with potent 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity.  Microdialysis studies revealed that both JJ-3-42 and lorcaserin reduced dopamine efflux in the infralimbic cortex, while only JJ-3-42 decreased it in striatum.  Collectively, these results provide addnl. evidence that 5-HT2C receptors are suitable drug targets with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related disorders than current APDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTwGQU6HLhHrVg90H21EOLACvtfcHk0lgMFsSC-PebKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D&md5=f4b074cad46559dd52e7d622c8af24f9</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.52%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3D5-HT2C%2520agonists%2520modulate%2520schizophrenia-like%2520behaviors%2520in%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D2163%26epage%3D2177%26doi%3D10.1038%2Fnpp.2017.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of functionally selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9866</span>– <span class="NLM_lpage">9880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9866-9880&author=J.+J.+Chengauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=H.+Zhuauthor=T.+Kenakinauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Design+and+discovery+of+functionally+selective+serotonin+2C+%285-HT2C%29+receptor+agonists&doi=10.1021%2Facs.jmedchem.6b01194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists</span></div><div class="casAuthors">Cheng, Jianjun; McCorvy, John D.; Giguere, Patrick M.; Zhu, Hu; Kenakin, Terry; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9866-9880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of the structural similarity of our previous 5-HT2C agonists with the melatonin receptor agonist tasimelteon and the putative biol. cross-talk between serotonergic and melatonergic systems, a series of new (2,3-dihydro)benzofuran-based compds. were designed and synthesized.  The compds. were evaluated for their selectivity toward 5-HT2A, 5-HT2B, and 5-HT2C receptors in the calcium flux assay with the ultimate goal to generate selective 5-HT2C agonists.  Selected compds. were studied for their functional selectivity by comparing their transduction efficiency at the G protein signaling pathway vs. β-arrestin recruitment.  The most functionally selective compd. (+)-7e produced weak β-arrestin recruitment and also demonstrated less receptor desensitization compared to serotonin in both calcium flux and phosphoinositide (PI) hydrolysis assays.  We report for the first time that selective 5-HT2C agonists possessing weak β-arrestin recruitment can produce distinct receptor desensitization properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaXMjfBCeBR7Vg90H21EOLACvtfcHk0lhJYqvNSgrP0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF&md5=bb0e1b524230649fac9f5b736ddc283d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01194%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520discovery%2520of%2520functionally%2520selective%2520serotonin%25202C%2520%25285-HT2C%2529%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9866%26epage%3D9880%26doi%3D10.1021%2Facs.jmedchem.6b01194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorello, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i>-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6288</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6273-6288&author=G.+Zhangauthor=J.+Chengauthor=J.+D.+McCorvyauthor=P.+J.+Lorelloauthor=B.+J.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Discovery+of+N-substituted+%282-phenylcyclopropyl%29methylamines+as+functionally+selective+serotonin+2C+receptor+agonists+for+potential+use+as+antipsychotic+medications&doi=10.1021%2Facs.jmedchem.7b00584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications</span></div><div class="casAuthors">Zhang, Guiping; Cheng, Jianjun; McCorvy, John D.; Lorello, Paul J.; Caldarone, Barbara J.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6273-6288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-substituted (2-phenylcyclopropyl)methylamines were designed and synthesized, with the aim of finding serotonin 2C (5-HT2C)-selective agonists with a preference for Gq signaling.  A no. of these compds. exhibit 5-HT2C selectivity with a preference for Gq-mediated signaling compared with β-arrestin recruitment.  Furthermore, the N-Me compd. I•HCl, which displayed an EC50 of 23 nM in the calcium flux assay while showing no β-arrestin recruitment activity, is the most functionally selective 5-HT2C agonist reported to date.  The N-benzyl compd. II•HCl, which showed an EC50 of 24 nM at the 5-HT2C receptor, is fully selective over the 5-HT2B receptor.  In an amphetamine-induced hyperactivity model, compd. II showed significant antipsychotic-drug-like activity.  These compds. shed light on the role of functional selectivity at the 5-HT2C receptor with respect to antipsychotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGjR92vyblbVg90H21EOLACvtfcHk0lhJYqvNSgrP0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK&md5=9da7c5db2f4e54db114a544d5f2e56b7</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00584%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DLorello%26aufirst%3DP.%2BJ.%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520N-substituted%2520%25282-phenylcyclopropyl%2529methylamines%2520as%2520functionally%2520selective%2520serotonin%25202C%2520receptor%2520agonists%2520for%2520potential%2520use%2520as%2520antipsychotic%2520medications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6273%26epage%3D6288%26doi%3D10.1021%2Facs.jmedchem.7b00584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stroth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svenningsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Arylpiperazine agonists of the serotonin 5-HT<sub>1A</sub> receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4824</span>– <span class="NLM_lpage">4830</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmc.2015.05.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26081758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4824-4830&author=N.+Strothauthor=M.+Nisoauthor=N.+A.+Colabufoauthor=R.+Perroneauthor=P.+Svenningssonauthor=E.+Lacivitaauthor=M.+Leopoldo&title=Arylpiperazine+agonists+of+the+serotonin+5-HT1A+receptor+preferentially+activate+cAMP+signaling+versus+recruitment+of+%CE%B2-arrestin-2&doi=10.1016%2Fj.bmc.2015.05.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2</span></div><div class="casAuthors">Stroth, Nikolas; Niso, Mauro; Colabufo, Nicola A.; Perrone, Roberto; Svenningsson, Per; Lacivita, Enza; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4824-4830</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) mediate biol. signal transduction through complex mol. pathways.  Therapeutic effects of GPCR-directed drugs are typically accompanied by unwanted side effects, owing in part to the parallel engagement of multiple signaling mechanisms.  The discovery of drugs that are 'functionally selective' towards therapeutic effects, based on their selective control of cellular responses through a given GPCR, is thus a major goal in pharmacol. today.  In the present study, we show that several arylpiperazine ligands of the serotonin 5-HT1A receptor (5-HT1AR) preferentially activate 3',5'-cyclic adenosine monophosphate (cAMP) signaling vs. β-arrestin-2 recruitment.  The pharmacol. of these compds. is thus qual. different from the endogenous agonist serotonin, indicating functional selectivity of 5-HT1AR-mediated response pathways.  Preliminary evidence suggests that phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) downstream of 5-HT1AR is a substrate of functionally selective signaling by partial agonists.  We propose that the compds. described in the present study are useful starting points for the development of signaling pathway-selective drugs targeting 5-HT1AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPeYBWeUhs9LVg90H21EOLACvtfcHk0lhJYqvNSgrP0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D&md5=58d15ba400884622e76923e88bbe6194</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.042%26sid%3Dliteratum%253Aachs%26aulast%3DStroth%26aufirst%3DN.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DArylpiperazine%2520agonists%2520of%2520the%2520serotonin%25205-HT1A%2520receptor%2520preferentially%2520activate%2520cAMP%2520signaling%2520versus%2520recruitment%2520of%2520%25CE%25B2-arrestin-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4824%26epage%3D4830%26doi%3D10.1016%2Fj.bmc.2015.05.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monczor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, N.</span></span> <span> </span><span class="NLM_article-title">Current knowledge and perspectives on histamine H<sub>1</sub> and H<sub>2</sub> receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1124/mol.116.105981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.116.105981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=640-648&author=F.+Monczorauthor=N.+Fernandez&title=Current+knowledge+and+perspectives+on+histamine+H1+and+H2+receptor+pharmacology%3A+functional+selectivity%2C+receptor+crosstalk%2C+and+repositioning+of+classic+histaminergic+ligands&doi=10.1124%2Fmol.116.105981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.105981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.105981%26sid%3Dliteratum%253Aachs%26aulast%3DMonczor%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DN.%26atitle%3DCurrent%2520knowledge%2520and%2520perspectives%2520on%2520histamine%2520H1%2520and%2520H2%2520receptor%2520pharmacology%253A%2520functional%2520selectivity%252C%2520receptor%2520crosstalk%252C%2520and%2520repositioning%2520of%2520classic%2520histaminergic%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D90%26spage%3D640%26epage%3D648%26doi%3D10.1124%2Fmol.116.105981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappia, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davio, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shayo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monczor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, N. C.</span></span> <span> </span><span class="NLM_article-title">Physiological implications of biased signaling at histamine H2 receptors</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3389%2Ffphar.2015.00045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25805997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC2MnnslSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=45&author=N.+Alonsoauthor=C.+D.+Zappiaauthor=M.+Cabreraauthor=C.+A.+Davioauthor=C.+Shayoauthor=F.+Monczorauthor=N.+C.+Fern%C3%A1ndez&title=Physiological+implications+of+biased+signaling+at+histamine+H2+receptors&doi=10.3389%2Ffphar.2015.00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological implications of biased signaling at histamine H2 receptors</span></div><div class="casAuthors">Alonso Natalia; Shayo Carina; Zappia Carlos D; Cabrera Maia; Monczor Federico; Fernandez Natalia C; Davio Carlos A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Histamine mediates numerous functions acting through its four receptor subtypes all belonging to the large family of seven transmembrane G-protein coupled receptors.  In particular, histamine H2 receptor (H2R) is mainly involved in gastric acid production, becoming a classic pharmacological target to treat Zollinger-Ellison disease and gastric and duodenal ulcers.  H2 ligands rank among the most widely prescribed and over the counter-sold drugs in the world.  Recent evidence indicate that some H2R ligands display biased agonism, selecting and triggering some, but not all, of the signaling pathways associated to the H2R.  The aim of the present work is to study whether famotidine, clinically widespread used ligand acting at H2R, exerts biased signaling.  Our findings indicate that while famotidine acts as inverse agonist diminishing cAMP basal levels, it mimics the effects of histamine and the agonist amthamine concerning receptor desensitization and internalization.  Moreover, the treatment of HEK293T transfected cells with any of the three ligands lead to a concentration dependent pERK increment.  Similarly in AGS gastric epithelial cells, famotidine treatment led to both, the reduction in cAMP levels as well as the increment in ERK phosphorylation, suggesting that this behavior could have pharmacological relevant implications.  Based on that, histidine decarboxylase expression was studied by quantitative PCR in AGS cells and its levels were increased by famotidine as well as by histamine and amthamine.  In all cases, the positive regulation was impeded by the MEK inhibitor PD98059, indicating that biased signaling toward ERK1/2 pathway is the responsible of such enzyme regulation.  These results support that ligand bias is not only a pharmacological curiosity but has physiological and pharmacological implications on cell metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbDjuDw8SFIftos8R3JUhXfW6udTcc2eZ1TEWJK6VGPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnnslSjsw%253D%253D&md5=b72e4abcabde48c76ca679770df6670d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00045%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DN.%26aulast%3DZappia%26aufirst%3DC.%2BD.%26aulast%3DCabrera%26aufirst%3DM.%26aulast%3DDavio%26aufirst%3DC.%2BA.%26aulast%3DShayo%26aufirst%3DC.%26aulast%3DMonczor%26aufirst%3DF.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DN.%2BC.%26atitle%3DPhysiological%2520implications%2520of%2520biased%2520signaling%2520at%2520histamine%2520H2%2520receptors%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D45%26doi%3D10.3389%2Ffphar.2015.00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampeli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiligada, E.</span></span> <span> </span><span class="NLM_article-title">The role of histamine H<sub>4</sub> receptor in immune and inflammatory disorders</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00151.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fj.1476-5381.2009.00151.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=19309354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2009&pages=24-33&author=E.+Zampeliauthor=E.+Tiligada&title=The+role+of+histamine+H4+receptor+in+immune+and+inflammatory+disorders&doi=10.1111%2Fj.1476-5381.2009.00151.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histamine H4 receptor in immune and inflammatory disorders</span></div><div class="casAuthors">Zampeli, E.; Tiligada, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Since its discovery at the beginning of the 20th century, histamine has been established to play a pathophysiol. regulatory role in cellular events through binding to four types of G-protein-coupled histamine receptors that are differentially expressed in various cell types.  The discovery, at the turn of the millennium, that the histamine H4 receptor is largely expressed in hemopoietic cells as well as its chemotactic properties designate its regulatory role in the immune system.  H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation.  H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.  The characterization of the H4 as the immune system histamine receptor directed growing attention towards its therapeutic exploitation in inflammatory disorders, such as allergy, asthma, chronic pruritus and autoimmune diseases.  The efficacy of a no. of H4 receptor ligands has been evaluated in in vivo and in vitro animal models of disease and in human biol. samples.  However, before reaching decisive conclusions on H4 receptor pathophysiol. functions and therapeutic exploitation, identification of genetic polymorphisms and interspecies differences in its relative actions and pharmacol. profile need to be addressed and taken into consideration.  Despite certain variations in the reported findings, the available data strongly point to the H4 receptor as a novel target for the pharmacol. modulation of histamine-transferred immune signals and offer an optimistic perspective for the therapeutic exploitation of this promising new drug target in inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAW6UpRFCXFLVg90H21EOLACvtfcHk0lhFO3hq8TElMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWls74%253D&md5=e850c2e825c0c62b59927854ccfb35c2</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00151.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00151.x%26sid%3Dliteratum%253Aachs%26aulast%3DZampeli%26aufirst%3DE.%26aulast%3DTiligada%26aufirst%3DE.%26atitle%3DThe%2520role%2520of%2520histamine%2520H4%2520receptor%2520in%2520immune%2520and%2520inflammatory%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D157%26spage%3D24%26epage%3D33%26doi%3D10.1111%2Fj.1476-5381.2009.00151.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung-Leung, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstra, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, L.</span></span> <span> </span><span class="NLM_article-title">A potent and selective histamine H<sub>4</sub> receptor antagonist with anti-inflammatory properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.061754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.103.061754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=14722321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFamurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=404-413&author=R.+L.+Thurmondauthor=P.+J.+Desaiauthor=P.+J.+Dunfordauthor=W.+P.+Fung-Leungauthor=C.+L.+Hofstraauthor=W.+Jiangauthor=S.+Nguyenauthor=J.+P.+Rileyauthor=S.+Sunauthor=K.+N.+Williamsauthor=J.+P.+Edwardsauthor=L.+Karlsson&title=A+potent+and+selective+histamine+H4+receptor+antagonist+with+anti-inflammatory+properties&doi=10.1124%2Fjpet.103.061754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties</span></div><div class="casAuthors">Thurmond, Robin L.; Desai, Pragnya J.; Dunford, Paul J.; Fung-Leung, Wai-Ping; Hofstra, Claudia L.; Jiang, Wen; Nguyen, Steven; Riley, Jason P.; Sun, Siquan; Williams, Kacy N.; Edwards, James P.; Karlsson, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">404-413</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Histamine mediates its physiol. function through binding to four known histamine receptors.  Here, we describe the first selective antagonist of the histamine H4 receptor, the newest member of the histamine receptor family, and provide evidence that such antagonists have anti-inflammatory activity in vivo.  1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (JNJ 7777120) has a Ki of 4.5 nM vs. the human receptor and a pA2 of 8.1.  It is equipotent against the human, mouse, and rat receptors.  It exhibits at least 1000-fold selectivity over H1, H2, or H3 receptors and has no cross-reactivity against 50 other targets.  This compd. has an oral bioavailability of ∼30% in rats and 100% in dogs, with a half-life of ∼3 h in both species.  JNJ 7777120 blocks histamine-induced chemotaxis and calcium influx in mouse bone marrow-derived mast cells.  In addn., it can block the histamine-induced migration of tracheal mast cells from the connective tissue toward the epithelium in mice.  JNJ 7777120 significantly blocks neutrophil infiltration in a mouse zymosan-induced peritonitis model.  This model is reported to be mast cell-dependent, which suggests that the compd. effect may be mediated by mast cells.  These results indicate that the histamine H4 receptor plays a role in the inflammatory process.  Selective H4 receptor antagonists like JNJ 7777120 may have the potential to be useful in treating inflammation in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR1GunqKtOlrVg90H21EOLACvtfcHk0lhFO3hq8TElMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFamurg%253D&md5=19ac13bd31555f3329b007d2aafe1133</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.061754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.061754%26sid%3Dliteratum%253Aachs%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DDesai%26aufirst%3DP.%2BJ.%26aulast%3DDunford%26aufirst%3DP.%2BJ.%26aulast%3DFung-Leung%26aufirst%3DW.%2BP.%26aulast%3DHofstra%26aufirst%3DC.%2BL.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DNguyen%26aufirst%3DS.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DKarlsson%26aufirst%3DL.%26atitle%3DA%2520potent%2520and%2520selective%2520histamine%2520H4%2520receptor%2520antagonist%2520with%2520anti-inflammatory%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D404%26epage%3D413%26doi%3D10.1124%2Fjpet.103.061754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosethorne, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Agonist-biased signaling at the histamine H<sub>4</sub> receptor: JNJ7777120 recruits β-arrestin without activating G proteins</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1124/mol.110.068395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.110.068395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21134907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOluro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=749-757&author=E.+M.+Rosethorneauthor=S.+J.+Charlton&title=Agonist-biased+signaling+at+the+histamine+H4+receptor%3A+JNJ7777120+recruits+%CE%B2-arrestin+without+activating+G+proteins&doi=10.1124%2Fmol.110.068395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins</span></div><div class="casAuthors">Rosethorne, Elizabeth M.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Gi/o-coupled histamine H4 receptor is highly expressed in hemopoietic cells and is a promising new target for the treatment of chronic inflammatory diseases.  1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methyl-piperazine (JNJ7777120) was described as a selective antagonist at the H4 receptor and is widely used to characterize the physiol. role of the H4 receptor.  We have investigated the pharmacol. properties of JNJ7777120 using 2 distinct downstream signaling measurements, G protein activation and β-arrestin recruitment.  The H4 receptor agonists histamine and clobenpropit, but not JNJ7777120, were able to induce [35S]GTPγS binding in membranes prepd. from U2OS-H4 cells.  Thioperamide, a dual H3/H4 receptor antagonist, and JNJ7777120 were both able to inhibit the [35S]GTPγS binding induced by clobenpropit.  Agonists and antagonists specific for other members of the histamine receptor family had no effect in this assay format.  Histamine and clobenpropit increased β-arrestin recruitment to the H4 receptor in a concn.-dependent manner.  This β-arrestin recruitment could be inhibited by preincubation with thioperamide.  We were surprised to find that preincubation with the H4-selective antagonist JNJ7777120 potentiated rather than antagonized the response to a submaximal concn. of clobenpropit.  JNJ7777120 treatment alone resulted in an increase in β-arrestin recruitment, which again could be inhibited by preincubation with thioperamide.  Schild anal. demonstrated competitive antagonism between thioperamide and both clobenpropit and JNJ7777120.  Histamine and clobenpropit had comparable potencies for both [35S]GTPγS binding and β-arrestin recruitment, suggesting little difference in the levels of receptor reserve between the 2 assays.  In conclusion, we have demonstrated that JNJ7777120 recruits β-arrestin to the H4 receptor, independent of G protein activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohxnqy7WSl-LVg90H21EOLACvtfcHk0lgTaE5FNZZiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOluro%253D&md5=2d00ef475b40e3eb7e064fe076836560</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.068395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.068395%26sid%3Dliteratum%253Aachs%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DAgonist-biased%2520signaling%2520at%2520the%2520histamine%2520H4%2520receptor%253A%2520JNJ7777120%2520recruits%2520%25CE%25B2-arrestin%2520without%2520activating%2520G%2520proteins%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D749%26epage%3D757%26doi%3D10.1124%2Fmol.110.068395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijmeijer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosethorne, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Detailed analysis of biased histamine H<sub>4</sub> receptor signalling by JNJ 7777120 analogues</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1111/bph.12117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fbph.12117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23351115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=78-88&author=S.+Nijmeijerauthor=H.+F.+Vischerauthor=F.+Sirciauthor=S.+Schultesauthor=H.+Engelhardtauthor=C.+de+Graafauthor=E.+M.+Rosethorneauthor=S.+J.+Charltonauthor=R.+Leurs&title=Detailed+analysis+of+biased+histamine+H4+receptor+signalling+by+JNJ+7777120+analogues&doi=10.1111%2Fbph.12117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Detailed analysis of biased histamine H4 receptor signalling by JNJ 7777120 analogues</span></div><div class="casAuthors">Nijmeijer, S.; Vischer, H. F.; Sirci, F.; Schultes, S.; Engelhardt, H.; de Graaf, C.; Rosethorne, E. M.; Charlton, S. J.; Leurs, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-88</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose The histamine H4 receptor, originally thought to signal merely through Gαi proteins, has recently been shown to also recruit and signal via β-arrestin2.  Following the discovery that the ref. antagonist indolecarboxamide JNJ 7777120 appears to be a partial agonist in β-arrestin2 recruitment, we have identified addnl. biased hH4R ligands that preferentially couple to Gαi or β-arrestin2 proteins.  In this study, we explored ligand and receptor regions that are important for biased hH4R signalling.  Exptl. Approach We evaluated a series of 48 indolecarboxamides with subtle structural differences for their ability to induce hH4R-mediated Gαi protein signalling or β-arrestin2 recruitment.  Subsequently, a Fingerprints for Ligands and Proteins three-dimensional quant. structure-activity relationship anal. correlated intrinsic activity values with structural ligand requirements.  Moreover, a hH4R homol. model was used to identify receptor regions important for biased hH4R signalling.  Key Results One indolecarboxamide (75) with a nitro substituent on position R7 of the arom. ring displayed an equal preference for the Gαi and β-arrestin2 pathway and was classified as unbiased hH4R ligand.  The other 47 indolecarboxamides were β-arrestin2-biased agonists.  Intrinsic activities of the unbiased as well as β-arrestin2-biased indolecarboxamides to induce β-arrestin2 recruitment could be correlated with different ligand features and hH4R regions.  Conclusion and Implications Small structural modifications resulted in diverse intrinsic activities for unbiased (75) and β-arrestin2-biased indolecarboxamides.  Anal. of ligand and receptor features revealed efficacy hotspots responsible for biased-β-arrestin2 recruitment.  This knowledge is useful for the design of hH4R ligands with biased intrinsic activities and aids our understanding of the mechanism of H4R activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppEoaA2rsLgrVg90H21EOLACvtfcHk0lgTaE5FNZZiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnJ&md5=490a939b05f2dd3508e96d21f541a783</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1111%2Fbph.12117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12117%26sid%3Dliteratum%253Aachs%26aulast%3DNijmeijer%26aufirst%3DS.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DSirci%26aufirst%3DF.%26aulast%3DSchultes%26aufirst%3DS.%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DDetailed%2520analysis%2520of%2520biased%2520histamine%2520H4%2520receptor%2520signalling%2520by%2520JNJ%25207777120%2520analogues%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D78%26epage%3D88%26doi%3D10.1111%2Fbph.12117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijmeijer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosethorne, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Analysis of multiple histamine H<sub>4</sub> receptor compound classes uncovers Gα<sub>i</sub> protein- and β-arrestin2-biased ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1174</span>– <span class="NLM_lpage">1182</span>, <span class="refDoi"> DOI: 10.1124/mol.112.080911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.080911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22973061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=1174-1182&author=S.+Nijmeijerauthor=H.+F.+Vischerauthor=E.+M.+Rosethorneauthor=S.+J.+Charltonauthor=R.+Leurs&title=Analysis+of+multiple+histamine+H4+receptor+compound+classes+uncovers+G%CE%B1i+protein-+and+%CE%B2-arrestin2-biased+ligands&doi=10.1124%2Fmol.112.080911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of multiple histamine H4 receptor compound classes uncovers Gαi protein- and β-arrestin2-biased ligands</span></div><div class="casAuthors">Nijmeijer, Saskia; Vischer, Henry F.; Rosethorne, Elizabeth M.; Charlton, Steven J.; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1174-1182</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">After the recent description of β-arrestin2 recruitment to the human histamine H4 receptor (hH4R) in response to the well known H4R antagonist 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methyl-piperazine (JNJ 7777120), we evaluated in this study the efficacy of 31 known hH4R ligands to induce Gαi protein signaling and β-arrestin2 recruitment by the hH4R.  The selected hH4R ligands belong to nine different structural classes that partly cover (pre)clin. trial candidates.  We have identified hH4R ligands with a significant bias for the Gαi protein or β-arrestin2 pathway on the basis of efficacy differences.  In addn., hH4R antagonists that did not show pos. efficacy in either functional readouts were found.  A common trend in pathway preference for the nine different ligand classes could not be obsd.  In particular, the isothiourea class shows very diverse results, varying from Gαi protein-biased or β-arrestin2-biased to nonbiased antagonists upon minor structural changes.  The identified biased hH4R ligands are important pharmacol. tools to unravel the significance of biased hH4R signaling in H4R pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVWY_qld1mi7Vg90H21EOLACvtfcHk0lgTaE5FNZZiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCltb3N&md5=6d65c275368ea2b8f2261d3e0cde3ec3</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.080911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.080911%26sid%3Dliteratum%253Aachs%26aulast%3DNijmeijer%26aufirst%3DS.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DAnalysis%2520of%2520multiple%2520histamine%2520H4%2520receptor%2520compound%2520classes%2520uncovers%2520G%25CE%25B1i%2520protein-%2520and%2520%25CE%25B2-arrestin2-biased%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D1174%26epage%3D1182%26doi%3D10.1124%2Fmol.112.080911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span> <span> </span><span class="NLM_article-title">Clinical development of histamine H<sub>4</sub> receptor antagonists</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1007/164_2016_130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2F164_2016_130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28233185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=2017&pages=301-320&author=R.+L.+Thurmondauthor=J.+Venableauthor=B.+Savallauthor=D.+Laauthor=S.+Snookauthor=P.+J.+Dunfordauthor=J.+P.+Edwards&title=Clinical+development+of+histamine+H4+receptor+antagonists&doi=10.1007%2F164_2016_130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of histamine H4 receptor antagonists</span></div><div class="casAuthors">Thurmond, Robin L.; Venable, Jennifer; Savall, Brad; La, David; Snook, Sandra; Dunford, Paul J.; Edwards, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">Histamine and Histamine Receptors in Health and Disease</span>),
    <span class="NLM_cas:pages">301-320</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The discovery of the histamine H4 receptor (H4R) provided a new avenue for the exploration of the physiol. role of histamine, as well as providing a new drug target for the development of novel antihistamines.  The first step in this process was the identification of selective antagonists to help unravel the pharmacol. of the H4R relative to other histamine receptors.  The discovery of the selective H4R antagonist JNJ 7777120 was vital for showing a role for the H4R in inflammation and pruritus.  While this compd. has been very successful as a tool for understanding the function of the receptor, it has drawbacks, including a short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clin. studies.  Further research let to the discovery of JNJ 39758979, which, similar to JNJ 7777120, was a potent and selective H4R antagonist and showed anti-inflammatory and anti-pruritic activity preclinically.  JNJ 39758979 advanced into human clin. studies and showed efficacy in reducing exptl. pruritus and in patients with atopic dermatitis.  However, development of this compd. was terminated due to the occurrence of drug-induced agranulocytosis.  This was overcome by developing another H4R antagonist with a different chem. structure, toreforant, that does not appear to have this side effect.  Toreforant has been tested in clin. studies in patients with rheumatoid arthritis, asthma, or psoriasis.  In conclusions there have been many H4R antagonists reported in the literature, but only a few have been studied in humans underscoring the difficulty in finding ligands with all of the properties necessary for testing in the clinic.  Nevertheless, the clin. data to date suggests that H4R antagonists can be beneficial in treating atopic dermatitis and pruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBP0zak99FDLVg90H21EOLACvtfcHk0lgTaE5FNZZiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGkt73I&md5=599a5ceb9b977b0952d27ead24570cc5</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2F164_2016_130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2016_130%26sid%3Dliteratum%253Aachs%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DVenable%26aufirst%3DJ.%26aulast%3DSavall%26aufirst%3DB.%26aulast%3DLa%26aufirst%3DD.%26aulast%3DSnook%26aufirst%3DS.%26aulast%3DDunford%26aufirst%3DP.%2BJ.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26atitle%3DClinical%2520development%2520of%2520histamine%2520H4%2520receptor%2520antagonists%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D241%26spage%3D301%26epage%3D320%26doi%3D10.1007%2F164_2016_130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L. A.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and the brain</span>. <i>Annu. Rev. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1146/annurev-psych-113011-143739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1146%2Fannurev-psych-113011-143739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22804774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=21-47&author=R.+Mechoulamauthor=L.+A.+Parker&title=The+endocannabinoid+system+and+the+brain&doi=10.1146%2Fannurev-psych-113011-143739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and the brain</span></div><div class="casAuthors">Mechoulam Raphael; Parker Linda A</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The psychoactive constituent in cannabis, Δ(9)-tetrahydrocannabinol (THC), was isolated in the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endogenous cannabinoids (anandamide and 2-arachidonoyl glycerol) were identified only 20 to 25 years later.  The cannabinoid system affects both central nervous system (CNS) and peripheral processes.  In this review, we have tried to summarize research--with an emphasis on recent publications--on the actions of the endocannabinoid system on anxiety, depression, neurogenesis, reward, cognition, learning, and memory.  The effects are at times biphasic--lower doses causing effects opposite to those seen at high doses.  Recently, numerous endocannabinoid-like compounds have been identified in the brain.  Only a few have been investigated for their CNS activity, and future investigations on their action may throw light on a wide spectrum of brain functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHFfYzzaa6fbBItaL1WaVAfW6udTcc2ebFOYDPl7pgILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D&md5=01c8b675ee9970bde0cb96d5e1b8a553</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1146%2Fannurev-psych-113011-143739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-psych-113011-143739%26sid%3Dliteratum%253Aachs%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DL.%2BA.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520the%2520brain%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2013%26volume%3D64%26spage%3D21%26epage%3D47%26doi%3D10.1146%2Fannurev-psych-113011-143739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry strategies to CB<sub>1</sub> cannabinoid receptor antagonists</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03427-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2FS1359-6446%2805%2903427-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=15896682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=693-702&author=J.+H.+M.+Langeauthor=C.+G.+Kruse&title=Medicinal+chemistry+strategies+to+CB1+cannabinoid+receptor+antagonists&doi=10.1016%2FS1359-6446%2805%2903427-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists</span></div><div class="casAuthors">Lange, Jos H. M.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-702</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The proven clin. efficacy of the CB1 cannabinoid receptor antagonist rimonabant in both obesity and smoking cessation and its therapeutic potential in other disorders has given a tremendous impetus to the discovery of novel CB1 antagonists.  The no. of disclosed patents wherein novel chem. entities having CB1 antagonistic or inverse agonistic properties have been claimed has exploded.  Besides novel compd. classes that were identified in screening, rational medicinal chem. approaches such as conformational constraint and scaffold hopping have been successfully applied.  CB1 receptor modeling has provided insight into crucial receptor-ligand interaction points thereby leading to a general CB1 inverse agonist pharmacophore model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCUMmcDw3bR7Vg90H21EOLACvtfcHk0lgJ9GWpoM7JaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslalt74%253D&md5=c760dfe5ba40c8de6af99f2752e7c690</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903427-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903427-6%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DMedicinal%2520chemistry%2520strategies%2520to%2520CB1%2520cannabinoid%2520receptor%2520antagonists%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D693%26epage%3D702%26doi%3D10.1016%2FS1359-6446%2805%2903427-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. N.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1002/med.21418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmed.21418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27879006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=441-474&author=T.+Nguyenauthor=J.+X.+Liauthor=B.+F.+Thomasauthor=J.+L.+Wileyauthor=T.+P.+Kenakinauthor=Y.+N.+Zhang&title=Allosteric+modulation%3A+an+alternate+approach+targeting+the+cannabinoid+CB1+receptor&doi=10.1002%2Fmed.21418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor</span></div><div class="casAuthors">Nguyen, Thuy; Li, Jun-Xu; Thomas, Brian F.; Wiley, Jenny L.; Kenakin, Terry P.; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-474</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The cannabinoid CB1 receptor is a G protein coupled receptor and plays an important role in many biol. processes and physiol. functions.  A variety of CB1 receptor agonists and antagonists, including endocannabinoids, phytocannabinoids, and synthetic cannabinoids, have been discovered or developed over the past 20 years.  In 2005, it was discovered that the CB1 receptor contains allosteric site(s) that can be recognized by small mols. or allosteric modulators.  A no. of CB1 receptor allosteric modulators, both pos. and neg., have since been reported and importantly, they display pharmacol. characteristics that are distinct from those of orthosteric agonists and antagonists.  Given the psychoactive effects commonly assocd. with CB1 receptor agonists and antagonists/inverse agonists, allosteric modulation may offer an alternate approach to attain potential therapeutic benefits while avoiding inherent side effects of orthosteric ligands.  This review details the complex pharmacol. profiles of these allosteric modulators, their structure-activity relationships, and efforts in elucidating binding modes and mechanisms of actions of reported CB1 allosteric modulators.  The ultimate development of CB1 receptor allosteric ligands could potentially lead to improved therapies for CB1-mediated neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn_UmNHz3IfrVg90H21EOLACvtfcHk0lgJ9GWpoM7JaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D&md5=3440e86c28aa07132de55c2c66640c2d</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fmed.21418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21418%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DZhang%26aufirst%3DY.%2BN.%26atitle%3DAllosteric%2520modulation%253A%2520an%2520alternate%2520approach%2520targeting%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D441%26epage%3D474%26doi%3D10.1002%2Fmed.21418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aghazadeh
Tabrizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB<sub>2</sub> receptor agonists</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00411</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00411" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=519-560&author=M.+Aghazadeh%0ATabriziauthor=P.+G.+Baraldiauthor=P.+A.+Boreaauthor=K.+Varani&title=Medicinal+chemistry%2C+pharmacology%2C+and+potential+therapeutic+benefits+of+cannabinoid+CB2+receptor+agonists&doi=10.1021%2Facs.chemrev.5b00411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists</span></div><div class="casAuthors">Aghazadeh Tabrizi, Mojgan; Baraldi, Pier Giovanni; Borea, Pier Andrea; Varani, Katia</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">519-560</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The purpose of this review is to analyze the mol. characterization, distribution and signal transduction pathways of CB2 receptors together with their pharmacol. role in some of the most relevant biol. systems.  The structure-activity relationships of several interesting CB2 agonists, including synthetic schemes to clarify the chem. involved in this field, are reported.  Moreover, the corresponding pharmacol. and beneficial potentials of selected CB2 compds. have been focused as well as the patent literature and the identification of promising therapeutic candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xG1QvGzO97Vg90H21EOLACvtfcHk0lj6kC_68Vn0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGmsr8%253D&md5=261a0d3c6eec03978630759378834d6c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00411%26sid%3Dliteratum%253Aachs%26aulast%3DAghazadeh%2BTabrizi%26aufirst%3DM.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DVarani%26aufirst%3DK.%26atitle%3DMedicinal%2520chemistry%252C%2520pharmacology%252C%2520and%2520potential%2520therapeutic%2520benefits%2520of%2520cannabinoid%2520CB2%2520receptor%2520agonists%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D519%26epage%3D560%26doi%3D10.1021%2Facs.chemrev.5b00411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor ligand bias: implications in the central nervous system</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.coph.2016.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27835801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOmt7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=32-43&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=E.+M.+Denovan-Wright&title=Cannabinoid+receptor+ligand+bias%3A+implications+in+the+central+nervous+system&doi=10.1016%2Fj.coph.2016.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor ligand bias: implications in the central nervous system</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-43</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The G protein-coupled cannabinoid receptors CB1, CB2, GPR18, and GPR55 regulate neurotransmission, pain, and inflammation and have been intensively investigated as potential drug targets.  Each of these GPCRs is coupled to multiple effector proteins mediating divergent cellular signals.  The ligand bias of cannabinoid-targeted compds. is only beginning to be quantified.  Research into cannabinoid bias is now revealing correlations between bias in cell culture and functional outcomes in vivo.  We present an example study of cannabinoid bias in the context of Huntington disease.  In future, an understanding of cannabinoid receptor structure and quantification of ligand bias will optimize drug selection matched to patient population and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrTHtEI8jybVg90H21EOLACvtfcHk0lj6kC_68Vn0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOmt7nL&md5=669daaa05a8798a2520a71f99be6d2da</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DCannabinoid%2520receptor%2520ligand%2520bias%253A%2520implications%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2017%26volume%3D32%26spage%3D32%26epage%3D43%26doi%3D10.1016%2Fj.coph.2016.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallipeddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity at G-protein coupled receptors: advancing cannabinoid receptors as drug targets</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2016.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27890725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=1-11&author=S.+Mallipeddiauthor=D.+R.+Janeroauthor=N.+Zvonokauthor=A.+Makriyannis&title=Functional+selectivity+at+G-protein+coupled+receptors%3A+advancing+cannabinoid+receptors+as+drug+targets&doi=10.1016%2Fj.bcp.2016.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets</span></div><div class="casAuthors">Mallipeddi, Srikrishnan; Janero, David R.; Zvonok, Nikolai; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design.  The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications.  Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clin. utility due to their propensity to incite on-target adverse events.  Chem. distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways.  In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists.  We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses.  The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBMv00pJezbVg90H21EOLACvtfcHk0lj6kC_68Vn0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K&md5=a447353e190125cdd3d7e363eab0e137</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DMallipeddi%26aufirst%3DS.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DFunctional%2520selectivity%2520at%2520G-protein%2520coupled%2520receptors%253A%2520advancing%2520cannabinoid%2520receptors%2520as%2520drug%2520targets%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D128%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.bcp.2016.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonhaus, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. R.</span></span> <span> </span><span class="NLM_article-title">Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">888</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=9864268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVShtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1998&pages=884-888&author=D.+W.+Bonhausauthor=L.+K.+Changauthor=J.+Kwanauthor=G.+R.+Martin&title=Dual+activation+and+inhibition+of+adenylyl+cyclase+by+cannabinoid+receptor+agonists%3A+evidence+for+agonist-specific+trafficking+of+intracellular+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses</span></div><div class="casAuthors">Bonhaus, D. W.; Chang, L. K.; Kwan, J.; Martin, G. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">884-888</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cannabinoid receptors couple to both Gs and Gi proteins and can consequently stimulate or inhibit the formation of cAMP.  To test whether there is specificity among cannabinoid receptor agonists in activating Gs - or Gi-coupled pathways, the potency and intrinsic activity of various cannabinoid receptor ligands in stimulating or inhibiting cAMP accumulation were quantified.  The rank order of potencies of cannabinoid receptor agonists in increasing or inhibiting forskolin-stimulated cAMP accumulation, in CHO cells expressing hCB1 receptors, was identical (HU-210 > CP-55,940 > THC > WIN-55212-2 > anandamide).  However, the activities of these agonists were different in the two assays with anandamide and CP-55,940 being markedly less efficacious in stimulating the accumulation of cAMP than in inhibiting its formation.  Studies examg. the effects of forskolin on cannabinoid receptor mediated stimulation of adenylyl cyclase also revealed differences among agonists in as much as forskolin enhanced the potency of HU-210 and CP-55,940 by ∼100-fold but, by contrast, had no effect on the potency of WIN-55212-2 or anandamide.  Taken together these findings demonstrate marked differences among cannabinoid receptor agonists in their activation of intracellular transduction pathways.  This provides support for the emerging concept of agonist-specific trafficking of cellular responses and further suggests strategies for developing receptor agonists with increased therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql3F1fTabcc7Vg90H21EOLACvtfcHk0lj6kC_68Vn0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVShtg%253D%253D&md5=15f484981e8136eaf9eee03c5ba50241</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonhaus%26aufirst%3DD.%2BW.%26aulast%3DChang%26aufirst%3DL.%2BK.%26aulast%3DKwan%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26atitle%3DDual%2520activation%2520and%2520inhibition%2520of%2520adenylyl%2520cyclase%2520by%2520cannabinoid%2520receptor%2520agonists%253A%2520evidence%2520for%2520agonist-specific%2520trafficking%2520of%2520intracellular%2520responses%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D287%26spage%3D884%26epage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupre, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">24845</span>– <span class="NLM_lpage">24862</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.557025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M114.557025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25037227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyrtbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=24845-24862&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+M.+Kellyauthor=D.+J.+Dupreauthor=E.+M.+Denovan-Wright&title=Type+1+cannabinoid+receptor+ligands+display+functional+selectivity+in+a+cell+culture+model+of+striatal+medium+spiny+projection+neurons&doi=10.1074%2Fjbc.M114.557025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Type 1 Cannabinoid Receptor Ligands Display Functional Selectivity in a Cell Culture Model of Striatal Medium Spiny Projection Neurons</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Kelly, Melanie E. M.; Dupre, Denis J.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">24845-24862</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Modulation of type 1 cannabinoid receptor (CB1) activity has been touted as a potential means of treating addiction, anxiety, depression, and neurodegeneration.  Different agonists of CB1 are known to evoke varied responses in vivo.  Functional selectivity is the ligand-specific activation of certain signal transduction pathways at a receptor that can signal through multiple pathways.  To understand cannabinoid-specific functional selectivity, different groups have examd. the effect of individual cannabinoids on various signaling pathways in heterologous expression systems.  In the current study, the authors compared the functional selectivity of six cannabinoids, including two endocannabinoids (2-arachidonyl glycerol (2-AG) and anandamide (AEA)), two synthetic cannabinoids (WIN55,212-2 and CP55,940), and two phytocannabinoids (cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC)) on arrestin-2-, Gαi/o-, Gβγ-, Gαs-, and Gαq-mediated intracellular signaling in the mouse STHdhQ7/Q7 cell culture model of striatal medium spiny projection neurons that endogenously express CB1.  In this system, 2-AG, THC, and CP55,940 were more potent mediators of arrestin-2 recruitment than other cannabinoids tested.  2-AG, AEA, and WIN55,212-2, enhanced Gαi/o and Gβγ signaling, with 2-AG and AEA treatment leading to increased total CB1 levels.  2-AG, AEA, THC, and WIN55,212-2 also activated Gαq-dependent pathways.  CP55,940 and CBD both signaled through Gαs.  CP55,940, but not CBD, activated downstream Gαs pathways via CB1 targets.  THC and CP55,940 promoted CB1 internalization and decreased CB1 protein levels over an 18-h period.  These data demonstrate that individual cannabinoids display functional selectivity at CB1 leading to activation of distinct signaling pathways.  To effectively match cannabinoids with therapeutic goals, these compds. must be screened for their signaling bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr29KklR0B1j7Vg90H21EOLACvtfcHk0lhXUkEyIr44aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyrtbzE&md5=d31b6f41051a572b6cbd6dffd700c7ae</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.557025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.557025%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DDupre%26aufirst%3DD.%2BJ.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DType%25201%2520cannabinoid%2520receptor%2520ligands%2520display%2520functional%2520selectivity%2520in%2520a%2520cell%2520culture%2520model%2520of%2520striatal%2520medium%2520spiny%2520projection%2520neurons%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D24845%26epage%3D24862%26doi%3D10.1074%2Fjbc.M114.557025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.115.101980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26700564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=364-375&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+M.+Kellyauthor=E.+M.+Denovan-Wright&title=Biased+type+1+cannabinoid+receptor+signaling+influences+neuronal+viability+in+a+cell+culture+model+of+Huntington+disease&doi=10.1124%2Fmol.115.101980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Kelly, Melanie E. M.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-375</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Huntington disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder with limited treatment options.  Prior to motor symptom onset or neuronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB1) decrease in the basal ganglia.  Decreasing CB1 levels are strongly correlated with chorea and cognitive deficit.  CB1 agonists are functionally selective (biased) for divergent signaling pathways.  In this study, six cannabinoids were tested for signaling bias in in vitro models of medium spiny projection neurons expressing wild-type (STHdhQ7/Q7) or mutant huntingtin protein (STHdhQ111/Q111).  Signaling bias was assessed using the Black and Leff operational model.  Relative activity [ΔlogR (τ/KA)] and system bias (ΔΔlogR) were calcd. relative to the ref. compd. WIN55,212-2 for Gαi/o, Gas, Gαq, Gβγ, and β-arrestin1 signaling following treatment with 2-arachidonoylglycerol (2-AG), anandamide (AEA), CP55,940, Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+CBD (1:1), and compared between wild-type and HD cells.  The Emax of Gαi/o-dependent extracellular signal-regulated kinase (ERK) signaling was 50% lower in HD cells compared with wild-type cells.  2-AG and AEA displayed Gαi/o/Gβγ bias and normalized CB1 protein levels and improved cell viability, whereas CP55,940 and THC displayed β-arrestin1 bias and reduced CB1 protein levels and cell viability in HD cells.  CBD was not a CB1 agonist but inhibited THC-dependent signaling (THC+CBD).  Therefore, enhancing Gαi/o-biased endocannabinoid signaling may be therapeutically beneficial in HD.  In contrast, cannabinoids that are β-arrestin-biased-such as THC found at high levels in modern varieties of marijuana-may be detrimental to CB1 signaling, particularly in HD where CB1 levels are already reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdgxoxZrX1ObVg90H21EOLACvtfcHk0lhXUkEyIr44aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP&md5=fe544fe3afc0ab0ca739ab887be7c971</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101980%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DBiased%2520type%25201%2520cannabinoid%2520receptor%2520signaling%2520influences%2520neuronal%2520viability%2520in%2520a%2520cell%2520culture%2520model%2520of%2520Huntington%2520disease%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D364%26epage%3D375%26doi%3D10.1124%2Fmol.115.101980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abushaar, M.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a peripheral receptor for cannabinoids</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/365061a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2F365061a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=7689702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=1993&pages=61-65&author=S.+Munroauthor=K.+L.+Thomasauthor=M.+Abushaar&title=Molecular+characterization+of+a+peripheral+receptor+for+cannabinoids&doi=10.1038%2F365061a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a peripheral receptor for cannabinoids</span></div><div class="casAuthors">Munro, Sean; Thomas, Kerrie L.; Abu-Shaar, Muna</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6441</span>),
    <span class="NLM_cas:pages">61-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The major active ingredient of marijuana, Δ9-tetrahydrocannabinol (Δ-THC), has been used as a psychoactive agent for thousands of years.  Marijuana, and Δ9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting.  The clin. application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochem. bases of their action.  Progress stemmed initially from the synthesis of potent derivs. of Δ9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids.  This receptor is expressed in the brain but not in the periphery, except for a low level in testes.  It has been proposed that the nonpsychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins.  Here the authors report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHsq4vy1XH17Vg90H21EOLACvtfcHk0lhXUkEyIr44aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D&md5=476435b57bd0f24483e2f24b813cc32f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2F365061a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F365061a0%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DAbushaar%26aufirst%3DM.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520peripheral%2520receptor%2520for%2520cannabinoids%26jtitle%3DNature%26date%3D1993%26volume%3D365%26spage%3D61%26epage%3D65%26doi%3D10.1038%2F365061a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atwood, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity in CB<sub>2</sub> cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB<sub>2</sub> ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1124/mol.111.074013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.111.074013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=250-263&author=B.+K.+Atwoodauthor=J.+Wager-Millerauthor=C.+Haskinsauthor=A.+Straikerauthor=K.+Mackie&title=Functional+selectivity+in+CB2+cannabinoid+receptor+signaling+and+regulation%3A+implications+for+the+therapeutic+potential+of+CB2+ligands&doi=10.1124%2Fmol.111.074013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.074013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.074013%26sid%3Dliteratum%253Aachs%26aulast%3DAtwood%26aufirst%3DB.%2BK.%26aulast%3DWager-Miller%26aufirst%3DJ.%26aulast%3DHaskins%26aufirst%3DC.%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DFunctional%2520selectivity%2520in%2520CB2%2520cannabinoid%2520receptor%2520signaling%2520and%2520regulation%253A%2520implications%2520for%2520the%2520therapeutic%2520potential%2520of%2520CB2%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D81%26spage%3D250%26epage%3D263%26doi%3D10.1124%2Fmol.111.074013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhopeshwarkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity of CB<sub>2</sub> cannabinoid receptor ligands at a canonical and noncanonical pathway</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.232561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.116.232561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27194477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCqtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=342-351&author=A.+Dhopeshwarkarauthor=K.+Mackie&title=Functional+selectivity+of+CB2+cannabinoid+receptor+ligands+at+a+canonical+and+noncanonical+pathway&doi=10.1124%2Fjpet.116.232561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathways</span></div><div class="casAuthors">Dhopeshwarkar, Amey; Mackie, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-351</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The CB2 cannabinoid receptor (CB2) remains a tantalizing, but unrealized therapeutic target.  CB2 receptor ligands belong to varied structural classes and display extreme-functional selectivity.  Here,we have screened diverse CB2 receptor ligands at canonical (inhibition of adenylyl cyclase) and noncanonical (arrestin recruitment) pathways.  The nonclassic cannabinoid (2)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP55940) was the most potent agonist for both pathways, while the classic cannabinoid ligand (6aR,10aR)-3-((1,1-Dimethylbutyl)-6a,7,10,10atetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran JWH133) was the most efficacious agonist among all the ligands profiled in cyclase assays.  In the cyclase assay, other classic cannabinoids showed little [(2)-trans-Δ9-tetrahydrocannabinol and (2)-(6aR,7,10,10aR)-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-6Hdibenzo[b,d]pyran-1-ol] (KM233) to no efficacy [(6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10atetrahydrobenzo[c]chromene(L759633) and (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,8,9,10,10a-hexahydro-1-methoxy-6,6-dimethyl-9-methylene-6H-dibenzo[b,d]pyran]L759656.  Most aminoalkylindoles, including [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate (WIN55212-2), were moderate efficacy agonists.  The cannabilactone 3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo(c)chromen-6-one (AM1710) was equiefficacious to CP55940 to inhibit adenylyl cyclase, albeit with lower potency.  In the arrestin recruitment assays, all classic cannabinoid ligands failed to recruit arrestins, indicating a bias toward G-protein coupling for this class of compd.  All aminoalkylindoles tested, except for WIN55212-2 and (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR144), failed to recruit arrestin.  WIN55212-2 was a low efficacy agonist for arrestin recruitment, while UR144 was arrestin biased with no significant inhibition of cyclase.  Endocannabinoids were G-protein biased with no arrestin recruitment.  The diarylpyrazole antagonist 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144258) was an inverse agonist in cyclase and arrestin recruitment assays while the aminoalkylindole 6-iodo-2-methyl-1-[[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630) and carboxamide N-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide (JTE907) were inverse agonists in cyclase but low efficacy agonists in arrestin recruitment assays.  Thus, CB2 receptor ligands display strong and varied functional selectivity at both pathways.  Therefore, extreme care must be exercised when using these compds. to infer the role of CB2 receptors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXMQ6mcUctrVg90H21EOLACvtfcHk0ljNLelaxqbmFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCqtbbF&md5=985b1124f434cf36163cb42867c8c266</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.232561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.232561%26sid%3Dliteratum%253Aachs%26aulast%3DDhopeshwarkar%26aufirst%3DA.%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DFunctional%2520selectivity%2520of%2520CB2%2520cannabinoid%2520receptor%2520ligands%2520at%2520a%2520canonical%2520and%2520noncanonical%2520pathway%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D342%26epage%3D351%26doi%3D10.1124%2Fjpet.116.232561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sam, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghatei, M. A.</span></span> <span> </span><span class="NLM_article-title">Rimonabant: from RIO to ban</span>. <i>J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">432607</span>, <span class="refDoi"> DOI: 10.1155/2011/432607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1155%2F2011%2F432607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21773005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=432607&author=A.+H.+Samauthor=V.+Salemauthor=M.+A.+Ghatei&title=Rimonabant%3A+from+RIO+to+ban&doi=10.1155%2F2011%2F432607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant: From RIO to Ban</span></div><div class="casAuthors">Sam Amir H; Salem Victoria; Ghatei Mohammad A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of obesity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">432607</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.  The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome.  However, the drug was quickly withdrawn due to the emergence of significant side effects-notably severe mood disorders.  This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgmzv1LvwoEZSWdIdmEou5fW6udTcc2eakXBVVG664Ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D&md5=03967572404bd633a2298bd1a62baff1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1155%2F2011%2F432607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F432607%26sid%3Dliteratum%253Aachs%26aulast%3DSam%26aufirst%3DA.%2BH.%26aulast%3DSalem%26aufirst%3DV.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26atitle%3DRimonabant%253A%2520from%2520RIO%2520to%2520ban%26jtitle%3DJ.%2520Obes.%26date%3D2011%26volume%3D2011%26spage%3D432607%26doi%3D10.1155%2F2011%2F432607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H. H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span> <span> </span><span class="NLM_article-title">A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/0378-1119(93)90495-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2F0378-1119%2893%2990495-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=8294032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFGnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1993&pages=355-360&author=B.+F.+O%E2%80%99Dowdauthor=M.+Heiberauthor=A.+Chanauthor=H.+H.+Q.+Hengauthor=L.+C.+Tsuiauthor=J.+L.+Kennedyauthor=X.+M.+Shiauthor=A.+Petronisauthor=S.+R.+Georgeauthor=T.+Nguyen&title=A+human+gene+that+shows+identity+with+the+gene+encoding+the+angiotensin+receptor+is+located+on+chromosome+11&doi=10.1016%2F0378-1119%2893%2990495-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11</span></div><div class="casAuthors">O'Dowd, Brian F.; Heiber, Michael; Chan, Audrey; Heng, Henry H. Q.; Tsui, Lap Chee; Kennedy, James L.; Shi, Xiaomei; Petronis, Arturas; George, Susan R.; Nguyen Tuan</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">355-60</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    </div><div class="casAbstract">The authors report the cloning of a gene, intron-less in its coding region, which the authors have named APJ.  This gene was cloned using the polymerase chain reaction (PCR), with a set of primers designed on the basis of the conservation that members of G protein-coupled receptors (GPCR) have in their transmembrane (TM) regions.  The putative receptor protein, APJ, shares closest identity to the angiotensin receptor (AT1) ranging from 40 to 50% in the hydrophobic TM regions of these receptors.  The transcripts for this gene were detected in many regions of the brain.  PCR anal. of somatic cell lines found APJ-related sequences to be only present on chromosome 11, and high-resoln. mapping by fluorescence in situ hybridization (FISH) sub-localized APJ on band q12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqp2kdIKETdbVg90H21EOLACvtfcHk0ljNLelaxqbmFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFGnsL0%253D&md5=4beb37696cbf0f919df6c1d22088e719</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2F0378-1119%2893%2990495-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-1119%252893%252990495-O%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26aulast%3DHeiber%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DHeng%26aufirst%3DH.%2BH.%2BQ.%26aulast%3DTsui%26aufirst%3DL.%2BC.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26aulast%3DShi%26aufirst%3DX.%2BM.%26aulast%3DPetronis%26aufirst%3DA.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DNguyen%26aufirst%3DT.%26atitle%3DA%2520human%2520gene%2520that%2520shows%2520identity%2520with%2520the%2520gene%2520encoding%2520the%2520angiotensin%2520receptor%2520is%2520located%2520on%2520chromosome%252011%26jtitle%3DGene%26date%3D1993%26volume%3D136%26spage%3D355%26epage%3D360%26doi%3D10.1016%2F0378-1119%2893%2990495-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runyon, S. P.</span></span> <span> </span><span class="NLM_article-title">Regulation of the apelinergic system and its potential in cardiovascular disease: peptides and small molecules as tools for discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7913</span>– <span class="NLM_lpage">7927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7913-7927&author=S.+Narayananauthor=D.+L.+Harrisauthor=R.+Maitraauthor=S.+P.+Runyon&title=Regulation+of+the+apelinergic+system+and+its+potential+in+cardiovascular+disease%3A+peptides+and+small+molecules+as+tools+for+discovery&doi=10.1021%2Facs.jmedchem.5b00527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery</span></div><div class="casAuthors">Narayanan, Sanju; Harris, Danni L.; Maitra, Rangan; Runyon, Scott P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7913-7927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apelin peptides and the apelin receptor represent a relatively new therapeutic axis for the potential treatment of cardiovascular disease.  Several reports suggest apelin receptor activation with apelin peptides results in cardioprotection as noted through pos. ionotropy, angiogenesis, redn. of mean arterial blood pressure, and apoptosis.  Considering the potential therapeutic benefit attainable through modulation of the apelinergic system, research is expanding to develop novel therapies that limit the inherent rapid degrdn. of endogenous apelin peptides and produce metabolically stable small mol. agonists and antagonists to more rigorously interrogate the apelin receptor system.  This review details the structure-activity relationships for chem. modified apelin peptides and recent disclosures of small mol. agonists and antagonists and summarizes the peer reviewed and patented literature.  Development of metabolically stable ligands of apelin receptor and their effects in various models over the coming years will hopefully lead to establishment of this receptor as a validated target for cardiovascular indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTIngNdWxX87Vg90H21EOLACvtfcHk0lhhleEV1IUTFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN&md5=6c116a42d7b523905e811c33c46e256f</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00527%26sid%3Dliteratum%253Aachs%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DD.%2BL.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DRunyon%26aufirst%3DS.%2BP.%26atitle%3DRegulation%2520of%2520the%2520apelinergic%2520system%2520and%2520its%2520potential%2520in%2520cardiovascular%2520disease%253A%2520peptides%2520and%2520small%2520molecules%2520as%2520tools%2520for%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7913%26epage%3D7927%26doi%3D10.1021%2Facs.jmedchem.5b00527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scimia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurtado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalucci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlasuk, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaliman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Lozano, P.</span></span> <span> </span><span class="NLM_article-title">APJ acts as a dual receptor in cardiac hypertrophy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nature11263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature11263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22810587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=394-398&author=M.+C.+Scimiaauthor=C.+Hurtadoauthor=S.+Rayauthor=S.+Metzlerauthor=K.+Weiauthor=J.+M.+Wangauthor=C.+E.+Woodsauthor=N.+H.+Purcellauthor=D.+Catalucciauthor=T.+Akasakaauthor=O.+F.+Buenoauthor=G.+P.+Vlasukauthor=P.+Kalimanauthor=R.+Bodmerauthor=L.+H.+Smithauthor=E.+Ashleyauthor=M.+Mercolaauthor=J.+H.+Brownauthor=P.+Ruiz-Lozano&title=APJ+acts+as+a+dual+receptor+in+cardiac+hypertrophy&doi=10.1038%2Fnature11263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">APJ acts as a dual receptor in cardiac hypertrophy</span></div><div class="casAuthors">Scimia, Maria Cecilia; Hurtado, Cecilia; Ray, Saugata; Metzler, Scott; Wei, Ke; Wang, Jianming; Woods, Chris E.; Purcell, Nicole H.; Catalucci, Daniele; Akasaka, Takashi; Bueno, Orlando F.; Vlasuk, George P.; Kaliman, Perla; Bodmer, Rolf; Smith, Layton H.; Ashley, Euan; Mercola, Mark; Brown, Joan Heller; Ruiz-Lozano, Pilar</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7411</span>),
    <span class="NLM_cas:pages">394-398</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cardiac hypertrophy is initiated as an adaptive response to sustained overload but progresses pathol. as heart failure ensues.  Here we report that genetic loss of APJ, a G-protein-coupled receptor, confers resistance to chronic pressure overload by markedly reducing myocardial hypertrophy and heart failure.  In contrast, mice lacking apelin (the endogenous APJ ligand) remain sensitive, suggesting an apelin-independent function of APJ.  Freshly isolated APJ-null cardiomyocytes exhibit an attenuated response to stretch, indicating that APJ is a mechanosensor.  Activation of APJ by stretch increases cardiomyocyte cell size and induces mol. markers of hypertrophy.  Whereas apelin stimulates APJ to activate Gαi and elicits a protective response, stretch signals in an APJ-dependent, G-protein-independent fashion to induce hypertrophy.  Stretch-mediated hypertrophy is prevented by knockdown of β-arrestins or by pharmacol. doses of apelin acting through Gαi.  Taken together, our data indicate that APJ is a bifunctional receptor for both mech. stretch and the endogenous peptide apelin.  By sensing the balance between these stimuli, APJ occupies a pivotal point linking sustained overload to cardiomyocyte hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3eGCo9h1pKbVg90H21EOLACvtfcHk0lhhleEV1IUTFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbjF&md5=a0aefb2d9793982b0a37f0f6046f34c2</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnature11263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11263%26sid%3Dliteratum%253Aachs%26aulast%3DScimia%26aufirst%3DM.%2BC.%26aulast%3DHurtado%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DMetzler%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%2BM.%26aulast%3DWoods%26aufirst%3DC.%2BE.%26aulast%3DPurcell%26aufirst%3DN.%2BH.%26aulast%3DCatalucci%26aufirst%3DD.%26aulast%3DAkasaka%26aufirst%3DT.%26aulast%3DBueno%26aufirst%3DO.%2BF.%26aulast%3DVlasuk%26aufirst%3DG.%2BP.%26aulast%3DKaliman%26aufirst%3DP.%26aulast%3DBodmer%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DAshley%26aufirst%3DE.%26aulast%3DMercola%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DRuiz-Lozano%26aufirst%3DP.%26atitle%3DAPJ%2520acts%2520as%2520a%2520dual%2520receptor%2520in%2520cardiac%2520hypertrophy%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D394%26epage%3D398%26doi%3D10.1038%2Fnature11263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span> <span> </span><span class="NLM_article-title">Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.114.05099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1161%2FHYPERTENSIONAHA.114.05099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25712721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVGrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=834-840&author=A.+L.+Brameauthor=J.+J.+Maguireauthor=P.+R.+Yangauthor=A.+Dysonauthor=R.+Torellaauthor=J.+Cheriyanauthor=M.+Singerauthor=R.+C.+Glenauthor=I.+B.+Wilkinsonauthor=A.+P.+Davenport&title=Design%2C+characterization%2C+and+first-in-human+study+of+the+vascular+actions+of+a+novel+biased+apelin+receptor+agonist&doi=10.1161%2FHYPERTENSIONAHA.114.05099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist</span></div><div class="casAuthors">Brame, Aimee L.; Maguire, Janet J.; Yang, Peiran; Dyson, Alex; Torella, Rubben; Cheriyan, Joseph; Singer, Mervyn; Glen, Robert C.; Wilkinson, Ian B.; Davenport, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">834-840</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">[Pyr]apelin-13 is an endogenous vasodilator and inotrope but is downregulated in pulmonary hypertension and heart failure, making the apelin receptor an attractive therapeutic target.  Agonists acting at the same G-protein-coupled receptor can be engineered to stabilize different conformational states and function as biased ligands, selectively stimulating either G-protein or β-arrestin pathways.  We used mol. dynamics simulations of apelin/receptor interactions to design cyclic analogs and identified MM07 as a biased agonist.  In β-arrestin and internalization assays (G-protein-independent), MM07 was 2 orders of magnitude less potent than [Pyr]apelin-13.  In a G-protein-dependent saphenous vein contraction assay, both peptides had comparable potency (pD2:[Pyr]apelin-13 9.93±0.24; MM07 9.54±0.42) and max. responses with a resulting bias for MM07 of ≈350- to 1300-fold for the G-protein pathway.  In rats, systemic infusions of MM07 (10-100 nmol) caused a dose-dependent increase in cardiac output that was significantly greater than the response to [Pyr]apelin-13.  Similarly, in human volunteers, MM07 produced a significant dose-dependent increase in forearm blood flow with a max. dilatation double that is seen with [Pyr]apelin-13.  Addnl., repeated doses of MM07 produced reproducible increases in forearm blood flow.  These responses are consistent with a more efficacious action of the biased agonist.  In human hand vein, both peptides reversed an established norepinephrine constrictor response and significantly increased venous flow.  Our results suggest that MM07 acting as a biased agonist at the apelin receptor can preferentially stimulate the G-protein pathway, which could translate to improved efficacy in the clinic by selectively stimulating vasodilatation and inotropic actions but avoiding activating detrimental β-arrestin-dependent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwBeW0p9RgbVg90H21EOLACvtfcHk0lhhleEV1IUTFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVGrtr0%253D&md5=908911768ffa6edcd2ef9b1e80c8826a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.05099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.05099%26sid%3Dliteratum%253Aachs%26aulast%3DBrame%26aufirst%3DA.%2BL.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BR.%26aulast%3DDyson%26aufirst%3DA.%26aulast%3DTorella%26aufirst%3DR.%26aulast%3DCheriyan%26aufirst%3DJ.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DWilkinson%26aufirst%3DI.%2BB.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DDesign%252C%2520characterization%252C%2520and%2520first-in-human%2520study%2520of%2520the%2520vascular%2520actions%2520of%2520a%2520novel%2520biased%2520apelin%2520receptor%2520agonist%26jtitle%3DHypertension%26date%3D2015%26volume%3D65%26spage%3D834%26epage%3D840%26doi%3D10.1161%2FHYPERTENSIONAHA.114.05099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainsily, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau-Cossette, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besserer-Offroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longpre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leduc, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumaine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesur, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger-Messier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarret, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of novel macrocyclic biased apelin receptor agonists</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1039/C6OB02247B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1039%2FC6OB02247B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27924341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKntLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=449-458&author=A.+Murzaauthor=X.+Sainsilyauthor=J.+Coteauthor=L.+Bruneau-Cossetteauthor=E.+Besserer-Offroyauthor=J.+M.+Longpreauthor=R.+Leducauthor=R.+Dumaineauthor=O.+Lesurauthor=M.+Auger-Messierauthor=P.+Sarretauthor=E.+Marsault&title=Structure-activity+relationship+of+novel+macrocyclic+biased+apelin+receptor+agonists&doi=10.1039%2FC6OB02247B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship of novel macrocyclic biased apelin receptor agonists</span></div><div class="casAuthors">Murza, Alexandre; Sainsily, Xavier; Cote, Jerome; Bruneau-Cossette, Laurent; Besserer-Offroy, Elie; Longpre, Jean-Michel; Leduc, Richard; Dumaine, Robert; Lesur, Olivier; Auger-Messier, Mannix; Sarret, Philippe; Marsault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">449-458</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Apelin is the endogenous ligand for the G protein-coupled receptor APJ and exerts a key role in regulating cardiovascular functions.  We report herein a novel series of macrocyclic analogs of apelin-13 in which the N- and C-terminal residues as well as the macrocycle compn. were chem. modified to modulate structure-activity relationships on the APJ receptor.  To this end, the binding affinity and the ability to engage G protein-dependent and G protein-independent signalling pathways of the resulting analogs were assessed.  In this series, the position and the nature of the C-terminal arom. residue is a determinant for APJ interaction and β-arrestin recruitment, as previously demonstrated for linear apelin-13 derivs.  We finally discovered compds. 1, 4, 11 and 15, four potent G protein-biased apelin receptor agonists exhibiting affinity in the nanomolar range for APJ.  These macrocyclic compds. represent very useful pharmacol. tools to explore the therapeutic potential of the apelinergic system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjP6pZHwKK7Vg90H21EOLACvtfcHk0lj5RWDvP33RzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKntLjE&md5=9af5862171abf95feab2e830d7702b90</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FC6OB02247B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB02247B%26sid%3Dliteratum%253Aachs%26aulast%3DMurza%26aufirst%3DA.%26aulast%3DSainsily%26aufirst%3DX.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DBruneau-Cossette%26aufirst%3DL.%26aulast%3DBesserer-Offroy%26aufirst%3DE.%26aulast%3DLongpre%26aufirst%3DJ.%2BM.%26aulast%3DLeduc%26aufirst%3DR.%26aulast%3DDumaine%26aufirst%3DR.%26aulast%3DLesur%26aufirst%3DO.%26aulast%3DAuger-Messier%26aufirst%3DM.%26aulast%3DSarret%26aufirst%3DP.%26aulast%3DMarsault%26aufirst%3DE.%26atitle%3DStructure-activity%2520relationship%2520of%2520novel%2520macrocyclic%2520biased%2520apelin%2520receptor%2520agonists%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26spage%3D449%26epage%3D458%26doi%3D10.1039%2FC6OB02247B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceraudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banegas-Font, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonegge, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvear-Perez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturrioz, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Biased signaling favoring G<sub>i</sub> over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">24599</span>– <span class="NLM_lpage">24610</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.541698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.541698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25012663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGjt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=24599-24610&author=E.+Ceraudoauthor=C.+Galanthauthor=E.+Carpentierauthor=I.+Banegas-Fontauthor=A.+M.+Schoneggeauthor=R.+Alvear-Perezauthor=X.+Iturriozauthor=M.+Bouvierauthor=C.+Llorens-Cortes&title=Biased+signaling+favoring+Gi+over+%CE%B2-arrestin+promoted+by+an+apelin+fragment+lacking+the+C-terminal+phenylalanine&doi=10.1074%2Fjbc.M113.541698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Signaling Favoring Gi over β-Arrestin Promoted by an Apelin Fragment Lacking the C-terminal Phenylalanine</span></div><div class="casAuthors">Ceraudo, Emilie; Galanth, Cecile; Carpentier, Eric; Banegas-Font, Inmaculada; Schonegge, Anne-Marie; Alvear-Perez, Rodrigo; Iturrioz, Xavier; Bouvier, Michel; Llorens-Cortes, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">24599-24610</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Apelin plays a prominent role in body fluid and cardiovascular homeostasis.  The authors previously showed that the C-terminal Phe of apelin 17 (K17F) is crucial for triggering apelin receptor internalization and decreasing blood pressure (BP) but is not required for apelin binding or Gi protein coupling.  Based on these findings, the authors hypothesized that the important role of the C-terminal Phe in BP decrease may be as a Gi-independent but β-arrestin-dependent signaling pathway that could involve MAPKs.  For this purpose, the authors have used apelin fragments K17F and K16P (K17F with the C-terminal Phe deleted), which exhibit opposite profiles on apelin receptor internalization and BP.  Using BRET-based biosensors, the authors showed that, whereas K17F activates Gi and promotes β-arrestin recruitment to the receptor, K16P had a much reduced ability to promote β-arrestin recruitment while maintaining its Gi activating property, revealing the biased agonist character of K16P.  The authors further show that both β-arrestin recruitment and apelin receptor internalization contribute to the K17F-stimulated ERK1/2 activity, whereas the K16P-promoted ERK1/2 activity is entirely Gi-dependent.  In addn. to providing new insights on the structural basis underlying the functional selectivity of apelin peptides, the authors' study indicates that the β-arrestin-dependent ERK1/2 activation and not the Gi-dependent signaling may participate in K17F-induced BP decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA2B14K-_mtLVg90H21EOLACvtfcHk0lj5RWDvP33RzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGjt7nJ&md5=3d412882bcb7944183ce2f5961ab58fd</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.541698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.541698%26sid%3Dliteratum%253Aachs%26aulast%3DCeraudo%26aufirst%3DE.%26aulast%3DGalanth%26aufirst%3DC.%26aulast%3DCarpentier%26aufirst%3DE.%26aulast%3DBanegas-Font%26aufirst%3DI.%26aulast%3DSchonegge%26aufirst%3DA.%2BM.%26aulast%3DAlvear-Perez%26aufirst%3DR.%26aulast%3DIturrioz%26aufirst%3DX.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DBiased%2520signaling%2520favoring%2520Gi%2520over%2520%25CE%25B2-arrestin%2520promoted%2520by%2520an%2520apelin%2520fragment%2520lacking%2520the%2520C-terminal%2520phenylalanine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D24599%26epage%3D24610%26doi%3D10.1074%2Fjbc.M113.541698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hachtel, S.</span>; <span class="NLM_string-name">Wohlfart, P.</span>; <span class="NLM_string-name">Weston, J.</span>; <span class="NLM_string-name">Müller, M.</span>; <span class="NLM_string-name">Defossa, E.</span>; <span class="NLM_string-name">Mertsch, K.</span>; <span class="NLM_string-name">Weng, J.
H.</span>; <span class="NLM_string-name">Binnie, R.
A.</span>; <span class="NLM_string-name">Abdul-Latif, F.</span>; <span class="NLM_string-name">Bock, W.
J.</span>; <span class="NLM_string-name">Walser, A.</span></span> <span> </span><span class="NLM_article-title">Benzoimidazole-Carboxylic Acid Amide Derivatives as APJ Receptor Modulators</span>. <span class="NLM_patent">WO 2014/044738 A1</span>, March 27, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Hachtel&author=P.+Wohlfart&author=J.+Weston&author=M.+M%C3%BCller&author=E.+Defossa&author=K.+Mertsch&author=J.%0AH.+Weng&author=R.%0AA.+Binnie&author=F.+Abdul-Latif&author=W.%0AJ.+Bock&author=A.+Walser&title=Benzoimidazole-Carboxylic+Acid+Amide+Derivatives+as+APJ+Receptor+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHachtel%26aufirst%3DS.%26atitle%3DBenzoimidazole-Carboxylic%2520Acid%2520Amide%2520Derivatives%2520as%2520APJ%2520Receptor%2520Modulators%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Read, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuc, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span> <span> </span><span class="NLM_article-title">Cardiac action of the first G protein biased small molecule apelin agonist</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2016.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27475715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GhtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=63-72&author=C.+Readauthor=C.+M.+Fitzpatrickauthor=P.+R.+Yangauthor=R.+E.+Kucauthor=J.+J.+Maguireauthor=R.+C.+Glenauthor=R.+E.+Fosterauthor=A.+P.+Davenport&title=Cardiac+action+of+the+first+G+protein+biased+small+molecule+apelin+agonist&doi=10.1016%2Fj.bcp.2016.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac action of the first G protein biased small molecule apelin agonist</span></div><div class="casAuthors">Read, Cai; Fitzpatrick, Christopher M.; Yang, Peiran; Kuc, Rhoda E.; Maguire, Janet J.; Glen, Robert C.; Foster, Richard E.; Davenport, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Apelin peptide analogs displaying bias towards G protein signalling pathways have beneficial cardiovascular actions compared with the native peptide in humans in vivo.  Our aim was to det. whether small mol. agonists could retain G protein bias.  We have identified a biased small mol., CMF-019 (I), and characterised it in vitro and in vivo.  In competition radioligand binding expts. in heart homogenates, CMF-019 bound to the human, rat and mouse apelin receptor with high affinity (pKi = 8.58 ± 0.04, 8.49 ± 0.04 and 8.71 ± 0.06 resp.).  In cell-based functional assays, whereas, CMF-019 showed similar potency for the Gαi pathway to the endogenous agonist [Pyr1]apelin-13 (pD2 = 10.00 ± 0.13 vs 9.34 ± 0.15), in β-arrestin and internalisation assays it was less potent (pD2 = 6.65 ± 0.15 vs 8.65 ± 0.10 and pD2 = 6.16 ± 0.21 vs 9.28 ± 0.10 resp.).  Anal. of these data demonstrated a bias of ∼400 for the Gαi over the β-arrestin pathway and ∼6000 over receptor internalisation.  CMF-019 was tested for in vivo activity using i.v. injections into anesthetized male Sprague-Dawley rats fitted with a pressure-vol. catheter in the left ventricle.  CMF-019 caused a significant increase in cardiac contractility of 606 ± 112 mmHg/s (p < 0.001) at 500 nmol.  CMF-019 is the first biased small mol. identified at the apelin receptor and increases cardiac contractility in vivo.  We have demonstrated that Gαi over β-arrestin/internalisation bias can be retained in a non-peptide analog and predict that such bias will have the therapeutic benefit following chronic use.  CMF-019 is suitable as a tool compd. and provides the basis for design of biased agonists with improved pharmacokinetics for treatment of cardiovascular conditions such as pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqmJ0WndHEdLVg90H21EOLACvtfcHk0lj5RWDvP33RzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GhtbnJ&md5=0a2ba0ccb57382ceda2e0d27ff46c61e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DC.%26aulast%3DFitzpatrick%26aufirst%3DC.%2BM.%26aulast%3DYang%26aufirst%3DP.%2BR.%26aulast%3DKuc%26aufirst%3DR.%2BE.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DFoster%26aufirst%3DR.%2BE.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DCardiac%2520action%2520of%2520the%2520first%2520G%2520protein%2520biased%2520small%2520molecule%2520apelin%2520agonist%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D116%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.bcp.2016.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagarsheth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W. P.</span></span> <span> </span><span class="NLM_article-title">Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnri.2017.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28555670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=559-572&author=N.+Nagarshethauthor=M.+S.+Wichaauthor=W.+P.+Zou&title=Chemokines+in+the+cancer+microenvironment+and+their+relevance+in+cancer+immunotherapy&doi=10.1038%2Fnri.2017.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</span></div><div class="casAuthors">Nagarsheth, Nisha; Wicha, Max S.; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">559-572</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The tumor microenvironment is the primary location in which tumor cells and the host immune system interact.  Different immune cell subsets are recruited into the tumor microenvironment via interactions between chemokines and chemokine receptors, and these populations have distinct effects on tumor progression and therapeutic outcomes.  In this Review, we focus on the main chemokines that are found in the human tumor microenvironment; we elaborate on their patterns of expression, their regulation and their roles in immune cell recruitment and in cancer and stromal cell biol., and we consider how they affect cancer immunity and tumorigenesis.  We also discuss the potential of targeting chemokine networks, in combination with other immunotherapies, for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEb-fH3CLf0bVg90H21EOLACvtfcHk0lgzqnhv2Kpo8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSjtr8%253D&md5=c102d8bf9475aa0e823e941c43fc5b54</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.49%26sid%3Dliteratum%253Aachs%26aulast%3DNagarsheth%26aufirst%3DN.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DZou%26aufirst%3DW.%2BP.%26atitle%3DChemokines%2520in%2520the%2520cancer%2520microenvironment%2520and%2520their%2520relevance%2520in%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2017%26volume%3D17%26spage%3D559%26epage%3D572%26doi%3D10.1038%2Fnri.2017.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. M.</span></span> <span> </span><span class="NLM_article-title">Biased and G protein-indepedent signalling of chemokine receptors</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2014.00277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3389%2Ffimmu.2014.00277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25002861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgt1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=277&author=A.+Steenauthor=O.+Larsenauthor=S.+Thieleauthor=M.+M.+Rosenkilde&title=Biased+and+G+protein-indepedent+signalling+of+chemokine+receptors&doi=10.3389%2Ffimmu.2014.00277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Biased and g protein-independent signaling of chemokine receptors</span></div><div class="casAuthors">Steen Anne; Larsen Olav; Thiele Stefanie; Rosenkilde Mette M</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">Biased signaling or functional selectivity occurs when a 7TM-receptor preferentially activates one of several available pathways.  It can be divided into three distinct forms: ligand bias, receptor bias, and tissue or cell bias, where it is mediated by different ligands (on the same receptor), different receptors (with the same ligand), or different tissues or cells (for the same ligand-receptor pair).  Most often biased signaling is differentiated into G protein-dependent and β-arrestin-dependent signaling.  Yet, it may also cover signaling differences within these groups.  Moreover, it may not be absolute, i.e., full versus no activation.  Here we discuss biased signaling in the chemokine system, including the structural basis for biased signaling in chemokine receptors, as well as in class A 7TM receptors in general.  This includes overall helical movements and the contributions of micro-switches based on recently published 7TM crystals and molecular dynamics studies.  All three forms of biased signaling are abundant in the chemokine system.  This challenges our understanding of "classic" redundancy inevitably ascribed to this system, where multiple chemokines bind to the same receptor and where a single chemokine may bind to several receptors - in both cases with the same functional outcome.  The ubiquitous biased signaling confers a hitherto unknown specificity to the chemokine system with a complex interaction pattern that is better described as promiscuous with context-defined roles and different functional outcomes in a ligand-, receptor-, or cell/tissue-defined manner.  As the low number of successful drug development plans implies, there are great difficulties in targeting chemokine receptors; in particular with regard to receptor antagonists as anti-inflammatory drugs.  Un-defined and putative non-selective targeting of the complete cellular signaling system could be the underlying cause of lack of success.  Therefore, biased ligands could be the solution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmZZF9dVtZQ4vKgEt20y1XfW6udTcc2eYmCp1RBd9E-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgt1OisQ%253D%253D&md5=814b5ab6c48f59e2543803e516b35bbf</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2014.00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2014.00277%26sid%3Dliteratum%253Aachs%26aulast%3DSteen%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DO.%26aulast%3DThiele%26aufirst%3DS.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26atitle%3DBiased%2520and%2520G%2520protein-indepedent%2520signalling%2520of%2520chemokine%2520receptors%26jtitle%3DFront.%2520Immunol.%26date%3D2014%26volume%3D5%26spage%3D277%26doi%3D10.3389%2Ffimmu.2014.00277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassoni, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T. S.</span></span> <span> </span><span class="NLM_article-title">Biased agonism as a mechanism for differential signaling by chemokine receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">35039</span>– <span class="NLM_lpage">35048</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.479113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.479113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24145037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWkurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=35039-35048&author=S.+Rajagopalauthor=D.+L.+Bassoniauthor=J.+J.+Campbellauthor=N.+P.+Gerardauthor=C.+Gerardauthor=T.+S.+Wehrman&title=Biased+agonism+as+a+mechanism+for+differential+signaling+by+chemokine+receptors&doi=10.1074%2Fjbc.M113.479113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Agonism as a Mechanism for Differential Signaling by Chemokine Receptors</span></div><div class="casAuthors">Rajagopal, Sudarshan; Bassoni, Daniel L.; Campbell, James J.; Gerard, Norma P.; Gerard, Craig; Wehrman, Tom S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">35039-35048</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Chemokines display considerable promiscuity with multiple ligands and receptors shared in common, a phenomenon that is thought to underlie their biochem. "redundancy.".  Their receptors are part of a larger seven-transmembrane receptor superfamily, commonly referred to as G protein-coupled receptors, which have been demonstrated to be able to signal with different efficacies to their multiple downstream signaling pathways, a phenomenon referred to as biased agonism.  Biased agonism has been primarily reported as a phenomenon of synthetic ligands, and the biol. prevalence and importance of such signaling are unclear.  Here, to assess the presence of biased agonism that may underlie differential signaling by chemokines targeting the same receptor, we performed a detailed pharmacol. anal. of a set of chemokine receptors with multiple endogenous ligands using assays for G protein signaling, β-arrestin recruitment, and receptor internalization.  We found that chemokines targeting the same receptor can display marked differences in their efficacies for G protein- or β-arrestin-mediated signaling or receptor internalization.  This ligand bias correlates with changes in leukocyte migration, consistent with different mechanisms underlying the signaling downstream of these receptors induced by their ligands.  These findings demonstrate that biased agonism is a common and likely evolutionarily conserved biol. mechanism for generating qual. distinct patterns of signaling via the same receptor in response to different endogenous ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyPY4PQ3oUn7Vg90H21EOLACvtfcHk0lgzqnhv2Kpo8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWkurbJ&md5=778d4347529e2c531bf6ed49c7b2bc0f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.479113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.479113%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DBassoni%26aufirst%3DD.%2BL.%26aulast%3DCampbell%26aufirst%3DJ.%2BJ.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26aulast%3DWehrman%26aufirst%3DT.%2BS.%26atitle%3DBiased%2520agonism%2520as%2520a%2520mechanism%2520for%2520differential%2520signaling%2520by%2520chemokine%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D35039%26epage%3D35048%26doi%3D10.1074%2Fjbc.M113.479113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbisier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszagh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springael, J. Y.</span></span> <span> </span><span class="NLM_article-title">Biased signaling at chemokine receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">9542</span>– <span class="NLM_lpage">9554</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.596098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M114.596098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=9542-9554&author=J.+Corbisierauthor=C.+Galesauthor=A.+Huszaghauthor=M.+Parmentierauthor=J.+Y.+Springael&title=Biased+signaling+at+chemokine+receptors&doi=10.1074%2Fjbc.M114.596098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.596098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.596098%26sid%3Dliteratum%253Aachs%26aulast%3DCorbisier%26aufirst%3DJ.%26aulast%3DGales%26aufirst%3DC.%26aulast%3DHuszagh%26aufirst%3DA.%26aulast%3DParmentier%26aufirst%3DM.%26aulast%3DSpringael%26aufirst%3DJ.%2BY.%26atitle%3DBiased%2520signaling%2520at%2520chemokine%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D9542%26epage%3D9554%26doi%3D10.1074%2Fjbc.M114.596098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milanos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklukar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waibel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsiedel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dürr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanović-Burmazović, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjortø, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of biased allosteric agonists of the chemokine receptor CXCR3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2222</span>– <span class="NLM_lpage">2243</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01965</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01965" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2222-2243&author=L.+Milanosauthor=R.+Broxauthor=T.+Frankauthor=G.+Poklukarauthor=R.+Palmisanoauthor=R.+Waibelauthor=J.+Einsiedelauthor=M.+D%C3%BCrrauthor=I.+Ivanovi%C4%87-Burmazovi%C4%87author=O.+Larsenauthor=G.+M.+Hjort%C3%B8author=M.+M.+Rosenkildeauthor=N.+Tschammer&title=Discovery+and+characterization+of+biased+allosteric+agonists+of+the+chemokine+receptor+CXCR3&doi=10.1021%2Facs.jmedchem.5b01965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01965%26sid%3Dliteratum%253Aachs%26aulast%3DMilanos%26aufirst%3DL.%26aulast%3DBrox%26aufirst%3DR.%26aulast%3DFrank%26aufirst%3DT.%26aulast%3DPoklukar%26aufirst%3DG.%26aulast%3DPalmisano%26aufirst%3DR.%26aulast%3DWaibel%26aufirst%3DR.%26aulast%3DEinsiedel%26aufirst%3DJ.%26aulast%3DD%25C3%25BCrr%26aufirst%3DM.%26aulast%3DIvanovi%25C4%2587-Burmazovi%25C4%2587%26aufirst%3DI.%26aulast%3DLarsen%26aufirst%3DO.%26aulast%3DHjort%25C3%25B8%26aufirst%3DG.%2BM.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DTschammer%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520biased%2520allosteric%2520agonists%2520of%2520the%2520chemokine%2520receptor%2520CXCR3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2222%26epage%3D2243%26doi%3D10.1021%2Facs.jmedchem.5b01965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zervosen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frère, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joris, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luxen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvage, E.</span></span> <span> </span><span class="NLM_article-title">Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">10839</span>– <span class="NLM_lpage">10848</span>, <span class="refDoi"> DOI: 10.1021/ja200696y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja200696y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFKhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=10839-10848&author=A.+Zervosenauthor=R.+Hermanauthor=F.+Kerffauthor=A.+Hermanauthor=A.+Bouillezauthor=F.+Pratiauthor=R.+F.+Prattauthor=J.-M.+Fr%C3%A8reauthor=B.+Jorisauthor=A.+Luxenauthor=P.+Charlierauthor=E.+Sauvage&title=Unexpected+tricovalent+binding+mode+of+boronic+acids+within+the+active+site+of+a+penicillin-binding+protein&doi=10.1021%2Fja200696y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Unexpected Tricovalent Binding Mode of Boronic Acids within the Active Site of a Penicillin-Binding Protein</span></div><div class="casAuthors">Zervosen, Astrid; Herman, Raphael; Kerff, Frederic; Herman, Alexandre; Bouillez, Andre; Prati, Fabio; Pratt, R. F.; Frere, Jean-Marie; Joris, Bernard; Luxen, Andre; Charlier, Paulette; Sauvage, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10839-10848</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Boronic acids bearing appropriate side chains are good inhibitors of serine amidohydrolases.  The boron usually adopts a tetrahedral conformation, bound to the nucleophilic serine of the active site and mimicking the transition state of the enzymic reaction.  We have solved the structures of complexes of a penicillin-binding protein (PBP), the DD-peptidase from Actinomadura sp. R39, with four amidomethylboronic acids (2,6-dimethoxybenzamidomethylboronic acid, phenylacetamidomethylboronic acid, 2-chlorobenzamidomethylboronic acid, and 2-nitrobenzamidomethylboronic acid) and the pinacol ester derived from phenylacetamidomethylboronic acid.  We found that in each case, the boron forms a tricovalent adduct with the Oγ from Ser49 and Ser298, and the terminal amine group of Lys410, three key residues involved in the catalytic mechanism of penicillin-binding proteins.  This represents the first tricovalent enzyme-inhibitor adducts obsd. by crystallog.  In two of the five R39-boronate structures, the boronic acid is found as a tricovalent adduct in two monomers of the asym. unit and as a monocovalent adduct with the active serine in the two remaining monomers of the asym. unit.  Formation of the tricovalent complex from a classical monocovalent complex may involve rotation around the Ser49 Cα-Cβ bond to place the boron in a position to interact with Ser298 and Lys410, and a twisting of the side-chain amide such that its carbonyl oxygen is able to hydrogen bond to the oxyanion hole NH of Thr413.  Biphasic kinetics were obsd. in three of the five cases, and details of the reaction between R39 and 2,6-dimethoxybenzamidomethylboronic acid were studied.  Observation of biphasic kinetics was not, however, thought to be correlated with formation of tricovalent complexes, assuming that the latter do form in soln.  On the basis of the crystallog. and kinetic results, a reaction scheme for this unexpected inhibition by boronic acids is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ewm48mQ5fLVg90H21EOLACvtfcHk0ljB8tuTjIRR-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFKhsr0%253D&md5=847cbfcb9458d610240b34d01a99a261</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fja200696y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja200696y%26sid%3Dliteratum%253Aachs%26aulast%3DZervosen%26aufirst%3DA.%26aulast%3DHerman%26aufirst%3DR.%26aulast%3DKerff%26aufirst%3DF.%26aulast%3DHerman%26aufirst%3DA.%26aulast%3DBouillez%26aufirst%3DA.%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DPratt%26aufirst%3DR.%2BF.%26aulast%3DFr%25C3%25A8re%26aufirst%3DJ.-M.%26aulast%3DJoris%26aufirst%3DB.%26aulast%3DLuxen%26aufirst%3DA.%26aulast%3DCharlier%26aufirst%3DP.%26aulast%3DSauvage%26aufirst%3DE.%26atitle%3DUnexpected%2520tricovalent%2520binding%2520mode%2520of%2520boronic%2520acids%2520within%2520the%2520active%2520site%2520of%2520a%2520penicillin-binding%2520protein%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D10839%26epage%3D10848%26doi%3D10.1021%2Fja200696y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Admas, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span> <span> </span><span class="NLM_article-title">Boronic acids as probes for investigation of allosteric modulation of the chemokine receptor CXCR3</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2664</span>– <span class="NLM_lpage">2677</span>, <span class="refDoi"> DOI: 10.1021/cb500678c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500678c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2664-2677&author=V.+Bernatauthor=T.+H.+Admasauthor=R.+Broxauthor=F.+W.+Heinemannauthor=N.+Tschammer&title=Boronic+acids+as+probes+for+investigation+of+allosteric+modulation+of+the+chemokine+receptor+CXCR3&doi=10.1021%2Fcb500678c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic Acids as Probes for Investigation of Allosteric Modulation of the Chemokine Receptor CXCR3</span></div><div class="casAuthors">Bernat, Viachaslau; Admas, Tizita Haimanot; Brox, Regine; Heinemann, Frank W.; Tschammer, Nuska</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2664-2677</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The chemokine receptor CXCR3 is a G protein-coupled receptor, which conveys extracellular signals into cells by changing its conformation upon agonist binding.  To facilitate the mechanistic understanding of allosteric modulation of CXCR3, we combined computational modeling with the synthesis of novel chem. tools contg. boronic acid moiety, site-directed mutagenesis, and detailed functional characterization.  The design of boronic acid derivs. was based on the predictions from homol. modeling and docking.  The choice of the boronic acid moiety was dictated by its unique ability to interact with proteins in a reversible covalent way, thereby influencing conformational dynamics of target biomols.  During the synthesis of the library we have developed a novel approach for the purifn. of drug-like boronic acids.  To validate the predicted binding mode and to identify amino acid residues responsible for the transduction of signal through CXCR3, we conducted a site-directed mutagenesis study.  With the use of allosteric radioligand RAMX3 we were able to establish the existence of a second allosteric binding pocket in CXCR3, which enables different binding modes of structurally closely related allosteric modulators of CXCR3.  We have also identified residues Trp1092.60 and Lys3007.35 inside the transmembrane bundle of the receptor as crucial for the regulation of the G protein activation.  Furthermore, we report the boronic acid 14 as the first biased neg. allosteric modulator of the receptor.  Overall, our data demonstrate that boronic acid derivs. represent an outstanding tool for detn. of key receptor-ligand interactions and induction of ligand-biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9piFXBc8fB7Vg90H21EOLACvtfcHk0ljB8tuTjIRR-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbP&md5=d0fd65b1179a29c074224090a4f9787a</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fcb500678c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500678c%26sid%3Dliteratum%253Aachs%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DAdmas%26aufirst%3DT.%2BH.%26aulast%3DBrox%26aufirst%3DR.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DTschammer%26aufirst%3DN.%26atitle%3DBoronic%2520acids%2520as%2520probes%2520for%2520investigation%2520of%2520allosteric%2520modulation%2520of%2520the%2520chemokine%2520receptor%2520CXCR3%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D2664%26epage%3D2677%26doi%3D10.1021%2Fcb500678c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberson, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span> <span> </span><span class="NLM_article-title">Ligand-biased and probe-dependent modulation of chemokine receptor CXCR3 signaling by negative allosteric modulators</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fcmdc.201402507" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=566-574&author=V.+Bernatauthor=R.+Broxauthor=M.+R.+Heinrichauthor=Y.+P.+Aubersonauthor=N.+Tschammer&title=Ligand-biased+and+probe-dependent+modulation+of+chemokine+receptor+CXCR3+signaling+by+negative+allosteric+modulators&doi=10.1002%2Fcmdc.201402507"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402507%26sid%3Dliteratum%253Aachs%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DBrox%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DM.%2BR.%26aulast%3DAuberson%26aufirst%3DY.%2BP.%26aulast%3DTschammer%26aufirst%3DN.%26atitle%3DLigand-biased%2520and%2520probe-dependent%2520modulation%2520of%2520chemokine%2520receptor%2520CXCR3%2520signaling%2520by%2520negative%2520allosteric%2520modulators%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D566%26epage%3D574%26doi%3D10.1002%2Fcmdc.201402507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesh, T.</span></span> <span> </span><span class="NLM_article-title">Prostanoid receptor EP2 as a therapeutic target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4454</span>– <span class="NLM_lpage">4465</span>, <span class="refDoi"> DOI: 10.1021/jm401431x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401431x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCmur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4454-4465&author=T.+Ganesh&title=Prostanoid+receptor+EP2+as+a+therapeutic+target&doi=10.1021%2Fjm401431x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Prostanoid Receptor EP2 as a Therapeutic Target</span></div><div class="casAuthors">Ganesh, Thota</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4454-4465</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Cycoloxygenase-2 (COX-2) induction is prevalent in a variety of (brain and peripheral) injury models where COX-2 levels correlate with disease progression.  Thus, COX-2 has been widely explored for anti-inflammatory therapy with COX-2 inhibitors, which proved to be effective in reducing the pain and inflammation in patients with arthritis and menstrual cramps, but they have not provided any benefit to patients with chronic inflammatory neurodegenerative disease.  Recently, two COX-2 drugs, rofecoxib and valdecoxib, were withdrawn from the United States market due to cardiovascular side effects.  Thus, future anti-inflammatory therapy could be targeted through a specific prostanoid receptor downstream of COX-2.  The PGE2 receptor EP2 is emerging as a pro-inflammatory target in a variety of CNS and peripheral diseases.  Here we highlight the latest developments on the role of EP2 in diseases, mechanism of activation, and small mol. discovery targeted either to enhance or to block the function of this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpanB_f3g_VUbVg90H21EOLACvtfcHk0lhlUROYZiXZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCmur%252FK&md5=405be9149d8abd1d2d1de4af042bf2a0</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm401431x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401431x%26sid%3Dliteratum%253Aachs%26aulast%3DGanesh%26aufirst%3DT.%26atitle%3DProstanoid%2520receptor%2520EP2%2520as%2520a%2520therapeutic%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4454%26epage%3D4465%26doi%3D10.1021%2Fjm401431x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCullough, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haughey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breyer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasson, K.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective function of the PGE<sub>2</sub> EP2 receptor in cerebral ischemia</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4485-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1523%2FJNEUROSCI.4485-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=14715958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2ltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=257-268&author=L.+McCulloughauthor=L.+Wuauthor=N.+Haugheyauthor=X.+Liangauthor=T.+Handauthor=Q.+Wangauthor=R.+M.+Breyerauthor=K.+Andreasson&title=Neuroprotective+function+of+the+PGE2+EP2+receptor+in+cerebral+ischemia&doi=10.1523%2FJNEUROSCI.4485-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia</span></div><div class="casAuthors">McCullough, Louise; Wu, Liejun; Haughey, Norman; Liang, Xibin; Hand, Tracey; Wang, Qian; Breyer, Richard M.; Andreasson, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">257-268</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The cyclooxygenases COX-1 and COX-2 catalyze the first committed step of prostaglandin synthesis from arachidonic acid.  Previous studies in rodent stroke models have shown that the inducible COX-2 isoform promotes neuronal injury, and the administration of COX-2 inhibitors reduces infarct vol.  We investigated the function of PGE2, a principal prostaglandin product of COX-2 enzymic activity, in neuronal survival in cerebral ischemia.  PGE2 exerts its downstream effects by signaling through a class of four distinct G-protein-coupled EP receptors (for E-prostanoid: EP1, EP2, EP3, and EP4) that have divergent effects on cAMP and phosphoinositol turnover and different anatomical distributions in brain.  The EP2 receptor subtype is abundantly expressed in cerebral cortex, striatum, and hippocampus, and is pos. coupled to cAMP prodn.  In vitro studies of dispersed neurons and organotypic hippocampal cultures demonstrated that activation of the EP2 receptor was neuroprotective in paradigms of NMDA toxicity and oxygen glucose deprivation.  Pharmacol. blockade of EP2 signaling by inhibition of protein kinase A activation reversed this protective effect, suggesting that EP2-mediated neuroprotection is dependent on cAMP signaling.  In the middle cerebral artery occlusion-reperfusion model of transient forebrain ischemia, genetic deletion of the EP2 receptor significantly increased cerebral infarction in cerebral cortex and subcortical structures.  These studies indicate that activation of the PGE2 EP2 receptor can protect against excitotoxic and anoxic injury in a cAMP-dependent manner.  Taken together, these data suggest a novel mechanism of neuroprotection mediated by a dominant PGE2 receptor subtype in brain that may provide a target for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjazLQgIyS47Vg90H21EOLACvtfcHk0lhlUROYZiXZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2ltQ%253D%253D&md5=73a862c6c9372fccb711bfacd07ff6d6</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4485-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4485-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMcCullough%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DHaughey%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHand%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBreyer%26aufirst%3DR.%2BM.%26aulast%3DAndreasson%26aufirst%3DK.%26atitle%3DNeuroprotective%2520function%2520of%2520the%2520PGE2%2520EP2%2520receptor%2520in%2520cerebral%2520ischemia%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D257%26epage%3D268%26doi%3D10.1523%2FJNEUROSCI.4485-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenbach, R.</span></span> <span> </span><span class="NLM_article-title">The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and β-arrestin1-dependent signaling pathways</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">39672</span>– <span class="NLM_lpage">39681</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.117689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M110.117689" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=39672-39681&author=K.+S.+Chunauthor=H.+C.+Laoauthor=R.+Langenbach&title=The+prostaglandin+E2+receptor%2C+EP2%2C+stimulates+keratinocyte+proliferation+in+mouse+skin+by+G+protein-dependent+and+%CE%B2-arrestin1-dependent+signaling+pathways&doi=10.1074%2Fjbc.M110.117689"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.117689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.117689%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DK.%2BS.%26aulast%3DLao%26aufirst%3DH.%2BC.%26aulast%3DLangenbach%26aufirst%3DR.%26atitle%3DThe%2520prostaglandin%2520E2%2520receptor%252C%2520EP2%252C%2520stimulates%2520keratinocyte%2520proliferation%2520in%2520mouse%2520skin%2520by%2520G%2520protein-dependent%2520and%2520%25CE%25B2-arrestin1-dependent%2520signaling%2520pathways%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D39672%26epage%3D39681%26doi%3D10.1074%2Fjbc.M110.117689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kigoshi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein-biased EP2 receptor agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00455</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00455" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=306-311&author=S.+Ogawaauthor=T.+Watanabeauthor=I.+Sugimotoauthor=K.+Moriyukiauthor=Y.+Gotoauthor=S.+Yamaneauthor=A.+Watanabeauthor=K.+Tsuboiauthor=A.+Kinoshitaauthor=H.+Kigoshiauthor=K.+Taniauthor=T.+Maruyama&title=Discovery+of+G+protein-biased+EP2+receptor+agonists&doi=10.1021%2Facsmedchemlett.5b00455"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00455%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DI.%26aulast%3DMoriyuki%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DYamane%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DKigoshi%26aufirst%3DH.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520G%2520protein-biased%2520EP2%2520receptor%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D306%26epage%3D311%26doi%3D10.1021%2Facsmedchemlett.5b00455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, T.</span></span> <span> </span><span class="NLM_article-title">Structural optimization and structure–functional selectivity relationship studies of G protein-biased EP2 receptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2446</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmcl.2016.03.110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2446-2449&author=S.+Ogawaauthor=T.+Watanabeauthor=K.+Moriyukiauthor=Y.+Gotoauthor=S.+Yamaneauthor=A.+Watanabeauthor=K.+Tsuboiauthor=A.+Kinoshitaauthor=T.+Okadaauthor=H.+Takedaauthor=K.+Taniauthor=T.+Maruyama&title=Structural+optimization+and+structure%E2%80%93functional+selectivity+relationship+studies+of+G+protein-biased+EP2+receptor+agonists&doi=10.1016%2Fj.bmcl.2016.03.110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.110%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DMoriyuki%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DYamane%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DTakeda%26aufirst%3DH.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DT.%26atitle%3DStructural%2520optimization%2520and%2520structure%25E2%2580%2593functional%2520selectivity%2520relationship%2520studies%2520of%2520G%2520protein-biased%2520EP2%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2446%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2016.03.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span>; <span class="NLM_string-name">Watanabe, T.</span>; <span class="NLM_string-name">Watanabe, A.</span>; <span class="NLM_string-name">Kinoshita, A.</span>; <span class="NLM_string-name">Tsuboi, K.</span>; <span class="NLM_string-name">Sugimoto, I.</span>; <span class="NLM_string-name">Moriyuki, K.</span>; <span class="NLM_string-name">Goto, Y.</span>; <span class="NLM_string-name">Yamane, S.</span>; <span class="NLM_string-name">Tani, K.</span>; <span class="NLM_string-name">Toru, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein biased EP2 receptor agonists</span>.  <i>Abstracts of Papers</i>, 250th National Meeting of the American Chemical Society; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Ogawa&author=T.+Watanabe&author=A.+Watanabe&author=A.+Kinoshita&author=K.+Tsuboi&author=I.+Sugimoto&author=K.+Moriyuki&author=Y.+Goto&author=S.+Yamane&author=K.+Tani&author=M.+Toru&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520G%2520protein%2520biased%2520EP2%2520receptor%2520agonists%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Endothelin-receptor antagonists beyond pulmonary arterial hypertension: cancer and fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8168</span>– <span class="NLM_lpage">8188</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8168-8188&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+antagonists+beyond+pulmonary+arterial+hypertension%3A+cancer+and+fibrosis&doi=10.1021%2Facs.jmedchem.5b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8168-8188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases.  Endothelin-receptor antagonists are in clin. use to treat pulmonary arterial hypertension and have been under clin. investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases.  In this Perspective, we review the mols. that have been evaluated in human clin. trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis.  We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists.  We will also consider which chem. characteristics are relevant to clin. use and the properties of mols. necessary for efficacy in treating diseases against which known mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfhFfiImWNbVg90H21EOLACvtfcHk0lhYIIqANF6pmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D&md5=b6f008d678c7e4ff5ded1db5f4a940c5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01781%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520antagonists%2520beyond%2520pulmonary%2520arterial%2520hypertension%253A%2520cancer%2520and%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8168%26epage%3D8188%26doi%3D10.1021%2Facs.jmedchem.5b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span> <span> </span><span class="NLM_article-title">Evidence for biased agonists and antagonists at the endothelin receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2016.02.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.lfs.2016.02.069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2016&pages=30-33&author=J.+J.+Maguire&title=Evidence+for+biased+agonists+and+antagonists+at+the+endothelin+receptors&doi=10.1016%2Fj.lfs.2016.02.069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2016.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2016.02.069%26sid%3Dliteratum%253Aachs%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26atitle%3DEvidence%2520for%2520biased%2520agonists%2520and%2520antagonists%2520at%2520the%2520endothelin%2520receptors%26jtitle%3DLife%2520Sci.%26date%3D2016%26volume%3D159%26spage%3D30%26epage%3D33%26doi%3D10.1016%2Fj.lfs.2016.02.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuc, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pell, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span> <span> </span><span class="NLM_article-title">Comparison of human ET<sub>A</sub> and ET<sub>B</sub> receptor signalling via G-protein and β-arrestin pathways</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.lfs.2012.03.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=544-549&author=J.+J.+Maguireauthor=R.+E.+Kucauthor=V.+R.+Pellauthor=A.+Greenauthor=M.+Brownauthor=S.+Kumarauthor=T.+Wehrmanauthor=E.+Quinnauthor=A.+P.+Davenport&title=Comparison+of+human+ETA+and+ETB+receptor+signalling+via+G-protein+and+%CE%B2-arrestin+pathways&doi=10.1016%2Fj.lfs.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DKuc%26aufirst%3DR.%2BE.%26aulast%3DPell%26aufirst%3DV.%2BR.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DWehrman%26aufirst%3DT.%26aulast%3DQuinn%26aufirst%3DE.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DComparison%2520of%2520human%2520ETA%2520and%2520ETB%2520receptor%2520signalling%2520via%2520G-protein%2520and%2520%25CE%25B2-arrestin%2520pathways%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D544%26epage%3D549%26doi%3D10.1016%2Fj.lfs.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrocca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semprucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Castro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, L.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2014.01.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.lfs.2014.01.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=179-184&author=R.+Cianfroccaauthor=P.+Tocciauthor=E.+Semprucciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=A.+Bagnatoauthor=L.+Rosano&title=%CE%B2-Arrestin+1+is+required+for+endothelin-1-induced+NF-%CE%BAB+activation+in+ovarian+cancer+cells&doi=10.1016%2Fj.lfs.2014.01.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2014.01.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2014.01.078%26sid%3Dliteratum%253Aachs%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSemprucci%26aufirst%3DE.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DRosano%26aufirst%3DL.%26atitle%3D%25CE%25B2-Arrestin%25201%2520is%2520required%2520for%2520endothelin-1-induced%2520NF-%25CE%25BAB%2520activation%2520in%2520ovarian%2520cancer%2520cells%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D179%26epage%3D184%26doi%3D10.1016%2Fj.lfs.2014.01.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrocca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Castro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biroccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicotra, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, A.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2811</span>, <span class="refDoi"> DOI: 10.1073/pnas.0807158106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0807158106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=2806-2811&author=L.+Rosanoauthor=R.+Cianfroccaauthor=S.+Masiauthor=F.+Spinellaauthor=V.+Di+Castroauthor=A.+Biroccioauthor=E.+Salvatiauthor=M.+R.+Nicotraauthor=P.+G.+Nataliauthor=A.+Bagnato&title=%CE%B2-Arrestin+links+endothelin+A+receptor+to+%CE%B2-catenin+signaling+to+induce+ovarian+cancer+cell+invasion+and+metastasis&doi=10.1073%2Fpnas.0807158106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0807158106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0807158106%26sid%3Dliteratum%253Aachs%26aulast%3DRosano%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DMasi%26aufirst%3DS.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DBiroccio%26aufirst%3DA.%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DNicotra%26aufirst%3DM.%2BR.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3D%25CE%25B2-Arrestin%2520links%2520endothelin%2520A%2520receptor%2520to%2520%25CE%25B2-catenin%2520signaling%2520to%2520induce%2520ovarian%2520cancer%2520cell%2520invasion%2520and%2520metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D2806%26epage%3D2811%26doi%3D10.1073%2Fpnas.0807158106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrocca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Castro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biroccio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, A.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">5066</span>– <span class="NLM_lpage">5077</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fonc.2012.527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=5066-5077&author=L.+Rosanoauthor=R.+Cianfroccaauthor=P.+Tocciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=F.+Spadaroauthor=E.+Salvatiauthor=A.+M.+Biroccioauthor=P.+G.+Nataliauthor=A.+Bagnato&title=%CE%B2-arrestin-1+is+a+nuclear+transcriptional+regulator+of+endothelin-1-induced+%CE%B2-catenin+signaling&doi=10.1038%2Fonc.2012.527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.527%26sid%3Dliteratum%253Aachs%26aulast%3DRosano%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DSpadaro%26aufirst%3DF.%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DBiroccio%26aufirst%3DA.%2BM.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3D%25CE%25B2-arrestin-1%2520is%2520a%2520nuclear%2520transcriptional%2520regulator%2520of%2520endothelin-1-induced%2520%25CE%25B2-catenin%2520signaling%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D5066%26epage%3D5077%26doi%3D10.1038%2Fonc.2012.527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamohara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushime, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, K.</span></span> <span> </span><span class="NLM_article-title">Molecular identification of nicotinic acid receptor</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(03)00342-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2FS0006-291X%2803%2900342-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2003&pages=364-369&author=T.+Sogaauthor=M.+Kamoharaauthor=J.+Takasakiauthor=S.-i.+Matsumotoauthor=T.+Saitoauthor=T.+Ohishiauthor=H.+Hiyamaauthor=A.+Matsuoauthor=H.+Matsushimeauthor=K.+Furuichi&title=Molecular+identification+of+nicotinic+acid+receptor&doi=10.1016%2FS0006-291X%2803%2900342-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2803%2900342-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252803%252900342-5%26sid%3Dliteratum%253Aachs%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DKamohara%26aufirst%3DM.%26aulast%3DTakasaki%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DS.-i.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DHiyama%26aufirst%3DH.%26aulast%3DMatsuo%26aufirst%3DA.%26aulast%3DMatsushime%26aufirst%3DH.%26aulast%3DFuruichi%26aufirst%3DK.%26atitle%3DMolecular%2520identification%2520of%2520nicotinic%2520acid%2520receptor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D303%26spage%3D364%26epage%3D369%26doi%3D10.1016%2FS0006-291X%2803%2900342-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muehlbauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1312</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1172/JCI36806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1172%2FJCI36806" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=1312-1321&author=R.+W.+Waltersauthor=A.+K.+Shuklaauthor=J.+J.+Kovacsauthor=J.+D.+Violinauthor=S.+M.+DeWireauthor=C.+M.+Lamauthor=J.+R.+Chenauthor=M.+J.+Muehlbauerauthor=E.+J.+Whalenauthor=R.+J.+Lefkowitz&title=%CE%B2-Arrestin1+mediates+nicotinic+acid-induced+flushing%2C+but+not+its+antilipolytic+effect%2C+in+mice&doi=10.1172%2FJCI36806"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1172%2FJCI36806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI36806%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DR.%2BW.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DKovacs%26aufirst%3DJ.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DLam%26aufirst%3DC.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BR.%26aulast%3DMuehlbauer%26aufirst%3DM.%2BJ.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3D%25CE%25B2-Arrestin1%2520mediates%2520nicotinic%2520acid-induced%2520flushing%252C%2520but%2520not%2520its%2520antilipolytic%2520effect%252C%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D1312%26epage%3D1321%26doi%3D10.1172%2FJCI36806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbaoui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boatman, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carballo-Jane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behan, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J. G.</span></span> <span> </span><span class="NLM_article-title">3-(1<i>H</i>-Tetrazol-5-yl)- 1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5101</span>– <span class="NLM_lpage">5108</span>, <span class="refDoi"> DOI: 10.1021/jm800258p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5101-5108&author=G.+Sempleauthor=P.+J.+Skinnerauthor=T.+Gharbaouiauthor=Y.+J.+Shinauthor=J.+K.+Jungauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=S.+Y.+Tamuraauthor=P.+D.+Boatmanauthor=C.+R.+Sageauthor=T.+O.+Schraderauthor=R.+Chenauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=M.+G.+Watersauthor=K.+Chengauthor=A.+K.+Taggartauthor=T.+Q.+Caiauthor=E.+Carballo-Janeauthor=D.+P.+Behanauthor=D.+T.+Connollyauthor=J.+G.+Richman&title=3-%281H-Tetrazol-5-yl%29-+1%2C4%2C5%2C6-tetrahydro-cyclopentapyrazole+%28MK-0354%29%3A+a+partial+agonist+of+the+nicotinic+acid+receptor%2C+G-protein+coupled+receptor+109a%2C+with+antilipolytic+but+no+vasodilatory+activity+in+mice&doi=10.1021%2Fjm800258p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm800258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800258p%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.%2BJ.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%2BY.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCai%26aufirst%3DT.%2BQ.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D3-%25281H-Tetrazol-5-yl%2529-%25201%252C4%252C5%252C6-tetrahydro-cyclopentapyrazole%2520%2528MK-0354%2529%253A%2520a%2520partial%2520agonist%2520of%2520the%2520nicotinic%2520acid%2520receptor%252C%2520G-protein%2520coupled%2520receptor%2520109a%252C%2520with%2520antilipolytic%2520but%2520no%2520vasodilatory%2520activity%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5101%26epage%3D5108%26doi%3D10.1021%2Fjm800258p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boatman, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauring, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carballo-Jane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J. G.</span></span> <span> </span><span class="NLM_article-title">(1a<i>R</i>,5a<i>R</i>)1a,3,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[a] pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3644</span>– <span class="NLM_lpage">3666</span>, <span class="refDoi"> DOI: 10.1021/jm2010964</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2010964" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3644-3666&author=P.+D.+Boatmanauthor=B.+Lauringauthor=T.+O.+Schraderauthor=M.+Kasemauthor=B.+R.+Johnsonauthor=P.+Skinnerauthor=J.+K.+Jungauthor=J.+Xuauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=G.+Sempleauthor=C.+R.+Sageauthor=J.+Knudsenauthor=R.+Chenauthor=W.+L.+Luoauthor=L.+Caroauthor=J.+Coteauthor=E.+Laiauthor=J.+Wagnerauthor=A.+K.+Taggartauthor=E.+Carballo-Janeauthor=M.+Hammondauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=D.+T.+Connollyauthor=M.+G.+Watersauthor=J.+G.+Richman&title=%281aR%2C5aR%291a%2C3%2C5%2C5a-Tetrahydro-1H-2%2C3-diaza-cyclopropa%5Ba%5D+pentalene-4-carboxylic+acid+%28MK-1903%29%3A+a+potent+GPR109a+agonist+that+lowers+free+fatty+acids+in+humans&doi=10.1021%2Fjm2010964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm2010964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2010964%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DLauring%26aufirst%3DB.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BR.%26aulast%3DSkinner%26aufirst%3DP.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DKnudsen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DW.%2BL.%26aulast%3DCaro%26aufirst%3DL.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DHammond%26aufirst%3DM.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D%25281aR%252C5aR%25291a%252C3%252C5%252C5a-Tetrahydro-1H-2%252C3-diaza-cyclopropa%255Ba%255D%2520pentalene-4-carboxylic%2520acid%2520%2528MK-1903%2529%253A%2520a%2520potent%2520GPR109a%2520agonist%2520that%2520lowers%2520free%2520fatty%2520acids%2520in%2520humans%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3644%26epage%3D3666%26doi%3D10.1021%2Fjm2010964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenewegen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaliti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttringer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumb, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallstrom, E.</span></span> <span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22646698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergelyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstrom&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span></div><div class="casAuthors">Gergely, P.; Nuesslein-Hildesheim, B.; Guerini, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J., Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1035-1047</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose BAF312 is a next-generation sphingosine 1-phosphate (S1P) receptor modulator, selective for S1P1 and S1P5 receptors.  S1P1 receptors are essential for lymphocyte egress from lymph nodes and a drug target in immune-mediated diseases.  Here, we have characterized the immunomodulatory potential of BAF312 and the S1P receptor-mediated effects on heart rate using preclin. and human data.  Exptl. Approach BAF312 was tested in a rat exptl. autoimmune encephalomyelitis (EAE) model.  Electrophysiol. recordings of G-protein-coupled inwardly rectifying potassium (GIRK) channels were carried out in human atrial myocytes.  A Phase I multiple-dose trial studied the pharmacokinetics, pharmacodynamics and safety of BAF312 in 48 healthy subjects.  Key Results BAF312 effectively suppressed EAE in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes.  In healthy volunteers, BAF312 caused preferential decreases in CD4+ T cells, Tnaive, Tcentral memory and B cells within 4-6 h.  Cell counts returned to normal ranges within a week after stopping treatment, in line with the elimination half-life of BAF312.  Despite sparing S1P3 receptors (assocd. with bradycardia in mice), BAF312 induced rapid, transient (day 1 only) bradycardia in humans.  BAF312-mediated activation of GIRK channels in human atrial myocytes can fully explain the bradycardia.  Conclusion and Implications This study illustrates species-specific differences in S1P receptor specificity for first-dose cardiac effects.  Based on its profound but rapidly reversible inhibition of lymphocyte trafficking, BAF312 may have potential as a treatment for immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42VfW58NMyLVg90H21EOLACvtfcHk0lj_rlk3BgSDCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE&md5=0034be62fb68b10abefff50f0220be2a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstrom%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical pharmacology of BMS-986104: a differentiated S1P<sub>1</sub> receptor modulator in clinical trials</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=283-288&author=T.+G.+M.+Dharauthor=H.+Y.+Xiaoauthor=J.+Xieauthor=L.+D.+Lehman-McKeemanauthor=D.+R.+Wuauthor=M.+Dabrosauthor=X.+Yangauthor=T.+L.+Taylorauthor=X.+D.+Zhouauthor=E.+M.+Heimrichauthor=R.+Thomasauthor=K.+W.+McIntyreauthor=B.+Warrackauthor=H.+Shiauthor=P.+C.+Levesqueauthor=J.+L.+Zhuauthor=J.+Hennanauthor=P.+Balimaneauthor=Z.+Yangauthor=A.+M.+Marinoauthor=G.+Corneliusauthor=C.+J.+D%E2%80%99Arienzoauthor=A.+Mathurauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+J.+Dyckman&title=Identification+and+preclinical+pharmacology+of+BMS-986104%3A+a+differentiated+S1P1+receptor+modulator+in+clinical+trials&doi=10.1021%2Facsmedchemlett.5b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials</span></div><div class="casAuthors">Dhar, T. G. Murali; Xiao, Hai-Yun; Xie, Jenny; Lehman-McKeeman, Lois D.; Wu, Dauh-Rurng; Dabros, Marta; Yang, Xiaoxia; Taylor, Tracy L.; Zhou, Xia D.; Heimrich, Elizabeth M.; Thomas, Rochelle; McIntyre, Kim W.; Warrack, Bethanne; Shi, Hong; Levesque, Paul C.; Zhu, Jia L.; Hennan, James; Balimane, Praveen; Yang, Zheng; Marino, Anthony M.; Cornelius, Georgia; D'Arienzo, Celia J.; Mathur, Arvind; Shen, Ding Ren; Cvijic, Mary Ellen; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Dyckman, Alaric J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya) as the first oral therapy for relapsing remitting multiple sclerosis.  However, fingolimod causes a dose-dependent redn. in the heart rate (bradycardia), which occurs within hours after first dose.  The authors disclose the identification of clin. compd. BMS-986104 I, a novel S1P1 receptor modulator, which demonstrates ligand-biased signaling and differentiates from fingolimod in terms of cardiovascular and pulmonary safety based on preclin. pharmacol. while showing equiv. efficacy in a T-cell transfer colitis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxpaIol_-7abVg90H21EOLACvtfcHk0lg-_sQ9KsWqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlGqtA%253D%253D&md5=b625957b1a8be2501e804905de1c8b06</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00448%26sid%3Dliteratum%253Aachs%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DZhou%26aufirst%3DX.%2BD.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DHennan%26aufirst%3DJ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarino%26aufirst%3DA.%2BM.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520and%2520preclinical%2520pharmacology%2520of%2520BMS-986104%253A%2520a%2520differentiated%2520S1P1%2520receptor%2520modulator%2520in%2520clinical%2520trials%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D283%26epage%3D288%26doi%3D10.1021%2Facsmedchemlett.5b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiozzo Fasiolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beggiato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borelli, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomierny-Chamiolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonelli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasini, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuxe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filip, M.</span></span> <span> </span><span class="NLM_article-title">Neurotensin: a role in substance use disorder?</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1177/0269881115622240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1177%2F0269881115622240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26755548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCiu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=112-127&author=L.+Ferraroauthor=L.+Tiozzo+Fasioloauthor=S.+Beggiatoauthor=A.+C.+Borelliauthor=L.+Pomierny-Chamioloauthor=M.+Frankowskaauthor=T.+Antonelliauthor=M.+C.+Tomasiniauthor=K.+Fuxeauthor=M.+Filip&title=Neurotensin%3A+a+role+in+substance+use+disorder%3F&doi=10.1177%2F0269881115622240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotensin: a role in substance use disorder?</span></div><div class="casAuthors">Ferraro, Luca; Fasiolo, Laura Tiozzo; Beggiato, Sarah; Borelli, Andrea C.; Pomierny-Chamiolo, Lucyna; Frankowska, Malgorzata; Antonelli, Tiziana; Tomasini, Maria C.; Fuxe, Kjell; Filip, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-127</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Neurotensin is a tridecapeptide originally identified in exts. of bovine hypothalamus.  This peptide has a close anatomical and functional relationship with the mesocorticolimbic and nigrostriatal dopamine system.  Neural circuits contg. neurotensin were originally proposed to play a role in the mechanism of action of antipsychotic agents.  Addnl., neurotensin-contg. pathways were demonstrated to mediate some of the rewarding and/or sensitizing properties of drugs of abuse.  This review attempts to contribute to the understanding of the role of neurotensin and its receptors in drug abuse.  In particular, we will summarize the potential relevance of neurotensin, its related compds. and neurotensin receptors in substance use disorders, with a focus on the preclin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0z4hA43w37Vg90H21EOLACvtfcHk0lg-_sQ9KsWqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCiu7bM&md5=a8de975d9e8db159440f29ff6bcc747a</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1177%2F0269881115622240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881115622240%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DL.%26aulast%3DTiozzo%2BFasiolo%26aufirst%3DL.%26aulast%3DBeggiato%26aufirst%3DS.%26aulast%3DBorelli%26aufirst%3DA.%2BC.%26aulast%3DPomierny-Chamiolo%26aufirst%3DL.%26aulast%3DFrankowska%26aufirst%3DM.%26aulast%3DAntonelli%26aufirst%3DT.%26aulast%3DTomasini%26aufirst%3DM.%2BC.%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DFilip%26aufirst%3DM.%26atitle%3DNeurotensin%253A%2520a%2520role%2520in%2520substance%2520use%2520disorder%253F%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2016%26volume%3D30%26spage%3D112%26epage%3D127%26doi%3D10.1177%2F0269881115622240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varshney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindie, E.</span></span> <span> </span><span class="NLM_article-title">Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1650</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.2967/jnumed.114.142000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.2967%2Fjnumed.114.142000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25189338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFyqtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1650-1657&author=C.+Morgatauthor=A.+K.+Mishraauthor=R.+Varshneyauthor=M.+Allardauthor=P.+Fernandezauthor=E.+Hindie&title=Targeting+neuropeptide+receptors+for+cancer+imaging+and+therapy%3A+perspectives+with+bombesin%2C+neurotensin%2C+and+neuropeptide-Y+receptors&doi=10.2967%2Fjnumed.114.142000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors</span></div><div class="casAuthors">Morgat, Clement; Mishra, Anil Kumar; Varshney, Raunak; Allard, Michele; Fernandez, Philippe; Hindie, Elif</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1650-1657</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">A review.  Receptors for some regulatory peptides are highly expressed in tumors.  Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacol. and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy.  The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets.  This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncol.  The underlying biol. of these peptide/receptor systems, their physiol. and pathol. roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers.  Radiolabeled analogs that selectively target these receptors are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSrhZnmdSzqbVg90H21EOLACvtfcHk0lgMgdc0guQY3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFyqtbvL&md5=10759e1728dad11df6b391371f228fc1</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.114.142000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.114.142000%26sid%3Dliteratum%253Aachs%26aulast%3DMorgat%26aufirst%3DC.%26aulast%3DMishra%26aufirst%3DA.%2BK.%26aulast%3DVarshney%26aufirst%3DR.%26aulast%3DAllard%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DHindie%26aufirst%3DE.%26atitle%3DTargeting%2520neuropeptide%2520receptors%2520for%2520cancer%2520imaging%2520and%2520therapy%253A%2520perspectives%2520with%2520bombesin%252C%2520neurotensin%252C%2520and%2520neuropeptide-Y%2520receptors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1650%26epage%3D1657%26doi%3D10.2967%2Fjnumed.114.142000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peddibhotla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosalia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen-Genel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salaniwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangravita-Novo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicchiarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of ML314, a brain penetrant nonpeptidic β-arrestin biased agonist of the neurotensin NTR1 receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1021/ml400176n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400176n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=846-851&author=S.+Peddibhotlaauthor=M.+P.+Hedrickauthor=P.+Hershbergerauthor=P.+R.+Maloneyauthor=Y.+Liauthor=M.+Milewskiauthor=P.+Gosaliaauthor=W.+Grayauthor=A.+Mehtaauthor=E.+Sugarmanauthor=B.+Hoodauthor=E.+Suyamaauthor=K.+Nguyenauthor=S.+Heynen-Genelauthor=S.+Vasileauthor=S.+Salaniwalauthor=D.+Stonichauthor=Y.+Suauthor=A.+Mangravita-Novoauthor=M.+Vicchiarelliauthor=G.+P.+Rothauthor=L.+H.+Smithauthor=T.+D.+Y.+Chungauthor=G.+R.+Hansonauthor=J.+B.+Thomasauthor=M.+G.+Caronauthor=L.+S.+Barakauthor=A.+B.+Pinkerton&title=Discovery+of+ML314%2C+a+brain+penetrant+nonpeptidic+%CE%B2-arrestin+biased+agonist+of+the+neurotensin+NTR1+receptor&doi=10.1021%2Fml400176n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fml400176n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400176n%26sid%3Dliteratum%253Aachs%26aulast%3DPeddibhotla%26aufirst%3DS.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DHershberger%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMilewski%26aufirst%3DM.%26aulast%3DGosalia%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DW.%26aulast%3DMehta%26aufirst%3DA.%26aulast%3DSugarman%26aufirst%3DE.%26aulast%3DHood%26aufirst%3DB.%26aulast%3DSuyama%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DHeynen-Genel%26aufirst%3DS.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DSalaniwal%26aufirst%3DS.%26aulast%3DStonich%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DMangravita-Novo%26aufirst%3DA.%26aulast%3DVicchiarelli%26aufirst%3DM.%26aulast%3DRoth%26aufirst%3DG.%2BP.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26aulast%3DThomas%26aufirst%3DJ.%2BB.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26atitle%3DDiscovery%2520of%2520ML314%252C%2520a%2520brain%2520penetrant%2520nonpeptidic%2520%25CE%25B2-arrestin%2520biased%2520agonist%2520of%2520the%2520neurotensin%2520NTR1%2520receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D846%26epage%3D851%26doi%3D10.1021%2Fml400176n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urs, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddibhotla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span> <span> </span><span class="NLM_article-title">ML314: a biased neurotensin receptor ligand for methamphetamine abuse</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1880</span>– <span class="NLM_lpage">1890</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00291</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2rtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1880-1890&author=L.+S.+Barakauthor=Y.+Baiauthor=S.+Petersonauthor=T.+Evronauthor=N.+M.+Ursauthor=S.+Peddibhotlaauthor=M.+P.+Hedrickauthor=P.+Hershbergerauthor=P.+R.+Maloneyauthor=T.+D.+Y.+Chungauthor=R.+M.+Rodriguizauthor=W.+C.+Wetselauthor=J.+B.+Thomasauthor=G.+R.+Hansonauthor=A.+B.+Pinkertonauthor=M.+G.+Caron&title=ML314%3A+a+biased+neurotensin+receptor+ligand+for+methamphetamine+abuse&doi=10.1021%2Facschembio.6b00291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse</span></div><div class="casAuthors">Barak, Larry S.; Bai, Yushi; Peterson, Sean; Evron, Tama; Urs, Nikhil M.; Peddibhotla, Satyamaheshwar; Hedrick, Michael P.; Hershberger, Paul; Maloney, Patrick R.; Chung, Thomas D. Y.; Rodriguiz, Ramona M.; Wetsel, William C.; Thomas, James B.; Hanson, Glen R.; Pinkerton, Anthony B.; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1890</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacol. treatment for methamphetamine addiction will provide important societal benefits.  Neurotensin receptor NTR1 and dopamine receptor distributions coincide in brain areas regulating methamphetamine-assocd. reward, and neurotensin peptides produce behaviors opposing psychostimulants.  Therefore, undesirable methamphetamine-assocd. activities should be treatable with druggable NTR1 agonists, but no such FDA-approved therapeutics exist.  We address this limitation with proof-of-concept data for ML314, a small-mol., brain penetrant, β-arrestin biased, NTR1 agonist.  ML314 attenuates amphetamine-like hyperlocomotion in dopamine transporter knockout mice, and in C57BL/6J mice it attenuates methamphetamine-induced hyperlocomotion, potentiates the psychostimulant inhibitory effects of a ghrelin antagonist, and reduces methamphetamine-assocd. conditioned place preference.  In rats, ML314 blocks methamphetamine self-administration.  ML314 acts as an allosteric enhancer of endogenous neurotensin, unmasking stoichiometric nos. of hidden NTR1 binding sites in transfected-cell membranes or mouse striatal membranes, while addnl. supporting NTR1 endocytosis in cells in the absence of NT peptide.  These results indicate ML314 is a viable, preclin. lead for methamphetamine abuse treatment and support an allosteric model of G protein-coupled receptor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRELv0YzCr9bVg90H21EOLACvtfcHk0lgdPXT7twZ9JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2rtbY%253D&md5=48872ea73457f91e63a8631117848ecd</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00291%26sid%3Dliteratum%253Aachs%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DEvron%26aufirst%3DT.%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DPeddibhotla%26aufirst%3DS.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DHershberger%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DThomas%26aufirst%3DJ.%2BB.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DML314%253A%2520a%2520biased%2520neurotensin%2520receptor%2520ligand%2520for%2520methamphetamine%2520abuse%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D1880%26epage%3D1890%26doi%3D10.1021%2Facschembio.6b00291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammendola, R.</span></span> <span> </span><span class="NLM_article-title">Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">7193</span>– <span class="NLM_lpage">7230</span>, <span class="refDoi"> DOI: 10.3390/ijms14047193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3390%2Fijms14047193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23549262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFWktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=7193-7230&author=F.+Cattaneoauthor=M.+Parisiauthor=R.+Ammendola&title=Distinct+signaling+cascades+elicited+by+different+formyl+peptide+receptor+2+%28FPR2%29+agonists&doi=10.3390%2Fijms14047193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists</span></div><div class="casAuthors">Cattaneo, Fabio; Parisi, Melania; Ammendola, Rosario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7193-7230</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The formyl peptide receptor 2 (FPR2) is a remarkably versatile transmembrane protein belonging to the G-protein coupled receptor (GPCR) family.  FPR2 is activated by an array of ligands, which include structurally unrelated lipids and peptide/proteins agonists, resulting in different intracellular responses in a ligand-specific fashion.  In addn. to the anti-inflammatory lipid, lipoxin A4, several other endogenous agonists also bind FPR2, including serum amyloid A, glucocorticoid-induced annexin 1, urokinase and its receptor, suggesting that the activation of FPR2 may result in potent pro- or anti-inflammatory responses.  Other endogenous ligands, also present in biol. samples, include resolvins, amyloidogenic proteins, such as beta amyloid (Aβ)-42 and prion protein (Prp)106-126, the neuroprotective peptide, humanin, antibacterial peptides, annexin 1-derived peptides, chemokine variants, the neuropeptides, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP)-27 and mitochondrial peptides.  Upon activation, intracellular domains of FPR2 mediate signaling to G-proteins, which trigger several agonist-dependent signal transduction pathways, including activation of phospholipase C (PLC), protein kinase C (PKC) isoforms, the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, the mitogen-activated protein kinase (MAPK) pathway, p38MAPK, as well as the phosphorylation of cytosolic tyrosine kinases, tyrosine kinase receptor transactivation, phosphorylation and nuclear translocation of regulatory transcriptional factors, release of calcium and prodn. of oxidants.  FPR2 is an attractive therapeutic target, because of its involvement in a range of normal physiol. processes and pathol. diseases.  Here, we review and discuss the most significant findings on the intracellular pathways and on the cross-communication between FPR2 and tyrosine kinase receptors triggered by different FPR2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKmHveSDBH7Vg90H21EOLACvtfcHk0lhVkyJEMNhdTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFWktr8%253D&md5=b3d1ed852ecb5a03e114d4d4a0beb036</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.3390%2Fijms14047193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms14047193%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DF.%26aulast%3DParisi%26aufirst%3DM.%26aulast%3DAmmendola%26aufirst%3DR.%26atitle%3DDistinct%2520signaling%2520cascades%2520elicited%2520by%2520different%2520formyl%2520peptide%2520receptor%25202%2520%2528FPR2%2529%2520agonists%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D7193%26epage%3D7230%26doi%3D10.3390%2Fijms14047193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corminboeuf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, X.</span></span> <span> </span><span class="NLM_article-title">FPR2/ALXR agonists and the resolution of inflammation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1021/jm501051x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501051x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=537-559&author=O.+Corminboeufauthor=X.+Leroy&title=FPR2%2FALXR+agonists+and+the+resolution+of+inflammation&doi=10.1021%2Fjm501051x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">FPR2/ALXR Agonists and the Resolution of Inflammation</span></div><div class="casAuthors">Corminboeuf, Olivier; Leroy, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">537-559</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The resoln. of inflammation (RoI), once believed to be a passive process, has lately been shown to be an active and delicately orchestrated process.  During the resoln. phase of acute inflammation, novel mediators, including lipoxins and resolvins, which are members of the specialized pro-resolving mediators of inflammation, are produced.  FPR2/ALXR, a receptor modulated by some of these lipids as well as by peptides (e.g., annexin A1), has been shown to be one of the receptors involved in the RoI.  The aim of this perspective is to present the concept of the RoI from a medicinal chem. point of view and to highlight the effort of the research community to discover and develop anti-inflammatory/pro-resoln. small mols. to orchestrate inflammation by activation of FPR2/ALXR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-uVie3v-44bVg90H21EOLACvtfcHk0lhVkyJEMNhdTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLbJ&md5=3b595d7c70e5d2336c6fb832b372ba7b</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fjm501051x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501051x%26sid%3Dliteratum%253Aachs%26aulast%3DCorminboeuf%26aufirst%3DO.%26aulast%3DLeroy%26aufirst%3DX.%26atitle%3DFPR2%252FALXR%2520agonists%2520and%2520the%2520resolution%2520of%2520inflammation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D537%26epage%3D559%26doi%3D10.1021%2Fjm501051x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forsman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bylund, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulay, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, C.</span></span> <span> </span><span class="NLM_article-title">The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1833</i></span>,  <span class="NLM_fpage">1914</span>– <span class="NLM_lpage">1923</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2013.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bbamcr.2013.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23562731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVGmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1833&publication_year=2013&pages=1914-1923&author=H.+Forsmanauthor=J.+Bylundauthor=T.+I.+Opreaauthor=A.+Karlssonauthor=F.+Boulayauthor=M.+J.+Rabietauthor=C.+Dahlgren&title=The+leukocyte+chemotactic+receptor+FPR2%2C+but+not+the+closely+related+FPR1%2C+is+sensitive+to+cell-penetrating+pepducins+with+amino+acid+sequences+descending+from+the+third+intracellular+receptor+loop&doi=10.1016%2Fj.bbamcr.2013.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop</span></div><div class="casAuthors">Forsman, Huamei; Bylund, Johan; Oprea, Tudor I.; Karlsson, Anna; Boulay, Francois; Rabiet, Marie-Josephe; Dahlgren, Claes</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1833</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1914-1923</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lipidated peptides (pepducins) can activate certain G-protein coupled receptors (GPCRs) through a unique allosteric modulation mechanism involving cytosolic receptor domains.  Pepducins with the amino acid sequence of the third intracellular loop of the neutrophil formyl peptide receptors (FPRs) as a common denominator were N-terminally conjugated with palmitic acid.  F2Pal16, contg. the 16 amino acids present in the third intracellular loop of FPR2, induced superoxide prodn. in human neutrophils and the activity was sensitive to FPR2 antagonists.  Cells over-expressing FPR2 were similarly responsive and responded with a transient increase in cytosolic calcium.  No such effects were obsd. with the corresponding FPR1 pepducin.  The peptide alone, lacking palmitic acid, did not activate neutrophils.  A ten amino acid long pepducin F2Pal10, that was a more potent neutrophil activator than F2Pal16, was used for amino acid substitution studies.  The sequences of FPR1 and FPR2 in the third intracellular loop differ by only two amino acids, and a pepducin with the FPR2-specific K231 replaced by the FPR1-specific Q231 lost all activity.  The active F2Pal10 pepducin also triggered a response in cells expressing a mutated FPR2 with the third intracellular loop identical to that of FPR1.  The data presented suggest that the same signaling pathways are activated when the signaling cascade is initiated by a classical receptor agonist (outside-in signaling) and when signaling starts on the cytosolic side of the membrane by a pepducin (inside-in signaling).  A fundamental difference is also disclosed between the two neutrophil FPRs regarding their sensitivities to third intracellular loop pepducins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Igw-hzfbprVg90H21EOLACvtfcHk0lhVkyJEMNhdTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVGmu7Y%253D&md5=a6d2f1d5eea58f49f84470a9c5f3b34a</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2013.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2013.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DForsman%26aufirst%3DH.%26aulast%3DBylund%26aufirst%3DJ.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DBoulay%26aufirst%3DF.%26aulast%3DRabiet%26aufirst%3DM.%2BJ.%26aulast%3DDahlgren%26aufirst%3DC.%26atitle%3DThe%2520leukocyte%2520chemotactic%2520receptor%2520FPR2%252C%2520but%2520not%2520the%2520closely%2520related%2520FPR1%252C%2520is%2520sensitive%2520to%2520cell-penetrating%2520pepducins%2520with%2520amino%2520acid%2520sequences%2520descending%2520from%2520the%2520third%2520intracellular%2520receptor%2520loop%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2013%26volume%3D1833%26spage%3D1914%26epage%3D1923%26doi%3D10.1016%2Fj.bbamcr.2013.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holdfeldt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsman, H.</span></span> <span> </span><span class="NLM_article-title">FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2017.08.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2017&pages=114-122&author=M.+Gablauthor=A.+Holdfeldtauthor=M.+Sundqvistauthor=J.+Lomeiauthor=C.+Dahlgrenauthor=H.+Forsman&title=FPR2+signaling+without+%CE%B2-arrestin+recruitment+alters+the+functional+repertoire+of+neutrophils&doi=10.1016%2Fj.bcp.2017.08.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DGabl%26aufirst%3DM.%26aulast%3DHoldfeldt%26aufirst%3DA.%26aulast%3DSundqvist%26aufirst%3DM.%26aulast%3DLomei%26aufirst%3DJ.%26aulast%3DDahlgren%26aufirst%3DC.%26aulast%3DForsman%26aufirst%3DH.%26atitle%3DFPR2%2520signaling%2520without%2520%25CE%25B2-arrestin%2520recruitment%2520alters%2520the%2520functional%2520repertoire%2520of%2520neutrophils%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D145%26spage%3D114%26epage%3D122%26doi%3D10.1016%2Fj.bcp.2017.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1211%2F0022357011775631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=11734617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=527-552&author=B.+B.+Fredholmauthor=A.+P.+Ijzermanauthor=K.+A.+Jacobsonauthor=K.+N.+Klotzauthor=J.+Linden&title=International+Union+of+Pharmacology.+XXV.+Nomenclature+and+classification+of+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors</span></div><div class="casAuthors">Fredholm, Bertil B.; IJzerman, Adriaan P.; Jacobson, Kenneth A.; Klotz, Karl-Norbert; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">527-552</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Four adenosine receptors have been cloned and characterized from several mammalian species.  The receptors are named adenosine A1, A2A, A2B, and A3.  The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins.  However, other G protein interactions have also been described.  Adenosine is the preferred endogenous agonist at all these receptors, but inosine can also activate the A3 receptor.  The levels of adenosine seen under basal conditions are sufficient to cause some activation of all the receptors, at least where they are abundantly expressed.  Adenosine levels during, e.g., ischemia can activate all receptors even when expressed in low abundance.  Accordingly, expts. with receptor antagonists and mice with targeted disruption of adenosine A1, A2A, and A3 expression reveal roles for these receptors under physiol. and particularly pathophysiol. conditions.  There are pharmacol. tools that can be used to classify A1, A2A, and A3 receptors but few drugs that interact selectively with A2B receptors.  Testable models of the interaction of these drugs with their receptors have been generated by site-directed mutagenesis and homol.-based modeling.  Both agonists and antagonists are being developed as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOCrJphTwDrVg90H21EOLACvtfcHk0lhFXsIMyC8GtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D&md5=060ea8a3d7b07fdc4b2c8acc3b4d4745</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1211%2F0022357011775631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357011775631%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXV.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D527%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verzijl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity of adenosine receptor ligands</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s11302-011-9232-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs11302-011-9232-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=171-192&author=D.+Verzijlauthor=A.+P.+IJzerman&title=Functional+selectivity+of+adenosine+receptor+ligands&doi=10.1007%2Fs11302-011-9232-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1007%2Fs11302-011-9232-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-011-9232-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerzijl%26aufirst%3DD.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DFunctional%2520selectivity%2520of%2520adenosine%2520receptor%2520ligands%26jtitle%3DPurinergic%2520Signalling%26date%3D2011%26volume%3D7%26spage%3D171%26epage%3D192%26doi%3D10.1007%2Fs11302-011-9232-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aurelio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuo, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4614</span>– <span class="NLM_lpage">4619</span>, <span class="refDoi"> DOI: 10.1073/pnas.1320962111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1320962111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24619092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Smsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4614-4619&author=C.+Valantauthor=L.+T.+Mayauthor=L.+Aurelioauthor=C.+H.+Chuoauthor=P.+J.+Whiteauthor=J.+A.+Baltosauthor=P.+M.+Sextonauthor=P.+J.+Scammellsauthor=A.+Christopoulos&title=Separation+of+on-target+efficacy+from+adverse+effects+through+rational+design+of+a+bitopic+adenosine+receptor+agonist&doi=10.1073%2Fpnas.1320962111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist</span></div><div class="casAuthors">Valant, Celine; May, Lauren T.; Aurelio, Luigi; Chuo, Chung Hui; White, Paul J.; Baltos, Jo-Anne; Sexton, Patrick M.; Scammells, Peter J.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4614-4619</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The concepts of allosteric modulation and biased agonism are revolutionizing modern approaches to drug discovery, particularly in the field of G protein-coupled receptors (GPCRs).  Both phenomena exploit topog. distinct binding sites to promote unique GPCR conformations that can lead to different patterns of cellular responsiveness.  The adenosine A1 GPCR (A1AR) is a major therapeutic target for cardioprotection, but current agents acting on the receptor are clin. limited for this indication because of on-target bradycardia as a serious adverse effect.  In the current study, the authors have rationally designed a novel A1AR ligand (VCP746)-a hybrid mol. comprising adenosine linked to a pos. allosteric modulator-specifically to engender biased signaling at the A1AR.  The authors validate that the interaction of VCP746 with the A1AR is consistent with a bitopic mode of receptor engagement (i.e., concomitant assocn. with orthosteric and allosteric sites) and that the compd. displays biased agonism relative to prototypical A1AR ligands.  Importantly, the authors also show that the unique pharmacol. of VCP746 is (patho)physiol. relevant, because the compd. protects against ischemic insult in native A1AR-expressing cardiomyoblasts and cardiomyocytes but does not affect rat atrial heart rate.  Thus, this study provides proof of concept that bitopic ligands can be designed as biased agonists to promote on-target efficacy without on-target side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWe6rXsi_ff7Vg90H21EOLACvtfcHk0lhFXsIMyC8GtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Smsb8%253D&md5=560f32d7a5dbbf24df9d049b23d0c5c1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320962111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320962111%26sid%3Dliteratum%253Aachs%26aulast%3DValant%26aufirst%3DC.%26aulast%3DMay%26aufirst%3DL.%2BT.%26aulast%3DAurelio%26aufirst%3DL.%26aulast%3DChuo%26aufirst%3DC.%2BH.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DBaltos%26aufirst%3DJ.%2BA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSeparation%2520of%2520on-target%2520efficacy%2520from%2520adverse%2520effects%2520through%2520rational%2520design%2520of%2520a%2520bitopic%2520adenosine%2520receptor%2520agonist%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D4614%26epage%3D4619%26doi%3D10.1073%2Fpnas.1320962111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span> <span> </span><span class="NLM_article-title">Quantification of adenosine A1 receptor biased agonism: implications for drug discovery</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2015.11.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=101-112&author=J.+A.+Baltosauthor=K.+J.+Gregoryauthor=P.+J.+Whiteauthor=P.+M.+Sextonauthor=A.+Christopoulosauthor=L.+T.+May&title=Quantification+of+adenosine+A1+receptor+biased+agonism%3A+implications+for+drug+discovery&doi=10.1016%2Fj.bcp.2015.11.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DBaltos%26aufirst%3DJ.%2BA.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DMay%26aufirst%3DL.%2BT.%26atitle%3DQuantification%2520of%2520adenosine%2520A1%2520receptor%2520biased%2520agonism%253A%2520implications%2520for%2520drug%2520discovery%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D99%26spage%3D101%26epage%3D112%26doi%3D10.1016%2Fj.bcp.2015.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aurelio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jörg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span> <span> </span><span class="NLM_article-title">A structure-activity relationship study of bitopic N<sup>6</sup>-substituted adenosine derivatives as biased adenosine A<sub>1</sub> receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2103</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00047</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00047" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2087-2103&author=L.+Aurelioauthor=J.-A.+Baltosauthor=L.+Fordauthor=A.+T.+N.+Nguyenauthor=M.+J%C3%B6rgauthor=S.+M.+Devineauthor=C.+Valantauthor=P.+J.+Whiteauthor=A.+Christopoulosauthor=L.+T.+Mayauthor=P.+J.+Scammells&title=A+structure-activity+relationship+study+of+bitopic+N6-substituted+adenosine+derivatives+as+biased+adenosine+A1+receptor+agonists&doi=10.1021%2Facs.jmedchem.8b00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Activity Relationship Study of Bitopic N6-Substituted Adenosine Derivatives as Biased Adenosine A1 Receptor Agonists</span></div><div class="casAuthors">Aurelio, Luigi; Baltos, Jo-Anne; Ford, Leigh; Nguyen, Anh T. N.; Jorg, Manuela; Devine, Shane M.; Valant, Celine; White, Paul J.; Christopoulos, Arthur; May, Lauren T.; Scammells, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2087-2103</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The adenosine A1 receptor (A1AR) is a potential novel therapeutic target for myocardial ischemia-reperfusion injury.  However, to date, clin. translation of prototypical A1AR agonists has been hindered due to dose limiting adverse effects.  Recently, we demonstrated that the biased bitopic agonist, consisting of an adenosine pharmacophore linked to an allosteric moiety, could stimulate cardioprotective A1AR signaling in the absence of unwanted bradycardia.  Modifications were made to the orthosteric adenosine pharmacophore, linker, and allosteric 2-amino-3-benzoylthiophene pharmacophore to probe the structure-activity relationships, particularly in terms of biased signaling, as well as A1AR activity and subtype selectivity.  Collectively, our findings demonstrate that the allosteric moiety, particularly the 4-(trifluoromethyl)phenyl substituent of the thiophene scaffold, is important in conferring bitopic ligand bias at the A1AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98BkLNsVOvbVg90H21EOLACvtfcHk0ljxOJy6DecIAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnsbc%253D&md5=f7b9f16a6d56c720437ae94d54b8615e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00047%26sid%3Dliteratum%253Aachs%26aulast%3DAurelio%26aufirst%3DL.%26aulast%3DBaltos%26aufirst%3DJ.-A.%26aulast%3DFord%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DA.%2BT.%2BN.%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DDevine%26aufirst%3DS.%2BM.%26aulast%3DValant%26aufirst%3DC.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DMay%26aufirst%3DL.%2BT.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26atitle%3DA%2520structure-activity%2520relationship%2520study%2520of%2520bitopic%2520N6-substituted%2520adenosine%2520derivatives%2520as%2520biased%2520adenosine%2520A1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2087%26epage%3D2103%26doi%3D10.1021%2Facs.jmedchem.8b00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Yehuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and therapeutic effects of A<sub>3</sub> adenosine receptor agonists</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.drudis.2011.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22033198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2isbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=359-366&author=P.+Fishmanauthor=S.+Bar-Yehudaauthor=B.+T.+Liangauthor=K.+A.+Jacobson&title=Pharmacological+and+therapeutic+effects+of+A3+adenosine+receptor+agonists&doi=10.1016%2Fj.drudis.2011.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and therapeutic effects of A3 adenosine receptor agonists</span></div><div class="casAuthors">Fishman, Pnina; Bar-Yehuda, Sara; Liang, Bruce T.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">359-366</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The A3 adenosine receptor (A3AR) coupled to Gi (inhibitory regulative guanine nucleotide-binding protein) mediates anti-inflammatory, anticancer and anti-ischemic protective effects.  The receptor is overexpressed in inflammatory and cancer cells, while low expression is found in normal cells, rendering the A3AR as a potential therapeutic target.  Highly selective A3AR agonists have been synthesized and mol. recognition in the binding site has been characterized.  In this article, we summarize preclin. and clin. human studies that demonstrate that A3AR agonists induce specific anti-inflammatory and anticancer effects through a mol. mechanism that entails modulation of the Wnt and the NF-κB signal transduction pathways.  At present, A3AR agonists are being developed for the treatment of inflammatory diseases, including rheumatoid arthritis (RA) and psoriasis; ophthalmic diseases such as dry eye syndrome and glaucoma; liver diseases such as hepatocellular carcinoma and hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCdToPXU4m7Vg90H21EOLACvtfcHk0ljxOJy6DecIAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2isbw%253D&md5=b7278bf446f320ca621a93dff383ca13</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DFishman%26aufirst%3DP.%26aulast%3DBar-Yehuda%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DB.%2BT.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DPharmacological%2520and%2520therapeutic%2520effects%2520of%2520A3%2520adenosine%2520receptor%2520agonists%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D359%26epage%3D366%26doi%3D10.1016%2Fj.drudis.2011.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosh, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity analysis of biased agonism at the human adenosine A<sub>3</sub> receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1124/mol.116.103283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.116.103283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27136943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2jsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=12-22&author=J.+A.+Baltosauthor=S.+Paolettaauthor=A.+T.+N.+Nguyenauthor=K.+J.+Gregoryauthor=D.+K.+Toshauthor=A.+Christopoulosauthor=K.+A.+Jacobsonauthor=L.+T.+May&title=Structure-activity+analysis+of+biased+agonism+at+the+human+adenosine+A3+receptor&doi=10.1124%2Fmol.116.103283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity analysis of biased agonism at the human adenosine A3 receptor</span></div><div class="casAuthors">Baltos, Jo-Anne; Paoletta, Silvia; Nguyen, Anh T. N.; Gregory, Karen J.; Tosh, Dilip K.; Christopoulos, Arthur; Jacobson, Kenneth A.; May, Lauren T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-22</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biased agonism at G protein-coupled receptors (GPCRs) has significant implications for current drug discovery, but mol. determinants that govern ligand bias remain largely unknown.  The adenosine A3 GPCR (A3AR) is a potential therapeutic target for various conditions, including cancer, inflammation, and ischemia, but for which biased agonism remains largely unexplored.  We now report the generation of bias "fingerprints" for prototypical ribose contg. A3AR agonists and rigidified (N)-methanocarba 5'-N-methyluronamide nucleoside derivs. with regard to their ability to mediate different signaling pathways.  Relative to the ref. prototypical agonist IB-MECA, (N)-methanocarba 5'-Nmethyluronamide nucleoside derivs. with significant N6 or C2 modifications, including elongated aryl-ethynyl groups, exhibited biased agonism.  Significant pos. correlation was obsd. between the C2 substituent length (in Å) and bias toward cell survival.  Mol. modeling suggests that extended C2 substituents on (N)-methanocarba 5'-N-methyluronamide nucleosides promote a progressive outward shift of the A3AR transmembrane domain 2, which may contribute to the subset of A3AR conformations stabilized on biased agonist binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5hv9s2PrlTLVg90H21EOLACvtfcHk0ljxOJy6DecIAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2jsL7K&md5=f7d9ede080d3794a330abafbbdcf6ac9</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.103283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.103283%26sid%3Dliteratum%253Aachs%26aulast%3DBaltos%26aufirst%3DJ.%2BA.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DA.%2BT.%2BN.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DTosh%26aufirst%3DD.%2BK.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DMay%26aufirst%3DL.%2BT.%26atitle%3DStructure-activity%2520analysis%2520of%2520biased%2520agonism%2520at%2520the%2520human%2520adenosine%2520A3%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D90%26spage%3D12%26epage%3D22%26doi%3D10.1124%2Fmol.116.103283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Allostery and biased agonism at class B G protein-coupled receptors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=111-138&author=D.+Woottenauthor=L.+J.+Millerauthor=C.+Kooleauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Allostery+and+biased+agonism+at+class+B+G+protein-coupled+receptors&doi=10.1021%2Facs.chemrev.6b00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Allostery and Biased Agonism at Class B G Protein-Coupled Receptors</span></div><div class="casAuthors">Wootten, Denise; Miller, Laurence J.; Koole, Cassandra; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-138</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission.  These receptors are targets for existing drugs that treat osteoporosis, hypercalcemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases.  Exploitation of class B receptors has been limited by difficulties with small mol. drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy.  Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development.  These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism.  In this review, current knowledge of biased signaling and small mol. allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addn. to those that remain largely unexplored with respect to these phenomena.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqipOVZPN9YzbVg90H21EOLACvtfcHk0ljp7BOvN3vNaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D&md5=658b38e14a6438d971cc564731d9e625</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00049%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DAllostery%2520and%2520biased%2520agonism%2520at%2520class%2520B%2520G%2520protein-coupled%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D111%26epage%3D138%26doi%3D10.1021%2Facs.chemrev.6b00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gesty-Palmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span> <span> </span><span class="NLM_article-title">A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1ra1</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3000071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscitranslmed.3000071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20368153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1ra1&author=D.+Gesty-Palmerauthor=P.+Flanneryauthor=L.+Yuanauthor=L.+Corsinoauthor=R.+Spurneyauthor=R.+J.+Lefkowitzauthor=L.+M.+Luttrell&title=A+%CE%B2-arrestin-biased+agonist+of+the+parathyroid+hormone+receptor+%28PTH1R%29+promotes+bone+formation+independent+of+G+protein+activation&doi=10.1126%2Fscitranslmed.3000071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span></div><div class="casAuthors">Gesty-Palmer Diane; Flannery Pat; Yuan Ling; Corsino Leonor; Spurney Robert; Lefkowitz Robert J; Luttrell Louis M</div><div class="citationInfo"><span class="NLM_cas:title">Science translational medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1ra1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">About 40% of the therapeutic agents in use today exert their effects through seven-transmembrane receptors (7TMRs).  When activated by ligands, these receptors trigger two pathways that independently transduce signals to the cell: one through heterotrimeric GTP-binding proteins (G proteins) and one through beta-arrestins; so-called biased agonists can selectively activate these distinct pathways.  Here, we investigate selective activation of these pathways through the use of a biased agonist for the type 1 parathyroid hormone (PTH)-PTH-related protein receptor (PTH1R), (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr), which activates beta-arrestin but not classic G protein signaling.  In mice, PTH-betaarr induces anabolic bone formation, as does the nonselective agonist PTH(1-34), which activates both mechanisms.  In beta-arrestin2-null mice, the increase in bone mineral density evoked by PTH(1-34) is attenuated and that stimulated by PTH-betaarr is ablated.  The beta-arrestin2-dependent pathway contributes primarily to trabecular bone formation and does not stimulate bone resorption.  These results show that a biased agonist selective for the beta-arrestin pathway can elicit a response in vivo distinct from that elicited by nonselective agonists.  Ligands with these properties may form the basis for improved 7TMR-directed pharmacologic agents with enhanced therapeutic specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmuM4aCIxthdXdcedVHT5tfW6udTcc2eYj1PPHtCBtBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D&md5=748e4367ded72b6b7e10fd759521ba62</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000071%26sid%3Dliteratum%253Aachs%26aulast%3DGesty-Palmer%26aufirst%3DD.%26aulast%3DFlannery%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCorsino%26aufirst%3DL.%26aulast%3DSpurney%26aufirst%3DR.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26atitle%3DA%2520%25CE%25B2-arrestin-biased%2520agonist%2520of%2520the%2520parathyroid%2520hormone%2520receptor%2520%2528PTH1R%2529%2520promotes%2520bone%2520formation%2520independent%2520of%2520G%2520protein%2520activation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D1ra1%26doi%3D10.1126%2Fscitranslmed.3000071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, J.</span></span> <span> </span><span class="NLM_article-title">GLP-1 as a target for therapeutic intervention</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.coph.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27591964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVegsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=44-49&author=S.+P.+Rajeevauthor=J.+Wilding&title=GLP-1+as+a+target+for+therapeutic+intervention&doi=10.1016%2Fj.coph.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1 as a target for therapeutic intervention</span></div><div class="casAuthors">Rajeev, Surya Panicker; Wilding, John</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Glucagon-like peptide receptor agonists (GLP-1 RA) have multiple effects, including control of glycemia via stimulation of insulin and suppression of glucagon secretion and redn. of adiposity by enhancing satiety, so are an attractive therapeutic option in type 2 diabetes management.  Five GLP-1 RA are used currently and more are in development.  The HbA1c redn. obtained varies from 1 to 2%; they reduce body wt. by about 2-3 kg when used to treat T2DM, while liraglutide results in greater wt. loss at a higher dose and has recently been approved for the management of obesity.  GLP-1 RA are usually used in combination with other glucose-lowering drugs, but dual combinations with basal insulin in a single injection have recently become available.  The next decade is likely to see the development of more potent and longer lasting agents as well as hybrid mols. with dual or triple actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSC_xIpZ0U7Vg90H21EOLACvtfcHk0ljp7BOvN3vNaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVegsrvP&md5=2e4f442cbb3b6bbd2681cd3774361271</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DRajeev%26aufirst%3DS.%2BP.%26aulast%3DWilding%26aufirst%3DJ.%26atitle%3DGLP-1%2520as%2520a%2520target%2520for%2520therapeutic%2520intervention%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D31%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.coph.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobarec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabreja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1632</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2016.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27315480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=1632-1643&author=D.+Woottenauthor=C.+A.+Reynoldsauthor=K.+J.+Smithauthor=J.+C.+Mobarecauthor=C.+Kooleauthor=E.+E.+Savageauthor=K.+Pabrejaauthor=J.+Simmsauthor=R.+Sridharauthor=S.+G.+B.+Furnessauthor=M.+J.+Liuauthor=P.+E.+Thompsonauthor=L.+J.+Millerauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=The+extracellular+surface+of+the+GLP-1+receptor+is+a+molecular+trigger+for+biased+agonism&doi=10.1016%2Fj.cell.2016.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism</span></div><div class="casAuthors">Wootten, Denise; Reynolds, Christopher A.; Smith, Kevin J.; Mobarec, Juan C.; Koole, Cassandra; Savage, Emilia E.; Pabreja, Kavita; Simms, John; Sridhar, Rohan; Furness, Sebastian G. B.; Liu, Mengjie; Thompson, Philip E.; Miller, Laurence J.; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1632-1643</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-directed signal bias offers opportunities for sculpting mol. events, with the promise of better, safer therapeutics.  Crit. to the exploitation of signal bias is an understanding of the mol. events coupling ligand binding to intracellular signaling.  Activation of class B G protein-coupled receptors is driven by interaction of the peptide N terminus with the receptor core.  To understand how this drives signaling, we have used advanced anal. methods that enable sepn. of effects on pathway-specific signaling from those that modify agonist affinity and mapped the functional consequence of receptor modification onto three-dimensional models of a receptor-ligand complex.  This yields mol. insights into the initiation of receptor activation and the mechanistic basis for biased agonism.  Our data reveal that peptide agonists can engage different elements of the receptor extracellular face to achieve effector coupling and biased signaling providing a foundation for rational design of biased agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomuDidtRAWb7Vg90H21EOLACvtfcHk0ljoBUusGbbqHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlurrN&md5=951e74f37bbf22a25f589ca69a6e4289</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DSmith%26aufirst%3DK.%2BJ.%26aulast%3DMobarec%26aufirst%3DJ.%2BC.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DSavage%26aufirst%3DE.%2BE.%26aulast%3DPabreja%26aufirst%3DK.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DLiu%26aufirst%3DM.%2BJ.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DThe%2520extracellular%2520surface%2520of%2520the%2520GLP-1%2520receptor%2520is%2520a%2520molecular%2520trigger%2520for%2520biased%2520agonism%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D1632%26epage%3D1643%26doi%3D10.1016%2Fj.cell.2016.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloop, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecular ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1124/mol.112.084525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.084525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=822-834&author=D.+Woottenauthor=E.+E.+Savageauthor=F.+S.+Willardauthor=A.+B.+Buenoauthor=K.+W.+Sloopauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Differential+activation+and+modulation+of+the+glucagon-like+peptide-1+receptor+by+small+molecular+ligands&doi=10.1124%2Fmol.112.084525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.084525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.084525%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSavage%26aufirst%3DE.%2BE.%26aulast%3DWillard%26aufirst%3DF.%2BS.%26aulast%3DBueno%26aufirst%3DA.%2BB.%26aulast%3DSloop%26aufirst%3DK.%2BW.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DDifferential%2520activation%2520and%2520modulation%2520of%2520the%2520glucagon-like%2520peptide-1%2520receptor%2520by%2520small%2520molecular%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D822%26epage%3D834%26doi%3D10.1124%2Fmol.112.084525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturchler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cistrone, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R. A.</span></span> <span> </span><span class="NLM_article-title">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8918</span>, <span class="refDoi"> DOI: 10.1038/ncomms9918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fncomms9918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26621478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8918&author=H.+Zhangauthor=E.+Sturchlerauthor=J.+Zhuauthor=A.+Nietoauthor=P.+A.+Cistroneauthor=J.+Xieauthor=L.+Heauthor=K.+Yeaauthor=T.+Jonesauthor=R.+Turnauthor=P.+S.+Di+Stefanoauthor=P.+R.+Griffinauthor=P.+E.+Dawsonauthor=P.+H.+McDonaldauthor=R.+A.+Lerner&title=Autocrine+selection+of+a+GLP-1R+G-protein+biased+agonist+with+potent+antidiabetic+effects&doi=10.1038%2Fncomms9918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span></div><div class="casAuthors">Zhang, Hongkai; Sturchler, Emmanuel; Zhu, Jiang; Nieto, Ainhoa; Cistrone, Philip A.; Xie, Jia; He, LinLing; Yea, Kyungmoo; Jones, Teresa; Turn, Rachel; Di Stefano, Peter S.; Griffin, Patrick R.; Dawson, Philip E.; McDonald, Patricia H.; Lerner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8918</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM).  GLP-1R signals through G-protein-dependent, and G-protein-independent pathways by engaging the scaffold protein β-arrestin; preferential signalling of ligands through one or the other of these branches is known as 'ligand bias'.  Here we report the discovery of the potent and selective GLP-1R G-protein-biased agonist, P5.  We identified P5 in a high-throughput autocrine-based screening of large combinatorial peptide libraries, and show that P5 promotes G-protein signalling comparable to GLP-1 and Exendin-4, but exhibited a significantly reduced β-arrestin response.  Preclin. studies using different mouse models of T2DM demonstrate that P5 is a weak insulin secretagogue.  Nevertheless, chronic treatment of diabetic mice with P5 increased adipogenesis, reduced adipose tissue inflammation as well as hepatic steatosis and was more effective at correcting hyperglycemia and lowering Hb A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agonists may provide a novel therapeutic approach to T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEBfb0W6bx47Vg90H21EOLACvtfcHk0ljoBUusGbbqHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ&md5=8d638fbc3fb3996f1f21779f4f8aa001</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fncomms9918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9918%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSturchler%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DNieto%26aufirst%3DA.%26aulast%3DCistrone%26aufirst%3DP.%2BA.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DTurn%26aufirst%3DR.%26aulast%3DDi%2BStefano%26aufirst%3DP.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26aulast%3DMcDonald%26aufirst%3DP.%2BH.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine%2520selection%2520of%2520a%2520GLP-1R%2520G-protein%2520biased%2520agonist%2520with%2520potent%2520antidiabetic%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8918%26doi%3D10.1038%2Fncomms9918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quoyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longuet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span> <span> </span><span class="NLM_article-title">GLP-1 mediates antiapoptotic effect by phosphorylating bad through a β-arrestin 1-mediated ERK1/2 activation in pancreatic β-cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.067207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M109.067207" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=1989-2002&author=J.+Quoyerauthor=C.+Longuetauthor=C.+Brocaauthor=N.+Linckauthor=S.+Costesauthor=E.+Varinauthor=J.+Bockaertauthor=G.+Bertrandauthor=S.+Dalle&title=GLP-1+mediates+antiapoptotic+effect+by+phosphorylating+bad+through+a+%CE%B2-arrestin+1-mediated+ERK1%2F2+activation+in+pancreatic+%CE%B2-cells&doi=10.1074%2Fjbc.M109.067207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.067207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.067207%26sid%3Dliteratum%253Aachs%26aulast%3DQuoyer%26aufirst%3DJ.%26aulast%3DLonguet%26aufirst%3DC.%26aulast%3DBroca%26aufirst%3DC.%26aulast%3DLinck%26aufirst%3DN.%26aulast%3DCostes%26aufirst%3DS.%26aulast%3DVarin%26aufirst%3DE.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DBertrand%26aufirst%3DG.%26aulast%3DDalle%26aufirst%3DS.%26atitle%3DGLP-1%2520mediates%2520antiapoptotic%2520effect%2520by%2520phosphorylating%2520bad%2520through%2520a%2520%25CE%25B2-arrestin%25201-mediated%2520ERK1%252F2%2520activation%2520in%2520pancreatic%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D1989%26epage%3D2002%26doi%3D10.1074%2Fjbc.M109.067207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hager, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellman, S. H.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-biased agonists of the GLP-1 receptor from β-amino acid residue incorporation into GLP-1 analogues</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">14970</span>– <span class="NLM_lpage">14979</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b08323</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b08323" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=14970-14979&author=M.+V.+Hagerauthor=L.+M.+Johnsonauthor=D.+Woottenauthor=P.+M.+Sextonauthor=S.+H.+Gellman&title=%CE%B2-Arrestin-biased+agonists+of+the+GLP-1+receptor+from+%CE%B2-amino+acid+residue+incorporation+into+GLP-1+analogues&doi=10.1021%2Fjacs.6b08323"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b08323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b08323%26sid%3Dliteratum%253Aachs%26aulast%3DHager%26aufirst%3DM.%2BV.%26aulast%3DJohnson%26aufirst%3DL.%2BM.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26atitle%3D%25CE%25B2-Arrestin-biased%2520agonists%2520of%2520the%2520GLP-1%2520receptor%2520from%2520%25CE%25B2-amino%2520acid%2520residue%2520incorporation%2520into%2520GLP-1%2520analogues%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D14970%26epage%3D14979%26doi%3D10.1021%2Fjacs.6b08323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nature22378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature22378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28514449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=312-315&author=G.+Songauthor=D.+Yangauthor=Y.+Wangauthor=C.+de+Graafauthor=Q.+Zhouauthor=S.+Jiangauthor=K.+Liuauthor=X.+Caiauthor=A.+Daiauthor=G.+Linauthor=D.+Liuauthor=F.+Wuauthor=Y.+Wuauthor=S.+Zhaoauthor=L.+Yeauthor=G.+W.+Hanauthor=J.+Lauauthor=B.+Wuauthor=M.+A.+Hansonauthor=Z.-J.+Liuauthor=M.-W.+Wangauthor=R.+C.+Stevens&title=Human+GLP-1+receptor+transmembrane+domain+structure+in+complex+with+allosteric+modulators&doi=10.1038%2Fnature22378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators</span></div><div class="casAuthors">Song, Gaojie; Yang, Dehua; Wang, Yuxia; de Graaf, Chris; Zhou, Qingtong; Jiang, Shanshan; Liu, Kaiwen; Cai, Xiaoqing; Dai, Antao; Lin, Guangyao; Liu, Dongsheng; Wu, Fan; Wu, Yiran; Zhao, Suwen; Ye, Li; Han, Gye Won; Lau, Jesper; Wu, Beili; Hanson, Michael A.; Liu, Zhi-Jie; Wang, Ming-Wei; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">312-315</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and have opposing physiol. roles in insulin release and glucose homeostasis.  The treatment of type 2 diabetes requires pos. modulation of GLP-1R to inhibit glucagon secretion and stimulate insulin secretion in a glucose-dependent manner.  Here we report crystal structures of the human GLP-1R transmembrane domain in complex with two different neg. allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 Å resoln., resp.  The structures reveal a common binding pocket for neg. allosteric modulators, present in both GLP-1R and GCGR and located outside helixes V-VII near the intracellular half of the receptor.  The receptor is in an inactive conformation with compds. that restrict movement of the intracellular tip of helix VI, a movement that is generally assocd. with activation mechanisms in class A GPCRs.  Mol. modeling and mutagenesis studies indicate that agonist pos. allosteric modulators target the same general region, but in a distinct sub-pocket at the interface between helixes V and VI, which may facilitate the formation of an intracellular binding site that enhances G-protein coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS5eoyz8skl7Vg90H21EOLACvtfcHk0ljYfLDJ08H_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs78%253D&md5=72cb9bfe8533b287db75cad3d9cef8f2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnature22378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22378%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DLiu%26aufirst%3DZ.-J.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHuman%2520GLP-1%2520receptor%2520transmembrane%2520domain%2520structure%2520in%2520complex%2520with%2520allosteric%2520modulators%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D312%26epage%3D315%26doi%3D10.1038%2Fnature22378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiez-Vandal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baig, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teobald, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the GLP-1 receptor bound to a peptide agonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1038/nature22800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature22800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28562585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=254-258&author=A.+Jazayeriauthor=M.+Rappasauthor=A.+J.+H.+Brownauthor=J.+Keanauthor=J.+C.+Erreyauthor=N.+J.+Robertsonauthor=C.+Fiez-Vandalauthor=S.+P.+Andrewsauthor=M.+Congreveauthor=A.+Bortolatoauthor=J.+S.+Masonauthor=A.+H.+Baigauthor=I.+Teobaldauthor=A.+S.+Doreauthor=M.+Weirauthor=R.+M.+Cookeauthor=F.+H.+Marshall&title=Crystal+structure+of+the+GLP-1+receptor+bound+to+a+peptide+agonist&doi=10.1038%2Fnature22800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the GLP-1 receptor bound to a peptide agonist</span></div><div class="casAuthors">Jazayeri, Ali; Rappas, Mathieu; Brown, Alastair J. H.; Kean, James; Errey, James C.; Robertson, Nathan J.; Fiez-Vandal, Cedric; Andrews, Stephen P.; Congreve, Miles; Bortolato, Andrea; Mason, Jonathan S.; Baig, Asma H.; Teobald, Iryna; Dore, Andrew S.; Weir, Malcolm; Cooke, Robert M.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">254-258</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) regulates glucose homeostasis through the control of insulin release from the pancreas.  GLP-1 peptide agonists are efficacious drugs for the treatment of diabetes.  To gain insight into the mol. mechanism of action of GLP-1 peptides, here we report the crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist.  The peptide agonist retains an α-helical conformation as it sits deep within the receptor-binding pocket.  The arrangement of the transmembrane helixes reveals hallmarks of an active conformation similar to that obsd. in class A receptors.  Guided by this structural information, we design peptide agonists with potent in vivo activity in a mouse model of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6Ibc110QxrVg90H21EOLACvtfcHk0ljYfLDJ08H_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D&md5=0a5c99161af8bae506a184e0ab6306c1</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1038%2Fnature22800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22800%26sid%3Dliteratum%253Aachs%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DRappas%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DKean%26aufirst%3DJ.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DRobertson%26aufirst%3DN.%2BJ.%26aulast%3DFiez-Vandal%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DBaig%26aufirst%3DA.%2BH.%26aulast%3DTeobald%26aufirst%3DI.%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520GLP-1%2520receptor%2520bound%2520to%2520a%2520peptide%2520agonist%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D254%26epage%3D258%26doi%3D10.1038%2Fnature22800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrasch, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiniotis, G.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/nature22394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature22394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28538729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=248-253&author=Y.+Zhangauthor=B.+Sunauthor=D.+Fengauthor=H.+Huauthor=M.+Chuauthor=Q.+Quauthor=J.+T.+Tarraschauthor=S.+Liauthor=T.+S.+Kobilkaauthor=B.+K.+Kobilkaauthor=G.+Skiniotis&title=Cryo-EM+structure+of+the+activated+GLP-1+receptor+in+complex+with+a+G+protein&doi=10.1038%2Fnature22394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</span></div><div class="casAuthors">Zhang, Yan; Sun, Bingfa; Feng, Dan; Hu, Hongli; Chu, Matthew; Qu, Qianhui; Tarrasch, Jeffrey T.; Li, Shane; Sun Kobilka, Tong; Kobilka, Brian K.; Skiniotis, Georgios</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) is a hormone with essential roles in regulating insulin secretion, carbohydrate metab. and appetite.  GLP-1 effects are mediated through binding to the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor (GPCR) that signals primarily through the stimulatory G protein Gs.  Class B GPCRs are important therapeutic targets; however, our understanding of their mechanism of action is limited by the lack of structural information on activated and full-length receptors.  Here we report the cryo-electron microscopy structure of the peptide-activated GLP-1R-Gs complex at near at. resoln.  The peptide is clasped between the N-terminal domain and the transmembrane core of the receptor, and further stabilized by extracellular loops.  Conformational changes in the transmembrane domain result in a sharp kink in the middle of transmembrane helix 6, which pivots its intracellular half outward to accommodate the α5-helix of the Ras-like domain of Gs.  These results provide a structural framework for understanding class B GPCR activation through hormone binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDRFGRwMs1bVg90H21EOLACvtfcHk0lgH4IiRJl9uwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D&md5=5e7ebd94012ba47ecc299ad0502975de</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fnature22394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22394%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DQ.%26aulast%3DTarrasch%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DSkiniotis%26aufirst%3DG.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520activated%2520GLP-1%2520receptor%2520in%2520complex%2520with%2520a%2520G%2520protein%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D248%26epage%3D253%26doi%3D10.1038%2Fnature22394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural diversity of G protein-coupled receptors and significance for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstromauthor=H.+B.+Schioth&title=Structural+diversity+of+G+protein-coupled+receptors+and+significance+for+drug+discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2eZGu0bevmuF37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520diversity%2520of%2520G%2520protein-coupled%2520receptors%2520and%2520significance%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pshenichkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takoudjou, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grajkowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wroblewski, J. T.</span></span> <span> </span><span class="NLM_article-title">The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, β-arrestin-1-dependent ERK phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">26041</span>– <span class="NLM_lpage">26048</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.139899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M110.139899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=26041-26048&author=A.+C.+Emeryauthor=S.+Pshenichkinauthor=G.+R.+Takoudjouauthor=E.+Grajkowskaauthor=B.+B.+Wolfeauthor=J.+T.+Wroblewski&title=The+protective+signaling+of+metabotropic+glutamate+receptor+1+is+mediated+by+sustained%2C+%CE%B2-arrestin-1-dependent+ERK+phosphorylation&doi=10.1074%2Fjbc.M110.139899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.139899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.139899%26sid%3Dliteratum%253Aachs%26aulast%3DEmery%26aufirst%3DA.%2BC.%26aulast%3DPshenichkin%26aufirst%3DS.%26aulast%3DTakoudjou%26aufirst%3DG.%2BR.%26aulast%3DGrajkowska%26aufirst%3DE.%26aulast%3DWolfe%26aufirst%3DB.%2BB.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520protective%2520signaling%2520of%2520metabotropic%2520glutamate%2520receptor%25201%2520is%2520mediated%2520by%2520sustained%252C%2520%25CE%25B2-arrestin-1-dependent%2520ERK%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D26041%26epage%3D26048%26doi%3D10.1074%2Fjbc.M110.139899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRaddo, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pshenichkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takoudjou, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grajkowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wroblewski, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1124/mol.112.078444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.078444" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=291-301&author=A.+C.+Emeryauthor=J.+O.+DiRaddoauthor=E.+Millerauthor=H.+A.+Hathawayauthor=S.+Pshenichkinauthor=G.+R.+Takoudjouauthor=E.+Grajkowskaauthor=R.+P.+Yasudaauthor=B.+B.+Wolfeauthor=J.+T.+Wroblewski&title=Ligand+bias+at+metabotropic+glutamate+1a+receptors%3A+molecular+determinants+that+distinguish+%CE%B2-arrestin-mediated+from+G+protein-mediated+signaling&doi=10.1124%2Fmol.112.078444"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.078444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.078444%26sid%3Dliteratum%253Aachs%26aulast%3DEmery%26aufirst%3DA.%2BC.%26aulast%3DDiRaddo%26aufirst%3DJ.%2BO.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DHathaway%26aufirst%3DH.%2BA.%26aulast%3DPshenichkin%26aufirst%3DS.%26aulast%3DTakoudjou%26aufirst%3DG.%2BR.%26aulast%3DGrajkowska%26aufirst%3DE.%26aulast%3DYasuda%26aufirst%3DR.%2BP.%26aulast%3DWolfe%26aufirst%3DB.%2BB.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520bias%2520at%2520metabotropic%2520glutamate%25201a%2520receptors%253A%2520molecular%2520determinants%2520that%2520distinguish%2520%25CE%25B2-arrestin-mediated%2520from%2520G%2520protein-mediated%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D291%26epage%3D301%26doi%3D10.1124%2Fmol.112.078444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6707</span>– <span class="NLM_lpage">6741</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=6707-6741&author=C.+W.+Lindsleyauthor=K.+A.+Emmitteauthor=C.+R.+Hopkinsauthor=T.+M.+Bridgesauthor=K.+J.+Gregoryauthor=C.+M.+Niswenderauthor=P.+J.+Conn&title=Practical+strategies+and+concepts+in+GPCR+allosteric+modulator+discovery%3A+recent+advances+with+metabotropic+glutamate+receptors&doi=10.1021%2Facs.chemrev.5b00656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors</span></div><div class="casAuthors">Lindsley, Craig W.; Emmitte, Kyle A.; Hopkins, Corey R.; Bridges, Thomas M.; Gregory, Karen J.; Niswender, Colleen M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6707-6741</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery, filled with therapeutic promise yet fraught with caveats.  Allosteric ligands stabilize unique conformations of the GPCR that afford fundamentally new receptors, capable of novel pharmacol., unprecedented subtype selectivity, and unique signal bias.  This review provides a comprehensive overview of the basics of GPCR allosteric pharmacol., medicinal chem., drug metab., and validated approaches to address each of the major challenges and caveats.  Then, the review narrows focus to highlight recent advances in the discovery of allosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu1-5,7) highlighting key concepts ("mol. switches", signal bias, heterodimers) and practical solns. to enable the development of tool compds. and clin. candidates.  The review closes with a section on late-breaking new advances with allosteric ligands for other GPCRs and emerging data for endogenous allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18XJrjVel-7Vg90H21EOLACvtfcHk0ljj_GXxkKdZAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D&md5=c12704b6602b6c50add92e7fd9350382</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00656%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DPractical%2520strategies%2520and%2520concepts%2520in%2520GPCR%2520allosteric%2520modulator%2520discovery%253A%2520recent%2520advances%2520with%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D6707%26epage%3D6741%26doi%3D10.1021%2Facs.chemrev.5b00656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1126/science.1249489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1249489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24603153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1eht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2014&pages=58-64&author=H.+X.+Wuauthor=C.+Wangauthor=K.+J.+Gregoryauthor=G.+W.+Hanauthor=H.+P.+Choauthor=Y.+Xiaauthor=C.+M.+Niswenderauthor=V.+Katritchauthor=J.+Meilerauthor=V.+Cherezovauthor=P.+J.+Connauthor=R.+C.+Stevens&title=Structure+of+a+class+C+GPCR+metabotropic+glutamate+receptor+1+bound+to+an+allosteric+modulator&doi=10.1126%2Fscience.1249489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator</span></div><div class="casAuthors">Wu, Huixian; Wang, Chong; Gregory, Karen J.; Han, Gye Won; Cho, Hyekyung P.; Xia, Yan; Niswender, Colleen M.; Katritch, Vsevolod; Meiler, Jens; Cherezov, Vadim; Conn, P. Jeffrey; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">6179</span>),
    <span class="NLM_cas:pages">58-64</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The excitatory neurotransmitter glutamate induces modulatory actions via the metabotropic glutamate receptors (mGlus), which are class C G protein-coupled receptors (GPCRs).  The authors detd. the structure of the human mGlu1 receptor seven-transmembrane (7TM) domain bound to a neg. allosteric modulator, FITM, at a resoln. of 2.8 angstroms.  The modulator binding site partially overlaps with the orthosteric binding sites of class A GPCRs but is more restricted than most other GPCRs.  The authors obsd. a parallel 7TM dimer mediated by cholesterols, which suggests that signaling initiated by glutamate's interaction with the extracellular domain might be mediated via 7TM interactions within the full-length receptor dimer.  A combination of crystallog., structure-activity relationships, mutagenesis, and full-length dimer modeling provides insights about the allosteric modulation and activation mechanism of class C GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVdhj4KmKV7LVg90H21EOLACvtfcHk0ljj_GXxkKdZAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1eht78%253D&md5=e552ac4646b8e67c52d1f5e0aa42ec5a</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1126%2Fscience.1249489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1249489%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCho%26aufirst%3DH.%2BP.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520a%2520class%2520C%2520GPCR%2520metabotropic%2520glutamate%2520receptor%25201%2520bound%2520to%2520an%2520allosteric%2520modulator%26jtitle%3DScience%26date%3D2014%26volume%3D344%26spage%3D58%26epage%3D64%26doi%3D10.1126%2Fscience.1249489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okrasa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Vega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiggin, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>511</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nature13396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature13396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25042998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=557-562&author=A.+S.+Doreauthor=K.+Okrasaauthor=J.+C.+Patelauthor=M.+Serrano-Vegaauthor=K.+Bennettauthor=R.+M.+Cookeauthor=J.+C.+Erreyauthor=A.+Jazayeriauthor=S.+Khanauthor=B.+Tehanauthor=M.+Weirauthor=G.+R.+Wigginauthor=F.+H.+Marshall&title=Structure+of+class+C+GPCR+metabotropic+glutamate+receptor+5+transmembrane+domain&doi=10.1038%2Fnature13396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span></div><div class="casAuthors">Dore, Andrew S.; Okrasa, Krzysztof; Patel, Jayesh C.; Serrano-Vega, Maria; Bennett, Kirstie; Cooke, Robert M.; Errey, James C.; Jazayeri, Ali; Khan, Samir; Tehan, Ben; Weir, Malcolm; Wiggin, Giselle R.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">557-562</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptors are class C G-protein-coupled receptors which respond to the neurotransmitter glutamate.  Structural studies have been restricted to the amino-terminal extracellular domain, providing little understanding of the membrane-spanning signal transduction domain.  Metabotropic glutamate receptor 5 (mGlu5 receptor) is of considerable interest as a drug target in the treatment of fragile X syndrome, autism, depression, anxiety, addiction and movement disorders.  Here we report the crystal structure of the transmembrane domain of the human receptor in complex with the neg. allosteric modulator, mavoglurant.  The structure provides detailed insight into the architecture of the transmembrane domain of class C receptors including the precise location of the allosteric binding site within the transmembrane domain and key micro-switches which regulate receptor signaling.  This structure also provides a model for all class C G-protein-coupled receptors and may aid in the design of new small-mol. drugs for the treatment of brain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4LiHVA8klWLVg90H21EOLACvtfcHk0ljj_GXxkKdZAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK&md5=43a1f0b72a923044fa718729f97c075d</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnature13396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13396%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DJ.%2BC.%26aulast%3DSerrano-Vega%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DWiggin%26aufirst%3DG.%2BR.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520class%2520C%2520GPCR%2520metabotropic%2520glutamate%2520receptor%25205%2520transmembrane%2520domain%26jtitle%3DNature%26date%3D2014%26volume%3D511%26spage%3D557%26epage%3D562%26doi%3D10.1038%2Fnature13396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stansley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.coph.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29486374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVCqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=31-36&author=B.+J.+Stansleyauthor=P.+J.+Conn&title=The+therapeutic+potential+of+metabotropic+glutamate+receptor+modulation+for+schizophrenia&doi=10.1016%2Fj.coph.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia</span></div><div class="casAuthors">Stansley, Branden J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-36</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence suggests that a dysregulation of the glutamatergic system exists in the brains of schizophrenia patients.  The metabotropic glutamate (mGlu) receptors are being investigated as novel drug targets for this disease, and have shown promise in both preclin. and clin. studies.  Activation of mGlu5 receptors may be efficacious for several symptom domains (pos., neg., and cognitive) and the potential for targeting mGlu5 receptors has been bolstered by recent research on mitigating toxicity profiles assocd. with mGlu5 activation.  Addnl., genetic profiling of schizophrenia patients suggests that genes encoding for mGlu1 and mGlu3 receptors are altered, prompting preclin. studies that have demonstrated potential antipsychotic and cognitive enhancing effects of agents that activate mGlu1 and mGlu3 receptors, resp.  Development of subtype-specific drugs for the mGlu receptors, such as allosteric modulators, could provide a path forward for more efficacious and tolerable therapeutics for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlmWIOOFO3qrVg90H21EOLACvtfcHk0lgA_WnxlQVQyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVCqs7s%253D&md5=c37830f179b1d47e7bfeb4bd64db371e</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DStansley%26aufirst%3DB.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520metabotropic%2520glutamate%2520receptor%2520modulation%2520for%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D38%26spage%3D31%26epage%3D36%26doi%3D10.1016%2Fj.coph.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier-Batteur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uslaner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magliaro, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Poul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosahl, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocher, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism based neurotoxicity of mGlu5 positive allosteric modulators - development challenges for a promising novel antipsychotic target</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.neuropharm.2012.12.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=161-173&author=S.+Parmentier-Batteurauthor=P.+H.+Hutsonauthor=K.+Menzelauthor=J.+M.+Uslanerauthor=B.+A.+Mattsonauthor=J.+A.+O%E2%80%99Brienauthor=B.+C.+Magliaroauthor=T.+Forestauthor=C.+A.+Stumpauthor=R.+M.+Tyneborauthor=N.+J.+Anthonyauthor=T.+J.+Tuckerauthor=X.+F.+Zhangauthor=R.+Gomezauthor=S.+L.+Huszarauthor=N.+Lambengauthor=H.+Faureauthor=E.+Le+Poulauthor=S.+Poliauthor=T.+W.+Rosahlauthor=J.+P.+Rocherauthor=R.+Hargreavesauthor=T.+M.+Williams&title=Mechanism+based+neurotoxicity+of+mGlu5+positive+allosteric+modulators+-+development+challenges+for+a+promising+novel+antipsychotic+target&doi=10.1016%2Fj.neuropharm.2012.12.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier-Batteur%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26aulast%3DMenzel%26aufirst%3DK.%26aulast%3DUslaner%26aufirst%3DJ.%2BM.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DMagliaro%26aufirst%3DB.%2BC.%26aulast%3DForest%26aufirst%3DT.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DHuszar%26aufirst%3DS.%2BL.%26aulast%3DLambeng%26aufirst%3DN.%26aulast%3DFaure%26aufirst%3DH.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DRosahl%26aufirst%3DT.%2BW.%26aulast%3DRocher%26aufirst%3DJ.%2BP.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26atitle%3DMechanism%2520based%2520neurotoxicity%2520of%2520mGlu5%2520positive%2520allosteric%2520modulators%2520-%2520development%2520challenges%2520for%2520a%2520promising%2520novel%2520antipsychotic%2520target%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D161%26epage%3D173%26doi%3D10.1016%2Fj.neuropharm.2012.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome-Nebreda, J.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Biased mGlu<sub>5</sub>-positive allosteric modulators provide in vivo efficacy without potentiating mGlu<sub>5</sub> modulation of NMDAR currents</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.neuron.2015.03.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25937172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1029-1040&author=J.+M.+Rookauthor=Z.+X.+Xiangauthor=X.+H.+Lvauthor=A.+Ghoshalauthor=J.+W.+Dickersonauthor=T.+M.+Bridgesauthor=K.+A.+Johnsonauthor=D.+J.+Fosterauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=A.+D.+Thompsonauthor=N.+Byunauthor=R.+L.+Collierauthor=M.+Bubserauthor=M.+T.+Nedelcovychauthor=R.+W.+Gouldauthor=S.+R.+Staufferauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=H.+Lavreysenauthor=C.+Mackieauthor=S.+Conde-Ceideauthor=J.+Alcazarauthor=J.%0AM.+Bartolome-Nebredaauthor=G.+J.+Macdonaldauthor=J.+C.+Talposauthor=T.+Stecklerauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Biased+mGlu5-positive+allosteric+modulators+provide+in+vivo+efficacy+without+potentiating+mGlu5+modulation+of+NMDAR+currents&doi=10.1016%2Fj.neuron.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents</span></div><div class="casAuthors">Rook, Jerri M.; Xiang, Zixiu; Lv, Xiaohui; Ghoshal, Ayan; Dickerson, Jonathan W.; Bridges, Thomas M.; Johnson, Kari A.; Foster, Daniel J.; Gregory, Karen J.; Vinson, Paige N.; Thompson, Analisa D.; Byun, Nellie; Collier, Rebekah L.; Bubser, Michael; Nedelcovych, Michael T.; Gould, Robert W.; Stauffer, Shaun R.; Daniels, J. Scott; Niswender, Colleen M.; Lavreysen, Hilde; Mackie, Claire; Conde-Ceide, Susana; Alcazar, Jesus; Bartolome-Nebreda, Jose M.; MacDonald, Gregor J.; Talpos, John C.; Steckler, Thomas; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1029-1040</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Schizophrenia is assocd. with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling.  The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely assocd. signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathol. of schizophrenia.  Efficacy of mGlu5 pos. allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function.  To directly test this hypothesis, we identified VU0409551 as a novel mGlu5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to Gαq-mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus.  Interestingly, VU0409551 produced robust antipsychotic-like and cognition-enhancing activity in animal models.  These data provide surprising new mechanistic insights into the actions of mGlu5 PAMs and suggest that modulation of NMDAR currents is not crit. for in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKRBBcza96rVg90H21EOLACvtfcHk0lgA_WnxlQVQyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D&md5=c5f0a8cf83e1b2d8e0d3541a39cd0529</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%2BX.%26aulast%3DLv%26aufirst%3DX.%2BH.%26aulast%3DGhoshal%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DByun%26aufirst%3DN.%26aulast%3DCollier%26aufirst%3DR.%2BL.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DBartolome-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTalpos%26aufirst%3DJ.%2BC.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DBiased%2520mGlu5-positive%2520allosteric%2520modulators%2520provide%2520in%2520vivo%2520efficacy%2520without%2520potentiating%2520mGlu5%2520modulation%2520of%2520NMDAR%2520currents%26jtitle%3DNeuron%26date%3D2015%26volume%3D86%26spage%3D1029%26epage%3D1040%26doi%3D10.1016%2Fj.neuron.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noetzel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manka, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1124/mol.112.082891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.082891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23348500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=835-847&author=M.+J.+Noetzelauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=J.+T.+Mankaauthor=S.+R.+Staufferauthor=C.+W.+Lindsleyauthor=C.+M.+Niswenderauthor=Z.+Xiangauthor=P.+J.+Conn&title=A+novel+metabotropic+glutamate+receptor+5+positive+allosteric+modulator+acts+at+a+unique+site+and+confers+stimulus+bias+to+mGlu5+signaling&doi=10.1124%2Fmol.112.082891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling</span></div><div class="casAuthors">Noetzel, M. J.; Gregory, K. J.; Vinson, P. N.; Manka, J. T.; Stauffer, S. R.; Lindsley, C. W.; Niswender, C. M.; Xiang, Z.; Conn, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">835-847</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 5 (mGlu5) is a target for the treatment of central nervous system (CNS) disorders, such as schizophrenia and Alzheimer's disease.  Furthermore, mGlu5 has been shown to play an important role in hippocampal synaptic plasticity, specifically in long-term depression (LTD) and long-term potentiation (LTP), which is thought to be involved in cognition.  Multiple mGlu5-pos. allosteric modulators (PAMs) have been developed from a variety of different scaffolds.  Previous work has extensively characterized a common allosteric site on mGlu5, termed the MPEP (2-Methyl-6-(phenylethynyl)pyridine) binding site.  However, one mGlu5 PAM, CPPHA (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a sep. allosteric site on mGlu5.  Using cell-based assays and brain slice prepns., we characterized the interaction of a potent and efficacious mGlu5 PAM from the CPPHA series termed NCFP (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).  NCFP binds to the CPPHA site on mGlu5 and potentiates mGlu5-mediated responses in both recombinant and native systems.  However, NCFP provides greater mGlu5 subtype selectivity than does CPPHA, making it more suitable for studies of effects on mGlu5 in CNS prepns.  Of interest, NCFP does not potentiate responses involved in hippocampal synaptic plasticity (LTD/LTP), setting it apart from other previously characterized MPEP site PAMs.  This suggests that although mGlu5 PAMs may have similar responses in some systems, they can induce differential effects on mGlu5-mediated physiol. responses in the CNS.  Such stimulus bias by mGlu5 PAMs may complicate drug discovery efforts but would also allow for specifically tailored therapies, if pharmacol. biases can be attributed to different therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrBH7IPviPNbVg90H21EOLACvtfcHk0ljsx3g6uOQm_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt7s%253D&md5=175d8e7aef535a8df57a73420200c8b0</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.082891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.082891%26sid%3Dliteratum%253Aachs%26aulast%3DNoetzel%26aufirst%3DM.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DManka%26aufirst%3DJ.%2BT.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DA%2520novel%2520metabotropic%2520glutamate%2520receptor%25205%2520positive%2520allosteric%2520modulator%2520acts%2520at%2520a%2520unique%2520site%2520and%2520confers%2520stimulus%2520bias%2520to%2520mGlu5%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D835%26epage%3D847%26doi%3D10.1124%2Fmol.112.082891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. T.</span></span> <span> </span><span class="NLM_article-title">Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/j.beem.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.beem.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23856262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=315-331&author=A.+D.+Conigraveauthor=D.+T.+Ward&title=Calcium-sensing+receptor+%28CaSR%29%3A+pharmacological+properties+and+signaling+pathways&doi=10.1016%2Fj.beem.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways</span></div><div class="casAuthors">Conigrave, Arthur D.; Ward, Donald T.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-331</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In this article we consider the mechanisms by which the calcium-sensing receptor (CaSR) induces its cellular responses via the control (activation or inhibition) of signaling pathways.  We consider key features of CaSR-mediated signaling including its control of the heterotrimeric G-proteins Gq/11, Gi/o and G12/13 and the downstream consequences recognizing that very few CaSR-mediated cell phenomena have been fully described.  We also consider the manner in which the CaSR contributes to the formation of specific signaling scaffolds via peptide recognition sequences in its intracellular C-terminal along with the origins of its high level of cooperativity, particularly for Ca2+o, and its remarkable resistance to desensitization.  We also consider the nature of the mechanisms by which the CaSR controls oscillatory and sustained Ca2+i mobilizing responses and inhibits or elevates cyclic adenosine monophosphate (cAMP) levels dependent on the cellular and signaling context.  Finally, we consider the diversity of the receptor's ligands, ligand binding sites and broader compartment-dependent physiol. roles leading to the identification of pronounced ligand-biased signaling for agonists including Sr2+ and modulators including l-amino acids and the clin. effective calcimimetic cinacalcet.  We note the implications of these findings for the development of new designer drugs that might target the CaSR in pathophysiol. contexts beyond those established for the treatment of disorders of calcium metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6fBNXb9flOLVg90H21EOLACvtfcHk0ljsx3g6uOQm_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyktLg%253D&md5=023e18c8f9b1fae085f2b2b7f4e00926</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DWard%26aufirst%3DD.%2BT.%26atitle%3DCalcium-sensing%2520receptor%2520%2528CaSR%2529%253A%2520pharmacological%2520properties%2520and%2520signaling%2520pathways%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D27%26spage%3D315%26epage%3D331%26doi%3D10.1016%2Fj.beem.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, A. R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hvidtfeldt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauner-Osborne, H.</span></span> <span> </span><span class="NLM_article-title">Biased agonism of the calcium-sensing receptor</span>. <i>Cell Calcium</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.ceca.2011.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.ceca.2011.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22192592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit12jt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=107-116&author=A.+R.+B.+Thomsenauthor=M.+Hvidtfeldtauthor=H.+Brauner-Osborne&title=Biased+agonism+of+the+calcium-sensing+receptor&doi=10.1016%2Fj.ceca.2011.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Biased agonism of the calcium-sensing receptor</span></div><div class="casAuthors">Thomsen, Alex Rojas Bie; Hvidtfeldt, Maja; Brauner-Osborne, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Cell Calcium</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">CECADV</span>;
        ISSN:<span class="NLM_cas:issn">0143-4160</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">After the discovery of mols. modulating G protein-coupled receptors (GPCRs) that are able to selectively affect one signaling pathway over others for a specific GPCR, thereby "biasing" the signaling, it has become obvious that the original model of GPCRs existing in either an "on" or "off" conformation is too simple.  The current explanation for this biased agonism is that GPCRs can adopt multiple active conformations stabilized by different mols., and that each conformation affects intracellular signaling in a different way.  In the present study we sought to investigate biased agonism of the calcium-sensing receptor (CaSR), by looking at 12 well-known orthosteric CaSR agonists in 3 different CaSR signaling pathways: Gq/11 protein, Gi/o protein, and extracellular signal-regulated kinases 1 and 2 (ERK1/2).  Here we show that apart from Gq/11 and Gi/o signaling, ERK1/2 is activated through recruitment of β-arrestins.  Next, by measuring activity of all three signaling pathways we found that barium, spermine, neomycin, and tobramycin act as biased agonist in terms of efficacy and/or potency.  Finally, polyamines and aminoglycosides in general were biased in their potencies toward ERK1/2 signaling.  In conclusion, the results of this study indicate that several active conformations of CaSR, stabilized by different mols., exist, which affect intracellular signaling distinctly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0OM03QDGPb7Vg90H21EOLACvtfcHk0ljsx3g6uOQm_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit12jt7g%253D&md5=c62a3f98063361bf90dea320f0b46156</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.ceca.2011.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceca.2011.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DA.%2BR.%2BB.%26aulast%3DHvidtfeldt%26aufirst%3DM.%26aulast%3DBrauner-Osborne%26aufirst%3DH.%26atitle%3DBiased%2520agonism%2520of%2520the%2520calcium-sensing%2520receptor%26jtitle%3DCell%2520Calcium%26date%3D2012%26volume%3D51%26spage%3D107%26epage%3D116%26doi%3D10.1016%2Fj.ceca.2011.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yousaf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charytan, C.</span></span> <span> </span><span class="NLM_article-title">Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism</span>. <i>Renal Failure</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.3109/0886022X.2013.832319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3109%2F0886022X.2013.832319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOgtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=131-138&author=F.+Yousafauthor=C.+Charytan&title=Review+of+cinacalcet+hydrochloride+in+the+management+of+secondary+hyperparathyroidism&doi=10.3109%2F0886022X.2013.832319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism</span></div><div class="casAuthors">Yousaf, Farhanah; Charytan, Chaim</div><div class="citationInfo"><span class="NLM_cas:title">Renal Failure</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-138</span>CODEN:
                <span class="NLM_cas:coden">REFAE8</span>;
        ISSN:<span class="NLM_cas:issn">0886-022X</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Cinacalcet is the first Food and Drug Administration-approved calcimimetic for the treatment of secondary hyperparathyroidism in dialysis patients.  It is effective in improving control of parathyroid hormone, serum calcium, phosphorus, and calcium-phosphorus product.  The calcium-lowering effect of cinacalcet overcomes the limitations of std. therapy assocd. hypercalcemia.  There is evidence to suggest that cinacalcet has important clin. implications, which extend beyond its relevance in the treatment of secondary hyperparathyroidism.  This review summarizes the evidence regarding the role of cinacalcet in the treatment of secondary hyperparathyroidism, disrupted bone mineral metab., cardiovascular disease, and mortality.  In addn., the cost implications of cinacalcet are briefly explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTQ-XEIVH1w7Vg90H21EOLACvtfcHk0lgkCl0UaZD1gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOgtL%252FE&md5=5dabf3246e7f872679b55b04274fd3ce</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.3109%2F0886022X.2013.832319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F0886022X.2013.832319%26sid%3Dliteratum%253Aachs%26aulast%3DYousaf%26aufirst%3DF.%26aulast%3DCharytan%26aufirst%3DC.%26atitle%3DReview%2520of%2520cinacalcet%2520hydrochloride%2520in%2520the%2520management%2520of%2520secondary%2520hyperparathyroidism%26jtitle%3DRenal%2520Failure%26date%3D2014%26volume%3D36%26spage%3D131%26epage%3D138%26doi%3D10.3109%2F0886022X.2013.832319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span> <span> </span><span class="NLM_article-title">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1111/bph.12937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fbph.12937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25220431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=185-200&author=A.+E.+Cookauthor=S.+N.+Mistryauthor=K.+J.+Gregoryauthor=S.+G.+B.+Furnessauthor=P.+M.+Sextonauthor=P.+J.+Scammellsauthor=A.+D.+Conigraveauthor=A.+Christopoulosauthor=K.+Leach&title=Biased+allosteric+modulation+at+the+CaS+receptor+engendered+by+structurally+diverse+calcimimetics&doi=10.1111%2Fbph.12937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span></div><div class="casAuthors">Cook, A. E.; Mistry, S. N.; Gregory, K. J.; Furness, S. G. B.; Sexton, P. M.; Scammells, P. J.; Conigrave, A. D.; Christopoulos, A.; Leach, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-200</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Clin. use of cinacalcet in hyperparathyroidism is complicated by its tendency to induce hypocalcemia, arising partly from activation of calcium-sensing receptors (CaS receptors) in the thyroid and stimulation of calcitonin release.  CaS receptor allosteric modulators that selectively bias signalling towards pathways that mediate desired effects [e.g. parathyroid hormone (PTH) suppression] rather than those mediating undesirable effects (e.g. elevated serum calcitonin), may offer better therapies.  Exptl. Approach : We characterized the ligand-biased profile of novel calcimimetics in HEK293 cells stably expressing human CaS receptors, by monitoring intracellular calcium (Ca2+i) mobilization, inositol phosphate (IP)1 accumulation, ERK1/2 phosphorylation (pERK1/2) and receptor expression.  Key Results : Phenylalkylamine calcimimetics were biased towards allosteric modulation of Ca2+i mobilization and IP1 accumulation.  S,R-calcimimetic B was biased only towards IP1 accumulation.  R,R-calcimimetic B and AC-265347 were biased towards IP1 accumulation and pERK1/2.  Nor-calcimimetic B was unbiased.  In contrast to phenylalkylamines and calcimimetic B analogs, AC-265347 did not promote trafficking of a loss-of-expression, naturally occurring, CaS receptor mutation (G670E).  Conclusions and Implications : The ability of R,R-calcimimetic B and AC-265347 to bias signalling towards pERK1/2 and IP1 accumulation may explain their suppression of PTH levels in vivo at concns. that have no effect on serum calcitonin levels.  The demonstration that AC-265347 promotes CaS receptor receptor signalling, but not trafficking reveals a novel profile of ligand-biased modulation at CaS receptors The identification of allosteric modulators that bias CaS receptor signalling towards distinct intracellular pathways provides an opportunity to develop desirable biased signalling profiles in vivo for mediating selective physiol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAjm2vqgRE7Vg90H21EOLACvtfcHk0lgkCl0UaZD1gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P&md5=238f469a40ace3cf598dc49584bf0497</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1111%2Fbph.12937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12937%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DA.%2BE.%26aulast%3DMistry%26aufirst%3DS.%2BN.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%26atitle%3DBiased%2520allosteric%2520modulation%2520at%2520the%2520CaS%2520receptor%2520engendered%2520by%2520structurally%2520diverse%2520calcimimetics%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D185%26epage%3D200%26doi%3D10.1111%2Fbph.12937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorvin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babinsky, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinauskas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schou, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanyaloglu, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebold, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannan, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakker, R. V.</span></span> <span> </span><span class="NLM_article-title">A calcium-sensing receptor mutation causing hypocalcemia disrupts a transmembrane salt bridge to activate β-arrestin-biased signaling</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaan3714</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aan3714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscisignal.aan3714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29463778" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=eaan3714&author=C.+M.+Gorvinauthor=V.+N.+Babinskyauthor=T.+Malinauskasauthor=P.+H.+Nissenauthor=A.+J.+Schouauthor=A.+C.+Hanyalogluauthor=C.+Sieboldauthor=E.+Y.+Jonesauthor=F.+M.+Hannanauthor=R.+V.+Thakker&title=A+calcium-sensing+receptor+mutation+causing+hypocalcemia+disrupts+a+transmembrane+salt+bridge+to+activate+%CE%B2-arrestin-biased+signaling&doi=10.1126%2Fscisignal.aan3714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aan3714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aan3714%26sid%3Dliteratum%253Aachs%26aulast%3DGorvin%26aufirst%3DC.%2BM.%26aulast%3DBabinsky%26aufirst%3DV.%2BN.%26aulast%3DMalinauskas%26aufirst%3DT.%26aulast%3DNissen%26aufirst%3DP.%2BH.%26aulast%3DSchou%26aufirst%3DA.%2BJ.%26aulast%3DHanyaloglu%26aufirst%3DA.%2BC.%26aulast%3DSiebold%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DHannan%26aufirst%3DF.%2BM.%26aulast%3DThakker%26aufirst%3DR.%2BV.%26atitle%3DA%2520calcium-sensing%2520receptor%2520mutation%2520causing%2520hypocalcemia%2520disrupts%2520a%2520transmembrane%2520salt%2520bridge%2520to%2520activate%2520%25CE%25B2-arrestin-biased%2520signaling%26jtitle%3DSci.%2520Signaling%26date%3D2018%26volume%3D11%26spage%3Deaan3714%26doi%3D10.1126%2Fscisignal.aan3714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, H. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeque, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarov, I.</span></span> <span> </span><span class="NLM_article-title">Kinetics of 5-HT<sub>2B</sub> receptor signaling: profound agonist-dependent effects on signaling onset and duration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.113.207670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24049061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=645-659&author=D.+J.+Unettauthor=J.+Gatlinauthor=T.+L.+Anthonyauthor=D.+J.+Buzardauthor=S.+Changauthor=C.+Chenauthor=X.+H.+Chenauthor=H.+T.+M.+Dangauthor=J.+Frazerauthor=M.+K.+Leauthor=A.+J.+M.+Sadequeauthor=C.+Xingauthor=I.+Gaidarov&title=Kinetics+of+5-HT2B+receptor+signaling%3A+profound+agonist-dependent+effects+on+signaling+onset+and+duration&doi=10.1124%2Fjpet.113.207670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Kinectics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration</span></div><div class="casAuthors">Unett, David J.; Gatlin, Joel; Anthony, Todd L.; Buzard, Daniel J.; Chang, Steve; Chen, Chuan; Chen, Xiaohua; Dang, Huong T.-M.; Frazer, John; Le, Minh K.; Sadeque, Abu J. M.; Xing, Charles; Gaidarov, Ibragim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">645-659</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The kinetics of drug-receptor interactions can profoundly influence in vivo and in vitro pharmacol.  In vitro, the potencies of slowly assocg. agonists may be underestimated in assays capturing transient signaling events.  When divergent receptor-mediated signaling pathways are evaluated using combinations of equil. and transient assays, potency differences driven by kinetics may be erroneously interpreted as biased signaling.  In vivo, drugs with slow dissocn. rates may display prolonged physiol. effects inconsistent with their pharmacokinetic profiles.  We evaluated a panel of 5-hydroxytryptamine2B (5-HT2B) receptor agonists in kinetic radioligand binding assays and in transient, calcium flux assays, and inositol phosphate accumulation assays; two functional readouts emanating from Gαq-mediated activation of phospholipase C.  In binding studies, ergot derivs. demonstrated slow receptor assocn. and dissocn. rates, resulting in significantly reduced potency in calcium assays relative to inositol phosphate accumulation assays.  Ergot potencies for activation of extracellular signal-regulated kinases 1 and 2 were also highly time-dependent.  A no. of ergots produced wash-resistant 5-HT2B signaling that persisted for many hours without appreciable loss of potency, which was not explained simply by slow receptor-dissocn. kinetics.  Mechanistic studies indicated that persistent signaling originated from internalized or sequestered receptors.  This study provides a mechanistic basis for the long durations of action in vivo and wash-resistant effects in ex vivo tissue models often obsd. for ergots.  The 5-HT2B agonist activity of a no. of ergot-derived therapeutics has been implicated in development of cardiac valvulopathy in man.  The novel, sustained nature of ergot signaling reported here may represent an addnl. mechanism contributing to the valvulopathic potential of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt4E22Qj45kbVg90H21EOLACvtfcHk0li3gIxsOiptAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jL&md5=afba8d117470704b64f74bb2320c0aac</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207670%26sid%3Dliteratum%253Aachs%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DGatlin%26aufirst%3DJ.%26aulast%3DAnthony%26aufirst%3DT.%2BL.%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DDang%26aufirst%3DH.%2BT.%2BM.%26aulast%3DFrazer%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DM.%2BK.%26aulast%3DSadeque%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DGaidarov%26aufirst%3DI.%26atitle%3DKinetics%2520of%25205-HT2B%2520receptor%2520signaling%253A%2520profound%2520agonist-dependent%2520effects%2520on%2520signaling%2520onset%2520and%2520duration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D645%26epage%3D659%26doi%3D10.1124%2Fjpet.113.207670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time-a case for G protein-coupled receptors</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/med.21307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmed.21307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24549504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=856-892&author=D.+Guoauthor=J.+M.+Hillgerauthor=A.+P.+IJzermanauthor=L.+H.+Heitman&title=Drug-target+residence+time-a+case+for+G+protein-coupled+receptors&doi=10.1002%2Fmed.21307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Target Residence Time-A Case for G Protein-Coupled Receptors</span></div><div class="casAuthors">Guo, Dong; Hillger, Julia M.; Ijzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">856-892</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A vast no. of marketed drugs act on G protein-coupled receptors (GPCRs), the most successful category of drug targets to date.  These drugs usually possess high target affinity and selectivity, and such combined features have been the driving force in the early phases of drug discovery.  However, attrition has also been high.  Many investigational new drugs eventually fail in clin. trials due to a demonstrated lack of efficacy.  A retrospective assessment of successfully launched drugs revealed that their beneficial effects in patients may be attributed to their long drug-target residence times (RTs).  Likewise, for some other GPCR drugs short RT could be beneficial to reduce the potential for on-target side effects.  Hence, the compds.' kinetics behavior might in fact be the guiding principle to obtain a desired and durable effect in vivo.  We therefore propose that drug-target RT should be taken into account as an addnl. parameter in the lead selection and optimization process.  This should ultimately lead to an increased no. of candidate drugs moving to the preclin. development phase and on to the market.  This review contains examples of the kinetics behavior of GPCR ligands with improved in vivo efficacy and summarizes methods for assessing drug-target RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN5vhWI93LMbVg90H21EOLACvtfcHk0li3gIxsOiptAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D&md5=af48cdedf3c60ecb608d5c9ad03a0bbe</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1002%2Fmed.21307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21307%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHillger%26aufirst%3DJ.%2BM.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DDrug-target%2520residence%2520time-a%2520case%2520for%2520G%2520protein-coupled%2520receptors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D856%26epage%3D892%26doi%3D10.1002%2Fmed.21307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D<sub>2</sub> receptors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">763</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00716-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fs41467-017-00716-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28970469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=763&author=D.+A.+Sykesauthor=H.+Mooreauthor=L.+Stottauthor=N.+Hollidayauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=S.+J.+Charlton&title=Extrapyramidal+side+effects+of+antipsychotics+are+linked+to+their+association+kinetics+at+dopamine+D2+receptors&doi=10.1038%2Fs41467-017-00716-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors</span></div><div class="casAuthors">Sykes David A; Stott Lisa; Holliday Nicholas; Charlton Steven J; Moore Holly; Javitch Jonathan A; Moore Holly; Javitch Jonathan A; Javitch Jonathan A; Lane J Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">763</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor.  However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions.  Here we show that association rates, but not dissociation rates, correlate with EPS.  We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses.  EPS are robustly predicted by a rebinding model that considers the microenvironment of postsynaptic D2 receptors and integrates association and dissociation rates to calculate the net rate of reversal of receptor blockade.  Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved therapeutic profile.Atypical antipsychotics show reduced extrapyramidal side effects compared to first generation drugs.  Here the authors use time-resolved FRET to measure binding kinetics, and show that side effects correlate with drug association rates to the D2 receptor, while dissociation rates correlate with prolactin elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAv7HAvl2UWlVwdslNBF-tfW6udTcc2eajeoyFzPQ547ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D&md5=6d5c8596da9a3565b7a95b55eceac3cf</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00716-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00716-z%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DStott%26aufirst%3DL.%26aulast%3DHolliday%26aufirst%3DN.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DExtrapyramidal%2520side%2520effects%2520of%2520antipsychotics%2520are%2520linked%2520to%2520their%2520association%2520kinetics%2520at%2520dopamine%2520D2%2520receptors%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D763%26doi%3D10.1038%2Fs41467-017-00716-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrage, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallanoce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bätz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klöckner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrobang-Ley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tränkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Amici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzgrabe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, K.</span></span> <span> </span><span class="NLM_article-title">The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1044</span>, <span class="refDoi"> DOI: 10.1038/ncomms2028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fncomms2028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22948826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC38bktFamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1044&author=A.+Bockauthor=N.+Mertenauthor=R.+Schrageauthor=C.+Dallanoceauthor=J.+B%C3%A4tzauthor=J.+Kl%C3%B6cknerauthor=J.+Schmitzauthor=C.+Materaauthor=K.+Simonauthor=A.+Kebigauthor=L.+Petersauthor=A.+M%C3%BCllerauthor=J.+Schrobang-Leyauthor=C.+Tr%C3%A4nkleauthor=C.+Hoffmannauthor=M.+De+Amiciauthor=U.+Holzgrabeauthor=E.+Kostenisauthor=K.+Mohr&title=The+allosteric+vestibule+of+a+seven+transmembrane+helical+receptor+controls+G-protein+coupling&doi=10.1038%2Fncomms2028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling</span></div><div class="casAuthors">Bock Andreas; Merten Nicole; Schrage Ramona; Dallanoce Clelia; Batz Julia; Klockner Jessica; Schmitz Jens; Matera Carlo; Simon Katharina; Kebig Anna; Peters Lucas; Muller Anke; Schrobang-Ley Jasmin; Trankle Christian; Hoffmann Carsten; De Amici Marco; Holzgrabe Ulrike; Kostenis Evi; Mohr Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1044</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Seven transmembrane helical receptors (7TMRs) modulate cell function via different types of G proteins, often in a ligand-specific manner.  Class A 7TMRs harbour allosteric vestibules in the entrance of their ligand-binding cavities, which are in the focus of current drug discovery.  However, their biological function remains enigmatic.  Here we present a new strategy for probing and manipulating conformational transitions in the allosteric vestibule of label-free 7TMRs using the M(2) acetylcholine receptor as a paradigm.  We designed dualsteric agonists as 'tailor-made' chemical probes to trigger graded receptor activation from the acetylcholine-binding site while simultaneously restricting spatial flexibility of the receptor's allosteric vestibule.  Our findings reveal for the first time that a 7TMR's allosteric vestibule controls the extent of receptor movement to govern a hierarchical order of G-protein coupling.  This is a new concept assigning a biological role to the allosteric vestibule for controlling fidelity of 7TMR signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqGm8leCElH6x48Rj5GnGofW6udTcc2eYZ55K17xSSu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bktFamtw%253D%253D&md5=73fe5fd5f8214a9acfb88cda22c9c174</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1038%2Fncomms2028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms2028%26sid%3Dliteratum%253Aachs%26aulast%3DBock%26aufirst%3DA.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DSchrage%26aufirst%3DR.%26aulast%3DDallanoce%26aufirst%3DC.%26aulast%3DB%25C3%25A4tz%26aufirst%3DJ.%26aulast%3DKl%25C3%25B6ckner%26aufirst%3DJ.%26aulast%3DSchmitz%26aufirst%3DJ.%26aulast%3DMatera%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DKebig%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DL.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DSchrobang-Ley%26aufirst%3DJ.%26aulast%3DTr%25C3%25A4nkle%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DDe%2BAmici%26aufirst%3DM.%26aulast%3DHolzgrabe%26aufirst%3DU.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DMohr%26aufirst%3DK.%26atitle%3DThe%2520allosteric%2520vestibule%2520of%2520a%2520seven%2520transmembrane%2520helical%2520receptor%2520controls%2520G-protein%2520coupling%26jtitle%3DNat.%2520Commun.%26date%3D2012%26volume%3D3%26spage%3D1044%26doi%3D10.1038%2Fncomms2028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perroy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walwyn, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. J.</span></span> <span> </span><span class="NLM_article-title">Agonist-specific recruitment of arrestin isoforms differentially modify delta opioid receptor function</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3541</span>– <span class="NLM_lpage">3551</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4124-15.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1523%2FJNEUROSCI.4124-15.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27013682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFelsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=3541-3551&author=A.+A.+Pradhanauthor=J.+Perroyauthor=W.+M.+Walwynauthor=M.+L.+Smithauthor=A.+Vicente-Sanchezauthor=L.+Seguraauthor=A.+Banaauthor=B.+L.+Kiefferauthor=C.+J.+Evans&title=Agonist-specific+recruitment+of+arrestin+isoforms+differentially+modify+delta+opioid+receptor+function&doi=10.1523%2FJNEUROSCI.4124-15.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-specific recruitment of arrestin isoforms differentially modify delta opioid receptor function</span></div><div class="casAuthors">Pradhan, Amynah A.; Perroy, Julie; Walwyn, Wendy M.; Smith, Monique L.; Vicente-Sanchez, Ana; Segura, Laura; Bana, Alia; Kieffer, Brigitte L.; Evans, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3541-3551</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Ligand-specific recruitment of arrestins facilitates functional selectivity of G-protein-coupled receptor signaling.  Here, we describe agonist-selective recruitment of different arrestin isoforms to the delta opioid receptor in mice.  A high-internalizing delta opioid receptor agonist (SNC80) preferentially recruited arrestin 2 and, in arrestin 2 knock-outs (KOs), we obsd. a significant increase in the potency of SNC80 to inhibit mech. hyperalgesia and decreased acute tolerance.  In contrast, the low-internalizing delta agonists (ARM390, JNJ20788560) preferentially recruited arrestin 3 with unaltered behavioral effects in arrestin 2 KOs.  Surprisingly, arrestin 3 KO revealed an acute tolerance to these low-internalizing agonists, an effect never obsd. in wild-type animals.  Furthermore, we examd. delta opioid receptor-Ca2+ channel coupling in dorsal root ganglia desensitized by ARM390 and the rate of resensitization was correspondingly decreased in arrestin 3 KOs.  Live-cell imaging in HEK293 cells revealed that delta opioid receptors are in pre-engaged complexes with arrestin 3 at the cell membrane and that ARM390 strengthens this membrane interaction.  The disruption of these complexes in arrestin 3 KOs likely accounts for the altered responses to low-internalizing agonists.  Together, our results show agonist-selective recruitment of arrestin isoforms and reveal a novel endogenous role of arrestin 3 as a facilitator of resensitization and an inhibitor of tolerance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-sMfeVaStbVg90H21EOLACvtfcHk0ljoQPpOO1fRsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFelsbzK&md5=16bedb12ca9d24e412c50af4f8702a49</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4124-15.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4124-15.2016%26sid%3Dliteratum%253Aachs%26aulast%3DPradhan%26aufirst%3DA.%2BA.%26aulast%3DPerroy%26aufirst%3DJ.%26aulast%3DWalwyn%26aufirst%3DW.%2BM.%26aulast%3DSmith%26aufirst%3DM.%2BL.%26aulast%3DVicente-Sanchez%26aufirst%3DA.%26aulast%3DSegura%26aufirst%3DL.%26aulast%3DBana%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26aulast%3DEvans%26aufirst%3DC.%2BJ.%26atitle%3DAgonist-specific%2520recruitment%2520of%2520arrestin%2520isoforms%2520differentially%2520modify%2520delta%2520opioid%2520receptor%2520function%26jtitle%3DJ.%2520Neurosci.%26date%3D2016%26volume%3D36%26spage%3D3541%26epage%3D3551%26doi%3D10.1523%2FJNEUROSCI.4124-15.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 47 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ana Mallo-Abreu, Irene Reyes-Resina, Jhonny Azuaje, Rafael Franco, Aitor García-Rey, Maria Majellaro, Darío Miranda-Pastoriza, Xerardo García-Mera, Willem Jespers, Hugo Gutiérrez-de-Terán, Gemma Navarro, <span class="NLM_string-name hlFld-ContribAuthor">Eddy Sotelo</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and Subtype-Selective Dopamine D2 Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8710-8726. <a href="https://doi.org/10.1021/acs.jmedchem.1c00704" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00704%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252BSubtype-Selective%252BDopamine%252BD2%252BReceptor%252BBiased%252BPartial%252BAgonists%252BDiscovered%252Bvia%252Ban%252BUgi-Based%252BApproach%26aulast%3DMallo-Abreu%26aufirst%3DAna%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19042021%26date%3D10062021%26volume%3D64%26issue%3D12%26spage%3D8710%26epage%3D8726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sumanta Garai, Luciana M. Leo, Anna-Maria Szczesniak, Dow P. Hurst, Peter C. Schaffer, Ayat Zagzoog, Tallan Black, Jeffrey R. Deschamps, Elke Miess, Stefan Schulz, David R. Janero, Alex Straiker, Roger G. Pertwee, Mary E. Abood, Melanie E. M. Kelly, Patricia H. Reggio, Robert B. Laprairie, <span class="NLM_string-name hlFld-ContribAuthor">Ganesh A. Thakur</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8104-8126. <a href="https://doi.org/10.1021/acs.jmedchem.1c00040" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00040%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BBiased%252BAllosteric%252BModulator%252Bfor%252BCannabinoid%252B1%252BReceptor%25253A%252BPreclinical%252BAnti-Glaucoma%252BEfficacy%26aulast%3DGarai%26aufirst%3DSumanta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D09012021%26date%3D07042021%26volume%3D64%26issue%3D12%26spage%3D8104%26epage%3D8126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shan Jiang, Christos Iliopoulos-Tsoutsouvas, Fei Tong, Christina A. Brust, Catherine M. Keenan, Jimit Girish Raghav, Tian Hua, Simiao Wu, Jo-Hao Ho, Yiran Wu, Travis W. Grim, Nikolai Zvonok, Ganesh A. Thakur, Zhi-Jie Liu, Keith A. Sharkey, Laura M. Bohn, Spyros P. Nikas, <span class="NLM_string-name hlFld-ContribAuthor">Alexandros Makriyannis</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3870-3884. <a href="https://doi.org/10.1021/acs.jmedchem.0c02053" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02053%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BFunctionalized%252BCannabinoid%252BReceptor%252BProbes%25253A%252BDevelopment%252Bof%252BExceptionally%252BPotent%252BAgonists%26aulast%3DJiang%26aufirst%3DShan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D25112020%26date%3D24032021%26volume%3D64%26issue%3D7%26spage%3D3870%26epage%3D3884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian B. M. Poulie, Anders A. Jensen, Adam L. Halberstadt, <span class="NLM_string-name hlFld-ContribAuthor">Jesper L. Kristensen</span>. </span><span class="cited-content_cbyCitation_article-title">DARK Classics in Chemical Neuroscience: NBOMes. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (23)
                                     , 3860-3869. <a href="https://doi.org/10.1021/acschemneuro.9b00528" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00528%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDARK%252BClassics%252Bin%252BChemical%252BNeuroscience%25253A%252BNBOMes%26aulast%3DPoulie%26aufirst%3DChristian%2BB.%2BM.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D01102019%26date%3D28102019%26date%3D12112019%26date%3D28102019%26volume%3D11%26issue%3D23%26spage%3D3860%26epage%3D3869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Victor Hernandez-Olmos, Jan Heering, Viktoria Planz, Ting Liu, Alexander Kaps, Rinusha Rajkumar, Matthias Gramzow, Astrid Kaiser, Manfred Schubert-Zsilavecz, Michael J. Parnham, Maike Windbergs, Dieter Steinhilber, <span class="NLM_string-name hlFld-ContribAuthor">Ewgenij Proschak</span>. </span><span class="cited-content_cbyCitation_article-title">First Structure–Activity Relationship Study of Potent BLT2 Agonists as Potential Wound-Healing Promoters. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11548-11572. <a href="https://doi.org/10.1021/acs.jmedchem.0c00588" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00588%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFirst%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudy%252Bof%252BPotent%252BBLT2%252BAgonists%252Bas%252BPotential%252BWound-Healing%252BPromoters%26aulast%3DHernandez-Olmos%26aufirst%3DVictor%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09042020%26date%3D06102020%26date%3D18092020%26volume%3D63%26issue%3D20%26spage%3D11548%26epage%3D11572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Salvatore Pacifico, Federica Ferrari, Valentina Albanese, Erika Marzola, Joaquim Azevedo Neto, Chiara Ruzza, Girolamo Calò, Delia Preti, <span class="NLM_string-name hlFld-ContribAuthor">Remo Guerrini</span>. </span><span class="cited-content_cbyCitation_article-title">Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1–13)-NH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10782-10795. <a href="https://doi.org/10.1021/acs.jmedchem.9b02057" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02057%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiased%252BAgonism%252Bat%252BNociceptin%25252FOrphanin%252BFQ%252BReceptors%25253A%252BA%252BStructure%252BActivity%252BStudy%252Bon%252BN%25252FOFQ%2525281%2525E2%252580%25259313%252529-NH2%26aulast%3DPacifico%26aufirst%3DSalvatore%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D11122019%26date%3D24092020%26date%3D09092020%26volume%3D63%26issue%3D19%26spage%3D10782%26epage%3D10795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liang Tan, Qingtong Zhou, Wenzhong Yan, Jian Sun, Alan P. Kozikowski, Suwen Zhao, Xi-Ping Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4579-4602. <a href="https://doi.org/10.1021/acs.jmedchem.9b01835" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01835</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01835%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BBitopic%252B2-Phenylcyclopropylmethylamine%252B%252528PCPMA%252529%252BDerivatives%252Bas%252BSelective%252BDopamine%252BD3%252BReceptor%252BLigands%26aulast%3DTan%26aufirst%3DLiang%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18112019%26date%3D23042020%26date%3D13042020%26volume%3D63%26issue%3D9%26spage%3D4579%26epage%3D4602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Martha E. Sommer, Jana Selent, Jens Carlsson, Chris De Graaf, David E. Gloriam, Gyorgy M. Keseru, Mickey Kosloff, Stefan Mordalski, Aurelien Rizk, Mette M. Rosenkilde, Eddy Sotelo, Johanna K. S. Tiemann, Andrew Tobin, Nina Vardjan, Maria Waldhoer, <span class="NLM_string-name hlFld-ContribAuthor">Peter Kolb</span>. </span><span class="cited-content_cbyCitation_article-title">The European Research Network on Signal Transduction (ERNEST): Toward a Multidimensional Holistic Understanding of G Protein-Coupled Receptor Signaling. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2020,</strong> <em>3 </em>
                                    (2)
                                     , 361-370. <a href="https://doi.org/10.1021/acsptsci.0c00024" title="DOI URL">https://doi.org/10.1021/acsptsci.0c00024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.0c00024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.0c00024%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DThe%252BEuropean%252BResearch%252BNetwork%252Bon%252BSignal%252BTransduction%252B%252528ERNEST%252529%25253A%252BToward%252Ba%252BMultidimensional%252BHolistic%252BUnderstanding%252Bof%252BG%252BProtein-Coupled%252BReceptor%252BSignaling%26aulast%3DSommer%26aufirst%3DMartha%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03032020%26date%3D31032020%26volume%3D3%26issue%3D2%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bingjie Zhang, Simeng Zhao, Dehua Yang, Yiran Wu, Ye Xin, Haijie Cao, Xi-Ping Huang, Xiaoqing Cai, Wen Sun, Na Ye, Yueming Xu, Yao Peng, Suwen Zhao, Zhi-Jie Liu, Guisheng Zhong, Ming-Wei Wang, <span class="NLM_string-name hlFld-ContribAuthor">Wenqing Shui</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel G Protein-Biased and Subtype-Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extracts. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2020,</strong> <em>6 </em>
                                    (2)
                                     , 213-225. <a href="https://doi.org/10.1021/acscentsci.9b01125" title="DOI URL">https://doi.org/10.1021/acscentsci.9b01125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.9b01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.9b01125%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DA%252BNovel%252BG%252BProtein-Biased%252Band%252BSubtype-Selective%252BAgonist%252Bfor%252Ba%252BG%252BProtein-Coupled%252BReceptor%252BDiscovered%252Bfrom%252BScreening%252BHerbal%252BExtracts%26aulast%3DZhang%26aufirst%3DBingjie%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D03112019%26date%3D23012020%26volume%3D6%26issue%3D2%26spage%3D213%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anna S. Pirzer, Roman Lasch, Heike Friedrich, Harald Hübner, Peter Gmeiner, <span class="NLM_string-name hlFld-ContribAuthor">Markus R. Heinrich</span>. </span><span class="cited-content_cbyCitation_article-title">Benzyl Phenylsemicarbazides: A Chemistry-Driven Approach Leading to G Protein-Biased Dopamine D4 Receptor Agonists with High Subtype Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9658-9679. <a href="https://doi.org/10.1021/acs.jmedchem.9b01085" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01085%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzyl%252BPhenylsemicarbazides%25253A%252BA%252BChemistry-Driven%252BApproach%252BLeading%252Bto%252BG%252BProtein-Biased%252BDopamine%252BD4%252BReceptor%252BAgonists%252Bwith%252BHigh%252BSubtype%252BSelectivity%26aulast%3DPirzer%26aufirst%3DAnna%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D05072019%26date%3D30102019%26date%3D15102019%26volume%3D62%26issue%3D21%26spage%3D9658%26epage%3D9679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yudao Shen, John D. McCorvy, Michael L. Martini, Ramona M. Rodriguiz, Vladimir M. Pogorelov, Karen M. Ward, William C. Wetsel, Jing Liu, Bryan L. Roth, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4755-4771. <a href="https://doi.org/10.1021/acs.jmedchem.9b00508" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00508%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DD2%252BDopamine%252BReceptor%252BG%252BProtein-Biased%252BPartial%252BAgonists%252BBased%252Bon%252BCariprazine%26aulast%3DShen%26aufirst%3DYudao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22032019%26date%3D18042019%26date%3D09042019%26volume%3D62%26issue%3D9%26spage%3D4755%26epage%3D4771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael
L. Martini, Jing Liu, Caroline Ray, Xufen Yu, Xi-Ping Huang, Aarti Urs, Nikhil Urs, John D. McCorvy, Marc G. Caron, Bryan L. Roth, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Defining Structure–Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D1 Receptor Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3753-3772. <a href="https://doi.org/10.1021/acs.jmedchem.9b00351" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00351%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDefining%252BStructure%2525E2%252580%252593Functional%252BSelectivity%252BRelationships%252B%252528SFSR%252529%252Bfor%252Ba%252BClass%252Bof%252BNon-Catechol%252BDopamine%252BD1%252BReceptor%252BAgonists%26aulast%3DMartini%26aufirst%3DMichael%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25022019%26date%3D27032019%26date%3D15032019%26volume%3D62%26issue%3D7%26spage%3D3753%26epage%3D3772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Francesco Merlino, Étienne Billard, Ali M. Yousif, Salvatore Di Maro, Diego Brancaccio, Luigi Abate, Alfonso Carotenuto, Rosa Bellavita, Roberta d’Emmanuele di Villa Bianca, Paolo Santicioli, Luciana Marinelli, Ettore Novellino, Terence E. Hébert, William D. Lubell, David Chatenet, <span class="NLM_string-name hlFld-ContribAuthor">Paolo Grieco</span>. </span><span class="cited-content_cbyCitation_article-title">Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1455-1467. <a href="https://doi.org/10.1021/acs.jmedchem.8b01601" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01601%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFunctional%252BSelectivity%252BRevealed%252Bby%252BN-Methylation%252BScanning%252Bof%252BHuman%252BUrotensin%252BII%252Band%252BRelated%252BPeptides%26aulast%3DMerlino%26aufirst%3DFrancesco%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D15102018%26date%3D23012019%26date%3D07012019%26volume%3D62%26issue%3D3%26spage%3D1455%26epage%3D1467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dehua  Yang</span>, <span class="hlFld-ContribAuthor ">Qingtong  Zhou</span>, <span class="hlFld-ContribAuthor ">Viktorija  Labroska</span>, <span class="hlFld-ContribAuthor ">Shanshan  Qin</span>, <span class="hlFld-ContribAuthor ">Sanaz  Darbalaei</span>, <span class="hlFld-ContribAuthor ">Yiran  Wu</span>, <span class="hlFld-ContribAuthor ">Elita  Yuliantie</span>, <span class="hlFld-ContribAuthor ">Linshan  Xie</span>, <span class="hlFld-ContribAuthor ">Houchao  Tao</span>, <span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">Qing  Liu</span>, <span class="hlFld-ContribAuthor ">Suwen  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenqing  Shui</span>, <span class="hlFld-ContribAuthor ">Yi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">G protein-coupled receptors: structure- and function-based drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-020-00435-w" title="DOI URL">https://doi.org/10.1038/s41392-020-00435-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-020-00435-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-020-00435-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DG%252Bprotein-coupled%252Breceptors%25253A%252Bstructure-%252Band%252Bfunction-based%252Bdrug%252Bdiscovery%26aulast%3DYang%26aufirst%3DDehua%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jolien  De Neve</span>, <span class="hlFld-ContribAuthor ">Thomas M. A.  Barlow</span>, <span class="hlFld-ContribAuthor ">Dirk  Tourwé</span>, <span class="hlFld-ContribAuthor ">Frédéric  Bihel</span>, <span class="hlFld-ContribAuthor ">Frédéric  Simonin</span>, <span class="hlFld-ContribAuthor ">Steven  Ballet</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 828-870. <a href="https://doi.org/10.1039/D1MD00041A" title="DOI URL">https://doi.org/10.1039/D1MD00041A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00041A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00041A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Boverview%252Bof%252Bbiased%252Bpharmacology%252Bat%252Bthe%252Bopioid%252Breceptors%25253A%252Bbiased%252Bligands%252Band%252Bbias%252Bfactors%26aulast%3DDe%2BNeve%26aufirst%3DJolien%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D6%26spage%3D828%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosmara  Infantino</span>, <span class="hlFld-ContribAuthor ">Consalvo  Mattia</span>, <span class="hlFld-ContribAuthor ">Pamela  Locarini</span>, <span class="hlFld-ContribAuthor ">Antonio Luigi  Pastore</span>, <span class="hlFld-ContribAuthor ">Sabatino  Maione</span>, <span class="hlFld-ContribAuthor ">Livio  Luongo</span>. </span><span class="cited-content_cbyCitation_article-title">Buprenorphine: Far Beyond the “Ceiling”. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (6)
                                     , 816. <a href="https://doi.org/10.3390/biom11060816" title="DOI URL">https://doi.org/10.3390/biom11060816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11060816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11060816%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DBuprenorphine%25253A%252BFar%252BBeyond%252Bthe%252B%2525E2%252580%25259CCeiling%2525E2%252580%25259D%26aulast%3DInfantino%26aufirst%3DRosmara%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D6%26spage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shintaro  Maeda</span>, <span class="hlFld-ContribAuthor ">Yuki  Shiimura</span>, <span class="hlFld-ContribAuthor ">Hidetsugu  Asada</span>, <span class="hlFld-ContribAuthor ">Kunio  Hirata</span>, <span class="hlFld-ContribAuthor ">Fangjia  Luo</span>, <span class="hlFld-ContribAuthor ">Eriko  Nango</span>, <span class="hlFld-ContribAuthor ">Nobuo  Tanaka</span>, <span class="hlFld-ContribAuthor ">Masayasu  Toyomoto</span>, <span class="hlFld-ContribAuthor ">Asuka  Inoue</span>, <span class="hlFld-ContribAuthor ">Junken  Aoki</span>, <span class="hlFld-ContribAuthor ">So  Iwata</span>, <span class="hlFld-ContribAuthor ">Masatoshi  Hagiwara</span>. </span><span class="cited-content_cbyCitation_article-title">Endogenous agonist–bound S1PR3 structure reveals determinants of G protein–subtype bias. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2021,</strong> <em>7 </em>
                                    (24)
                                     , eabf5325. <a href="https://doi.org/10.1126/sciadv.abf5325" title="DOI URL">https://doi.org/10.1126/sciadv.abf5325</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.abf5325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.abf5325%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DEndogenous%252Bagonist%2525E2%252580%252593bound%252BS1PR3%252Bstructure%252Breveals%252Bdeterminants%252Bof%252BG%252Bprotein%2525E2%252580%252593subtype%252Bbias%26aulast%3DMaeda%26aufirst%3DShintaro%26date%3D2021%26date%3D2021%26volume%3D7%26issue%3D24%26spage%3Deabf5325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joaquim  Azevedo Neto</span>, <span class="hlFld-ContribAuthor ">Chiara  Ruzza</span>, <span class="hlFld-ContribAuthor ">Chiara  Sturaro</span>, <span class="hlFld-ContribAuthor ">Davide  Malfacini</span>, <span class="hlFld-ContribAuthor ">Salvatore  Pacifico</span>, <span class="hlFld-ContribAuthor ">Nurulain T.  Zaveri</span>, <span class="hlFld-ContribAuthor ">Girolamo  Calò</span>. </span><span class="cited-content_cbyCitation_article-title">Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neuroscience</span><span> <strong>2021,</strong> <em>15 </em><a href="https://doi.org/10.3389/fnins.2021.657153" title="DOI URL">https://doi.org/10.3389/fnins.2021.657153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnins.2021.657153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnins.2021.657153%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neuroscience%26atitle%3DFunctional%252BSelectivity%252BDoes%252BNot%252BPredict%252BAntinociceptive%25252FLocomotor%252BImpairing%252BPotencies%252Bof%252BNOP%252BReceptor%252BAgonists%26aulast%3DAzevedo%2BNeto%26aufirst%3DJoaquim%26date%3D2021%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengtian  Yu</span>, <span class="hlFld-ContribAuthor ">Wen  Xiao</span>, <span class="hlFld-ContribAuthor ">Shaoyong  Lu</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric binding sites at the receptor–lipid bilayer interface: novel targets for GPCR drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (3)
                                     , 690-703. <a href="https://doi.org/10.1016/j.drudis.2020.12.001" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DAllosteric%252Bbinding%252Bsites%252Bat%252Bthe%252Breceptor%2525E2%252580%252593lipid%252Bbilayer%252Binterface%25253A%252Bnovel%252Btargets%252Bfor%252BGPCR%252Bdrug%252Bdiscovery%26aulast%3DWang%26aufirst%3DYing%26date%3D2021%26volume%3D26%26issue%3D3%26spage%3D690%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Shuxiang  Li</span>, <span class="hlFld-ContribAuthor ">Hongbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Liang-Liang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2021,</strong> <em>90 </em>, 107405. <a href="https://doi.org/10.1016/j.compbiolchem.2020.107405" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2020.107405</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2020.107405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2020.107405%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotentially%252Bbiased%252Bagonists%252Bof%252Bmu-opioid%252Breceptor%252B%252528MOR%252529%252Bthrough%252Bmolecular%252Bdocking%25252C%252Bpharmacophore%252Bmodeling%25252C%252Band%252BMD%252Bsimulation%26aulast%3DJiang%26aufirst%3DXuan%26date%3D2021%26volume%3D90%26spage%3D107405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gianfabio  Giorgioni</span>, <span class="hlFld-ContribAuthor ">Fabio  Del Bello</span>, <span class="hlFld-ContribAuthor ">Pegi  Pavletić</span>, <span class="hlFld-ContribAuthor ">Wilma  Quaglia</span>, <span class="hlFld-ContribAuthor ">Luca  Botticelli</span>, <span class="hlFld-ContribAuthor ">Carlo  Cifani</span>, <span class="hlFld-ContribAuthor ">Emanuela  Micioni Di Bonaventura</span>, <span class="hlFld-ContribAuthor ">Maria Vittoria  Micioni Di Bonaventura</span>, <span class="hlFld-ContribAuthor ">Alessandro  Piergentili</span>. </span><span class="cited-content_cbyCitation_article-title">Recent findings leading to the discovery of selective dopamine D4 receptor ligands for the treatment of widespread diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113141. <a href="https://doi.org/10.1016/j.ejmech.2020.113141" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113141</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113141%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bfindings%252Bleading%252Bto%252Bthe%252Bdiscovery%252Bof%252Bselective%252Bdopamine%252BD4%252Breceptor%252Bligands%252Bfor%252Bthe%252Btreatment%252Bof%252Bwidespread%252Bdiseases%26aulast%3DGiorgioni%26aufirst%3DGianfabio%26date%3D2021%26volume%3D212%26spage%3D113141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mario  Zanaty</span>, <span class="hlFld-ContribAuthor ">Fernando A.C.  Seara</span>, <span class="hlFld-ContribAuthor ">Pablo  Nakagawa</span>, <span class="hlFld-ContribAuthor ">Guorui  Deng</span>, <span class="hlFld-ContribAuthor ">Natalia M.  Mathieu</span>, <span class="hlFld-ContribAuthor ">Kirthikaa  Balapattabi</span>, <span class="hlFld-ContribAuthor ">Sadashiva S.  Karnik</span>, <span class="hlFld-ContribAuthor ">Justin L.  Grobe</span>, <span class="hlFld-ContribAuthor ">Curt D.  Sigmund</span>. </span><span class="cited-content_cbyCitation_article-title">β-Arrestin–Biased Agonist Targeting the Brain AT
              1
              R (Angiotensin II Type 1 Receptor) Increases Aversion to Saline and Lowers Blood Pressure in Deoxycorticosterone Acetate–Salt Hypertension. </span><span class="cited-content_cbyCitation_journal-name">Hypertension</span><span> <strong>2021,</strong> <em>77 </em>
                                    (2)
                                     , 420-431. <a href="https://doi.org/10.1161/HYPERTENSIONAHA.120.15793" title="DOI URL">https://doi.org/10.1161/HYPERTENSIONAHA.120.15793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/HYPERTENSIONAHA.120.15793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FHYPERTENSIONAHA.120.15793%26sid%3Dliteratum%253Aachs%26jtitle%3DHypertension%26atitle%3D%2525CE%2525B2-Arrestin%2525E2%252580%252593Biased%252BAgonist%252BTargeting%252Bthe%252BBrain%252BAT%252B1%252BR%252B%252528Angiotensin%252BII%252BType%252B1%252BReceptor%252529%252BIncreases%252BAversion%252Bto%252BSaline%252Band%252BLowers%252BBlood%252BPressure%252Bin%252BDeoxycorticosterone%252BAcetate%2525E2%252580%252593Salt%252BHypertension%26aulast%3DZanaty%26aufirst%3DMario%26date%3D2021%26volume%3D77%26issue%3D2%26spage%3D420%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brittany M.  Craft</span>, <span class="hlFld-ContribAuthor ">Danial E.  Baker</span>. </span><span class="cited-content_cbyCitation_article-title">Oliceridine. </span><span class="cited-content_cbyCitation_journal-name">Hospital Pharmacy</span><span> <strong>2021,</strong> <em> </em>, 001857872098713. <a href="https://doi.org/10.1177/0018578720987137" title="DOI URL">https://doi.org/10.1177/0018578720987137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0018578720987137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0018578720987137%26sid%3Dliteratum%253Aachs%26jtitle%3DHospital%2520Pharmacy%26atitle%3DOliceridine%26aulast%3DCraft%26aufirst%3DBrittany%2BM.%26date%3D2021%26date%3D2021%26spage%3D001857872098713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin E.  Blass</span>. </span><span class="cited-content_cbyCitation_article-title">Classical targets in drug discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 111-183. <a href="https://doi.org/10.1016/B978-0-12-817214-8.00003-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-817214-8.00003-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-817214-8.00003-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-817214-8.00003-8%26sid%3Dliteratum%253Aachs%26atitle%3DClassical%252Btargets%252Bin%252Bdrug%252Bdiscovery%26aulast%3DBlass%26aufirst%3DBenjamin%2BE.%26date%3D2021%26spage%3D111%26epage%3D183%26pub%3DElsevier%26atitle%3DBasic%252BPrinciples%252Bof%252BDrug%252BDiscovery%252Band%252BDevelopment%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eline  Pottie</span>, <span class="hlFld-ContribAuthor ">Peter  Dedecker</span>, <span class="hlFld-ContribAuthor ">Christophe P.  Stove</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114251. <a href="https://doi.org/10.1016/j.bcp.2020.114251" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114251</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114251%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DIdentification%252Bof%252Bpsychedelic%252Bnew%252Bpsychoactive%252Bsubstances%252B%252528NPS%252529%252Bshowing%252Bbiased%252Bagonism%252Bat%252Bthe%252B5-HT2AR%252Bthrough%252Bsimultaneous%252Buse%252Bof%252B%2525CE%2525B2-arrestin%252B2%252Band%252BminiG%2525CE%2525B1q%252Bbioassays%26aulast%3DPottie%26aufirst%3DEline%26date%3D2020%26volume%3D182%26spage%3D114251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Álvaro  Velasco‐Rubio</span>, <span class="hlFld-ContribAuthor ">Jesús A.  Varela</span>, <span class="hlFld-ContribAuthor ">Carlos  Saá</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Transition‐Metal‐Catalyzed Oxidative Annulations to Benzazepines and Benzodiazepines. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (22)
                                     , 4861-4875. <a href="https://doi.org/10.1002/adsc.202000808" title="DOI URL">https://doi.org/10.1002/adsc.202000808</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000808%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DRecent%252BAdvances%252Bin%252BTransition%2525E2%252580%252590Metal%2525E2%252580%252590Catalyzed%252BOxidative%252BAnnulations%252Bto%252BBenzazepines%252Band%252BBenzodiazepines%26aulast%3DVelasco%25E2%2580%2590Rubio%26aufirst%3D%25C3%2581lvaro%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D22%26spage%3D4861%26epage%3D4875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Attila  Egyed</span>, <span class="hlFld-ContribAuthor ">Katalin  Domány-Kovács</span>, <span class="hlFld-ContribAuthor ">Bence  Koványi</span>, <span class="hlFld-ContribAuthor ">Ferenc  Horti</span>, <span class="hlFld-ContribAuthor ">Dalma  Kurkó</span>, <span class="hlFld-ContribAuthor ">Dóra Judit  Kiss</span>, <span class="hlFld-ContribAuthor ">Gáspár  Pándy-Szekeres</span>, <span class="hlFld-ContribAuthor ">István  Greiner</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Controlling receptor function from the extracellular vestibule of G-protein coupled receptors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (91)
                                     , 14167-14170. <a href="https://doi.org/10.1039/D0CC05532H" title="DOI URL">https://doi.org/10.1039/D0CC05532H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC05532H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC05532H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DControlling%252Breceptor%252Bfunction%252Bfrom%252Bthe%252Bextracellular%252Bvestibule%252Bof%252BG-protein%252Bcoupled%252Breceptors%26aulast%3DEgyed%26aufirst%3DAttila%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D91%26spage%3D14167%26epage%3D14170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Louiza  Belkacemi</span>, <span class="hlFld-ContribAuthor ">Nissar A.  Darmani</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>161 </em>, 105124. <a href="https://doi.org/10.1016/j.phrs.2020.105124" title="DOI URL">https://doi.org/10.1016/j.phrs.2020.105124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2020.105124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2020.105124%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DDopamine%252Breceptors%252Bin%252Bemesis%25253A%252BMolecular%252Bmechanisms%252Band%252Bpotential%252Btherapeutic%252Bfunction%26aulast%3DBelkacemi%26aufirst%3DLouiza%26date%3D2020%26volume%3D161%26spage%3D105124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joaquim  Azevedo Neto</span>, <span class="hlFld-ContribAuthor ">Anna  Costanzini</span>, <span class="hlFld-ContribAuthor ">Roberto  De Giorgio</span>, <span class="hlFld-ContribAuthor ">David G.  Lambert</span>, <span class="hlFld-ContribAuthor ">Chiara  Ruzza</span>, <span class="hlFld-ContribAuthor ">Girolamo  Calò</span>. </span><span class="cited-content_cbyCitation_article-title">Biased versus Partial Agonism in the Search for Safer Opioid Analgesics. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (17)
                                     , 3870. <a href="https://doi.org/10.3390/molecules25173870" title="DOI URL">https://doi.org/10.3390/molecules25173870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25173870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25173870%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBiased%252Bversus%252BPartial%252BAgonism%252Bin%252Bthe%252BSearch%252Bfor%252BSafer%252BOpioid%252BAnalgesics%26aulast%3DAzevedo%2BNeto%26aufirst%3DJoaquim%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D17%26spage%3D3870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark W.  Majewski</span>, <span class="hlFld-ContribAuthor ">Disha M.  Gandhi</span>, <span class="hlFld-ContribAuthor ">Trudy  Holyst</span>, <span class="hlFld-ContribAuthor ">Zhengli  Wang</span>, <span class="hlFld-ContribAuthor ">Irene  Hernandez</span>, <span class="hlFld-ContribAuthor ">Ricardo  Rosas</span>, <span class="hlFld-ContribAuthor ">Jieqing  Zhu</span>, <span class="hlFld-ContribAuthor ">Hartmut  Weiler</span>, <span class="hlFld-ContribAuthor ">Chris  Dockendorff</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (8)
                                     , 940-949. <a href="https://doi.org/10.1039/D0MD00098A" title="DOI URL">https://doi.org/10.1039/D0MD00098A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00098A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00098A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Binitial%252Bpharmacology%252Bof%252Bdual-targeting%252Bligands%252Bfor%252Bputative%252Bcomplexes%252Bof%252Bintegrin%252B%2525CE%2525B1V%2525CE%2525B23%252Band%252BPAR2%26aulast%3DMajewski%26aufirst%3DMark%2BW.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D8%26spage%3D940%26epage%3D949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amirhossein  Mafi</span>, <span class="hlFld-ContribAuthor ">Soo-Kyung  Kim</span>, <span class="hlFld-ContribAuthor ">William A.  Goddard</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2020,</strong> <em>117 </em>
                                    (28)
                                     , 16346-16355. <a href="https://doi.org/10.1073/pnas.1918264117" title="DOI URL">https://doi.org/10.1073/pnas.1918264117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1918264117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1918264117%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DMechanism%252Bof%252B%2525CE%2525B2-arrestin%252Brecruitment%252Bby%252Bthe%252B%2525CE%2525BC-opioid%252BG%252Bprotein-coupled%252Breceptor%26aulast%3DMafi%26aufirst%3DAmirhossein%26date%3D2020%26date%3D2020%26volume%3D117%26issue%3D28%26spage%3D16346%26epage%3D16355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria M.  Shchepinova</span>, <span class="hlFld-ContribAuthor ">Aylin C.  Hanyaloglu</span>, <span class="hlFld-ContribAuthor ">Gary S.  Frost</span>, <span class="hlFld-ContribAuthor ">Edward W.  Tate</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical biology of noncanonical G protein–coupled receptor signaling: Toward advanced therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>56 </em>, 98-110. <a href="https://doi.org/10.1016/j.cbpa.2020.04.012" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.04.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.04.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DChemical%252Bbiology%252Bof%252Bnoncanonical%252BG%252Bprotein%2525E2%252580%252593coupled%252Breceptor%252Bsignaling%25253A%252BToward%2525C2%2525A0advanced%252Btherapeutics%26aulast%3DShchepinova%26aufirst%3DMaria%2BM.%26date%3D2020%26volume%3D56%26spage%3D98%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carl-Mikael  Suomivuori</span>, <span class="hlFld-ContribAuthor ">Naomi R.  Latorraca</span>, <span class="hlFld-ContribAuthor ">Laura M.  Wingler</span>, <span class="hlFld-ContribAuthor ">Stephan  Eismann</span>, <span class="hlFld-ContribAuthor ">Matthew C.  King</span>, <span class="hlFld-ContribAuthor ">Alissa L. W.  Kleinhenz</span>, <span class="hlFld-ContribAuthor ">Meredith A.  Skiba</span>, <span class="hlFld-ContribAuthor ">Dean P.  Staus</span>, <span class="hlFld-ContribAuthor ">Andrew C.  Kruse</span>, <span class="hlFld-ContribAuthor ">Robert J.  Lefkowitz</span>, <span class="hlFld-ContribAuthor ">Ron O.  Dror</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor. </span><span class="cited-content_cbyCitation_journal-name">Science</span><span> <strong>2020,</strong> <em>367 </em>
                                    (6480)
                                     , 881-887. <a href="https://doi.org/10.1126/science.aaz0326" title="DOI URL">https://doi.org/10.1126/science.aaz0326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/science.aaz0326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscience.aaz0326%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%26atitle%3DMolecular%252Bmechanism%252Bof%252Bbiased%252Bsignaling%252Bin%252Ba%252Bprototypical%252BG%252Bprotein%2525E2%252580%252593coupled%252Breceptor%26aulast%3DSuomivuori%26aufirst%3DCarl-Mikael%26date%3D2020%26date%3D2020%26volume%3D367%26issue%3D6480%26spage%3D881%26epage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander  Heifetz</span>, <span class="hlFld-ContribAuthor ">Andrea  Townsend-Nicholson</span>. </span><span class="cited-content_cbyCitation_article-title">Characterizing Rhodopsin-Arrestin Interactions with the Fragment Molecular Orbital (FMO) Method. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 177-186. <a href="https://doi.org/10.1007/978-1-0716-0282-9_12" title="DOI URL">https://doi.org/10.1007/978-1-0716-0282-9_12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-0716-0282-9_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-0716-0282-9_12%26sid%3Dliteratum%253Aachs%26atitle%3DCharacterizing%252BRhodopsin-Arrestin%252BInteractions%252Bwith%252Bthe%252BFragment%252BMolecular%252BOrbital%252B%252528FMO%252529%252BMethod%26aulast%3DHeifetz%26aufirst%3DAlexander%26date%3D2020%26date%3D2020%26spage%3D177%26epage%3D186%26pub%3DSpringer%2520US%26atitle%3DQuantum%252BMechanics%252Bin%252BDrug%252BDiscovery%26aulast%3DHeifetz%26aufirst%3DAlexander%26date%3D2020%26volume%3D2114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hirotaka  Mizuno</span>, <span class="hlFld-ContribAuthor ">Yasuyuki  Kihara</span>. </span><span class="cited-content_cbyCitation_article-title">Druggable Lipid GPCRs: Past, Present, and Prospects. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 223-258. <a href="https://doi.org/10.1007/978-3-030-50621-6_10" title="DOI URL">https://doi.org/10.1007/978-3-030-50621-6_10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-50621-6_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-50621-6_10%26sid%3Dliteratum%253Aachs%26atitle%3DDruggable%252BLipid%252BGPCRs%25253A%252BPast%25252C%252BPresent%25252C%252Band%252BProspects%26aulast%3DMizuno%26aufirst%3DHirotaka%26date%3D2020%26date%3D2020%26spage%3D223%26epage%3D258%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDruggable%252BLipid%252BSignaling%252BPathways%26aulast%3DKihara%26aufirst%3DYasuyuki%26date%3D2020%26volume%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingtong  Zhou</span>, <span class="hlFld-ContribAuthor ">Dehua  Yang</span>, <span class="hlFld-ContribAuthor ">Meng  Wu</span>, <span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Wanjing  Guo</span>, <span class="hlFld-ContribAuthor ">Li  Zhong</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Cai</span>, <span class="hlFld-ContribAuthor ">Antao  Dai</span>, <span class="hlFld-ContribAuthor ">Wonjo  Jang</span>, <span class="hlFld-ContribAuthor ">Eugene I  Shakhnovich</span>, <span class="hlFld-ContribAuthor ">Zhi-Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Raymond C  Stevens</span>, <span class="hlFld-ContribAuthor ">Nevin A  Lambert</span>, <span class="hlFld-ContribAuthor ">M Madan  Babu</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Suwen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Common activation mechanism of class A GPCRs. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2019,</strong> <em>8 </em><a href="https://doi.org/10.7554/eLife.50279" title="DOI URL">https://doi.org/10.7554/eLife.50279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.50279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.50279%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DCommon%252Bactivation%252Bmechanism%252Bof%252Bclass%252BA%252BGPCRs%26aulast%3DZhou%26aufirst%3DQingtong%26date%3D2019%26date%3D2019%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rita  Turnaturi</span>, <span class="hlFld-ContribAuthor ">Santina  Chiechio</span>, <span class="hlFld-ContribAuthor ">Loredana  Salerno</span>, <span class="hlFld-ContribAuthor ">Antonio  Rescifina</span>, <span class="hlFld-ContribAuthor ">Valeria  Pittalà</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Cantarella</span>, <span class="hlFld-ContribAuthor ">Emilia  Tomarchio</span>, <span class="hlFld-ContribAuthor ">Carmela  Parenti</span>, <span class="hlFld-ContribAuthor ">Lorella  Pasquinucci</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the development of more effective and safer analgesics for pain management. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111701. <a href="https://doi.org/10.1016/j.ejmech.2019.111701" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111701%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Bin%252Bthe%252Bdevelopment%252Bof%252Bmore%252Beffective%252Band%252Bsafer%252Banalgesics%252Bfor%252Bpain%252Bmanagement%26aulast%3DTurnaturi%26aufirst%3DRita%26date%3D2019%26volume%3D183%26spage%3D111701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elise  Wouters</span>, <span class="hlFld-ContribAuthor ">Jolien  Walraed</span>, <span class="hlFld-ContribAuthor ">Samuel D.  Banister</span>, <span class="hlFld-ContribAuthor ">Christophe P.  Stove</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2019,</strong> <em>169 </em>, 113623. <a href="https://doi.org/10.1016/j.bcp.2019.08.025" title="DOI URL">https://doi.org/10.1016/j.bcp.2019.08.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2019.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2019.08.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DInsights%252Binto%252Bbiased%252Bsignaling%252Bat%252Bcannabinoid%252Breceptors%25253A%252Bsynthetic%252Bcannabinoid%252Breceptor%252Bagonists%26aulast%3DWouters%26aufirst%3DElise%26date%3D2019%26volume%3D169%26spage%3D113623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taneisha  Gillyard</span>, <span class="hlFld-ContribAuthor ">Katelyn  Fowler</span>, <span class="hlFld-ContribAuthor ">Savannah Y.  Williams</span>, <span class="hlFld-ContribAuthor ">Roger D.  Cone</span>. </span><span class="cited-content_cbyCitation_article-title">Obesity‐associated mutant melanocortin‐4 receptors with normal Gα
              s
              coupling frequently exhibit other discoverable pharmacological and biochemical defects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuroendocrinology</span><span> <strong>2019,</strong> <em>31 </em>
                                    (10)
                                     <a href="https://doi.org/10.1111/jne.12795" title="DOI URL">https://doi.org/10.1111/jne.12795</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jne.12795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjne.12795%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuroendocrinology%26atitle%3DObesity%2525E2%252580%252590associated%252Bmutant%252Bmelanocortin%2525E2%252580%2525904%252Breceptors%252Bwith%252Bnormal%252BG%2525CE%2525B1%252Bs%252Bcoupling%252Bfrequently%252Bexhibit%252Bother%252Bdiscoverable%252Bpharmacological%252Band%252Bbiochemical%252Bdefects%26aulast%3DGillyard%26aufirst%3DTaneisha%26date%3D2019%26date%3D2019%26volume%3D31%26issue%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael L.  Martini</span>, <span class="hlFld-ContribAuthor ">Sean N.  Neifert</span>, <span class="hlFld-ContribAuthor ">J  Mocco</span>, <span class="hlFld-ContribAuthor ">Fedor  Panov</span>, <span class="hlFld-ContribAuthor ">Winona  Tse</span>, <span class="hlFld-ContribAuthor ">Ruth H.  Walker</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>, <span class="hlFld-ContribAuthor ">Fiona  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Movement Disorders</span><span> <strong>2019,</strong> <em>12 </em>
                                    (3)
                                     , 161-165. <a href="https://doi.org/10.14802/jmd.19029" title="DOI URL">https://doi.org/10.14802/jmd.19029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14802/jmd.19029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14802%2Fjmd.19029%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Movement%2520Disorders%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BExperimental%252BTherapeutics%252Bfor%252BLevodopa-Induced%252BDyskinesia%26aulast%3DMartini%26aufirst%3DMichael%2BL.%26date%3D2019%26volume%3D12%26issue%3D3%26spage%3D161%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel E.  Felsing</span>, <span class="hlFld-ContribAuthor ">Manish K.  Jain</span>, <span class="hlFld-ContribAuthor ">John A.  Allen</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (16)
                                     , 1365-1380. <a href="https://doi.org/10.2174/1568026619666190712210903" title="DOI URL">https://doi.org/10.2174/1568026619666190712210903</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190712210903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190712210903%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DAdvances%252Bin%252BDopamine%252BD1%252BReceptor%252BLigands%252Bfor%252BNeurotherapeutics%26aulast%3DFelsing%26aufirst%3DDaniel%2BE.%26date%3D2019%26volume%3D19%26issue%3D16%26spage%3D1365%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katarzyna  Rzęsikowska</span>, <span class="hlFld-ContribAuthor ">Anna  Krawczuk</span>, <span class="hlFld-ContribAuthor ">Justyna  Kalinowska-Tłuścik</span>. </span><span class="cited-content_cbyCitation_article-title">Electrostatic potential and non-covalent interactions analysis for the design of selective 5-HT7 ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2019,</strong> <em>91 </em>, 130-139. <a href="https://doi.org/10.1016/j.jmgm.2019.06.007" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.06.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.06.007%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DElectrostatic%252Bpotential%252Band%252Bnon-covalent%252Binteractions%252Banalysis%252Bfor%252Bthe%252Bdesign%252Bof%252Bselective%252B5-HT7%252Bligands%26aulast%3DRz%25C4%2599sikowska%26aufirst%3DKatarzyna%26date%3D2019%26volume%3D91%26spage%3D130%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ammar A.H.  Azzam</span>, <span class="hlFld-ContribAuthor ">John  McDonald</span>, <span class="hlFld-ContribAuthor ">David G.  Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">Hot topics in opioid pharmacology: mixed and biased opioids. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Anaesthesia</span><span> <strong>2019,</strong> <em>122 </em>
                                    (6)
                                     , e136-e145. <a href="https://doi.org/10.1016/j.bja.2019.03.006" title="DOI URL">https://doi.org/10.1016/j.bja.2019.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bja.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bja.2019.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Anaesthesia%26atitle%3DHot%252Btopics%252Bin%252Bopioid%252Bpharmacology%25253A%252Bmixed%252Band%252Bbiased%252Bopioids%26aulast%3DAzzam%26aufirst%3DAmmar%2BA.H.%26date%3D2019%26volume%3D122%26issue%3D6%26spage%3De136%26epage%3De145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcel  Bermudez</span>, <span class="hlFld-ContribAuthor ">Trung Ngoc  Nguyen</span>, <span class="hlFld-ContribAuthor ">Christian  Omieczynski</span>, <span class="hlFld-ContribAuthor ">Gerhard  Wolber</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for the discovery of biased GPCR ligands. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (4)
                                     , 1031-1037. <a href="https://doi.org/10.1016/j.drudis.2019.02.010" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DStrategies%252Bfor%252Bthe%252Bdiscovery%252Bof%252Bbiased%252BGPCR%252Bligands%26aulast%3DBermudez%26aufirst%3DMarcel%26date%3D2019%26volume%3D24%26issue%3D4%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Terry  Kenakin</span>, . </span><span class="cited-content_cbyCitation_article-title">Biased Receptor Signaling in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2019,</strong> <em>71 </em>
                                    (2)
                                     , 267-315. <a href="https://doi.org/10.1124/pr.118.016790" title="DOI URL">https://doi.org/10.1124/pr.118.016790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.118.016790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.118.016790%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DBiased%252BReceptor%252BSignaling%252Bin%252BDrug%252BDiscovery%26aulast%3DKenakin%26aufirst%3DTerry%26date%3D2019%26date%3D2019%26volume%3D71%26issue%3D2%26spage%3D267%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Javier  García-Cárceles</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Strategies Targeting G-Protein-Coupled Receptors: An Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1-9. <a href="https://doi.org/10.1002/9780470015902.a0028406" title="DOI URL">https://doi.org/10.1002/9780470015902.a0028406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9780470015902.a0028406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9780470015902.a0028406%26sid%3Dliteratum%253Aachs%26atitle%3DNovel%252BStrategies%252BTargeting%252BG-Protein-Coupled%252BReceptors%25253A%252BAn%252BOverview%26aulast%3DGarc%25C3%25ADa-C%25C3%25A1rceles%26aufirst%3DJavier%26date%3D2018%26date%3D2018%26spage%3D1%26epage%3D9%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DeLS%26aulast%3DJohn%2BWiley%2B%2526%2BSons%2BLtd%26date%3D2001%26date%3D2001%26volume%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Morales</span>, <span class="hlFld-ContribAuthor ">Pilar  Goya</span>, <span class="hlFld-ContribAuthor ">Nadine  Jagerovic</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2018,</strong> <em>157 </em>, 8-17. <a href="https://doi.org/10.1016/j.bcp.2018.07.031" title="DOI URL">https://doi.org/10.1016/j.bcp.2018.07.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2018.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2018.07.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DEmerging%252Bstrategies%252Btargeting%252BCB2%252Bcannabinoid%252Breceptor%25253A%252BBiased%252Bagonism%252Band%252Ballosterism%26aulast%3DMorales%26aufirst%3DPaula%26date%3D2018%26volume%3D157%26spage%3D8%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Biased signaling at a glance. GPCR represented is from the crystal structure of β2 adrenergic receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RH1">2RH1</a>). The GPCR-G protein complex represented is from the β2 adrenergic receptor-G protein complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SN6">3SN6</a>), and the GPCR-β-arrestin complex represented is from the structure of rhodopsin-β-arrestin complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWJ">4ZWJ</a>). Throughout this review, G-protein-dependent activity of ligands is represented in red, and G-protein-independent signaling in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Biased ligands have been reported for 30 GPCR targets: ADORA1, adenosine A<sub>1</sub> receptor (A<sub>1</sub>AR); ADORA3, adenosine A<sub>3</sub> receptor (A<sub>3</sub>AR); ADRB1, adrenergic β<sub>1</sub> receptor (β<sub>1</sub>AR); ADRB2, adrenergic β<sub>2</sub> receptor (β<sub>2</sub>AR); AGTR1, angiotensin II receptor type 1 (AT<sub>1</sub>R); AGTRL1, apelin receptor (APJ); CASR, calcium-sensing receptor (CaSR); CNR1, cannabinoid receptor 1 (CB<sub>1</sub>R); CNR2, cannabinoid receptor 2 (CB<sub>2</sub>R); CXCR3, chemokine receptor CXCR3; DRD1, dopamine D<sub>1</sub> receptor (D<sub>1</sub>R); DRD2, dopamine D<sub>2</sub> receptor (D<sub>2</sub>R); EDG1, sphingosine 1-phosphate receptor 1 (S1P<sub>1</sub>R); EDNRA, endothelin A receptor (ET<sub>A</sub>); FPR2, formyl peptide receptor 2; GLP1R, glucagon-like peptide 1 receptor; GRM1, metabotropic glutamate receptor 1 (mGlu<sub>1</sub>R); GRM5, metabotropic glutamate receptor 5 (mGlu<sub>5</sub>R); HM74, niacin receptor (HM74A for GPR109A); HRH2, histamine H<sub>2</sub> receptor (H<sub>2</sub>R); HRH4, histamine H<sub>4</sub> receptor (H<sub>4</sub>R); HTR1A, serotonin 1A receptor (5-HT<sub>1A</sub>R); HTR2B, serotonin 2B receptor (5-HT<sub>2B</sub>R); HTR2C, serotonin 2C receptor (5-HT<sub>2C</sub>R); NTSR1, neurotensin receptor type 1 (NT<sub>1</sub>R); OPRK1, κ opioid receptor (KOR); OPRL1, nociception receptor (NOPR); OPRM1, μ opioid receptor (MOR); PTGER2, prostaglandin E2 receptor 2 (EP<sub>2</sub>R); PTHR1, parathyroid hormone 1 receptor. The graph was produced based on the dendrogram of the human GPCR superfamily (“Figure 1” in Katritch et al., “Structure-Function of the G Protein-Coupled Receptor Superfamily”<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>), with permission from the authors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Catecholamine derivatives that are β-arrrestin-biased agonists of βARs. The “bias factor” was calculated as a ratio of β-arrestin efficacy (in β-arrestin translocation FRET assay) to G protein efficacy (in cAMP assay).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Some β blockers are β-arrestin-biased agonists of βARs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. β-Arrestin-biased AT<sub>1</sub>R agonists. The amino acid sequences are shown from the N-terminus (left) to the C-terminus (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. G-protein-biased ligands at MOR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Piperidine compounds as G-protein-biased agonists of MOR. DAMGO was the reference compound for the calculation of bias factors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. G-protein-biased ligands at KOR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. G-protein-biased ligands at NOPR (ND, no determinable EC<sub>50</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Aripiprazole-based biased agonists at D<sub>2</sub>R (N/A, not applicable).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure-based design of β-arrestin-biased D<sub>2</sub>R agonists. Bias factors were calculated based on transduction coefficients using quinpirole as the reference compound.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Other 1,4-DAPs scaffold-based G-protein-biased agonists of D<sub>2</sub>R. The values of pEC<sub>50</sub> and <i>E</i><sub>max</sub> can be found in the Supporting Information of the refs <a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and <a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a>. Dopamine was used as the reference compound for the calculation of transduction coefficients.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. G-protein-biased D<sub>2</sub>R agonist derived from sumanirole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. BRD5814 is a G protein pathway agonist and β-arrestin pathway antagonist at D<sub>2</sub>R (red, inhibition of cAMP accumulation; blue, β-arrestin2 recruitment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. G-protein-biased agonists at D<sub>1</sub>R (red, stimulation of cAMP accumulation; blue, β-arrestin2 recruitment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Non-catechol, G-protein-biased agonists of D<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Biased agonists at serotonin receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Biased ligands at H<sub>4</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Biased agonists at CB<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Biased ligands at CB<sub>2</sub>R. “NA” indicates not applicable (activation <20% threshold), and negative <i>E</i><sub>max</sub> values (for <b>106</b> and <b>107</b>) represent inverse agonist activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. G-protein-biased APJ agonists. The amino acid sequences of the peptides are shown from the N-terminus (left) to the C-terminus (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Biased allosteric modulators of CXCR3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Biased prostaglandin EP<sub>2</sub> agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Biased ligands at the ET<sub>A</sub> receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. MK-0354 is a G-protein-biased GPR109A agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. BMS-986104 phosphate is a G-protein-biased agonist at S1P<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. ML314 is a β-arrestin-biased agonist at NTR1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. F2Pal<sub>10</sub> is a G-protein-biased agonist of FPR2. The amino acid sequences of each peptide are shown from the N-terminus (left) to the C-terminus (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. VCP746 and analogues as biased A<sub>1</sub>AR bitopic agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Biased agonists of A<sub>3</sub>AR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Biased agonists of GLP-1R. The amino acid sequences of the peptides are shown from the N-terminus (left) to the C-terminus (right), while a terminal “–NH<sub>2</sub>” indicates a primary amide at the C-terminus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Biased agonists of mGlu<sub>1</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Biased PAMs of mGlu<sub>5</sub>R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/medium/jm-2018-00435h_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Biased PAMs of CaSR. PAM cooperativity (αβ) were compared between compounds for quantification. pERK1/2 effects of CaSR can be mediated by both G protein and β-arrestin.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00435/20181119/images/large/jm-2018-00435h_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00435&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48111" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48111" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 200 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural diversity of G protein-coupled receptors and significance for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstromauthor=H.+B.+Schioth&title=Structural+diversity+of+G+protein-coupled+receptors+and+significance+for+drug+discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2eZAOEUec42q7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520diversity%2520of%2520G%2520protein-coupled%2520receptors%2520and%2520significance%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1124/mol.63.6.1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.63.6.1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=12761335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1256-1272&author=R.+Fredrikssonauthor=M.+C.+Lagerstromauthor=L.+G.+Lundinauthor=H.+B.+Schioth&title=The+G-protein-coupled+receptors+in+the+human+genome+form+five+main+families.+Phylogenetic+analysis%2C+paralogon+groups%2C+and+fingerprints&doi=10.1124%2Fmol.63.6.1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span></div><div class="casAuthors">Fredriksson, Robert; Lagerstrom, Malin C.; Lundin, Lars-Gustav; Schioth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1256-1272</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The superfamily of G-protein-coupled receptors (GPCRs) is very diverse in structure and function and its members are among the most pursued targets for drug development.  We identified more than 800 human GPCR sequences and simultaneously analyzed 342 unique functional nonolfactory human GPCR sequences with phylogenetic analyses.  Our results show, with high bootstrap support, five main families, named glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin, forming the GRAFS classification system.  The rhodopsin family is the largest and forms four main groups with 13 subbranches.  Positions of the GPCRs in chromosomal paralogons regions indicate the importance of tetraploidizations or local gene duplication events for their creation.  We also searched for "fingerprint" motifs using Hidden Markov Models delineating the putative inter-relationship of the GRAFS families.  We show several common structural features indicating that the human GPCRs in the GRAFS families share a common ancestor.  This study represents the first overall map of the GPCRs in a single mammalian genome.  Our novel approach of analyzing such large and diverse sequence sets may be useful for studies on GPCRs in other genomes and divergent protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdX4VhTsaDzrVg90H21EOLACvtfcHk0lit8HuZQ-j-Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D&md5=504ea873ee8469cd0b6016bc94943836</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fmol.63.6.1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.63.6.1256%26sid%3Dliteratum%253Aachs%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DLundin%26aufirst%3DL.%2BG.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DThe%2520G-protein-coupled%2520receptors%2520in%2520the%2520human%2520genome%2520form%2520five%2520main%2520families.%2520Phylogenetic%2520analysis%252C%2520paralogon%2520groups%252C%2520and%2520fingerprints%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D63%26spage%3D1256%26epage%3D1272%26doi%3D10.1124%2Fmol.63.6.1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuthrich, K.</span></span> <span> </span><span class="NLM_article-title">The GPCR network: a large-scale collaboration to determine human GPCR structure and function</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd3859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd3859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23237917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=25-34&author=R.+C.+Stevensauthor=V.+Cherezovauthor=V.+Katritchauthor=R.+Abagyanauthor=P.+Kuhnauthor=H.+Rosenauthor=K.+Wuthrich&title=The+GPCR+network%3A+a+large-scale+collaboration+to+determine+human+GPCR+structure+and+function&doi=10.1038%2Fnrd3859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The GPCR Network: a large-scale collaboration to determine human GPCR structure and function</span></div><div class="casAuthors">Stevens, Raymond C.; Cherezov, Vadim; Katritch, Vsevolod; Abagyan, Ruben; Kuhn, Peter; Rosen, Hugh; Wuethrich, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are targeted by ∼30-40% of marketed drugs, and their key roles in normal physiol. and in disease demonstrate that an understanding of their structure and function is valuable to researchers in both basic science and drug discovery.  However, until recently, detailed structural information on this protein family was limited by challenges in X-ray crystallog. anal. of such membrane proteins.  The GPCR Network was created in 2010 with the goal of structurally characterizing 15-25 representative human GPCRs within 5 years, based on an active outreach program addressing an interdisciplinary community of scientists interested in GPCR structure, chem. and biol.  Here, we provide an overview of how this collaborative effort has enabled the structural detn. and characterization of eight human GPCRs so far, and discuss some of the challenges that remain in gaining more detailed insights into structure-function relationships in this receptor superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBDUU5HjYCg7Vg90H21EOLACvtfcHk0ljFwxoaWKJV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVekurzI&md5=8c303038034b529c6efd3492716fad19</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3859%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DWuthrich%26aufirst%3DK.%26atitle%3DThe%2520GPCR%2520network%253A%2520a%2520large-scale%2520collaboration%2520to%2520determine%2520human%2520GPCR%2520structure%2520and%2520function%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D25%26epage%3D34%26doi%3D10.1038%2Fnrd3859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0ljFwxoaWKJV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR drug discovery: new agents, targets and indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schiothauthor=D.+E.+Gloriam&title=Trends+in+GPCR+drug+discovery%3A+new+agents%2C+targets+and+indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (∼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which ∼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0ljFwxoaWKJV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520drug%2520discovery%253A%2520new%2520agents%252C%2520targets%2520and%2520indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.010909.105800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1146%2Fannurev.pharmtox.010909.105800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21942629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=179-197&author=E.+Reiterauthor=S.+Ahnauthor=A.+K.+Shuklaauthor=R.+J.+Lefkowitz&title=Molecular+mechanism+of+%CE%B2-arrestin-biased+agonism+at+seven-transmembrane+receptors&doi=10.1146%2Fannurev.pharmtox.010909.105800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors</span></div><div class="casAuthors">Reiter, Eric; Ahn, Seungkirl; Shukla, Arun K.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-197</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The concept of biased agonism has recently come to the fore with the realization that seven-transmembrane receptors (7TMRs, also known as G protein-coupled receptors, or GPCRs) activate complex signaling networks and can adopt multiple active conformations upon agonist binding.  As a consequence, the "efficacy" of receptors, which was classically considered linear, is now recognized as pluridimensional.  Biased agonists selectively stabilize only a subset of receptor conformations induced by the natural "unbiased" ligand, thus preferentially activating certain signaling mechanisms.  Such agonists thus reveal the intriguing possibility that one can direct cellular signaling with unprecedented precision and specificity and support the notion that biased agonists may identify new classes of therapeutic agents that have fewer side effects.  This review focuses on one particular class of biased ligands that has the ability to alter the balance between G protein-dependent and β-arrestin-dependent signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-dMKnViGurVg90H21EOLACvtfcHk0lgt2btdg6Hanw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D&md5=05065a33108ddeebc36923b3cc821037</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.010909.105800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.010909.105800%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520mechanism%2520of%2520%25CE%25B2-arrestin-biased%2520agonism%2520at%2520seven-transmembrane%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2012%26volume%3D52%26spage%3D179%26epage%3D197%26doi%3D10.1146%2Fannurev.pharmtox.010909.105800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Teaching old receptors new tricks: biasing seven-transmembrane receptors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1038/nrd3024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd3024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20431569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=373-386&author=S.+Rajagopalauthor=K.+Rajagopalauthor=R.+J.+Lefkowitz&title=Teaching+old+receptors+new+tricks%3A+biasing+seven-transmembrane+receptors&doi=10.1038%2Fnrd3024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Teaching old receptors new tricks: biasing seven-transmembrane receptors</span></div><div class="casAuthors">Rajagopal, Sudarshan; Rajagopal, Keshava; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-386</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Seven-transmembrane receptors (7TMRs; also known as G protein-coupled receptors) are the largest class of receptors in the human genome and are common targets for therapeutics.  Originally identified as mediators of 7TMR desensitization, β-arrestins (arrestin 2 and arrestin 3) are now recognized as true adaptor proteins that transduce signals to multiple effector pathways.  Signaling that is mediated by β-arrestins has distinct biochem. and functional consequences from those mediated by G proteins, and several biased ligands and receptors have been identified that preferentially signal through either G protein- or β-arrestin-mediated pathways.  These ligands are not only useful tools for investigating the biochem. of 7TMR signaling, but they also have the potential to be developed into new classes of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuN6jivmOErVg90H21EOLACvtfcHk0lgt2btdg6Hanw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWjs7k%253D&md5=ff525016c0ba5aa0ebc4ed86f87594d0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd3024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3024%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DRajagopal%26aufirst%3DK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DTeaching%2520old%2520receptors%2520new%2520tricks%253A%2520biasing%2520seven-transmembrane%2520receptors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D373%26epage%3D386%26doi%3D10.1038%2Fnrd3024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, G. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struts, A. V.</span></span> <span> </span><span class="NLM_article-title">Retinal dynamics during light activation of rhodopsin revealed by solid-state NMR spectroscopy</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1798</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2009.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bbamem.2009.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=19716801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1798&publication_year=2010&pages=177-193&author=M.+F.+Brownauthor=G.+F.+J.+Salgadoauthor=A.+V.+Struts&title=Retinal+dynamics+during+light+activation+of+rhodopsin+revealed+by+solid-state+NMR+spectroscopy&doi=10.1016%2Fj.bbamem.2009.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal dynamics during light activation of rhodopsin revealed by solid-state NMR spectroscopy</span></div><div class="casAuthors">Brown, Michael F.; Salgado, Gilmar F. J.; Struts, Andrey V.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1798</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-193</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Rhodopsin (I) is a canonical member of class A of the G protein-coupled receptors (GPCRs) that are implicated in many of the drug interventions in humans and are of great pharmaceutical interest.  The mol. mechanism of I activation remains unknown as atomistic structural information for the active metarhodopsin II state is currently lacking.  Solid-state 2H NMR constitutes a powerful approach to study at.-level dynamics of membrane proteins.  In the present application, the authors describe how information is obtained about interactions of the retinal cofactor with I that change with light activation of the photoreceptor.  The retinal Me groups play an important role in I function by directing conformational changes upon transition into the active state.  Site-specific 2H labels have been introduced into the Me groups of retinal and solid-state 2H NMR methods applied to obtain order parameters and correlation times that quantify the mobility of the cofactor in the inactive dark state, as well as the cryotrapped metarhodopsin I and metarhodopsin II states.  Anal. of the angular-dependent 2H NMR line shapes for selectively deuterated Me groups of I in aligned membranes enables detn. of the av. ligand conformation within the binding pocket.  The relaxation data suggest that the β-ionone ring is not expelled from its hydrophobic pocket in the transition from the pre-activated metarhodopsin I to the active metarhodopsin II state.  Rather, the major structural changes of the retinal cofactor occur already at the metarhodopsin I state in the activation process.  The metarhodopsin I to metarhodopsin II transition involves mainly conformational changes of the protein within the membrane lipid bilayer rather than the ligand.  The dynamics of the retinylidene Me groups upon isomerization are explained by an activation mechanism involving cooperative rearrangements of extracellular loop E2 together with transmembrane helixes H5 and H6.  These activating movements are triggered by steric clashes of the isomerized all-trans retinal with the β4 strand of the E2 loop and the side-chains of Glu-122 and Trp-265 within the binding pocket.  The solid-state 2H NMR data are discussed with regard to the pathway of the energy flow in the receptor activation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvC-879pt3bVg90H21EOLACvtfcHk0lgt2btdg6Hanw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGksro%253D&md5=99ce51bdee9eb0eac44f493200f1c675</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2009.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2009.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DSalgado%26aufirst%3DG.%2BF.%2BJ.%26aulast%3DStruts%26aufirst%3DA.%2BV.%26atitle%3DRetinal%2520dynamics%2520during%2520light%2520activation%2520of%2520rhodopsin%2520revealed%2520by%2520solid-state%2520NMR%2520spectroscopy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2010%26volume%3D1798%26spage%3D177%26epage%3D193%26doi%3D10.1016%2Fj.bbamem.2009.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span> <span> </span><span class="NLM_article-title">Agonist-receptor efficacy II: agonist trafficking of receptor signals</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(00)89032-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2FS0165-6147%2800%2989032-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=232-238&author=T.+Kenakin&title=Agonist-receptor+efficacy+II%3A+agonist+trafficking+of+receptor+signals&doi=10.1016%2FS0165-6147%2800%2989032-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2800%2989032-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252800%252989032-X%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DAgonist-receptor%2520efficacy%2520II%253A%2520agonist%2520trafficking%2520of%2520receptor%2520signals%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1995%26volume%3D16%26spage%3D232%26epage%3D238%26doi%3D10.1016%2FS0165-6147%2800%2989032-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spedding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailman, R. B.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity and classical concepts of quantitative pharmacology</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.104463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.106.104463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=16803859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=1-13&author=J.+D.+Urbanauthor=W.+P.+Clarkeauthor=M.+von+Zastrowauthor=D.+E.+Nicholsauthor=B.+Kobilkaauthor=H.+Weinsteinauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=A.+Christopoulosauthor=P.+M.+Sextonauthor=K.+J.+Millerauthor=M.+Speddingauthor=R.+B.+Mailman&title=Functional+selectivity+and+classical+concepts+of+quantitative+pharmacology&doi=10.1124%2Fjpet.106.104463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and classical concepts of quantitative pharmacology</span></div><div class="casAuthors">Urban, Jonathan D.; Clarke, William P.; von Zastrow, Mark; Nichols, David E.; Kobilka, Brian; Weinstein, Harel; Javitch, Jonathan A.; Roth, Bryan L.; Christopoulos, Arthur; Sexton, Patrick M.; Miller, Keith J.; Spedding, Michael; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The concept of intrinsic efficacy has been enshrined in pharmacol. for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy.  Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism.  At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor.  Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems.  A variety of mechanisms may influence this apparently ubiquitous phenomenon.  It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the β2-adrenergic receptor.  Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers.  Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism).  Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action.  It also may be timely to revise classic concepts in quant. pharmacol. and relevant pharmacol. conventions to incorporate these new concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GzdtvWZRkbVg90H21EOLACvtfcHk0liqQT6wigS3Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D&md5=54465473b5996d0755baeee89eeb0ba9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.104463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.104463%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520and%2520classical%2520concepts%2520of%2520quantitative%2520pharmacology%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D1%26epage%3D13%26doi%3D10.1124%2Fjpet.106.104463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. S. H.</span></span> <span> </span><span class="NLM_article-title">Ensemble of G protein-coupled receptor active states</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1146</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.2174/092986712799320619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.2174%2F092986712799320619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22300048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Kktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1146-1154&author=P.+S.+H.+Park&title=Ensemble+of+G+protein-coupled+receptor+active+states&doi=10.2174%2F092986712799320619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ensemble of G protein-coupled receptor active states</span></div><div class="casAuthors">Park, P. S.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1146-1154</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) play crit. roles in cellular signal transduction and are important targets for therapeutics.  Although these receptors have been intensely studied for quite some time, our understanding about their mechanism of action is still incomplete.  GPCR activity has traditionally been viewed within the context of two-state models where the receptor is in equil. between a single inactive state and a single active state.  This framework is too simple and restrictive to accommodate more recent observations made on these receptors, which instead point to a situation where the receptor can adopt several different active conformational substates with distinct functional effects.  Structural and functional evidence for this emerging view is presented in this review.  Implications of this emerging view in rationalizing diseased states and in drug discovery are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptjXS9j8v_aLVg90H21EOLACvtfcHk0liqQT6wigS3Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Kktrw%253D&md5=12f9384c6b98cdcb3070e4e84aa7d172</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F092986712799320619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712799320619%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DP.%2BS.%2BH.%26atitle%3DEnsemble%2520of%2520G%2520protein-coupled%2520receptor%2520active%2520states%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D1146%26epage%3D1154%26doi%3D10.2174%2F092986712799320619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+bias+in+new+drug+discovery%3A+detection%2C+quantification+and+therapeutic+impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0liqQT6wigS3Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520bias%2520in%2520new%2520drug%2520discovery%253A%2520detection%252C%2520quantification%2520and%2520therapeutic%2520impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1330</span>, <span class="refDoi"> DOI: 10.1002/med.21318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmed.21318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24796277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1286-1330&author=J.+Shonbergauthor=L.+Lopezauthor=P.+J.+Scammellsauthor=A.+Christopoulosauthor=B.+Capuanoauthor=J.+R.+Lane&title=Biased+agonism+at+G+protein-coupled+receptors%3A+the+promise+and+the+challenges%2D%2Da+medicinal+chemistry+perspective&doi=10.1002%2Fmed.21318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Agonism at G Protein-Coupled Receptors: The Promise and the Challenges-A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Shonberg, Jeremy; Lopez, Laura; Scammells, Peter J.; Christopoulos, Arthur; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1286-1330</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Historically, detn. of G protein-coupled receptor (GPCR) ligand efficacy has often been restricted to identifying the ligand as an agonist or antagonist at a given signaling pathway.  This classification was deemed sufficient to predict compd. efficacy at all signaling endpoints, including the therapeutically relevant one(s).  However, it is now apparent that ligands acting at the same GPCR can stabilize multiple, distinct, receptor conformations linked to different functional outcomes.  This phenomenon, known as biased agonism, stimulus bias, or functional selectivity offers the opportunity to sep. on-target therapeutic effects from side effects through the design of drugs that show pathway selectivity.  However, the medicinal chemist faces numerous challenges to develop biased ligands, including the detection and quantification of biased agonism.  This review summarizes the current state of the field of research into biased agonism at GPCRs, with a particular focus on efforts to relate biased agonism to ligand structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-egFZpSKvbVg90H21EOLACvtfcHk0liSMCxlsKEi5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ&md5=85a5b385750d21856ae044391c46ee75</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fmed.21318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21318%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DBiased%2520agonism%2520at%2520G%2520protein-coupled%2520receptors%253A%2520the%2520promise%2520and%2520the%2520challenges--a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D1286%26epage%3D1330%26doi%3D10.1002%2Fmed.21318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span> <span> </span><span class="NLM_article-title">Biased ligands at G-protein-coupled receptors: promise and progress</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.tips.2014.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24878326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=308-316&author=J.+D.+Violinauthor=A.+L.+Crombieauthor=D.+G.+Soergelauthor=M.+W.+Lark&title=Biased+ligands+at+G-protein-coupled+receptors%3A+promise+and+progress&doi=10.1016%2Fj.tips.2014.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligands at G-protein-coupled receptors: promise and progress</span></div><div class="casAuthors">Violin, Jonathan D.; Crombie, Aimee L.; Soergel, David G.; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug discovery targeting G protein-coupled receptors (GPCRs) is no longer limited to seeking agonists or antagonists to stimulate or block cellular responses assocd. with a particular receptor.  GPCRs are now known to support a diversity of pharmacol. profiles, a concept broadly referred to as functional selectivity.  In particular, the concept of ligand bias, whereby a ligand stabilizes subsets of receptor conformations to engender novel pharmacol. profiles, has recently gained increasing prominence.  This review discusses how biased ligands may deliver safer, better tolerated, and more efficacious drugs, and highlights several biased ligands that are in clin. development.  Biased ligands targeting the angiotensin II type 1 receptor and the μ opioid receptor illustrate the translation of the biased ligand concept from basic biol. to clin. drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBma1S1zZ0-7Vg90H21EOLACvtfcHk0liSMCxlsKEi5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D&md5=768953e7aa5726d1a47ecbdb068469d8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DBiased%2520ligands%2520at%2520G-protein-coupled%2520receptors%253A%2520promise%2520and%2520progress%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D308%26epage%3D316%26doi%3D10.1016%2Fj.tips.2014.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Correll, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span> <span> </span><span class="NLM_article-title">Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6887</span>– <span class="NLM_lpage">6896</span>, <span class="refDoi"> DOI: 10.1021/jm401677g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401677g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Crt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6887-6896&author=C.+C.+Correllauthor=B.+A.+McKittrick&title=Biased+ligand+modulation+of+seven+transmembrane+receptors+%287TMRs%29%3A+functional+implications+for+drug+discovery&doi=10.1021%2Fjm401677g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligand Modulation of Seven Transmembrane Receptors (7TMRs): Functional Implications for Drug Discovery</span></div><div class="casAuthors">Correll, Craig C.; McKittrick, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6887-6896</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Seven transmembrane receptors (7TMRs), also known as G-protein-coupled receptors (GPCRs), have proven to be valuable targets for the development of therapeutics.  The expansion of our understanding of 7TMR downstream signaling pathways beyond G-proteins has broadened our appreciation of the versatility of these cell surface receptors.  In particular, the increased awareness of 7TMR engagement of β-arrestin signaling has opened up addnl. avenues for drug discovery.  7TMRs can adopt different conformations and in response to various ligands can lead to a bias in downstream signaling mechanisms when comparing the overall efficacy between G-protein and β-arrestin dependent pathways.  In 2012, we organized a session at the Spring National Meeting of the American Chem. Society on biased signaling in 7TMRs.  Building on that experience, we provide in this Miniperspective some examples that exemplify developments in the area of biased 7TMR signaling and highlight some cautionary notes as well as some of the exciting opportunities for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKS2Tnu19QArVg90H21EOLACvtfcHk0liSMCxlsKEi5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Crt7k%253D&md5=8fe16f8a57c68f2134ed15948ee67454</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm401677g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401677g%26sid%3Dliteratum%253Aachs%26aulast%3DCorrell%26aufirst%3DC.%2BC.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26atitle%3DBiased%2520ligand%2520modulation%2520of%2520seven%2520transmembrane%2520receptors%2520%25287TMRs%2529%253A%2520functional%2520implications%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6887%26epage%3D6896%26doi%3D10.1021%2Fjm401677g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Biased agonism: an emerging paradigm in GPCR drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmcl.2015.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26707396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKrur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=241-250&author=Z.+Rankovicauthor=T.+F.+Brustauthor=L.+M.+Bohn&title=Biased+agonism%3A+an+emerging+paradigm+in+GPCR+drug+discovery&doi=10.1016%2Fj.bmcl.2015.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Biased agonism: An emerging paradigm in GPCR drug discovery</span></div><div class="casAuthors">Rankovic, Zoran; Brust, Tarsis F.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-250</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein coupled receptors have historically been one of the most druggable classes of cellular proteins.  The members of this large receptor gene family couple to primary effectors, G proteins, that have built in mechanisms for regeneration and amplification of signaling with each engagement of receptor and ligand, a kinetic event in itself.  In recent years GPCRs, have been found to interact with arrestin proteins to initiate signal propagation in the absence of G protein interactions.  This pinnacle observation has changed a previously held notion of the linear spectrum of GPCR efficacy and uncovered a new paradigm in GPCR research and drug discovery that relies on multidimensionality of GPCR signaling.  Ligands were found that selectively confer activity in one pathway over another, and this phenomenon has been referred to as 'biased agonism' or 'functional selectivity'.  While great strides in the understanding of this phenomenon have been made in recent years, two crit. questions still dominate the field: How can we rationally design biased GPCR ligands, and ultimately, which physiol. responses are due to G protein vs. arrestin interactions.  This review will discuss the current understanding of some of the key aspects of biased signaling that are related to these questions, including mechanistic insights in the nature of biased signaling and methods for measuring ligand bias, as well as relevant examples of drug discovery applications and medicinal chem. strategies that highlight the challenges and opportunities in this rapidly evolving field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3Aj3zqZmKLVg90H21EOLACvtfcHk0liRohWAhwpoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKrur%252FL&md5=2e8612099c46749d9ce52b49086a8ef8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DBrust%26aufirst%3DT.%2BF.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBiased%2520agonism%253A%2520an%2520emerging%2520paradigm%2520in%2520GPCR%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D241%26epage%3D250%26doi%3D10.1016%2Fj.bmcl.2015.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bologna, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span> <span> </span><span class="NLM_article-title">Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2016.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.4062%2Fbiomolther.2016.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=12-25&author=Z.+Bolognaauthor=J.+P.+Teohauthor=A.+S.+Bayoumiauthor=Y.+Tangauthor=I.+M.+Kim&title=Biased+G+protein-coupled+receptor+signaling%3A+new+player+in+modulating+physiology+and+pathology&doi=10.4062%2Fbiomolther.2016.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology</span></div><div class="casAuthors">Bologna Zuzana; Teoh Jian-Peng; Bayoumi Ahmed S; Tang Yaoliang; Kim Il-Man; Kim Il-Man</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-25</span>
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are a family of cell-surface proteins that play critical roles in regulating a variety of pathophysiological processes and thus are targeted by almost a third of currently available therapeutics.  It was originally thought that GPCRs convert extracellular stimuli into intracellular signals through activating G proteins, whereas β-arrestins have important roles in internalization and desensitization of the receptor.  Over the past decade, several novel functional aspects of β-arrestins in regulating GPCR signaling have been discovered.  These previously unanticipated roles of β-arrestins to act as signal transducers and mediators of G protein-independent signaling have led to the concept of biased agonism.  Biased GPCR ligands are able to engage with their target receptors in a manner that preferentially activates only G protein- or β-arrestin-mediated downstream signaling.  This offers the potential for next generation drugs with high selectivity to therapeutically relevant GPCR signaling pathways.  In this review, we provide a summary of the recent studies highlighting G protein- or β-arrestin-biased GPCR signaling and the effects of biased ligands on disease pathogenesis and regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRshPzvVvIEzJVVjGoY74BafW6udTcc2eaB414xBwKb0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D&md5=7cfe8440b5d4e23b6c94d450662e8e54</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2016.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2016.165%26sid%3Dliteratum%253Aachs%26aulast%3DBologna%26aufirst%3DZ.%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DBayoumi%26aufirst%3DA.%2BS.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DI.%2BM.%26atitle%3DBiased%2520G%2520protein-coupled%2520receptor%2520signaling%253A%2520new%2520player%2520in%2520modulating%2520physiology%2520and%2520pathology%26jtitle%3DBiomol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D12%26epage%3D25%26doi%3D10.4062%2Fbiomolther.2016.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure-function of the G protein-coupled receptor superfamily</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-032112-135923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1146%2Fannurev-pharmtox-032112-135923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23140243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1Wgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=531-556&author=V.+Katritchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure-function+of+the+G+protein-coupled+receptor+superfamily&doi=10.1146%2Fannurev-pharmtox-032112-135923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function of the G protein-coupled receptor superfamily</span></div><div class="casAuthors">Katritch, Vsevolod; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">531-556</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  During the past few years, crystallog. of G protein-coupled receptors (GPCRs) has experienced exponential growth, resulting in the detn. of the structures of 16 distinct receptors-9 of them in 2012 alone.  Including closely related subtype homol. models, this coverage amts. to approx. 12% of the human GPCR superfamily.  The adrenergic, rhodopsin, and adenosine receptor systems are also described by agonist-bound active-state structures, including a structure of the receptor-G protein complex for the β2-adrenergic receptor.  Biochem. and biophys. techniques, such as NMR and hydrogen-deuterium exchange coupled with mass spectrometry, are providing complementary insights into ligand-dependent dynamic equil. between different functional states.  Addnl. details revealed by high-resoln. structures illustrate the receptors as allosteric machines that are controlled not only by ligands but also by ions, lipids, cholesterol, and water.  This wealth of data is helping redefine the authors' knowledge of how GPCRs recognize such a diverse array of ligands and how they transmit signals 30 angstroms across the cell membrane; it also is shedding light on a structural basis of GPCR allosteric modulation and biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUVW-rEZbvrVg90H21EOLACvtfcHk0liRohWAhwpoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1Wgurc%253D&md5=5e8c26100a9eb33a32755af09199138d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-032112-135923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-032112-135923%26sid%3Dliteratum%253Aachs%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure-function%2520of%2520the%2520G%2520protein-coupled%2520receptor%2520superfamily%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D53%26spage%3D531%26epage%3D556%26doi%3D10.1146%2Fannurev-pharmtox-032112-135923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Seven-transmembrane-spanning receptors and heart function</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1038/415206a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2F415206a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2002&pages=206-212&author=H.+A.+Rockmanauthor=W.+J.+Kochauthor=R.+J.+Lefkowitz&title=Seven-transmembrane-spanning+receptors+and+heart+function&doi=10.1038%2F415206a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F415206a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F415206a%26sid%3Dliteratum%253Aachs%26aulast%3DRockman%26aufirst%3DH.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSeven-transmembrane-spanning%2520receptors%2520and%2520heart%2520function%26jtitle%3DNature%26date%3D2002%26volume%3D415%26spage%3D206%26epage%3D212%26doi%3D10.1038%2F415206a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burghammer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnala, V. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanishvili, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischetti, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schertler, G. F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human β<sub>2</sub> adrenergic G-protein-coupled receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/nature06325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature06325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=17952055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=383-387&author=S.+G.+F.+Rasmussenauthor=H.+J.+Choiauthor=D.+M.+Rosenbaumauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=P.+C.+Edwardsauthor=M.+Burghammerauthor=V.+R.+P.+Ratnalaauthor=R.+Sanishviliauthor=R.+F.+Fischettiauthor=G.+F.+X.+Schertlerauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+human+%CE%B22+adrenergic+G-protein-coupled+receptor&doi=10.1038%2Fnature06325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human β2 adrenergic G-protein-coupled receptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Rosenbaum, Daniel M.; Kobilka, Tong Sun; Thian, Foon Sun; Edwards, Patricia C.; Burghammer, Manfred; Ratnala, Venkata R. P.; Sanishvili, Ruslan; Fischetti, Robert F.; Schertler, Gebhard F. X.; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7168</span>),
    <span class="NLM_cas:pages">383-387</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Structural anal. of G-protein-coupled receptors (GPCRs) for hormones and neurotransmitters has been hindered by their low natural abundance, inherent structural flexibility, and instability in detergent solns.  Here we report a structure of the human β2 adrenoceptor (β2AR), which was crystd. in a lipid environment when bound to an inverse agonist and in complex with a Fab that binds to the third intracellular loop.  Diffraction data were obtained by high-brilliance microcrystallog. and the structure detd. at 3.4 Å/3.7 Å resoln.  The cytoplasmic ends of the β2AR transmembrane segments and the connecting loops are well resolved, whereas the extracellular regions of the β2AR are not seen.  The β2AR structure differs from rhodopsin in having weaker interactions between the cytoplasmic ends of transmembrane (TM)3 and TM6, involving the conserved E/DRY sequences.  These differences may be responsible for the relatively high basal activity and structural instability of the β2AR, and contribute to the challenges in obtaining diffraction-quality crystals of non-rhodopsin GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTx0B_3Vn2M7Vg90H21EOLACvtfcHk0lj7PaF7F0GJtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N&md5=79026a0a69ddb4b0ea25063e409ad2cd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature06325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06325%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DBurghammer%26aufirst%3DM.%26aulast%3DRatnala%26aufirst%3DV.%2BR.%2BP.%26aulast%3DSanishvili%26aufirst%3DR.%26aulast%3DFischetti%26aufirst%3DR.%2BF.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520%25CE%25B22%2520adrenergic%2520G-protein-coupled%2520receptor%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D383%26epage%3D387%26doi%3D10.1038%2Fnature06325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">High-resolution crystal structure of an engineered human β<sub>2</sub>-adrenergic G protein-coupled receptor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1126/science.1150577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258-1265&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+F.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.+J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-resolution+crystal+structure+of+an+engineered+human+%CE%B22-adrenergic+G+protein-coupled+receptor&doi=10.1126%2Fscience.1150577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the β2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human β2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the β2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0lj7PaF7F0GJtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520an%2520engineered%2520human%2520%25CE%25B22-adrenergic%2520G%2520protein-coupled%2520receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26epage%3D1265%26doi%3D10.1126%2Fscience.1150577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-biased agonism at the β<sub>2</sub>-adrenergic receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">5669</span>– <span class="NLM_lpage">5676</span>, <span class="refDoi"> DOI: 10.1074/jbc.M708118200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M708118200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=5669-5676&author=M.+T.+Drakeauthor=J.+D.+Violinauthor=E.+J.+Whalenauthor=J.+W.+Wislerauthor=S.+K.+Shenoyauthor=R.+J.+Lefkowitz&title=%CE%B2-Arrestin-biased+agonism+at+the+%CE%B22-adrenergic+receptor&doi=10.1074%2Fjbc.M708118200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708118200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708118200%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DM.%2BT.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DWisler%26aufirst%3DJ.%2BW.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3D%25CE%25B2-Arrestin-biased%2520agonism%2520at%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D5669%26epage%3D5676%26doi%3D10.1074%2Fjbc.M708118200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakaya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyanagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohdo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, H.</span></span> <span> </span><span class="NLM_article-title">Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent signaling pathways</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">35669</span>– <span class="NLM_lpage">35677</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.357871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M112.357871" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=35669-35677&author=M.+Nakayaauthor=S.+Chikuraauthor=K.+Watariauthor=N.+Mizunoauthor=K.+Mochinagaauthor=S.+Mangmoolauthor=S.+Koyanagiauthor=S.+Ohdoauthor=Y.+Satoauthor=T.+Ideauthor=M.+Nishidaauthor=H.+Kurose&title=Induction+of+cardiac+fibrosis+by+%CE%B2-blocker+in+G+protein-independent+and+G+protein-coupled+receptor+kinase+5%2F%CE%B2-arrestin2-dependent+signaling+pathways&doi=10.1074%2Fjbc.M112.357871"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.357871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.357871%26sid%3Dliteratum%253Aachs%26aulast%3DNakaya%26aufirst%3DM.%26aulast%3DChikura%26aufirst%3DS.%26aulast%3DWatari%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DN.%26aulast%3DMochinaga%26aufirst%3DK.%26aulast%3DMangmool%26aufirst%3DS.%26aulast%3DKoyanagi%26aufirst%3DS.%26aulast%3DOhdo%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DIde%26aufirst%3DT.%26aulast%3DNishida%26aufirst%3DM.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DInduction%2520of%2520cardiac%2520fibrosis%2520by%2520%25CE%25B2-blocker%2520in%2520G%2520protein-independent%2520and%2520G%2520protein-coupled%2520receptor%2520kinase%25205%252F%25CE%25B2-arrestin2-dependent%2520signaling%2520pathways%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D35669%26epage%3D35677%26doi%3D10.1074%2Fjbc.M112.357871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">14555</span>– <span class="NLM_lpage">14560</span>, <span class="refDoi"> DOI: 10.1073/pnas.0804745105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0804745105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=14555-14560&author=I.+M.+Kimauthor=D.+G.+Tilleyauthor=J.+Chenauthor=N.+C.+Salazarauthor=E.+J.+Whalenauthor=J.+D.+Violinauthor=H.+A.+Rockman&title=%CE%B2-Blockers+alprenolol+and+carvedilol+stimulate+%CE%B2-arrestin-mediated+EGFR+transactivation&doi=10.1073%2Fpnas.0804745105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0804745105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0804745105%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%2BM.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSalazar%26aufirst%3DN.%2BC.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-Blockers%2520alprenolol%2520and%2520carvedilol%2520stimulate%2520%25CE%25B2-arrestin-mediated%2520EGFR%2520transactivation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D14555%26epage%3D14560%26doi%3D10.1073%2Fpnas.0804745105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">16657</span>– <span class="NLM_lpage">16662</span>, <span class="refDoi"> DOI: 10.1073/pnas.0707936104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0707936104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=16657-16662&author=J.+W.+Wislerauthor=S.+M.+DeWireauthor=E.+J.+Whalenauthor=J.+D.+Violinauthor=M.+T.+Drakeauthor=S.+Ahnauthor=S.+K.+Shenoyauthor=R.+J.+Lefkowitz&title=A+unique+mechanism+of+%CE%B2-blocker+action%3A+carvedilol+stimulates+%CE%B2-arrestin+signaling&doi=10.1073%2Fpnas.0707936104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0707936104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0707936104%26sid%3Dliteratum%253Aachs%26aulast%3DWisler%26aufirst%3DJ.%2BW.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDrake%26aufirst%3DM.%2BT.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520unique%2520mechanism%2520of%2520%25CE%25B2-blocker%2520action%253A%2520carvedilol%2520stimulates%2520%25CE%25B2-arrestin%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D16657%26epage%3D16662%26doi%3D10.1073%2Fpnas.0707936104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohout, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineyro, G.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">11406</span>– <span class="NLM_lpage">11411</span>, <span class="refDoi"> DOI: 10.1073/pnas.1936664100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1936664100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11406-11411&author=M.+Azziauthor=P.+G.+Charestauthor=S.+Angersauthor=G.+Rousseauauthor=T.+Kohoutauthor=M.+Bouvierauthor=G.+Pineyro&title=%CE%B2-Arrestin-mediated+activation+of+MAPK+by+inverse+agonists+reveals+distinct+active+conformations+for+G+protein-coupled+receptors&doi=10.1073%2Fpnas.1936664100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1936664100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1936664100%26sid%3Dliteratum%253Aachs%26aulast%3DAzzi%26aufirst%3DM.%26aulast%3DCharest%26aufirst%3DP.%2BG.%26aulast%3DAngers%26aufirst%3DS.%26aulast%3DRousseau%26aufirst%3DG.%26aulast%3DKohout%26aufirst%3DT.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DPineyro%26aufirst%3DG.%26atitle%3D%25CE%25B2-Arrestin-mediated%2520activation%2520of%2520MAPK%2520by%2520inverse%2520agonists%2520reveals%2520distinct%2520active%2520conformations%2520for%2520G%2520protein-coupled%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D11406%26epage%3D11411%26doi%3D10.1073%2Fpnas.1936664100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuthrich, K.</span></span> <span> </span><span class="NLM_article-title">Biased signaling pathways in β<sub>2</sub>-adrenergic receptor characterized by <sup>19</sup>F-NMR</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">1106</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1126/science.1215802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1215802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22267580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGhtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2012&pages=1106-1110&author=J.+J.+Liuauthor=R.+Horstauthor=V.+Katritchauthor=R.+C.+Stevensauthor=K.+Wuthrich&title=Biased+signaling+pathways+in+%CE%B22-adrenergic+receptor+characterized+by+19F-NMR&doi=10.1126%2Fscience.1215802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR</span></div><div class="casAuthors">Liu, Jeffrey J.; Horst, Reto; Katritch, Vsevolod; Stevens, Raymond C.; Wuethrich, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">6072</span>),
    <span class="NLM_cas:pages">1106-1110</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Extracellular ligand binding to G protein-coupled receptors (GPCRs) modulates G protein and β-arrestin signaling by changing the conformational states of the cytoplasmic region of the receptor.  Using site-specific 19F-NMR (fluorine-19 NMR) labels in the β2-adrenergic receptor (β2AR) in complexes with various ligands, we obsd. that the cytoplasmic ends of helixes VI and VII adopt two major conformational states.  Changes in the NMR signals reveal that agonist binding primarily shifts the equil. toward the G protein-specific active state of helix VI.  In contrast, β-arrestin-biased ligands predominantly impact the conformational states of helix VII.  The selective effects of different ligands on the conformational equil. involving helixes VI and VII provide insights into the long-range structural plasticity of β2AR in partial and biased agonist signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5pzYJjjhMLVg90H21EOLACvtfcHk0lj7HKQcuz-NyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGhtrs%253D&md5=abae5755ddcacf42a029e7fd0dd4fdc9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.1215802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1215802%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DHorst%26aufirst%3DR.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWuthrich%26aufirst%3DK.%26atitle%3DBiased%2520signaling%2520pathways%2520in%2520%25CE%25B22-adrenergic%2520receptor%2520characterized%2520by%252019F-NMR%26jtitle%3DScience%26date%3D2012%26volume%3D335%26spage%3D1106%26epage%3D1110%26doi%3D10.1126%2Fscience.1215802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span> <span> </span><span class="NLM_article-title">Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.173005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.110.173005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20801892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=572-579&author=J.+D.+Violinauthor=S.+M.+DeWireauthor=D.+Yamashitaauthor=D.+H.+Romingerauthor=L.+Nguyenauthor=K.+Schillerauthor=E.+J.+Whalenauthor=M.+Gowenauthor=M.+W.+Lark&title=Selectively+engaging+%CE%B2-arrestins+at+the+angiotensin+II+type+1+receptor+reduces+blood+pressure+and+increases+cardiac+performance&doi=10.1124%2Fjpet.110.173005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance</span></div><div class="casAuthors">Violin, Jonathan D.; DeWire, Scott M.; Yamashita, Dennis; Rominger, David H.; Nguyen, Lisa; Schiller, Kevin; Whalen, Erin J.; Gowen, Maxine; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-579</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biased G protein-coupled ligands engage subsets of the receptor signals normally stimulated by unbiased agonists.  However, it is unclear whether ligand bias can elicit differentiated pharmacol. in vivo.  Here, we describe the discovery of a potent, selective β-arrestin biased ligand of the angiotensin II type 1 receptor.  TRV 120027 (Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH) competitively antagonizes angiotensin II-stimulated G protein signaling, but stimulates β-arrestin recruitment and activates several kinase pathways, including p42/44 mitogen-activated protein kinase, Src, and endothelial nitric-oxide synthase phosphorylation via β-arrestin coupling.  Consistent with β-arrestin efficacy, and unlike unbiased antagonists, TRV 120027 increased cardiomyocyte contractility in vitro.  In rats, TRV 120027 reduced mean arterial pressure, as did the unbiased antagonists losartan and telmisartan.  However, unlike the unbiased antagonists, which decreased cardiac performance, TRV 120027 increased cardiac performance and preserved cardiac stroke vol.  These striking differences in vivo between unbiased and β-arrestin biased ligands validate the use of biased ligands to selectively target specific receptor functions in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaaai_REGvbVg90H21EOLACvtfcHk0lj7HKQcuz-NyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF&md5=a896363e71830f706b103d8153c97f83</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173005%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DGowen%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DSelectively%2520engaging%2520%25CE%25B2-arrestins%2520at%2520the%2520angiotensin%2520II%2520type%25201%2520receptor%2520reduces%2520blood%2520pressure%2520and%2520increases%2520cardiac%2520performance%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D572%26epage%3D579%26doi%3D10.1124%2Fjpet.110.173005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">10782</span>– <span class="NLM_lpage">10787</span>, <span class="refDoi"> DOI: 10.1073/pnas.1834556100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1834556100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=12949261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslyntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=10782-10787&author=H.+J.+Weiauthor=S.+Ahnauthor=S.+K.+Shenoyauthor=S.+S.+Karnikauthor=L.+Hunyadyauthor=L.+M.+Luttrellauthor=R.+J.+Lefkowitz&title=Independent+%CE%B2-arrestin+2+and+G+protein-mediated+pathways+for+angiotensin+II+activation+of+extracellular+signal-regulated+kinases+1+and+2&doi=10.1073%2Fpnas.1834556100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2</span></div><div class="casAuthors">Wei, Huijun; Ahn, Seungkirl; Shenoy, Sudha K.; Karnik, Sadashiva S.; Hunyady, Laszlo; Luttrell, Louis M.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10782-10787</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Stimulation of a mutant angiotensin type 1A receptor (DRY/AAY) with angiotensin II (Ang II) or of a wild-type receptor with an Ang II analog ([sarcosine1,Ile4,Ile8]Ang II) fails to activate classical heterotrimeric G protein signaling but does lead to recruitment of β-arrestin 2-GFP and activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (max. stimulation ≈50% of wild type).  This G protein-independent activation of mitogen-activated protein kinase is abolished by depletion of cellular β-arrestin 2 but is unaffected by the PKC inhibitor Ro-31-8425.  In parallel, stimulation of the wild-type angiotensin type 1A receptor with Ang II robustly stimulates ERK1/2 activation with ≈60% of the response blocked by the PKC inhibitor (G protein dependent) and the rest of the response blocked by depletion of cellular β-arrestin 2 by small interfering RNA (β-arrestin dependent).  These findings imply the existence of independent G protein- and β-arrestin 2-mediated pathways leading to ERK1/2 activation and the existence of distinct "active" conformations of a seven-membrane-spanning receptor coupled to each.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYG_kDWRPMAbVg90H21EOLACvtfcHk0lj7HKQcuz-NyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslyntrk%253D&md5=48f0fc02a5f4f7e2616170788a26aa23</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1834556100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1834556100%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DH.%2BJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DKarnik%26aufirst%3DS.%2BS.%26aulast%3DHunyady%26aufirst%3DL.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DIndependent%2520%25CE%25B2-arrestin%25202%2520and%2520G%2520protein-mediated%2520pathways%2520for%2520angiotensin%2520II%2520activation%2520of%2520extracellular%2520signal-regulated%2520kinases%25201%2520and%25202%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D10782%26epage%3D10787%26doi%3D10.1073%2Fpnas.1834556100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teerlink, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharucha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felker, G. M.</span></span> <span> </span><span class="NLM_article-title">Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2364</span>– <span class="NLM_lpage">2373</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehx196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1093%2Feurheartj%2Fehx196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28459958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFGksbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=2364-2373&author=P.+S.+Pangauthor=J.+Butlerauthor=S.+P.+Collinsauthor=G.+Cotterauthor=B.+A.+Davisonauthor=J.+A.+Ezekowitzauthor=G.+Filippatosauthor=P.+D.+Levyauthor=M.+Metraauthor=P.+Ponikowskiauthor=J.+R.+Teerlinkauthor=A.+A.+Voorsauthor=D.+Bharuchaauthor=K.+Goinauthor=D.+G.+Soergelauthor=G.+M.+Felker&title=Biased+ligand+of+the+angiotensin+II+type+1+receptor+in+patients+with+acute+heart+failure%3A+a+randomized%2C+double-blind%2C+placebo-controlled%2C+phase+IIB%2C+dose+ranging+trial+%28BLAST-AHF%29&doi=10.1093%2Feurheartj%2Fehx196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)</span></div><div class="casAuthors">Pang, Peter S.; Butler, Javed; Collins, Sean P.; Cotter, Gad; Davison, Beth A.; Ezekowitz, Justin A.; Filippatos, Gerasimos; Levy, Phillip D.; Metra, Marco; Ponikowski, Piotr; Teerlink, John R.; Voors, Adriaan A.; Bharucha, David; Goin, Kathleen; Soergel, David G.; Michael Felker, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">2364-2373</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">1522-9645</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Currently, no acute heart failure (AHF) therapy definitively improves outcomes.  Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need.  TRV027 is a novel 'biased' ligand of the angiotensin II type 1 receptor (AT1R), selectively antagonizing the neg. effects of angiotensin II, while preserving the potential procontractility effects of AT1R stimulation.  BLAST-AHF was designed to det. the safety, efficacy, and opti- mal dose of TRV027 to advance into future studies.  Methods and results: BLAST-AHF was a multi-center, international, randomized, double-blind, placebo-controlled, parallel group, phase IIb dose-ranging study, enrolling patients with AHF into 4 groups: placebo, 1, 5, or 25 mg/h of TRV027.  Treatment was by IV infusion for 48-96 h.  The primary composite endpoint was comprised of the following: (i) time from baseline to death through day 30, (ii) time from baseline to heart failure re-hospitalization through day 30, (iii) the first assessment time point following worsening heart failure through day 5, (iv) change in dyspnea visual analog scale (VAS) score calcd. as the area under the curve (AUC) representing the change from baseline over time from baseline through day 5, and (v) length of initial hospital stay (in days) from baseline.  Analyses were by modified intention-to-treat.  Overall, 621 patients were enrolled.  After 254 patients, a pre-specified interim anal. resulted in several protocol changes, including a lower blood pressure inclusion criterion as well as a new allocation scheme of 2:1:2:1, overweighting both placebo, and the 5 mg/h dose.  TRV027 did not confer any benefit over placebo at any dose with regards to the primary composite endpoint or any of the individual components.  There were no significant safety issues with TRV027.  Conclusion: In this phase IIb dose-ranging AHF study, TRV027 did not improve clin. status through 30-day follow-up compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogmz48ioAiJ7Vg90H21EOLACvtfcHk0ljmGN350HPDSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFGksbvO&md5=62e28c6fa244809d87e52d8f979ce629</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehx196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehx196%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DS.%2BP.%26aulast%3DCotter%26aufirst%3DG.%26aulast%3DDavison%26aufirst%3DB.%2BA.%26aulast%3DEzekowitz%26aufirst%3DJ.%2BA.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLevy%26aufirst%3DP.%2BD.%26aulast%3DMetra%26aufirst%3DM.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DTeerlink%26aufirst%3DJ.%2BR.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DBharucha%26aufirst%3DD.%26aulast%3DGoin%26aufirst%3DK.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DFelker%26aufirst%3DG.%2BM.%26atitle%3DBiased%2520ligand%2520of%2520the%2520angiotensin%2520II%2520type%25201%2520receptor%2520in%2520patients%2520with%2520acute%2520heart%2520failure%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%2520IIB%252C%2520dose%2520ranging%2520trial%2520%2528BLAST-AHF%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2017%26volume%3D38%26spage%3D2364%26epage%3D2373%26doi%3D10.1093%2Feurheartj%2Fehx196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, P. P.</span></span> <span> </span><span class="NLM_article-title">Relationship between improvements in long term outcomes and baseline systolic blood pressure in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">Suppl. S1</span>),  <span class="NLM_fpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=36&issue=Suppl.+S1&author=G.+Cotterauthor=P.+P.+Pang&title=Relationship+between+improvements+in+long+term+outcomes+and+baseline+systolic+blood+pressure+in+acute+heart+failure+patients+treated+with+TRV027%3A+an+exploratory+subgroup+analysis+of+BLAST-AHF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCotter%26aufirst%3DG.%26aulast%3DPang%26aufirst%3DP.%2BP.%26atitle%3DRelationship%2520between%2520improvements%2520in%2520long%2520term%2520outcomes%2520and%2520baseline%2520systolic%2520blood%2520pressure%2520in%2520acute%2520heart%2520failure%2520patients%2520treated%2520with%2520TRV027%253A%2520an%2520exploratory%2520subgroup%2520analysis%2520of%2520BLAST-AHF%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2017%26volume%3D19%26issue%3DSuppl.%2520S1%26spage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felker, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teerlink, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharucha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, P. S.</span></span> <span> </span><span class="NLM_article-title">Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF</span>. <i>Clin. Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">170</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1007/s00392-017-1168-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs00392-017-1168-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28986703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FmtFOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2018&pages=170-181&author=G.+Cotterauthor=B.+A.+Davisonauthor=J.+Butlerauthor=S.+P.+Collinsauthor=J.+A.+Ezekowitzauthor=G.+M.+Felkerauthor=G.+Filippatosauthor=P.+D.+Levyauthor=M.+Metraauthor=P.+Ponikowskiauthor=J.+R.+Teerlinkauthor=A.+A.+Voorsauthor=S.+Sengerauthor=D.+Bharuchaauthor=K.+Goinauthor=D.+G.+Soergelauthor=P.+S.+Pang&title=Relationship+between+baseline+systolic+blood+pressure+and+long-term+outcomes+in+acute+heart+failure+patients+treated+with+TRV027%3A+an+exploratory+subgroup+analysis+of+BLAST-AHF&doi=10.1007%2Fs00392-017-1168-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF</span></div><div class="casAuthors">Cotter Gad; Davison Beth A; Senger Stefanie; Butler Javed; Collins Sean P; Ezekowitz Justin A; Felker G Michael; Filippatos Gerasimos; Levy Phillip D; Metra Marco; Ponikowski Piotr; Teerlink John R; Voors Adriaan A; Bharucha David; Goin Kathleen; Soergel David G; Pang Peter S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical research in cardiology : official journal of the German Cardiac Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  TRV027, a 'biased' ligand of the angiotensin II type 1 receptor (AT1R), did not affect a composite clinical outcome at 30 days in a phase 2b acute heart failure (AHF) trial (BLAST-AHF).  METHODS:  Post-hoc analyses from BLAST-AHF (n = 618) examined the effects of TRV027 by baseline systolic blood pressure (SBP) on changes in renal function and 180-day outcomes.  Interactions between baseline SBP and select endpoints were identified utilizing a subpopulation treatment effect pattern plots (STEPP) analysis, then grouping of patients by SBP tertile: < 127, ≥ 127 to < 140, and ≥ 140 mmHg.  RESULTS:  A trend towards increased creatinine in the first 3 days was noted in the lower SBP tertile, while in those in the higher two tertiles, TRV027, especially the 1 mg/h dose, reduced creatinine at days 5 and 30.  Beneficial effects on 180-day all-cause mortality and cardiovascular (CV) death or readmission were observed in the two higher SBP tertiles (SBP ≥ 127 mmHg) in the TRV027 1 mg/h dose group (all-cause mortality HR 0.39, 95% CI 0.14-1.06, p = 0.056; CV death or HF/RF rehospitalization HR 0.53, 95% CI 0.28-1.01, p = 0.049), while more adverse outcomes were observed in patients in the lower SBP tertile.  CONCLUSIONS:  This post-hoc analysis of the BLAST-AHF study suggests contrasting effects of TRV027 by baseline SBP, with trends towards lower 180-day event rates in patients enrolled with higher baseline SBP, especially when given lower doses of TRV027.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVx3wC5R7hFBgd2Wuil24tfW6udTcc2eZ4jCVjaa097bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FmtFOgtQ%253D%253D&md5=451991132f97da98640e0ab6788ba182</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00392-017-1168-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00392-017-1168-0%26sid%3Dliteratum%253Aachs%26aulast%3DCotter%26aufirst%3DG.%26aulast%3DDavison%26aufirst%3DB.%2BA.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DS.%2BP.%26aulast%3DEzekowitz%26aufirst%3DJ.%2BA.%26aulast%3DFelker%26aufirst%3DG.%2BM.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLevy%26aufirst%3DP.%2BD.%26aulast%3DMetra%26aufirst%3DM.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DTeerlink%26aufirst%3DJ.%2BR.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DSenger%26aufirst%3DS.%26aulast%3DBharucha%26aufirst%3DD.%26aulast%3DGoin%26aufirst%3DK.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DPang%26aufirst%3DP.%2BS.%26atitle%3DRelationship%2520between%2520baseline%2520systolic%2520blood%2520pressure%2520and%2520long-term%2520outcomes%2520in%2520acute%2520heart%2520failure%2520patients%2520treated%2520with%2520TRV027%253A%2520an%2520exploratory%2520subgroup%2520analysis%2520of%2520BLAST-AHF%26jtitle%3DClin.%2520Res.%2520Cardiol.%26date%3D2018%26volume%3D107%26spage%3D170%26epage%3D181%26doi%3D10.1007%2Fs00392-017-1168-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-T.</span></span> <span> </span><span class="NLM_article-title">Enhanced morphine analgesia in mice lacking β-arrestin 2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">2495</span>– <span class="NLM_lpage">2498</span>, <span class="refDoi"> DOI: 10.1126/science.286.5449.2495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.286.5449.2495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10617462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVKg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=2495-2498&author=L.+M.+Bohnauthor=R.+J.+Lefkowitzauthor=R.+R.+Gainetdinovauthor=K.+Peppelauthor=M.+G.+Caronauthor=F.-T.+Lin&title=Enhanced+morphine+analgesia+in+mice+lacking+%CE%B2-arrestin+2&doi=10.1126%2Fscience.286.5449.2495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced morphine analgesia in mice lacking β-arrestin 2</span></div><div class="casAuthors">Bohn, Laura M.; Lefkowitz, Robert J.; Gainetdinov, Raul R.; Peppel, Karsten; Caron, Marc G.; Lin, Fang-Tsyr</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5449</span>),
    <span class="NLM_cas:pages">2495-2498</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The ability of morphine to alleviate pain is mediated through a heterotrimeric guanine nucleotide binding protein (G protein)-coupled heptahelical receptor (GPCR), the μ opioid receptor (μOR).  The efficiency of GPCR signaling is tightly regulated and ultimately limited by the coordinated phosphorylation of the receptors by specific GPCR kinases and the subsequent interaction of the phosphorylated receptors with β-arrestin 1 and β-arrestin 2.  Functional deletion of the β-arrestin 2 gene in mice resulted in remarkable potentiation and prolongation of the analgesic effect of morphine, suggesting that μOR desensitization was impaired.  These results provide evidence in vivo for the physiol. importance of β-arrestin 2 in regulating the function of a specific GPCR, the μOR.  Moreover, they suggest that inhibition of β-arrestin 2 function might lead to enhanced analgesic effectiveness of morphine and provide potential new avenues for the study and treatment of pain, narcotic tolerance, and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSeiDXvYdnz7Vg90H21EOLACvtfcHk0lhH1updyHpBeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVKg&md5=95f67b133e86422f385d1a7f8165d772</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5449.2495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5449.2495%26sid%3Dliteratum%253Aachs%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DPeppel%26aufirst%3DK.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLin%26aufirst%3DF.-T.%26atitle%3DEnhanced%2520morphine%2520analgesia%2520in%2520mice%2520lacking%2520%25CE%25B2-arrestin%25202%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D2495%26epage%3D2498%26doi%3D10.1126%2Fscience.286.5449.2495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raehal, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Morphine side effects in β-arrestin 2 knockout mice</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.087254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.105.087254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=15917400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=1195-1201&author=K.+M.+Raehalauthor=J.+K.+L.+Walkerauthor=L.+M.+Bohn&title=Morphine+side+effects+in+%CE%B2-arrestin+2+knockout+mice&doi=10.1124%2Fjpet.105.087254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Morphine side effects in β-arrestin 2 knockout mice</span></div><div class="casAuthors">Raehal, Kirsten M.; Walker, Julia K. L.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1195-1201</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Morphine is a potent analgesic, yet, like most opioid narcotics, it exerts unwanted side effects such as constipation and respiratory suppression, thereby limiting its clin. utility.  Pharmacol. approaches taken to preserve the analgesic properties, while eliminating the unwanted side effects, have met with very limited success.  Here, we provide evidence that altering μ opioid receptor regulation may provide a novel approach to discriminate morphine's beneficial and deleterious effects in vivo.  We have previously reported that mice lacking the G protein-coupled receptor regulatory protein, β-arrestin 2, display profoundly altered morphine responses.  β-Arrestin 2 knockout mice have enhanced and prolonged morphine analgesia with very little morphine tolerance.  In this report, we examine whether the side effects of morphine treatment are also augmented in this animal model.  Surprisingly, the genetic disruption of opioid receptor regulation, while enhancing and prolonging analgesia, dramatically attenuates the respiratory suppression and acute constipation caused by morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGg-s6s4R0F7Vg90H21EOLACvtfcHk0lhH1updyHpBeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsLw%253D&md5=0d3696e563ae3a6f6ce2cb2570cbb890</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.087254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.087254%26sid%3Dliteratum%253Aachs%26aulast%3DRaehal%26aufirst%3DK.%2BM.%26aulast%3DWalker%26aufirst%3DJ.%2BK.%2BL.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DMorphine%2520side%2520effects%2520in%2520%25CE%25B2-arrestin%25202%2520knockout%2520mice%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D1195%26epage%3D1201%26doi%3D10.1124%2Fjpet.105.087254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9<i>R</i>)-9-(pyridin-2-yl)-6- oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&author=X.+T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+Dewireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure-activity+relationships+and+discovery+of+a+G+protein+biased+%CE%BC+opioid+receptor+ligand%2C+%5B%283-methoxythiophen-2-yl%29methyl%5D%28%7B2-%5B%289R%29-9-%28pyridin-2-yl%29-6-+oxaspiro-%5B4.5%5Ddecan-+9-yl%5Dethyl%7D%29amine+%28TRV130%29%2C+for+the+treatment+of+acute+severe+pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDewire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure-activity%2520relationships%2520and%2520discovery%2520of%2520a%2520G%2520protein%2520biased%2520%25CE%25BC%2520opioid%2520receptor%2520ligand%252C%2520%255B%25283-methoxythiophen-2-yl%2529methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528pyridin-2-yl%2529-6-%2520oxaspiro-%255B4.5%255Ddecan-%25209-yl%255Dethyl%257D%2529amine%2520%2528TRV130%2529%252C%2520for%2520the%2520treatment%2520of%2520acute%2520severe%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masic, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolenc, M. S.</span></span> <span> </span><span class="NLM_article-title">Bioactivation potential of thiophene-containing drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1344</span>– <span class="NLM_lpage">1358</span>, <span class="refDoi"> DOI: 10.1021/tx500134g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500134g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFelurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=1344-1358&author=D.+Gramecauthor=L.+P.+Masicauthor=M.+S.+Dolenc&title=Bioactivation+potential+of+thiophene-containing+drugs&doi=10.1021%2Ftx500134g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation Potential of Thiophene-Containing Drugs</span></div><div class="casAuthors">Gramec, Darja; Peterlin Masic, Lucija; Sollner Dolenc, Marija</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1344-1358</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Thiophene is a five-membered, sulfur-contg. heteroarom. ring commonly used as a building block in drugs.  It is considered to be a structural alert, as its metab. can lead to the formation of reactive metabolites.  Thiophene S-oxides and thiophene epoxides are highly reactive electrophilic thiophene metabolites whose formation is cytochrome P 450-dependent.  These reactive thiophene-based metabolites are quite often responsible for drug-induced hepatotoxicity.  Tienilic acid is an example of a thiophene-based drug that was withdrawn from the market after only a few months of use, due to severe cases of immune hepatitis.  However, inclusion of the thiophene moiety in drugs does not necessarily result in toxic effects.  The presence of other, less toxic metabolic pathways, as well as an effective detoxification system in our body, protects us from the bioactivation potential of the thiophene ring.  Thus, the presence of a structural alert itself is insufficient to predict a compd.'s toxicity.  The question therefore arises as to which factors significantly influence the toxicity of thiophene-contg. drugs.  There is no easy way to answer this question.  However, the findings presented here indicate that, for a no. of reasons, daily dose and alternative metabolic pathways are important factors when predicting toxicity and will therefore be discussed together with examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0KnyHFkaMsrVg90H21EOLACvtfcHk0lhHP88BSLcDJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFelurjL&md5=65733d5665c8ac67050a60707a2e828b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx500134g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500134g%26sid%3Dliteratum%253Aachs%26aulast%3DGramec%26aufirst%3DD.%26aulast%3DMasic%26aufirst%3DL.%2BP.%26aulast%3DDolenc%26aufirst%3DM.%2BS.%26atitle%3DBioactivation%2520potential%2520of%2520thiophene-containing%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D1344%26epage%3D1358%26doi%3D10.1021%2Ftx500134g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graczyk, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.112.201616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23300227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=708-717&author=S.+M.+DeWireauthor=D.+S.+Yamashitaauthor=D.+H.+Romingerauthor=G.+Liuauthor=C.+L.+Cowanauthor=T.+M.+Graczykauthor=X.+T.+Chenauthor=P.+M.+Pitisauthor=D.+Gotchevauthor=C.+Yuanauthor=M.+Koblishauthor=M.+W.+Larkauthor=J.+D.+Violin&title=A+G+protein-biased+ligand+at+the+%CE%BC-opioid+receptor+is+potently+analgesic+with+reduced+gastrointestinal+and+respiratory+dysfunction+compared+with+morphine&doi=10.1124%2Fjpet.112.201616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span></div><div class="casAuthors">DeWire, Scott M.; Yamashita, Dennis S.; Rominger, David H.; Liu, Guodong; Cowan, Conrad L.; Graczyk, Thomas M.; Chen, Xiao-Tao; Pitis, Philip M.; Gotchev, Dimitar; Yuan, Catherine; Koblish, Michael; Lark, Michael W.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics.  Morphine pharmacol. in β-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the μ-opioid receptor (MOR) to G proteins, but not β-arrestins, would result in higher analgesic efficacy, less gastrointestinal dysfunction, and less respiratory suppression than morphine.  Here we report the discovery of TRV130 ([(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine), a novel MOR G protein-biased ligand.  In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization.  In mice and rats, TRV130 is potently analgesic while causing less gastrointestinal dysfunction and respiratory suppression than morphine at equianalgesic doses.  TRV130 successfully translates evidence that analgesic and adverse MOR signaling pathways are distinct into a biased ligand with differentiated pharmacol.  These preclin. data suggest that TRV130 may be a safer and more tolerable therapeutic for treating severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3tTP2BOOKrVg90H21EOLACvtfcHk0lhHP88BSLcDJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D&md5=33a685cd1952dd9cb1fb82afe78452af</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201616%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DGraczyk%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%2BM.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520G%2520protein-biased%2520ligand%2520at%2520the%2520%25CE%25BC-opioid%2520receptor%2520is%2520potently%2520analgesic%2520with%2520reduced%2520gastrointestinal%2520and%2520respiratory%2520dysfunction%2520compared%2520with%2520morphine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D708%26epage%3D717%26doi%3D10.1124%2Fjpet.112.201616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aryal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of opioid analgesics with reduced side effects</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=X.-P.+Huangauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Daauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Structure-based+discovery+of+opioid+analgesics+with+reduced+side+effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0lhHP88BSLcDJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDa%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-based%2520discovery%2520of%2520opioid%2520analgesics%2520with%2520reduced%2520side%2520effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiesen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the μ-opioid receptor bound to a morphinan antagonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1038/nature10954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature10954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22437502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=321-326&author=A.+Manglikauthor=A.+C.+Kruseauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=J.+M.+Mathiesenauthor=R.+K.+Sunaharaauthor=L.+Pardoauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=S.+Granier&title=Crystal+structure+of+the+%CE%BC-opioid+receptor+bound+to+a+morphinan+antagonist&doi=10.1038%2Fnature10954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the μ-opioid receptor bound to a morphinan antagonist</span></div><div class="casAuthors">Manglik, Aashish; Kruse, Andrew C.; Kobilka, Tong Sun; Thian, Foon Sun; Mathiesen, Jesper M.; Sunahara, Roger K.; Pardo, Leonardo; Weis, William I.; Kobilka, Brian K.; Granier, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7398</span>),
    <span class="NLM_cas:pages">321-326</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opium is one of the world's oldest drugs, and its derivs. morphine and codeine are among the most used clin. drugs to relieve severe pain.  These prototypical opioids produce analgesia as well as many undesirable side effects (sedation, apnea and dependence) by binding to and activating the G-protein-coupled μ-opioid receptor (μ-OR) in the central nervous system.  Here the authors describe the 2.8 Å crystal structure of the mouse μ-OR in complex with an irreversible morphinan antagonist.  Compared to the buried binding pocket obsd. in most G-protein-coupled receptors published so far, the morphinan ligand binds deeply within a large solvent-exposed pocket.  Of particular interest, the μ-OR crystallizes as a two-fold sym. dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6.  These high-resoln. insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2q4tys639jrVg90H21EOLACvtfcHk0ljd0v0DKTfwIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D&md5=563d5ebda53f9a408be21d60a7e5a97d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnature10954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10954%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGranier%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520%25CE%25BC-opioid%2520receptor%2520bound%2520to%2520a%2520morphinan%2520antagonist%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D321%26epage%3D326%26doi%3D10.1038%2Fnature10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conibear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, G.</span></span> <span> </span><span class="NLM_article-title">The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2653</span>– <span class="NLM_lpage">2661</span>, <span class="refDoi"> DOI: 10.1111/bph.14224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fbph.14224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29582414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2653-2661&author=R.+Hillauthor=A.+Disneyauthor=A.+Conibearauthor=K.+Sutcliffeauthor=W.+Deweyauthor=S.+Husbandsauthor=C.+Baileyauthor=E.+Kellyauthor=G.+Henderson&title=The+novel+%CE%BC-opioid+receptor+agonist+PZM21+depresses+respiration+and+induces+tolerance+to+antinociception&doi=10.1111%2Fbph.14224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception</span></div><div class="casAuthors">Hill, Rob; Disney, Alex; Conibear, Alex; Sutcliffe, Katy; Dewey, William; Husbands, Stephen; Bailey, Chris; Kelly, Eamonn; Henderson, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2653-2661</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PZM21 is a novel μ-opioid receptor ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ receptor ligands such as morphine.  We have re-examd. the signalling profile of PZM21 and its ability to depress respiration.  G protein (Gi) activation and arrestin-3 translocation were measured in vitro, using BRET assays, in HEK 293 cells expressing μ receptors.  Respiration (rate and tidal vol.) was measured in awake, freely moving mice by whole-body plethysmog., and antinociception was measured by the hot plate test.  PZM21 (10-9 - 3 × 10-5 M) produced concn.-dependent Gi activation and arrestin-3 translocation.  Comparison with responses evoked by morphine and DAMGO revealed that PZM21 was a low efficacy agonist in both signalling assays.  PZM21 (10-80 mg·kg-1) depressed respiration in a dose-dependent manner.  The respiratory depression was due to a decrease in the rate of breathing not a decrease in tidal vol.  On repeated daily administration of PZM21 (twice daily doses of 40 mg·kg-1), complete tolerance developed to the antinociceptive effect of PZM21 over 3 days but no tolerance developed to its respiratory depressant effect.  These data demonstrate that PZM21 is a low efficacy μ receptor agonist for both G protein and arrestin signalling.  Contrary to a previous report, PZM21 depresses respiration in a manner similar to morphine, the classical opioid receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeVaQW_N9c4LVg90H21EOLACvtfcHk0ljd0v0DKTfwIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCmt7o%253D&md5=adb5bbba116f6d3df8d860754434af16</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fbph.14224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14224%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%26aulast%3DDisney%26aufirst%3DA.%26aulast%3DConibear%26aufirst%3DA.%26aulast%3DSutcliffe%26aufirst%3DK.%26aulast%3DDewey%26aufirst%3DW.%26aulast%3DHusbands%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DHenderson%26aufirst%3DG.%26atitle%3DThe%2520novel%2520%25CE%25BC-opioid%2520receptor%2520agonist%2520PZM21%2520depresses%2520respiration%2520and%2520induces%2520tolerance%2520to%2520antinociception%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2653%26epage%3D2661%26doi%3D10.1111%2Fbph.14224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rouzic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrath, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunkele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagirsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eans, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span> <span> </span><span class="NLM_article-title">Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8381</span>– <span class="NLM_lpage">8397</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00748</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00748" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8381-8397&author=A.+Varadiauthor=G.+F.+Marroneauthor=T.+C.+Palmerauthor=A.+Narayanauthor=M.+R.+Szaboauthor=V.+Le+Rouzicauthor=S.+G.+Grinnellauthor=J.+J.+Subrathauthor=E.+Warnerauthor=S.+Kalraauthor=A.+Hunkeleauthor=J.+Pagirskyauthor=S.+O.+Eansauthor=J.+M.+Medinaauthor=J.+Xuauthor=Y.+X.+Panauthor=A.+Boricsauthor=G.+W.+Pasternakauthor=J.+P.+McLaughlinauthor=S.+Majumdar&title=Mitragynine%2Fcorynantheidine+pseudoindoxyls+as+opioid+analgesics+with+mu+agonism+and+delta+antagonism%2C+which+do+not+recruit+%CE%B2-arrestin-2&doi=10.1021%2Facs.jmedchem.6b00748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00748%26sid%3Dliteratum%253Aachs%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DMarrone%26aufirst%3DG.%2BF.%26aulast%3DPalmer%26aufirst%3DT.%2BC.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DM.%2BR.%26aulast%3DLe%2BRouzic%26aufirst%3DV.%26aulast%3DGrinnell%26aufirst%3DS.%2BG.%26aulast%3DSubrath%26aufirst%3DJ.%2BJ.%26aulast%3DWarner%26aufirst%3DE.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DHunkele%26aufirst%3DA.%26aulast%3DPagirsky%26aufirst%3DJ.%26aulast%3DEans%26aufirst%3DS.%2BO.%26aulast%3DMedina%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%2BX.%26aulast%3DBorics%26aufirst%3DA.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DMajumdar%26aufirst%3DS.%26atitle%3DMitragynine%252Fcorynantheidine%2520pseudoindoxyls%2520as%2520opioid%2520analgesics%2520with%2520mu%2520agonism%2520and%2520delta%2520antagonism%252C%2520which%2520do%2520not%2520recruit%2520%25CE%25B2-arrestin-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8381%26epage%3D8397%26doi%3D10.1021%2Facs.jmedchem.6b00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenweck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Bias factor and therapeutic window correlate to predict safer opioid analgesics</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1175</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2017.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29149605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=1165-1175&author=C.+L.+Schmidauthor=N.+M.+Kennedyauthor=N.+C.+Rossauthor=K.+M.+Lovellauthor=Z.+Z.+Yueauthor=J.+Morgenweckauthor=M.+D.+Cameronauthor=T.+D.+Bannisterauthor=L.+M.+Bohn&title=Bias+factor+and+therapeutic+window+correlate+to+predict+safer+opioid+analgesics&doi=10.1016%2Fj.cell.2017.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics</span></div><div class="casAuthors">Schmid, Cullen L.; Kennedy, Nicole M.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Morgenweck, Jenny; Cameron, Michael D.; Bannister, Thomas D.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1165-1175.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Biased agonism has been proposed as a means to sep. desirable and adverse drug responses downstream of G protein-coupled receptor (GPCR) targets.  Herein, we describe structural features of a series of mu-opioid-receptor (MOR)-selective agonists that preferentially activate receptors to couple to G proteins or to recruit βarrestin proteins.  By comparing relative bias for MOR-mediated signaling in each pathway, we demonstrate a strong correlation between the respiratory suppression/antinociception therapeutic window in a series of compds. spanning a wide range of signaling bias.  We find that β-arrestin-biased compds., such as fentanyl, are more likely to induce respiratory suppression at weak analgesic doses, while G protein signaling bias broadens the therapeutic window, allowing for antinociception in the absence of respiratory suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfthQaadgklLVg90H21EOLACvtfcHk0lhQ4taU4JngSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE&md5=6d3f21c03fb40bc83adbe62c3ea331fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DRoss%26aufirst%3DN.%2BC.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DYue%26aufirst%3DZ.%2BZ.%26aulast%3DMorgenweck%26aufirst%3DJ.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBias%2520factor%2520and%2520therapeutic%2520window%2520correlate%2520to%2520predict%2520safer%2520opioid%2520analgesics%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D1165%26epage%3D1175%26doi%3D10.1016%2Fj.cell.2017.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slauson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Development of functionally selective, small molecule agonists at kappa opioid receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">36703</span>– <span class="NLM_lpage">36716</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.504381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.504381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24187130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=36703-36716&author=L.+Zhouauthor=K.+M.+Lovellauthor=K.+J.+Frankowskiauthor=S.+R.+Slausonauthor=A.+M.+Phillipsauthor=J.+M.+Streicherauthor=E.+Stahlauthor=C.+L.+Schmidauthor=P.+Hodderauthor=F.+Madouxauthor=M.+D.+Cameronauthor=T.+E.+Prisinzanoauthor=J.+Aub%C3%A9author=L.+M.+Bohn&title=Development+of+functionally+selective%2C+small+molecule+agonists+at+kappa+opioid+receptors&doi=10.1074%2Fjbc.M113.504381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors</span></div><div class="casAuthors">Zhou, Lei; Lovell, Kimberly M.; Frankowski, Kevin J.; Slauson, Stephen R.; Phillips, Angela M.; Streicher, John M.; Stahl, Edward; Schmid, Cullen L.; Hodder, Peter; Madoux, Franck; Cameron, Michael D.; Prisinzano, Thomas E.; Aube, Jeffrey; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">36703-36716</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The kappa opioid receptor (KOR) is widely expressed in the CNS and can serve as a means to modulate pain perception, stress responses, and affective reward states.  Therefore, the KOR has become a prominent drug discovery target toward treating pain, depression, and drug addiction.  Agonists at KOR can promote G protein coupling and βarrestin2 recruitment as well as multiple downstream signaling pathways, including ERK1/2 MAPK activation.  It has been suggested that the physiol. effects of KOR activation result from different signaling cascades, with analgesia being G protein-mediated and dysphoria being mediated through βarrestin2 recruitment.  Dysphoria assocd. with KOR activation limits the therapeutic potential in the use of KOR agonists as analgesics; therefore, it may be beneficial to develop KOR agonists that are biased toward G protein coupling and away from βarrestin2 recruitment.  Here, we describe two classes of biased KOR agonists that potently activate G protein coupling but weakly recruit βarrestin2.  These potent and functionally selective small mol. compds. may prove to be useful tools for refining the therapeutic potential of KOR-directed signaling in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWUfaW03T6nbVg90H21EOLACvtfcHk0lhQ4taU4JngSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF&md5=372edf0156cc1fb156e76e15fa25682a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.504381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.504381%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DSlauson%26aufirst%3DS.%2BR.%26aulast%3DPhillips%26aufirst%3DA.%2BM.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DMadoux%26aufirst%3DF.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DDevelopment%2520of%2520functionally%2520selective%252C%2520small%2520molecule%2520agonists%2520at%2520kappa%2520opioid%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D36703%26epage%3D36716%26doi%3D10.1074%2Fjbc.M113.504381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Land, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melief, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4458-07.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1523%2FJNEUROSCI.4458-07.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18184783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252Fit1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=407-414&author=B.+B.+Landauthor=M.+R.+Bruchasauthor=J.+C.+Lemosauthor=M.+Xuauthor=E.+J.+Meliefauthor=C.+Chavkin&title=The+dysphoric+component+of+stress+is+encoded+by+activation+of+the+dynorphin+%CE%BA-opioid+system&doi=10.1523%2FJNEUROSCI.4458-07.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system</span></div><div class="casAuthors">Land Benjamin B; Bruchas Michael R; Lemos Julia C; Xu Mei; Melief Erica J; Chavkin Charles</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of neuroscience : the official journal of the Society for Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Stress is a complex human experience having both positive and negative motivational properties.  When chronic and uncontrollable, the adverse effects of stress on human health are considerable and yet poorly understood.  Here, we report that the dysphoric properties of chronic stress are encoded by the endogenous opioid peptide dynorphin acting on specific stress-related neuronal circuits.  Using different forms of stress presumed to evoke dysphoria in mice, we found that repeated forced swim and inescapable footshock both produced aversive behaviors that were blocked by a kappa-opioid receptor (KOR) antagonist and absent in mice lacking dynorphin.  Injection of corticotropin-releasing factor (CRF) or urocortin III, key mediators of the stress response, produced place aversion that was also blocked by dynorphin gene deletion or KOR antagonism.  CRF-induced place aversion was blocked by the CRF2 receptor antagonist antisauvigine-30, but not by the CRF1 receptor antagonist antalarmin.  In contrast, place aversion induced by the KOR agonist U50,488 was not blocked by antisauvigine-30.  These results suggest that the aversive effects of stress were mediated by CRF2 receptor stimulation of dynorphin release and subsequent KOR activation.  Using a phospho-selective antibody directed against the activated KOR to image sites of dynorphin action in the brain, we found that stress and CRF each caused dynorphin-dependent KOR activation in the basolateral amygdala, nucleus accumbens, dorsal raphe, and hippocampus.  The convergence of stress-induced aversive inputs on the dynorphin system was unexpected, implicates dynorphin as a key mediator of dysphoria, and emphasizes kappa-receptor antagonists as promising therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQif2_pEJNWVgxyojvcjibhfW6udTcc2eZM0GqkFl0sG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252Fit1Gltw%253D%253D&md5=ded3df191648ad1c51faa6e2e19fac36</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4458-07.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4458-07.2008%26sid%3Dliteratum%253Aachs%26aulast%3DLand%26aufirst%3DB.%2BB.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DLemos%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DMelief%26aufirst%3DE.%2BJ.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DThe%2520dysphoric%2520component%2520of%2520stress%2520is%2520encoded%2520by%2520activation%2520of%2520the%2520dynorphin%2520%25CE%25BA-opioid%2520system%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D407%26epage%3D414%26doi%3D10.1523%2FJNEUROSCI.4458-07.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Kinase cascades and ligand-directed signaling at the kappa opioid receptor</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1007/s00213-010-1806-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs00213-010-1806-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20401607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVGntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=137-147&author=M.+R.+Bruchasauthor=C.+Chavkin&title=Kinase+cascades+and+ligand-directed+signaling+at+the+kappa+opioid+receptor&doi=10.1007%2Fs00213-010-1806-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase cascades and ligand-directed signaling at the kappa opioid receptor</span></div><div class="casAuthors">Bruchas, Michael R.; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-147</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Background and Rationale: The dynorphin/kappa opioid receptor (KOR) system has been implicated as a crit. component of the stress response.  Stress-induced activation of dynorphin-KOR is well known to produce analgesia, and more recently, it has been implicated as a mediator of stress-induced responses including anxiety, depression, and reinstatement of drug seeking.  Objective: Drugs selectively targeting specific KOR signaling pathways may prove potentially useful as therapeutic treatments for mood and addiction disorders.  Results: KOR is a member of the seven transmembrane spanning (7TM) G-protein coupled receptor (GPCR) superfamily.  KOR activation of pertussis toxin-sensitive G proteins leads to Gαi/o inhibition of adenylyl cyclase prodn. of cAMP and releases Gβγ, which modulates the conductances of Ca+2 and K+ channels.  In addn., KOR agonists activate kinase cascades including G-protein coupled Receptor Kinases (GRK) and members of the mitogen-activated protein kinase (MAPK) family: ERK1/2, p38 and JNK.  Recent pharmacol. data suggests that GPCRs exist as dynamic, multi-conformational protein complexes that can be directed by specific ligands towards distinct signaling pathways.  Ligand-induced conformations of KOR that evoke β-arrestin-dependent p38 MAPK activation result in aversion; whereas ligand-induced conformations that activate JNK without activating arrestin produce long-lasting inactivation of KOR signaling.  Conclusions: In this review, we discuss the current status of KOR signal transduction research and the data that support two novel hypotheses: (1) KOR selective partial agonists that do not efficiently activate p38 MAPK may be useful analgesics without producing the dysphoric or hallucinogenic effects of selective, highly efficacious KOR agonists and (2) KOR antagonists that do not activate JNK may be effective short-acting drugs that may promote stress-resilience.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri-YlQylmWJbVg90H21EOLACvtfcHk0lgRdd3HknzMzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVGntLg%253D&md5=f717d1ea83969f853ad5743b5026e003</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs00213-010-1806-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-010-1806-y%26sid%3Dliteratum%253Aachs%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DKinase%2520cascades%2520and%2520ligand-directed%2520signaling%2520at%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DPsychopharmacology%26date%3D2010%26volume%3D210%26spage%3D137%26epage%3D147%26doi%3D10.1007%2Fs00213-010-1806-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dogra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, P. N.</span></span> <span> </span><span class="NLM_article-title">Biased agonism at kappa opioid receptors: implication in pain and mood disorders</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>763</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.ejphar.2015.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26164787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=763&publication_year=2015&pages=184-190&author=S.+Dograauthor=P.+N.+Yadav&title=Biased+agonism+at+kappa+opioid+receptors%3A+implication+in+pain+and+mood+disorders&doi=10.1016%2Fj.ejphar.2015.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Biased agonism at kappa opioid receptors: Implication in pain and mood disorders</span></div><div class="casAuthors">Dogra, Shalini; Yadav, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">763</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">184-190</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kappa opioid receptor (k receptor) and its endogenous ligand dynorphin have received significant attention due to their involvement in pathophysiol. of mood disorders, drug addiction, psychotic disorders and pain.  Multiple lines of evidences suggest that the k receptor modulates overlapping neurocircuits connecting brainstem monoaminergic nuclei with forebrain limbic structures and thereby regulates neurobiol. effects of stress and psychostimulants.  The emerging concept of "biased agonism" (also known as functional selectivity) for G Protein Coupled Receptor (GPCR) ligands have provided new insights into overall response generated by a ligand, which could be exploited for drug discovery.  According to this concept, every ligand possesses the unique ability (coded in its structure) that dictates distinct signalling pattern, and consequently beneficial or adverse response.  Although still a long way to comprehend the clin. potential of biased GPCR ligands, such ligand could be vital pharmacol. probes.  This article highlights various lines of evidence, which indicates different ligands of k receptor as "biased", and their potential implications in mood and pain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa9u79NzRMt7Vg90H21EOLACvtfcHk0lgRdd3HknzMzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktLjN&md5=2aacd81253e158b23d721eaf1b1985c6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DDogra%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26atitle%3DBiased%2520agonism%2520at%2520kappa%2520opioid%2520receptors%253A%2520implication%2520in%2520pain%2520and%2520mood%2520disorders%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D763%26spage%3D184%26epage%3D190%26doi%3D10.1016%2Fj.ejphar.2015.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosalia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariharan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen-Genel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangravita-Novo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicchiarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1021/cn200128x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200128x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=221-236&author=K.+J.+Frankowskiauthor=M.+P.+Hedrickauthor=P.+Gosaliaauthor=K.+Liauthor=S.+Shiauthor=D.+Whippleauthor=P.+Ghoshauthor=T.+E.+Prisinzanoauthor=F.+J.+Schoenenauthor=Y.+Suauthor=S.+Vasileauthor=E.+Sergienkoauthor=W.+Grayauthor=S.+Hariharanauthor=L.+Milanauthor=S.+Heynen-Genelauthor=A.+Mangravita-Novoauthor=M.+Vicchiarelliauthor=L.+H.+Smithauthor=J.+M.+Streicherauthor=M.+G.+Caronauthor=L.+S.+Barakauthor=L.+M.+Bohnauthor=T.+D.+Y.+Chungauthor=J.+Aub%C3%A9&title=Discovery+of+small+molecule+kappa+opioid+receptor+agonist+and+antagonist+chemotypes+through+a+HTS+and+hit+refinement+strategy&doi=10.1021%2Fcn200128x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of small molecule kappa Opioid receptor agonist and antagonist chemotypes through a HTS and Hit refinement strategy</span></div><div class="casAuthors">Frankowski, Kevin J.; Hedrick, Michael P.; Gosalia, Palak; Li, Kelin; Shi, Shenghua; Whipple, David; Ghosh, Partha; Prisinzano, Thomas E.; Schoenen, Frank J.; Su, Ying; Vasile, S.; Sergienko, Eduard; Gray, Wilson; Hariharan, Santosh; Milan, Loribelle; Heynen-Genel, Susanne; Mangravita-Novo, Arianna; Vicchiarelli, Michael; Smith, Layton H.; Streicher, John M.; Caron, Marc G.; Barak, Lawrence S.; Bohn, Laura M.; Chung, Thomas D. Y.; Aube, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-236</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we present the outcome of a high throughput screening (HTS) campaign-based strategy for the rapid identification and optimization of selective and general chemotypes for both kappa (κ) opioid receptor (KOR) activation and inhibition.  In this program, we have developed potent antagonists (IC50 < 120 nM) or agonists of high binding affinity (Ki < 3 nM).  In contrast to many important KOR ligands, the compds. presented here are highly modular, readily synthesized, and, in most cases, achiral.  The four new chemotypes hold promise for further development into chem. tools for studying the KOR or as potential therapeutic lead candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3ty8Q-FTHjLVg90H21EOLACvtfcHk0lgRdd3HknzMzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslGgug%253D%253D&md5=d8e230e7b797dc2d581d1d7e1dc98ecd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fcn200128x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200128x%26sid%3Dliteratum%253Aachs%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DGosalia%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWhipple%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DSchoenen%26aufirst%3DF.%2BJ.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DSergienko%26aufirst%3DE.%26aulast%3DGray%26aufirst%3DW.%26aulast%3DHariharan%26aufirst%3DS.%26aulast%3DMilan%26aufirst%3DL.%26aulast%3DHeynen-Genel%26aufirst%3DS.%26aulast%3DMangravita-Novo%26aufirst%3DA.%26aulast%3DVicchiarelli%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520small%2520molecule%2520kappa%2520opioid%2520receptor%2520agonist%2520and%2520antagonist%2520chemotypes%2520through%2520a%2520HTS%2520and%2520hit%2520refinement%2520strategy%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D221%26epage%3D236%26doi%3D10.1021%2Fcn200128x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slauson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Development of functionally selective, small molecule agonists at kappa opioid receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">36703</span>– <span class="NLM_lpage">36716</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.504381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.504381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24187130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=36703-36716&author=L.+Zhouauthor=K.+M.+Lovellauthor=K.+J.+Frankowskiauthor=S.+R.+Slausonauthor=A.+M.+Phillipsauthor=J.+M.+Streicherauthor=E.+Stahlauthor=C.+L.+Schmidauthor=P.+Hodderauthor=F.+Madouxauthor=M.+D.+Cameronauthor=T.+E.+Prisinzanoauthor=J.+Aub%C3%A9author=L.+M.+Bohn&title=Development+of+functionally+selective%2C+small+molecule+agonists+at+kappa+opioid+receptors&doi=10.1074%2Fjbc.M113.504381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors</span></div><div class="casAuthors">Zhou, Lei; Lovell, Kimberly M.; Frankowski, Kevin J.; Slauson, Stephen R.; Phillips, Angela M.; Streicher, John M.; Stahl, Edward; Schmid, Cullen L.; Hodder, Peter; Madoux, Franck; Cameron, Michael D.; Prisinzano, Thomas E.; Aube, Jeffrey; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">36703-36716</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The kappa opioid receptor (KOR) is widely expressed in the CNS and can serve as a means to modulate pain perception, stress responses, and affective reward states.  Therefore, the KOR has become a prominent drug discovery target toward treating pain, depression, and drug addiction.  Agonists at KOR can promote G protein coupling and βarrestin2 recruitment as well as multiple downstream signaling pathways, including ERK1/2 MAPK activation.  It has been suggested that the physiol. effects of KOR activation result from different signaling cascades, with analgesia being G protein-mediated and dysphoria being mediated through βarrestin2 recruitment.  Dysphoria assocd. with KOR activation limits the therapeutic potential in the use of KOR agonists as analgesics; therefore, it may be beneficial to develop KOR agonists that are biased toward G protein coupling and away from βarrestin2 recruitment.  Here, we describe two classes of biased KOR agonists that potently activate G protein coupling but weakly recruit βarrestin2.  These potent and functionally selective small mol. compds. may prove to be useful tools for refining the therapeutic potential of KOR-directed signaling in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWUfaW03T6nbVg90H21EOLACvtfcHk0liqAdSLoc9Y_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFymtLbF&md5=372edf0156cc1fb156e76e15fa25682a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.504381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.504381%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DSlauson%26aufirst%3DS.%2BR.%26aulast%3DPhillips%26aufirst%3DA.%2BM.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DMadoux%26aufirst%3DF.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DDevelopment%2520of%2520functionally%2520selective%252C%2520small%2520molecule%2520agonists%2520at%2520kappa%2520opioid%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D36703%26epage%3D36716%26doi%3D10.1074%2Fjbc.M113.504381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slauson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1419</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Ogt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1411-1419&author=K.+M.+Lovellauthor=K.+J.+Frankowskiauthor=E.+L.+Stahlauthor=S.+R.+Slausonauthor=E.+Yooauthor=T.+E.+Prisinzanoauthor=J.+Aub%C3%A9author=L.+M.+Bohn&title=Structure%E2%80%93activity+relationship+studies+of+functionally+selective+kappa+opioid+receptor+agonists+that+modulate+ERK+1%2F2+phosphorylation+while+preserving+G+protein+over+%CE%B2arrestin2+signaling+bias&doi=10.1021%2Facschemneuro.5b00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over βArrestin2 Signaling Bias</span></div><div class="casAuthors">Lovell, Kimberly M.; Frankowski, Kevin J.; Stahl, Edward L.; Slauson, Stephen R.; Yoo, Euna; Prisinzano, Thomas E.; Aube, Jeffrey; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1411-1419</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kappa opioid receptor (KOR) modulation is a promising target for drug discovery efforts due to KOR involvement in pain, depression, and addiction behaviors.  The authors recently reported a new class of triazole KOR agonists that displays significant bias toward G protein signaling over βarrestin2 recruitment; interestingly, these compds. also induce less activation of ERK1/2 map kinases than the balanced agonist, U69,593.  The authors have identified structure-activity relationships around the triazole scaffold that allows for decreasing the bias for G protein signaling over ERK1/2 activation while maintaining the bias for G protein signaling over βarrestin2 recruitment.  The development of novel compds., with different downstream signaling outcomes, independent of G protein/βarrestin2 bias, provides a more diverse pharmacol. toolset for use in defining complex KOR signaling and elucidating the significance of KOR-mediated signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8XRgsF9nR4rVg90H21EOLACvtfcHk0liqAdSLoc9Y_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Ogt7o%253D&md5=ea13ffe0d040ea989d0fd21da421e7d7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00092%26sid%3Dliteratum%253Aachs%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DSlauson%26aufirst%3DS.%2BR.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520studies%2520of%2520functionally%2520selective%2520kappa%2520opioid%2520receptor%2520agonists%2520that%2520modulate%2520ERK%25201%252F2%2520phosphorylation%2520while%2520preserving%2520G%2520protein%2520over%2520%25CE%25B2arrestin2%2520signaling%2520bias%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1411%26epage%3D1419%26doi%3D10.1021%2Facschemneuro.5b00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a novel class of selective and nonbasic nitrogen-containing κ-opioid receptor ligands</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1021/ml100040t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100040t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=189-193&author=K.+J.+Frankowskiauthor=P.+Ghoshauthor=V.+Setolaauthor=T.+B.+Tranauthor=B.+L.+Rothauthor=J.+Aub%C3%A9&title=N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides%3A+a+novel+class+of+selective+and+nonbasic+nitrogen-containing+%CE%BA-opioid+receptor+ligands&doi=10.1021%2Fml100040t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fml100040t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100040t%26sid%3Dliteratum%253Aachs%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26atitle%3DN-Alkyl-octahydroisoquinolin-1-one-8-carboxamides%253A%2520a%2520novel%2520class%2520of%2520selective%2520and%2520nonbasic%2520nitrogen-containing%2520%25CE%25BA-opioid%2520receptor%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D189%26epage%3D193%26doi%3D10.1021%2Fml100040t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scopton, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikbulatov, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepally, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zjawiony, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Identification of novel functionally selective κ-opioid receptor scaffolds</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1124/mol.113.089649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.113.089649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=83-90&author=K.+L.+Whiteauthor=A.+P.+Scoptonauthor=M.+L.+Rivesauthor=R.+V.+Bikbulatovauthor=P.+R.+Polepallyauthor=P.+J.+Brownauthor=T.+Kenakinauthor=J.+A.+Javitchauthor=J.+K.+Zjawionyauthor=B.+L.+Roth&title=Identification+of+novel+functionally+selective+%CE%BA-opioid+receptor+scaffolds&doi=10.1124%2Fmol.113.089649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.089649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.089649%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DScopton%26aufirst%3DA.%2BP.%26aulast%3DRives%26aufirst%3DM.%2BL.%26aulast%3DBikbulatov%26aufirst%3DR.%2BV.%26aulast%3DPolepally%26aufirst%3DP.%2BR.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DZjawiony%26aufirst%3DJ.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DIdentification%2520of%2520novel%2520functionally%2520selective%2520%25CE%25BA-opioid%2520receptor%2520scaffolds%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D85%26spage%3D83%26epage%3D90%26doi%3D10.1124%2Fmol.113.089649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBerto, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepally, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zjawiony, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malanga, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.216820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.114.216820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25320048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=98-109&author=K.+L.+Whiteauthor=J.+E.+Robinsonauthor=H.+Zhuauthor=J.+F.+DiBertoauthor=P.+R.+Polepallyauthor=J.+K.+Zjawionyauthor=D.+E.+Nicholsauthor=C.+J.+Malangaauthor=B.+L.+Roth&title=The+G+protein-biased+%CE%BA-opioid+receptor+agonist+RB-64+is+analgesic+with+a+unique+spectrum+of+activities+in+vivo&doi=10.1124%2Fjpet.114.216820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo</span></div><div class="casAuthors">White, Kate L.; Robinson, J. Elliott; Zhu, Hu; DiBerto, Jeffrey F.; Polepally, Prabhakar R.; Zjawiony, Jordan K.; Nichols, David E.; Malanga, C. J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-109, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The hypothesis that functionally selective G protein-coupled receptor (GPCR) agonists may have enhanced therapeutic benefits has revitalized interest for many GPCR targets.  In particular, although κ-opioid receptor (KOR) agonists are analgesic with a low risk of dependence and abuse, their use is limited by a propensity to induce sedation, motor incoordination, hallucinations, and dysphoria-like states.  Several labs. have produced a body of work suggesting that G protein-biased KOR agonists might be analgesic with fewer side effects.  Although that has been an intriguing hypothesis, suitable KOR-selective and G protein-biased agonists have not been available to test this idea.  Here we provide data using a G protein-biased agonist, RB-64 (22-thiocyanatosalvinorin A), which suggests that KOR-mediated G protein signaling induces analgesia and aversion, whereas β-arrestin-2 signaling may be assocd. with motor incoordination.  Addnl., unlike unbiased KOR agonists, the G protein-biased ligand RB-64 does not induce sedation and does not have anhedonia-like actions, suggesting that a mechanism other than G protein signaling mediates these effects.  Our findings provide the first evidence for a highly selective and G protein-biased tool compd. for which many, but not all, of the neg. side effects of KOR agonists can be minimized by creating G protein-biased KOR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGporsYw3knd37Vg90H21EOLACvtfcHk0liWiCSkKQl1uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM&md5=686b5b718e2919aaf08e34855cc39ebf</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.216820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.216820%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DDiBerto%26aufirst%3DJ.%2BF.%26aulast%3DPolepally%26aufirst%3DP.%2BR.%26aulast%3DZjawiony%26aufirst%3DJ.%2BK.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMalanga%26aufirst%3DC.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520G%2520protein-biased%2520%25CE%25BA-opioid%2520receptor%2520agonist%2520RB-64%2520is%2520analgesic%2520with%2520a%2520unique%2520spectrum%2520of%2520activities%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D98%26epage%3D109%26doi%3D10.1124%2Fjpet.114.216820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Chen, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span> <span> </span><span class="NLM_article-title">6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">27050</span>– <span class="NLM_lpage">27054</span>, <span class="refDoi"> DOI: 10.1074/jbc.C112.387332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.C112.387332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22736766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFaqtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=27050-27054&author=M.+L.+Rivesauthor=M.+Rossilloauthor=L.+Y.+Liu-Chenauthor=J.+A.+Javitch&title=6%E2%80%B2-Guanidinonaltrindole+%286%E2%80%B2-GNTI%29+is+a+G+protein-biased+%CE%BA-opioid+receptor+agonist+that+inhibits+arrestin+recruitment&doi=10.1074%2Fjbc.C112.387332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">6'-Guanidinonaltrindole (6'-GNTI) Is a G Protein-biased κ-Opioid Receptor Agonist That Inhibits Arrestin Recruitment</span></div><div class="casAuthors">Rives, Marie-Laure; Rossillo, Mary; Liu-Chen, Lee-Yuan; Javitch, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">27050-27054</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">κ-Opioid receptor (KOR) agonists do not activate the reward pathway stimulated by morphine-like μ-opioid receptor (MOR) agonists and thus have been considered to be promising nonaddictive analgesics.  However, KOR agonists produce other adverse effects, including dysphoria, diuresis, and constipation.  The therapeutic promise of KOR agonists has nonetheless recently been revived by studies showing that their dysphoric effects require arrestin recruitment, whereas their analgesic effects do not.  Moreover, KOR agonist-induced antinociceptive tolerance obsd. in vivo has also been proposed to be correlated to the ability to induce arrestin-dependent phosphorylation, desensitization, and internalization of the receptor.  The discovery of functionally selective drugs that are therapeutically effective without the adverse effects triggered by the arrestin pathway is thus an important goal.  We have identified such an extreme G protein-biased KOR compd., 6'-guanidinonaltrindole (6'-GNTI), a potent partial agonist at the KOR receptor for the G protein activation pathway that does not recruit arrestin.  Indeed, 6'-GNTI functions as an antagonist to block the arrestin recruitment and KOR internalization induced by other nonbiased agonists.  As an extremely G protein-biased KOR agonist, 6'-GNTI represents a promising lead compd. in the search for nonaddictive opioid analgesic as its signaling profile suggests that it will be without the dysphoria and other adverse effects promoted by arrestin recruitment and its downstream signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQZcVC9i_2wLVg90H21EOLACvtfcHk0liWiCSkKQl1uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFaqtrvN&md5=6f1d6365e77b2f318597a6123dcb565c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C112.387332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C112.387332%26sid%3Dliteratum%253Aachs%26aulast%3DRives%26aufirst%3DM.%2BL.%26aulast%3DRossillo%26aufirst%3DM.%26aulast%3DLiu-Chen%26aufirst%3DL.%2BY.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26atitle%3D6%25E2%2580%25B2-Guanidinonaltrindole%2520%25286%25E2%2580%25B2-GNTI%2529%2520is%2520a%2520G%2520protein-biased%2520%25CE%25BA-opioid%2520receptor%2520agonist%2520that%2520inhibits%2520arrestin%2520recruitment%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D27050%26epage%3D27054%26doi%3D10.1074%2Fjbc.C112.387332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streicher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity of 6′-guanidinonaltrindole (6′-GNTI) at κ-opioid receptors in striatal neurons</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">22387</span>– <span class="NLM_lpage">22398</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.476234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.476234" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=22387-22398&author=C.+L.+Schmidauthor=J.+M.+Streicherauthor=C.+E.+Groerauthor=T.+A.+Munroauthor=L.+Zhouauthor=L.+M.+Bohn&title=Functional+selectivity+of+6%E2%80%B2-guanidinonaltrindole+%286%E2%80%B2-GNTI%29+at+%CE%BA-opioid+receptors+in+striatal+neurons&doi=10.1074%2Fjbc.M113.476234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.476234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.476234%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DStreicher%26aufirst%3DJ.%2BM.%26aulast%3DGroer%26aufirst%3DC.%2BE.%26aulast%3DMunro%26aufirst%3DT.%2BA.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DFunctional%2520selectivity%2520of%25206%25E2%2580%25B2-guanidinonaltrindole%2520%25286%25E2%2580%25B2-GNTI%2529%2520at%2520%25CE%25BA-opioid%2520receptors%2520in%2520striatal%2520neurons%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D22387%26epage%3D22398%26doi%3D10.1074%2Fjbc.M113.476234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schattauer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cellsig.2017.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28088389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=59-65&author=S.+S.+Schattauerauthor=J.+R.+Kuharauthor=A.+Songauthor=C.+Chavkin&title=Nalfurafine+is+a+G-protein+biased+agonist+having+significantly+greater+bias+at+the+human+than+rodent+form+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.cellsig.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span></div><div class="casAuthors">Schattauer, Selena S.; Kuhar, Jamie R.; Song, Allisa; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Nalfurafine is a moderately selective kappa opioid receptor (KOR) analgesic with low incidence of dysphoric side effects in clin. development for the treatment of uremic pruritis.  The basis for its reduced dysphoric effect compared to other KOR agonists is not clear, but prior studies suggest that the aversive properties of KOR agonists require p38α MAPK activation through an arrestin-dependent mechanism.  To det. whether nalfurafine is a functionally selective KOR agonist, we measured its potency to activate the G protein-dependent early phase of Extracellular Signal-Regulated Kinase (ERK1/2) phosphorylation and the arrestin-dependent late phase of p38 MAPK signaling.  Nalfurafine was approx. 250 fold more potent for ERK1/2 activation as compared to p38 MAPK activation in human KOR (hKOR) expressing HEK293 cells, and approx. 20 fold more potent for ERK1/2 activation than p38 activation in rodent KOR (rKOR) expressing HEK293 cells.  The 10-fold greater G-bias at the hKOR than rKOR was unexpected, however the G protein biased effect of nalfurafine is consistent with its reduced dysphoric effects in human and rodent models.  Although nalfurafine is reported to have low receptor selectivity in radioligand binding assays, its antinociceptive effect was blocked by the selective KOR antagonist norbinaltorphimine.  Nalfurafine pretreatment also resulted in a KOR-dependent and mu opioid receptor-independent redn. in scratching induced by 5'-GNTI.  These findings suggest that nalfurafine is a functionally selective KOR agonist and that KOR agonists able to selectively activate G protein signaling without activating p38α MAPK may have therapeutic potential as non-dysphoric antipruritic analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqJR2Iu_bivbVg90H21EOLACvtfcHk0ljhOCQ8aNADng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D&md5=13799707352aa7133e92eff7e6f32b71</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DSchattauer%26aufirst%3DS.%2BS.%26aulast%3DKuhar%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DNalfurafine%2520is%2520a%2520G-protein%2520biased%2520agonist%2520having%2520significantly%2520greater%2520bias%2520at%2520the%2520human%2520than%2520rodent%2520form%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DCell.%2520Signalling%26date%3D2017%26volume%3D32%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.cellsig.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazenka, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moerke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s00213-017-4758-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs00213-017-4758-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29063139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2018&pages=203-213&author=M.+L.+Lazenkaauthor=M.+J.+Moerkeauthor=E.+A.+Townsendauthor=K.+B.+Freemanauthor=F.+I.+Carrollauthor=S.+S.+Negus&title=Dissociable+effects+of+the+kappa+opioid+receptor+agonist+nalfurafine+on+pain%2Fitch-stimulated+and+pain%2Fitch-depressed+behaviors+in+male+rats&doi=10.1007%2Fs00213-017-4758-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span></div><div class="casAuthors">Lazenka, Matthew L.; Moerke, Megan J.; Townsend, E. Andrew; Freeman, Kevin B.; Carroll, F. Ivy; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">203-213</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Nalfurafine is a G protein signaling-biased kappa opioid receptor (KOR) agonist approved in Japan for second-line treatment of uremic pruritus.  Neither nalfurafine nor any other KOR agonist is currently approved anywhere for treatment of pain, but recent evidence suggests that G protein signaling-biased KOR agonists may have promise as candidate analgesics/antipruritics with reduced side effects compared to nonbiased or ss-arrestin-signaling-biased KOR agonists.  Objectives: This study compared nalfurafine effects in rats using assays of pain-stimulated and pain-depressed behavior used previously to evaluate other candidate analgesics.  Nalfurafine effects were also examd. in complementary assays of itch-stimulated and itch-depressed behavior.  Methods: I.p. lactic acid (IP acid) and intradermal serotonin (ID 5HT) served as noxious and pruritic stimuli, resp., in male Sprague Dawley rats to stimulate stretching (IP acid) or scratching (ID 5HT) or to depress pos. reinforced operant responding in an assay of intracranial self-stimulation (ICSS; both stimuli).  Results: Nalfurafine was equipotent to decrease IP acid-stimulated stretching and ID 5HT-stimulated scratching; however, doses of nalfurafine that decreased these pain/itch-stimulated behaviors also decreased control ICSS performance.  Moreover, nalfurafine failed to alleviate either IP acid- or ID 5HT-induced depression of ICSS.  Conclusions: These results suggest that nalfurafine-induced decreases in pain/itch-stimulated behaviors may reflect nonselective decreases in motivated behavior rather than analgesia or antipruritus against the noxious and pruritic stimuli used here.  This conclusion agrees with the absence of clin. data for nalfurafine analgesia and the weak clin. data for nalfurafine antipruritus.  Nalfurafine bias for G protein signaling may not be sufficient for clin. safe and reliable analgesia or antipruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkm4nAMagerVg90H21EOLACvtfcHk0ljhOCQ8aNADng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K&md5=13f9d2d5f4340b136971eb1bc2bbfc5e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00213-017-4758-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-017-4758-7%26sid%3Dliteratum%253Aachs%26aulast%3DLazenka%26aufirst%3DM.%2BL.%26aulast%3DMoerke%26aufirst%3DM.%2BJ.%26aulast%3DTownsend%26aufirst%3DE.%2BA.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DDissociable%2520effects%2520of%2520the%2520kappa%2520opioid%2520receptor%2520agonist%2520nalfurafine%2520on%2520pain%252Fitch-stimulated%2520and%2520pain%252Fitch-depressed%2520behaviors%2520in%2520male%2520rats%26jtitle%3DPsychopharmacology%26date%3D2018%26volume%3D235%26spage%3D203%26epage%3D213%26doi%3D10.1007%2Fs00213-017-4758-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7011</span>– <span class="NLM_lpage">7028</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7011-7028&author=N.+T.+Zaveri&title=Nociceptin+opioid+receptor+%28NOP%29+as+a+therapeutic+target%3A+progress+in+translation+from+preclinical+research+to+clinical+utility&doi=10.1021%2Facs.jmedchem.5b01499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility</span></div><div class="casAuthors">Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7011-7028</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the two decades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in understanding the pharmacol. of this fourth opioid receptor/peptide system, aided by genetic and pharmacol. approaches.  This research spawned an explosion of small-mol. NOP receptor ligands from discovery programs in major pharmaceutical companies.  NOP agonists have been investigated for their efficacy in preclin. models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urinary incontinence, whereas NOP antagonists have been investigated for treatment of pain, depression, and motor symptoms in Parkinson's disease.  Translation of preclin. findings into the clinic is guided by PET and receptor occupancy studies, particularly for NOP antagonists.  Recent progress in preclin. NOP research suggests that NOP agonists may have clin. utility for pain treatment and substance abuse pharmacotherapy.  This review discusses the progress toward validating the NOP-N/OFQ system as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo51w0U-7QparVg90H21EOLACvtfcHk0ljhOCQ8aNADng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D&md5=b9746257e225a423dfa0539d8bf407c9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01499%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DNociceptin%2520opioid%2520receptor%2520%2528NOP%2529%2520as%2520a%2520therapeutic%2520target%253A%2520progress%2520in%2520translation%2520from%2520preclinical%2520research%2520to%2520clinical%2520utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7011%26epage%3D7028%26doi%3D10.1021%2Facs.jmedchem.5b01499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarella, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span> <span> </span><span class="NLM_article-title">Quantitative signaling and structure-activity analyses demonstrate functional selectivity at the nociceptin/orphanin FQ opioid receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1124/mol.115.099150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.115.099150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26134494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=502-511&author=S.+D.+Changauthor=S.+W.+Mascarellaauthor=S.+M.+Spanglerauthor=V.+V.+Gurevichauthor=H.+A.+Navarroauthor=F.+I.+Carrollauthor=M.+R.+Bruchas&title=Quantitative+signaling+and+structure-activity+analyses+demonstrate+functional+selectivity+at+the+nociceptin%2Forphanin+FQ+opioid+receptor&doi=10.1124%2Fmol.115.099150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative signaling and structure-activity analyses demonstrate functional selectivity at the nociceptin/orphanin FQ opioid receptor</span></div><div class="casAuthors">Chang, Steven D.; Mascarella, S. Wayne; Spangler, Skylar M.; Gurevich, Vsevolod V.; Navarro, Hernan A.; Carroll, F. Ivy; Bruchas, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">502-511</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pancreatic cancer has the lowest 5-yr survival rate of all major cancers despite decades of effort to design and implement novel, more effective treatment options.  In this study, we tested whether the dual phosphoinositide 3-kinase/mechanistic target of rapamycin inhibitor BEZ235 (BEZ) potentiates the antitumor effects of doxorubicin (DOX) against pancreatic cancer.  Cotreatment of BEZ235 with DOX resulted in dose-dependent inhibition of the phosphoinositide 3-kinase/mechanistic target of rapamycin survival pathway, which corresponded with an increase in poly ADP ribose polymerase cleavage.  Moreover, BEZ cotreatment significantly improved the effects of DOX toward both cell viability and cell death in part through reduced Bcl-2 expression and increased expression of the shorter, more cytotoxic forms of BIM.  BEZ also facilitated intracellular accumulation of DOX, which led to enhanced DNA damage and reactive oxygen species generation.  Furthermore, BEZ in combination with gemcitabine reduced MiaPaca2 cell proliferation but failed to increase reactive oxygen species generation or BIM expression, resulting in reduced necrosis and apoptosis.  Treatment with BEZ and DOX in mice bearing tumor xenographs significantly repressed tumor growth as compared with BEZ, DOX, or gemcitabine.  Addnl., in contrast to the enhanced expression seen in MiaPaca2 cells, BEZ and DOX cotreatment reduced BIM expression in H9C2 cardiomyocytes.  Also, the Bcl-2/Bax ratio was increased, which was assocd. with a redn. in cell death.  In vivo echocardiog. showed decreased cardiac function with DOX treatment, which was not improved by combination treatment with BEZ.  Thus, we propose that combining BEZ with DOX would be a better option for patients than current std. of care by providing a more effective tumor response without the assocd. increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowdAZqtUuLx7Vg90H21EOLACvtfcHk0liyQxymH62jMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyktLrI&md5=2bbd01f7e2c6b21e01a2406b69971eef</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.099150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.099150%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BD.%26aulast%3DMascarella%26aufirst%3DS.%2BW.%26aulast%3DSpangler%26aufirst%3DS.%2BM.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DNavarro%26aufirst%3DH.%2BA.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26atitle%3DQuantitative%2520signaling%2520and%2520structure-activity%2520analyses%2520demonstrate%2520functional%2520selectivity%2520at%2520the%2520nociceptin%252Forphanin%2520FQ%2520opioid%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D502%26epage%3D511%26doi%3D10.1124%2Fmol.115.099150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohlweg, R.</span></span> <span> </span><span class="NLM_article-title">(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8- triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fsj.bjp.0703661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=11053209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFemsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2000&pages=903-908&author=C.+Thomsenauthor=R.+Hohlweg&title=%288-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1%2C3%2C8-+triaza-spiro%5B4.5%5Ddec-3-yl%29-acetic+acid+methyl+ester+%28NNC+63-0532%29+is+a+novel+potent+nociceptin+receptor+agonist&doi=10.1038%2Fsj.bjp.0703661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl)acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist</span></div><div class="casAuthors">Thomsen, Christian; Hohlweg, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">903-908</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Spiroxatrine was identified as a moderately potent (Ki = 118 nM) but non-selective agonist at the human nociceptin/orphanin FQ receptor, ORL1.  This compd. was subject to chem. modification and one of the resulting compds., NNC 63-0532 was shown to have high affinity for ORL1 (Ki = 7.3 nM).  NNC 63-0532 showed only moderate affinity for the following receptors (Ki values in parentheses): μ-opioid (140 nM), κ-opioid (405 nM), dopamine D2S (209 nM), dopamine D3 (133 nM) and dopamine D4.4 (107 nM) out of 75 different receptors, ion-channels and transporters.  In functional assays, NNC 63-0532 was shown to be an agonist at ORL1 (EC50 = 305 nM), a much weaker agonist at the μ-opioid receptor (EC50>10 μM) and an antagonist or weak partial agonist at dopamine D2S (IC50 = 2830 nM).  Thus, NNC 63-0532 is a novel non-peptide agonist with ∼ 12 fold selectivity for ORL1 and may be useful for exploring the physiol. roles of this receptor owing to its brain-penetrating properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqch9CqavIc-rVg90H21EOLACvtfcHk0liyQxymH62jMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFemsLc%253D&md5=6c28da889af05c7b60a6efb9bf2d901b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703661%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DC.%26aulast%3DHohlweg%26aufirst%3DR.%26atitle%3D%25288-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1%252C3%252C8-%2520triaza-spiro%255B4.5%255Ddec-3-yl%2529-acetic%2520acid%2520methyl%2520ester%2520%2528NNC%252063-0532%2529%2520is%2520a%2520novel%2520potent%2520nociceptin%2520receptor%2520agonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D131%26spage%3D903%26epage%3D908%26doi%3D10.1038%2Fsj.bjp.0703661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">The physiology, signaling, and pharmacology of dopamine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fpr.110.002642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21303898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=182-217&author=J.+M.+Beaulieuauthor=R.+R.+Gainetdinov&title=The+physiology%2C+signaling%2C+and+pharmacology+of+dopamine+receptors&doi=10.1124%2Fpr.110.002642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, signaling, and pharmacology of dopamine receptors</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-217</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiol. functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension.  Pharmacol. agents targeting dopaminergic neurotransmission have been clin. used in the management of several neurol. and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD1), and Tourette's syndrome.  Numerous advances have occurred in understanding the general structural, biochem., and functional properties of dopamine receptors that have led to the development of multiple pharmacol. active compds. that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics.  Recent progress in understanding the complex biol. of dopamine receptor-related signal transduction mechanisms has revealed that, in addn. to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins.  One of the future directions in managing dopamine-related pathol. conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacol.  In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms.  In addn., we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacol. and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp84qmbSbA7Vg90H21EOLACvtfcHk0liyQxymH62jMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D&md5=53e6841062c98abe60c732692109e498</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002642%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DThe%2520physiology%252C%2520signaling%252C%2520and%2520pharmacology%2520of%2520dopamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D182%26epage%3D217%26doi%3D10.1124%2Fpr.110.002642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kehne, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andree, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, J. N.</span></span> <span> </span><span class="NLM_article-title">D2 receptor partial agonists: treatment of CNS disorders of dopamine function</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1088</span>, <span class="refDoi"> DOI: 10.2174/156802608785161394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.2174%2F156802608785161394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18691133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1068-1088&author=J.+H.+Kehneauthor=T.+H.+Andreeauthor=J.+N.+Heinrich&title=D2+receptor+partial+agonists%3A+treatment+of+CNS+disorders+of+dopamine+function&doi=10.2174%2F156802608785161394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">D2 receptor partial agonists: treatment of CNS disorders of dopamine function</span></div><div class="casAuthors">Kehne, John H.; Andree, Terrance H.; Heinrich, Julia N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1068-1088</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  A remarkable diversity of psychiatric and neurol. disorders have been assocd. with dysfunction of dopamine (DA)-contg. neurons, including schizophrenia, bipolar disorder (BD), Parkinson's disease (PD), and restless legs syndrome (RLS).  In such disorders, transmission in discrete DA pathways may range from hypoactivation to hyperactivation of DA receptors, particularly those of the D2 subtype, providing the rationale for treatment approaches that activate or block D2 receptors, resp.  However, full agonists or pure D2 receptor antagonists may not be optimal therapeutic approaches for their resp. disorders for a no. of reasons, including an inability to restore the aberrant DA pathways to a normal level of basal tone.  D2 receptor partial agonists (D2PAs) are proposed to stabilize activity in DA pathways by dampening excessive (and/or by restoring deficient) D2 receptor stimulation thereby shepherding DA neurons back to a desired level of basal activity.  Stabilizing aberrant DA activity without disrupting non-dysfunctional DA neurons may provide a potentially improved approach for treating DA disorders.  The status of DA D2PAs and their potential application to schizophrenia, BD, PD, and RLS is reviewed.  Preclin. and clin. evidence supports the idea that dysfunctions of D2 receptors contribute to these CNS disorders.  Diseases in which both hyper- and hypofunction of DA pathways are present may be particularly promising, and challenging, targets for D2PAs.  Furthermore, different DA disorders may respond optimally to D2PAs with differing levels of intrinsic activity, with "DA deficiency" diseases responding more effectively to higher intrinsic activity D2PAs than "DA hyperactivation" diseases.  Overall, current evidence supports the conclusion that D2PAs have significant potential as improved CNS therapies relative to classic full agonists and antagonists at D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYXnz0ClAI_LVg90H21EOLACvtfcHk0ljWowAljU6bKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ohtbw%253D&md5=e2501665b430e96d34941f0101b98190</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F156802608785161394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785161394%26sid%3Dliteratum%253Aachs%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26aulast%3DHeinrich%26aufirst%3DJ.%2BN.%26atitle%3DD2%2520receptor%2520partial%2520agonists%253A%2520treatment%2520of%2520CNS%2520disorders%2520of%2520dopamine%2520function%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1068%26epage%3D1088%26doi%3D10.2174%2F156802608785161394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M.</span></span> <span> </span><span class="NLM_article-title">Dopamine in schizophrenia: a review and reconceptualization</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1474</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1176/ajp.148.11.1474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1176%2Fajp.148.11.1474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1681750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=1991&pages=1474-1486&author=K.+L.+Davisauthor=R.+S.+Kahnauthor=G.+Koauthor=M.+Davidson&title=Dopamine+in+schizophrenia%3A+a+review+and+reconceptualization&doi=10.1176%2Fajp.148.11.1474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine in schizophrenia: a review and reconceptualization</span></div><div class="casAuthors">Davis K L; Kahn R S; Ko G; Davidson M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1474-86</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The initial hypothesis that schizophrenia is a manifestation of hyperdopaminergia has recently been faulted.  However, several new findings suggest that abnormal, although not necessarily excessive, dopamine activity is an important factor in schizophrenia.  The authors discuss these findings and their implications.  METHOD:  All published studies regarding dopamine and schizophrenia and all studies on the role of dopamine in cognition were reviewed.  Attention has focused on post-mortem studies, positron emission tomography, neuroleptic drug actions, plasma levels of the dopamine metabolite homovanillic acid (HVA), and cerebral blood flow.  RESULTS:  Evidence, particularly from intracellular recording studies in animals and plasma HVA measurements, suggests that neuroleptics act by reducing dopamine activity in mesolimbic dopamine neurons.  Post-mortem studies have shown high dopamine and HVA concentrations in various subcortical brain regions and greater than normal dopamine receptor densities in the brains of schizophrenic patients.  On the other hand, the negative/deficit symptom complex of schizophrenia may be associated with low dopamine activity in the prefrontal cortex.  Recent animal and human studies suggest that prefrontal dopamine neurons inhibit subcortical dopamine activity.  The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity (causing deficit symptoms) leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms).  CONCLUSIONS:  The possible co-occurrence of high and low dopamine activity in schizophrenia has implications for the conceptualization of dopamine's role in schizophrenia.  It would explain the concurrent presence of negative and positive symptoms.  This hypothesis is testable and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjdRe5bVrnXhJ5E29YNGvQfW6udTcc2eZ2QJ4gKPIB4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D&md5=15af042ac86f1634ea1c0b7c0fb76582</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1176%2Fajp.148.11.1474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.148.11.1474%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26aulast%3DKo%26aufirst%3DG.%26aulast%3DDavidson%26aufirst%3DM.%26atitle%3DDopamine%2520in%2520schizophrenia%253A%2520a%2520review%2520and%2520reconceptualization%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1991%26volume%3D148%26spage%3D1474%26epage%3D1486%26doi%3D10.1176%2Fajp.148.11.1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrington, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiodo, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailman, R.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1411</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fsj.npp.1300203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=12784105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1400-1411&author=D.+A.+Shapiroauthor=S.+Renockauthor=E.+Arringtonauthor=L.+A.+Chiodoauthor=L.+X.+Liuauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=R.+Mailman&title=Aripiprazole%2C+a+novel+atypical+antipsychotic+drug+with+a+unique+and+robust+pharmacology&doi=10.1038%2Fsj.npp.1300203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span></div><div class="casAuthors">Shapiro, David A.; Renock, Sean; Arrington, Elaine; Chiodo, Louis A.; Liu, Li-Xin; Sibley, David R.; Roth, Bryan L.; Mailman, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1400-1411</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders.  The current clin. approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)).  Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist.  We now provide a comprehensive pharmacol. profile of aripiprazole at a large no. of cloned G protein-coupled receptors, transporters, and ion channels.  These data reveal a no. of interesting and potentially important mol. targets for which aripiprazole has affinity.  Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3-dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors.  Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors.  Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors.  Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examd.  This mixt. of functional actions at D2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has functionally selective' actions.  Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors-particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc1m1pKWaDH7Vg90H21EOLACvtfcHk0ljWowAljU6bKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D&md5=a90dfc24826c78d9a630ae4831d99cb0</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300203%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DD.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DArrington%26aufirst%3DE.%26aulast%3DChiodo%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMailman%26aufirst%3DR.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520atypical%2520antipsychotic%2520drug%2520with%2520a%2520unique%2520and%2520robust%2520pharmacology%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1400%26epage%3D1411%26doi%3D10.1038%2Fsj.npp.1300203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caroff, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurford, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lybrand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, E. C.</span></span> <span> </span><span class="NLM_article-title">Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial</span>. <i>Neurol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/j.ncl.2010.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.ncl.2010.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21172575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FlslSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=127-148&author=S.+N.+Caroffauthor=I.+Hurfordauthor=J.+Lybrandauthor=E.+C.+Campbell&title=Movement+disorders+induced+by+antipsychotic+drugs%3A+implications+of+the+CATIE+schizophrenia+trial&doi=10.1016%2Fj.ncl.2010.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial</span></div><div class="casAuthors">Caroff Stanley N; Hurford Irene; Lybrand Janice; Campbell E Cabrina</div><div class="citationInfo"><span class="NLM_cas:title">Neurologic clinics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-48, viii</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced movement disorders have dramatically declined with the widespread use of second-generation antipsychotics, but remain important in clinical practice and for understanding antipsychotic pharmacology.  The diagnosis and management of dystonia, parkinsonism, akathisia, catatonia, neuroleptic malignant syndrome, and tardive dyskinesia are reviewed in relation to the decreased liability of the second-generation antipsychotics contrasted with evidence from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.  Data from the CATIE trial imply that advantages of second-generation antipsychotics in significantly reducing extrapyramidal side effects compared with haloperidol may be diminished when compared with modest doses of lower-potency first-generation drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBIN3LUXilvJdYoSR9eyvsfW6udTcc2eZ2QJ4gKPIB4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FlslSruw%253D%253D&md5=c7fd6d2ec77cd158cd6aec0cce9f91d1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2010.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2010.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DS.%2BN.%26aulast%3DHurford%26aufirst%3DI.%26aulast%3DLybrand%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DE.%2BC.%26atitle%3DMovement%2520disorders%2520induced%2520by%2520antipsychotic%2520drugs%253A%2520implications%2520of%2520the%2520CATIE%2520schizophrenia%2520trial%26jtitle%3DNeurol.%2520Clin.%26date%3D2011%26volume%3D29%26spage%3D127%26epage%3D148%26doi%3D10.1016%2Fj.ncl.2010.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selfani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soland, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span> <span> </span><span class="NLM_article-title">Movement disorders induced by the “atypical” antipsychotic aripiprazole</span>. <i>Neurologist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1097/NRL.0000000000000096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1097%2FNRL.0000000000000096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=24-28&author=K.+Selfaniauthor=V.+L.+Solandauthor=S.+Chouinardauthor=P.+Huot&title=Movement+disorders+induced+by+the+%E2%80%9Catypical%E2%80%9D+antipsychotic+aripiprazole&doi=10.1097%2FNRL.0000000000000096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1097%2FNRL.0000000000000096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FNRL.0000000000000096%26sid%3Dliteratum%253Aachs%26aulast%3DSelfani%26aufirst%3DK.%26aulast%3DSoland%26aufirst%3DV.%2BL.%26aulast%3DChouinard%26aufirst%3DS.%26aulast%3DHuot%26aufirst%3DP.%26atitle%3DMovement%2520disorders%2520induced%2520by%2520the%2520%25E2%2580%259Catypical%25E2%2580%259D%2520antipsychotic%2520aripiprazole%26jtitle%3DNeurologist%26date%3D2017%26volume%3D22%26spage%3D24%26epage%3D28%26doi%3D10.1097%2FNRL.0000000000000096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailman, R. B.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fsj.npp.1301071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=16554739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=67-77&author=J.+D.+Urbanauthor=G.+A.+Vargasauthor=M.+von+Zastrowauthor=R.+B.+Mailman&title=Aripiprazole+has+functionally+selective+actions+at+dopamine+D2+receptor-mediated+signaling+pathways&doi=10.1038%2Fsj.npp.1301071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways</span></div><div class="casAuthors">Urban, Jonathan D.; Vargas, Gabriel A.; von Zastrow, Mark; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aripiprazole is a unique atypical antipsychotic drug with an excellent side-effect profile presumed, in part, to be due to lack of typical D2 dopamine receptor antagonist properties.  Whether aripiprazole is a typical D2 partial agonist, or a functionally selective D2 ligand, remains controversial (eg D2-mediated inhibition of adenylate cyclase is system dependent; aripiprazole antagonizes D2 receptor-mediated G-protein-coupled inwardly rectifying potassium channels and guanosine triphosphate nucleotide (GTP)γS coupling).  The current study examd. the D2L receptor binding properties of aripiprazole, as well as the effects of the drug on three downstream D2 receptor-mediated functional effectors: mitogen-activated protein kinase (MAPK) phosphorylation, potentiation of arachidonic acid (AA) release, and D2 receptor internalization.  Unlike quinpirole (a full D2 agonist) or (-)3PPP (S(-)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochloride, a D2 partial agonist), the apparent D2 affinity of aripiprazole was not decreased significantly by GTP.  Moreover, full or partial agonists are expected to have Hill slopes <1.0, yet that of aripiprazole was significantly >1.0.  Whereas aripiprazole partially activated both the MAPK and AA pathways, its potency vs MAPK phosphorylation was much lower relative to potencies in assays either of AA release or inhibition of cyclic adenosine 3',5'-cyclic monophosphate accumulation.  In addn., unlike typical agonists, neither aripiprazole nor (-)3PPP produced significant internalization of the D2L receptor.  These data are clear evidence that aripiprazole affects D2L-mediated signaling pathways in a differential manner.  The results are consistent with the hypothesis that aripiprazole is a functionally selective D2 ligand rather than a simple partial agonist.  Such data may be useful in understanding the novel clin. actions of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-qAW7cvG3i7Vg90H21EOLACvtfcHk0liWiIEg9gVrqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqtbrJ&md5=20b9edb05787dadb09fb4c778205f0b2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301071%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DG.%2BA.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DAripiprazole%2520has%2520functionally%2520selective%2520actions%2520at%2520dopamine%2520D2%2520receptor-mediated%2520signaling%2520pathways%26jtitle%3DNeuropsychopharmacology%26date%3D2007%26volume%3D32%26spage%3D67%26epage%3D77%26doi%3D10.1038%2Fsj.npp.1301071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yost, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">18488</span>– <span class="NLM_lpage">18493</span>, <span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22025698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+%CE%B2-arrestin-biased+dopamine+D2+ligands+for+probing+signal+transduction+pathways+essential+for+antipsychotic+efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span></div><div class="casAuthors">Allen, John A.; Yost, Julianne M.; Setola, Vincent; Chen, Xin; Sassano, Maria F.; Chen, Meng; Peterson, Sean; Yadav, Prem N.; Huang, Xi-Ping; Feng, Bo; Jensen, Niels H.; Che, Xin; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Caron, Marc G.; Javitch, Jonathan A.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18488-18493, S18488/1-S18488/15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies.  Recent work has highlighted noncanonical modes of dopamine D2 receptor (D2R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents.  We thus sought to create unique D2R agonists that display signaling bias via β-arrestinergic signaling.  Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3); and UNC9994 (4) as unprecedented β-arrestin-biased D2R ligands.  These compds. also represent unprecedented β-arrestin-biased ligands for a Gi-coupled G protein-coupled receptor (GPCR).  Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of Gi-regulated cAMP prodn. and partial agonists for D2R/β-arrestin-2 interactions.  Importantly, VNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo.  Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic .drug with a high propensity to induce catalepsy.  Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin-biased D2R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice.  Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects.  These functionally selective, β-arrestin-biased D2R ligands represent valuable chem. probes for further investigations of D2R signaling in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87mjP6jm447Vg90H21EOLACvtfcHk0liWiIEg9gVrqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK&md5=d5b06e4ac4d2cc4cd04fd1de760ec628</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520%25CE%25B2-arrestin-biased%2520dopamine%2520D2%2520ligands%2520for%2520probing%2520signal%2520transduction%2520pathways%2520essential%2520for%2520antipsychotic%2520efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7141</span>– <span class="NLM_lpage">7153</span>, <span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-functional+selectivity+relationship+studies+of+%CE%B2-arrestin-biased+dopamine+D2+receptor+agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D2 Receptor Agonists</span></div><div class="casAuthors">Chen, Xin; Sassano, Maria F.; Zheng, Lianyou; Setola, Vincent; Chen, Meng; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7141-7153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side effects of drugs.  However, few such ligands have been created, and very little purposeful attention has been devoted to studying what we term: "structure-functional selectivity relationships" (SFSR).  We recently disclosed the first β-arrestin-biased dopamine D2 receptor (D2R) agonists UNC9975 (44) and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities.  Here we report the first comprehensive SFSR studies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery of these β-arrestin-biased D2R agonists.  These studies provide a successful proof-of-concept for how functionally selective ligands can be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoG1fasQ6GLVg90H21EOLACvtfcHk0ljmw3qv8cYRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK&md5=00b0613e62ce7b5a4c98cb5212fea3b5</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-functional%2520selectivity%2520relationship%2520studies%2520of%2520%25CE%25B2-arrestin-biased%2520dopamine%2520D2%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5130</span>– <span class="NLM_lpage">5141</span>, <span class="refDoi"> DOI: 10.1021/jm400520c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400520c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5130-5141&author=C.+Hillerauthor=R.+C.+Klingauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D2%2FD3+receptor+agonists+comprising+an+enyne+moiety&doi=10.1021%2Fjm400520c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Selective Dopamine D2/D3 Receptor Agonists Comprising an Enyne Moiety</span></div><div class="casAuthors">Hiller, Christine; Kling, Ralf C.; Heinemann, Frank W.; Meyer, Karsten; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5130-5141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic ethynylcyclohexynylamines I and ent-I {R = 1,1'-biphenyl-4-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-3-yl, 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl, benzo[b]thiophene-2-yl, ferrocenyl} were prepd. as dopamine receptor agonists with atypical catechol isosteres; their selectivities for dopamine receptors and for activating receptors through G-protein subunits Go and Gi and the metabolic stability of rac-I (R = 4-PhC6H4) were detd.  The ethynylcyclohexynylamines bound to D2-like receptors with high affinities.  Ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) selectively activated D2slow-promoted Go activation over Gi coupling; the most significant functional bias obsd. was for ent-I {R = 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl} which selectively activated Go over Gi coupling at D2long receptors.  Functional selectivity for β-arrestin recruitment over Gi activation was obsd. for I (R = 1,1'-biphenyl-4-yl) and ent-I (R = benzothiophene-2-yl), while ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) preferred β-arrestin recruitment compared to Go coupling.  The structure of a nonracemic N-(ethynylcyclohexenyl)dinitrobenzamide was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXn2SrS-IBCrVg90H21EOLACvtfcHk0ljmw3qv8cYRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D&md5=3855de949f505a83ed3aa561ca182e75</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm400520c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400520c%26sid%3Dliteratum%253Aachs%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D2%252FD3%2520receptor%2520agonists%2520comprising%2520an%2520enyne%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5130%26epage%3D5141%26doi%3D10.1021%2Fjm400520c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span> <span> </span><span class="NLM_article-title">Effects of β-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnpp.2015.196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26129680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=704-715&author=S.+M.+Parkauthor=M.+Chenauthor=C.+M.+Schmerbergauthor=R.+S.+Dulmanauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=J.+Jinauthor=W.+C.+Wetsel&title=Effects+of+%CE%B2-arrestin-biased+dopamine+D2+receptor+ligands+on+schizophrenia-like+behavior+in+hypoglutamatergic+mice&doi=10.1038%2Fnpp.2015.196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice</span></div><div class="casAuthors">Park, Su M.; Chen, Meng; Schmerberg, Claire M.; Dulman, Russell S.; Rodriguiz, Ramona M.; Caron, Marc G.; Jin, Jian; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">704-715</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Current antipsychotic drugs (APDs) show efficacy with pos. symptoms, but are limited in treating neg. or cognitive features of schizophrenia.  Whereas all currently FDA-approved medications target primarily the dopamine D2 receptor (D2R) to inhibit Gi/o-mediated adenylyl cyclase, a recent study has shown that many APDs affect not only Gi/o- but they can also influence β-arrestin- (βArr)-mediated signaling.  The ability of ligands to differentially affect signaling through these pathways is termed functional selectivity.  We have developed ligands that are devoid of D2R-mediated Gi/o protein signaling, but are simultaneously partial agonists for D2R/βArr interactions.  The purpose of this study was to test the effectiveness of UNC9975 or UNC9994 on schizophrenia-like behaviors in phencyclidine-treated or NR1-knockdown hypoglutamatergic mice.  We have found the UNC compds. reduce hyperlocomotion in the open field, restore PPI, improve novel object recognition memory, partially normalize social behavior, decrease conditioned avoidance responding, and elicit a much lower level of catalepsy than haloperidol.  These preclin. results suggest that exploitation of functional selectivity may provide unique opportunities to develop drugs with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related conditions than medications that are currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuhB8VxuXDbVg90H21EOLACvtfcHk0ljmw3qv8cYRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO&md5=82de207db3a78d50ff86a48cda2d2e28</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.196%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DDulman%26aufirst%3DR.%2BS.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3DEffects%2520of%2520%25CE%25B2-arrestin-biased%2520dopamine%2520D2%2520receptor%2520ligands%2520on%2520schizophrenia-like%2520behavior%2520in%2520hypoglutamatergic%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26spage%3D704%26epage%3D715%26doi%3D10.1038%2Fnpp.2015.196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Möller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skultety, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Functionally selective dopamine D2, D3 receptor partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4861</span>– <span class="NLM_lpage">4875</span>, <span class="refDoi"> DOI: 10.1021/jm5004039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4861-4875&author=D.+M%C3%B6llerauthor=R.+C.+Klingauthor=M.+Skultetyauthor=K.+Leunerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D2%2C+D3+receptor+partial+agonists&doi=10.1021%2Fjm5004039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm5004039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004039%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DLeuner%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D2%252C%2520D3%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4861%26epage%3D4875%26doi%3D10.1021%2Fjm5004039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein-biased D2 dopamine receptor partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10601</span>– <span class="NLM_lpage">10618</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10601-10618&author=X.+Chenauthor=J.+D.+McCorvyauthor=M.+G.+Fischerauthor=K.+V.+Butlerauthor=Y.+Shenauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+G+protein-biased+D2+dopamine+receptor+partial+agonists&doi=10.1021%2Facs.jmedchem.6b01208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists</span></div><div class="casAuthors">Chen, Xin; McCorvy, John D.; Fischer, Matthew G.; Butler, Kyle V.; Shen, Yudao; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10601-10618</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease.  Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands.  The authors previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist.  In the authors' continuing efforts to identify biased agonists of D2R, the authors unexpectedly discovered a G protein-biased agonist of D2R, compd. 1 (5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[d]thiazole), which is the first G protein-biased D2R agonist from the aripiprazole scaffold.  The authors designed and synthesized novel analogs to explore two regions of 1 and conducted structure-functional selectivity relationship (SFSR) studies.  Here the authors report the discovery of 1, findings from the authors' SFSR studies, and characterization of novel G protein-biased D2R agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeKlhGCqSPxLVg90H21EOLACvtfcHk0lgOrIRwjUwwPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK&md5=81b1435b1ae82438aa3f270f7ee4f853</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DFischer%26aufirst%3DM.%2BG.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520G%2520protein-biased%2520D2%2520dopamine%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10601%26epage%3D10618%26doi%3D10.1021%2Facs.jmedchem.6b01208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Möller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzuneser, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skultety, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzheimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein-biased dopaminergics with a pyrazolo[1,5-a]pyridine substructure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2908</span>– <span class="NLM_lpage">2929</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01857</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01857" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2908-2929&author=D.+M%C3%B6llerauthor=A.+Banerjeeauthor=T.+C.+Uzuneserauthor=M.+Skultetyauthor=T.+Huthauthor=B.+Plouffeauthor=H.+H%C3%BCbnerauthor=C.+Alzheimerauthor=K.+Friedlandauthor=C.+P.+M%C3%BCllerauthor=M.+Bouvierauthor=P.+Gmeiner&title=Discovery+of+G+protein-biased+dopaminergics+with+a+pyrazolo%5B1%2C5-a%5Dpyridine+substructure&doi=10.1021%2Facs.jmedchem.6b01857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure</span></div><div class="casAuthors">Moller Dorothee; Banerjee Ashutosh; Skultety Marika; Hubner Harald; Gmeiner Peter; Uzuneser Taygun C; Muller Christian P; Huth Tobias; Alzheimer Christian; Plouffe Bianca; Bouvier Michel; Friedland Kristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2908-2929</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors.  Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties.  In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists.  Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over β-arrestin recruitment at dopamine D2 receptors.  The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo.  Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSsvEaQplNsM25P7XSLhESfW6udTcc2eZjqRsXyz9n-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D&md5=208855de29fed6b821fd6e4a5bfb412f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01857%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DUzuneser%26aufirst%3DT.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DHuth%26aufirst%3DT.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DAlzheimer%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BP.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520G%2520protein-biased%2520dopaminergics%2520with%2520a%2520pyrazolo%255B1%252C5-a%255Dpyridine%2520substructure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2908%26epage%3D2929%26doi%3D10.1021%2Facs.jmedchem.6b01857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechsteiner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormos, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnchembio.2527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29227473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFGmur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=126-134&author=J.+D.+McCorvyauthor=K.+V.+Butlerauthor=B.+Kellyauthor=K.+Rechsteinerauthor=J.+Karpiakauthor=R.+M.+Betzauthor=B.+L.+Kormosauthor=B.+K.+Shoichetauthor=R.+O.+Drorauthor=J.+Jinauthor=B.+L.+Roth&title=Structure-inspired+design+of+%CE%B2-arrestin-biased+ligands+for+aminergic+GPCRs&doi=10.1038%2Fnchembio.2527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs</span></div><div class="casAuthors">McCorvy, John D.; Butler, Kyle V.; Kelly, Brendan; Rechsteiner, Katie; Karpiak, Joel; Betz, Robin M.; Kormos, Bethany L.; Shoichet, Brian K.; Dror, Ron O.; Jin, Jian; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-134</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Development of biased ligands targeting G protein-coupled receptors (GPCRs) is a promising approach for current drug discovery.  Although structure-based drug design of biased agonists remains challenging even with an abundance of GPCR crystal structures, the authors present an approach for translating GPCR structural data into β-arrestin-biased ligands for aminergic GPCRs.  The authors identified specific amino acid-ligand contacts at transmembrane helix 5 (TM5) and extracellular loop 2 (EL2) responsible for Gi/o and β-arrestin signaling, resp., and targeted those residues to develop biased ligands.  For these ligands, the authors found that bias is conserved at other aminergic GPCRs that retain similar residues at TM5 and EL2.  The authors' approach provides a template for generating arrestin-biased ligands by modifying predicted ligand interactions that block TM5 interactions and promote EL2 interactions.  This strategy may facilitate the structure-guided design of arrestin-biased ligands at other GPCRs, including polypharmacol. biased ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVs9TaoxiFubVg90H21EOLACvtfcHk0lgOrIRwjUwwPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFGmur3I&md5=2725e8487638cc07ce5e6a655fcd29f2</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2527%26sid%3Dliteratum%253Aachs%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKelly%26aufirst%3DB.%26aulast%3DRechsteiner%26aufirst%3DK.%26aulast%3DKarpiak%26aufirst%3DJ.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DKormos%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure-inspired%2520design%2520of%2520%25CE%25B2-arrestin-biased%2520ligands%2520for%2520aminergic%2520GPCRs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D126%26epage%3D134%26doi%3D10.1038%2Fnchembio.2527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schools, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of an LSD-bound human serotonin receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2016.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28129538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=377-389&author=D.+Wackerauthor=S.+Wangauthor=J.+D.+McCorvyauthor=R.+M.+Betzauthor=A.+J.+Venkatakrishnanauthor=A.+Levitauthor=K.+Lansuauthor=Z.+L.+Schoolsauthor=T.+Cheauthor=D.+E.+Nicholsauthor=B.+K.+Shoichetauthor=R.+O.+Drorauthor=B.+L.+Roth&title=Crystal+structure+of+an+LSD-bound+human+serotonin+receptor&doi=10.1016%2Fj.cell.2016.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an LSD-bound human serotonin receptor</span></div><div class="casAuthors">Wacker, Daniel; Wang, Sheng; McCorvy, John D.; Betz, Robin M.; Venkatakrishnan, A. J.; Levit, Anat; Lansu, Katherine; Schools, Zachary L.; Che, Tao; Nichols, David E.; Shoichet, Brian K.; Dror, Ron O.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">377-389.e12</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The prototypical hallucinogen, LSD, acts via serotonin receptors, and here the authors describe the crystal structure of LSD in complex with human serotonin receptor 5-HT2B.  The complex revealed conformational rearrangements to accommodate LSD, providing a structural explanation for the conformational selectivity of LSD's key diethylamide moiety.  LSD dissocd. exceptionally slow from both 5-HT2BR and 5-HT2AR, a major target for its psychoactivity.  Mol. dynamics (MD) simulations suggested that LSD's slow binding kinetics may be due to a "lid" formed by extracellular loop 2 (EL2) at the entrance to the binding pocket.  A mutation predicted to increase the mobility of this lid greatly accelerated LSD's binding kinetics and selectively dampened LSD-mediated β-arrestin 2 recruitment.  Thus, this study reveals an unexpected binding mode of LSD, illuminates key features of its kinetics, stereochem., and signaling, and provides a mol. explanation for LSD's actions at human serotonin receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcU-96ccslG7Vg90H21EOLACvtfcHk0lgPu_rDxPSq-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaqs7g%253D&md5=5eee71a2d385d97d9891b669e8c5afa1</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DSchools%26aufirst%3DZ.%2BL.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DCrystal%2520structure%2520of%2520an%2520LSD-bound%2520human%2520serotonin%2520receptor%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D377%26epage%3D389%26doi%3D10.1016%2Fj.cell.2016.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agai-Csongor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domany, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogradi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galambos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vago, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlovszky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vastag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tihanyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyertyan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajer-Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemesi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szombathelyi, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3437</span>– <span class="NLM_lpage">3440</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmcl.2012.03.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22537450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3437-3440&author=E.+Agai-Csongorauthor=G.+Domanyauthor=K.+Nogradiauthor=J.+Galambosauthor=I.+Vagoauthor=G.+M.+Keseruauthor=I.+Greinerauthor=I.+Laszlovszkyauthor=A.+Gereauthor=E.+Schmidtauthor=B.+Kissauthor=M.+Vastagauthor=K.+Tihanyiauthor=K.+Saghyauthor=J.+Laszyauthor=I.+Gyertyanauthor=M.+Zajer-Balazsauthor=L.+Gemesiauthor=M.+Kapasauthor=Z.+Szombathelyi&title=Discovery+of+cariprazine+%28RGH-188%29%3A+a+novel+antipsychotic+acting+on+dopamine+D3%2FD2+receptors&doi=10.1016%2Fj.bmcl.2012.03.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors</span></div><div class="casAuthors">Agai-Csongor, Eva; Domany, Gyorgy; Nogradi, Katalin; Galambos, Janos; Vago, Istvan; Keseru, Gyorgy Miklos; Greiner, Istvan; Laszlovszky, Istvan; Gere, Aniko; Schmidt, Eva; Kiss, Bela; Vastag, Monika; Tihanyi, Karoly; Saghy, Katalin; Laszy, Judit; Gyertyan, Istvan; Zajer-Balazs, Maria; Gemesi, Larisza; Kapas, Margit; Szombathelyi, Zsolt</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3437-3440</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Medicinal chem. optimization of an impurity isolated during the scale-up synthesis of a pyridylsulfonamide type dopamine D3/D2 compd. (1, I) led to a series of new piperazine derivs. having affinity to both dopamine D3 and D2 receptors.  Several members of this group showed excellent pharmacokinetic and pharmacodynamic properties as demonstrated by outstanding activities in different antipsychotic tests.  The most promising representative, 2m (cariprazine) had good absorption, excellent brain penetration and advantageous safety profile.  Based on its successful clin. development we are looking forward to the NDA filing of cariprazine in 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgEXo42Fb5i7Vg90H21EOLACvtfcHk0lgPu_rDxPSq-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D&md5=c70cd98791c4d5c2da5ac1f3904a8b98</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.104%26sid%3Dliteratum%253Aachs%26aulast%3DAgai-Csongor%26aufirst%3DE.%26aulast%3DDomany%26aufirst%3DG.%26aulast%3DNogradi%26aufirst%3DK.%26aulast%3DGalambos%26aufirst%3DJ.%26aulast%3DVago%26aufirst%3DI.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DGreiner%26aufirst%3DI.%26aulast%3DLaszlovszky%26aufirst%3DI.%26aulast%3DGere%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DE.%26aulast%3DKiss%26aufirst%3DB.%26aulast%3DVastag%26aufirst%3DM.%26aulast%3DTihanyi%26aufirst%3DK.%26aulast%3DSaghy%26aufirst%3DK.%26aulast%3DLaszy%26aufirst%3DJ.%26aulast%3DGyertyan%26aufirst%3DI.%26aulast%3DZajer-Balazs%26aufirst%3DM.%26aulast%3DGemesi%26aufirst%3DL.%26aulast%3DKapas%26aufirst%3DM.%26aulast%3DSzombathelyi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520cariprazine%2520%2528RGH-188%2529%253A%2520a%2520novel%2520antipsychotic%2520acting%2520on%2520dopamine%2520D3%252FD2%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3437%26epage%3D3440%26doi%3D10.1016%2Fj.bmcl.2012.03.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herenbrink, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">A structure-activity analysis of biased agonism at the dopamine D2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9199</span>– <span class="NLM_lpage">9221</span>, <span class="refDoi"> DOI: 10.1021/jm401318w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401318w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9199-9221&author=J.+Shonbergauthor=C.+K.+Herenbrinkauthor=L.+Lopezauthor=A.+Christopoulosauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=J.+R.+Lane&title=A+structure-activity+analysis+of+biased+agonism+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm401318w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Activity Analysis of Biased Agonism at the Dopamine D2 Receptor</span></div><div class="casAuthors">Shonberg, Jeremy; Herenbrink, Carmen Klein; Lopez, Laura; Christopoulos, Arthur; Scammells, Peter J.; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9199-9221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs.  A no. of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia.  As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor.  The authors have generated SAR based on a novel D2R partial agonist, tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate.  This ligand shares structural similarity to cariprazine, a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points.  The authors synthesized a no. of derivs. of tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate with subtle structural modifications, including incorporation of cariprazine fragments.  By combining pharmacol. profiling with anal. methodol. to identify and to quantify bias, the authors have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group contg. the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocktbsOBHWB7Vg90H21EOLACvtfcHk0lgPu_rDxPSq-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ&md5=124b940132336819740ec30d2962a3a3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm401318w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401318w%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DHerenbrink%26aufirst%3DC.%2BK.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DA%2520structure-activity%2520analysis%2520of%2520biased%2520agonism%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9199%26epage%3D9221%26doi%3D10.1021%2Fjm401318w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4924</span>– <span class="NLM_lpage">4939</span>, <span class="refDoi"> DOI: 10.1021/jm500457x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500457x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4924-4939&author=M.+Szaboauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Structure-activity+relationships+of+privileged+structures+lead+to+the+discovery+of+novel+biased+ligands+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm500457x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Privileged Structures Lead to the Discovery of Novel Biased Ligands at the Dopamine D2 Receptor</span></div><div class="casAuthors">Szabo, Monika; Klein Herenbrink, Carmen; Christopoulos, Arthur; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4924-4939</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism at GPCRs highlights the potential for the discovery and design of pathway-selective ligands and may confer therapeutic advantages to ligands targeting the dopamine D2 receptor (D2R).  We investigated the determinants of efficacy, affinity, and bias for three privileged structures for the D2R, exploring changes to linker length and incorporation of a heterocyclic unit.  Profiling the compds. in two signaling assays (cAMP and pERK1/2) allowed us to identify and quantify determinants of biased agonism at the D2R.  Substitution on the phenylpiperazine privileged structures (2-methoxy vs 2,3-dichloro) influenced bias when the thienopyridine heterocycle was absent.  Upon inclusion of the thienopyridine unit, the substitution pattern (4,6-di-Me vs 5-chloro-6-methoxy-4-methyl) had a significant effect on bias that overruled the effect of the phenylpiperazine substitution pattern.  This latter observation could be reconciled with an extended binding mode for these compds., whereby the interaction of the heterocycle with a secondary binding pocket may engender bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvED1_D7mzdLVg90H21EOLACvtfcHk0lgUnodwwVs-9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVans70%253D&md5=944e53ea2b1abf220e4c76a7d33d6f15</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm500457x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500457x%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DStructure-activity%2520relationships%2520of%2520privileged%2520structures%2520lead%2520to%2520the%2520discovery%2520of%2520novel%2520biased%2520ligands%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4924%26epage%3D4939%26doi%3D10.1021%2Fjm500457x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span> <span> </span><span class="NLM_article-title">Multiple signaling routes involved in the regulation of adenylyl cyclase and extracellular regulated kinase by dopamine D<sub>2</sub> and D<sub>3</sub> receptors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.phrs.2012.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23059541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCkurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=31-41&author=M.+Jinauthor=C.+Minauthor=M.+Zhengauthor=D.+I.+Choauthor=S.+J.+Cheongauthor=H.+Kuroseauthor=K.+M.+Kim&title=Multiple+signaling+routes+involved+in+the+regulation+of+adenylyl+cyclase+and+extracellular+regulated+kinase+by+dopamine+D2+and+D3+receptors&doi=10.1016%2Fj.phrs.2012.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple signaling routes involved in the regulation of adenylyl cyclase and extracellular regulated kinase by dopamine D2 and D3 receptors</span></div><div class="casAuthors">Jin, Mingli; Min, Chengchun; Zheng, Mei; Cho, Dong-Im; Cheong, Soo-Jin; Kurose, Hitosh; Kim, Kyeong-Man</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most G protein coupled receptors (GPCR) regulate multiple cellular processes by coupling to more than one kind of G protein.  Furthermore, recent studies have reported G protein-independent/β-arrestin-dependent signaling pathway for some GPCRs.  Dopamine D2 and D3 receptors (D2R, D3R), the major targets of currently used antipsychotic drugs, are co-expressed in some of the same dopaminergic neurons and regulate the same overlapping effectors.  However, the specific subunits of G proteins that regulate each signaling pathway are not clearly identified.  In addn., the existence of β-arrestin-dependent/G protein-independent signaling is not clear for these receptors.  In this study, we detd. the G protein subtypes and β-arrestin dependency involved in the signaling of D2R and D3R, which was measured by inhibition of adenylyl cyclase and extracellular signal-regulated kinase (ERK) activation.  For the inhibition of cAMP prodn. in HEK-293 cells, D2R used the Gαo subunit but D3R used the βγ subunit of Gi family proteins.  For the regulation of ERK activation, D2R used the α subunits of Gi/o proteins both in HEK-293 cells and COS-7 cells, but D3R used Gαo and Gβγ in HEK-293 cells and COS-7 cells, resp. β-Arrestin-dependent/G protein-independent ERK activation was not obsd. for both D2R and D3R.  Agonist-induced β-arrestin translocation was obsd. with D2R but not with D3R, and β-arrestins exerted inhibitory influences on G protein-dependent ERK activation by D2R, but not D3R.  These results show that the D2R and D3R, which have overlapping cellular expressions and functional roles, employ distinct G protein subunits depending on the cell types and the effectors they control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVXecuPvPD8LVg90H21EOLACvtfcHk0lgUnodwwVs-9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCkurvK&md5=87783b85dd9c38aae8c8eb8f3d3f4137</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%26aulast%3DMin%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DD.%2BI.%26aulast%3DCheong%26aufirst%3DS.%2BJ.%26aulast%3DKurose%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BM.%26atitle%3DMultiple%2520signaling%2520routes%2520involved%2520in%2520the%2520regulation%2520of%2520adenylyl%2520cyclase%2520and%2520extracellular%2520regulated%2520kinase%2520by%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D67%26spage%3D31%26epage%3D41%26doi%3D10.1016%2Fj.phrs.2012.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) biased agonism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2890-2907&author=A.+Bonifaziauthor=H.+Yanoauthor=M.+P.+Ellenbergerauthor=L.+Mullerauthor=V.+Kumarauthor=M.+F.+Zouauthor=N.+S.+Caiauthor=A.+M.+Guerreroauthor=A.+S.+Woodsauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+bivalent+ligands+based+on+the+sumanirole+pharmacophore+reveal+dopamine+D2+receptor+%28D2R%29+biased+agonism&doi=10.1021%2Facs.jmedchem.6b01875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Ellenberger, Michael P.; Muller, Ludovic; Kumar, Vivek; Zou, Mu-Fa; Cai, Ning Sheng; Guerrero, Adrian M.; Woods, Amina S.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2890-2907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype.  The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways.  Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore.  We found that substitutions in the N-1- and/or N-5-positions, physiochem. properties of those substituents, and secondary arom. pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment.  Compd. 19 was identified as a new lead for its selective D2 G-protein biased agonism with an EC50 in the subnanomolar range.  Structure-activity correlations were obsd. between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compds. to selectively activate G-proteins vs. β-arrestin recruitment in D2R-BRET functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprfScHokUgP7Vg90H21EOLACvtfcHk0ljNZPH1PKnR-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D&md5=24bf22a101756e44fbc8f8345d2c1fe4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01875%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520bivalent%2520ligands%2520based%2520on%2520the%2520sumanirole%2520pharmacophore%2520reveal%2520dopamine%2520D2%2520receptor%2520%2528D2R%2529%2520biased%2520agonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2890%26epage%3D2907%26doi%3D10.1021%2Facs.jmedchem.6b01875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, Z.</span></span> <span> </span><span class="NLM_article-title">Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1002/mds.21191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmds.21191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=483-489&author=P.+Baroneauthor=J.+Lambauthor=A.+Ellisauthor=Z.+Clarke&title=Sumanirole+versus+placebo+or+ropinirole+for+the+adjunctive+treatment+of+patients+with+advanced+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.21191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1002%2Fmds.21191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.21191%26sid%3Dliteratum%253Aachs%26aulast%3DBarone%26aufirst%3DP.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DZ.%26atitle%3DSumanirole%2520versus%2520placebo%2520or%2520ropinirole%2520for%2520the%2520adjunctive%2520treatment%2520of%2520patients%2520with%2520advanced%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2007%26volume%3D22%26spage%3D483%26epage%3D489%26doi%3D10.1002%2Fmds.21191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Borreguero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versavel, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study</span>. <i>Sleep Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.sleep.2006.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.sleep.2006.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=17239657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FptlChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=119-127&author=D.+Garcia-Borregueroauthor=J.+Winkelmanauthor=A.+Adamsauthor=A.+Ellisauthor=M.+Morrisauthor=J.+Lambauthor=G.+Laytonauthor=M.+Versavel&title=Efficacy+and+tolerability+of+sumanirole+in+restless+legs+syndrome%3A+a+phase+II%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+dose-response+study&doi=10.1016%2Fj.sleep.2006.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study</span></div><div class="casAuthors">Garcia-Borreguero Diego; Winkelman John; Adams Alieu; Ellis Amanda; Morris Mark; Lamb Janice; Layton Gary; Versavel Mark</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-27</span>
        ISSN:<span class="NLM_cas:issn">1389-9457</span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare the efficacy, safety and tolerability of sumanirole with placebo in patients with idiopathic restless legs syndrome (RLS).  METHODS:  In this double-blind, placebo-controlled, randomized, parallel-group, dose-response study, 270 patients with idiopathic RLS were enrolled and randomized to receive sumanirole 0.5, 1.0, 2.0, or 4.0mg, or placebo.  The primary efficacy endpoint was mean change of the total score of the International Restless Legs Scale (IRLS-10), a 10-item scale, from baseline to end of maintenance.  Secondary assessments included polysomnography (PSG) variables.  RESULTS:  Treatment with sumanirole was well tolerated.  Mean change in IRLS-10 showed no statistically significant change compared with placebo at any dose, although the mean change with the 4.0-mg dose was numerically greater than the other doses and placebo.  PSG variables, specifically the periodic leg movements during sleep, showed statistically significant dose-related improvement in favor of sumanirole.  Consistent with earlier multinational, multicenter studies in RLS, high placebo response rates were seen with IRLS-10 but not with PSG variables.  CONCLUSIONS:  Given data published in Parkinson's disease, the dose range of sumanirole selected here may have been too low.  Alternatively, dopamine D(2) selective agents could be intrinsically less effective than agonists with combined D(2)/D(3) activity.  Sumanirole demonstrated an excellent safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0REIOVoKVNDEwO064Z95rfW6udTcc2eaAa1l-4zN-fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FptlChtw%253D%253D&md5=aeeae1bc95f4cbd3678ad89c9ebd368e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2006.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2006.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Borreguero%26aufirst%3DD.%26aulast%3DWinkelman%26aufirst%3DJ.%26aulast%3DAdams%26aufirst%3DA.%26aulast%3DEllis%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DM.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DLayton%26aufirst%3DG.%26aulast%3DVersavel%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520sumanirole%2520in%2520restless%2520legs%2520syndrome%253A%2520a%2520phase%2520II%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-response%2520study%26jtitle%3DSleep%2520Med.%26date%3D2007%26volume%3D8%26spage%3D119%26epage%3D127%26doi%3D10.1016%2Fj.sleep.2006.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Bittner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Đordevic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacher, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skepner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennehy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faloon, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Functionally biased D2R antagonists: targeting the β-arrestin pathway to improve antipsychotic treatment</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00168</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00168" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlOrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1038-1047&author=M.+We%C3%AFwerauthor=Q.+Xuauthor=J.+P.+Galeauthor=M.+Lewisauthor=A.+J.+Campbellauthor=F.+A.+Schroederauthor=G.+C.+Van+de+Bittnerauthor=M.+Walkauthor=A.+Amayaauthor=P.+Suauthor=L.+%C4%90ordevicauthor=J.+R.+Sacherauthor=A.+Skepnerauthor=D.+Feiauthor=K.+Dennehyauthor=S.+Nguyenauthor=P.+W.+Faloonauthor=J.+Perezauthor=J.+R.+Cottrellauthor=F.+Liuauthor=M.+Palmerauthor=J.+Q.+Panauthor=J.+M.+Hookerauthor=Y.+L.+Zhangauthor=E.+Scolnickauthor=F.+F.+Wagnerauthor=E.+B.+Holson&title=Functionally+biased+D2R+antagonists%3A+targeting+the+%CE%B2-arrestin+pathway+to+improve+antipsychotic+treatment&doi=10.1021%2Facschembio.8b00168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment</span></div><div class="casAuthors">Weiwer, Michel; Xu, Qihong; Gale, Jennifer P.; Lewis, Michael; Campbell, Arthur J.; Schroeder, Frederick A.; Van de Bittner, Genevieve C.; Walk, Michelle; Amaya, Aldo; Su, Ping; Dordevic, Luka; Sacher, Joshua R.; Skepner, Adam; Fei, David; Dennehy, Kelly; Nguyen, Shannon; Faloon, Patrick W.; Perez, Jose; Cottrell, Jeffrey R.; Liu, Fang; Palmer, Michelle; Pan, Jen Q.; Hooker, Jacob M.; Zhang, Yan-Ling; Scolnick, Edward; Wagner, Florence F.; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1038-1047</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Schizophrenia is a severe neuropsychiatric disease that lacks completely effective and safe therapies.  As a polygenic disorder, genetic studies have only started to shed light on its complex etiol.  To date, the pos. symptoms of schizophrenia are well-managed by antipsychotic drugs, which primarily target the dopamine D2 receptor (D2R).  However, these antipsychotics are often accompanied by severe side effects, including motoric symptoms.  At D2R, antipsychotic drugs antagonize both G-protein dependent (Gαi/o) signaling and G-protein independent (β-arrestin) signaling.  However, the relevant contributions of the distinct D2R signaling pathways to antipsychotic efficacy and on-target side effects (motoric) are still incompletely understood.  Recent evidence from mouse genetic and pharmacol. studies point to β-arrestin signaling as the major driver of antipsychotic efficacy and suggest that a β-arrestin biased D2R antagonist could achieve an addnl. level of selectivity at D2R, increasing the therapeutic index of next generation antipsychotics.  Here, we characterize BRD5814, a highly brain penetrant β-arrestin biased D2R antagonist.  BRD5814 demonstrated good target engagement via PET imaging, achieving efficacy in an amphetamine-induced hyperlocomotion mouse model with strongly reduced motoric side effects in a rotarod performance test.  This proof of concept study opens the possibility for the development of a new generation of pathway selective antipsychotics at D2R with reduced side effect profiles for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPBrMik6d7a7Vg90H21EOLACvtfcHk0ljNZPH1PKnR-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlOrtbw%253D&md5=51d636dd2a0ebfc83d58a6158a1da40e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00168%26sid%3Dliteratum%253Aachs%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DVan%2Bde%2BBittner%26aufirst%3DG.%2BC.%26aulast%3DWalk%26aufirst%3DM.%26aulast%3DAmaya%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DP.%26aulast%3D%25C4%2590ordevic%26aufirst%3DL.%26aulast%3DSacher%26aufirst%3DJ.%2BR.%26aulast%3DSkepner%26aufirst%3DA.%26aulast%3DFei%26aufirst%3DD.%26aulast%3DDennehy%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DS.%26aulast%3DFaloon%26aufirst%3DP.%2BW.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DCottrell%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DJ.%2BQ.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DScolnick%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DFunctionally%2520biased%2520D2R%2520antagonists%253A%2520targeting%2520the%2520%25CE%25B2-arrestin%2520pathway%2520to%2520improve%2520antipsychotic%2520treatment%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D1038%26epage%3D1047%26doi%3D10.1021%2Facschembio.8b00168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D<sub>2L</sub> receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1124/mol.110.068106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.110.068106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=575-585&author=N.+Tschammerauthor=S.+Bollingerauthor=T.+Kenakinauthor=P.+Gmeiner&title=Histidine+6.55+is+a+major+determinant+of+ligand-biased+signaling+in+dopamine+D2L+receptor&doi=10.1124%2Fmol.110.068106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.068106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.068106%26sid%3Dliteratum%253Aachs%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DBollinger%26aufirst%3DS.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DHistidine%25206.55%2520is%2520a%2520major%2520determinant%2520of%2520ligand-biased%2520signaling%2520in%2520dopamine%2520D2L%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D575%26epage%3D585%26doi%3D10.1124%2Fmol.110.068106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0lit9vDGLmUdnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12ltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=681-692&author=J.+L.+Conroyauthor=R.+B.+Freeauthor=D.+R.+Sibley&title=Identification+of+G+protein-biased+agonists+that+fail+to+recruit+%CE%B2-arrestin+or+promote+internalization+of+the+D1+dopamine+receptor&doi=10.1021%2Facschemneuro.5b00020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of G Protein-Biased Agonists That Fail To Recruit β-Arrestin or Promote Internalization of the D1 Dopamine Receptor</span></div><div class="casAuthors">Conroy, Jennie L.; Free, R. Benjamin; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-692</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The D1 dopamine receptor (D1R) has been implicated in numerous neuropsychiatric disorders, and D1R-selective ligands have potential as therapeutic agents.  Previous studies have identified substituted benzazepines as D1R-selective agonists, but the in vivo effects of these compds. have not correlated well with their in vitro pharmacol. activities.  A series of substituted benzazepines, and structurally dissimilar D1R-selective agonists, were tested for their functional effects on D1R-mediated cAMP accumulation, D1R-promoted β-arrestin recruitment, and D1R internalization using live cell functional assays.  All compds. tested elicited an increase in the level of cAMP accumulation, albeit with a range of efficacies.  However, when the compds. were evaluated for β-arrestin recruitment, a subset of substituted benzazepines, SKF 83959, SKF 38393, SKF 82957, SKF 77434, and SKF 75670, failed to activate this pathway, whereas the others showed similar activation efficacies as seen with cAMP accumulation.  When tested as antagonists, the five biased compds. all inhibited dopamine-stimulated β-arrestin recruitment.  Further, D1R internalization assays revealed a corroborating pattern of activity in that the G protein-biased compds. failed to promote D1R internalization.  Interestingly, the biased signaling was unique for the D1R, as the same compds. were agonists of the related D5 dopamine receptor (D5R), but revealed no signaling bias.  We have identified a group of substituted benzazepine ligands that are agonists at D1R-mediated G protein signaling, but antagonists of D1R recruitment of β-arrestin, and also devoid of agonist-induced receptor endocytosis.  These data may be useful for interpreting the contrasting effects of these compds. in vitro vs. in vivo, and also for the understanding of pathway-selective signaling of the D1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSzHbUv0uO9LVg90H21EOLACvtfcHk0lit9vDGLmUdnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12ltbg%253D&md5=5f955a73b220ec7c20e483e6192be737</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00020%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DIdentification%2520of%2520G%2520protein-biased%2520agonists%2520that%2520fail%2520to%2520recruit%2520%25CE%25B2-arrestin%2520or%2520promote%2520internalization%2520of%2520the%2520D1%2520dopamine%2520receptor%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D681%26epage%3D692%26doi%3D10.1021%2Facschemneuro.5b00020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, M. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ghundi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span> <span> </span><span class="NLM_article-title">D1–D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of G<sub>q/11</sub> in the striatum</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1073/pnas.0604049104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0604049104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=654-659&author=A.+J.+Rashidauthor=C.+H.+Soauthor=M.+M.+C.+Kongauthor=T.+Furtakauthor=M.+El-Ghundiauthor=R.+Chengauthor=B.+F.+O%E2%80%99Dowdauthor=S.+R.+George&title=D1%E2%80%93D2+dopamine+receptor+heterooligomers+with+unique+pharmacology+are+coupled+to+rapid+activation+of+Gq%2F11+in+the+striatum&doi=10.1073%2Fpnas.0604049104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0604049104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0604049104%26sid%3Dliteratum%253Aachs%26aulast%3DRashid%26aufirst%3DA.%2BJ.%26aulast%3DSo%26aufirst%3DC.%2BH.%26aulast%3DKong%26aufirst%3DM.%2BM.%2BC.%26aulast%3DFurtak%26aufirst%3DT.%26aulast%3DEl-Ghundi%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26atitle%3DD1%25E2%2580%2593D2%2520dopamine%2520receptor%2520heterooligomers%2520with%2520unique%2520pharmacology%2520are%2520coupled%2520to%2520rapid%2520activation%2520of%2520Gq%252F11%2520in%2520the%2520striatum%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D654%26epage%3D659%26doi%3D10.1073%2Fpnas.0604049104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volfson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilmette, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salafia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M. D.</span></span> <span> </span><span class="NLM_article-title">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">674</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02776-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fs41467-017-02776-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29445200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=674&author=D.+L.+Grayauthor=J.+A.+Allenauthor=S.+Menteauthor=R.+E.+O%E2%80%99Connorauthor=G.+J.+DeMarcoauthor=I.+Efremovauthor=P.+Tierneyauthor=D.+Volfsonauthor=J.+Davorenauthor=E.+Guilmetteauthor=M.+Salafiaauthor=R.+Kozakauthor=M.+D.+Ehlers&title=Impaired+%CE%B2-arrestin+recruitment+and+reduced+desensitization+by+non-catechol+agonists+of+the+D1+dopamine+receptor&doi=10.1038%2Fs41467-017-02776-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span></div><div class="casAuthors">Gray David L; Mente Scot; Efremov Ivan; Davoren Jennifer; Gray David L; Allen John A; Tierney Patrick; Volfson Dmitri; Guilmette Edward; Kozak Rouba; Ehlers Michael D; Allen John A; O'Connor Rebecca E; Salafia Michelle; DeMarco George J; Ehlers Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">674</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Selective activation of dopamine D1 receptors (D1Rs) has been pursued for 40 years as a therapeutic strategy for neurologic and psychiatric diseases due to the fundamental role of D1Rs in motor function, reward processing, and cognition.  All known D1R-selective agonists are catechols, which are rapidly metabolized and desensitize the D1R after prolonged exposure, reducing agonist response.  As such, drug-like selective D1R agonists have remained elusive.  Here we report a novel series of selective, potent non-catechol D1R agonists with promising in vivo pharmacokinetic properties.  These ligands stimulate adenylyl cyclase signaling and are efficacious in a rodent model of Parkinson's disease after oral administration.  They exhibit distinct binding to the D1R orthosteric site and a novel functional profile including minimal receptor desensitization, reduced recruitment of β-arrestin, and sustained in vivo efficacy.  These results reveal a novel class of D1 agonists with favorable drug-like properties, and define the molecular basis for catechol-specific recruitment of β-arrestin to D1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShdJOozuyZkBe4jJGKT5N0fW6udTcc2eZ1HiL-D4FxTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D&md5=2ba64bda304b083647eedff999f3fdcd</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02776-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02776-7%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DD.%2BL.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DDeMarco%26aufirst%3DG.%2BJ.%26aulast%3DEfremov%26aufirst%3DI.%26aulast%3DTierney%26aufirst%3DP.%26aulast%3DVolfson%26aufirst%3DD.%26aulast%3DDavoren%26aufirst%3DJ.%26aulast%3DGuilmette%26aufirst%3DE.%26aulast%3DSalafia%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DR.%26aulast%3DEhlers%26aufirst%3DM.%2BD.%26atitle%3DImpaired%2520%25CE%25B2-arrestin%2520recruitment%2520and%2520reduced%2520desensitization%2520by%2520non-catechol%2520agonists%2520of%2520the%2520D1%2520dopamine%2520receptor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D674%26doi%3D10.1038%2Fs41467-017-02776-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span> <span> </span><span class="NLM_article-title">Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.071092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.104.071092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=15292458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=1008-1015&author=E.+M.+Jutkiewiczauthor=J.+Bergman&title=Effects+of+dopamine+D1+ligands+on+eye+blinking+in+monkeys%3A+efficacy%2C+antagonism%2C+and+D1%2FD2+interactions&doi=10.1124%2Fjpet.104.071092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dopamine D1 ligands on eye blinking in monkeys: Efficacy, antagonism, and D1/D2 interactions</span></div><div class="casAuthors">Jutkiewicz, Emily M.; Bergman, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1008-1015</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dopamine D1 ligands have been classified and ordered according to efficacy in both in vitro and in vivo studies.  In the present expts., dopamine D1 ligands reported to differ in in vitro efficacy were evaluated for efficacy-related effects on eye blinking in squirrel monkeys.  Addnl. comparisons were made with the effects of D2 receptor agonists and indirect dopamine agonists.  The results show that D1 agonists increased eye blinking in an efficacy-related manner, whereas the D1 receptor blocker SCH 39166 only decreased rates of eye blinking.  D1 high-efficacy agonists induced rates of eye blinking that were 2- to 3-fold greater than obsd. with dopamine D2 agonists and indirect agonists.  In drug combination expts., increases in eye blinking induced by the D1 high-efficacy agonist R-(+)-6-Br-APB [R-(+)-6-bromo-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] were antagonized by both the D1 antagonist SCH 39166 and the lower efficacy agonist SKF 83959, consistent with dopamine D1 receptor mediation of these behavioral effects.  The dopamine D2 agonist (+)-PHNO [(+)-N-propyl-hydroxynaphthoxazine], which selectively activates dopamine D2 receptors, also attenuated D1 agonist-induced increase in eye blinking, suggesting that D2 receptor actions may inhibit D1-mediated increases in eye blinking.  Overall, eye blink rate appears to be a robust behavioral measure that can be used to measure changes in dopaminergic D1 signaling and as a functional assay of agonist efficacy at dopamine D1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrldySt7xAQHrVg90H21EOLACvtfcHk0lhyYpAticCJNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmtLzF&md5=1071e52cc321c4ec2fb910d0f3fef5a1</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.071092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.071092%26sid%3Dliteratum%253Aachs%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DBergman%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520dopamine%2520D1%2520ligands%2520on%2520eye%2520blinking%2520in%2520monkeys%253A%2520efficacy%252C%2520antagonism%252C%2520and%2520D1%252FD2%2520interactions%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D1008%26epage%3D1015%26doi%3D10.1124%2Fjpet.104.071092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure and function of serotonin G protein-coupled receptors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.pharmthera.2015.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25601315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2015&pages=129-142&author=J.+D.+McCorvyauthor=B.+L.+Roth&title=Structure+and+function+of+serotonin+G+protein-coupled+receptors&doi=10.1016%2Fj.pharmthera.2015.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of serotonin G protein-coupled receptors</span></div><div class="casAuthors">McCorvy, John D.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-142</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Serotonin receptors are prevalent throughout the nervous system and the periphery, and remain one of the most lucrative and promising drug discovery targets for disorders ranging from migraine headaches to neuropsychiatric disorders such as schizophrenia and depression.  There are 14 distinct serotonin receptors, of which 13 are G protein-coupled receptors (GPCRs), which are targets for approx. 40% of the approved medicines.  Recent crystallog. and biochem. evidence has provided a converging understanding of the basic structure and functional mechanics of GPCR activation.  Currently, two GPCR crystal structures exist for the serotonin family, the 5-HT1B and 5-HT2B receptor, with the antimigraine and valvulopathic drug ergotamine bound.  The first serotonin crystal structures not only provide the first evidence of serotonin receptor topog. but also provide mechanistic explanations into functional selectivity or biased agonism.  This review will detail the findings of these crystal structures from a mol. and mutagenesis perspective for driving rational drug design for novel therapeutics incorporating biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpapliz37oS9bVg90H21EOLACvtfcHk0lhyYpAticCJNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisbs%253D&md5=0fcfbc57dfb7047f6ffb7c74d437b5b4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520and%2520function%2520of%2520serotonin%2520G%2520protein-coupled%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D150%26spage%3D129%26epage%3D142%26doi%3D10.1016%2Fj.pharmthera.2015.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maayani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramellini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W. P.</span></span> <span> </span><span class="NLM_article-title">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1124/mol.54.1.94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.54.1.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=9658194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=94-104&author=K.+A.+Bergauthor=S.+Maayaniauthor=J.+Goldfarbauthor=C.+Scaramelliniauthor=P.+Leffauthor=W.+P.+Clarke&title=Effector+pathway-dependent+relative+efficacy+at+serotonin+type+2A+and+2C+receptors%3A+evidence+for+agonist-directed+trafficking+of+receptor+stimulus&doi=10.1124%2Fmol.54.1.94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus</span></div><div class="casAuthors">Berg, Kelly A.; Maayani, Saul; Goldfarb, Joseph; Scaramellini, Clare; Leff, Paul; Clarke, William P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">There are many examples of a single receptor coupling directly to more than one cellular signal transduction pathway.  Although traditional receptor theory allows for activation of multiple cellular effectors by agonists, it predicts that the relative degree of activation of each effector pathway by an agonist (relative efficacy) must be the same.  In the current expts., we demonstrate that agonists at the human serotonin2A (5-HT2A) and 5-HT2C receptors activate differentially two signal transduction pathways independently coupled to the receptors [phospholipase C (PLC)-mediated inositol phosphate (IP) accumulation and phospholipase A2 (PLA2)-mediated arachidonic acid (AA) release].  The relative efficacies of agonists differed depending on which signal transduction pathway was measured.  Moreover, relative to 5-HT, some 5-HT2C agonists (e.g., 3-trifluoromethylphenyl-piperazine) preferentially activated the PLC-IP pathway, whereas others (e.g., lysergic acid diethylamide) favored the PLA2-AA pathway.  In contrast, when two dependent responses were measured (IP accumulation and calcium mobilization), agonist relative efficacies were not different.  These data strongly support the hypothesis termed "agonist-directed trafficking of receptor stimulus" recently proposed by Kenakin [Trends Pharmacol Sci 16:232-238 (1995)].  Concn.-response curves to 5-HT2C agonists were fit well by a three-state model of receptor activation, suggesting that two active receptor states may be sufficient to explain pathway-dependent agonist efficacy.  Rational drug design that optimizes preferential effector activity within a group of receptor-selective drugs holds the promise of increased selectivity in clin. useful agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpidEqbbZNg07Vg90H21EOLACvtfcHk0li-JD1k5KHPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVKqt7w%253D&md5=99239b54cc498d1254aad42298ea5684</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fmol.54.1.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.54.1.94%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DK.%2BA.%26aulast%3DMaayani%26aufirst%3DS.%26aulast%3DGoldfarb%26aufirst%3DJ.%26aulast%3DScaramellini%26aufirst%3DC.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26atitle%3DEffector%2520pathway-dependent%2520relative%2520efficacy%2520at%2520serotonin%2520type%25202A%2520and%25202C%2520receptors%253A%2520evidence%2520for%2520agonist-directed%2520trafficking%2520of%2520receptor%2520stimulus%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D54%26spage%3D94%26epage%3D104%26doi%3D10.1124%2Fmol.54.1.94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpsoe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> receptor structures reveal the structural basis of GPCR polypharmacology</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2018.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29398112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=719-730&author=Y.+Pengauthor=J.+D.+McCorvyauthor=K.+Harpsoeauthor=K.+Lansuauthor=S.+G.+Yuanauthor=P.+Popovauthor=L.+Quauthor=M.+C.+Puauthor=T.+Cheauthor=L.+F.+Nikolajsenauthor=X.+P.+Huangauthor=Y.+R.+Wuauthor=L.+Shenauthor=W.+E.+Bjorn-Yoshimotoauthor=K.+Dingauthor=D.+Wackerauthor=G.+W.+Hanauthor=J.+J.+Chengauthor=V.+Katritchauthor=A.+A.+Jensenauthor=M.+A.+Hansonauthor=S.+W.+Zhaoauthor=D.+E.+Gloriamauthor=B.+L.+Rothauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=5-HT2C+receptor+structures+reveal+the+structural+basis+of+GPCR+polypharmacology&doi=10.1016%2Fj.cell.2018.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span></div><div class="casAuthors">Peng, Yao; McCorvy, John D.; Harpsoee, Kasper; Lansu, Katherine; Yuan, Shuguang; Popov, Petr; Qu, Lu; Pu, Mengchen; Che, Tao; Nikolajsen, Louise F.; Huang, Xi-Ping; Wu, Yiran; Shen, Ling; Bjoern-Yoshimoto, Walden E.; Ding, Kang; Wacker, Daniel; Han, Gye Won; Cheng, Jianjun; Katritch, Vsevolod; Jensen, Anders A.; Hanson, Michael A.; Zhao, Suwen; Gloriam, David E.; Roth, Bryan L.; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-730.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs frequently require interactions with multiple targets-via a process known as polypharmacol.-to achieve their therapeutic actions.  Currently, drugs targeting several serotonin receptors, including the 5-HT2C receptor, are useful for treating obesity, drug abuse, and schizophrenia.  The competing challenges of developing selective 5-HT2C receptor ligands or creating drugs with a defined polypharmacol. profile, esp. aimed at G protein-coupled receptors (GPCRs), remain extremely difficult.  Here, we solved two structures of the 5-HT2C receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT2A-C receptor-selective inverse agonist ritanserin at resolns. of 3.0 Å and 2.7 Å, resp.  We analyzed their resp. binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacol. actions.  This study investigates the structural basis of polypharmacol. at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooMwdaPWz7FLVg90H21EOLACvtfcHk0li-JD1k5KHPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D&md5=b6c7f55568544a8c363794fa12f18175</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DHarpsoe%26aufirst%3DK.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DS.%2BG.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%2BC.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DWu%26aufirst%3DY.%2BR.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%2BJ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DZhao%26aufirst%3DS.%2BW.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3D5-HT2C%2520receptor%2520structures%2520reveal%2520the%2520structural%2520basis%2520of%2520GPCR%2520polypharmacology%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D719%26epage%3D730%26doi%3D10.1016%2Fj.cell.2018.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural features for functional selectivity at serotonin receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1126/science.1232808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1232808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23519215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=615-619&author=D.+Wackerauthor=C.+Wangauthor=V.+Katritchauthor=G.+W.+Hanauthor=X.+P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=Y.+Jiangauthor=M.+Chuauthor=F.+Y.+Siuauthor=W.+Liuauthor=H.+E.+Xuauthor=V.+Cherezovauthor=B.+L.+Rothauthor=R.+C.+Stevens&title=Structural+features+for+functional+selectivity+at+serotonin+receptors&doi=10.1126%2Fscience.1232808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Features for Functional Selectivity at Serotonin Receptors</span></div><div class="casAuthors">Wacker, Daniel; Wang, Chong; Katritch, Vsevolod; Han, Gye Won; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Jiang, Yi; Chu, Meihua; Siu, Fai Yiu; Liu, Wei; Xu, H. Eric; Cherezov, Vadim; Roth, Bryan L.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">615-619</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Drugs active at G protein-coupled receptors (GPCRs) can differentially modulate either canonical or noncanonical signaling pathways via a phenomenon known as functional selectivity or biased signaling.  The authors report biochem. studies showing that the hallucinogen lysergic acid diethylamide, its precursor ergotamine (ERG), and related ergolines display strong functional selectivity for β-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are relatively unbiased at the 5-HT1B receptor.  To investigate the structural basis for biased signaling, the authors detd. the crystal structure of the human 5-HT2B receptor bound to ERG and compared it with the 5-HT1B/ERG structure.  Given the relatively poor understanding of GPCR structure and function to date, insight into different GPCR signaling pathways is important to better understand both adverse and favorable therapeutic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreo_QegM-j7bVg90H21EOLACvtfcHk0liRtXkjvtN6cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksb0%253D&md5=16e96d0255be3ac367aeda7187aa4c15</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232808%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DM.%26aulast%3DSiu%26aufirst%3DF.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DH.%2BE.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520features%2520for%2520functional%2520selectivity%2520at%2520serotonin%2520receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D615%26epage%3D619%26doi%3D10.1126%2Fscience.1232808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for molecular recognition at serotonin receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1126/science.1232807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1232807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23519210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=610-614&author=C.+Wangauthor=Y.+Jiangauthor=J.+M.+Maauthor=H.+X.+Wuauthor=D.+Wackerauthor=V.+Katritchauthor=G.+W.+Hanauthor=W.+Liuauthor=X.+P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=X.+Gaoauthor=X.+E.+Zhouauthor=K.+Melcherauthor=C.+H.+Zhangauthor=F.+Baiauthor=H.+Y.+Yangauthor=L.+L.+Yangauthor=H.+L.+Jiangauthor=B.+L.+Rothauthor=V.+Cherezovauthor=R.+C.+Stevensauthor=H.+E.+Xu&title=Structural+basis+for+molecular+recognition+at+serotonin+receptors&doi=10.1126%2Fscience.1232807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Molecular Recognition at Serotonin Receptors</span></div><div class="casAuthors">Wang, Chong; Jiang, Yi; Ma, Jinming; Wu, Huixian; Wacker, Daniel; Katritch, Vsevolod; Han, Gye Won; Liu, Wei; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Gao, Xiang; Zhou, X. Edward; Melcher, Karsten; Zhang, Chenghai; Bai, Fang; Yang, Huaiyu; Yang, Linlin; Jiang, Hualiang; Roth, Bryan L.; Cherezov, Vadim; Stevens, Raymond C.; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">610-614</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiol. through the 5-HT receptor family.  The authors report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine and dihydroergotamine.  The structures reveal similar binding modes for these ligands, which occupy the orthosteric pocket and an extended binding pocket close to the extracellular loops.  The orthosteric pocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist activity of 5-HT.  Compared with the structure of the 5-HT2B receptor, the 5-HT1B receptor displays a 3 angstrom outward shift at the extracellular end of helix V, resulting in a more open extended pocket that explains subtype selectivity.  Together with docking and mutagenesis studies, these structures provide a comprehensive structural basis for understanding receptor-ligand interactions and designing subtype-selective serotonergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLc0rOIqg_2bVg90H21EOLACvtfcHk0liRtXkjvtN6cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D&md5=ce0773088a86f6a2c83b6cb77a63e708</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232807%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DH.%2BX.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%2BE.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520basis%2520for%2520molecular%2520recognition%2520at%2520serotonin%2520receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D610%26epage%3D614%26doi%3D10.1126%2Fscience.1232807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">We need 2C but not 2B: developing serotonin 2C (5-HT<sub>2C</sub>) receptor agonists for the treatment of CNS disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fcmdc.201500437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26507582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1963-1967&author=J.+J.+Chengauthor=A.+P.+Kozikowski&title=We+need+2C+but+not+2B%3A+developing+serotonin+2C+%285-HT2C%29+receptor+agonists+for+the+treatment+of+CNS+disorders&doi=10.1002%2Fcmdc.201500437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders</span></div><div class="casAuthors">Cheng, Jianjun; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serotonin 2C (5-HT2C) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia.  In this Viewpoint article, recent progress in developing selective 5-HT2C agonists for use in treating these disorders is summarized, including the work of our group.  Challenges in this field and the possible future directions are described.  Homol. modeling as a method to predict the binding modes of 5-HT2C ligands to the receptor is also discussed.  Compared to known ligands, the improved pharmacol. profiles of the 2-phenylcyclopropylmethylamine-based 5-HT2C agonists make them preferred candidates for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr43VsLXn0mBLVg90H21EOLACvtfcHk0liRtXkjvtN6cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J&md5=4a7f2040f4c57da292c7ebac2de8d726</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWe%2520need%25202C%2520but%2520not%25202B%253A%2520developing%2520serotonin%25202C%2520%25285-HT2C%2529%2520receptor%2520agonists%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fcmdc.201500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pogorelov, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmerberg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> agonists modulate schizophrenia-like behaviors in mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2177</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnpp.2017.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28294132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=2163-2177&author=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=J.+Chengauthor=M.+Huangauthor=C.+M.+Schmerbergauthor=H.+Y.+Meltzerauthor=B.+L.+Rothauthor=A.+P.+Kozikowskiauthor=W.+C.+Wetsel&title=5-HT2C+agonists+modulate+schizophrenia-like+behaviors+in+mice&doi=10.1038%2Fnpp.2017.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice</span></div><div class="casAuthors">Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Cheng, Jianjun; Huang, Mei; Schmerberg, Claire M.; Meltzer, Herbert Y.; Roth, Bryan L.; Kozikowski, Alan P.; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2163-2177</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D2 or serotonin (5-HT2A) receptors, or both; however, these medications are not universally effective, they may produce undesirable side effects, and provide only partial amelioration of neg. and cognitive symptoms.  The heterogeneity of pharmacol. responses in schizophrenic patients suggests that addnl. drug targets may be effective in improving aspects of this syndrome.  Recent evidence suggests that 5-HT2C receptors may be a promising target for schizophrenia since their activation reduces mesolimbic nigrostriatal dopamine release (which conveys antipsychotic action), they are expressed almost exclusively in CNS, and have wt.-loss-promoting capabilities.  A difficulty in developing 5-HT2C agonists is that most ligands also possess 5-HT2B and/or 5-HT2A activities.  We have developed selective 5-HT2C ligands and herein describe their preclin. effectiveness for treating schizophrenia-like behaviors.  JJ-3-45, JJ-3-42, and JJ-5-34 reduced amphetamine-stimulated hyperlocomotion, restored amphetamine-disrupted prepulse inhibition, improved social behavior, and novel object recognition memory in NMDA receptor hypofunctioning NR1-knockdown mice, and were essentially devoid of catalepsy.  However, they decreased motivation in a breakpoint assay and did not promote reversal learning in MK-801-treated mice.  Somewhat similar effects were obsd. with lorcaserin, a 5-HT2C agonist with potent 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity.  Microdialysis studies revealed that both JJ-3-42 and lorcaserin reduced dopamine efflux in the infralimbic cortex, while only JJ-3-42 decreased it in striatum.  Collectively, these results provide addnl. evidence that 5-HT2C receptors are suitable drug targets with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related disorders than current APDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTwGQU6HLhHrVg90H21EOLACvtfcHk0lidsqIr_xAvYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFWrtL0%253D&md5=f4b074cad46559dd52e7d622c8af24f9</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.52%26sid%3Dliteratum%253Aachs%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3D5-HT2C%2520agonists%2520modulate%2520schizophrenia-like%2520behaviors%2520in%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D2163%26epage%3D2177%26doi%3D10.1038%2Fnpp.2017.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of functionally selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9866</span>– <span class="NLM_lpage">9880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9866-9880&author=J.+J.+Chengauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=H.+Zhuauthor=T.+Kenakinauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Design+and+discovery+of+functionally+selective+serotonin+2C+%285-HT2C%29+receptor+agonists&doi=10.1021%2Facs.jmedchem.6b01194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists</span></div><div class="casAuthors">Cheng, Jianjun; McCorvy, John D.; Giguere, Patrick M.; Zhu, Hu; Kenakin, Terry; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9866-9880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of the structural similarity of our previous 5-HT2C agonists with the melatonin receptor agonist tasimelteon and the putative biol. cross-talk between serotonergic and melatonergic systems, a series of new (2,3-dihydro)benzofuran-based compds. were designed and synthesized.  The compds. were evaluated for their selectivity toward 5-HT2A, 5-HT2B, and 5-HT2C receptors in the calcium flux assay with the ultimate goal to generate selective 5-HT2C agonists.  Selected compds. were studied for their functional selectivity by comparing their transduction efficiency at the G protein signaling pathway vs. β-arrestin recruitment.  The most functionally selective compd. (+)-7e produced weak β-arrestin recruitment and also demonstrated less receptor desensitization compared to serotonin in both calcium flux and phosphoinositide (PI) hydrolysis assays.  We report for the first time that selective 5-HT2C agonists possessing weak β-arrestin recruitment can produce distinct receptor desensitization properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaXMjfBCeBR7Vg90H21EOLACvtfcHk0lidsqIr_xAvYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnF&md5=bb0e1b524230649fac9f5b736ddc283d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01194%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520discovery%2520of%2520functionally%2520selective%2520serotonin%25202C%2520%25285-HT2C%2529%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9866%26epage%3D9880%26doi%3D10.1021%2Facs.jmedchem.6b01194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorello, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarone, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i>-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6288</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00584</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00584" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6273-6288&author=G.+Zhangauthor=J.+Chengauthor=J.+D.+McCorvyauthor=P.+J.+Lorelloauthor=B.+J.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Discovery+of+N-substituted+%282-phenylcyclopropyl%29methylamines+as+functionally+selective+serotonin+2C+receptor+agonists+for+potential+use+as+antipsychotic+medications&doi=10.1021%2Facs.jmedchem.7b00584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications</span></div><div class="casAuthors">Zhang, Guiping; Cheng, Jianjun; McCorvy, John D.; Lorello, Paul J.; Caldarone, Barbara J.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6273-6288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-substituted (2-phenylcyclopropyl)methylamines were designed and synthesized, with the aim of finding serotonin 2C (5-HT2C)-selective agonists with a preference for Gq signaling.  A no. of these compds. exhibit 5-HT2C selectivity with a preference for Gq-mediated signaling compared with β-arrestin recruitment.  Furthermore, the N-Me compd. I•HCl, which displayed an EC50 of 23 nM in the calcium flux assay while showing no β-arrestin recruitment activity, is the most functionally selective 5-HT2C agonist reported to date.  The N-benzyl compd. II•HCl, which showed an EC50 of 24 nM at the 5-HT2C receptor, is fully selective over the 5-HT2B receptor.  In an amphetamine-induced hyperactivity model, compd. II showed significant antipsychotic-drug-like activity.  These compds. shed light on the role of functional selectivity at the 5-HT2C receptor with respect to antipsychotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGjR92vyblbVg90H21EOLACvtfcHk0lidsqIr_xAvYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLrK&md5=9da7c5db2f4e54db114a544d5f2e56b7</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00584%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DLorello%26aufirst%3DP.%2BJ.%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520N-substituted%2520%25282-phenylcyclopropyl%2529methylamines%2520as%2520functionally%2520selective%2520serotonin%25202C%2520receptor%2520agonists%2520for%2520potential%2520use%2520as%2520antipsychotic%2520medications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6273%26epage%3D6288%26doi%3D10.1021%2Facs.jmedchem.7b00584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stroth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svenningsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Arylpiperazine agonists of the serotonin 5-HT<sub>1A</sub> receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4824</span>– <span class="NLM_lpage">4830</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmc.2015.05.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26081758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4824-4830&author=N.+Strothauthor=M.+Nisoauthor=N.+A.+Colabufoauthor=R.+Perroneauthor=P.+Svenningssonauthor=E.+Lacivitaauthor=M.+Leopoldo&title=Arylpiperazine+agonists+of+the+serotonin+5-HT1A+receptor+preferentially+activate+cAMP+signaling+versus+recruitment+of+%CE%B2-arrestin-2&doi=10.1016%2Fj.bmc.2015.05.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2</span></div><div class="casAuthors">Stroth, Nikolas; Niso, Mauro; Colabufo, Nicola A.; Perrone, Roberto; Svenningsson, Per; Lacivita, Enza; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4824-4830</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) mediate biol. signal transduction through complex mol. pathways.  Therapeutic effects of GPCR-directed drugs are typically accompanied by unwanted side effects, owing in part to the parallel engagement of multiple signaling mechanisms.  The discovery of drugs that are 'functionally selective' towards therapeutic effects, based on their selective control of cellular responses through a given GPCR, is thus a major goal in pharmacol. today.  In the present study, we show that several arylpiperazine ligands of the serotonin 5-HT1A receptor (5-HT1AR) preferentially activate 3',5'-cyclic adenosine monophosphate (cAMP) signaling vs. β-arrestin-2 recruitment.  The pharmacol. of these compds. is thus qual. different from the endogenous agonist serotonin, indicating functional selectivity of 5-HT1AR-mediated response pathways.  Preliminary evidence suggests that phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) downstream of 5-HT1AR is a substrate of functionally selective signaling by partial agonists.  We propose that the compds. described in the present study are useful starting points for the development of signaling pathway-selective drugs targeting 5-HT1AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPeYBWeUhs9LVg90H21EOLACvtfcHk0lhbcyUS5UNTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLg%253D&md5=58d15ba400884622e76923e88bbe6194</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.042%26sid%3Dliteratum%253Aachs%26aulast%3DStroth%26aufirst%3DN.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DArylpiperazine%2520agonists%2520of%2520the%2520serotonin%25205-HT1A%2520receptor%2520preferentially%2520activate%2520cAMP%2520signaling%2520versus%2520recruitment%2520of%2520%25CE%25B2-arrestin-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4824%26epage%3D4830%26doi%3D10.1016%2Fj.bmc.2015.05.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monczor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, N.</span></span> <span> </span><span class="NLM_article-title">Current knowledge and perspectives on histamine H<sub>1</sub> and H<sub>2</sub> receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1124/mol.116.105981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.116.105981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=640-648&author=F.+Monczorauthor=N.+Fernandez&title=Current+knowledge+and+perspectives+on+histamine+H1+and+H2+receptor+pharmacology%3A+functional+selectivity%2C+receptor+crosstalk%2C+and+repositioning+of+classic+histaminergic+ligands&doi=10.1124%2Fmol.116.105981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.105981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.105981%26sid%3Dliteratum%253Aachs%26aulast%3DMonczor%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DN.%26atitle%3DCurrent%2520knowledge%2520and%2520perspectives%2520on%2520histamine%2520H1%2520and%2520H2%2520receptor%2520pharmacology%253A%2520functional%2520selectivity%252C%2520receptor%2520crosstalk%252C%2520and%2520repositioning%2520of%2520classic%2520histaminergic%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D90%26spage%3D640%26epage%3D648%26doi%3D10.1124%2Fmol.116.105981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappia, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davio, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shayo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monczor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, N. C.</span></span> <span> </span><span class="NLM_article-title">Physiological implications of biased signaling at histamine H2 receptors</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3389%2Ffphar.2015.00045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25805997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC2MnnslSjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=45&author=N.+Alonsoauthor=C.+D.+Zappiaauthor=M.+Cabreraauthor=C.+A.+Davioauthor=C.+Shayoauthor=F.+Monczorauthor=N.+C.+Fern%C3%A1ndez&title=Physiological+implications+of+biased+signaling+at+histamine+H2+receptors&doi=10.3389%2Ffphar.2015.00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological implications of biased signaling at histamine H2 receptors</span></div><div class="casAuthors">Alonso Natalia; Shayo Carina; Zappia Carlos D; Cabrera Maia; Monczor Federico; Fernandez Natalia C; Davio Carlos A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Histamine mediates numerous functions acting through its four receptor subtypes all belonging to the large family of seven transmembrane G-protein coupled receptors.  In particular, histamine H2 receptor (H2R) is mainly involved in gastric acid production, becoming a classic pharmacological target to treat Zollinger-Ellison disease and gastric and duodenal ulcers.  H2 ligands rank among the most widely prescribed and over the counter-sold drugs in the world.  Recent evidence indicate that some H2R ligands display biased agonism, selecting and triggering some, but not all, of the signaling pathways associated to the H2R.  The aim of the present work is to study whether famotidine, clinically widespread used ligand acting at H2R, exerts biased signaling.  Our findings indicate that while famotidine acts as inverse agonist diminishing cAMP basal levels, it mimics the effects of histamine and the agonist amthamine concerning receptor desensitization and internalization.  Moreover, the treatment of HEK293T transfected cells with any of the three ligands lead to a concentration dependent pERK increment.  Similarly in AGS gastric epithelial cells, famotidine treatment led to both, the reduction in cAMP levels as well as the increment in ERK phosphorylation, suggesting that this behavior could have pharmacological relevant implications.  Based on that, histidine decarboxylase expression was studied by quantitative PCR in AGS cells and its levels were increased by famotidine as well as by histamine and amthamine.  In all cases, the positive regulation was impeded by the MEK inhibitor PD98059, indicating that biased signaling toward ERK1/2 pathway is the responsible of such enzyme regulation.  These results support that ligand bias is not only a pharmacological curiosity but has physiological and pharmacological implications on cell metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbDjuDw8SFIftos8R3JUhXfW6udTcc2eZV8EWRdy3OY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnnslSjsw%253D%253D&md5=b72e4abcabde48c76ca679770df6670d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00045%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DN.%26aulast%3DZappia%26aufirst%3DC.%2BD.%26aulast%3DCabrera%26aufirst%3DM.%26aulast%3DDavio%26aufirst%3DC.%2BA.%26aulast%3DShayo%26aufirst%3DC.%26aulast%3DMonczor%26aufirst%3DF.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DN.%2BC.%26atitle%3DPhysiological%2520implications%2520of%2520biased%2520signaling%2520at%2520histamine%2520H2%2520receptors%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D45%26doi%3D10.3389%2Ffphar.2015.00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampeli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiligada, E.</span></span> <span> </span><span class="NLM_article-title">The role of histamine H<sub>4</sub> receptor in immune and inflammatory disorders</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00151.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fj.1476-5381.2009.00151.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=19309354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2009&pages=24-33&author=E.+Zampeliauthor=E.+Tiligada&title=The+role+of+histamine+H4+receptor+in+immune+and+inflammatory+disorders&doi=10.1111%2Fj.1476-5381.2009.00151.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histamine H4 receptor in immune and inflammatory disorders</span></div><div class="casAuthors">Zampeli, E.; Tiligada, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Since its discovery at the beginning of the 20th century, histamine has been established to play a pathophysiol. regulatory role in cellular events through binding to four types of G-protein-coupled histamine receptors that are differentially expressed in various cell types.  The discovery, at the turn of the millennium, that the histamine H4 receptor is largely expressed in hemopoietic cells as well as its chemotactic properties designate its regulatory role in the immune system.  H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation.  H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.  The characterization of the H4 as the immune system histamine receptor directed growing attention towards its therapeutic exploitation in inflammatory disorders, such as allergy, asthma, chronic pruritus and autoimmune diseases.  The efficacy of a no. of H4 receptor ligands has been evaluated in in vivo and in vitro animal models of disease and in human biol. samples.  However, before reaching decisive conclusions on H4 receptor pathophysiol. functions and therapeutic exploitation, identification of genetic polymorphisms and interspecies differences in its relative actions and pharmacol. profile need to be addressed and taken into consideration.  Despite certain variations in the reported findings, the available data strongly point to the H4 receptor as a novel target for the pharmacol. modulation of histamine-transferred immune signals and offer an optimistic perspective for the therapeutic exploitation of this promising new drug target in inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAW6UpRFCXFLVg90H21EOLACvtfcHk0lhbcyUS5UNTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWls74%253D&md5=e850c2e825c0c62b59927854ccfb35c2</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00151.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00151.x%26sid%3Dliteratum%253Aachs%26aulast%3DZampeli%26aufirst%3DE.%26aulast%3DTiligada%26aufirst%3DE.%26atitle%3DThe%2520role%2520of%2520histamine%2520H4%2520receptor%2520in%2520immune%2520and%2520inflammatory%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D157%26spage%3D24%26epage%3D33%26doi%3D10.1111%2Fj.1476-5381.2009.00151.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung-Leung, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstra, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, L.</span></span> <span> </span><span class="NLM_article-title">A potent and selective histamine H<sub>4</sub> receptor antagonist with anti-inflammatory properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.061754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.103.061754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=14722321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFamurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=404-413&author=R.+L.+Thurmondauthor=P.+J.+Desaiauthor=P.+J.+Dunfordauthor=W.+P.+Fung-Leungauthor=C.+L.+Hofstraauthor=W.+Jiangauthor=S.+Nguyenauthor=J.+P.+Rileyauthor=S.+Sunauthor=K.+N.+Williamsauthor=J.+P.+Edwardsauthor=L.+Karlsson&title=A+potent+and+selective+histamine+H4+receptor+antagonist+with+anti-inflammatory+properties&doi=10.1124%2Fjpet.103.061754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties</span></div><div class="casAuthors">Thurmond, Robin L.; Desai, Pragnya J.; Dunford, Paul J.; Fung-Leung, Wai-Ping; Hofstra, Claudia L.; Jiang, Wen; Nguyen, Steven; Riley, Jason P.; Sun, Siquan; Williams, Kacy N.; Edwards, James P.; Karlsson, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">404-413</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Histamine mediates its physiol. function through binding to four known histamine receptors.  Here, we describe the first selective antagonist of the histamine H4 receptor, the newest member of the histamine receptor family, and provide evidence that such antagonists have anti-inflammatory activity in vivo.  1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (JNJ 7777120) has a Ki of 4.5 nM vs. the human receptor and a pA2 of 8.1.  It is equipotent against the human, mouse, and rat receptors.  It exhibits at least 1000-fold selectivity over H1, H2, or H3 receptors and has no cross-reactivity against 50 other targets.  This compd. has an oral bioavailability of ∼30% in rats and 100% in dogs, with a half-life of ∼3 h in both species.  JNJ 7777120 blocks histamine-induced chemotaxis and calcium influx in mouse bone marrow-derived mast cells.  In addn., it can block the histamine-induced migration of tracheal mast cells from the connective tissue toward the epithelium in mice.  JNJ 7777120 significantly blocks neutrophil infiltration in a mouse zymosan-induced peritonitis model.  This model is reported to be mast cell-dependent, which suggests that the compd. effect may be mediated by mast cells.  These results indicate that the histamine H4 receptor plays a role in the inflammatory process.  Selective H4 receptor antagonists like JNJ 7777120 may have the potential to be useful in treating inflammation in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR1GunqKtOlrVg90H21EOLACvtfcHk0lg-MtkqmHGX7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFamurg%253D&md5=19ac13bd31555f3329b007d2aafe1133</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.061754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.061754%26sid%3Dliteratum%253Aachs%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DDesai%26aufirst%3DP.%2BJ.%26aulast%3DDunford%26aufirst%3DP.%2BJ.%26aulast%3DFung-Leung%26aufirst%3DW.%2BP.%26aulast%3DHofstra%26aufirst%3DC.%2BL.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DNguyen%26aufirst%3DS.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DKarlsson%26aufirst%3DL.%26atitle%3DA%2520potent%2520and%2520selective%2520histamine%2520H4%2520receptor%2520antagonist%2520with%2520anti-inflammatory%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D404%26epage%3D413%26doi%3D10.1124%2Fjpet.103.061754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosethorne, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Agonist-biased signaling at the histamine H<sub>4</sub> receptor: JNJ7777120 recruits β-arrestin without activating G proteins</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1124/mol.110.068395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.110.068395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21134907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOluro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=749-757&author=E.+M.+Rosethorneauthor=S.+J.+Charlton&title=Agonist-biased+signaling+at+the+histamine+H4+receptor%3A+JNJ7777120+recruits+%CE%B2-arrestin+without+activating+G+proteins&doi=10.1124%2Fmol.110.068395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins</span></div><div class="casAuthors">Rosethorne, Elizabeth M.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Gi/o-coupled histamine H4 receptor is highly expressed in hemopoietic cells and is a promising new target for the treatment of chronic inflammatory diseases.  1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methyl-piperazine (JNJ7777120) was described as a selective antagonist at the H4 receptor and is widely used to characterize the physiol. role of the H4 receptor.  We have investigated the pharmacol. properties of JNJ7777120 using 2 distinct downstream signaling measurements, G protein activation and β-arrestin recruitment.  The H4 receptor agonists histamine and clobenpropit, but not JNJ7777120, were able to induce [35S]GTPγS binding in membranes prepd. from U2OS-H4 cells.  Thioperamide, a dual H3/H4 receptor antagonist, and JNJ7777120 were both able to inhibit the [35S]GTPγS binding induced by clobenpropit.  Agonists and antagonists specific for other members of the histamine receptor family had no effect in this assay format.  Histamine and clobenpropit increased β-arrestin recruitment to the H4 receptor in a concn.-dependent manner.  This β-arrestin recruitment could be inhibited by preincubation with thioperamide.  We were surprised to find that preincubation with the H4-selective antagonist JNJ7777120 potentiated rather than antagonized the response to a submaximal concn. of clobenpropit.  JNJ7777120 treatment alone resulted in an increase in β-arrestin recruitment, which again could be inhibited by preincubation with thioperamide.  Schild anal. demonstrated competitive antagonism between thioperamide and both clobenpropit and JNJ7777120.  Histamine and clobenpropit had comparable potencies for both [35S]GTPγS binding and β-arrestin recruitment, suggesting little difference in the levels of receptor reserve between the 2 assays.  In conclusion, we have demonstrated that JNJ7777120 recruits β-arrestin to the H4 receptor, independent of G protein activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohxnqy7WSl-LVg90H21EOLACvtfcHk0lg-MtkqmHGX7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOluro%253D&md5=2d00ef475b40e3eb7e064fe076836560</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.068395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.068395%26sid%3Dliteratum%253Aachs%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DAgonist-biased%2520signaling%2520at%2520the%2520histamine%2520H4%2520receptor%253A%2520JNJ7777120%2520recruits%2520%25CE%25B2-arrestin%2520without%2520activating%2520G%2520proteins%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D749%26epage%3D757%26doi%3D10.1124%2Fmol.110.068395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijmeijer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosethorne, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Detailed analysis of biased histamine H<sub>4</sub> receptor signalling by JNJ 7777120 analogues</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1111/bph.12117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fbph.12117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23351115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=78-88&author=S.+Nijmeijerauthor=H.+F.+Vischerauthor=F.+Sirciauthor=S.+Schultesauthor=H.+Engelhardtauthor=C.+de+Graafauthor=E.+M.+Rosethorneauthor=S.+J.+Charltonauthor=R.+Leurs&title=Detailed+analysis+of+biased+histamine+H4+receptor+signalling+by+JNJ+7777120+analogues&doi=10.1111%2Fbph.12117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Detailed analysis of biased histamine H4 receptor signalling by JNJ 7777120 analogues</span></div><div class="casAuthors">Nijmeijer, S.; Vischer, H. F.; Sirci, F.; Schultes, S.; Engelhardt, H.; de Graaf, C.; Rosethorne, E. M.; Charlton, S. J.; Leurs, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-88</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose The histamine H4 receptor, originally thought to signal merely through Gαi proteins, has recently been shown to also recruit and signal via β-arrestin2.  Following the discovery that the ref. antagonist indolecarboxamide JNJ 7777120 appears to be a partial agonist in β-arrestin2 recruitment, we have identified addnl. biased hH4R ligands that preferentially couple to Gαi or β-arrestin2 proteins.  In this study, we explored ligand and receptor regions that are important for biased hH4R signalling.  Exptl. Approach We evaluated a series of 48 indolecarboxamides with subtle structural differences for their ability to induce hH4R-mediated Gαi protein signalling or β-arrestin2 recruitment.  Subsequently, a Fingerprints for Ligands and Proteins three-dimensional quant. structure-activity relationship anal. correlated intrinsic activity values with structural ligand requirements.  Moreover, a hH4R homol. model was used to identify receptor regions important for biased hH4R signalling.  Key Results One indolecarboxamide (75) with a nitro substituent on position R7 of the arom. ring displayed an equal preference for the Gαi and β-arrestin2 pathway and was classified as unbiased hH4R ligand.  The other 47 indolecarboxamides were β-arrestin2-biased agonists.  Intrinsic activities of the unbiased as well as β-arrestin2-biased indolecarboxamides to induce β-arrestin2 recruitment could be correlated with different ligand features and hH4R regions.  Conclusion and Implications Small structural modifications resulted in diverse intrinsic activities for unbiased (75) and β-arrestin2-biased indolecarboxamides.  Anal. of ligand and receptor features revealed efficacy hotspots responsible for biased-β-arrestin2 recruitment.  This knowledge is useful for the design of hH4R ligands with biased intrinsic activities and aids our understanding of the mechanism of H4R activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppEoaA2rsLgrVg90H21EOLACvtfcHk0lg-MtkqmHGX7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnJ&md5=490a939b05f2dd3508e96d21f541a783</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1111%2Fbph.12117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12117%26sid%3Dliteratum%253Aachs%26aulast%3DNijmeijer%26aufirst%3DS.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DSirci%26aufirst%3DF.%26aulast%3DSchultes%26aufirst%3DS.%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DDetailed%2520analysis%2520of%2520biased%2520histamine%2520H4%2520receptor%2520signalling%2520by%2520JNJ%25207777120%2520analogues%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D78%26epage%3D88%26doi%3D10.1111%2Fbph.12117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijmeijer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosethorne, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Analysis of multiple histamine H<sub>4</sub> receptor compound classes uncovers Gα<sub>i</sub> protein- and β-arrestin2-biased ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1174</span>– <span class="NLM_lpage">1182</span>, <span class="refDoi"> DOI: 10.1124/mol.112.080911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.080911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22973061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=1174-1182&author=S.+Nijmeijerauthor=H.+F.+Vischerauthor=E.+M.+Rosethorneauthor=S.+J.+Charltonauthor=R.+Leurs&title=Analysis+of+multiple+histamine+H4+receptor+compound+classes+uncovers+G%CE%B1i+protein-+and+%CE%B2-arrestin2-biased+ligands&doi=10.1124%2Fmol.112.080911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of multiple histamine H4 receptor compound classes uncovers Gαi protein- and β-arrestin2-biased ligands</span></div><div class="casAuthors">Nijmeijer, Saskia; Vischer, Henry F.; Rosethorne, Elizabeth M.; Charlton, Steven J.; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1174-1182</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">After the recent description of β-arrestin2 recruitment to the human histamine H4 receptor (hH4R) in response to the well known H4R antagonist 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methyl-piperazine (JNJ 7777120), we evaluated in this study the efficacy of 31 known hH4R ligands to induce Gαi protein signaling and β-arrestin2 recruitment by the hH4R.  The selected hH4R ligands belong to nine different structural classes that partly cover (pre)clin. trial candidates.  We have identified hH4R ligands with a significant bias for the Gαi protein or β-arrestin2 pathway on the basis of efficacy differences.  In addn., hH4R antagonists that did not show pos. efficacy in either functional readouts were found.  A common trend in pathway preference for the nine different ligand classes could not be obsd.  In particular, the isothiourea class shows very diverse results, varying from Gαi protein-biased or β-arrestin2-biased to nonbiased antagonists upon minor structural changes.  The identified biased hH4R ligands are important pharmacol. tools to unravel the significance of biased hH4R signaling in H4R pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVWY_qld1mi7Vg90H21EOLACvtfcHk0lg4KTvF9pqVEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCltb3N&md5=6d65c275368ea2b8f2261d3e0cde3ec3</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.080911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.080911%26sid%3Dliteratum%253Aachs%26aulast%3DNijmeijer%26aufirst%3DS.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DAnalysis%2520of%2520multiple%2520histamine%2520H4%2520receptor%2520compound%2520classes%2520uncovers%2520G%25CE%25B1i%2520protein-%2520and%2520%25CE%25B2-arrestin2-biased%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D1174%26epage%3D1182%26doi%3D10.1124%2Fmol.112.080911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snook, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span> <span> </span><span class="NLM_article-title">Clinical development of histamine H<sub>4</sub> receptor antagonists</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1007/164_2016_130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2F164_2016_130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28233185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=2017&pages=301-320&author=R.+L.+Thurmondauthor=J.+Venableauthor=B.+Savallauthor=D.+Laauthor=S.+Snookauthor=P.+J.+Dunfordauthor=J.+P.+Edwards&title=Clinical+development+of+histamine+H4+receptor+antagonists&doi=10.1007%2F164_2016_130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of histamine H4 receptor antagonists</span></div><div class="casAuthors">Thurmond, Robin L.; Venable, Jennifer; Savall, Brad; La, David; Snook, Sandra; Dunford, Paul J.; Edwards, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">Histamine and Histamine Receptors in Health and Disease</span>),
    <span class="NLM_cas:pages">301-320</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The discovery of the histamine H4 receptor (H4R) provided a new avenue for the exploration of the physiol. role of histamine, as well as providing a new drug target for the development of novel antihistamines.  The first step in this process was the identification of selective antagonists to help unravel the pharmacol. of the H4R relative to other histamine receptors.  The discovery of the selective H4R antagonist JNJ 7777120 was vital for showing a role for the H4R in inflammation and pruritus.  While this compd. has been very successful as a tool for understanding the function of the receptor, it has drawbacks, including a short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clin. studies.  Further research let to the discovery of JNJ 39758979, which, similar to JNJ 7777120, was a potent and selective H4R antagonist and showed anti-inflammatory and anti-pruritic activity preclinically.  JNJ 39758979 advanced into human clin. studies and showed efficacy in reducing exptl. pruritus and in patients with atopic dermatitis.  However, development of this compd. was terminated due to the occurrence of drug-induced agranulocytosis.  This was overcome by developing another H4R antagonist with a different chem. structure, toreforant, that does not appear to have this side effect.  Toreforant has been tested in clin. studies in patients with rheumatoid arthritis, asthma, or psoriasis.  In conclusions there have been many H4R antagonists reported in the literature, but only a few have been studied in humans underscoring the difficulty in finding ligands with all of the properties necessary for testing in the clinic.  Nevertheless, the clin. data to date suggests that H4R antagonists can be beneficial in treating atopic dermatitis and pruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBP0zak99FDLVg90H21EOLACvtfcHk0lg4KTvF9pqVEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGkt73I&md5=599a5ceb9b977b0952d27ead24570cc5</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2F164_2016_130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2016_130%26sid%3Dliteratum%253Aachs%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DVenable%26aufirst%3DJ.%26aulast%3DSavall%26aufirst%3DB.%26aulast%3DLa%26aufirst%3DD.%26aulast%3DSnook%26aufirst%3DS.%26aulast%3DDunford%26aufirst%3DP.%2BJ.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26atitle%3DClinical%2520development%2520of%2520histamine%2520H4%2520receptor%2520antagonists%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D241%26spage%3D301%26epage%3D320%26doi%3D10.1007%2F164_2016_130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L. A.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and the brain</span>. <i>Annu. Rev. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1146/annurev-psych-113011-143739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1146%2Fannurev-psych-113011-143739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22804774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=21-47&author=R.+Mechoulamauthor=L.+A.+Parker&title=The+endocannabinoid+system+and+the+brain&doi=10.1146%2Fannurev-psych-113011-143739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and the brain</span></div><div class="casAuthors">Mechoulam Raphael; Parker Linda A</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The psychoactive constituent in cannabis, Δ(9)-tetrahydrocannabinol (THC), was isolated in the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endogenous cannabinoids (anandamide and 2-arachidonoyl glycerol) were identified only 20 to 25 years later.  The cannabinoid system affects both central nervous system (CNS) and peripheral processes.  In this review, we have tried to summarize research--with an emphasis on recent publications--on the actions of the endocannabinoid system on anxiety, depression, neurogenesis, reward, cognition, learning, and memory.  The effects are at times biphasic--lower doses causing effects opposite to those seen at high doses.  Recently, numerous endocannabinoid-like compounds have been identified in the brain.  Only a few have been investigated for their CNS activity, and future investigations on their action may throw light on a wide spectrum of brain functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHFfYzzaa6fbBItaL1WaVAfW6udTcc2ebdmajdI1r5JLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D&md5=01c8b675ee9970bde0cb96d5e1b8a553</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1146%2Fannurev-psych-113011-143739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-psych-113011-143739%26sid%3Dliteratum%253Aachs%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DL.%2BA.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520the%2520brain%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2013%26volume%3D64%26spage%3D21%26epage%3D47%26doi%3D10.1146%2Fannurev-psych-113011-143739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry strategies to CB<sub>1</sub> cannabinoid receptor antagonists</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03427-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2FS1359-6446%2805%2903427-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=15896682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=693-702&author=J.+H.+M.+Langeauthor=C.+G.+Kruse&title=Medicinal+chemistry+strategies+to+CB1+cannabinoid+receptor+antagonists&doi=10.1016%2FS1359-6446%2805%2903427-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists</span></div><div class="casAuthors">Lange, Jos H. M.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-702</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The proven clin. efficacy of the CB1 cannabinoid receptor antagonist rimonabant in both obesity and smoking cessation and its therapeutic potential in other disorders has given a tremendous impetus to the discovery of novel CB1 antagonists.  The no. of disclosed patents wherein novel chem. entities having CB1 antagonistic or inverse agonistic properties have been claimed has exploded.  Besides novel compd. classes that were identified in screening, rational medicinal chem. approaches such as conformational constraint and scaffold hopping have been successfully applied.  CB1 receptor modeling has provided insight into crucial receptor-ligand interaction points thereby leading to a general CB1 inverse agonist pharmacophore model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCUMmcDw3bR7Vg90H21EOLACvtfcHk0liwdDpIyXKf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslalt74%253D&md5=c760dfe5ba40c8de6af99f2752e7c690</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903427-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903427-6%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DMedicinal%2520chemistry%2520strategies%2520to%2520CB1%2520cannabinoid%2520receptor%2520antagonists%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D693%26epage%3D702%26doi%3D10.1016%2FS1359-6446%2805%2903427-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. N.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1002/med.21418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmed.21418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27879006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=441-474&author=T.+Nguyenauthor=J.+X.+Liauthor=B.+F.+Thomasauthor=J.+L.+Wileyauthor=T.+P.+Kenakinauthor=Y.+N.+Zhang&title=Allosteric+modulation%3A+an+alternate+approach+targeting+the+cannabinoid+CB1+receptor&doi=10.1002%2Fmed.21418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor</span></div><div class="casAuthors">Nguyen, Thuy; Li, Jun-Xu; Thomas, Brian F.; Wiley, Jenny L.; Kenakin, Terry P.; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-474</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The cannabinoid CB1 receptor is a G protein coupled receptor and plays an important role in many biol. processes and physiol. functions.  A variety of CB1 receptor agonists and antagonists, including endocannabinoids, phytocannabinoids, and synthetic cannabinoids, have been discovered or developed over the past 20 years.  In 2005, it was discovered that the CB1 receptor contains allosteric site(s) that can be recognized by small mols. or allosteric modulators.  A no. of CB1 receptor allosteric modulators, both pos. and neg., have since been reported and importantly, they display pharmacol. characteristics that are distinct from those of orthosteric agonists and antagonists.  Given the psychoactive effects commonly assocd. with CB1 receptor agonists and antagonists/inverse agonists, allosteric modulation may offer an alternate approach to attain potential therapeutic benefits while avoiding inherent side effects of orthosteric ligands.  This review details the complex pharmacol. profiles of these allosteric modulators, their structure-activity relationships, and efforts in elucidating binding modes and mechanisms of actions of reported CB1 allosteric modulators.  The ultimate development of CB1 receptor allosteric ligands could potentially lead to improved therapies for CB1-mediated neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn_UmNHz3IfrVg90H21EOLACvtfcHk0liwdDpIyXKf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D&md5=3440e86c28aa07132de55c2c66640c2d</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fmed.21418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21418%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DZhang%26aufirst%3DY.%2BN.%26atitle%3DAllosteric%2520modulation%253A%2520an%2520alternate%2520approach%2520targeting%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D441%26epage%3D474%26doi%3D10.1002%2Fmed.21418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aghazadeh
Tabrizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB<sub>2</sub> receptor agonists</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00411</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00411" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=519-560&author=M.+Aghazadeh%0ATabriziauthor=P.+G.+Baraldiauthor=P.+A.+Boreaauthor=K.+Varani&title=Medicinal+chemistry%2C+pharmacology%2C+and+potential+therapeutic+benefits+of+cannabinoid+CB2+receptor+agonists&doi=10.1021%2Facs.chemrev.5b00411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists</span></div><div class="casAuthors">Aghazadeh Tabrizi, Mojgan; Baraldi, Pier Giovanni; Borea, Pier Andrea; Varani, Katia</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">519-560</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The purpose of this review is to analyze the mol. characterization, distribution and signal transduction pathways of CB2 receptors together with their pharmacol. role in some of the most relevant biol. systems.  The structure-activity relationships of several interesting CB2 agonists, including synthetic schemes to clarify the chem. involved in this field, are reported.  Moreover, the corresponding pharmacol. and beneficial potentials of selected CB2 compds. have been focused as well as the patent literature and the identification of promising therapeutic candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xG1QvGzO97Vg90H21EOLACvtfcHk0liwdDpIyXKf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGmsr8%253D&md5=261a0d3c6eec03978630759378834d6c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00411%26sid%3Dliteratum%253Aachs%26aulast%3DAghazadeh%2BTabrizi%26aufirst%3DM.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DVarani%26aufirst%3DK.%26atitle%3DMedicinal%2520chemistry%252C%2520pharmacology%252C%2520and%2520potential%2520therapeutic%2520benefits%2520of%2520cannabinoid%2520CB2%2520receptor%2520agonists%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D519%26epage%3D560%26doi%3D10.1021%2Facs.chemrev.5b00411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor ligand bias: implications in the central nervous system</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.coph.2016.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27835801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOmt7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=32-43&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=E.+M.+Denovan-Wright&title=Cannabinoid+receptor+ligand+bias%3A+implications+in+the+central+nervous+system&doi=10.1016%2Fj.coph.2016.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor ligand bias: implications in the central nervous system</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-43</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The G protein-coupled cannabinoid receptors CB1, CB2, GPR18, and GPR55 regulate neurotransmission, pain, and inflammation and have been intensively investigated as potential drug targets.  Each of these GPCRs is coupled to multiple effector proteins mediating divergent cellular signals.  The ligand bias of cannabinoid-targeted compds. is only beginning to be quantified.  Research into cannabinoid bias is now revealing correlations between bias in cell culture and functional outcomes in vivo.  We present an example study of cannabinoid bias in the context of Huntington disease.  In future, an understanding of cannabinoid receptor structure and quantification of ligand bias will optimize drug selection matched to patient population and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNrTHtEI8jybVg90H21EOLACvtfcHk0ljH5pinvqfiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOmt7nL&md5=669daaa05a8798a2520a71f99be6d2da</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DCannabinoid%2520receptor%2520ligand%2520bias%253A%2520implications%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2017%26volume%3D32%26spage%3D32%26epage%3D43%26doi%3D10.1016%2Fj.coph.2016.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallipeddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity at G-protein coupled receptors: advancing cannabinoid receptors as drug targets</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2016.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27890725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=1-11&author=S.+Mallipeddiauthor=D.+R.+Janeroauthor=N.+Zvonokauthor=A.+Makriyannis&title=Functional+selectivity+at+G-protein+coupled+receptors%3A+advancing+cannabinoid+receptors+as+drug+targets&doi=10.1016%2Fj.bcp.2016.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets</span></div><div class="casAuthors">Mallipeddi, Srikrishnan; Janero, David R.; Zvonok, Nikolai; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design.  The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications.  Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clin. utility due to their propensity to incite on-target adverse events.  Chem. distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways.  In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists.  We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses.  The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBMv00pJezbVg90H21EOLACvtfcHk0ljH5pinvqfiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K&md5=a447353e190125cdd3d7e363eab0e137</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DMallipeddi%26aufirst%3DS.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DFunctional%2520selectivity%2520at%2520G-protein%2520coupled%2520receptors%253A%2520advancing%2520cannabinoid%2520receptors%2520as%2520drug%2520targets%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D128%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.bcp.2016.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonhaus, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. R.</span></span> <span> </span><span class="NLM_article-title">Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">888</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=9864268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVShtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1998&pages=884-888&author=D.+W.+Bonhausauthor=L.+K.+Changauthor=J.+Kwanauthor=G.+R.+Martin&title=Dual+activation+and+inhibition+of+adenylyl+cyclase+by+cannabinoid+receptor+agonists%3A+evidence+for+agonist-specific+trafficking+of+intracellular+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses</span></div><div class="casAuthors">Bonhaus, D. W.; Chang, L. K.; Kwan, J.; Martin, G. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">884-888</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cannabinoid receptors couple to both Gs and Gi proteins and can consequently stimulate or inhibit the formation of cAMP.  To test whether there is specificity among cannabinoid receptor agonists in activating Gs - or Gi-coupled pathways, the potency and intrinsic activity of various cannabinoid receptor ligands in stimulating or inhibiting cAMP accumulation were quantified.  The rank order of potencies of cannabinoid receptor agonists in increasing or inhibiting forskolin-stimulated cAMP accumulation, in CHO cells expressing hCB1 receptors, was identical (HU-210 > CP-55,940 > THC > WIN-55212-2 > anandamide).  However, the activities of these agonists were different in the two assays with anandamide and CP-55,940 being markedly less efficacious in stimulating the accumulation of cAMP than in inhibiting its formation.  Studies examg. the effects of forskolin on cannabinoid receptor mediated stimulation of adenylyl cyclase also revealed differences among agonists in as much as forskolin enhanced the potency of HU-210 and CP-55,940 by ∼100-fold but, by contrast, had no effect on the potency of WIN-55212-2 or anandamide.  Taken together these findings demonstrate marked differences among cannabinoid receptor agonists in their activation of intracellular transduction pathways.  This provides support for the emerging concept of agonist-specific trafficking of cellular responses and further suggests strategies for developing receptor agonists with increased therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql3F1fTabcc7Vg90H21EOLACvtfcHk0ljH5pinvqfiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVShtg%253D%253D&md5=15f484981e8136eaf9eee03c5ba50241</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonhaus%26aufirst%3DD.%2BW.%26aulast%3DChang%26aufirst%3DL.%2BK.%26aulast%3DKwan%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26atitle%3DDual%2520activation%2520and%2520inhibition%2520of%2520adenylyl%2520cyclase%2520by%2520cannabinoid%2520receptor%2520agonists%253A%2520evidence%2520for%2520agonist-specific%2520trafficking%2520of%2520intracellular%2520responses%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D287%26spage%3D884%26epage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupre, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">24845</span>– <span class="NLM_lpage">24862</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.557025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M114.557025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25037227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyrtbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=24845-24862&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+M.+Kellyauthor=D.+J.+Dupreauthor=E.+M.+Denovan-Wright&title=Type+1+cannabinoid+receptor+ligands+display+functional+selectivity+in+a+cell+culture+model+of+striatal+medium+spiny+projection+neurons&doi=10.1074%2Fjbc.M114.557025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Type 1 Cannabinoid Receptor Ligands Display Functional Selectivity in a Cell Culture Model of Striatal Medium Spiny Projection Neurons</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Kelly, Melanie E. M.; Dupre, Denis J.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">24845-24862</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Modulation of type 1 cannabinoid receptor (CB1) activity has been touted as a potential means of treating addiction, anxiety, depression, and neurodegeneration.  Different agonists of CB1 are known to evoke varied responses in vivo.  Functional selectivity is the ligand-specific activation of certain signal transduction pathways at a receptor that can signal through multiple pathways.  To understand cannabinoid-specific functional selectivity, different groups have examd. the effect of individual cannabinoids on various signaling pathways in heterologous expression systems.  In the current study, the authors compared the functional selectivity of six cannabinoids, including two endocannabinoids (2-arachidonyl glycerol (2-AG) and anandamide (AEA)), two synthetic cannabinoids (WIN55,212-2 and CP55,940), and two phytocannabinoids (cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC)) on arrestin-2-, Gαi/o-, Gβγ-, Gαs-, and Gαq-mediated intracellular signaling in the mouse STHdhQ7/Q7 cell culture model of striatal medium spiny projection neurons that endogenously express CB1.  In this system, 2-AG, THC, and CP55,940 were more potent mediators of arrestin-2 recruitment than other cannabinoids tested.  2-AG, AEA, and WIN55,212-2, enhanced Gαi/o and Gβγ signaling, with 2-AG and AEA treatment leading to increased total CB1 levels.  2-AG, AEA, THC, and WIN55,212-2 also activated Gαq-dependent pathways.  CP55,940 and CBD both signaled through Gαs.  CP55,940, but not CBD, activated downstream Gαs pathways via CB1 targets.  THC and CP55,940 promoted CB1 internalization and decreased CB1 protein levels over an 18-h period.  These data demonstrate that individual cannabinoids display functional selectivity at CB1 leading to activation of distinct signaling pathways.  To effectively match cannabinoids with therapeutic goals, these compds. must be screened for their signaling bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr29KklR0B1j7Vg90H21EOLACvtfcHk0lilxAE6npO-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyrtbzE&md5=d31b6f41051a572b6cbd6dffd700c7ae</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.557025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.557025%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DDupre%26aufirst%3DD.%2BJ.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DType%25201%2520cannabinoid%2520receptor%2520ligands%2520display%2520functional%2520selectivity%2520in%2520a%2520cell%2520culture%2520model%2520of%2520striatal%2520medium%2520spiny%2520projection%2520neurons%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D24845%26epage%3D24862%26doi%3D10.1074%2Fjbc.M114.557025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.115.101980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26700564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=364-375&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+M.+Kellyauthor=E.+M.+Denovan-Wright&title=Biased+type+1+cannabinoid+receptor+signaling+influences+neuronal+viability+in+a+cell+culture+model+of+Huntington+disease&doi=10.1124%2Fmol.115.101980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Kelly, Melanie E. M.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-375</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Huntington disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder with limited treatment options.  Prior to motor symptom onset or neuronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB1) decrease in the basal ganglia.  Decreasing CB1 levels are strongly correlated with chorea and cognitive deficit.  CB1 agonists are functionally selective (biased) for divergent signaling pathways.  In this study, six cannabinoids were tested for signaling bias in in vitro models of medium spiny projection neurons expressing wild-type (STHdhQ7/Q7) or mutant huntingtin protein (STHdhQ111/Q111).  Signaling bias was assessed using the Black and Leff operational model.  Relative activity [ΔlogR (τ/KA)] and system bias (ΔΔlogR) were calcd. relative to the ref. compd. WIN55,212-2 for Gαi/o, Gas, Gαq, Gβγ, and β-arrestin1 signaling following treatment with 2-arachidonoylglycerol (2-AG), anandamide (AEA), CP55,940, Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+CBD (1:1), and compared between wild-type and HD cells.  The Emax of Gαi/o-dependent extracellular signal-regulated kinase (ERK) signaling was 50% lower in HD cells compared with wild-type cells.  2-AG and AEA displayed Gαi/o/Gβγ bias and normalized CB1 protein levels and improved cell viability, whereas CP55,940 and THC displayed β-arrestin1 bias and reduced CB1 protein levels and cell viability in HD cells.  CBD was not a CB1 agonist but inhibited THC-dependent signaling (THC+CBD).  Therefore, enhancing Gαi/o-biased endocannabinoid signaling may be therapeutically beneficial in HD.  In contrast, cannabinoids that are β-arrestin-biased-such as THC found at high levels in modern varieties of marijuana-may be detrimental to CB1 signaling, particularly in HD where CB1 levels are already reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdgxoxZrX1ObVg90H21EOLACvtfcHk0lilxAE6npO-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP&md5=fe544fe3afc0ab0ca739ab887be7c971</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101980%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DBiased%2520type%25201%2520cannabinoid%2520receptor%2520signaling%2520influences%2520neuronal%2520viability%2520in%2520a%2520cell%2520culture%2520model%2520of%2520Huntington%2520disease%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D364%26epage%3D375%26doi%3D10.1124%2Fmol.115.101980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abushaar, M.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a peripheral receptor for cannabinoids</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/365061a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2F365061a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=7689702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=1993&pages=61-65&author=S.+Munroauthor=K.+L.+Thomasauthor=M.+Abushaar&title=Molecular+characterization+of+a+peripheral+receptor+for+cannabinoids&doi=10.1038%2F365061a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a peripheral receptor for cannabinoids</span></div><div class="casAuthors">Munro, Sean; Thomas, Kerrie L.; Abu-Shaar, Muna</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6441</span>),
    <span class="NLM_cas:pages">61-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The major active ingredient of marijuana, Δ9-tetrahydrocannabinol (Δ-THC), has been used as a psychoactive agent for thousands of years.  Marijuana, and Δ9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting.  The clin. application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochem. bases of their action.  Progress stemmed initially from the synthesis of potent derivs. of Δ9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids.  This receptor is expressed in the brain but not in the periphery, except for a low level in testes.  It has been proposed that the nonpsychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins.  Here the authors report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHsq4vy1XH17Vg90H21EOLACvtfcHk0lilxAE6npO-zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D&md5=476435b57bd0f24483e2f24b813cc32f</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2F365061a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F365061a0%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DAbushaar%26aufirst%3DM.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520peripheral%2520receptor%2520for%2520cannabinoids%26jtitle%3DNature%26date%3D1993%26volume%3D365%26spage%3D61%26epage%3D65%26doi%3D10.1038%2F365061a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atwood, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity in CB<sub>2</sub> cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB<sub>2</sub> ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1124/mol.111.074013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.111.074013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=250-263&author=B.+K.+Atwoodauthor=J.+Wager-Millerauthor=C.+Haskinsauthor=A.+Straikerauthor=K.+Mackie&title=Functional+selectivity+in+CB2+cannabinoid+receptor+signaling+and+regulation%3A+implications+for+the+therapeutic+potential+of+CB2+ligands&doi=10.1124%2Fmol.111.074013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.074013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.074013%26sid%3Dliteratum%253Aachs%26aulast%3DAtwood%26aufirst%3DB.%2BK.%26aulast%3DWager-Miller%26aufirst%3DJ.%26aulast%3DHaskins%26aufirst%3DC.%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DFunctional%2520selectivity%2520in%2520CB2%2520cannabinoid%2520receptor%2520signaling%2520and%2520regulation%253A%2520implications%2520for%2520the%2520therapeutic%2520potential%2520of%2520CB2%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D81%26spage%3D250%26epage%3D263%26doi%3D10.1124%2Fmol.111.074013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhopeshwarkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity of CB<sub>2</sub> cannabinoid receptor ligands at a canonical and noncanonical pathway</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.232561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.116.232561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27194477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCqtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=342-351&author=A.+Dhopeshwarkarauthor=K.+Mackie&title=Functional+selectivity+of+CB2+cannabinoid+receptor+ligands+at+a+canonical+and+noncanonical+pathway&doi=10.1124%2Fjpet.116.232561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathways</span></div><div class="casAuthors">Dhopeshwarkar, Amey; Mackie, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-351</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The CB2 cannabinoid receptor (CB2) remains a tantalizing, but unrealized therapeutic target.  CB2 receptor ligands belong to varied structural classes and display extreme-functional selectivity.  Here,we have screened diverse CB2 receptor ligands at canonical (inhibition of adenylyl cyclase) and noncanonical (arrestin recruitment) pathways.  The nonclassic cannabinoid (2)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP55940) was the most potent agonist for both pathways, while the classic cannabinoid ligand (6aR,10aR)-3-((1,1-Dimethylbutyl)-6a,7,10,10atetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran JWH133) was the most efficacious agonist among all the ligands profiled in cyclase assays.  In the cyclase assay, other classic cannabinoids showed little [(2)-trans-Δ9-tetrahydrocannabinol and (2)-(6aR,7,10,10aR)-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-6Hdibenzo[b,d]pyran-1-ol] (KM233) to no efficacy [(6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10atetrahydrobenzo[c]chromene(L759633) and (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,8,9,10,10a-hexahydro-1-methoxy-6,6-dimethyl-9-methylene-6H-dibenzo[b,d]pyran]L759656.  Most aminoalkylindoles, including [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate (WIN55212-2), were moderate efficacy agonists.  The cannabilactone 3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo(c)chromen-6-one (AM1710) was equiefficacious to CP55940 to inhibit adenylyl cyclase, albeit with lower potency.  In the arrestin recruitment assays, all classic cannabinoid ligands failed to recruit arrestins, indicating a bias toward G-protein coupling for this class of compd.  All aminoalkylindoles tested, except for WIN55212-2 and (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR144), failed to recruit arrestin.  WIN55212-2 was a low efficacy agonist for arrestin recruitment, while UR144 was arrestin biased with no significant inhibition of cyclase.  Endocannabinoids were G-protein biased with no arrestin recruitment.  The diarylpyrazole antagonist 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144258) was an inverse agonist in cyclase and arrestin recruitment assays while the aminoalkylindole 6-iodo-2-methyl-1-[[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630) and carboxamide N-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide (JTE907) were inverse agonists in cyclase but low efficacy agonists in arrestin recruitment assays.  Thus, CB2 receptor ligands display strong and varied functional selectivity at both pathways.  Therefore, extreme care must be exercised when using these compds. to infer the role of CB2 receptors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXMQ6mcUctrVg90H21EOLACvtfcHk0lhYP9g1C95jHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCqtbbF&md5=985b1124f434cf36163cb42867c8c266</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.232561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.232561%26sid%3Dliteratum%253Aachs%26aulast%3DDhopeshwarkar%26aufirst%3DA.%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DFunctional%2520selectivity%2520of%2520CB2%2520cannabinoid%2520receptor%2520ligands%2520at%2520a%2520canonical%2520and%2520noncanonical%2520pathway%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D342%26epage%3D351%26doi%3D10.1124%2Fjpet.116.232561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sam, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghatei, M. A.</span></span> <span> </span><span class="NLM_article-title">Rimonabant: from RIO to ban</span>. <i>J. Obes.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">432607</span>, <span class="refDoi"> DOI: 10.1155/2011/432607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1155%2F2011%2F432607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=21773005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=432607&author=A.+H.+Samauthor=V.+Salemauthor=M.+A.+Ghatei&title=Rimonabant%3A+from+RIO+to+ban&doi=10.1155%2F2011%2F432607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant: From RIO to Ban</span></div><div class="casAuthors">Sam Amir H; Salem Victoria; Ghatei Mohammad A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of obesity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">432607</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.  The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome.  However, the drug was quickly withdrawn due to the emergence of significant side effects-notably severe mood disorders.  This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgmzv1LvwoEZSWdIdmEou5fW6udTcc2eaTyPIHMuhhtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnps1SnsQ%253D%253D&md5=03967572404bd633a2298bd1a62baff1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1155%2F2011%2F432607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F432607%26sid%3Dliteratum%253Aachs%26aulast%3DSam%26aufirst%3DA.%2BH.%26aulast%3DSalem%26aufirst%3DV.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26atitle%3DRimonabant%253A%2520from%2520RIO%2520to%2520ban%26jtitle%3DJ.%2520Obes.%26date%3D2011%26volume%3D2011%26spage%3D432607%26doi%3D10.1155%2F2011%2F432607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H. H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span> <span> </span><span class="NLM_article-title">A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/0378-1119(93)90495-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2F0378-1119%2893%2990495-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=8294032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFGnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1993&pages=355-360&author=B.+F.+O%E2%80%99Dowdauthor=M.+Heiberauthor=A.+Chanauthor=H.+H.+Q.+Hengauthor=L.+C.+Tsuiauthor=J.+L.+Kennedyauthor=X.+M.+Shiauthor=A.+Petronisauthor=S.+R.+Georgeauthor=T.+Nguyen&title=A+human+gene+that+shows+identity+with+the+gene+encoding+the+angiotensin+receptor+is+located+on+chromosome+11&doi=10.1016%2F0378-1119%2893%2990495-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11</span></div><div class="casAuthors">O'Dowd, Brian F.; Heiber, Michael; Chan, Audrey; Heng, Henry H. Q.; Tsui, Lap Chee; Kennedy, James L.; Shi, Xiaomei; Petronis, Arturas; George, Susan R.; Nguyen Tuan</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">355-60</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    </div><div class="casAbstract">The authors report the cloning of a gene, intron-less in its coding region, which the authors have named APJ.  This gene was cloned using the polymerase chain reaction (PCR), with a set of primers designed on the basis of the conservation that members of G protein-coupled receptors (GPCR) have in their transmembrane (TM) regions.  The putative receptor protein, APJ, shares closest identity to the angiotensin receptor (AT1) ranging from 40 to 50% in the hydrophobic TM regions of these receptors.  The transcripts for this gene were detected in many regions of the brain.  PCR anal. of somatic cell lines found APJ-related sequences to be only present on chromosome 11, and high-resoln. mapping by fluorescence in situ hybridization (FISH) sub-localized APJ on band q12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqp2kdIKETdbVg90H21EOLACvtfcHk0lhYP9g1C95jHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFGnsL0%253D&md5=4beb37696cbf0f919df6c1d22088e719</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2F0378-1119%2893%2990495-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-1119%252893%252990495-O%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26aulast%3DHeiber%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DHeng%26aufirst%3DH.%2BH.%2BQ.%26aulast%3DTsui%26aufirst%3DL.%2BC.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26aulast%3DShi%26aufirst%3DX.%2BM.%26aulast%3DPetronis%26aufirst%3DA.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DNguyen%26aufirst%3DT.%26atitle%3DA%2520human%2520gene%2520that%2520shows%2520identity%2520with%2520the%2520gene%2520encoding%2520the%2520angiotensin%2520receptor%2520is%2520located%2520on%2520chromosome%252011%26jtitle%3DGene%26date%3D1993%26volume%3D136%26spage%3D355%26epage%3D360%26doi%3D10.1016%2F0378-1119%2893%2990495-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runyon, S. P.</span></span> <span> </span><span class="NLM_article-title">Regulation of the apelinergic system and its potential in cardiovascular disease: peptides and small molecules as tools for discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7913</span>– <span class="NLM_lpage">7927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7913-7927&author=S.+Narayananauthor=D.+L.+Harrisauthor=R.+Maitraauthor=S.+P.+Runyon&title=Regulation+of+the+apelinergic+system+and+its+potential+in+cardiovascular+disease%3A+peptides+and+small+molecules+as+tools+for+discovery&doi=10.1021%2Facs.jmedchem.5b00527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery</span></div><div class="casAuthors">Narayanan, Sanju; Harris, Danni L.; Maitra, Rangan; Runyon, Scott P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7913-7927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apelin peptides and the apelin receptor represent a relatively new therapeutic axis for the potential treatment of cardiovascular disease.  Several reports suggest apelin receptor activation with apelin peptides results in cardioprotection as noted through pos. ionotropy, angiogenesis, redn. of mean arterial blood pressure, and apoptosis.  Considering the potential therapeutic benefit attainable through modulation of the apelinergic system, research is expanding to develop novel therapies that limit the inherent rapid degrdn. of endogenous apelin peptides and produce metabolically stable small mol. agonists and antagonists to more rigorously interrogate the apelin receptor system.  This review details the structure-activity relationships for chem. modified apelin peptides and recent disclosures of small mol. agonists and antagonists and summarizes the peer reviewed and patented literature.  Development of metabolically stable ligands of apelin receptor and their effects in various models over the coming years will hopefully lead to establishment of this receptor as a validated target for cardiovascular indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTIngNdWxX87Vg90H21EOLACvtfcHk0lgf6_XXX4alHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN&md5=6c116a42d7b523905e811c33c46e256f</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00527%26sid%3Dliteratum%253Aachs%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DD.%2BL.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DRunyon%26aufirst%3DS.%2BP.%26atitle%3DRegulation%2520of%2520the%2520apelinergic%2520system%2520and%2520its%2520potential%2520in%2520cardiovascular%2520disease%253A%2520peptides%2520and%2520small%2520molecules%2520as%2520tools%2520for%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7913%26epage%3D7927%26doi%3D10.1021%2Facs.jmedchem.5b00527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scimia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurtado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalucci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlasuk, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaliman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Lozano, P.</span></span> <span> </span><span class="NLM_article-title">APJ acts as a dual receptor in cardiac hypertrophy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nature11263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature11263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22810587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=394-398&author=M.+C.+Scimiaauthor=C.+Hurtadoauthor=S.+Rayauthor=S.+Metzlerauthor=K.+Weiauthor=J.+M.+Wangauthor=C.+E.+Woodsauthor=N.+H.+Purcellauthor=D.+Catalucciauthor=T.+Akasakaauthor=O.+F.+Buenoauthor=G.+P.+Vlasukauthor=P.+Kalimanauthor=R.+Bodmerauthor=L.+H.+Smithauthor=E.+Ashleyauthor=M.+Mercolaauthor=J.+H.+Brownauthor=P.+Ruiz-Lozano&title=APJ+acts+as+a+dual+receptor+in+cardiac+hypertrophy&doi=10.1038%2Fnature11263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">APJ acts as a dual receptor in cardiac hypertrophy</span></div><div class="casAuthors">Scimia, Maria Cecilia; Hurtado, Cecilia; Ray, Saugata; Metzler, Scott; Wei, Ke; Wang, Jianming; Woods, Chris E.; Purcell, Nicole H.; Catalucci, Daniele; Akasaka, Takashi; Bueno, Orlando F.; Vlasuk, George P.; Kaliman, Perla; Bodmer, Rolf; Smith, Layton H.; Ashley, Euan; Mercola, Mark; Brown, Joan Heller; Ruiz-Lozano, Pilar</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7411</span>),
    <span class="NLM_cas:pages">394-398</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cardiac hypertrophy is initiated as an adaptive response to sustained overload but progresses pathol. as heart failure ensues.  Here we report that genetic loss of APJ, a G-protein-coupled receptor, confers resistance to chronic pressure overload by markedly reducing myocardial hypertrophy and heart failure.  In contrast, mice lacking apelin (the endogenous APJ ligand) remain sensitive, suggesting an apelin-independent function of APJ.  Freshly isolated APJ-null cardiomyocytes exhibit an attenuated response to stretch, indicating that APJ is a mechanosensor.  Activation of APJ by stretch increases cardiomyocyte cell size and induces mol. markers of hypertrophy.  Whereas apelin stimulates APJ to activate Gαi and elicits a protective response, stretch signals in an APJ-dependent, G-protein-independent fashion to induce hypertrophy.  Stretch-mediated hypertrophy is prevented by knockdown of β-arrestins or by pharmacol. doses of apelin acting through Gαi.  Taken together, our data indicate that APJ is a bifunctional receptor for both mech. stretch and the endogenous peptide apelin.  By sensing the balance between these stimuli, APJ occupies a pivotal point linking sustained overload to cardiomyocyte hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3eGCo9h1pKbVg90H21EOLACvtfcHk0lgf6_XXX4alHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbjF&md5=a0aefb2d9793982b0a37f0f6046f34c2</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnature11263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11263%26sid%3Dliteratum%253Aachs%26aulast%3DScimia%26aufirst%3DM.%2BC.%26aulast%3DHurtado%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DMetzler%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%2BM.%26aulast%3DWoods%26aufirst%3DC.%2BE.%26aulast%3DPurcell%26aufirst%3DN.%2BH.%26aulast%3DCatalucci%26aufirst%3DD.%26aulast%3DAkasaka%26aufirst%3DT.%26aulast%3DBueno%26aufirst%3DO.%2BF.%26aulast%3DVlasuk%26aufirst%3DG.%2BP.%26aulast%3DKaliman%26aufirst%3DP.%26aulast%3DBodmer%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DAshley%26aufirst%3DE.%26aulast%3DMercola%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DRuiz-Lozano%26aufirst%3DP.%26atitle%3DAPJ%2520acts%2520as%2520a%2520dual%2520receptor%2520in%2520cardiac%2520hypertrophy%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D394%26epage%3D398%26doi%3D10.1038%2Fnature11263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span> <span> </span><span class="NLM_article-title">Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.114.05099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1161%2FHYPERTENSIONAHA.114.05099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25712721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVGrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=834-840&author=A.+L.+Brameauthor=J.+J.+Maguireauthor=P.+R.+Yangauthor=A.+Dysonauthor=R.+Torellaauthor=J.+Cheriyanauthor=M.+Singerauthor=R.+C.+Glenauthor=I.+B.+Wilkinsonauthor=A.+P.+Davenport&title=Design%2C+characterization%2C+and+first-in-human+study+of+the+vascular+actions+of+a+novel+biased+apelin+receptor+agonist&doi=10.1161%2FHYPERTENSIONAHA.114.05099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist</span></div><div class="casAuthors">Brame, Aimee L.; Maguire, Janet J.; Yang, Peiran; Dyson, Alex; Torella, Rubben; Cheriyan, Joseph; Singer, Mervyn; Glen, Robert C.; Wilkinson, Ian B.; Davenport, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">834-840</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">[Pyr]apelin-13 is an endogenous vasodilator and inotrope but is downregulated in pulmonary hypertension and heart failure, making the apelin receptor an attractive therapeutic target.  Agonists acting at the same G-protein-coupled receptor can be engineered to stabilize different conformational states and function as biased ligands, selectively stimulating either G-protein or β-arrestin pathways.  We used mol. dynamics simulations of apelin/receptor interactions to design cyclic analogs and identified MM07 as a biased agonist.  In β-arrestin and internalization assays (G-protein-independent), MM07 was 2 orders of magnitude less potent than [Pyr]apelin-13.  In a G-protein-dependent saphenous vein contraction assay, both peptides had comparable potency (pD2:[Pyr]apelin-13 9.93±0.24; MM07 9.54±0.42) and max. responses with a resulting bias for MM07 of ≈350- to 1300-fold for the G-protein pathway.  In rats, systemic infusions of MM07 (10-100 nmol) caused a dose-dependent increase in cardiac output that was significantly greater than the response to [Pyr]apelin-13.  Similarly, in human volunteers, MM07 produced a significant dose-dependent increase in forearm blood flow with a max. dilatation double that is seen with [Pyr]apelin-13.  Addnl., repeated doses of MM07 produced reproducible increases in forearm blood flow.  These responses are consistent with a more efficacious action of the biased agonist.  In human hand vein, both peptides reversed an established norepinephrine constrictor response and significantly increased venous flow.  Our results suggest that MM07 acting as a biased agonist at the apelin receptor can preferentially stimulate the G-protein pathway, which could translate to improved efficacy in the clinic by selectively stimulating vasodilatation and inotropic actions but avoiding activating detrimental β-arrestin-dependent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwBeW0p9RgbVg90H21EOLACvtfcHk0lgf6_XXX4alHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVGrtr0%253D&md5=908911768ffa6edcd2ef9b1e80c8826a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.05099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.05099%26sid%3Dliteratum%253Aachs%26aulast%3DBrame%26aufirst%3DA.%2BL.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BR.%26aulast%3DDyson%26aufirst%3DA.%26aulast%3DTorella%26aufirst%3DR.%26aulast%3DCheriyan%26aufirst%3DJ.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DWilkinson%26aufirst%3DI.%2BB.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DDesign%252C%2520characterization%252C%2520and%2520first-in-human%2520study%2520of%2520the%2520vascular%2520actions%2520of%2520a%2520novel%2520biased%2520apelin%2520receptor%2520agonist%26jtitle%3DHypertension%26date%3D2015%26volume%3D65%26spage%3D834%26epage%3D840%26doi%3D10.1161%2FHYPERTENSIONAHA.114.05099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainsily, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau-Cossette, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besserer-Offroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longpre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leduc, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumaine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesur, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger-Messier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarret, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of novel macrocyclic biased apelin receptor agonists</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1039/C6OB02247B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1039%2FC6OB02247B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27924341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKntLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=449-458&author=A.+Murzaauthor=X.+Sainsilyauthor=J.+Coteauthor=L.+Bruneau-Cossetteauthor=E.+Besserer-Offroyauthor=J.+M.+Longpreauthor=R.+Leducauthor=R.+Dumaineauthor=O.+Lesurauthor=M.+Auger-Messierauthor=P.+Sarretauthor=E.+Marsault&title=Structure-activity+relationship+of+novel+macrocyclic+biased+apelin+receptor+agonists&doi=10.1039%2FC6OB02247B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship of novel macrocyclic biased apelin receptor agonists</span></div><div class="casAuthors">Murza, Alexandre; Sainsily, Xavier; Cote, Jerome; Bruneau-Cossette, Laurent; Besserer-Offroy, Elie; Longpre, Jean-Michel; Leduc, Richard; Dumaine, Robert; Lesur, Olivier; Auger-Messier, Mannix; Sarret, Philippe; Marsault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">449-458</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Apelin is the endogenous ligand for the G protein-coupled receptor APJ and exerts a key role in regulating cardiovascular functions.  We report herein a novel series of macrocyclic analogs of apelin-13 in which the N- and C-terminal residues as well as the macrocycle compn. were chem. modified to modulate structure-activity relationships on the APJ receptor.  To this end, the binding affinity and the ability to engage G protein-dependent and G protein-independent signalling pathways of the resulting analogs were assessed.  In this series, the position and the nature of the C-terminal arom. residue is a determinant for APJ interaction and β-arrestin recruitment, as previously demonstrated for linear apelin-13 derivs.  We finally discovered compds. 1, 4, 11 and 15, four potent G protein-biased apelin receptor agonists exhibiting affinity in the nanomolar range for APJ.  These macrocyclic compds. represent very useful pharmacol. tools to explore the therapeutic potential of the apelinergic system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjP6pZHwKK7Vg90H21EOLACvtfcHk0lhIz9YV75JSDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKntLjE&md5=9af5862171abf95feab2e830d7702b90</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FC6OB02247B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB02247B%26sid%3Dliteratum%253Aachs%26aulast%3DMurza%26aufirst%3DA.%26aulast%3DSainsily%26aufirst%3DX.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DBruneau-Cossette%26aufirst%3DL.%26aulast%3DBesserer-Offroy%26aufirst%3DE.%26aulast%3DLongpre%26aufirst%3DJ.%2BM.%26aulast%3DLeduc%26aufirst%3DR.%26aulast%3DDumaine%26aufirst%3DR.%26aulast%3DLesur%26aufirst%3DO.%26aulast%3DAuger-Messier%26aufirst%3DM.%26aulast%3DSarret%26aufirst%3DP.%26aulast%3DMarsault%26aufirst%3DE.%26atitle%3DStructure-activity%2520relationship%2520of%2520novel%2520macrocyclic%2520biased%2520apelin%2520receptor%2520agonists%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26spage%3D449%26epage%3D458%26doi%3D10.1039%2FC6OB02247B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceraudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banegas-Font, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonegge, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvear-Perez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturrioz, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Biased signaling favoring G<sub>i</sub> over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">24599</span>– <span class="NLM_lpage">24610</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.541698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.541698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25012663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGjt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=24599-24610&author=E.+Ceraudoauthor=C.+Galanthauthor=E.+Carpentierauthor=I.+Banegas-Fontauthor=A.+M.+Schoneggeauthor=R.+Alvear-Perezauthor=X.+Iturriozauthor=M.+Bouvierauthor=C.+Llorens-Cortes&title=Biased+signaling+favoring+Gi+over+%CE%B2-arrestin+promoted+by+an+apelin+fragment+lacking+the+C-terminal+phenylalanine&doi=10.1074%2Fjbc.M113.541698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Signaling Favoring Gi over β-Arrestin Promoted by an Apelin Fragment Lacking the C-terminal Phenylalanine</span></div><div class="casAuthors">Ceraudo, Emilie; Galanth, Cecile; Carpentier, Eric; Banegas-Font, Inmaculada; Schonegge, Anne-Marie; Alvear-Perez, Rodrigo; Iturrioz, Xavier; Bouvier, Michel; Llorens-Cortes, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">24599-24610</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Apelin plays a prominent role in body fluid and cardiovascular homeostasis.  The authors previously showed that the C-terminal Phe of apelin 17 (K17F) is crucial for triggering apelin receptor internalization and decreasing blood pressure (BP) but is not required for apelin binding or Gi protein coupling.  Based on these findings, the authors hypothesized that the important role of the C-terminal Phe in BP decrease may be as a Gi-independent but β-arrestin-dependent signaling pathway that could involve MAPKs.  For this purpose, the authors have used apelin fragments K17F and K16P (K17F with the C-terminal Phe deleted), which exhibit opposite profiles on apelin receptor internalization and BP.  Using BRET-based biosensors, the authors showed that, whereas K17F activates Gi and promotes β-arrestin recruitment to the receptor, K16P had a much reduced ability to promote β-arrestin recruitment while maintaining its Gi activating property, revealing the biased agonist character of K16P.  The authors further show that both β-arrestin recruitment and apelin receptor internalization contribute to the K17F-stimulated ERK1/2 activity, whereas the K16P-promoted ERK1/2 activity is entirely Gi-dependent.  In addn. to providing new insights on the structural basis underlying the functional selectivity of apelin peptides, the authors' study indicates that the β-arrestin-dependent ERK1/2 activation and not the Gi-dependent signaling may participate in K17F-induced BP decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA2B14K-_mtLVg90H21EOLACvtfcHk0lhIz9YV75JSDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGjt7nJ&md5=3d412882bcb7944183ce2f5961ab58fd</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.541698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.541698%26sid%3Dliteratum%253Aachs%26aulast%3DCeraudo%26aufirst%3DE.%26aulast%3DGalanth%26aufirst%3DC.%26aulast%3DCarpentier%26aufirst%3DE.%26aulast%3DBanegas-Font%26aufirst%3DI.%26aulast%3DSchonegge%26aufirst%3DA.%2BM.%26aulast%3DAlvear-Perez%26aufirst%3DR.%26aulast%3DIturrioz%26aufirst%3DX.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DBiased%2520signaling%2520favoring%2520Gi%2520over%2520%25CE%25B2-arrestin%2520promoted%2520by%2520an%2520apelin%2520fragment%2520lacking%2520the%2520C-terminal%2520phenylalanine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D24599%26epage%3D24610%26doi%3D10.1074%2Fjbc.M113.541698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hachtel, S.</span>; <span class="NLM_string-name">Wohlfart, P.</span>; <span class="NLM_string-name">Weston, J.</span>; <span class="NLM_string-name">Müller, M.</span>; <span class="NLM_string-name">Defossa, E.</span>; <span class="NLM_string-name">Mertsch, K.</span>; <span class="NLM_string-name">Weng, J.
H.</span>; <span class="NLM_string-name">Binnie, R.
A.</span>; <span class="NLM_string-name">Abdul-Latif, F.</span>; <span class="NLM_string-name">Bock, W.
J.</span>; <span class="NLM_string-name">Walser, A.</span></span> <span> </span><span class="NLM_article-title">Benzoimidazole-Carboxylic Acid Amide Derivatives as APJ Receptor Modulators</span>. <span class="NLM_patent">WO 2014/044738 A1</span>, March 27, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Hachtel&author=P.+Wohlfart&author=J.+Weston&author=M.+M%C3%BCller&author=E.+Defossa&author=K.+Mertsch&author=J.%0AH.+Weng&author=R.%0AA.+Binnie&author=F.+Abdul-Latif&author=W.%0AJ.+Bock&author=A.+Walser&title=Benzoimidazole-Carboxylic+Acid+Amide+Derivatives+as+APJ+Receptor+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHachtel%26aufirst%3DS.%26atitle%3DBenzoimidazole-Carboxylic%2520Acid%2520Amide%2520Derivatives%2520as%2520APJ%2520Receptor%2520Modulators%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Read, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuc, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span> <span> </span><span class="NLM_article-title">Cardiac action of the first G protein biased small molecule apelin agonist</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2016.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27475715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GhtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=63-72&author=C.+Readauthor=C.+M.+Fitzpatrickauthor=P.+R.+Yangauthor=R.+E.+Kucauthor=J.+J.+Maguireauthor=R.+C.+Glenauthor=R.+E.+Fosterauthor=A.+P.+Davenport&title=Cardiac+action+of+the+first+G+protein+biased+small+molecule+apelin+agonist&doi=10.1016%2Fj.bcp.2016.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac action of the first G protein biased small molecule apelin agonist</span></div><div class="casAuthors">Read, Cai; Fitzpatrick, Christopher M.; Yang, Peiran; Kuc, Rhoda E.; Maguire, Janet J.; Glen, Robert C.; Foster, Richard E.; Davenport, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Apelin peptide analogs displaying bias towards G protein signalling pathways have beneficial cardiovascular actions compared with the native peptide in humans in vivo.  Our aim was to det. whether small mol. agonists could retain G protein bias.  We have identified a biased small mol., CMF-019 (I), and characterised it in vitro and in vivo.  In competition radioligand binding expts. in heart homogenates, CMF-019 bound to the human, rat and mouse apelin receptor with high affinity (pKi = 8.58 ± 0.04, 8.49 ± 0.04 and 8.71 ± 0.06 resp.).  In cell-based functional assays, whereas, CMF-019 showed similar potency for the Gαi pathway to the endogenous agonist [Pyr1]apelin-13 (pD2 = 10.00 ± 0.13 vs 9.34 ± 0.15), in β-arrestin and internalisation assays it was less potent (pD2 = 6.65 ± 0.15 vs 8.65 ± 0.10 and pD2 = 6.16 ± 0.21 vs 9.28 ± 0.10 resp.).  Anal. of these data demonstrated a bias of ∼400 for the Gαi over the β-arrestin pathway and ∼6000 over receptor internalisation.  CMF-019 was tested for in vivo activity using i.v. injections into anesthetized male Sprague-Dawley rats fitted with a pressure-vol. catheter in the left ventricle.  CMF-019 caused a significant increase in cardiac contractility of 606 ± 112 mmHg/s (p < 0.001) at 500 nmol.  CMF-019 is the first biased small mol. identified at the apelin receptor and increases cardiac contractility in vivo.  We have demonstrated that Gαi over β-arrestin/internalisation bias can be retained in a non-peptide analog and predict that such bias will have the therapeutic benefit following chronic use.  CMF-019 is suitable as a tool compd. and provides the basis for design of biased agonists with improved pharmacokinetics for treatment of cardiovascular conditions such as pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqmJ0WndHEdLVg90H21EOLACvtfcHk0ljOIDDFMBQ1ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GhtbnJ&md5=0a2ba0ccb57382ceda2e0d27ff46c61e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DC.%26aulast%3DFitzpatrick%26aufirst%3DC.%2BM.%26aulast%3DYang%26aufirst%3DP.%2BR.%26aulast%3DKuc%26aufirst%3DR.%2BE.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DFoster%26aufirst%3DR.%2BE.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DCardiac%2520action%2520of%2520the%2520first%2520G%2520protein%2520biased%2520small%2520molecule%2520apelin%2520agonist%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D116%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.bcp.2016.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagarsheth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W. P.</span></span> <span> </span><span class="NLM_article-title">Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnri.2017.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28555670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=559-572&author=N.+Nagarshethauthor=M.+S.+Wichaauthor=W.+P.+Zou&title=Chemokines+in+the+cancer+microenvironment+and+their+relevance+in+cancer+immunotherapy&doi=10.1038%2Fnri.2017.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</span></div><div class="casAuthors">Nagarsheth, Nisha; Wicha, Max S.; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">559-572</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The tumor microenvironment is the primary location in which tumor cells and the host immune system interact.  Different immune cell subsets are recruited into the tumor microenvironment via interactions between chemokines and chemokine receptors, and these populations have distinct effects on tumor progression and therapeutic outcomes.  In this Review, we focus on the main chemokines that are found in the human tumor microenvironment; we elaborate on their patterns of expression, their regulation and their roles in immune cell recruitment and in cancer and stromal cell biol., and we consider how they affect cancer immunity and tumorigenesis.  We also discuss the potential of targeting chemokine networks, in combination with other immunotherapies, for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEb-fH3CLf0bVg90H21EOLACvtfcHk0ljOIDDFMBQ1ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSjtr8%253D&md5=c102d8bf9475aa0e823e941c43fc5b54</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.49%26sid%3Dliteratum%253Aachs%26aulast%3DNagarsheth%26aufirst%3DN.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DZou%26aufirst%3DW.%2BP.%26atitle%3DChemokines%2520in%2520the%2520cancer%2520microenvironment%2520and%2520their%2520relevance%2520in%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2017%26volume%3D17%26spage%3D559%26epage%3D572%26doi%3D10.1038%2Fnri.2017.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. M.</span></span> <span> </span><span class="NLM_article-title">Biased and G protein-indepedent signalling of chemokine receptors</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2014.00277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3389%2Ffimmu.2014.00277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25002861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgt1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=277&author=A.+Steenauthor=O.+Larsenauthor=S.+Thieleauthor=M.+M.+Rosenkilde&title=Biased+and+G+protein-indepedent+signalling+of+chemokine+receptors&doi=10.3389%2Ffimmu.2014.00277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Biased and g protein-independent signaling of chemokine receptors</span></div><div class="casAuthors">Steen Anne; Larsen Olav; Thiele Stefanie; Rosenkilde Mette M</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">Biased signaling or functional selectivity occurs when a 7TM-receptor preferentially activates one of several available pathways.  It can be divided into three distinct forms: ligand bias, receptor bias, and tissue or cell bias, where it is mediated by different ligands (on the same receptor), different receptors (with the same ligand), or different tissues or cells (for the same ligand-receptor pair).  Most often biased signaling is differentiated into G protein-dependent and β-arrestin-dependent signaling.  Yet, it may also cover signaling differences within these groups.  Moreover, it may not be absolute, i.e., full versus no activation.  Here we discuss biased signaling in the chemokine system, including the structural basis for biased signaling in chemokine receptors, as well as in class A 7TM receptors in general.  This includes overall helical movements and the contributions of micro-switches based on recently published 7TM crystals and molecular dynamics studies.  All three forms of biased signaling are abundant in the chemokine system.  This challenges our understanding of "classic" redundancy inevitably ascribed to this system, where multiple chemokines bind to the same receptor and where a single chemokine may bind to several receptors - in both cases with the same functional outcome.  The ubiquitous biased signaling confers a hitherto unknown specificity to the chemokine system with a complex interaction pattern that is better described as promiscuous with context-defined roles and different functional outcomes in a ligand-, receptor-, or cell/tissue-defined manner.  As the low number of successful drug development plans implies, there are great difficulties in targeting chemokine receptors; in particular with regard to receptor antagonists as anti-inflammatory drugs.  Un-defined and putative non-selective targeting of the complete cellular signaling system could be the underlying cause of lack of success.  Therefore, biased ligands could be the solution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmZZF9dVtZQ4vKgEt20y1XfW6udTcc2eae0PS_C9aQcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgt1OisQ%253D%253D&md5=814b5ab6c48f59e2543803e516b35bbf</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2014.00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2014.00277%26sid%3Dliteratum%253Aachs%26aulast%3DSteen%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DO.%26aulast%3DThiele%26aufirst%3DS.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26atitle%3DBiased%2520and%2520G%2520protein-indepedent%2520signalling%2520of%2520chemokine%2520receptors%26jtitle%3DFront.%2520Immunol.%26date%3D2014%26volume%3D5%26spage%3D277%26doi%3D10.3389%2Ffimmu.2014.00277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassoni, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T. S.</span></span> <span> </span><span class="NLM_article-title">Biased agonism as a mechanism for differential signaling by chemokine receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">35039</span>– <span class="NLM_lpage">35048</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.479113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M113.479113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24145037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWkurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=35039-35048&author=S.+Rajagopalauthor=D.+L.+Bassoniauthor=J.+J.+Campbellauthor=N.+P.+Gerardauthor=C.+Gerardauthor=T.+S.+Wehrman&title=Biased+agonism+as+a+mechanism+for+differential+signaling+by+chemokine+receptors&doi=10.1074%2Fjbc.M113.479113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Agonism as a Mechanism for Differential Signaling by Chemokine Receptors</span></div><div class="casAuthors">Rajagopal, Sudarshan; Bassoni, Daniel L.; Campbell, James J.; Gerard, Norma P.; Gerard, Craig; Wehrman, Tom S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">35039-35048</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Chemokines display considerable promiscuity with multiple ligands and receptors shared in common, a phenomenon that is thought to underlie their biochem. "redundancy.".  Their receptors are part of a larger seven-transmembrane receptor superfamily, commonly referred to as G protein-coupled receptors, which have been demonstrated to be able to signal with different efficacies to their multiple downstream signaling pathways, a phenomenon referred to as biased agonism.  Biased agonism has been primarily reported as a phenomenon of synthetic ligands, and the biol. prevalence and importance of such signaling are unclear.  Here, to assess the presence of biased agonism that may underlie differential signaling by chemokines targeting the same receptor, we performed a detailed pharmacol. anal. of a set of chemokine receptors with multiple endogenous ligands using assays for G protein signaling, β-arrestin recruitment, and receptor internalization.  We found that chemokines targeting the same receptor can display marked differences in their efficacies for G protein- or β-arrestin-mediated signaling or receptor internalization.  This ligand bias correlates with changes in leukocyte migration, consistent with different mechanisms underlying the signaling downstream of these receptors induced by their ligands.  These findings demonstrate that biased agonism is a common and likely evolutionarily conserved biol. mechanism for generating qual. distinct patterns of signaling via the same receptor in response to different endogenous ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyPY4PQ3oUn7Vg90H21EOLACvtfcHk0lhER0E4rb8Ecw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWkurbJ&md5=778d4347529e2c531bf6ed49c7b2bc0f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.479113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.479113%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DBassoni%26aufirst%3DD.%2BL.%26aulast%3DCampbell%26aufirst%3DJ.%2BJ.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26aulast%3DWehrman%26aufirst%3DT.%2BS.%26atitle%3DBiased%2520agonism%2520as%2520a%2520mechanism%2520for%2520differential%2520signaling%2520by%2520chemokine%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D35039%26epage%3D35048%26doi%3D10.1074%2Fjbc.M113.479113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbisier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszagh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springael, J. Y.</span></span> <span> </span><span class="NLM_article-title">Biased signaling at chemokine receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">9542</span>– <span class="NLM_lpage">9554</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.596098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M114.596098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=9542-9554&author=J.+Corbisierauthor=C.+Galesauthor=A.+Huszaghauthor=M.+Parmentierauthor=J.+Y.+Springael&title=Biased+signaling+at+chemokine+receptors&doi=10.1074%2Fjbc.M114.596098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.596098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.596098%26sid%3Dliteratum%253Aachs%26aulast%3DCorbisier%26aufirst%3DJ.%26aulast%3DGales%26aufirst%3DC.%26aulast%3DHuszagh%26aufirst%3DA.%26aulast%3DParmentier%26aufirst%3DM.%26aulast%3DSpringael%26aufirst%3DJ.%2BY.%26atitle%3DBiased%2520signaling%2520at%2520chemokine%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D9542%26epage%3D9554%26doi%3D10.1074%2Fjbc.M114.596098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milanos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklukar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waibel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsiedel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dürr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanović-Burmazović, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjortø, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of biased allosteric agonists of the chemokine receptor CXCR3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2222</span>– <span class="NLM_lpage">2243</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01965</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01965" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2222-2243&author=L.+Milanosauthor=R.+Broxauthor=T.+Frankauthor=G.+Poklukarauthor=R.+Palmisanoauthor=R.+Waibelauthor=J.+Einsiedelauthor=M.+D%C3%BCrrauthor=I.+Ivanovi%C4%87-Burmazovi%C4%87author=O.+Larsenauthor=G.+M.+Hjort%C3%B8author=M.+M.+Rosenkildeauthor=N.+Tschammer&title=Discovery+and+characterization+of+biased+allosteric+agonists+of+the+chemokine+receptor+CXCR3&doi=10.1021%2Facs.jmedchem.5b01965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01965%26sid%3Dliteratum%253Aachs%26aulast%3DMilanos%26aufirst%3DL.%26aulast%3DBrox%26aufirst%3DR.%26aulast%3DFrank%26aufirst%3DT.%26aulast%3DPoklukar%26aufirst%3DG.%26aulast%3DPalmisano%26aufirst%3DR.%26aulast%3DWaibel%26aufirst%3DR.%26aulast%3DEinsiedel%26aufirst%3DJ.%26aulast%3DD%25C3%25BCrr%26aufirst%3DM.%26aulast%3DIvanovi%25C4%2587-Burmazovi%25C4%2587%26aufirst%3DI.%26aulast%3DLarsen%26aufirst%3DO.%26aulast%3DHjort%25C3%25B8%26aufirst%3DG.%2BM.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DTschammer%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520biased%2520allosteric%2520agonists%2520of%2520the%2520chemokine%2520receptor%2520CXCR3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2222%26epage%3D2243%26doi%3D10.1021%2Facs.jmedchem.5b01965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zervosen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frère, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joris, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luxen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvage, E.</span></span> <span> </span><span class="NLM_article-title">Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">10839</span>– <span class="NLM_lpage">10848</span>, <span class="refDoi"> DOI: 10.1021/ja200696y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja200696y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFKhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=10839-10848&author=A.+Zervosenauthor=R.+Hermanauthor=F.+Kerffauthor=A.+Hermanauthor=A.+Bouillezauthor=F.+Pratiauthor=R.+F.+Prattauthor=J.-M.+Fr%C3%A8reauthor=B.+Jorisauthor=A.+Luxenauthor=P.+Charlierauthor=E.+Sauvage&title=Unexpected+tricovalent+binding+mode+of+boronic+acids+within+the+active+site+of+a+penicillin-binding+protein&doi=10.1021%2Fja200696y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Unexpected Tricovalent Binding Mode of Boronic Acids within the Active Site of a Penicillin-Binding Protein</span></div><div class="casAuthors">Zervosen, Astrid; Herman, Raphael; Kerff, Frederic; Herman, Alexandre; Bouillez, Andre; Prati, Fabio; Pratt, R. F.; Frere, Jean-Marie; Joris, Bernard; Luxen, Andre; Charlier, Paulette; Sauvage, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10839-10848</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Boronic acids bearing appropriate side chains are good inhibitors of serine amidohydrolases.  The boron usually adopts a tetrahedral conformation, bound to the nucleophilic serine of the active site and mimicking the transition state of the enzymic reaction.  We have solved the structures of complexes of a penicillin-binding protein (PBP), the DD-peptidase from Actinomadura sp. R39, with four amidomethylboronic acids (2,6-dimethoxybenzamidomethylboronic acid, phenylacetamidomethylboronic acid, 2-chlorobenzamidomethylboronic acid, and 2-nitrobenzamidomethylboronic acid) and the pinacol ester derived from phenylacetamidomethylboronic acid.  We found that in each case, the boron forms a tricovalent adduct with the Oγ from Ser49 and Ser298, and the terminal amine group of Lys410, three key residues involved in the catalytic mechanism of penicillin-binding proteins.  This represents the first tricovalent enzyme-inhibitor adducts obsd. by crystallog.  In two of the five R39-boronate structures, the boronic acid is found as a tricovalent adduct in two monomers of the asym. unit and as a monocovalent adduct with the active serine in the two remaining monomers of the asym. unit.  Formation of the tricovalent complex from a classical monocovalent complex may involve rotation around the Ser49 Cα-Cβ bond to place the boron in a position to interact with Ser298 and Lys410, and a twisting of the side-chain amide such that its carbonyl oxygen is able to hydrogen bond to the oxyanion hole NH of Thr413.  Biphasic kinetics were obsd. in three of the five cases, and details of the reaction between R39 and 2,6-dimethoxybenzamidomethylboronic acid were studied.  Observation of biphasic kinetics was not, however, thought to be correlated with formation of tricovalent complexes, assuming that the latter do form in soln.  On the basis of the crystallog. and kinetic results, a reaction scheme for this unexpected inhibition by boronic acids is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ewm48mQ5fLVg90H21EOLACvtfcHk0lgGtHKi9wWrjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFKhsr0%253D&md5=847cbfcb9458d610240b34d01a99a261</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fja200696y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja200696y%26sid%3Dliteratum%253Aachs%26aulast%3DZervosen%26aufirst%3DA.%26aulast%3DHerman%26aufirst%3DR.%26aulast%3DKerff%26aufirst%3DF.%26aulast%3DHerman%26aufirst%3DA.%26aulast%3DBouillez%26aufirst%3DA.%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DPratt%26aufirst%3DR.%2BF.%26aulast%3DFr%25C3%25A8re%26aufirst%3DJ.-M.%26aulast%3DJoris%26aufirst%3DB.%26aulast%3DLuxen%26aufirst%3DA.%26aulast%3DCharlier%26aufirst%3DP.%26aulast%3DSauvage%26aufirst%3DE.%26atitle%3DUnexpected%2520tricovalent%2520binding%2520mode%2520of%2520boronic%2520acids%2520within%2520the%2520active%2520site%2520of%2520a%2520penicillin-binding%2520protein%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D10839%26epage%3D10848%26doi%3D10.1021%2Fja200696y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Admas, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span> <span> </span><span class="NLM_article-title">Boronic acids as probes for investigation of allosteric modulation of the chemokine receptor CXCR3</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2664</span>– <span class="NLM_lpage">2677</span>, <span class="refDoi"> DOI: 10.1021/cb500678c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500678c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2664-2677&author=V.+Bernatauthor=T.+H.+Admasauthor=R.+Broxauthor=F.+W.+Heinemannauthor=N.+Tschammer&title=Boronic+acids+as+probes+for+investigation+of+allosteric+modulation+of+the+chemokine+receptor+CXCR3&doi=10.1021%2Fcb500678c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic Acids as Probes for Investigation of Allosteric Modulation of the Chemokine Receptor CXCR3</span></div><div class="casAuthors">Bernat, Viachaslau; Admas, Tizita Haimanot; Brox, Regine; Heinemann, Frank W.; Tschammer, Nuska</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2664-2677</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The chemokine receptor CXCR3 is a G protein-coupled receptor, which conveys extracellular signals into cells by changing its conformation upon agonist binding.  To facilitate the mechanistic understanding of allosteric modulation of CXCR3, we combined computational modeling with the synthesis of novel chem. tools contg. boronic acid moiety, site-directed mutagenesis, and detailed functional characterization.  The design of boronic acid derivs. was based on the predictions from homol. modeling and docking.  The choice of the boronic acid moiety was dictated by its unique ability to interact with proteins in a reversible covalent way, thereby influencing conformational dynamics of target biomols.  During the synthesis of the library we have developed a novel approach for the purifn. of drug-like boronic acids.  To validate the predicted binding mode and to identify amino acid residues responsible for the transduction of signal through CXCR3, we conducted a site-directed mutagenesis study.  With the use of allosteric radioligand RAMX3 we were able to establish the existence of a second allosteric binding pocket in CXCR3, which enables different binding modes of structurally closely related allosteric modulators of CXCR3.  We have also identified residues Trp1092.60 and Lys3007.35 inside the transmembrane bundle of the receptor as crucial for the regulation of the G protein activation.  Furthermore, we report the boronic acid 14 as the first biased neg. allosteric modulator of the receptor.  Overall, our data demonstrate that boronic acid derivs. represent an outstanding tool for detn. of key receptor-ligand interactions and induction of ligand-biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9piFXBc8fB7Vg90H21EOLACvtfcHk0lgGtHKi9wWrjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbP&md5=d0fd65b1179a29c074224090a4f9787a</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fcb500678c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500678c%26sid%3Dliteratum%253Aachs%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DAdmas%26aufirst%3DT.%2BH.%26aulast%3DBrox%26aufirst%3DR.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DTschammer%26aufirst%3DN.%26atitle%3DBoronic%2520acids%2520as%2520probes%2520for%2520investigation%2520of%2520allosteric%2520modulation%2520of%2520the%2520chemokine%2520receptor%2520CXCR3%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D2664%26epage%3D2677%26doi%3D10.1021%2Fcb500678c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brox, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberson, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschammer, N.</span></span> <span> </span><span class="NLM_article-title">Ligand-biased and probe-dependent modulation of chemokine receptor CXCR3 signaling by negative allosteric modulators</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fcmdc.201402507" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=566-574&author=V.+Bernatauthor=R.+Broxauthor=M.+R.+Heinrichauthor=Y.+P.+Aubersonauthor=N.+Tschammer&title=Ligand-biased+and+probe-dependent+modulation+of+chemokine+receptor+CXCR3+signaling+by+negative+allosteric+modulators&doi=10.1002%2Fcmdc.201402507"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402507%26sid%3Dliteratum%253Aachs%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DBrox%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DM.%2BR.%26aulast%3DAuberson%26aufirst%3DY.%2BP.%26aulast%3DTschammer%26aufirst%3DN.%26atitle%3DLigand-biased%2520and%2520probe-dependent%2520modulation%2520of%2520chemokine%2520receptor%2520CXCR3%2520signaling%2520by%2520negative%2520allosteric%2520modulators%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D566%26epage%3D574%26doi%3D10.1002%2Fcmdc.201402507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesh, T.</span></span> <span> </span><span class="NLM_article-title">Prostanoid receptor EP2 as a therapeutic target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4454</span>– <span class="NLM_lpage">4465</span>, <span class="refDoi"> DOI: 10.1021/jm401431x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401431x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCmur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4454-4465&author=T.+Ganesh&title=Prostanoid+receptor+EP2+as+a+therapeutic+target&doi=10.1021%2Fjm401431x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Prostanoid Receptor EP2 as a Therapeutic Target</span></div><div class="casAuthors">Ganesh, Thota</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4454-4465</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Cycoloxygenase-2 (COX-2) induction is prevalent in a variety of (brain and peripheral) injury models where COX-2 levels correlate with disease progression.  Thus, COX-2 has been widely explored for anti-inflammatory therapy with COX-2 inhibitors, which proved to be effective in reducing the pain and inflammation in patients with arthritis and menstrual cramps, but they have not provided any benefit to patients with chronic inflammatory neurodegenerative disease.  Recently, two COX-2 drugs, rofecoxib and valdecoxib, were withdrawn from the United States market due to cardiovascular side effects.  Thus, future anti-inflammatory therapy could be targeted through a specific prostanoid receptor downstream of COX-2.  The PGE2 receptor EP2 is emerging as a pro-inflammatory target in a variety of CNS and peripheral diseases.  Here we highlight the latest developments on the role of EP2 in diseases, mechanism of activation, and small mol. discovery targeted either to enhance or to block the function of this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpanB_f3g_VUbVg90H21EOLACvtfcHk0lhnAPoONPActQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCmur%252FK&md5=405be9149d8abd1d2d1de4af042bf2a0</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm401431x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401431x%26sid%3Dliteratum%253Aachs%26aulast%3DGanesh%26aufirst%3DT.%26atitle%3DProstanoid%2520receptor%2520EP2%2520as%2520a%2520therapeutic%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4454%26epage%3D4465%26doi%3D10.1021%2Fjm401431x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCullough, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haughey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breyer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasson, K.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective function of the PGE<sub>2</sub> EP2 receptor in cerebral ischemia</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4485-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1523%2FJNEUROSCI.4485-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=14715958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2ltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=257-268&author=L.+McCulloughauthor=L.+Wuauthor=N.+Haugheyauthor=X.+Liangauthor=T.+Handauthor=Q.+Wangauthor=R.+M.+Breyerauthor=K.+Andreasson&title=Neuroprotective+function+of+the+PGE2+EP2+receptor+in+cerebral+ischemia&doi=10.1523%2FJNEUROSCI.4485-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia</span></div><div class="casAuthors">McCullough, Louise; Wu, Liejun; Haughey, Norman; Liang, Xibin; Hand, Tracey; Wang, Qian; Breyer, Richard M.; Andreasson, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">257-268</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The cyclooxygenases COX-1 and COX-2 catalyze the first committed step of prostaglandin synthesis from arachidonic acid.  Previous studies in rodent stroke models have shown that the inducible COX-2 isoform promotes neuronal injury, and the administration of COX-2 inhibitors reduces infarct vol.  We investigated the function of PGE2, a principal prostaglandin product of COX-2 enzymic activity, in neuronal survival in cerebral ischemia.  PGE2 exerts its downstream effects by signaling through a class of four distinct G-protein-coupled EP receptors (for E-prostanoid: EP1, EP2, EP3, and EP4) that have divergent effects on cAMP and phosphoinositol turnover and different anatomical distributions in brain.  The EP2 receptor subtype is abundantly expressed in cerebral cortex, striatum, and hippocampus, and is pos. coupled to cAMP prodn.  In vitro studies of dispersed neurons and organotypic hippocampal cultures demonstrated that activation of the EP2 receptor was neuroprotective in paradigms of NMDA toxicity and oxygen glucose deprivation.  Pharmacol. blockade of EP2 signaling by inhibition of protein kinase A activation reversed this protective effect, suggesting that EP2-mediated neuroprotection is dependent on cAMP signaling.  In the middle cerebral artery occlusion-reperfusion model of transient forebrain ischemia, genetic deletion of the EP2 receptor significantly increased cerebral infarction in cerebral cortex and subcortical structures.  These studies indicate that activation of the PGE2 EP2 receptor can protect against excitotoxic and anoxic injury in a cAMP-dependent manner.  Taken together, these data suggest a novel mechanism of neuroprotection mediated by a dominant PGE2 receptor subtype in brain that may provide a target for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjazLQgIyS47Vg90H21EOLACvtfcHk0lhnAPoONPActQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2ltQ%253D%253D&md5=73a862c6c9372fccb711bfacd07ff6d6</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4485-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4485-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMcCullough%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DHaughey%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHand%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBreyer%26aufirst%3DR.%2BM.%26aulast%3DAndreasson%26aufirst%3DK.%26atitle%3DNeuroprotective%2520function%2520of%2520the%2520PGE2%2520EP2%2520receptor%2520in%2520cerebral%2520ischemia%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D257%26epage%3D268%26doi%3D10.1523%2FJNEUROSCI.4485-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenbach, R.</span></span> <span> </span><span class="NLM_article-title">The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and β-arrestin1-dependent signaling pathways</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">39672</span>– <span class="NLM_lpage">39681</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.117689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M110.117689" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=39672-39681&author=K.+S.+Chunauthor=H.+C.+Laoauthor=R.+Langenbach&title=The+prostaglandin+E2+receptor%2C+EP2%2C+stimulates+keratinocyte+proliferation+in+mouse+skin+by+G+protein-dependent+and+%CE%B2-arrestin1-dependent+signaling+pathways&doi=10.1074%2Fjbc.M110.117689"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.117689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.117689%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DK.%2BS.%26aulast%3DLao%26aufirst%3DH.%2BC.%26aulast%3DLangenbach%26aufirst%3DR.%26atitle%3DThe%2520prostaglandin%2520E2%2520receptor%252C%2520EP2%252C%2520stimulates%2520keratinocyte%2520proliferation%2520in%2520mouse%2520skin%2520by%2520G%2520protein-dependent%2520and%2520%25CE%25B2-arrestin1-dependent%2520signaling%2520pathways%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D39672%26epage%3D39681%26doi%3D10.1074%2Fjbc.M110.117689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kigoshi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein-biased EP2 receptor agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00455</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00455" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=306-311&author=S.+Ogawaauthor=T.+Watanabeauthor=I.+Sugimotoauthor=K.+Moriyukiauthor=Y.+Gotoauthor=S.+Yamaneauthor=A.+Watanabeauthor=K.+Tsuboiauthor=A.+Kinoshitaauthor=H.+Kigoshiauthor=K.+Taniauthor=T.+Maruyama&title=Discovery+of+G+protein-biased+EP2+receptor+agonists&doi=10.1021%2Facsmedchemlett.5b00455"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00455%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DI.%26aulast%3DMoriyuki%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DYamane%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DKigoshi%26aufirst%3DH.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520G%2520protein-biased%2520EP2%2520receptor%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D306%26epage%3D311%26doi%3D10.1021%2Facsmedchemlett.5b00455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, T.</span></span> <span> </span><span class="NLM_article-title">Structural optimization and structure–functional selectivity relationship studies of G protein-biased EP2 receptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2446</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bmcl.2016.03.110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2446-2449&author=S.+Ogawaauthor=T.+Watanabeauthor=K.+Moriyukiauthor=Y.+Gotoauthor=S.+Yamaneauthor=A.+Watanabeauthor=K.+Tsuboiauthor=A.+Kinoshitaauthor=T.+Okadaauthor=H.+Takedaauthor=K.+Taniauthor=T.+Maruyama&title=Structural+optimization+and+structure%E2%80%93functional+selectivity+relationship+studies+of+G+protein-biased+EP2+receptor+agonists&doi=10.1016%2Fj.bmcl.2016.03.110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.110%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DMoriyuki%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DYamane%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DTsuboi%26aufirst%3DK.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DTakeda%26aufirst%3DH.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DT.%26atitle%3DStructural%2520optimization%2520and%2520structure%25E2%2580%2593functional%2520selectivity%2520relationship%2520studies%2520of%2520G%2520protein-biased%2520EP2%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2446%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2016.03.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span>; <span class="NLM_string-name">Watanabe, T.</span>; <span class="NLM_string-name">Watanabe, A.</span>; <span class="NLM_string-name">Kinoshita, A.</span>; <span class="NLM_string-name">Tsuboi, K.</span>; <span class="NLM_string-name">Sugimoto, I.</span>; <span class="NLM_string-name">Moriyuki, K.</span>; <span class="NLM_string-name">Goto, Y.</span>; <span class="NLM_string-name">Yamane, S.</span>; <span class="NLM_string-name">Tani, K.</span>; <span class="NLM_string-name">Toru, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of G protein biased EP2 receptor agonists</span>.  <i>Abstracts of Papers</i>, 250th National Meeting of the American Chemical Society; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Ogawa&author=T.+Watanabe&author=A.+Watanabe&author=A.+Kinoshita&author=K.+Tsuboi&author=I.+Sugimoto&author=K.+Moriyuki&author=Y.+Goto&author=S.+Yamane&author=K.+Tani&author=M.+Toru&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520G%2520protein%2520biased%2520EP2%2520receptor%2520agonists%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Endothelin-receptor antagonists beyond pulmonary arterial hypertension: cancer and fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8168</span>– <span class="NLM_lpage">8188</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8168-8188&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+antagonists+beyond+pulmonary+arterial+hypertension%3A+cancer+and+fibrosis&doi=10.1021%2Facs.jmedchem.5b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8168-8188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases.  Endothelin-receptor antagonists are in clin. use to treat pulmonary arterial hypertension and have been under clin. investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases.  In this Perspective, we review the mols. that have been evaluated in human clin. trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis.  We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists.  We will also consider which chem. characteristics are relevant to clin. use and the properties of mols. necessary for efficacy in treating diseases against which known mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfhFfiImWNbVg90H21EOLACvtfcHk0ligWimCFpppEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D&md5=b6f008d678c7e4ff5ded1db5f4a940c5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01781%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520antagonists%2520beyond%2520pulmonary%2520arterial%2520hypertension%253A%2520cancer%2520and%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8168%26epage%3D8188%26doi%3D10.1021%2Facs.jmedchem.5b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span> <span> </span><span class="NLM_article-title">Evidence for biased agonists and antagonists at the endothelin receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2016.02.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.lfs.2016.02.069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2016&pages=30-33&author=J.+J.+Maguire&title=Evidence+for+biased+agonists+and+antagonists+at+the+endothelin+receptors&doi=10.1016%2Fj.lfs.2016.02.069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2016.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2016.02.069%26sid%3Dliteratum%253Aachs%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26atitle%3DEvidence%2520for%2520biased%2520agonists%2520and%2520antagonists%2520at%2520the%2520endothelin%2520receptors%26jtitle%3DLife%2520Sci.%26date%3D2016%26volume%3D159%26spage%3D30%26epage%3D33%26doi%3D10.1016%2Fj.lfs.2016.02.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuc, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pell, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span> <span> </span><span class="NLM_article-title">Comparison of human ET<sub>A</sub> and ET<sub>B</sub> receptor signalling via G-protein and β-arrestin pathways</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.lfs.2012.03.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=544-549&author=J.+J.+Maguireauthor=R.+E.+Kucauthor=V.+R.+Pellauthor=A.+Greenauthor=M.+Brownauthor=S.+Kumarauthor=T.+Wehrmanauthor=E.+Quinnauthor=A.+P.+Davenport&title=Comparison+of+human+ETA+and+ETB+receptor+signalling+via+G-protein+and+%CE%B2-arrestin+pathways&doi=10.1016%2Fj.lfs.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DKuc%26aufirst%3DR.%2BE.%26aulast%3DPell%26aufirst%3DV.%2BR.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DWehrman%26aufirst%3DT.%26aulast%3DQuinn%26aufirst%3DE.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DComparison%2520of%2520human%2520ETA%2520and%2520ETB%2520receptor%2520signalling%2520via%2520G-protein%2520and%2520%25CE%25B2-arrestin%2520pathways%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D544%26epage%3D549%26doi%3D10.1016%2Fj.lfs.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrocca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semprucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Castro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, L.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2014.01.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.lfs.2014.01.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=179-184&author=R.+Cianfroccaauthor=P.+Tocciauthor=E.+Semprucciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=A.+Bagnatoauthor=L.+Rosano&title=%CE%B2-Arrestin+1+is+required+for+endothelin-1-induced+NF-%CE%BAB+activation+in+ovarian+cancer+cells&doi=10.1016%2Fj.lfs.2014.01.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2014.01.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2014.01.078%26sid%3Dliteratum%253Aachs%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSemprucci%26aufirst%3DE.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DRosano%26aufirst%3DL.%26atitle%3D%25CE%25B2-Arrestin%25201%2520is%2520required%2520for%2520endothelin-1-induced%2520NF-%25CE%25BAB%2520activation%2520in%2520ovarian%2520cancer%2520cells%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D179%26epage%3D184%26doi%3D10.1016%2Fj.lfs.2014.01.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrocca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Castro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biroccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicotra, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, A.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2811</span>, <span class="refDoi"> DOI: 10.1073/pnas.0807158106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.0807158106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=2806-2811&author=L.+Rosanoauthor=R.+Cianfroccaauthor=S.+Masiauthor=F.+Spinellaauthor=V.+Di+Castroauthor=A.+Biroccioauthor=E.+Salvatiauthor=M.+R.+Nicotraauthor=P.+G.+Nataliauthor=A.+Bagnato&title=%CE%B2-Arrestin+links+endothelin+A+receptor+to+%CE%B2-catenin+signaling+to+induce+ovarian+cancer+cell+invasion+and+metastasis&doi=10.1073%2Fpnas.0807158106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0807158106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0807158106%26sid%3Dliteratum%253Aachs%26aulast%3DRosano%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DMasi%26aufirst%3DS.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DBiroccio%26aufirst%3DA.%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DNicotra%26aufirst%3DM.%2BR.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3D%25CE%25B2-Arrestin%2520links%2520endothelin%2520A%2520receptor%2520to%2520%25CE%25B2-catenin%2520signaling%2520to%2520induce%2520ovarian%2520cancer%2520cell%2520invasion%2520and%2520metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D2806%26epage%3D2811%26doi%3D10.1073%2Fpnas.0807158106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrocca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tocci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Castro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biroccio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnato, A.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">5066</span>– <span class="NLM_lpage">5077</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fonc.2012.527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=5066-5077&author=L.+Rosanoauthor=R.+Cianfroccaauthor=P.+Tocciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=F.+Spadaroauthor=E.+Salvatiauthor=A.+M.+Biroccioauthor=P.+G.+Nataliauthor=A.+Bagnato&title=%CE%B2-arrestin-1+is+a+nuclear+transcriptional+regulator+of+endothelin-1-induced+%CE%B2-catenin+signaling&doi=10.1038%2Fonc.2012.527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.527%26sid%3Dliteratum%253Aachs%26aulast%3DRosano%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DSpadaro%26aufirst%3DF.%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DBiroccio%26aufirst%3DA.%2BM.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3D%25CE%25B2-arrestin-1%2520is%2520a%2520nuclear%2520transcriptional%2520regulator%2520of%2520endothelin-1-induced%2520%25CE%25B2-catenin%2520signaling%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D5066%26epage%3D5077%26doi%3D10.1038%2Fonc.2012.527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamohara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushime, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, K.</span></span> <span> </span><span class="NLM_article-title">Molecular identification of nicotinic acid receptor</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(03)00342-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2FS0006-291X%2803%2900342-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2003&pages=364-369&author=T.+Sogaauthor=M.+Kamoharaauthor=J.+Takasakiauthor=S.-i.+Matsumotoauthor=T.+Saitoauthor=T.+Ohishiauthor=H.+Hiyamaauthor=A.+Matsuoauthor=H.+Matsushimeauthor=K.+Furuichi&title=Molecular+identification+of+nicotinic+acid+receptor&doi=10.1016%2FS0006-291X%2803%2900342-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2803%2900342-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252803%252900342-5%26sid%3Dliteratum%253Aachs%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DKamohara%26aufirst%3DM.%26aulast%3DTakasaki%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DS.-i.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DHiyama%26aufirst%3DH.%26aulast%3DMatsuo%26aufirst%3DA.%26aulast%3DMatsushime%26aufirst%3DH.%26aulast%3DFuruichi%26aufirst%3DK.%26atitle%3DMolecular%2520identification%2520of%2520nicotinic%2520acid%2520receptor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D303%26spage%3D364%26epage%3D369%26doi%3D10.1016%2FS0006-291X%2803%2900342-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muehlbauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1312</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1172/JCI36806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1172%2FJCI36806" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=1312-1321&author=R.+W.+Waltersauthor=A.+K.+Shuklaauthor=J.+J.+Kovacsauthor=J.+D.+Violinauthor=S.+M.+DeWireauthor=C.+M.+Lamauthor=J.+R.+Chenauthor=M.+J.+Muehlbauerauthor=E.+J.+Whalenauthor=R.+J.+Lefkowitz&title=%CE%B2-Arrestin1+mediates+nicotinic+acid-induced+flushing%2C+but+not+its+antilipolytic+effect%2C+in+mice&doi=10.1172%2FJCI36806"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1172%2FJCI36806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI36806%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DR.%2BW.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DKovacs%26aufirst%3DJ.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DLam%26aufirst%3DC.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BR.%26aulast%3DMuehlbauer%26aufirst%3DM.%2BJ.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3D%25CE%25B2-Arrestin1%2520mediates%2520nicotinic%2520acid-induced%2520flushing%252C%2520but%2520not%2520its%2520antilipolytic%2520effect%252C%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D1312%26epage%3D1321%26doi%3D10.1172%2FJCI36806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbaoui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boatman, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carballo-Jane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behan, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J. G.</span></span> <span> </span><span class="NLM_article-title">3-(1<i>H</i>-Tetrazol-5-yl)- 1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5101</span>– <span class="NLM_lpage">5108</span>, <span class="refDoi"> DOI: 10.1021/jm800258p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5101-5108&author=G.+Sempleauthor=P.+J.+Skinnerauthor=T.+Gharbaouiauthor=Y.+J.+Shinauthor=J.+K.+Jungauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=S.+Y.+Tamuraauthor=P.+D.+Boatmanauthor=C.+R.+Sageauthor=T.+O.+Schraderauthor=R.+Chenauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=M.+G.+Watersauthor=K.+Chengauthor=A.+K.+Taggartauthor=T.+Q.+Caiauthor=E.+Carballo-Janeauthor=D.+P.+Behanauthor=D.+T.+Connollyauthor=J.+G.+Richman&title=3-%281H-Tetrazol-5-yl%29-+1%2C4%2C5%2C6-tetrahydro-cyclopentapyrazole+%28MK-0354%29%3A+a+partial+agonist+of+the+nicotinic+acid+receptor%2C+G-protein+coupled+receptor+109a%2C+with+antilipolytic+but+no+vasodilatory+activity+in+mice&doi=10.1021%2Fjm800258p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm800258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800258p%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DP.%2BJ.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DShin%26aufirst%3DY.%2BJ.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%2BY.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCai%26aufirst%3DT.%2BQ.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D3-%25281H-Tetrazol-5-yl%2529-%25201%252C4%252C5%252C6-tetrahydro-cyclopentapyrazole%2520%2528MK-0354%2529%253A%2520a%2520partial%2520agonist%2520of%2520the%2520nicotinic%2520acid%2520receptor%252C%2520G-protein%2520coupled%2520receptor%2520109a%252C%2520with%2520antilipolytic%2520but%2520no%2520vasodilatory%2520activity%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5101%26epage%3D5108%26doi%3D10.1021%2Fjm800258p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boatman, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauring, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carballo-Jane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletti, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J. G.</span></span> <span> </span><span class="NLM_article-title">(1a<i>R</i>,5a<i>R</i>)1a,3,5,5a-Tetrahydro-1<i>H</i>-2,3-diaza-cyclopropa[a] pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3644</span>– <span class="NLM_lpage">3666</span>, <span class="refDoi"> DOI: 10.1021/jm2010964</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2010964" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3644-3666&author=P.+D.+Boatmanauthor=B.+Lauringauthor=T.+O.+Schraderauthor=M.+Kasemauthor=B.+R.+Johnsonauthor=P.+Skinnerauthor=J.+K.+Jungauthor=J.+Xuauthor=M.+C.+Cherrierauthor=P.+J.+Webbauthor=G.+Sempleauthor=C.+R.+Sageauthor=J.+Knudsenauthor=R.+Chenauthor=W.+L.+Luoauthor=L.+Caroauthor=J.+Coteauthor=E.+Laiauthor=J.+Wagnerauthor=A.+K.+Taggartauthor=E.+Carballo-Janeauthor=M.+Hammondauthor=S.+L.+Collettiauthor=J.+R.+Tataauthor=D.+T.+Connollyauthor=M.+G.+Watersauthor=J.+G.+Richman&title=%281aR%2C5aR%291a%2C3%2C5%2C5a-Tetrahydro-1H-2%2C3-diaza-cyclopropa%5Ba%5D+pentalene-4-carboxylic+acid+%28MK-1903%29%3A+a+potent+GPR109a+agonist+that+lowers+free+fatty+acids+in+humans&doi=10.1021%2Fjm2010964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm2010964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2010964%26sid%3Dliteratum%253Aachs%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DLauring%26aufirst%3DB.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BR.%26aulast%3DSkinner%26aufirst%3DP.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DCherrier%26aufirst%3DM.%2BC.%26aulast%3DWebb%26aufirst%3DP.%2BJ.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DKnudsen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DW.%2BL.%26aulast%3DCaro%26aufirst%3DL.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DTaggart%26aufirst%3DA.%2BK.%26aulast%3DCarballo-Jane%26aufirst%3DE.%26aulast%3DHammond%26aufirst%3DM.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DConnolly%26aufirst%3DD.%2BT.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DRichman%26aufirst%3DJ.%2BG.%26atitle%3D%25281aR%252C5aR%25291a%252C3%252C5%252C5a-Tetrahydro-1H-2%252C3-diaza-cyclopropa%255Ba%255D%2520pentalene-4-carboxylic%2520acid%2520%2528MK-1903%2529%253A%2520a%2520potent%2520GPR109a%2520agonist%2520that%2520lowers%2520free%2520fatty%2520acids%2520in%2520humans%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3644%26epage%3D3666%26doi%3D10.1021%2Fjm2010964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenewegen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaliti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttringer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumb, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallstrom, E.</span></span> <span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22646698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergelyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstrom&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span></div><div class="casAuthors">Gergely, P.; Nuesslein-Hildesheim, B.; Guerini, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J., Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1035-1047</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose BAF312 is a next-generation sphingosine 1-phosphate (S1P) receptor modulator, selective for S1P1 and S1P5 receptors.  S1P1 receptors are essential for lymphocyte egress from lymph nodes and a drug target in immune-mediated diseases.  Here, we have characterized the immunomodulatory potential of BAF312 and the S1P receptor-mediated effects on heart rate using preclin. and human data.  Exptl. Approach BAF312 was tested in a rat exptl. autoimmune encephalomyelitis (EAE) model.  Electrophysiol. recordings of G-protein-coupled inwardly rectifying potassium (GIRK) channels were carried out in human atrial myocytes.  A Phase I multiple-dose trial studied the pharmacokinetics, pharmacodynamics and safety of BAF312 in 48 healthy subjects.  Key Results BAF312 effectively suppressed EAE in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes.  In healthy volunteers, BAF312 caused preferential decreases in CD4+ T cells, Tnaive, Tcentral memory and B cells within 4-6 h.  Cell counts returned to normal ranges within a week after stopping treatment, in line with the elimination half-life of BAF312.  Despite sparing S1P3 receptors (assocd. with bradycardia in mice), BAF312 induced rapid, transient (day 1 only) bradycardia in humans.  BAF312-mediated activation of GIRK channels in human atrial myocytes can fully explain the bradycardia.  Conclusion and Implications This study illustrates species-specific differences in S1P receptor specificity for first-dose cardiac effects.  Based on its profound but rapidly reversible inhibition of lymphocyte trafficking, BAF312 may have potential as a treatment for immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42VfW58NMyLVg90H21EOLACvtfcHk0lj2GNRHAI55mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE&md5=0034be62fb68b10abefff50f0220be2a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstrom%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical pharmacology of BMS-986104: a differentiated S1P<sub>1</sub> receptor modulator in clinical trials</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XptlGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=283-288&author=T.+G.+M.+Dharauthor=H.+Y.+Xiaoauthor=J.+Xieauthor=L.+D.+Lehman-McKeemanauthor=D.+R.+Wuauthor=M.+Dabrosauthor=X.+Yangauthor=T.+L.+Taylorauthor=X.+D.+Zhouauthor=E.+M.+Heimrichauthor=R.+Thomasauthor=K.+W.+McIntyreauthor=B.+Warrackauthor=H.+Shiauthor=P.+C.+Levesqueauthor=J.+L.+Zhuauthor=J.+Hennanauthor=P.+Balimaneauthor=Z.+Yangauthor=A.+M.+Marinoauthor=G.+Corneliusauthor=C.+J.+D%E2%80%99Arienzoauthor=A.+Mathurauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+J.+Dyckman&title=Identification+and+preclinical+pharmacology+of+BMS-986104%3A+a+differentiated+S1P1+receptor+modulator+in+clinical+trials&doi=10.1021%2Facsmedchemlett.5b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials</span></div><div class="casAuthors">Dhar, T. G. Murali; Xiao, Hai-Yun; Xie, Jenny; Lehman-McKeeman, Lois D.; Wu, Dauh-Rurng; Dabros, Marta; Yang, Xiaoxia; Taylor, Tracy L.; Zhou, Xia D.; Heimrich, Elizabeth M.; Thomas, Rochelle; McIntyre, Kim W.; Warrack, Bethanne; Shi, Hong; Levesque, Paul C.; Zhu, Jia L.; Hennan, James; Balimane, Praveen; Yang, Zheng; Marino, Anthony M.; Cornelius, Georgia; D'Arienzo, Celia J.; Mathur, Arvind; Shen, Ding Ren; Cvijic, Mary Ellen; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Dyckman, Alaric J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya) as the first oral therapy for relapsing remitting multiple sclerosis.  However, fingolimod causes a dose-dependent redn. in the heart rate (bradycardia), which occurs within hours after first dose.  The authors disclose the identification of clin. compd. BMS-986104 I, a novel S1P1 receptor modulator, which demonstrates ligand-biased signaling and differentiates from fingolimod in terms of cardiovascular and pulmonary safety based on preclin. pharmacol. while showing equiv. efficacy in a T-cell transfer colitis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxpaIol_-7abVg90H21EOLACvtfcHk0ljcPG_TugQzpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptlGqtA%253D%253D&md5=b625957b1a8be2501e804905de1c8b06</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00448%26sid%3Dliteratum%253Aachs%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DWu%26aufirst%3DD.%2BR.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DZhou%26aufirst%3DX.%2BD.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DHennan%26aufirst%3DJ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarino%26aufirst%3DA.%2BM.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520and%2520preclinical%2520pharmacology%2520of%2520BMS-986104%253A%2520a%2520differentiated%2520S1P1%2520receptor%2520modulator%2520in%2520clinical%2520trials%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D283%26epage%3D288%26doi%3D10.1021%2Facsmedchemlett.5b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiozzo Fasiolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beggiato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borelli, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomierny-Chamiolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonelli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasini, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuxe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filip, M.</span></span> <span> </span><span class="NLM_article-title">Neurotensin: a role in substance use disorder?</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1177/0269881115622240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1177%2F0269881115622240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26755548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCiu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=112-127&author=L.+Ferraroauthor=L.+Tiozzo+Fasioloauthor=S.+Beggiatoauthor=A.+C.+Borelliauthor=L.+Pomierny-Chamioloauthor=M.+Frankowskaauthor=T.+Antonelliauthor=M.+C.+Tomasiniauthor=K.+Fuxeauthor=M.+Filip&title=Neurotensin%3A+a+role+in+substance+use+disorder%3F&doi=10.1177%2F0269881115622240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotensin: a role in substance use disorder?</span></div><div class="casAuthors">Ferraro, Luca; Fasiolo, Laura Tiozzo; Beggiato, Sarah; Borelli, Andrea C.; Pomierny-Chamiolo, Lucyna; Frankowska, Malgorzata; Antonelli, Tiziana; Tomasini, Maria C.; Fuxe, Kjell; Filip, Malgorzata</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-127</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Neurotensin is a tridecapeptide originally identified in exts. of bovine hypothalamus.  This peptide has a close anatomical and functional relationship with the mesocorticolimbic and nigrostriatal dopamine system.  Neural circuits contg. neurotensin were originally proposed to play a role in the mechanism of action of antipsychotic agents.  Addnl., neurotensin-contg. pathways were demonstrated to mediate some of the rewarding and/or sensitizing properties of drugs of abuse.  This review attempts to contribute to the understanding of the role of neurotensin and its receptors in drug abuse.  In particular, we will summarize the potential relevance of neurotensin, its related compds. and neurotensin receptors in substance use disorders, with a focus on the preclin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP0z4hA43w37Vg90H21EOLACvtfcHk0li5jdUEEbbD_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCiu7bM&md5=a8de975d9e8db159440f29ff6bcc747a</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1177%2F0269881115622240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881115622240%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DL.%26aulast%3DTiozzo%2BFasiolo%26aufirst%3DL.%26aulast%3DBeggiato%26aufirst%3DS.%26aulast%3DBorelli%26aufirst%3DA.%2BC.%26aulast%3DPomierny-Chamiolo%26aufirst%3DL.%26aulast%3DFrankowska%26aufirst%3DM.%26aulast%3DAntonelli%26aufirst%3DT.%26aulast%3DTomasini%26aufirst%3DM.%2BC.%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DFilip%26aufirst%3DM.%26atitle%3DNeurotensin%253A%2520a%2520role%2520in%2520substance%2520use%2520disorder%253F%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2016%26volume%3D30%26spage%3D112%26epage%3D127%26doi%3D10.1177%2F0269881115622240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varshney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindie, E.</span></span> <span> </span><span class="NLM_article-title">Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1650</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.2967/jnumed.114.142000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.2967%2Fjnumed.114.142000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25189338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFyqtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1650-1657&author=C.+Morgatauthor=A.+K.+Mishraauthor=R.+Varshneyauthor=M.+Allardauthor=P.+Fernandezauthor=E.+Hindie&title=Targeting+neuropeptide+receptors+for+cancer+imaging+and+therapy%3A+perspectives+with+bombesin%2C+neurotensin%2C+and+neuropeptide-Y+receptors&doi=10.2967%2Fjnumed.114.142000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors</span></div><div class="casAuthors">Morgat, Clement; Mishra, Anil Kumar; Varshney, Raunak; Allard, Michele; Fernandez, Philippe; Hindie, Elif</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1650-1657</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">A review.  Receptors for some regulatory peptides are highly expressed in tumors.  Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacol. and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy.  The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets.  This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncol.  The underlying biol. of these peptide/receptor systems, their physiol. and pathol. roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers.  Radiolabeled analogs that selectively target these receptors are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSrhZnmdSzqbVg90H21EOLACvtfcHk0li5jdUEEbbD_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFyqtbvL&md5=10759e1728dad11df6b391371f228fc1</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.114.142000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.114.142000%26sid%3Dliteratum%253Aachs%26aulast%3DMorgat%26aufirst%3DC.%26aulast%3DMishra%26aufirst%3DA.%2BK.%26aulast%3DVarshney%26aufirst%3DR.%26aulast%3DAllard%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DHindie%26aufirst%3DE.%26atitle%3DTargeting%2520neuropeptide%2520receptors%2520for%2520cancer%2520imaging%2520and%2520therapy%253A%2520perspectives%2520with%2520bombesin%252C%2520neurotensin%252C%2520and%2520neuropeptide-Y%2520receptors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1650%26epage%3D1657%26doi%3D10.2967%2Fjnumed.114.142000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peddibhotla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosalia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen-Genel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salaniwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangravita-Novo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicchiarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of ML314, a brain penetrant nonpeptidic β-arrestin biased agonist of the neurotensin NTR1 receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1021/ml400176n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400176n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=846-851&author=S.+Peddibhotlaauthor=M.+P.+Hedrickauthor=P.+Hershbergerauthor=P.+R.+Maloneyauthor=Y.+Liauthor=M.+Milewskiauthor=P.+Gosaliaauthor=W.+Grayauthor=A.+Mehtaauthor=E.+Sugarmanauthor=B.+Hoodauthor=E.+Suyamaauthor=K.+Nguyenauthor=S.+Heynen-Genelauthor=S.+Vasileauthor=S.+Salaniwalauthor=D.+Stonichauthor=Y.+Suauthor=A.+Mangravita-Novoauthor=M.+Vicchiarelliauthor=G.+P.+Rothauthor=L.+H.+Smithauthor=T.+D.+Y.+Chungauthor=G.+R.+Hansonauthor=J.+B.+Thomasauthor=M.+G.+Caronauthor=L.+S.+Barakauthor=A.+B.+Pinkerton&title=Discovery+of+ML314%2C+a+brain+penetrant+nonpeptidic+%CE%B2-arrestin+biased+agonist+of+the+neurotensin+NTR1+receptor&doi=10.1021%2Fml400176n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fml400176n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400176n%26sid%3Dliteratum%253Aachs%26aulast%3DPeddibhotla%26aufirst%3DS.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DHershberger%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMilewski%26aufirst%3DM.%26aulast%3DGosalia%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DW.%26aulast%3DMehta%26aufirst%3DA.%26aulast%3DSugarman%26aufirst%3DE.%26aulast%3DHood%26aufirst%3DB.%26aulast%3DSuyama%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DHeynen-Genel%26aufirst%3DS.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DSalaniwal%26aufirst%3DS.%26aulast%3DStonich%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DMangravita-Novo%26aufirst%3DA.%26aulast%3DVicchiarelli%26aufirst%3DM.%26aulast%3DRoth%26aufirst%3DG.%2BP.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26aulast%3DThomas%26aufirst%3DJ.%2BB.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26atitle%3DDiscovery%2520of%2520ML314%252C%2520a%2520brain%2520penetrant%2520nonpeptidic%2520%25CE%25B2-arrestin%2520biased%2520agonist%2520of%2520the%2520neurotensin%2520NTR1%2520receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D846%26epage%3D851%26doi%3D10.1021%2Fml400176n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urs, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddibhotla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span> <span> </span><span class="NLM_article-title">ML314: a biased neurotensin receptor ligand for methamphetamine abuse</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1880</span>– <span class="NLM_lpage">1890</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00291</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2rtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1880-1890&author=L.+S.+Barakauthor=Y.+Baiauthor=S.+Petersonauthor=T.+Evronauthor=N.+M.+Ursauthor=S.+Peddibhotlaauthor=M.+P.+Hedrickauthor=P.+Hershbergerauthor=P.+R.+Maloneyauthor=T.+D.+Y.+Chungauthor=R.+M.+Rodriguizauthor=W.+C.+Wetselauthor=J.+B.+Thomasauthor=G.+R.+Hansonauthor=A.+B.+Pinkertonauthor=M.+G.+Caron&title=ML314%3A+a+biased+neurotensin+receptor+ligand+for+methamphetamine+abuse&doi=10.1021%2Facschembio.6b00291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse</span></div><div class="casAuthors">Barak, Larry S.; Bai, Yushi; Peterson, Sean; Evron, Tama; Urs, Nikhil M.; Peddibhotla, Satyamaheshwar; Hedrick, Michael P.; Hershberger, Paul; Maloney, Patrick R.; Chung, Thomas D. Y.; Rodriguiz, Ramona M.; Wetsel, William C.; Thomas, James B.; Hanson, Glen R.; Pinkerton, Anthony B.; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1890</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacol. treatment for methamphetamine addiction will provide important societal benefits.  Neurotensin receptor NTR1 and dopamine receptor distributions coincide in brain areas regulating methamphetamine-assocd. reward, and neurotensin peptides produce behaviors opposing psychostimulants.  Therefore, undesirable methamphetamine-assocd. activities should be treatable with druggable NTR1 agonists, but no such FDA-approved therapeutics exist.  We address this limitation with proof-of-concept data for ML314, a small-mol., brain penetrant, β-arrestin biased, NTR1 agonist.  ML314 attenuates amphetamine-like hyperlocomotion in dopamine transporter knockout mice, and in C57BL/6J mice it attenuates methamphetamine-induced hyperlocomotion, potentiates the psychostimulant inhibitory effects of a ghrelin antagonist, and reduces methamphetamine-assocd. conditioned place preference.  In rats, ML314 blocks methamphetamine self-administration.  ML314 acts as an allosteric enhancer of endogenous neurotensin, unmasking stoichiometric nos. of hidden NTR1 binding sites in transfected-cell membranes or mouse striatal membranes, while addnl. supporting NTR1 endocytosis in cells in the absence of NT peptide.  These results indicate ML314 is a viable, preclin. lead for methamphetamine abuse treatment and support an allosteric model of G protein-coupled receptor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRELv0YzCr9bVg90H21EOLACvtfcHk0lgRS94dXWplBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2rtbY%253D&md5=48872ea73457f91e63a8631117848ecd</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00291%26sid%3Dliteratum%253Aachs%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DEvron%26aufirst%3DT.%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DPeddibhotla%26aufirst%3DS.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DHershberger%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DThomas%26aufirst%3DJ.%2BB.%26aulast%3DHanson%26aufirst%3DG.%2BR.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DML314%253A%2520a%2520biased%2520neurotensin%2520receptor%2520ligand%2520for%2520methamphetamine%2520abuse%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D1880%26epage%3D1890%26doi%3D10.1021%2Facschembio.6b00291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammendola, R.</span></span> <span> </span><span class="NLM_article-title">Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">7193</span>– <span class="NLM_lpage">7230</span>, <span class="refDoi"> DOI: 10.3390/ijms14047193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3390%2Fijms14047193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23549262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFWktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=7193-7230&author=F.+Cattaneoauthor=M.+Parisiauthor=R.+Ammendola&title=Distinct+signaling+cascades+elicited+by+different+formyl+peptide+receptor+2+%28FPR2%29+agonists&doi=10.3390%2Fijms14047193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists</span></div><div class="casAuthors">Cattaneo, Fabio; Parisi, Melania; Ammendola, Rosario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7193-7230</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The formyl peptide receptor 2 (FPR2) is a remarkably versatile transmembrane protein belonging to the G-protein coupled receptor (GPCR) family.  FPR2 is activated by an array of ligands, which include structurally unrelated lipids and peptide/proteins agonists, resulting in different intracellular responses in a ligand-specific fashion.  In addn. to the anti-inflammatory lipid, lipoxin A4, several other endogenous agonists also bind FPR2, including serum amyloid A, glucocorticoid-induced annexin 1, urokinase and its receptor, suggesting that the activation of FPR2 may result in potent pro- or anti-inflammatory responses.  Other endogenous ligands, also present in biol. samples, include resolvins, amyloidogenic proteins, such as beta amyloid (Aβ)-42 and prion protein (Prp)106-126, the neuroprotective peptide, humanin, antibacterial peptides, annexin 1-derived peptides, chemokine variants, the neuropeptides, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP)-27 and mitochondrial peptides.  Upon activation, intracellular domains of FPR2 mediate signaling to G-proteins, which trigger several agonist-dependent signal transduction pathways, including activation of phospholipase C (PLC), protein kinase C (PKC) isoforms, the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, the mitogen-activated protein kinase (MAPK) pathway, p38MAPK, as well as the phosphorylation of cytosolic tyrosine kinases, tyrosine kinase receptor transactivation, phosphorylation and nuclear translocation of regulatory transcriptional factors, release of calcium and prodn. of oxidants.  FPR2 is an attractive therapeutic target, because of its involvement in a range of normal physiol. processes and pathol. diseases.  Here, we review and discuss the most significant findings on the intracellular pathways and on the cross-communication between FPR2 and tyrosine kinase receptors triggered by different FPR2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKmHveSDBH7Vg90H21EOLACvtfcHk0lgRS94dXWplBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFWktr8%253D&md5=b3d1ed852ecb5a03e114d4d4a0beb036</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.3390%2Fijms14047193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms14047193%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DF.%26aulast%3DParisi%26aufirst%3DM.%26aulast%3DAmmendola%26aufirst%3DR.%26atitle%3DDistinct%2520signaling%2520cascades%2520elicited%2520by%2520different%2520formyl%2520peptide%2520receptor%25202%2520%2528FPR2%2529%2520agonists%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D7193%26epage%3D7230%26doi%3D10.3390%2Fijms14047193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corminboeuf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, X.</span></span> <span> </span><span class="NLM_article-title">FPR2/ALXR agonists and the resolution of inflammation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1021/jm501051x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501051x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=537-559&author=O.+Corminboeufauthor=X.+Leroy&title=FPR2%2FALXR+agonists+and+the+resolution+of+inflammation&doi=10.1021%2Fjm501051x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">FPR2/ALXR Agonists and the Resolution of Inflammation</span></div><div class="casAuthors">Corminboeuf, Olivier; Leroy, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">537-559</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The resoln. of inflammation (RoI), once believed to be a passive process, has lately been shown to be an active and delicately orchestrated process.  During the resoln. phase of acute inflammation, novel mediators, including lipoxins and resolvins, which are members of the specialized pro-resolving mediators of inflammation, are produced.  FPR2/ALXR, a receptor modulated by some of these lipids as well as by peptides (e.g., annexin A1), has been shown to be one of the receptors involved in the RoI.  The aim of this perspective is to present the concept of the RoI from a medicinal chem. point of view and to highlight the effort of the research community to discover and develop anti-inflammatory/pro-resoln. small mols. to orchestrate inflammation by activation of FPR2/ALXR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-uVie3v-44bVg90H21EOLACvtfcHk0lgRS94dXWplBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLbJ&md5=3b595d7c70e5d2336c6fb832b372ba7b</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fjm501051x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501051x%26sid%3Dliteratum%253Aachs%26aulast%3DCorminboeuf%26aufirst%3DO.%26aulast%3DLeroy%26aufirst%3DX.%26atitle%3DFPR2%252FALXR%2520agonists%2520and%2520the%2520resolution%2520of%2520inflammation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D537%26epage%3D559%26doi%3D10.1021%2Fjm501051x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forsman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bylund, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulay, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, C.</span></span> <span> </span><span class="NLM_article-title">The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1833</i></span>,  <span class="NLM_fpage">1914</span>– <span class="NLM_lpage">1923</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2013.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bbamcr.2013.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23562731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVGmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1833&publication_year=2013&pages=1914-1923&author=H.+Forsmanauthor=J.+Bylundauthor=T.+I.+Opreaauthor=A.+Karlssonauthor=F.+Boulayauthor=M.+J.+Rabietauthor=C.+Dahlgren&title=The+leukocyte+chemotactic+receptor+FPR2%2C+but+not+the+closely+related+FPR1%2C+is+sensitive+to+cell-penetrating+pepducins+with+amino+acid+sequences+descending+from+the+third+intracellular+receptor+loop&doi=10.1016%2Fj.bbamcr.2013.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop</span></div><div class="casAuthors">Forsman, Huamei; Bylund, Johan; Oprea, Tudor I.; Karlsson, Anna; Boulay, Francois; Rabiet, Marie-Josephe; Dahlgren, Claes</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1833</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1914-1923</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lipidated peptides (pepducins) can activate certain G-protein coupled receptors (GPCRs) through a unique allosteric modulation mechanism involving cytosolic receptor domains.  Pepducins with the amino acid sequence of the third intracellular loop of the neutrophil formyl peptide receptors (FPRs) as a common denominator were N-terminally conjugated with palmitic acid.  F2Pal16, contg. the 16 amino acids present in the third intracellular loop of FPR2, induced superoxide prodn. in human neutrophils and the activity was sensitive to FPR2 antagonists.  Cells over-expressing FPR2 were similarly responsive and responded with a transient increase in cytosolic calcium.  No such effects were obsd. with the corresponding FPR1 pepducin.  The peptide alone, lacking palmitic acid, did not activate neutrophils.  A ten amino acid long pepducin F2Pal10, that was a more potent neutrophil activator than F2Pal16, was used for amino acid substitution studies.  The sequences of FPR1 and FPR2 in the third intracellular loop differ by only two amino acids, and a pepducin with the FPR2-specific K231 replaced by the FPR1-specific Q231 lost all activity.  The active F2Pal10 pepducin also triggered a response in cells expressing a mutated FPR2 with the third intracellular loop identical to that of FPR1.  The data presented suggest that the same signaling pathways are activated when the signaling cascade is initiated by a classical receptor agonist (outside-in signaling) and when signaling starts on the cytosolic side of the membrane by a pepducin (inside-in signaling).  A fundamental difference is also disclosed between the two neutrophil FPRs regarding their sensitivities to third intracellular loop pepducins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Igw-hzfbprVg90H21EOLACvtfcHk0lj_12gePsH5tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVGmu7Y%253D&md5=a6d2f1d5eea58f49f84470a9c5f3b34a</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2013.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2013.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DForsman%26aufirst%3DH.%26aulast%3DBylund%26aufirst%3DJ.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DBoulay%26aufirst%3DF.%26aulast%3DRabiet%26aufirst%3DM.%2BJ.%26aulast%3DDahlgren%26aufirst%3DC.%26atitle%3DThe%2520leukocyte%2520chemotactic%2520receptor%2520FPR2%252C%2520but%2520not%2520the%2520closely%2520related%2520FPR1%252C%2520is%2520sensitive%2520to%2520cell-penetrating%2520pepducins%2520with%2520amino%2520acid%2520sequences%2520descending%2520from%2520the%2520third%2520intracellular%2520receptor%2520loop%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2013%26volume%3D1833%26spage%3D1914%26epage%3D1923%26doi%3D10.1016%2Fj.bbamcr.2013.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holdfeldt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsman, H.</span></span> <span> </span><span class="NLM_article-title">FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2017.08.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2017&pages=114-122&author=M.+Gablauthor=A.+Holdfeldtauthor=M.+Sundqvistauthor=J.+Lomeiauthor=C.+Dahlgrenauthor=H.+Forsman&title=FPR2+signaling+without+%CE%B2-arrestin+recruitment+alters+the+functional+repertoire+of+neutrophils&doi=10.1016%2Fj.bcp.2017.08.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DGabl%26aufirst%3DM.%26aulast%3DHoldfeldt%26aufirst%3DA.%26aulast%3DSundqvist%26aufirst%3DM.%26aulast%3DLomei%26aufirst%3DJ.%26aulast%3DDahlgren%26aufirst%3DC.%26aulast%3DForsman%26aufirst%3DH.%26atitle%3DFPR2%2520signaling%2520without%2520%25CE%25B2-arrestin%2520recruitment%2520alters%2520the%2520functional%2520repertoire%2520of%2520neutrophils%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D145%26spage%3D114%26epage%3D122%26doi%3D10.1016%2Fj.bcp.2017.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1211%2F0022357011775631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=11734617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=527-552&author=B.+B.+Fredholmauthor=A.+P.+Ijzermanauthor=K.+A.+Jacobsonauthor=K.+N.+Klotzauthor=J.+Linden&title=International+Union+of+Pharmacology.+XXV.+Nomenclature+and+classification+of+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors</span></div><div class="casAuthors">Fredholm, Bertil B.; IJzerman, Adriaan P.; Jacobson, Kenneth A.; Klotz, Karl-Norbert; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">527-552</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Four adenosine receptors have been cloned and characterized from several mammalian species.  The receptors are named adenosine A1, A2A, A2B, and A3.  The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins.  However, other G protein interactions have also been described.  Adenosine is the preferred endogenous agonist at all these receptors, but inosine can also activate the A3 receptor.  The levels of adenosine seen under basal conditions are sufficient to cause some activation of all the receptors, at least where they are abundantly expressed.  Adenosine levels during, e.g., ischemia can activate all receptors even when expressed in low abundance.  Accordingly, expts. with receptor antagonists and mice with targeted disruption of adenosine A1, A2A, and A3 expression reveal roles for these receptors under physiol. and particularly pathophysiol. conditions.  There are pharmacol. tools that can be used to classify A1, A2A, and A3 receptors but few drugs that interact selectively with A2B receptors.  Testable models of the interaction of these drugs with their receptors have been generated by site-directed mutagenesis and homol.-based modeling.  Both agonists and antagonists are being developed as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOCrJphTwDrVg90H21EOLACvtfcHk0lj_12gePsH5tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D&md5=060ea8a3d7b07fdc4b2c8acc3b4d4745</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1211%2F0022357011775631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357011775631%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXV.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D527%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verzijl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity of adenosine receptor ligands</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s11302-011-9232-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1007%2Fs11302-011-9232-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=171-192&author=D.+Verzijlauthor=A.+P.+IJzerman&title=Functional+selectivity+of+adenosine+receptor+ligands&doi=10.1007%2Fs11302-011-9232-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1007%2Fs11302-011-9232-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-011-9232-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerzijl%26aufirst%3DD.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DFunctional%2520selectivity%2520of%2520adenosine%2520receptor%2520ligands%26jtitle%3DPurinergic%2520Signalling%26date%3D2011%26volume%3D7%26spage%3D171%26epage%3D192%26doi%3D10.1007%2Fs11302-011-9232-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aurelio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuo, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4614</span>– <span class="NLM_lpage">4619</span>, <span class="refDoi"> DOI: 10.1073/pnas.1320962111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1073%2Fpnas.1320962111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24619092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Smsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4614-4619&author=C.+Valantauthor=L.+T.+Mayauthor=L.+Aurelioauthor=C.+H.+Chuoauthor=P.+J.+Whiteauthor=J.+A.+Baltosauthor=P.+M.+Sextonauthor=P.+J.+Scammellsauthor=A.+Christopoulos&title=Separation+of+on-target+efficacy+from+adverse+effects+through+rational+design+of+a+bitopic+adenosine+receptor+agonist&doi=10.1073%2Fpnas.1320962111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist</span></div><div class="casAuthors">Valant, Celine; May, Lauren T.; Aurelio, Luigi; Chuo, Chung Hui; White, Paul J.; Baltos, Jo-Anne; Sexton, Patrick M.; Scammells, Peter J.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4614-4619</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The concepts of allosteric modulation and biased agonism are revolutionizing modern approaches to drug discovery, particularly in the field of G protein-coupled receptors (GPCRs).  Both phenomena exploit topog. distinct binding sites to promote unique GPCR conformations that can lead to different patterns of cellular responsiveness.  The adenosine A1 GPCR (A1AR) is a major therapeutic target for cardioprotection, but current agents acting on the receptor are clin. limited for this indication because of on-target bradycardia as a serious adverse effect.  In the current study, the authors have rationally designed a novel A1AR ligand (VCP746)-a hybrid mol. comprising adenosine linked to a pos. allosteric modulator-specifically to engender biased signaling at the A1AR.  The authors validate that the interaction of VCP746 with the A1AR is consistent with a bitopic mode of receptor engagement (i.e., concomitant assocn. with orthosteric and allosteric sites) and that the compd. displays biased agonism relative to prototypical A1AR ligands.  Importantly, the authors also show that the unique pharmacol. of VCP746 is (patho)physiol. relevant, because the compd. protects against ischemic insult in native A1AR-expressing cardiomyoblasts and cardiomyocytes but does not affect rat atrial heart rate.  Thus, this study provides proof of concept that bitopic ligands can be designed as biased agonists to promote on-target efficacy without on-target side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWe6rXsi_ff7Vg90H21EOLACvtfcHk0lgEzzPMk6HfMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Smsb8%253D&md5=560f32d7a5dbbf24df9d049b23d0c5c1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320962111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320962111%26sid%3Dliteratum%253Aachs%26aulast%3DValant%26aufirst%3DC.%26aulast%3DMay%26aufirst%3DL.%2BT.%26aulast%3DAurelio%26aufirst%3DL.%26aulast%3DChuo%26aufirst%3DC.%2BH.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DBaltos%26aufirst%3DJ.%2BA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSeparation%2520of%2520on-target%2520efficacy%2520from%2520adverse%2520effects%2520through%2520rational%2520design%2520of%2520a%2520bitopic%2520adenosine%2520receptor%2520agonist%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D4614%26epage%3D4619%26doi%3D10.1073%2Fpnas.1320962111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span> <span> </span><span class="NLM_article-title">Quantification of adenosine A1 receptor biased agonism: implications for drug discovery</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.bcp.2015.11.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=101-112&author=J.+A.+Baltosauthor=K.+J.+Gregoryauthor=P.+J.+Whiteauthor=P.+M.+Sextonauthor=A.+Christopoulosauthor=L.+T.+May&title=Quantification+of+adenosine+A1+receptor+biased+agonism%3A+implications+for+drug+discovery&doi=10.1016%2Fj.bcp.2015.11.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DBaltos%26aufirst%3DJ.%2BA.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DMay%26aufirst%3DL.%2BT.%26atitle%3DQuantification%2520of%2520adenosine%2520A1%2520receptor%2520biased%2520agonism%253A%2520implications%2520for%2520drug%2520discovery%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D99%26spage%3D101%26epage%3D112%26doi%3D10.1016%2Fj.bcp.2015.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aurelio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jörg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span> <span> </span><span class="NLM_article-title">A structure-activity relationship study of bitopic N<sup>6</sup>-substituted adenosine derivatives as biased adenosine A<sub>1</sub> receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2103</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00047</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00047" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2087-2103&author=L.+Aurelioauthor=J.-A.+Baltosauthor=L.+Fordauthor=A.+T.+N.+Nguyenauthor=M.+J%C3%B6rgauthor=S.+M.+Devineauthor=C.+Valantauthor=P.+J.+Whiteauthor=A.+Christopoulosauthor=L.+T.+Mayauthor=P.+J.+Scammells&title=A+structure-activity+relationship+study+of+bitopic+N6-substituted+adenosine+derivatives+as+biased+adenosine+A1+receptor+agonists&doi=10.1021%2Facs.jmedchem.8b00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Activity Relationship Study of Bitopic N6-Substituted Adenosine Derivatives as Biased Adenosine A1 Receptor Agonists</span></div><div class="casAuthors">Aurelio, Luigi; Baltos, Jo-Anne; Ford, Leigh; Nguyen, Anh T. N.; Jorg, Manuela; Devine, Shane M.; Valant, Celine; White, Paul J.; Christopoulos, Arthur; May, Lauren T.; Scammells, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2087-2103</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The adenosine A1 receptor (A1AR) is a potential novel therapeutic target for myocardial ischemia-reperfusion injury.  However, to date, clin. translation of prototypical A1AR agonists has been hindered due to dose limiting adverse effects.  Recently, we demonstrated that the biased bitopic agonist, consisting of an adenosine pharmacophore linked to an allosteric moiety, could stimulate cardioprotective A1AR signaling in the absence of unwanted bradycardia.  Modifications were made to the orthosteric adenosine pharmacophore, linker, and allosteric 2-amino-3-benzoylthiophene pharmacophore to probe the structure-activity relationships, particularly in terms of biased signaling, as well as A1AR activity and subtype selectivity.  Collectively, our findings demonstrate that the allosteric moiety, particularly the 4-(trifluoromethyl)phenyl substituent of the thiophene scaffold, is important in conferring bitopic ligand bias at the A1AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98BkLNsVOvbVg90H21EOLACvtfcHk0lgEzzPMk6HfMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnsbc%253D&md5=f7b9f16a6d56c720437ae94d54b8615e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00047%26sid%3Dliteratum%253Aachs%26aulast%3DAurelio%26aufirst%3DL.%26aulast%3DBaltos%26aufirst%3DJ.-A.%26aulast%3DFord%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DA.%2BT.%2BN.%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DDevine%26aufirst%3DS.%2BM.%26aulast%3DValant%26aufirst%3DC.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DMay%26aufirst%3DL.%2BT.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26atitle%3DA%2520structure-activity%2520relationship%2520study%2520of%2520bitopic%2520N6-substituted%2520adenosine%2520derivatives%2520as%2520biased%2520adenosine%2520A1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2087%26epage%3D2103%26doi%3D10.1021%2Facs.jmedchem.8b00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Yehuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and therapeutic effects of A<sub>3</sub> adenosine receptor agonists</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.drudis.2011.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22033198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2isbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=359-366&author=P.+Fishmanauthor=S.+Bar-Yehudaauthor=B.+T.+Liangauthor=K.+A.+Jacobson&title=Pharmacological+and+therapeutic+effects+of+A3+adenosine+receptor+agonists&doi=10.1016%2Fj.drudis.2011.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and therapeutic effects of A3 adenosine receptor agonists</span></div><div class="casAuthors">Fishman, Pnina; Bar-Yehuda, Sara; Liang, Bruce T.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">359-366</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The A3 adenosine receptor (A3AR) coupled to Gi (inhibitory regulative guanine nucleotide-binding protein) mediates anti-inflammatory, anticancer and anti-ischemic protective effects.  The receptor is overexpressed in inflammatory and cancer cells, while low expression is found in normal cells, rendering the A3AR as a potential therapeutic target.  Highly selective A3AR agonists have been synthesized and mol. recognition in the binding site has been characterized.  In this article, we summarize preclin. and clin. human studies that demonstrate that A3AR agonists induce specific anti-inflammatory and anticancer effects through a mol. mechanism that entails modulation of the Wnt and the NF-κB signal transduction pathways.  At present, A3AR agonists are being developed for the treatment of inflammatory diseases, including rheumatoid arthritis (RA) and psoriasis; ophthalmic diseases such as dry eye syndrome and glaucoma; liver diseases such as hepatocellular carcinoma and hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCdToPXU4m7Vg90H21EOLACvtfcHk0lgEzzPMk6HfMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2isbw%253D&md5=b7278bf446f320ca621a93dff383ca13</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DFishman%26aufirst%3DP.%26aulast%3DBar-Yehuda%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DB.%2BT.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DPharmacological%2520and%2520therapeutic%2520effects%2520of%2520A3%2520adenosine%2520receptor%2520agonists%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D359%26epage%3D366%26doi%3D10.1016%2Fj.drudis.2011.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosh, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity analysis of biased agonism at the human adenosine A<sub>3</sub> receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1124/mol.116.103283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.116.103283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27136943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2jsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=12-22&author=J.+A.+Baltosauthor=S.+Paolettaauthor=A.+T.+N.+Nguyenauthor=K.+J.+Gregoryauthor=D.+K.+Toshauthor=A.+Christopoulosauthor=K.+A.+Jacobsonauthor=L.+T.+May&title=Structure-activity+analysis+of+biased+agonism+at+the+human+adenosine+A3+receptor&doi=10.1124%2Fmol.116.103283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity analysis of biased agonism at the human adenosine A3 receptor</span></div><div class="casAuthors">Baltos, Jo-Anne; Paoletta, Silvia; Nguyen, Anh T. N.; Gregory, Karen J.; Tosh, Dilip K.; Christopoulos, Arthur; Jacobson, Kenneth A.; May, Lauren T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-22</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biased agonism at G protein-coupled receptors (GPCRs) has significant implications for current drug discovery, but mol. determinants that govern ligand bias remain largely unknown.  The adenosine A3 GPCR (A3AR) is a potential therapeutic target for various conditions, including cancer, inflammation, and ischemia, but for which biased agonism remains largely unexplored.  We now report the generation of bias "fingerprints" for prototypical ribose contg. A3AR agonists and rigidified (N)-methanocarba 5'-N-methyluronamide nucleoside derivs. with regard to their ability to mediate different signaling pathways.  Relative to the ref. prototypical agonist IB-MECA, (N)-methanocarba 5'-Nmethyluronamide nucleoside derivs. with significant N6 or C2 modifications, including elongated aryl-ethynyl groups, exhibited biased agonism.  Significant pos. correlation was obsd. between the C2 substituent length (in Å) and bias toward cell survival.  Mol. modeling suggests that extended C2 substituents on (N)-methanocarba 5'-N-methyluronamide nucleosides promote a progressive outward shift of the A3AR transmembrane domain 2, which may contribute to the subset of A3AR conformations stabilized on biased agonist binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5hv9s2PrlTLVg90H21EOLACvtfcHk0lg0_H68-XQaaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2jsL7K&md5=f7d9ede080d3794a330abafbbdcf6ac9</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.103283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.103283%26sid%3Dliteratum%253Aachs%26aulast%3DBaltos%26aufirst%3DJ.%2BA.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DA.%2BT.%2BN.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DTosh%26aufirst%3DD.%2BK.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DMay%26aufirst%3DL.%2BT.%26atitle%3DStructure-activity%2520analysis%2520of%2520biased%2520agonism%2520at%2520the%2520human%2520adenosine%2520A3%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D90%26spage%3D12%26epage%3D22%26doi%3D10.1124%2Fmol.116.103283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Allostery and biased agonism at class B G protein-coupled receptors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=111-138&author=D.+Woottenauthor=L.+J.+Millerauthor=C.+Kooleauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Allostery+and+biased+agonism+at+class+B+G+protein-coupled+receptors&doi=10.1021%2Facs.chemrev.6b00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Allostery and Biased Agonism at Class B G Protein-Coupled Receptors</span></div><div class="casAuthors">Wootten, Denise; Miller, Laurence J.; Koole, Cassandra; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-138</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission.  These receptors are targets for existing drugs that treat osteoporosis, hypercalcemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases.  Exploitation of class B receptors has been limited by difficulties with small mol. drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy.  Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development.  These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism.  In this review, current knowledge of biased signaling and small mol. allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addn. to those that remain largely unexplored with respect to these phenomena.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqipOVZPN9YzbVg90H21EOLACvtfcHk0lg0_H68-XQaaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D&md5=658b38e14a6438d971cc564731d9e625</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00049%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DAllostery%2520and%2520biased%2520agonism%2520at%2520class%2520B%2520G%2520protein-coupled%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D111%26epage%3D138%26doi%3D10.1021%2Facs.chemrev.6b00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gesty-Palmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span> <span> </span><span class="NLM_article-title">A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1ra1</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3000071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscitranslmed.3000071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=20368153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1ra1&author=D.+Gesty-Palmerauthor=P.+Flanneryauthor=L.+Yuanauthor=L.+Corsinoauthor=R.+Spurneyauthor=R.+J.+Lefkowitzauthor=L.+M.+Luttrell&title=A+%CE%B2-arrestin-biased+agonist+of+the+parathyroid+hormone+receptor+%28PTH1R%29+promotes+bone+formation+independent+of+G+protein+activation&doi=10.1126%2Fscitranslmed.3000071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span></div><div class="casAuthors">Gesty-Palmer Diane; Flannery Pat; Yuan Ling; Corsino Leonor; Spurney Robert; Lefkowitz Robert J; Luttrell Louis M</div><div class="citationInfo"><span class="NLM_cas:title">Science translational medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1ra1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">About 40% of the therapeutic agents in use today exert their effects through seven-transmembrane receptors (7TMRs).  When activated by ligands, these receptors trigger two pathways that independently transduce signals to the cell: one through heterotrimeric GTP-binding proteins (G proteins) and one through beta-arrestins; so-called biased agonists can selectively activate these distinct pathways.  Here, we investigate selective activation of these pathways through the use of a biased agonist for the type 1 parathyroid hormone (PTH)-PTH-related protein receptor (PTH1R), (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr), which activates beta-arrestin but not classic G protein signaling.  In mice, PTH-betaarr induces anabolic bone formation, as does the nonselective agonist PTH(1-34), which activates both mechanisms.  In beta-arrestin2-null mice, the increase in bone mineral density evoked by PTH(1-34) is attenuated and that stimulated by PTH-betaarr is ablated.  The beta-arrestin2-dependent pathway contributes primarily to trabecular bone formation and does not stimulate bone resorption.  These results show that a biased agonist selective for the beta-arrestin pathway can elicit a response in vivo distinct from that elicited by nonselective agonists.  Ligands with these properties may form the basis for improved 7TMR-directed pharmacologic agents with enhanced therapeutic specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmuM4aCIxthdXdcedVHT5tfW6udTcc2eY0rBlWiCsW7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D&md5=748e4367ded72b6b7e10fd759521ba62</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000071%26sid%3Dliteratum%253Aachs%26aulast%3DGesty-Palmer%26aufirst%3DD.%26aulast%3DFlannery%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCorsino%26aufirst%3DL.%26aulast%3DSpurney%26aufirst%3DR.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26atitle%3DA%2520%25CE%25B2-arrestin-biased%2520agonist%2520of%2520the%2520parathyroid%2520hormone%2520receptor%2520%2528PTH1R%2529%2520promotes%2520bone%2520formation%2520independent%2520of%2520G%2520protein%2520activation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D1ra1%26doi%3D10.1126%2Fscitranslmed.3000071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, J.</span></span> <span> </span><span class="NLM_article-title">GLP-1 as a target for therapeutic intervention</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.coph.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27591964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVegsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=44-49&author=S.+P.+Rajeevauthor=J.+Wilding&title=GLP-1+as+a+target+for+therapeutic+intervention&doi=10.1016%2Fj.coph.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1 as a target for therapeutic intervention</span></div><div class="casAuthors">Rajeev, Surya Panicker; Wilding, John</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Glucagon-like peptide receptor agonists (GLP-1 RA) have multiple effects, including control of glycemia via stimulation of insulin and suppression of glucagon secretion and redn. of adiposity by enhancing satiety, so are an attractive therapeutic option in type 2 diabetes management.  Five GLP-1 RA are used currently and more are in development.  The HbA1c redn. obtained varies from 1 to 2%; they reduce body wt. by about 2-3 kg when used to treat T2DM, while liraglutide results in greater wt. loss at a higher dose and has recently been approved for the management of obesity.  GLP-1 RA are usually used in combination with other glucose-lowering drugs, but dual combinations with basal insulin in a single injection have recently become available.  The next decade is likely to see the development of more potent and longer lasting agents as well as hybrid mols. with dual or triple actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSC_xIpZ0U7Vg90H21EOLACvtfcHk0liyvATppf4jwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVegsrvP&md5=2e4f442cbb3b6bbd2681cd3774361271</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DRajeev%26aufirst%3DS.%2BP.%26aulast%3DWilding%26aufirst%3DJ.%26atitle%3DGLP-1%2520as%2520a%2520target%2520for%2520therapeutic%2520intervention%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D31%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.coph.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobarec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabreja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1632</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.cell.2016.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27315480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=1632-1643&author=D.+Woottenauthor=C.+A.+Reynoldsauthor=K.+J.+Smithauthor=J.+C.+Mobarecauthor=C.+Kooleauthor=E.+E.+Savageauthor=K.+Pabrejaauthor=J.+Simmsauthor=R.+Sridharauthor=S.+G.+B.+Furnessauthor=M.+J.+Liuauthor=P.+E.+Thompsonauthor=L.+J.+Millerauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=The+extracellular+surface+of+the+GLP-1+receptor+is+a+molecular+trigger+for+biased+agonism&doi=10.1016%2Fj.cell.2016.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism</span></div><div class="casAuthors">Wootten, Denise; Reynolds, Christopher A.; Smith, Kevin J.; Mobarec, Juan C.; Koole, Cassandra; Savage, Emilia E.; Pabreja, Kavita; Simms, John; Sridhar, Rohan; Furness, Sebastian G. B.; Liu, Mengjie; Thompson, Philip E.; Miller, Laurence J.; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1632-1643</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-directed signal bias offers opportunities for sculpting mol. events, with the promise of better, safer therapeutics.  Crit. to the exploitation of signal bias is an understanding of the mol. events coupling ligand binding to intracellular signaling.  Activation of class B G protein-coupled receptors is driven by interaction of the peptide N terminus with the receptor core.  To understand how this drives signaling, we have used advanced anal. methods that enable sepn. of effects on pathway-specific signaling from those that modify agonist affinity and mapped the functional consequence of receptor modification onto three-dimensional models of a receptor-ligand complex.  This yields mol. insights into the initiation of receptor activation and the mechanistic basis for biased agonism.  Our data reveal that peptide agonists can engage different elements of the receptor extracellular face to achieve effector coupling and biased signaling providing a foundation for rational design of biased agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomuDidtRAWb7Vg90H21EOLACvtfcHk0liyvATppf4jwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlurrN&md5=951e74f37bbf22a25f589ca69a6e4289</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DSmith%26aufirst%3DK.%2BJ.%26aulast%3DMobarec%26aufirst%3DJ.%2BC.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DSavage%26aufirst%3DE.%2BE.%26aulast%3DPabreja%26aufirst%3DK.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DLiu%26aufirst%3DM.%2BJ.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DThe%2520extracellular%2520surface%2520of%2520the%2520GLP-1%2520receptor%2520is%2520a%2520molecular%2520trigger%2520for%2520biased%2520agonism%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D1632%26epage%3D1643%26doi%3D10.1016%2Fj.cell.2016.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloop, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecular ligands</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1124/mol.112.084525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.084525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=822-834&author=D.+Woottenauthor=E.+E.+Savageauthor=F.+S.+Willardauthor=A.+B.+Buenoauthor=K.+W.+Sloopauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Differential+activation+and+modulation+of+the+glucagon-like+peptide-1+receptor+by+small+molecular+ligands&doi=10.1124%2Fmol.112.084525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.084525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.084525%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSavage%26aufirst%3DE.%2BE.%26aulast%3DWillard%26aufirst%3DF.%2BS.%26aulast%3DBueno%26aufirst%3DA.%2BB.%26aulast%3DSloop%26aufirst%3DK.%2BW.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DDifferential%2520activation%2520and%2520modulation%2520of%2520the%2520glucagon-like%2520peptide-1%2520receptor%2520by%2520small%2520molecular%2520ligands%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D822%26epage%3D834%26doi%3D10.1124%2Fmol.112.084525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturchler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cistrone, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R. A.</span></span> <span> </span><span class="NLM_article-title">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8918</span>, <span class="refDoi"> DOI: 10.1038/ncomms9918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fncomms9918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=26621478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8918&author=H.+Zhangauthor=E.+Sturchlerauthor=J.+Zhuauthor=A.+Nietoauthor=P.+A.+Cistroneauthor=J.+Xieauthor=L.+Heauthor=K.+Yeaauthor=T.+Jonesauthor=R.+Turnauthor=P.+S.+Di+Stefanoauthor=P.+R.+Griffinauthor=P.+E.+Dawsonauthor=P.+H.+McDonaldauthor=R.+A.+Lerner&title=Autocrine+selection+of+a+GLP-1R+G-protein+biased+agonist+with+potent+antidiabetic+effects&doi=10.1038%2Fncomms9918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span></div><div class="casAuthors">Zhang, Hongkai; Sturchler, Emmanuel; Zhu, Jiang; Nieto, Ainhoa; Cistrone, Philip A.; Xie, Jia; He, LinLing; Yea, Kyungmoo; Jones, Teresa; Turn, Rachel; Di Stefano, Peter S.; Griffin, Patrick R.; Dawson, Philip E.; McDonald, Patricia H.; Lerner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8918</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM).  GLP-1R signals through G-protein-dependent, and G-protein-independent pathways by engaging the scaffold protein β-arrestin; preferential signalling of ligands through one or the other of these branches is known as 'ligand bias'.  Here we report the discovery of the potent and selective GLP-1R G-protein-biased agonist, P5.  We identified P5 in a high-throughput autocrine-based screening of large combinatorial peptide libraries, and show that P5 promotes G-protein signalling comparable to GLP-1 and Exendin-4, but exhibited a significantly reduced β-arrestin response.  Preclin. studies using different mouse models of T2DM demonstrate that P5 is a weak insulin secretagogue.  Nevertheless, chronic treatment of diabetic mice with P5 increased adipogenesis, reduced adipose tissue inflammation as well as hepatic steatosis and was more effective at correcting hyperglycemia and lowering Hb A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agonists may provide a novel therapeutic approach to T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEBfb0W6bx47Vg90H21EOLACvtfcHk0lhu7QsKtYCnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ&md5=8d638fbc3fb3996f1f21779f4f8aa001</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fncomms9918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9918%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSturchler%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DNieto%26aufirst%3DA.%26aulast%3DCistrone%26aufirst%3DP.%2BA.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DTurn%26aufirst%3DR.%26aulast%3DDi%2BStefano%26aufirst%3DP.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26aulast%3DMcDonald%26aufirst%3DP.%2BH.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine%2520selection%2520of%2520a%2520GLP-1R%2520G-protein%2520biased%2520agonist%2520with%2520potent%2520antidiabetic%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8918%26doi%3D10.1038%2Fncomms9918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quoyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longuet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span> <span> </span><span class="NLM_article-title">GLP-1 mediates antiapoptotic effect by phosphorylating bad through a β-arrestin 1-mediated ERK1/2 activation in pancreatic β-cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.067207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M109.067207" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=1989-2002&author=J.+Quoyerauthor=C.+Longuetauthor=C.+Brocaauthor=N.+Linckauthor=S.+Costesauthor=E.+Varinauthor=J.+Bockaertauthor=G.+Bertrandauthor=S.+Dalle&title=GLP-1+mediates+antiapoptotic+effect+by+phosphorylating+bad+through+a+%CE%B2-arrestin+1-mediated+ERK1%2F2+activation+in+pancreatic+%CE%B2-cells&doi=10.1074%2Fjbc.M109.067207"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.067207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.067207%26sid%3Dliteratum%253Aachs%26aulast%3DQuoyer%26aufirst%3DJ.%26aulast%3DLonguet%26aufirst%3DC.%26aulast%3DBroca%26aufirst%3DC.%26aulast%3DLinck%26aufirst%3DN.%26aulast%3DCostes%26aufirst%3DS.%26aulast%3DVarin%26aufirst%3DE.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DBertrand%26aufirst%3DG.%26aulast%3DDalle%26aufirst%3DS.%26atitle%3DGLP-1%2520mediates%2520antiapoptotic%2520effect%2520by%2520phosphorylating%2520bad%2520through%2520a%2520%25CE%25B2-arrestin%25201-mediated%2520ERK1%252F2%2520activation%2520in%2520pancreatic%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D1989%26epage%3D2002%26doi%3D10.1074%2Fjbc.M109.067207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hager, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellman, S. H.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-biased agonists of the GLP-1 receptor from β-amino acid residue incorporation into GLP-1 analogues</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">14970</span>– <span class="NLM_lpage">14979</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b08323</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b08323" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=14970-14979&author=M.+V.+Hagerauthor=L.+M.+Johnsonauthor=D.+Woottenauthor=P.+M.+Sextonauthor=S.+H.+Gellman&title=%CE%B2-Arrestin-biased+agonists+of+the+GLP-1+receptor+from+%CE%B2-amino+acid+residue+incorporation+into+GLP-1+analogues&doi=10.1021%2Fjacs.6b08323"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b08323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b08323%26sid%3Dliteratum%253Aachs%26aulast%3DHager%26aufirst%3DM.%2BV.%26aulast%3DJohnson%26aufirst%3DL.%2BM.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26atitle%3D%25CE%25B2-Arrestin-biased%2520agonists%2520of%2520the%2520GLP-1%2520receptor%2520from%2520%25CE%25B2-amino%2520acid%2520residue%2520incorporation%2520into%2520GLP-1%2520analogues%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26spage%3D14970%26epage%3D14979%26doi%3D10.1021%2Fjacs.6b08323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nature22378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature22378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28514449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=312-315&author=G.+Songauthor=D.+Yangauthor=Y.+Wangauthor=C.+de+Graafauthor=Q.+Zhouauthor=S.+Jiangauthor=K.+Liuauthor=X.+Caiauthor=A.+Daiauthor=G.+Linauthor=D.+Liuauthor=F.+Wuauthor=Y.+Wuauthor=S.+Zhaoauthor=L.+Yeauthor=G.+W.+Hanauthor=J.+Lauauthor=B.+Wuauthor=M.+A.+Hansonauthor=Z.-J.+Liuauthor=M.-W.+Wangauthor=R.+C.+Stevens&title=Human+GLP-1+receptor+transmembrane+domain+structure+in+complex+with+allosteric+modulators&doi=10.1038%2Fnature22378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators</span></div><div class="casAuthors">Song, Gaojie; Yang, Dehua; Wang, Yuxia; de Graaf, Chris; Zhou, Qingtong; Jiang, Shanshan; Liu, Kaiwen; Cai, Xiaoqing; Dai, Antao; Lin, Guangyao; Liu, Dongsheng; Wu, Fan; Wu, Yiran; Zhao, Suwen; Ye, Li; Han, Gye Won; Lau, Jesper; Wu, Beili; Hanson, Michael A.; Liu, Zhi-Jie; Wang, Ming-Wei; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">312-315</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and have opposing physiol. roles in insulin release and glucose homeostasis.  The treatment of type 2 diabetes requires pos. modulation of GLP-1R to inhibit glucagon secretion and stimulate insulin secretion in a glucose-dependent manner.  Here we report crystal structures of the human GLP-1R transmembrane domain in complex with two different neg. allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 Å resoln., resp.  The structures reveal a common binding pocket for neg. allosteric modulators, present in both GLP-1R and GCGR and located outside helixes V-VII near the intracellular half of the receptor.  The receptor is in an inactive conformation with compds. that restrict movement of the intracellular tip of helix VI, a movement that is generally assocd. with activation mechanisms in class A GPCRs.  Mol. modeling and mutagenesis studies indicate that agonist pos. allosteric modulators target the same general region, but in a distinct sub-pocket at the interface between helixes V and VI, which may facilitate the formation of an intracellular binding site that enhances G-protein coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS5eoyz8skl7Vg90H21EOLACvtfcHk0lhu7QsKtYCnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs78%253D&md5=72cb9bfe8533b287db75cad3d9cef8f2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnature22378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22378%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DLiu%26aufirst%3DZ.-J.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHuman%2520GLP-1%2520receptor%2520transmembrane%2520domain%2520structure%2520in%2520complex%2520with%2520allosteric%2520modulators%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D312%26epage%3D315%26doi%3D10.1038%2Fnature22378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiez-Vandal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baig, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teobald, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the GLP-1 receptor bound to a peptide agonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1038/nature22800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature22800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28562585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=254-258&author=A.+Jazayeriauthor=M.+Rappasauthor=A.+J.+H.+Brownauthor=J.+Keanauthor=J.+C.+Erreyauthor=N.+J.+Robertsonauthor=C.+Fiez-Vandalauthor=S.+P.+Andrewsauthor=M.+Congreveauthor=A.+Bortolatoauthor=J.+S.+Masonauthor=A.+H.+Baigauthor=I.+Teobaldauthor=A.+S.+Doreauthor=M.+Weirauthor=R.+M.+Cookeauthor=F.+H.+Marshall&title=Crystal+structure+of+the+GLP-1+receptor+bound+to+a+peptide+agonist&doi=10.1038%2Fnature22800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the GLP-1 receptor bound to a peptide agonist</span></div><div class="casAuthors">Jazayeri, Ali; Rappas, Mathieu; Brown, Alastair J. H.; Kean, James; Errey, James C.; Robertson, Nathan J.; Fiez-Vandal, Cedric; Andrews, Stephen P.; Congreve, Miles; Bortolato, Andrea; Mason, Jonathan S.; Baig, Asma H.; Teobald, Iryna; Dore, Andrew S.; Weir, Malcolm; Cooke, Robert M.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">254-258</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) regulates glucose homeostasis through the control of insulin release from the pancreas.  GLP-1 peptide agonists are efficacious drugs for the treatment of diabetes.  To gain insight into the mol. mechanism of action of GLP-1 peptides, here we report the crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist.  The peptide agonist retains an α-helical conformation as it sits deep within the receptor-binding pocket.  The arrangement of the transmembrane helixes reveals hallmarks of an active conformation similar to that obsd. in class A receptors.  Guided by this structural information, we design peptide agonists with potent in vivo activity in a mouse model of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX6Ibc110QxrVg90H21EOLACvtfcHk0liXMrrSwmpPWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFCrs70%253D&md5=0a5c99161af8bae506a184e0ab6306c1</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1038%2Fnature22800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22800%26sid%3Dliteratum%253Aachs%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DRappas%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DKean%26aufirst%3DJ.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DRobertson%26aufirst%3DN.%2BJ.%26aulast%3DFiez-Vandal%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DBaig%26aufirst%3DA.%2BH.%26aulast%3DTeobald%26aufirst%3DI.%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520GLP-1%2520receptor%2520bound%2520to%2520a%2520peptide%2520agonist%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D254%26epage%3D258%26doi%3D10.1038%2Fnature22800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrasch, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiniotis, G.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/nature22394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature22394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28538729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=248-253&author=Y.+Zhangauthor=B.+Sunauthor=D.+Fengauthor=H.+Huauthor=M.+Chuauthor=Q.+Quauthor=J.+T.+Tarraschauthor=S.+Liauthor=T.+S.+Kobilkaauthor=B.+K.+Kobilkaauthor=G.+Skiniotis&title=Cryo-EM+structure+of+the+activated+GLP-1+receptor+in+complex+with+a+G+protein&doi=10.1038%2Fnature22394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</span></div><div class="casAuthors">Zhang, Yan; Sun, Bingfa; Feng, Dan; Hu, Hongli; Chu, Matthew; Qu, Qianhui; Tarrasch, Jeffrey T.; Li, Shane; Sun Kobilka, Tong; Kobilka, Brian K.; Skiniotis, Georgios</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7657</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) is a hormone with essential roles in regulating insulin secretion, carbohydrate metab. and appetite.  GLP-1 effects are mediated through binding to the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor (GPCR) that signals primarily through the stimulatory G protein Gs.  Class B GPCRs are important therapeutic targets; however, our understanding of their mechanism of action is limited by the lack of structural information on activated and full-length receptors.  Here we report the cryo-electron microscopy structure of the peptide-activated GLP-1R-Gs complex at near at. resoln.  The peptide is clasped between the N-terminal domain and the transmembrane core of the receptor, and further stabilized by extracellular loops.  Conformational changes in the transmembrane domain result in a sharp kink in the middle of transmembrane helix 6, which pivots its intracellular half outward to accommodate the α5-helix of the Ras-like domain of Gs.  These results provide a structural framework for understanding class B GPCR activation through hormone binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDRFGRwMs1bVg90H21EOLACvtfcHk0liXMrrSwmpPWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVagtLo%253D&md5=5e7ebd94012ba47ecc299ad0502975de</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fnature22394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22394%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DQ.%26aulast%3DTarrasch%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DSkiniotis%26aufirst%3DG.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520activated%2520GLP-1%2520receptor%2520in%2520complex%2520with%2520a%2520G%2520protein%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D248%26epage%3D253%26doi%3D10.1038%2Fnature22394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural diversity of G protein-coupled receptors and significance for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstromauthor=H.+B.+Schioth&title=Structural+diversity+of+G+protein-coupled+receptors+and+significance+for+drug+discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2eZi7knXuHItwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520diversity%2520of%2520G%2520protein-coupled%2520receptors%2520and%2520significance%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pshenichkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takoudjou, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grajkowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wroblewski, J. T.</span></span> <span> </span><span class="NLM_article-title">The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, β-arrestin-1-dependent ERK phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">26041</span>– <span class="NLM_lpage">26048</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.139899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1074%2Fjbc.M110.139899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=26041-26048&author=A.+C.+Emeryauthor=S.+Pshenichkinauthor=G.+R.+Takoudjouauthor=E.+Grajkowskaauthor=B.+B.+Wolfeauthor=J.+T.+Wroblewski&title=The+protective+signaling+of+metabotropic+glutamate+receptor+1+is+mediated+by+sustained%2C+%CE%B2-arrestin-1-dependent+ERK+phosphorylation&doi=10.1074%2Fjbc.M110.139899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.139899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.139899%26sid%3Dliteratum%253Aachs%26aulast%3DEmery%26aufirst%3DA.%2BC.%26aulast%3DPshenichkin%26aufirst%3DS.%26aulast%3DTakoudjou%26aufirst%3DG.%2BR.%26aulast%3DGrajkowska%26aufirst%3DE.%26aulast%3DWolfe%26aufirst%3DB.%2BB.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520protective%2520signaling%2520of%2520metabotropic%2520glutamate%2520receptor%25201%2520is%2520mediated%2520by%2520sustained%252C%2520%25CE%25B2-arrestin-1-dependent%2520ERK%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D26041%26epage%3D26048%26doi%3D10.1074%2Fjbc.M110.139899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRaddo, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hathaway, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pshenichkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takoudjou, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grajkowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wroblewski, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1124/mol.112.078444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.078444" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=291-301&author=A.+C.+Emeryauthor=J.+O.+DiRaddoauthor=E.+Millerauthor=H.+A.+Hathawayauthor=S.+Pshenichkinauthor=G.+R.+Takoudjouauthor=E.+Grajkowskaauthor=R.+P.+Yasudaauthor=B.+B.+Wolfeauthor=J.+T.+Wroblewski&title=Ligand+bias+at+metabotropic+glutamate+1a+receptors%3A+molecular+determinants+that+distinguish+%CE%B2-arrestin-mediated+from+G+protein-mediated+signaling&doi=10.1124%2Fmol.112.078444"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.078444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.078444%26sid%3Dliteratum%253Aachs%26aulast%3DEmery%26aufirst%3DA.%2BC.%26aulast%3DDiRaddo%26aufirst%3DJ.%2BO.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DHathaway%26aufirst%3DH.%2BA.%26aulast%3DPshenichkin%26aufirst%3DS.%26aulast%3DTakoudjou%26aufirst%3DG.%2BR.%26aulast%3DGrajkowska%26aufirst%3DE.%26aulast%3DYasuda%26aufirst%3DR.%2BP.%26aulast%3DWolfe%26aufirst%3DB.%2BB.%26aulast%3DWroblewski%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520bias%2520at%2520metabotropic%2520glutamate%25201a%2520receptors%253A%2520molecular%2520determinants%2520that%2520distinguish%2520%25CE%25B2-arrestin-mediated%2520from%2520G%2520protein-mediated%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D291%26epage%3D301%26doi%3D10.1124%2Fmol.112.078444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6707</span>– <span class="NLM_lpage">6741</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=6707-6741&author=C.+W.+Lindsleyauthor=K.+A.+Emmitteauthor=C.+R.+Hopkinsauthor=T.+M.+Bridgesauthor=K.+J.+Gregoryauthor=C.+M.+Niswenderauthor=P.+J.+Conn&title=Practical+strategies+and+concepts+in+GPCR+allosteric+modulator+discovery%3A+recent+advances+with+metabotropic+glutamate+receptors&doi=10.1021%2Facs.chemrev.5b00656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors</span></div><div class="casAuthors">Lindsley, Craig W.; Emmitte, Kyle A.; Hopkins, Corey R.; Bridges, Thomas M.; Gregory, Karen J.; Niswender, Colleen M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6707-6741</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery, filled with therapeutic promise yet fraught with caveats.  Allosteric ligands stabilize unique conformations of the GPCR that afford fundamentally new receptors, capable of novel pharmacol., unprecedented subtype selectivity, and unique signal bias.  This review provides a comprehensive overview of the basics of GPCR allosteric pharmacol., medicinal chem., drug metab., and validated approaches to address each of the major challenges and caveats.  Then, the review narrows focus to highlight recent advances in the discovery of allosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu1-5,7) highlighting key concepts ("mol. switches", signal bias, heterodimers) and practical solns. to enable the development of tool compds. and clin. candidates.  The review closes with a section on late-breaking new advances with allosteric ligands for other GPCRs and emerging data for endogenous allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18XJrjVel-7Vg90H21EOLACvtfcHk0li0u5i56TTb7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D&md5=c12704b6602b6c50add92e7fd9350382</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00656%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DPractical%2520strategies%2520and%2520concepts%2520in%2520GPCR%2520allosteric%2520modulator%2520discovery%253A%2520recent%2520advances%2520with%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D6707%26epage%3D6741%26doi%3D10.1021%2Facs.chemrev.5b00656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1126/science.1249489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscience.1249489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24603153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1eht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2014&pages=58-64&author=H.+X.+Wuauthor=C.+Wangauthor=K.+J.+Gregoryauthor=G.+W.+Hanauthor=H.+P.+Choauthor=Y.+Xiaauthor=C.+M.+Niswenderauthor=V.+Katritchauthor=J.+Meilerauthor=V.+Cherezovauthor=P.+J.+Connauthor=R.+C.+Stevens&title=Structure+of+a+class+C+GPCR+metabotropic+glutamate+receptor+1+bound+to+an+allosteric+modulator&doi=10.1126%2Fscience.1249489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator</span></div><div class="casAuthors">Wu, Huixian; Wang, Chong; Gregory, Karen J.; Han, Gye Won; Cho, Hyekyung P.; Xia, Yan; Niswender, Colleen M.; Katritch, Vsevolod; Meiler, Jens; Cherezov, Vadim; Conn, P. Jeffrey; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">6179</span>),
    <span class="NLM_cas:pages">58-64</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The excitatory neurotransmitter glutamate induces modulatory actions via the metabotropic glutamate receptors (mGlus), which are class C G protein-coupled receptors (GPCRs).  The authors detd. the structure of the human mGlu1 receptor seven-transmembrane (7TM) domain bound to a neg. allosteric modulator, FITM, at a resoln. of 2.8 angstroms.  The modulator binding site partially overlaps with the orthosteric binding sites of class A GPCRs but is more restricted than most other GPCRs.  The authors obsd. a parallel 7TM dimer mediated by cholesterols, which suggests that signaling initiated by glutamate's interaction with the extracellular domain might be mediated via 7TM interactions within the full-length receptor dimer.  A combination of crystallog., structure-activity relationships, mutagenesis, and full-length dimer modeling provides insights about the allosteric modulation and activation mechanism of class C GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVdhj4KmKV7LVg90H21EOLACvtfcHk0lhk3-c0YF7NTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1eht78%253D&md5=e552ac4646b8e67c52d1f5e0aa42ec5a</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1126%2Fscience.1249489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1249489%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCho%26aufirst%3DH.%2BP.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520a%2520class%2520C%2520GPCR%2520metabotropic%2520glutamate%2520receptor%25201%2520bound%2520to%2520an%2520allosteric%2520modulator%26jtitle%3DScience%26date%3D2014%26volume%3D344%26spage%3D58%26epage%3D64%26doi%3D10.1126%2Fscience.1249489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okrasa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Vega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiggin, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>511</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nature13396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fnature13396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25042998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=557-562&author=A.+S.+Doreauthor=K.+Okrasaauthor=J.+C.+Patelauthor=M.+Serrano-Vegaauthor=K.+Bennettauthor=R.+M.+Cookeauthor=J.+C.+Erreyauthor=A.+Jazayeriauthor=S.+Khanauthor=B.+Tehanauthor=M.+Weirauthor=G.+R.+Wigginauthor=F.+H.+Marshall&title=Structure+of+class+C+GPCR+metabotropic+glutamate+receptor+5+transmembrane+domain&doi=10.1038%2Fnature13396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain</span></div><div class="casAuthors">Dore, Andrew S.; Okrasa, Krzysztof; Patel, Jayesh C.; Serrano-Vega, Maria; Bennett, Kirstie; Cooke, Robert M.; Errey, James C.; Jazayeri, Ali; Khan, Samir; Tehan, Ben; Weir, Malcolm; Wiggin, Giselle R.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">557-562</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptors are class C G-protein-coupled receptors which respond to the neurotransmitter glutamate.  Structural studies have been restricted to the amino-terminal extracellular domain, providing little understanding of the membrane-spanning signal transduction domain.  Metabotropic glutamate receptor 5 (mGlu5 receptor) is of considerable interest as a drug target in the treatment of fragile X syndrome, autism, depression, anxiety, addiction and movement disorders.  Here we report the crystal structure of the transmembrane domain of the human receptor in complex with the neg. allosteric modulator, mavoglurant.  The structure provides detailed insight into the architecture of the transmembrane domain of class C receptors including the precise location of the allosteric binding site within the transmembrane domain and key micro-switches which regulate receptor signaling.  This structure also provides a model for all class C G-protein-coupled receptors and may aid in the design of new small-mol. drugs for the treatment of brain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4LiHVA8klWLVg90H21EOLACvtfcHk0lhk3-c0YF7NTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnK&md5=43a1f0b72a923044fa718729f97c075d</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnature13396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13396%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DJ.%2BC.%26aulast%3DSerrano-Vega%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DWiggin%26aufirst%3DG.%2BR.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520class%2520C%2520GPCR%2520metabotropic%2520glutamate%2520receptor%25205%2520transmembrane%2520domain%26jtitle%3DNature%26date%3D2014%26volume%3D511%26spage%3D557%26epage%3D562%26doi%3D10.1038%2Fnature13396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stansley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.coph.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29486374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVCqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=31-36&author=B.+J.+Stansleyauthor=P.+J.+Conn&title=The+therapeutic+potential+of+metabotropic+glutamate+receptor+modulation+for+schizophrenia&doi=10.1016%2Fj.coph.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia</span></div><div class="casAuthors">Stansley, Branden J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-36</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence suggests that a dysregulation of the glutamatergic system exists in the brains of schizophrenia patients.  The metabotropic glutamate (mGlu) receptors are being investigated as novel drug targets for this disease, and have shown promise in both preclin. and clin. studies.  Activation of mGlu5 receptors may be efficacious for several symptom domains (pos., neg., and cognitive) and the potential for targeting mGlu5 receptors has been bolstered by recent research on mitigating toxicity profiles assocd. with mGlu5 activation.  Addnl., genetic profiling of schizophrenia patients suggests that genes encoding for mGlu1 and mGlu3 receptors are altered, prompting preclin. studies that have demonstrated potential antipsychotic and cognitive enhancing effects of agents that activate mGlu1 and mGlu3 receptors, resp.  Development of subtype-specific drugs for the mGlu receptors, such as allosteric modulators, could provide a path forward for more efficacious and tolerable therapeutics for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlmWIOOFO3qrVg90H21EOLACvtfcHk0lhk3-c0YF7NTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVCqs7s%253D&md5=c37830f179b1d47e7bfeb4bd64db371e</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DStansley%26aufirst%3DB.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520metabotropic%2520glutamate%2520receptor%2520modulation%2520for%2520schizophrenia%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D38%26spage%3D31%26epage%3D36%26doi%3D10.1016%2Fj.coph.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier-Batteur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uslaner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magliaro, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Poul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosahl, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocher, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism based neurotoxicity of mGlu5 positive allosteric modulators - development challenges for a promising novel antipsychotic target</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.neuropharm.2012.12.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=161-173&author=S.+Parmentier-Batteurauthor=P.+H.+Hutsonauthor=K.+Menzelauthor=J.+M.+Uslanerauthor=B.+A.+Mattsonauthor=J.+A.+O%E2%80%99Brienauthor=B.+C.+Magliaroauthor=T.+Forestauthor=C.+A.+Stumpauthor=R.+M.+Tyneborauthor=N.+J.+Anthonyauthor=T.+J.+Tuckerauthor=X.+F.+Zhangauthor=R.+Gomezauthor=S.+L.+Huszarauthor=N.+Lambengauthor=H.+Faureauthor=E.+Le+Poulauthor=S.+Poliauthor=T.+W.+Rosahlauthor=J.+P.+Rocherauthor=R.+Hargreavesauthor=T.+M.+Williams&title=Mechanism+based+neurotoxicity+of+mGlu5+positive+allosteric+modulators+-+development+challenges+for+a+promising+novel+antipsychotic+target&doi=10.1016%2Fj.neuropharm.2012.12.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier-Batteur%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26aulast%3DMenzel%26aufirst%3DK.%26aulast%3DUslaner%26aufirst%3DJ.%2BM.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DMagliaro%26aufirst%3DB.%2BC.%26aulast%3DForest%26aufirst%3DT.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DHuszar%26aufirst%3DS.%2BL.%26aulast%3DLambeng%26aufirst%3DN.%26aulast%3DFaure%26aufirst%3DH.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DRosahl%26aufirst%3DT.%2BW.%26aulast%3DRocher%26aufirst%3DJ.%2BP.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26atitle%3DMechanism%2520based%2520neurotoxicity%2520of%2520mGlu5%2520positive%2520allosteric%2520modulators%2520-%2520development%2520challenges%2520for%2520a%2520promising%2520novel%2520antipsychotic%2520target%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D161%26epage%3D173%26doi%3D10.1016%2Fj.neuropharm.2012.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome-Nebreda, J.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Biased mGlu<sub>5</sub>-positive allosteric modulators provide in vivo efficacy without potentiating mGlu<sub>5</sub> modulation of NMDAR currents</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.neuron.2015.03.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25937172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1029-1040&author=J.+M.+Rookauthor=Z.+X.+Xiangauthor=X.+H.+Lvauthor=A.+Ghoshalauthor=J.+W.+Dickersonauthor=T.+M.+Bridgesauthor=K.+A.+Johnsonauthor=D.+J.+Fosterauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=A.+D.+Thompsonauthor=N.+Byunauthor=R.+L.+Collierauthor=M.+Bubserauthor=M.+T.+Nedelcovychauthor=R.+W.+Gouldauthor=S.+R.+Staufferauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=H.+Lavreysenauthor=C.+Mackieauthor=S.+Conde-Ceideauthor=J.+Alcazarauthor=J.%0AM.+Bartolome-Nebredaauthor=G.+J.+Macdonaldauthor=J.+C.+Talposauthor=T.+Stecklerauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Biased+mGlu5-positive+allosteric+modulators+provide+in+vivo+efficacy+without+potentiating+mGlu5+modulation+of+NMDAR+currents&doi=10.1016%2Fj.neuron.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents</span></div><div class="casAuthors">Rook, Jerri M.; Xiang, Zixiu; Lv, Xiaohui; Ghoshal, Ayan; Dickerson, Jonathan W.; Bridges, Thomas M.; Johnson, Kari A.; Foster, Daniel J.; Gregory, Karen J.; Vinson, Paige N.; Thompson, Analisa D.; Byun, Nellie; Collier, Rebekah L.; Bubser, Michael; Nedelcovych, Michael T.; Gould, Robert W.; Stauffer, Shaun R.; Daniels, J. Scott; Niswender, Colleen M.; Lavreysen, Hilde; Mackie, Claire; Conde-Ceide, Susana; Alcazar, Jesus; Bartolome-Nebreda, Jose M.; MacDonald, Gregor J.; Talpos, John C.; Steckler, Thomas; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1029-1040</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Schizophrenia is assocd. with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling.  The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely assocd. signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathol. of schizophrenia.  Efficacy of mGlu5 pos. allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function.  To directly test this hypothesis, we identified VU0409551 as a novel mGlu5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to Gαq-mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus.  Interestingly, VU0409551 produced robust antipsychotic-like and cognition-enhancing activity in animal models.  These data provide surprising new mechanistic insights into the actions of mGlu5 PAMs and suggest that modulation of NMDAR currents is not crit. for in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKRBBcza96rVg90H21EOLACvtfcHk0ljs4iutP2Ywlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D&md5=c5f0a8cf83e1b2d8e0d3541a39cd0529</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%2BX.%26aulast%3DLv%26aufirst%3DX.%2BH.%26aulast%3DGhoshal%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DByun%26aufirst%3DN.%26aulast%3DCollier%26aufirst%3DR.%2BL.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DBartolome-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTalpos%26aufirst%3DJ.%2BC.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DBiased%2520mGlu5-positive%2520allosteric%2520modulators%2520provide%2520in%2520vivo%2520efficacy%2520without%2520potentiating%2520mGlu5%2520modulation%2520of%2520NMDAR%2520currents%26jtitle%3DNeuron%26date%3D2015%26volume%3D86%26spage%3D1029%26epage%3D1040%26doi%3D10.1016%2Fj.neuron.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noetzel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manka, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1124/mol.112.082891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fmol.112.082891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23348500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=835-847&author=M.+J.+Noetzelauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=J.+T.+Mankaauthor=S.+R.+Staufferauthor=C.+W.+Lindsleyauthor=C.+M.+Niswenderauthor=Z.+Xiangauthor=P.+J.+Conn&title=A+novel+metabotropic+glutamate+receptor+5+positive+allosteric+modulator+acts+at+a+unique+site+and+confers+stimulus+bias+to+mGlu5+signaling&doi=10.1124%2Fmol.112.082891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling</span></div><div class="casAuthors">Noetzel, M. J.; Gregory, K. J.; Vinson, P. N.; Manka, J. T.; Stauffer, S. R.; Lindsley, C. W.; Niswender, C. M.; Xiang, Z.; Conn, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">835-847</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 5 (mGlu5) is a target for the treatment of central nervous system (CNS) disorders, such as schizophrenia and Alzheimer's disease.  Furthermore, mGlu5 has been shown to play an important role in hippocampal synaptic plasticity, specifically in long-term depression (LTD) and long-term potentiation (LTP), which is thought to be involved in cognition.  Multiple mGlu5-pos. allosteric modulators (PAMs) have been developed from a variety of different scaffolds.  Previous work has extensively characterized a common allosteric site on mGlu5, termed the MPEP (2-Methyl-6-(phenylethynyl)pyridine) binding site.  However, one mGlu5 PAM, CPPHA (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a sep. allosteric site on mGlu5.  Using cell-based assays and brain slice prepns., we characterized the interaction of a potent and efficacious mGlu5 PAM from the CPPHA series termed NCFP (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).  NCFP binds to the CPPHA site on mGlu5 and potentiates mGlu5-mediated responses in both recombinant and native systems.  However, NCFP provides greater mGlu5 subtype selectivity than does CPPHA, making it more suitable for studies of effects on mGlu5 in CNS prepns.  Of interest, NCFP does not potentiate responses involved in hippocampal synaptic plasticity (LTD/LTP), setting it apart from other previously characterized MPEP site PAMs.  This suggests that although mGlu5 PAMs may have similar responses in some systems, they can induce differential effects on mGlu5-mediated physiol. responses in the CNS.  Such stimulus bias by mGlu5 PAMs may complicate drug discovery efforts but would also allow for specifically tailored therapies, if pharmacol. biases can be attributed to different therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrBH7IPviPNbVg90H21EOLACvtfcHk0lhbT2q3Rab1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt7s%253D&md5=175d8e7aef535a8df57a73420200c8b0</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.082891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.082891%26sid%3Dliteratum%253Aachs%26aulast%3DNoetzel%26aufirst%3DM.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DManka%26aufirst%3DJ.%2BT.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DA%2520novel%2520metabotropic%2520glutamate%2520receptor%25205%2520positive%2520allosteric%2520modulator%2520acts%2520at%2520a%2520unique%2520site%2520and%2520confers%2520stimulus%2520bias%2520to%2520mGlu5%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D835%26epage%3D847%26doi%3D10.1124%2Fmol.112.082891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. T.</span></span> <span> </span><span class="NLM_article-title">Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/j.beem.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.beem.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=23856262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=315-331&author=A.+D.+Conigraveauthor=D.+T.+Ward&title=Calcium-sensing+receptor+%28CaSR%29%3A+pharmacological+properties+and+signaling+pathways&doi=10.1016%2Fj.beem.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways</span></div><div class="casAuthors">Conigrave, Arthur D.; Ward, Donald T.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-331</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In this article we consider the mechanisms by which the calcium-sensing receptor (CaSR) induces its cellular responses via the control (activation or inhibition) of signaling pathways.  We consider key features of CaSR-mediated signaling including its control of the heterotrimeric G-proteins Gq/11, Gi/o and G12/13 and the downstream consequences recognizing that very few CaSR-mediated cell phenomena have been fully described.  We also consider the manner in which the CaSR contributes to the formation of specific signaling scaffolds via peptide recognition sequences in its intracellular C-terminal along with the origins of its high level of cooperativity, particularly for Ca2+o, and its remarkable resistance to desensitization.  We also consider the nature of the mechanisms by which the CaSR controls oscillatory and sustained Ca2+i mobilizing responses and inhibits or elevates cyclic adenosine monophosphate (cAMP) levels dependent on the cellular and signaling context.  Finally, we consider the diversity of the receptor's ligands, ligand binding sites and broader compartment-dependent physiol. roles leading to the identification of pronounced ligand-biased signaling for agonists including Sr2+ and modulators including l-amino acids and the clin. effective calcimimetic cinacalcet.  We note the implications of these findings for the development of new designer drugs that might target the CaSR in pathophysiol. contexts beyond those established for the treatment of disorders of calcium metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6fBNXb9flOLVg90H21EOLACvtfcHk0lhbT2q3Rab1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyktLg%253D&md5=023e18c8f9b1fae085f2b2b7f4e00926</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DWard%26aufirst%3DD.%2BT.%26atitle%3DCalcium-sensing%2520receptor%2520%2528CaSR%2529%253A%2520pharmacological%2520properties%2520and%2520signaling%2520pathways%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D27%26spage%3D315%26epage%3D331%26doi%3D10.1016%2Fj.beem.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, A. R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hvidtfeldt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauner-Osborne, H.</span></span> <span> </span><span class="NLM_article-title">Biased agonism of the calcium-sensing receptor</span>. <i>Cell Calcium</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.ceca.2011.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1016%2Fj.ceca.2011.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22192592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit12jt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=107-116&author=A.+R.+B.+Thomsenauthor=M.+Hvidtfeldtauthor=H.+Brauner-Osborne&title=Biased+agonism+of+the+calcium-sensing+receptor&doi=10.1016%2Fj.ceca.2011.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Biased agonism of the calcium-sensing receptor</span></div><div class="casAuthors">Thomsen, Alex Rojas Bie; Hvidtfeldt, Maja; Brauner-Osborne, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Cell Calcium</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">CECADV</span>;
        ISSN:<span class="NLM_cas:issn">0143-4160</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">After the discovery of mols. modulating G protein-coupled receptors (GPCRs) that are able to selectively affect one signaling pathway over others for a specific GPCR, thereby "biasing" the signaling, it has become obvious that the original model of GPCRs existing in either an "on" or "off" conformation is too simple.  The current explanation for this biased agonism is that GPCRs can adopt multiple active conformations stabilized by different mols., and that each conformation affects intracellular signaling in a different way.  In the present study we sought to investigate biased agonism of the calcium-sensing receptor (CaSR), by looking at 12 well-known orthosteric CaSR agonists in 3 different CaSR signaling pathways: Gq/11 protein, Gi/o protein, and extracellular signal-regulated kinases 1 and 2 (ERK1/2).  Here we show that apart from Gq/11 and Gi/o signaling, ERK1/2 is activated through recruitment of β-arrestins.  Next, by measuring activity of all three signaling pathways we found that barium, spermine, neomycin, and tobramycin act as biased agonist in terms of efficacy and/or potency.  Finally, polyamines and aminoglycosides in general were biased in their potencies toward ERK1/2 signaling.  In conclusion, the results of this study indicate that several active conformations of CaSR, stabilized by different mols., exist, which affect intracellular signaling distinctly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0OM03QDGPb7Vg90H21EOLACvtfcHk0lhbT2q3Rab1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit12jt7g%253D&md5=c62a3f98063361bf90dea320f0b46156</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.ceca.2011.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceca.2011.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DA.%2BR.%2BB.%26aulast%3DHvidtfeldt%26aufirst%3DM.%26aulast%3DBrauner-Osborne%26aufirst%3DH.%26atitle%3DBiased%2520agonism%2520of%2520the%2520calcium-sensing%2520receptor%26jtitle%3DCell%2520Calcium%26date%3D2012%26volume%3D51%26spage%3D107%26epage%3D116%26doi%3D10.1016%2Fj.ceca.2011.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yousaf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charytan, C.</span></span> <span> </span><span class="NLM_article-title">Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism</span>. <i>Renal Failure</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.3109/0886022X.2013.832319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.3109%2F0886022X.2013.832319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOgtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=131-138&author=F.+Yousafauthor=C.+Charytan&title=Review+of+cinacalcet+hydrochloride+in+the+management+of+secondary+hyperparathyroidism&doi=10.3109%2F0886022X.2013.832319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism</span></div><div class="casAuthors">Yousaf, Farhanah; Charytan, Chaim</div><div class="citationInfo"><span class="NLM_cas:title">Renal Failure</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-138</span>CODEN:
                <span class="NLM_cas:coden">REFAE8</span>;
        ISSN:<span class="NLM_cas:issn">0886-022X</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Cinacalcet is the first Food and Drug Administration-approved calcimimetic for the treatment of secondary hyperparathyroidism in dialysis patients.  It is effective in improving control of parathyroid hormone, serum calcium, phosphorus, and calcium-phosphorus product.  The calcium-lowering effect of cinacalcet overcomes the limitations of std. therapy assocd. hypercalcemia.  There is evidence to suggest that cinacalcet has important clin. implications, which extend beyond its relevance in the treatment of secondary hyperparathyroidism.  This review summarizes the evidence regarding the role of cinacalcet in the treatment of secondary hyperparathyroidism, disrupted bone mineral metab., cardiovascular disease, and mortality.  In addn., the cost implications of cinacalcet are briefly explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTQ-XEIVH1w7Vg90H21EOLACvtfcHk0lhbT2q3Rab1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOgtL%252FE&md5=5dabf3246e7f872679b55b04274fd3ce</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.3109%2F0886022X.2013.832319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F0886022X.2013.832319%26sid%3Dliteratum%253Aachs%26aulast%3DYousaf%26aufirst%3DF.%26aulast%3DCharytan%26aufirst%3DC.%26atitle%3DReview%2520of%2520cinacalcet%2520hydrochloride%2520in%2520the%2520management%2520of%2520secondary%2520hyperparathyroidism%26jtitle%3DRenal%2520Failure%26date%3D2014%26volume%3D36%26spage%3D131%26epage%3D138%26doi%3D10.3109%2F0886022X.2013.832319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span> <span> </span><span class="NLM_article-title">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1111/bph.12937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1111%2Fbph.12937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=25220431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=185-200&author=A.+E.+Cookauthor=S.+N.+Mistryauthor=K.+J.+Gregoryauthor=S.+G.+B.+Furnessauthor=P.+M.+Sextonauthor=P.+J.+Scammellsauthor=A.+D.+Conigraveauthor=A.+Christopoulosauthor=K.+Leach&title=Biased+allosteric+modulation+at+the+CaS+receptor+engendered+by+structurally+diverse+calcimimetics&doi=10.1111%2Fbph.12937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span></div><div class="casAuthors">Cook, A. E.; Mistry, S. N.; Gregory, K. J.; Furness, S. G. B.; Sexton, P. M.; Scammells, P. J.; Conigrave, A. D.; Christopoulos, A.; Leach, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-200</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Clin. use of cinacalcet in hyperparathyroidism is complicated by its tendency to induce hypocalcemia, arising partly from activation of calcium-sensing receptors (CaS receptors) in the thyroid and stimulation of calcitonin release.  CaS receptor allosteric modulators that selectively bias signalling towards pathways that mediate desired effects [e.g. parathyroid hormone (PTH) suppression] rather than those mediating undesirable effects (e.g. elevated serum calcitonin), may offer better therapies.  Exptl. Approach : We characterized the ligand-biased profile of novel calcimimetics in HEK293 cells stably expressing human CaS receptors, by monitoring intracellular calcium (Ca2+i) mobilization, inositol phosphate (IP)1 accumulation, ERK1/2 phosphorylation (pERK1/2) and receptor expression.  Key Results : Phenylalkylamine calcimimetics were biased towards allosteric modulation of Ca2+i mobilization and IP1 accumulation.  S,R-calcimimetic B was biased only towards IP1 accumulation.  R,R-calcimimetic B and AC-265347 were biased towards IP1 accumulation and pERK1/2.  Nor-calcimimetic B was unbiased.  In contrast to phenylalkylamines and calcimimetic B analogs, AC-265347 did not promote trafficking of a loss-of-expression, naturally occurring, CaS receptor mutation (G670E).  Conclusions and Implications : The ability of R,R-calcimimetic B and AC-265347 to bias signalling towards pERK1/2 and IP1 accumulation may explain their suppression of PTH levels in vivo at concns. that have no effect on serum calcitonin levels.  The demonstration that AC-265347 promotes CaS receptor receptor signalling, but not trafficking reveals a novel profile of ligand-biased modulation at CaS receptors The identification of allosteric modulators that bias CaS receptor signalling towards distinct intracellular pathways provides an opportunity to develop desirable biased signalling profiles in vivo for mediating selective physiol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAjm2vqgRE7Vg90H21EOLACvtfcHk0lgoj6rT20rurw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P&md5=238f469a40ace3cf598dc49584bf0497</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1111%2Fbph.12937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12937%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DA.%2BE.%26aulast%3DMistry%26aufirst%3DS.%2BN.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%26atitle%3DBiased%2520allosteric%2520modulation%2520at%2520the%2520CaS%2520receptor%2520engendered%2520by%2520structurally%2520diverse%2520calcimimetics%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D185%26epage%3D200%26doi%3D10.1111%2Fbph.12937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorvin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babinsky, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinauskas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schou, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanyaloglu, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebold, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannan, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakker, R. V.</span></span> <span> </span><span class="NLM_article-title">A calcium-sensing receptor mutation causing hypocalcemia disrupts a transmembrane salt bridge to activate β-arrestin-biased signaling</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaan3714</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aan3714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1126%2Fscisignal.aan3714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=29463778" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=eaan3714&author=C.+M.+Gorvinauthor=V.+N.+Babinskyauthor=T.+Malinauskasauthor=P.+H.+Nissenauthor=A.+J.+Schouauthor=A.+C.+Hanyalogluauthor=C.+Sieboldauthor=E.+Y.+Jonesauthor=F.+M.+Hannanauthor=R.+V.+Thakker&title=A+calcium-sensing+receptor+mutation+causing+hypocalcemia+disrupts+a+transmembrane+salt+bridge+to+activate+%CE%B2-arrestin-biased+signaling&doi=10.1126%2Fscisignal.aan3714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aan3714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aan3714%26sid%3Dliteratum%253Aachs%26aulast%3DGorvin%26aufirst%3DC.%2BM.%26aulast%3DBabinsky%26aufirst%3DV.%2BN.%26aulast%3DMalinauskas%26aufirst%3DT.%26aulast%3DNissen%26aufirst%3DP.%2BH.%26aulast%3DSchou%26aufirst%3DA.%2BJ.%26aulast%3DHanyaloglu%26aufirst%3DA.%2BC.%26aulast%3DSiebold%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DHannan%26aufirst%3DF.%2BM.%26aulast%3DThakker%26aufirst%3DR.%2BV.%26atitle%3DA%2520calcium-sensing%2520receptor%2520mutation%2520causing%2520hypocalcemia%2520disrupts%2520a%2520transmembrane%2520salt%2520bridge%2520to%2520activate%2520%25CE%25B2-arrestin-biased%2520signaling%26jtitle%3DSci.%2520Signaling%26date%3D2018%26volume%3D11%26spage%3Deaan3714%26doi%3D10.1126%2Fscisignal.aan3714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, H. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeque, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarov, I.</span></span> <span> </span><span class="NLM_article-title">Kinetics of 5-HT<sub>2B</sub> receptor signaling: profound agonist-dependent effects on signaling onset and duration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1124%2Fjpet.113.207670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24049061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=645-659&author=D.+J.+Unettauthor=J.+Gatlinauthor=T.+L.+Anthonyauthor=D.+J.+Buzardauthor=S.+Changauthor=C.+Chenauthor=X.+H.+Chenauthor=H.+T.+M.+Dangauthor=J.+Frazerauthor=M.+K.+Leauthor=A.+J.+M.+Sadequeauthor=C.+Xingauthor=I.+Gaidarov&title=Kinetics+of+5-HT2B+receptor+signaling%3A+profound+agonist-dependent+effects+on+signaling+onset+and+duration&doi=10.1124%2Fjpet.113.207670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Kinectics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration</span></div><div class="casAuthors">Unett, David J.; Gatlin, Joel; Anthony, Todd L.; Buzard, Daniel J.; Chang, Steve; Chen, Chuan; Chen, Xiaohua; Dang, Huong T.-M.; Frazer, John; Le, Minh K.; Sadeque, Abu J. M.; Xing, Charles; Gaidarov, Ibragim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">645-659</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The kinetics of drug-receptor interactions can profoundly influence in vivo and in vitro pharmacol.  In vitro, the potencies of slowly assocg. agonists may be underestimated in assays capturing transient signaling events.  When divergent receptor-mediated signaling pathways are evaluated using combinations of equil. and transient assays, potency differences driven by kinetics may be erroneously interpreted as biased signaling.  In vivo, drugs with slow dissocn. rates may display prolonged physiol. effects inconsistent with their pharmacokinetic profiles.  We evaluated a panel of 5-hydroxytryptamine2B (5-HT2B) receptor agonists in kinetic radioligand binding assays and in transient, calcium flux assays, and inositol phosphate accumulation assays; two functional readouts emanating from Gαq-mediated activation of phospholipase C.  In binding studies, ergot derivs. demonstrated slow receptor assocn. and dissocn. rates, resulting in significantly reduced potency in calcium assays relative to inositol phosphate accumulation assays.  Ergot potencies for activation of extracellular signal-regulated kinases 1 and 2 were also highly time-dependent.  A no. of ergots produced wash-resistant 5-HT2B signaling that persisted for many hours without appreciable loss of potency, which was not explained simply by slow receptor-dissocn. kinetics.  Mechanistic studies indicated that persistent signaling originated from internalized or sequestered receptors.  This study provides a mechanistic basis for the long durations of action in vivo and wash-resistant effects in ex vivo tissue models often obsd. for ergots.  The 5-HT2B agonist activity of a no. of ergot-derived therapeutics has been implicated in development of cardiac valvulopathy in man.  The novel, sustained nature of ergot signaling reported here may represent an addnl. mechanism contributing to the valvulopathic potential of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt4E22Qj45kbVg90H21EOLACvtfcHk0lgoj6rT20rurw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jL&md5=afba8d117470704b64f74bb2320c0aac</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207670%26sid%3Dliteratum%253Aachs%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DGatlin%26aufirst%3DJ.%26aulast%3DAnthony%26aufirst%3DT.%2BL.%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DDang%26aufirst%3DH.%2BT.%2BM.%26aulast%3DFrazer%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DM.%2BK.%26aulast%3DSadeque%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DGaidarov%26aufirst%3DI.%26atitle%3DKinetics%2520of%25205-HT2B%2520receptor%2520signaling%253A%2520profound%2520agonist-dependent%2520effects%2520on%2520signaling%2520onset%2520and%2520duration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D645%26epage%3D659%26doi%3D10.1124%2Fjpet.113.207670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time-a case for G protein-coupled receptors</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/med.21307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1002%2Fmed.21307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=24549504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=856-892&author=D.+Guoauthor=J.+M.+Hillgerauthor=A.+P.+IJzermanauthor=L.+H.+Heitman&title=Drug-target+residence+time-a+case+for+G+protein-coupled+receptors&doi=10.1002%2Fmed.21307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Target Residence Time-A Case for G Protein-Coupled Receptors</span></div><div class="casAuthors">Guo, Dong; Hillger, Julia M.; Ijzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">856-892</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A vast no. of marketed drugs act on G protein-coupled receptors (GPCRs), the most successful category of drug targets to date.  These drugs usually possess high target affinity and selectivity, and such combined features have been the driving force in the early phases of drug discovery.  However, attrition has also been high.  Many investigational new drugs eventually fail in clin. trials due to a demonstrated lack of efficacy.  A retrospective assessment of successfully launched drugs revealed that their beneficial effects in patients may be attributed to their long drug-target residence times (RTs).  Likewise, for some other GPCR drugs short RT could be beneficial to reduce the potential for on-target side effects.  Hence, the compds.' kinetics behavior might in fact be the guiding principle to obtain a desired and durable effect in vivo.  We therefore propose that drug-target RT should be taken into account as an addnl. parameter in the lead selection and optimization process.  This should ultimately lead to an increased no. of candidate drugs moving to the preclin. development phase and on to the market.  This review contains examples of the kinetics behavior of GPCR ligands with improved in vivo efficacy and summarizes methods for assessing drug-target RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN5vhWI93LMbVg90H21EOLACvtfcHk0lhCPLS2rNaSKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D&md5=af48cdedf3c60ecb608d5c9ad03a0bbe</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1002%2Fmed.21307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21307%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHillger%26aufirst%3DJ.%2BM.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DDrug-target%2520residence%2520time-a%2520case%2520for%2520G%2520protein-coupled%2520receptors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D856%26epage%3D892%26doi%3D10.1002%2Fmed.21307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D<sub>2</sub> receptors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">763</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00716-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fs41467-017-00716-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=28970469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=763&author=D.+A.+Sykesauthor=H.+Mooreauthor=L.+Stottauthor=N.+Hollidayauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=S.+J.+Charlton&title=Extrapyramidal+side+effects+of+antipsychotics+are+linked+to+their+association+kinetics+at+dopamine+D2+receptors&doi=10.1038%2Fs41467-017-00716-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors</span></div><div class="casAuthors">Sykes David A; Stott Lisa; Holliday Nicholas; Charlton Steven J; Moore Holly; Javitch Jonathan A; Moore Holly; Javitch Jonathan A; Javitch Jonathan A; Lane J Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">763</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor.  However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions.  Here we show that association rates, but not dissociation rates, correlate with EPS.  We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses.  EPS are robustly predicted by a rebinding model that considers the microenvironment of postsynaptic D2 receptors and integrates association and dissociation rates to calculate the net rate of reversal of receptor blockade.  Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved therapeutic profile.Atypical antipsychotics show reduced extrapyramidal side effects compared to first generation drugs.  Here the authors use time-resolved FRET to measure binding kinetics, and show that side effects correlate with drug association rates to the D2 receptor, while dissociation rates correlate with prolactin elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAv7HAvl2UWlVwdslNBF-tfW6udTcc2eZtTkznb0YL9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D&md5=6d5c8596da9a3565b7a95b55eceac3cf</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00716-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00716-z%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DStott%26aufirst%3DL.%26aulast%3DHolliday%26aufirst%3DN.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DExtrapyramidal%2520side%2520effects%2520of%2520antipsychotics%2520are%2520linked%2520to%2520their%2520association%2520kinetics%2520at%2520dopamine%2520D2%2520receptors%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D763%26doi%3D10.1038%2Fs41467-017-00716-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrage, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallanoce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bätz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klöckner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kebig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrobang-Ley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tränkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Amici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzgrabe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, K.</span></span> <span> </span><span class="NLM_article-title">The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1044</span>, <span class="refDoi"> DOI: 10.1038/ncomms2028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1038%2Fncomms2028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=22948826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A280%3ADC%252BC38bktFamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1044&author=A.+Bockauthor=N.+Mertenauthor=R.+Schrageauthor=C.+Dallanoceauthor=J.+B%C3%A4tzauthor=J.+Kl%C3%B6cknerauthor=J.+Schmitzauthor=C.+Materaauthor=K.+Simonauthor=A.+Kebigauthor=L.+Petersauthor=A.+M%C3%BCllerauthor=J.+Schrobang-Leyauthor=C.+Tr%C3%A4nkleauthor=C.+Hoffmannauthor=M.+De+Amiciauthor=U.+Holzgrabeauthor=E.+Kostenisauthor=K.+Mohr&title=The+allosteric+vestibule+of+a+seven+transmembrane+helical+receptor+controls+G-protein+coupling&doi=10.1038%2Fncomms2028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling</span></div><div class="casAuthors">Bock Andreas; Merten Nicole; Schrage Ramona; Dallanoce Clelia; Batz Julia; Klockner Jessica; Schmitz Jens; Matera Carlo; Simon Katharina; Kebig Anna; Peters Lucas; Muller Anke; Schrobang-Ley Jasmin; Trankle Christian; Hoffmann Carsten; De Amici Marco; Holzgrabe Ulrike; Kostenis Evi; Mohr Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1044</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Seven transmembrane helical receptors (7TMRs) modulate cell function via different types of G proteins, often in a ligand-specific manner.  Class A 7TMRs harbour allosteric vestibules in the entrance of their ligand-binding cavities, which are in the focus of current drug discovery.  However, their biological function remains enigmatic.  Here we present a new strategy for probing and manipulating conformational transitions in the allosteric vestibule of label-free 7TMRs using the M(2) acetylcholine receptor as a paradigm.  We designed dualsteric agonists as 'tailor-made' chemical probes to trigger graded receptor activation from the acetylcholine-binding site while simultaneously restricting spatial flexibility of the receptor's allosteric vestibule.  Our findings reveal for the first time that a 7TMR's allosteric vestibule controls the extent of receptor movement to govern a hierarchical order of G-protein coupling.  This is a new concept assigning a biological role to the allosteric vestibule for controlling fidelity of 7TMR signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqGm8leCElH6x48Rj5GnGofW6udTcc2eZtTkznb0YL9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bktFamtw%253D%253D&md5=73fe5fd5f8214a9acfb88cda22c9c174</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1038%2Fncomms2028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms2028%26sid%3Dliteratum%253Aachs%26aulast%3DBock%26aufirst%3DA.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DSchrage%26aufirst%3DR.%26aulast%3DDallanoce%26aufirst%3DC.%26aulast%3DB%25C3%25A4tz%26aufirst%3DJ.%26aulast%3DKl%25C3%25B6ckner%26aufirst%3DJ.%26aulast%3DSchmitz%26aufirst%3DJ.%26aulast%3DMatera%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DKebig%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DL.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DSchrobang-Ley%26aufirst%3DJ.%26aulast%3DTr%25C3%25A4nkle%26aufirst%3DC.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DDe%2BAmici%26aufirst%3DM.%26aulast%3DHolzgrabe%26aufirst%3DU.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DMohr%26aufirst%3DK.%26atitle%3DThe%2520allosteric%2520vestibule%2520of%2520a%2520seven%2520transmembrane%2520helical%2520receptor%2520controls%2520G-protein%2520coupling%26jtitle%3DNat.%2520Commun.%26date%3D2012%26volume%3D3%26spage%3D1044%26doi%3D10.1038%2Fncomms2028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perroy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walwyn, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. J.</span></span> <span> </span><span class="NLM_article-title">Agonist-specific recruitment of arrestin isoforms differentially modify delta opioid receptor function</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3541</span>– <span class="NLM_lpage">3551</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4124-15.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=10.1523%2FJNEUROSCI.4124-15.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=27013682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFelsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=3541-3551&author=A.+A.+Pradhanauthor=J.+Perroyauthor=W.+M.+Walwynauthor=M.+L.+Smithauthor=A.+Vicente-Sanchezauthor=L.+Seguraauthor=A.+Banaauthor=B.+L.+Kiefferauthor=C.+J.+Evans&title=Agonist-specific+recruitment+of+arrestin+isoforms+differentially+modify+delta+opioid+receptor+function&doi=10.1523%2FJNEUROSCI.4124-15.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-specific recruitment of arrestin isoforms differentially modify delta opioid receptor function</span></div><div class="casAuthors">Pradhan, Amynah A.; Perroy, Julie; Walwyn, Wendy M.; Smith, Monique L.; Vicente-Sanchez, Ana; Segura, Laura; Bana, Alia; Kieffer, Brigitte L.; Evans, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3541-3551</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Ligand-specific recruitment of arrestins facilitates functional selectivity of G-protein-coupled receptor signaling.  Here, we describe agonist-selective recruitment of different arrestin isoforms to the delta opioid receptor in mice.  A high-internalizing delta opioid receptor agonist (SNC80) preferentially recruited arrestin 2 and, in arrestin 2 knock-outs (KOs), we obsd. a significant increase in the potency of SNC80 to inhibit mech. hyperalgesia and decreased acute tolerance.  In contrast, the low-internalizing delta agonists (ARM390, JNJ20788560) preferentially recruited arrestin 3 with unaltered behavioral effects in arrestin 2 KOs.  Surprisingly, arrestin 3 KO revealed an acute tolerance to these low-internalizing agonists, an effect never obsd. in wild-type animals.  Furthermore, we examd. delta opioid receptor-Ca2+ channel coupling in dorsal root ganglia desensitized by ARM390 and the rate of resensitization was correspondingly decreased in arrestin 3 KOs.  Live-cell imaging in HEK293 cells revealed that delta opioid receptors are in pre-engaged complexes with arrestin 3 at the cell membrane and that ARM390 strengthens this membrane interaction.  The disruption of these complexes in arrestin 3 KOs likely accounts for the altered responses to low-internalizing agonists.  Together, our results show agonist-selective recruitment of arrestin isoforms and reveal a novel endogenous role of arrestin 3 as a facilitator of resensitization and an inhibitor of tolerance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-sMfeVaStbVg90H21EOLACvtfcHk0ligjvy7RdI-Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFelsbzK&md5=16bedb12ca9d24e412c50af4f8702a49</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4124-15.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4124-15.2016%26sid%3Dliteratum%253Aachs%26aulast%3DPradhan%26aufirst%3DA.%2BA.%26aulast%3DPerroy%26aufirst%3DJ.%26aulast%3DWalwyn%26aufirst%3DW.%2BM.%26aulast%3DSmith%26aufirst%3DM.%2BL.%26aulast%3DVicente-Sanchez%26aufirst%3DA.%26aulast%3DSegura%26aufirst%3DL.%26aulast%3DBana%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26aulast%3DEvans%26aufirst%3DC.%2BJ.%26atitle%3DAgonist-specific%2520recruitment%2520of%2520arrestin%2520isoforms%2520differentially%2520modify%2520delta%2520opioid%2520receptor%2520function%26jtitle%3DJ.%2520Neurosci.%26date%3D2016%26volume%3D36%26spage%3D3541%26epage%3D3551%26doi%3D10.1523%2FJNEUROSCI.4124-15.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RH1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RH1','PDB','2RH1'); return false;">PDB: 2RH1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SN6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SN6','PDB','3SN6'); return false;">PDB: 3SN6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWJ','PDB','4ZWJ'); return false;">PDB: 4ZWJ</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-22%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00435%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00435" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b70cdfb703c76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
